227508	Naloxone reverses the antihypertensive effect of clonidine .|In unanesthetized , spontaneously hypertensive rats the decrease in blood pressure and heart rate produced by intravenous clonidine , 5 to 20 micrograms / kg , was inhibited or reversed by nalozone , 0 . 2 to 2 mg / kg .|The hypotensive effect of 100 mg / kg alpha - methyldopa was also partially reversed by naloxone .|Naloxone alone did not affect either blood pressure or heart rate .|In brain membranes from spontaneously hypertensive rats clonidine , 10 ( - 8 ) to 10 ( - 5 ) M , did not influence stereoselective binding of [ 3H ] - naloxone ( 8 nM ) , and naloxone , 10 ( - 8 ) to 10 ( - 4 ) M , did not influence clonidine - suppressible binding of [ 3H ] - dihydroergocryptine ( 1 nM ) .|These findings indicate that in spontaneously hypertensive rats the effects of central alpha - adrenoceptor stimulation involve activation of opiate receptors .|As naloxone and clonidine do not appear to interact with the same receptor site , the observed functional antagonism suggests the release of an endogenous opiate by clonidine or alpha - methyldopa and the possible role of the opiate in the central control of sympathetic tone .	1:CID:2	R2L	NON-CROSS	58-61	51-52	D008750	alpha - methyldopa|alpha - methyldopa	Chemical	58:203	61:206	2:6	D007022	hypotensive	Disease	51	52	2	1:NR:2	L2R	NON-CROSS	0-1	12-13	D009270	Naloxone|naloxone|Naloxone|naloxone|naloxone	Chemical	0:66:68:119:175	1:67:69:120:176	0:2:3:4:6	D006973	hypertensive|hypertensive|hypertensive	Disease	12:85:158	13:86:159	1:4:5	1:NR:2	L2R	NON-CROSS	51-52	66-67	D009270	Naloxone|naloxone|Naloxone|naloxone|naloxone	Chemical	0:66:68:119:175	1:67:69:120:176	0:2:3:4:6	D007022	hypotensive	Disease	51	52	2	1:NR:2	L2R	NON-CROSS	85-86	87-88	D003000	clonidine|clonidine|clonidine|clonidine|clonidine|clonidine	Chemical	6:25:87:137:177:201	7:26:88:138:178:202	0:1:4:4:6:6	D006973	hypertensive|hypertensive|hypertensive	Disease	12:85:158	13:86:159	1:4:5	1:NR:2	L2R	CROSS	25-26	51-52	D003000	clonidine|clonidine|clonidine|clonidine|clonidine|clonidine	Chemical	6:25:87:137:177:201	7:26:88:138:178:202	0:1:4:4:6:6	D007022	hypotensive	Disease	51	52	2	1:NR:2	R2L	CROSS	85-86	58-61	D008750	alpha - methyldopa|alpha - methyldopa	Chemical	58:203	61:206	2:6	D006973	hypertensive|hypertensive|hypertensive	Disease	12:85:158	13:86:159	1:4:5
354896	Lidocaine - induced cardiac asystole .|Intravenous administration of a single 50 - mg bolus of lidocaine in a 67 - year - old man resulted in profound depression of the activity of the sinoatrial and atrioventricular nodal pacemakers .|The patient had no apparent associated conditions which might have predisposed him to the development of bradyarrhythmias ; and , thus , this probably represented a true idiosyncrasy to lidocaine .	1:CID:2	L2R	NON-CROSS	0-1	3-5	D008012	Lidocaine|lidocaine|lidocaine	Chemical	0:16:69	1:17:70	0:1:2	D006323	cardiac asystole	Disease	3	5	0	1:NR:2	L2R	NON-CROSS	16-17	28-29	D008012	Lidocaine|lidocaine|lidocaine	Chemical	0:16:69	1:17:70	0:1:2	D003866	depression	Disease	28	29	1	1:NR:2	L2R	NON-CROSS	56-57	69-70	D008012	Lidocaine|lidocaine|lidocaine	Chemical	0:16:69	1:17:70	0:1:2	D001919	bradyarrhythmias	Disease	56	57	2
435349	Suxamethonium infusion rate and observed fasciculations .|A dose - response study .|Suxamethonium chloride ( Sch ) was administered i . v .|to 36 adult males at six rates : 0 . 25 mg s - 1 to 20 mg s - 1 .|The infusion was discontinued either when there was no muscular response to tetanic stimulation of the ulnar nerve or when Sch 120 mg was exceeded .|Six additional patients received a 30 - mg i . v .|bolus dose .|Fasciculations in six areas of the body were scored from 0 to 3 and summated as a total fasciculation score .|The times to first fasciculation , twitch suppression and tetanus suppression were inversely related to the infusion rates .|Fasciculations in the six areas and the total fasciculation score were related directly to the rate of infusion .|Total fasciculation scores in the 30 - mg bolus group and the 5 - mg s - 1 and 20 - mg s - 1 infusion groups were not significantly different .	1:CID:2	L2R	NON-CROSS	0-1	5-6	D013390	Suxamethonium|Suxamethonium chloride|Sch|Sch	Chemical	0:13:16:66	1:15:17:67	0:2:2:4	D005207	fasciculations|Fasciculations|fasciculation|fasciculation|Fasciculations|fasciculation|fasciculation	Disease	5:87:105:112:127:135:147	6:88:106:113:128:136:148	0:7:7:8:9:9:10	1:NR:2	L2R	NON-CROSS	58-59	66-67	D013390	Suxamethonium|Suxamethonium chloride|Sch|Sch	Chemical	0:13:16:66	1:15:17:67	0:2:2:4	D013746	tetanic|twitch|tetanus	Disease	58:114:117	59:115:118	4:8:8
603022	Galanthamine hydrobromide , a longer acting anticholinesterase drug , in the treatment of the central effects of scopolamine ( Hyoscine ) .|Galanthamine hydrobromide , an anticholinesterase drug capable of penetrating the blood - brain barrier , was used in a patient demonstrating central effects of scopolamine ( hyoscine ) overdosage .|It is longer acting than physostigmine and is used in anaesthesia to reverse the non - depolarizing neuromuscular block .|However , studies into the dose necessary to combating scopolamine intoxication are indicated .	1:CID:2	L2R	NON-CROSS	48-49	50-51	D012601	scopolamine|Hyoscine|scopolamine|hyoscine|scopolamine	Chemical	17:19:46:48:81	18:20:47:49:82	0:0:1:1:3	D062787	overdosage	Disease	50	51	1	1:NR:2	L2R	NON-CROSS	22-24	50-51	D005702	Galanthamine hydrobromide|Galanthamine hydrobromide	Chemical	0:22	2:24	0:1	D062787	overdosage	Disease	50	51	1	1:NR:2	R2L	CROSS	57-58	50-51	D010830	physostigmine	Chemical	57	58	2	D062787	overdosage	Disease	50	51	1
1378968	Effects of uninephrectomy and high protein feeding on lithium - induced chronic renal failure in rats .|Rats with lithium - induced nephropathy were subjected to high protein ( HP ) feeding , uninephrectomy ( NX ) or a combination of these , in an attempt to induce glomerular hyperfiltration and further progression of renal failure .|Newborn female Wistar rats were fed a lithium - containing diet ( 50 mmol / kg ) for 8 weeks and then randomized to normal diet , HP diet ( 40 vs . 19 % ) , NX or HP + NX for another 8 weeks .|Corresponding non - lithium pretreated groups were generated .|When comparing all lithium treated versus non - lithium - treated groups , lithium caused a reduction in glomerular filtration rate ( GFR ) without significant changes in effective renal plasma flow ( as determined by a marker secreted into the proximal tubules ) or lithium clearance .|Consequently , lithium pretreatment caused a fall in filtration fraction and an increase in fractional Li excretion .|Lithium also caused proteinuria and systolic hypertension in absence of glomerulosclerosis .|HP failed to accentuante progression of renal failure and in fact tended to increase GFR and decrease plasma creatinine levels in lithium pretreated rats .|NX caused an additive deterioration in GFR which , however , was ameliorated by HP .|NX + HP caused a further rise in blood pressure in Li - pretreated rats .|The results indicate that Li - induced nephropathy , even when the GFR is only modestly reduced , is associated with proteinuria and arterial systolic hypertension .|In this model of chronic renal failure the decline in GFR is not accompanied by a corresponding fall in effective renal plasma flow , which may be the functional expression of the formation of nonfiltrating atubular glomeruli .|The fractional reabsorption of tubular fluid by the proximal tubules is reduced , leaving the distal delivery unchanged . ( ABSTRACT TRUNCATED AT 250 WORDS )	1:CID:2	L2R	NON-CROSS	8-9	11-14	D008094	lithium|lithium|lithium|lithium|lithium|lithium|lithium|lithium|lithium|Li|Lithium|lithium|Li|Li	Chemical	8:19:64:107:116:121:126:158:163:176:179:212:243:252	9:20:65:108:117:122:127:159:164:177:180:213:244:253	0:1:2:3:4:4:4:4:5:5:6:7:9:10	D007676	chronic renal failure|chronic renal failure	Disease	11:279	14:282	0:11	1:CID:2	L2R	NON-CROSS	179-180	182-183	D008094	lithium|lithium|lithium|lithium|lithium|lithium|lithium|lithium|lithium|Li|Lithium|lithium|Li|Li	Chemical	8:19:64:107:116:121:126:158:163:176:179:212:243:252	9:20:65:108:117:122:127:159:164:177:180:213:244:253	0:1:2:3:4:4:4:4:5:5:6:7:9:10	D011507	proteinuria|proteinuria	Disease	182:269	183:270	6:10	1:CID:2	L2R	NON-CROSS	179-180	185-186	D008094	lithium|lithium|lithium|lithium|lithium|lithium|lithium|lithium|lithium|Li|Lithium|lithium|Li|Li	Chemical	8:19:64:107:116:121:126:158:163:176:179:212:243:252	9:20:65:108:117:122:127:159:164:177:180:213:244:253	0:1:2:3:4:4:4:4:5:5:6:7:9:10	D006973	hypertension|hypertension	Disease	185:273	186:274	6:10	not_include	L2R	NON-CROSS	19-20	22-23	D008094	lithium|lithium|lithium|lithium|lithium|lithium|lithium|lithium|lithium|Li|Lithium|lithium|Li|Li	Chemical	8:19:64:107:116:121:126:158:163:176:179:212:243:252	9:20:65:108:117:122:127:159:164:177:180:213:244:253	0:1:2:3:4:4:4:4:5:5:6:7:9:10	D007674	nephropathy|nephropathy	Disease	22:255	23:256	1:10	not_include	L2R	NON-CROSS	54-56	64-65	D008094	lithium|lithium|lithium|lithium|lithium|lithium|lithium|lithium|lithium|Li|Lithium|lithium|Li|Li	Chemical	8:19:64:107:116:121:126:158:163:176:179:212:243:252	9:20:65:108:117:122:127:159:164:177:180:213:244:253	0:1:2:3:4:4:4:4:5:5:6:7:9:10	D051437	renal failure|renal failure	Disease	54:197	56:199	1:7	1:NR:2	L2R	NON-CROSS	179-180	189-190	D008094	lithium|lithium|lithium|lithium|lithium|lithium|lithium|lithium|lithium|Li|Lithium|lithium|Li|Li	Chemical	8:19:64:107:116:121:126:158:163:176:179:212:243:252	9:20:65:108:117:122:127:159:164:177:180:213:244:253	0:1:2:3:4:4:4:4:5:5:6:7:9:10	D005921	glomerulosclerosis	Disease	189	190	6	1:NR:2	R2L	CROSS	279-282	209-210	D003404	creatinine	Chemical	209	210	7	D007676	chronic renal failure|chronic renal failure	Disease	11:279	14:282	0:11	1:NR:2	R2L	CROSS	255-256	209-210	D003404	creatinine	Chemical	209	210	7	D007674	nephropathy|nephropathy	Disease	22:255	23:256	1:10	1:NR:2	R2L	NON-CROSS	209-210	197-199	D003404	creatinine	Chemical	209	210	7	D051437	renal failure|renal failure	Disease	54:197	56:199	1:7	1:NR:2	R2L	CROSS	209-210	182-183	D003404	creatinine	Chemical	209	210	7	D011507	proteinuria|proteinuria	Disease	182:269	183:270	6:10	1:NR:2	R2L	CROSS	209-210	185-186	D003404	creatinine	Chemical	209	210	7	D006973	hypertension|hypertension	Disease	185:273	186:274	6:10	1:NR:2	R2L	CROSS	209-210	189-190	D003404	creatinine	Chemical	209	210	7	D005921	glomerulosclerosis	Disease	189	190	6
1420741	Treatment of Crohn 's disease with fusidic acid : an antibiotic with immunosuppressive properties similar to cyclosporin .|Fusidic acid is an antibiotic with T - cell specific immunosuppressive effects similar to those of cyclosporin .|Because of the need for the development of new treatments for Crohn 's disease , a pilot study was undertaken to estimate the pharmacodynamics and tolerability of fusidic acid treatment in chronic active , therapy - resistant patients .|Eight Crohn 's disease patients were included .|Fusidic acid was administered orally in a dose of 500 mg t . d . s .|and the treatment was planned to last 8 weeks .|The disease activity was primarily measured by a modified individual grading score .|Five of 8 patients ( 63 % ) improved during fusidic acid treatment : 3 at two weeks and 2 after four weeks .|There were no serious clinical side effects , but dose reduction was required in two patients because of nausea .|Biochemically , an increase in alkaline phosphatases was noted in 5 of 8 cases ( 63 % ) , and the greatest increases were seen in those who had elevated levels prior to treatment .|All reversed to pre - treatment levels after cessation of treatment .|The results of this pilot study suggest that fusidic acid may be of benefit in selected chronic active Crohn 's disease patients in whom conventional treatment is ineffective .|Because there seems to exist a scientific rationale for the use of fusidic acid at the cytokine level in inflammatory bowel disease , we suggest that the role of this treatment should be further investigated .	1:CID:2	L2R	CROSS	133-135	165-166	D005672	fusidic acid|fusidic acid|Fusidic acid|fusidic acid|fusidic acid|fusidic acid	Chemical	6:63:83:133:222:255	8:65:85:135:224:257	0:2:4:7:11:12	D009325	nausea	Disease	165	166	8	1:NR:2	R2L	NON-CROSS	6-8	2-5	D005672	fusidic acid|fusidic acid|Fusidic acid|fusidic acid|fusidic acid|fusidic acid	Chemical	6:63:83:133:222:255	8:65:85:135:224:257	0:2:4:7:11:12	D003424	Crohn 's disease|Crohn 's disease|Crohn 's disease|Crohn 's disease	Disease	2:47:76:232	5:50:79:235	0:2:3:11	1:NR:2	R2L	NON-CROSS	16-17	2-5	D016572	cyclosporin|cyclosporin	Chemical	16:34	17:35	0:1	D003424	Crohn 's disease|Crohn 's disease|Crohn 's disease|Crohn 's disease	Disease	2:47:76:232	5:50:79:235	0:2:3:11	1:NR:2	L2R	NON-CROSS	255-257	262-265	D005672	fusidic acid|fusidic acid|Fusidic acid|fusidic acid|fusidic acid|fusidic acid	Chemical	6:63:83:133:222:255	8:65:85:135:224:257	0:2:4:7:11:12	D015212	inflammatory bowel disease	Disease	262	265	12	1:NR:2	L2R	CROSS	34-35	165-166	D016572	cyclosporin|cyclosporin	Chemical	16:34	17:35	0:1	D009325	nausea	Disease	165	166	8	1:NR:2	L2R	CROSS	34-35	262-265	D016572	cyclosporin|cyclosporin	Chemical	16:34	17:35	0:1	D015212	inflammatory bowel disease	Disease	262	265	12
1601297	Electrocardiographic evidence of myocardial injury in psychiatrically hospitalized cocaine abusers .|The electrocardiograms ( ECG ) of 99 cocaine - abusing patients were compared with the ECGs of 50 schizophrenic controls .|Eleven of the cocaine abusers and none of the controls had ECG evidence of significant myocardial injury defined as myocardial infarction , ischemia , and bundle branch block .	1:CID:2	L2R	NON-CROSS	35-36	51-53	D003042	cocaine|cocaine|cocaine	Chemical	8:18:35	9:19:36	0:1:2	D009203	myocardial infarction	Disease	51	53	2	1:CID:2	L2R	NON-CROSS	35-36	57-60	D003042	cocaine|cocaine|cocaine	Chemical	8:18:35	9:19:36	0:1:2	D002037	bundle branch block	Disease	57	60	2	1:NR:2	R2L	NON-CROSS	8-9	3-5	D003042	cocaine|cocaine|cocaine	Chemical	8:18:35	9:19:36	0:1:2	D009202	myocardial injury|myocardial injury	Disease	3:47	5:49	0:2	1:NR:2	L2R	NON-CROSS	29-30	35-36	D003042	cocaine|cocaine|cocaine	Chemical	8:18:35	9:19:36	0:1:2	D012559	schizophrenic	Disease	29	30	1	1:NR:2	L2R	NON-CROSS	35-36	54-55	D003042	cocaine|cocaine|cocaine	Chemical	8:18:35	9:19:36	0:1:2	D007511	ischemia	Disease	54	55	2
1967484	Sulpiride - induced tardive dystonia .|Sulpiride is a selective D2 - receptor antagonist with antipsychotic and antidepressant properties .|Although initially thought to be free of extrapyramidal side effects , sulpiride - induced tardive dyskinesia and parkinsonism have been reported occasionally .|We studied a 37 - year - old man who developed persistent segmental dystonia within 2 months after starting sulpiride therapy .|We could not find any previous reports of sulpiride - induced tardive dystonia .	1:CID:2	L2R	NON-CROSS	3-5	6-7	D013469	Sulpiride|Sulpiride|sulpiride|sulpiride|sulpiride	Chemical	0:6:31:62:73	1:7:32:63:74	0:1:2:3:4	D004421	tardive dystonia|dystonia|tardive dystonia	Disease	3:56:76	5:57:78	0:3:4	1:NR:2	L2R	NON-CROSS	31-32	34-36	D013469	Sulpiride|Sulpiride|sulpiride|sulpiride|sulpiride	Chemical	0:6:31:62:73	1:7:32:63:74	0:1:2:3:4	D004409	tardive dyskinesia	Disease	34	36	2	1:NR:2	L2R	NON-CROSS	31-32	37-38	D013469	Sulpiride|Sulpiride|sulpiride|sulpiride|sulpiride	Chemical	0:6:31:62:73	1:7:32:63:74	0:1:2:3:4	D010302	parkinsonism	Disease	37	38	2	1:NR:2	R2L	CROSS	17-18	3-5	D000928	antidepressant	Chemical	17	18	1	D004421	tardive dystonia|dystonia|tardive dystonia	Disease	3:56:76	5:57:78	0:3:4	1:NR:2	L2R	CROSS	17-18	34-36	D000928	antidepressant	Chemical	17	18	1	D004409	tardive dyskinesia	Disease	34	36	2	1:NR:2	L2R	CROSS	17-18	37-38	D000928	antidepressant	Chemical	17	18	1	D010302	parkinsonism	Disease	37	38	2
2234245	Ocular and auditory toxicity in hemodialyzed patients receiving desferrioxamine .|During an 18 - month period of study 41 hemodialyzed patients receiving desferrioxamine ( 10 - 40 mg / kg BW / 3 times weekly ) for the first time were monitored for detection of audiovisual toxicity .|6 patients presented clinical symptoms of visual or auditory toxicity .|Moreover , detailed ophthalmologic and audiologic studies disclosed abnormalities in 7 more asymptomatic patients .|Visual toxicity was of retinal origin and was characterized by a tritan - type dyschromatopsy , sometimes associated with a loss of visual acuity and pigmentary retinal deposits .|Auditory toxicity was characterized by a mid - to high - frequency neurosensorial hearing loss and the lesion was of the cochlear type .|Desferrioxamine withdrawal resulted in a complete recovery of visual function in 1 patient and partial recovery in 3 , and a complete reversal of hearing loss in 3 patients and partial recovery in 3 .|This toxicity appeared in patients receiving the higher doses of desferrioxamine or coincided with the normalization of ferritin or aluminium serum levels .|The data indicate that audiovisual toxicity is not an infrequent complication in hemodialyzed patients receiving desferrioxamine .|Periodical audiovisual monitoring should be performed on hemodialyzed patients receiving the drug in order to detect adverse effects as early as possible .	1:CID:2	R2L	NON-CROSS	8-9	0-4	D003676	desferrioxamine|desferrioxamine|Desferrioxamine|desferrioxamine|desferrioxamine	Chemical	8:22:127:172:200	9:23:128:173:201	0:1:6:7:8	D014786	Ocular and auditory toxicity|audiovisual toxicity|visual or auditory toxicity|Visual toxicity|a loss of visual acuity|audiovisual toxicity	Disease	0:45:54:74:93:189	4:47:58:76:98:191	0:1:2:4:4:8	1:CID:2	L2R	CROSS	99-102	127-128	D003676	desferrioxamine|desferrioxamine|Desferrioxamine|desferrioxamine|desferrioxamine	Chemical	8:22:127:172:200	9:23:128:173:201	0:1:6:7:8	D012164	pigmentary retinal deposits	Disease	99	102	4	1:CID:2	L2R	CROSS	115-118	127-128	D003676	desferrioxamine|desferrioxamine|Desferrioxamine|desferrioxamine|desferrioxamine	Chemical	8:22:127:172:200	9:23:128:173:201	0:1:6:7:8	D006319	neurosensorial hearing loss	Disease	115	118	5	not_include	R2L	NON-CROSS	8-9	0-4	D003676	desferrioxamine|desferrioxamine|Desferrioxamine|desferrioxamine|desferrioxamine	Chemical	8:22:127:172:200	9:23:128:173:201	0:1:6:7:8	D006311	Ocular and auditory toxicity|audiovisual toxicity|visual or auditory toxicity|Auditory toxicity|audiovisual toxicity	Disease	0:45:54:103:189	4:47:58:105:191	0:1:2:5:8	not_include	L2R	NON-CROSS	151-153	172-173	D003676	desferrioxamine|desferrioxamine|Desferrioxamine|desferrioxamine|desferrioxamine	Chemical	8:22:127:172:200	9:23:128:173:201	0:1:6:7:8	D034381	hearing loss	Disease	151	153	6	1:NR:2	L2R	NON-CROSS	163-164	172-173	D003676	desferrioxamine|desferrioxamine|Desferrioxamine|desferrioxamine|desferrioxamine	Chemical	8:22:127:172:200	9:23:128:173:201	0:1:6:7:8	D064420	toxicity	Disease	163	164	7
2385256	Myasthenia gravis presenting as weakness after magnesium administration .|We studied a patient with no prior history of neuromuscular disease who became virtually quadriplegic after parenteral magnesium administration for preeclampsia .|The serum magnesium concentration was 3 . 0 mEq / L , which is usually well tolerated .|The magnesium was stopped and she recovered over a few days .|While she was weak , 2 - Hz repetitive stimulation revealed a decrement without significant facilitation at rapid rates or after exercise , suggesting postsynaptic neuromuscular blockade .|After her strength returned , repetitive stimulation was normal , but single fiber EMG revealed increased jitter and blocking .|Her acetylcholine receptor antibody level was markedly elevated .|Although paralysis after magnesium administration has been described in patients with known myasthenia gravis , it has not previously been reported to be the initial or only manifestation of the disease .|Patients who are unusually sensitive to the neuromuscular effects of magnesium should be suspected of having an underlying disorder of neuromuscular transmission .	1:CID:2	R2L	NON-CROSS	6-7	0-2	D008274	magnesium|magnesium|magnesium|magnesium|magnesium|magnesium	Chemical	6:26:33:50:121:160	7:27:34:51:122:161	0:1:2:3:7:8	D009157	Myasthenia gravis|myasthenia gravis	Disease	0:130	2:132	0:7	1:NR:2	R2L	CROSS	130-132	110-111	D000109	acetylcholine	Chemical	110	111	6	D009157	Myasthenia gravis|myasthenia gravis	Disease	0:130	2:132	0:7	not_include	L2R	NON-CROSS	18-20	26-27	D008274	magnesium|magnesium|magnesium|magnesium|magnesium|magnesium	Chemical	6:26:33:50:121:160	7:27:34:51:122:161	0:1:2:3:7:8	D009468	neuromuscular disease|postsynaptic neuromuscular blockade	Disease	18:85	20:88	1:4	1:NR:2	L2R	NON-CROSS	23-24	26-27	D008274	magnesium|magnesium|magnesium|magnesium|magnesium|magnesium	Chemical	6:26:33:50:121:160	7:27:34:51:122:161	0:1:2:3:7:8	D011782	quadriplegic	Disease	23	24	1	1:NR:2	L2R	NON-CROSS	26-27	29-30	D008274	magnesium|magnesium|magnesium|magnesium|magnesium|magnesium	Chemical	6:26:33:50:121:160	7:27:34:51:122:161	0:1:2:3:7:8	D011225	preeclampsia	Disease	29	30	1	1:NR:2	L2R	NON-CROSS	119-120	121-122	D008274	magnesium|magnesium|magnesium|magnesium|magnesium|magnesium	Chemical	6:26:33:50:121:160	7:27:34:51:122:161	0:1:2:3:7:8	D010243	paralysis	Disease	119	120	7	not_include	L2R	NON-CROSS	160-161	168-172	D008274	magnesium|magnesium|magnesium|magnesium|magnesium|magnesium	Chemical	6:26:33:50:121:160	7:27:34:51:122:161	0:1:2:3:7:8	D020511	disorder of neuromuscular transmission	Disease	168	172	8	1:NR:2	R2L	CROSS	110-111	85-88	D000109	acetylcholine	Chemical	110	111	6	D009468	neuromuscular disease|postsynaptic neuromuscular blockade	Disease	18:85	20:88	1:4	1:NR:2	R2L	CROSS	110-111	23-24	D000109	acetylcholine	Chemical	110	111	6	D011782	quadriplegic	Disease	23	24	1	1:NR:2	R2L	CROSS	110-111	29-30	D000109	acetylcholine	Chemical	110	111	6	D011225	preeclampsia	Disease	29	30	1	1:NR:2	L2R	CROSS	110-111	119-120	D000109	acetylcholine	Chemical	110	111	6	D010243	paralysis	Disease	119	120	7	1:NR:2	L2R	CROSS	110-111	168-172	D000109	acetylcholine	Chemical	110	111	6	D020511	disorder of neuromuscular transmission	Disease	168	172	8
2505783	Chloroacetaldehyde and its contribution to urotoxicity during treatment with cyclophosphamide or ifosfamide .|An experimental study / short communication .|Based on clinical data , indicating that chloroacetaldehyde ( CAA ) is an important metabolite of oxazaphosphorine cytostatics , an experimental study was carried out in order to elucidate the role of CAA in the development of hemorrhagic cystitis .|The data demonstrate that CAA after i . v .|administration does not contribute to bladder damage .|When instilled directly into the bladder , CAA exerts urotoxic effects , it is , however , susceptible to detoxification with mesna .	1:CID:2	L2R	NON-CROSS	52-53	57-59	C004656	Chloroacetaldehyde|chloroacetaldehyde|CAA|CAA|CAA|CAA	Chemical	0:27:29:52:64:85	1:28:30:53:65:86	0:2:2:2:3:5	D006470	hemorrhagic cystitis	Disease	57	59	2	1:CID:2	L2R	NON-CROSS	52-53	57-59	C004656	Chloroacetaldehyde|chloroacetaldehyde|CAA|CAA|CAA|CAA	Chemical	0:27:29:52:64:85	1:28:30:53:65:86	0:2:2:2:3:5	D003556	hemorrhagic cystitis	Disease	57	59	2	not_include	L2R	CROSS	75-77	85-86	C004656	Chloroacetaldehyde|chloroacetaldehyde|CAA|CAA|CAA|CAA	Chemical	0:27:29:52:64:85	1:28:30:53:65:86	0:2:2:2:3:5	D001745	bladder damage	Disease	75	77	4	1:NR:2	L2R	CROSS	9-10	57-59	D003520	cyclophosphamide	Chemical	9	10	0	D006470	hemorrhagic cystitis	Disease	57	59	2	1:NR:2	L2R	CROSS	9-10	57-59	D003520	cyclophosphamide	Chemical	9	10	0	D003556	hemorrhagic cystitis	Disease	57	59	2	1:NR:2	L2R	CROSS	9-10	75-77	D003520	cyclophosphamide	Chemical	9	10	0	D001745	bladder damage	Disease	75	77	4	1:NR:2	L2R	CROSS	11-12	57-59	D007069	ifosfamide	Chemical	11	12	0	D006470	hemorrhagic cystitis	Disease	57	59	2	1:NR:2	L2R	CROSS	11-12	57-59	D007069	ifosfamide	Chemical	11	12	0	D003556	hemorrhagic cystitis	Disease	57	59	2	1:NR:2	L2R	CROSS	11-12	75-77	D007069	ifosfamide	Chemical	11	12	0	D001745	bladder damage	Disease	75	77	4	1:NR:2	R2L	CROSS	99-100	57-59	D015080	mesna	Chemical	99	100	5	D006470	hemorrhagic cystitis	Disease	57	59	2	1:NR:2	R2L	CROSS	99-100	57-59	D015080	mesna	Chemical	99	100	5	D003556	hemorrhagic cystitis	Disease	57	59	2	1:NR:2	R2L	CROSS	99-100	75-77	D015080	mesna	Chemical	99	100	5	D001745	bladder damage	Disease	75	77	4
2515254	Source of pain and primitive dysfunction in migraine : an identical site ?|Twenty common migraine patients received a one sided frontotemporal application of nitroglycerin ( 10 patients ) or placebo ointment ( 10 patients ) in a double blind study .|Early onset migraine attacks were induced by nitroglycerin in seven out of 10 patients versus no patient in the placebo group .|Subsequently 20 migraine patients , who developed an early onset attack with frontotemporal nitroglycerin , received the drug in a second induction test at other body areas .|No early onset migraine was observed .|Thus the migraine - inducing effect of nitroglycerin seems to depend on direct stimulation of the habitual site of pain , suggesting that the frontotemporal region is of crucial importance in the development of a migraine crisis .|This is not consistent with a CNS origin of migraine attack .	1:CID:2	R2L	NON-CROSS	49-50	44-45	D005996	nitroglycerin|nitroglycerin|nitroglycerin|nitroglycerin	Chemical	24:49:77:106	25:50:78:107	1:2:3:5	D008881	migraine|migraine|migraine|migraine|migraine|migraine|migraine|migraine	Disease	7:15:44:66:95:101:134:146	8:16:45:67:96:102:135:147	0:1:2:3:4:5:5:6	1:NR:2	R2L	NON-CROSS	118-119	106-107	D005996	nitroglycerin|nitroglycerin|nitroglycerin|nitroglycerin	Chemical	24:49:77:106	25:50:78:107	1:2:3:5	D010146	pain|pain	Disease	2:118	3:119	0:5
2572625	Clotiazepam - induced acute hepatitis .|We report the case of a patient who developed acute hepatitis with extensive hepatocellular necrosis , 7 months after the onset of administration of clotiazepam , a thienodiazepine derivative .|Clotiazepam withdrawal was followed by prompt recovery .|The administration of several benzodiazepines , chemically related to clotiazepam , did not interfere with recovery and did not induce any relapse of hepatitis .|This observation shows that clotiazepam can induce acute hepatitis and suggests that there is no cross hepatotoxicity between clotiazepam and several benzodiazepines .	1:CID:2	L2R	NON-CROSS	85-86	87-88	C084599	Clotiazepam|clotiazepam|Clotiazepam|clotiazepam|clotiazepam|clotiazepam	Chemical	0:30:36:53:73:87	1:31:37:54:74:88	0:1:2:3:4:4	D056486	hepatitis|hepatitis|hepatitis|hepatitis|hepatotoxicity	Disease	4:16:67:77:85	5:17:68:78:86	0:1:3:4:4	1:NR:2	L2R	NON-CROSS	18-21	30-31	C084599	Clotiazepam|clotiazepam|Clotiazepam|clotiazepam|clotiazepam|clotiazepam	Chemical	0:30:36:53:73:87	1:31:37:54:74:88	0:1:2:3:4:4	D047508	extensive hepatocellular necrosis	Disease	18	21	1	1:NR:2	R2L	NON-CROSS	33-34	16-17	C013295	thienodiazepine	Chemical	33	34	1	D056486	hepatitis|hepatitis|hepatitis|hepatitis|hepatotoxicity	Disease	4:16:67:77:85	5:17:68:78:86	0:1:3:4:4	1:NR:2	R2L	NON-CROSS	90-91	85-86	D001569	benzodiazepines|benzodiazepines	Chemical	48:90	49:91	3:4	D056486	hepatitis|hepatitis|hepatitis|hepatitis|hepatotoxicity	Disease	4:16:67:77:85	5:17:68:78:86	0:1:3:4:4	1:NR:2	R2L	NON-CROSS	33-34	18-21	C013295	thienodiazepine	Chemical	33	34	1	D047508	extensive hepatocellular necrosis	Disease	18	21	1	1:NR:2	R2L	CROSS	48-49	18-21	D001569	benzodiazepines|benzodiazepines	Chemical	48:90	49:91	3:4	D047508	extensive hepatocellular necrosis	Disease	18	21	1
2632720	Arterial hypertension as a complication of prolonged ketoconazole treatment .|Two of 14 patients with Cushing 's syndrome treated on a long - term basis with ketoconazole developed sustained hypertension .|In both cases normal plasma and urinary free cortisol levels had been achieved following ketoconazole therapy , yet continuous blood pressure monitoring demonstrated hypertension 31 ( patient 1 ) and 52 weeks ( patient 2 ) after treatment .|In patient 1 , plasma levels of deoxycorticosterone and 11 - deoxycortisol were elevated .|In patient 2 , in addition to an increase in both deoxycorticosterone and 11 - deoxycortisol levels , plasma aldosterone values were raised , with a concomitant suppression of renin levels .|Our findings show that long - term treatment with high doses of ketoconazole may induce enzyme blockade leading to mineralocorticoid - related hypertension .	1:CID:2	R2L	NON-CROSS	29-30	26-27	D007654	ketoconazole|ketoconazole|ketoconazole|ketoconazole	Chemical	7:26:45:129	8:27:46:130	0:1:2:5	D006973	hypertension|hypertension|hypertension|hypertension	Disease	1:29:54:139	2:30:55:140	0:1:2:5	1:NR:2	R2L	NON-CROSS	39-40	29-30	D006854	cortisol	Chemical	39	40	2	D006973	hypertension|hypertension|hypertension|hypertension	Disease	1:29:54:139	2:30:55:140	0:1:2:5	1:NR:2	R2L	CROSS	77-78	54-55	D003900	deoxycorticosterone|deoxycorticosterone	Chemical	77:96	78:97	3:4	D006973	hypertension|hypertension|hypertension|hypertension	Disease	1:29:54:139	2:30:55:140	0:1:2:5	1:NR:2	R2L	CROSS	79-82	54-55	D003350	11 - deoxycortisol|11 - deoxycortisol	Chemical	79:98	82:101	3:4	D006973	hypertension|hypertension|hypertension|hypertension	Disease	1:29:54:139	2:30:55:140	0:1:2:5	1:NR:2	R2L	CROSS	139-140	104-105	D000450	aldosterone	Chemical	104	105	4	D006973	hypertension|hypertension|hypertension|hypertension	Disease	1:29:54:139	2:30:55:140	0:1:2:5	1:NR:2	L2R	NON-CROSS	7-8	15-18	D007654	ketoconazole|ketoconazole|ketoconazole|ketoconazole	Chemical	7:26:45:129	8:27:46:130	0:1:2:5	D003480	Cushing 's syndrome	Disease	15	18	1	1:NR:2	R2L	CROSS	39-40	15-18	D006854	cortisol	Chemical	39	40	2	D003480	Cushing 's syndrome	Disease	15	18	1	1:NR:2	R2L	CROSS	77-78	15-18	D003900	deoxycorticosterone|deoxycorticosterone	Chemical	77:96	78:97	3:4	D003480	Cushing 's syndrome	Disease	15	18	1	1:NR:2	R2L	CROSS	79-82	15-18	D003350	11 - deoxycortisol|11 - deoxycortisol	Chemical	79:98	82:101	3:4	D003480	Cushing 's syndrome	Disease	15	18	1	1:NR:2	R2L	CROSS	104-105	15-18	D000450	aldosterone	Chemical	104	105	4	D003480	Cushing 's syndrome	Disease	15	18	1
2670794	Effects of an inhibitor of angiotensin converting enzyme ( Captopril ) on pulmonary and renal insufficiency due to intravascular coagulation in the rat .|Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid ( AMCA ) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or sepsis in man .|Injection of Captopril ( 1 mg / kg ) , an inhibitor of angiotensin converting enzyme ( ACE ) , reduced both pulmonary and renal insufficiency in this rat model .|The lung weights were lower and PaO2 was improved in rats given this enzyme - blocking agent .|The contents of albumin in the lungs were not changed , indicating that Captopril did not influence the extravasation of protein .|Renal damage as reflected by an increase in serum urea and in kidney weight was prevented by Captopril .|The amount of fibrin in the kidneys was also considerably lower than in animals which received thrombin and AMCA alone .|It is suggested that the effects of Captopril on the lungs may be attributable to a vasodilatory effect due to a reduction in the circulating level of Angiotension II and an increase in prostacyclin ( secondary to an increase in bradykinin ) .|Captopril may , by the same mechanism , reduce the increase in glomerular filtration that is known to occur after an injection of thrombin , thereby diminishing the aggregation of fibrin monomers in the glomeruli , with the result that less fibrin will be deposited and thus less kidney damage will be produced .	1:CID:2	R2L	NON-CROSS	37-39	26-28	D014148	tranexamic acid|AMCA|AMCA	Chemical	37:40:170	39:41:171	1:1:6	D004211	intravascular coagulation|intravascular coagulation	Disease	18:26	20:28	0:1	1:NR:2	L2R	NON-CROSS	5-6	12-16	D000809	angiotensin|angiotensin	Chemical	5:75	6:76	0:2	D011665	pulmonary and renal insufficiency|pulmonary and renal insufficiency|pulmonary and renal insufficiency	Disease	12:48:84	16:52:88	0:1:2	1:NR:2	L2R	NON-CROSS	5-6	12-16	D000809	angiotensin|angiotensin	Chemical	5:75	6:76	0:2	D051437	pulmonary and renal insufficiency|pulmonary and renal insufficiency|pulmonary and renal insufficiency	Disease	12:48:84	16:52:88	0:1:2	1:NR:2	L2R	NON-CROSS	5-6	18-20	D000809	angiotensin|angiotensin	Chemical	5:75	6:76	0:2	D004211	intravascular coagulation|intravascular coagulation	Disease	18:26	20:28	0:1	1:NR:2	L2R	CROSS	56-57	75-76	D000809	angiotensin|angiotensin	Chemical	5:75	6:76	0:2	D014947	trauma	Disease	56	57	1	1:NR:2	L2R	CROSS	58-59	75-76	D000809	angiotensin|angiotensin	Chemical	5:75	6:76	0:2	D018805	sepsis	Disease	58	59	1	1:NR:2	L2R	CROSS	75-76	133-135	D000809	angiotensin|angiotensin	Chemical	5:75	6:76	0:2	D007674	Renal damage|kidney damage	Disease	133:264	135:266	5:8	1:NR:2	L2R	NON-CROSS	9-10	12-16	D002216	Captopril|Captopril|Captopril|Captopril|Captopril|Captopril	Chemical	9:64:124:150:180:216	10:65:125:151:181:217	0:2:4:5:7:8	D011665	pulmonary and renal insufficiency|pulmonary and renal insufficiency|pulmonary and renal insufficiency	Disease	12:48:84	16:52:88	0:1:2	1:NR:2	L2R	NON-CROSS	9-10	12-16	D002216	Captopril|Captopril|Captopril|Captopril|Captopril|Captopril	Chemical	9:64:124:150:180:216	10:65:125:151:181:217	0:2:4:5:7:8	D051437	pulmonary and renal insufficiency|pulmonary and renal insufficiency|pulmonary and renal insufficiency	Disease	12:48:84	16:52:88	0:1:2	1:NR:2	L2R	NON-CROSS	9-10	18-20	D002216	Captopril|Captopril|Captopril|Captopril|Captopril|Captopril	Chemical	9:64:124:150:180:216	10:65:125:151:181:217	0:2:4:5:7:8	D004211	intravascular coagulation|intravascular coagulation	Disease	18:26	20:28	0:1	1:NR:2	L2R	CROSS	56-57	64-65	D002216	Captopril|Captopril|Captopril|Captopril|Captopril|Captopril	Chemical	9:64:124:150:180:216	10:65:125:151:181:217	0:2:4:5:7:8	D014947	trauma	Disease	56	57	1	1:NR:2	L2R	CROSS	58-59	64-65	D002216	Captopril|Captopril|Captopril|Captopril|Captopril|Captopril	Chemical	9:64:124:150:180:216	10:65:125:151:181:217	0:2:4:5:7:8	D018805	sepsis	Disease	58	59	1	1:NR:2	L2R	NON-CROSS	124-125	133-135	D002216	Captopril|Captopril|Captopril|Captopril|Captopril|Captopril	Chemical	9:64:124:150:180:216	10:65:125:151:181:217	0:2:4:5:7:8	D007674	Renal damage|kidney damage	Disease	133:264	135:266	5:8	1:NR:2	R2L	NON-CROSS	48-52	40-41	D014148	tranexamic acid|AMCA|AMCA	Chemical	37:40:170	39:41:171	1:1:6	D011665	pulmonary and renal insufficiency|pulmonary and renal insufficiency|pulmonary and renal insufficiency	Disease	12:48:84	16:52:88	0:1:2	1:NR:2	R2L	CROSS	142-143	84-88	D014508	urea	Chemical	142	143	5	D011665	pulmonary and renal insufficiency|pulmonary and renal insufficiency|pulmonary and renal insufficiency	Disease	12:48:84	16:52:88	0:1:2	1:NR:2	R2L	CROSS	200-202	84-88	D000804	Angiotension II	Chemical	200	202	7	D011665	pulmonary and renal insufficiency|pulmonary and renal insufficiency|pulmonary and renal insufficiency	Disease	12:48:84	16:52:88	0:1:2	1:NR:2	R2L	CROSS	206-207	84-88	D011464	prostacyclin	Chemical	206	207	7	D011665	pulmonary and renal insufficiency|pulmonary and renal insufficiency|pulmonary and renal insufficiency	Disease	12:48:84	16:52:88	0:1:2	1:NR:2	R2L	CROSS	213-214	84-88	D001920	bradykinin	Chemical	213	214	7	D011665	pulmonary and renal insufficiency|pulmonary and renal insufficiency|pulmonary and renal insufficiency	Disease	12:48:84	16:52:88	0:1:2	1:NR:2	R2L	NON-CROSS	48-52	40-41	D014148	tranexamic acid|AMCA|AMCA	Chemical	37:40:170	39:41:171	1:1:6	D051437	pulmonary and renal insufficiency|pulmonary and renal insufficiency|pulmonary and renal insufficiency	Disease	12:48:84	16:52:88	0:1:2	1:NR:2	R2L	CROSS	142-143	84-88	D014508	urea	Chemical	142	143	5	D051437	pulmonary and renal insufficiency|pulmonary and renal insufficiency|pulmonary and renal insufficiency	Disease	12:48:84	16:52:88	0:1:2	1:NR:2	R2L	CROSS	200-202	84-88	D000804	Angiotension II	Chemical	200	202	7	D051437	pulmonary and renal insufficiency|pulmonary and renal insufficiency|pulmonary and renal insufficiency	Disease	12:48:84	16:52:88	0:1:2	1:NR:2	R2L	CROSS	206-207	84-88	D011464	prostacyclin	Chemical	206	207	7	D051437	pulmonary and renal insufficiency|pulmonary and renal insufficiency|pulmonary and renal insufficiency	Disease	12:48:84	16:52:88	0:1:2	1:NR:2	R2L	CROSS	213-214	84-88	D001920	bradykinin	Chemical	213	214	7	D051437	pulmonary and renal insufficiency|pulmonary and renal insufficiency|pulmonary and renal insufficiency	Disease	12:48:84	16:52:88	0:1:2	1:NR:2	R2L	CROSS	142-143	26-28	D014508	urea	Chemical	142	143	5	D004211	intravascular coagulation|intravascular coagulation	Disease	18:26	20:28	0:1	1:NR:2	R2L	CROSS	200-202	26-28	D000804	Angiotension II	Chemical	200	202	7	D004211	intravascular coagulation|intravascular coagulation	Disease	18:26	20:28	0:1	1:NR:2	R2L	CROSS	206-207	26-28	D011464	prostacyclin	Chemical	206	207	7	D004211	intravascular coagulation|intravascular coagulation	Disease	18:26	20:28	0:1	1:NR:2	R2L	CROSS	213-214	26-28	D001920	bradykinin	Chemical	213	214	7	D004211	intravascular coagulation|intravascular coagulation	Disease	18:26	20:28	0:1	1:NR:2	L2R	NON-CROSS	40-41	56-57	D014148	tranexamic acid|AMCA|AMCA	Chemical	37:40:170	39:41:171	1:1:6	D014947	trauma	Disease	56	57	1	1:NR:2	L2R	NON-CROSS	40-41	58-59	D014148	tranexamic acid|AMCA|AMCA	Chemical	37:40:170	39:41:171	1:1:6	D018805	sepsis	Disease	58	59	1	1:NR:2	L2R	CROSS	133-135	170-171	D014148	tranexamic acid|AMCA|AMCA	Chemical	37:40:170	39:41:171	1:1:6	D007674	Renal damage|kidney damage	Disease	133:264	135:266	5:8	1:NR:2	R2L	CROSS	142-143	56-57	D014508	urea	Chemical	142	143	5	D014947	trauma	Disease	56	57	1	1:NR:2	R2L	CROSS	200-202	56-57	D000804	Angiotension II	Chemical	200	202	7	D014947	trauma	Disease	56	57	1	1:NR:2	R2L	CROSS	206-207	56-57	D011464	prostacyclin	Chemical	206	207	7	D014947	trauma	Disease	56	57	1	1:NR:2	R2L	CROSS	213-214	56-57	D001920	bradykinin	Chemical	213	214	7	D014947	trauma	Disease	56	57	1	1:NR:2	R2L	CROSS	142-143	58-59	D014508	urea	Chemical	142	143	5	D018805	sepsis	Disease	58	59	1	1:NR:2	R2L	CROSS	200-202	58-59	D000804	Angiotension II	Chemical	200	202	7	D018805	sepsis	Disease	58	59	1	1:NR:2	R2L	CROSS	206-207	58-59	D011464	prostacyclin	Chemical	206	207	7	D018805	sepsis	Disease	58	59	1	1:NR:2	R2L	CROSS	213-214	58-59	D001920	bradykinin	Chemical	213	214	7	D018805	sepsis	Disease	58	59	1	1:NR:2	R2L	NON-CROSS	142-143	133-135	D014508	urea	Chemical	142	143	5	D007674	Renal damage|kidney damage	Disease	133:264	135:266	5:8	1:NR:2	R2L	CROSS	264-266	200-202	D000804	Angiotension II	Chemical	200	202	7	D007674	Renal damage|kidney damage	Disease	133:264	135:266	5:8	1:NR:2	R2L	CROSS	264-266	206-207	D011464	prostacyclin	Chemical	206	207	7	D007674	Renal damage|kidney damage	Disease	133:264	135:266	5:8	1:NR:2	R2L	CROSS	264-266	213-214	D001920	bradykinin	Chemical	213	214	7	D007674	Renal damage|kidney damage	Disease	133:264	135:266	5:8
2696505	A randomized comparison of labetalol and nitroprusside for induced hypotension .|In a randomized study , labetalol - induced hypotension and nitroprusside - induced hypotension were compared in 20 patients ( 10 in each group ) scheduled for major orthopedic procedures .|Each patient was subjected to an identical anesthetic protocol and similar drug - induced reductions in mean arterial blood pressure ( BP ) ( 50 to 55 mmHg ) .|Nitroprusside infusion was associated with a significant ( p less than 0 . 05 ) increase in heart rate and cardiac output ; rebound hypertension was observed in three patients after discontinuation of nitroprusside .|Labetalol administration was not associated with any of these findings .|Arterial PO2 decreased in both groups .|It was concluded that labetalol offers advantages over nitroprusside .	1:CID:2	L2R	NON-CROSS	16-17	19-20	D007741	labetalol|labetalol|Labetalol|labetalol	Chemical	4:16:107:129	5:17:108:130	0:1:4:6	D007022	hypotension|hypotension|hypotension|reductions in mean arterial blood pressure	Disease	9:19:24:56	10:20:25:62	0:1:1:2	1:CID:2	L2R	NON-CROSS	19-20	21-22	D009599	nitroprusside|nitroprusside|nitroprusside|nitroprusside	Chemical	6:21:105:133	7:22:106:134	0:1:3:6	D007022	hypotension|hypotension|hypotension|reductions in mean arterial blood pressure	Disease	9:19:24:56	10:20:25:62	0:1:1:2	1:CID:2	L2R	NON-CROSS	87-94	105-106	D009599	nitroprusside|nitroprusside|nitroprusside|nitroprusside	Chemical	6:21:105:133	7:22:106:134	0:1:3:6	D016534	increase in heart rate and cardiac output	Disease	87	94	3	1:NR:2	L2R	CROSS	87-94	107-108	D007741	labetalol|labetalol|Labetalol|labetalol	Chemical	4:16:107:129	5:17:108:130	0:1:4:6	D016534	increase in heart rate and cardiac output	Disease	87	94	3	1:NR:2	L2R	CROSS	96-97	107-108	D007741	labetalol|labetalol|Labetalol|labetalol	Chemical	4:16:107:129	5:17:108:130	0:1:4:6	D006973	hypertension	Disease	96	97	3	1:NR:2	L2R	NON-CROSS	96-97	105-106	D009599	nitroprusside|nitroprusside|nitroprusside|nitroprusside	Chemical	6:21:105:133	7:22:106:134	0:1:3:6	D006973	hypertension	Disease	96	97	3	1:NR:2	R2L	CROSS	119-120	56-62	C093415	PO2	Chemical	119	120	5	D007022	hypotension|hypotension|hypotension|reductions in mean arterial blood pressure	Disease	9:19:24:56	10:20:25:62	0:1:1:2	1:NR:2	R2L	CROSS	119-120	87-94	C093415	PO2	Chemical	119	120	5	D016534	increase in heart rate and cardiac output	Disease	87	94	3	1:NR:2	R2L	CROSS	119-120	96-97	C093415	PO2	Chemical	119	120	5	D006973	hypertension	Disease	96	97	3
2924746	Chronic carbamazepine treatment in the rat : efficacy , toxicity , and effect on plasma and tissue folate concentrations .|Folate depletion has often been a problem in chronic antiepileptic drug ( AED ) therapy .|Carbamazepine ( CBZ ) , a commonly used AED , has been implicated in some clinical studies .|A rat model was developed to examine the effects of chronic CBZ treatment on folate concentrations in the rat .|In the course of developing this model , a common vehicle , propylene glycol , by itself in high doses , was found to exhibit protective properties against induced seizures and inhibited weight gain .|Seizures induced by hexafluorodiethyl ether ( HFDE ) were also found to be a more sensitive measure of protection by CBZ than seizures induced by maximal electroshock ( MES ) .|Oral administration of CBZ as an aqueous suspension every 8 h at a dose of 250 mg / kg was continuously protective against HFDE - induced seizures and was minimally toxic as measured by weight gain over 8 weeks of treatment .|The CBZ levels measured in plasma and brain of these animals , however , were below those normally considered protective .|This treatment with CBZ had no apparent adverse effect on folate concentrations in the rat , and , indeed , the folate concentration increased in liver after 6 weeks of treatment and in plasma at 8 weeks of treatment .	1:CID:2	R2L	NON-CROSS	112-114	109-110	D005481	hexafluorodiethyl ether|HFDE|HFDE	Chemical	112:115:163	114:116:164	5:5:6	D012640	seizures|Seizures|seizures|seizures	Disease	103:109:131:166	104:110:132:167	4:5:5:6	1:NR:2	L2R	NON-CROSS	1-2	9-10	D002220	carbamazepine|Carbamazepine|CBZ|CBZ|CBZ|CBZ|CBZ|CBZ	Chemical	1:36:38:65:129:143:183:206	2:37:39:66:130:144:184:207	0:2:2:3:5:6:7:8	D064420	toxicity	Disease	9	10	0	1:NR:2	L2R	NON-CROSS	129-130	131-132	D002220	carbamazepine|Carbamazepine|CBZ|CBZ|CBZ|CBZ|CBZ|CBZ	Chemical	1:36:38:65:129:143:183:206	2:37:39:66:130:144:184:207	0:2:2:3:5:6:7:8	D012640	seizures|Seizures|seizures|seizures	Disease	103:109:131:166	104:110:132:167	4:5:5:6	1:NR:2	L2R	NON-CROSS	174-176	183-184	D002220	carbamazepine|Carbamazepine|CBZ|CBZ|CBZ|CBZ|CBZ|CBZ	Chemical	1:36:38:65:129:143:183:206	2:37:39:66:130:144:184:207	0:2:2:3:5:6:7:8	D015430	weight gain|weight gain	Disease	106:174	108:176	4:6	1:NR:2	R2L	NON-CROSS	17-18	9-10	D005492	folate|Folate|folate|folate|folate	Chemical	17:20:68:213:224	18:21:69:214:225	0:1:3:8:8	D064420	toxicity	Disease	9	10	0	1:NR:2	R2L	CROSS	86-88	9-10	D019946	propylene glycol	Chemical	86	88	4	D064420	toxicity	Disease	9	10	0	1:NR:2	R2L	CROSS	112-114	9-10	D005481	hexafluorodiethyl ether|HFDE|HFDE	Chemical	112:115:163	114:116:164	5:5:6	D064420	toxicity	Disease	9	10	0	1:NR:2	L2R	CROSS	68-69	103-104	D005492	folate|Folate|folate|folate|folate	Chemical	17:20:68:213:224	18:21:69:214:225	0:1:3:8:8	D012640	seizures|Seizures|seizures|seizures	Disease	103:109:131:166	104:110:132:167	4:5:5:6	1:NR:2	L2R	CROSS	68-69	106-108	D005492	folate|Folate|folate|folate|folate	Chemical	17:20:68:213:224	18:21:69:214:225	0:1:3:8:8	D015430	weight gain|weight gain	Disease	106:174	108:176	4:6	1:NR:2	L2R	NON-CROSS	86-88	103-104	D019946	propylene glycol	Chemical	86	88	4	D012640	seizures|Seizures|seizures|seizures	Disease	103:109:131:166	104:110:132:167	4:5:5:6	1:NR:2	L2R	NON-CROSS	86-88	106-108	D019946	propylene glycol	Chemical	86	88	4	D015430	weight gain|weight gain	Disease	106:174	108:176	4:6	1:NR:2	R2L	NON-CROSS	112-114	106-108	D005481	hexafluorodiethyl ether|HFDE|HFDE	Chemical	112:115:163	114:116:164	5:5:6	D015430	weight gain|weight gain	Disease	106:174	108:176	4:6
2951327	Inhibition of sympathoadrenal activity by atrial natriuretic factor in dogs .|In six conscious , trained dogs , maintained on a normal sodium intake of 2 to 4 mEq / kg / day , sympathetic activity was assessed as the release rate of norepinephrine and epinephrine during 15 - minute i . v .|infusions of human alpha - atrial natriuretic factor .|Mean arterial pressure ( as a percentage of control + / - SEM ) during randomized infusions of 0 . 03 , 0 . 1 , 0 . 3 , or 1 . 0 microgram / kg / min was 99 + / - 1 , 95 + / - 1 ( p less than 0 . 05 ) , 93 + / - 1 ( p less than 0 . 01 ) , or 79 + / - 6 % ( p less than 0 . 001 ) , respectively , but no tachycardia and no augmentation of the norepinephrine release rate ( up to 0 . 3 microgram / kg / min ) were observed , which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin .|The release rate of epinephrine ( control , 6 . 7 + / - 0 . 6 ng / kg / min ) declined immediately during infusions of atrial natriuretic factor to a minimum of 49 + / - 5 % of control ( p less than 0 . 001 ) during 0 . 1 microgram / kg / min and to 63 + / - 5 % ( 0 . 1 greater than p greater than 0 . 05 ) or 95 + / - 13 % ( not significant ) during 0 . 3 or 1 . 0 microgram / kg / min .|Steady state arterial plasma concentrations of atrial natriuretic factor were 39 + / - 10 pg / ml ( n = 6 ) during infusions of saline and 284 + / - 24 pg / ml ( n = 6 ) and 1520 + / - 300 pg / ml ( n = 9 ) during 0 . 03 and 0 . 1 microgram / kg / min infusions of the factor . ( ABSTRACT TRUNCATED AT 250 WORDS )	1:CID:2	R2L	NON-CROSS	190-191	187-188	D006830	hydralazine	Chemical	190	191	3	D007022	hypotension	Disease	187	188	3	1:CID:2	R2L	NON-CROSS	192-193	187-188	D005996	nitroglycerin	Chemical	192	193	3	D007022	hypotension	Disease	187	188	3	1:NR:2	L2R	CROSS	22-23	157-158	D012964	sodium	Chemical	22	23	1	D013610	tachycardia	Disease	157	158	3	1:NR:2	L2R	CROSS	22-23	187-188	D012964	sodium	Chemical	22	23	1	D007022	hypotension	Disease	187	188	3	1:NR:2	L2R	NON-CROSS	157-158	163-164	D009638	norepinephrine|norepinephrine	Chemical	43:163	44:164	1:3	D013610	tachycardia	Disease	157	158	3	1:NR:2	L2R	NON-CROSS	163-164	187-188	D009638	norepinephrine|norepinephrine	Chemical	43:163	44:164	1:3	D007022	hypotension	Disease	187	188	3	1:NR:2	L2R	CROSS	157-158	198-199	D004837	epinephrine|epinephrine	Chemical	45:198	46:199	1:4	D013610	tachycardia	Disease	157	158	3	1:NR:2	L2R	CROSS	187-188	198-199	D004837	epinephrine|epinephrine	Chemical	45:198	46:199	1:4	D007022	hypotension	Disease	187	188	3	1:NR:2	R2L	NON-CROSS	190-191	157-158	D006830	hydralazine	Chemical	190	191	3	D013610	tachycardia	Disease	157	158	3	1:NR:2	R2L	NON-CROSS	192-193	157-158	D005996	nitroglycerin	Chemical	192	193	3	D013610	tachycardia	Disease	157	158	3
3192036	Death from chemotherapy in gestational trophoblastic disease .|Multiple cytotoxic drug administration is the generally accepted treatment of patients with a high - risk stage of choriocarcinoma .|Based on this principle a 27 - year old woman , classified as being in the high - risk group ( Goldstein and Berkowitz score : 11 ) , was treated with multiple cytotoxic drugs .|The multiple drug schema consisted of : Etoposide 16 . 213 , Methotrexate , Cyclophosphamide , Actomycin - D , and Cisplatin .|On the first day of the schedule , moderate high doses of Methotrexate , Etoposide and Cyclophosphamide were administered .|Within 8 hours after initiation of therapy the patient died with a clinical picture resembling massive pulmonary obstruction due to choriocarcinomic tissue plugs , probably originating from the uterus .|Formation of these plugs was probably due to extensive tumor necrosis at the level of the walls of the major uterine veins , which resulted in an open exchange of tumor plugs to the vascular spaces ; decrease in tumor tissue coherence secondary to chemotherapy may have further contributed to the formation of tumor emboli .|In view of the close time association between the start of chemotherapy and the acute onset of massive embolism other explanations , such as spontaneous necrosis , must be considered less likely .|Patients with large pelvic tumor loads are , according to existing classifications , at high risk to die and to develop drug resistance .|Notwithstanding these facts our findings suggest that these patients might benefit from relatively mild initial treatment , especially true for patients not previously exposed to this drug .|Close observation of the response status both clinically and with beta - hCG values may indicate whether and when more agressive combination chemotherapy should be started . ( ABSTRACT TRUNCATED AT 250 WORDS )	1:CID:2	L2R	CROSS	101-102	123-125	D005047	Etoposide|Etoposide	Chemical	71:101	72:102	3:4	D011655	pulmonary obstruction	Disease	123	125	5	1:CID:2	L2R	CROSS	99-100	123-125	D008727	Methotrexate|Methotrexate	Chemical	76:99	77:100	3:4	D011655	pulmonary obstruction	Disease	123	125	5	1:CID:2	L2R	CROSS	103-104	123-125	D003520	Cyclophosphamide|Cyclophosphamide	Chemical	78:103	79:104	3:4	D011655	pulmonary obstruction	Disease	123	125	5	1:NR:2	R2L	CROSS	71-72	0-1	D005047	Etoposide|Etoposide	Chemical	71:101	72:102	3:4	D003643	Death	Disease	0	1	0	1:NR:2	R2L	CROSS	76-77	0-1	D008727	Methotrexate|Methotrexate	Chemical	76:99	77:100	3:4	D003643	Death	Disease	0	1	0	1:NR:2	R2L	CROSS	78-79	0-1	D003520	Cyclophosphamide|Cyclophosphamide	Chemical	78:103	79:104	3:4	D003643	Death	Disease	0	1	0	1:NR:2	R2L	CROSS	80-83	0-1	D003609	Actomycin - D	Chemical	80	83	3	D003643	Death	Disease	0	1	0	1:NR:2	R2L	CROSS	85-86	0-1	D002945	Cisplatin	Chemical	85	86	3	D003643	Death	Disease	0	1	0	1:NR:2	R2L	CROSS	71-72	4-7	D005047	Etoposide|Etoposide	Chemical	71:101	72:102	3:4	D031901	gestational trophoblastic disease	Disease	4	7	0	1:NR:2	R2L	CROSS	76-77	4-7	D008727	Methotrexate|Methotrexate	Chemical	76:99	77:100	3:4	D031901	gestational trophoblastic disease	Disease	4	7	0	1:NR:2	R2L	CROSS	78-79	4-7	D003520	Cyclophosphamide|Cyclophosphamide	Chemical	78:103	79:104	3:4	D031901	gestational trophoblastic disease	Disease	4	7	0	1:NR:2	R2L	CROSS	80-83	4-7	D003609	Actomycin - D	Chemical	80	83	3	D031901	gestational trophoblastic disease	Disease	4	7	0	1:NR:2	R2L	CROSS	85-86	4-7	D002945	Cisplatin	Chemical	85	86	3	D031901	gestational trophoblastic disease	Disease	4	7	0	1:NR:2	R2L	CROSS	71-72	26-27	D005047	Etoposide|Etoposide	Chemical	71:101	72:102	3:4	D002822	choriocarcinoma	Disease	26	27	1	1:NR:2	R2L	CROSS	76-77	26-27	D008727	Methotrexate|Methotrexate	Chemical	76:99	77:100	3:4	D002822	choriocarcinoma	Disease	26	27	1	1:NR:2	R2L	CROSS	78-79	26-27	D003520	Cyclophosphamide|Cyclophosphamide	Chemical	78:103	79:104	3:4	D002822	choriocarcinoma	Disease	26	27	1	1:NR:2	R2L	CROSS	80-83	26-27	D003609	Actomycin - D	Chemical	80	83	3	D002822	choriocarcinoma	Disease	26	27	1	1:NR:2	R2L	CROSS	85-86	26-27	D002945	Cisplatin	Chemical	85	86	3	D002822	choriocarcinoma	Disease	26	27	1	1:NR:2	L2R	CROSS	101-102	146-147	D005047	Etoposide|Etoposide	Chemical	71:101	72:102	3:4	D009369	tumor|tumor|tumor|tumor	Disease	146:167:176:190	147:168:177:191	6:6:6:6	1:NR:2	L2R	CROSS	101-102	147-148	D005047	Etoposide|Etoposide	Chemical	71:101	72:102	3:4	D009336	necrosis|necrosis	Disease	147:218	148:219	6:7	not_include	L2R	CROSS	101-102	211-212	D005047	Etoposide|Etoposide	Chemical	71:101	72:102	3:4	D004617	embolism	Disease	211	212	7	1:NR:2	L2R	CROSS	101-102	229-231	D005047	Etoposide|Etoposide	Chemical	71:101	72:102	3:4	D010386	pelvic tumor	Disease	229	231	8	1:NR:2	L2R	CROSS	99-100	146-147	D008727	Methotrexate|Methotrexate	Chemical	76:99	77:100	3:4	D009369	tumor|tumor|tumor|tumor	Disease	146:167:176:190	147:168:177:191	6:6:6:6	1:NR:2	L2R	CROSS	99-100	147-148	D008727	Methotrexate|Methotrexate	Chemical	76:99	77:100	3:4	D009336	necrosis|necrosis	Disease	147:218	148:219	6:7	not_include	L2R	CROSS	99-100	211-212	D008727	Methotrexate|Methotrexate	Chemical	76:99	77:100	3:4	D004617	embolism	Disease	211	212	7	1:NR:2	L2R	CROSS	99-100	229-231	D008727	Methotrexate|Methotrexate	Chemical	76:99	77:100	3:4	D010386	pelvic tumor	Disease	229	231	8	1:NR:2	L2R	CROSS	103-104	146-147	D003520	Cyclophosphamide|Cyclophosphamide	Chemical	78:103	79:104	3:4	D009369	tumor|tumor|tumor|tumor	Disease	146:167:176:190	147:168:177:191	6:6:6:6	1:NR:2	L2R	CROSS	103-104	147-148	D003520	Cyclophosphamide|Cyclophosphamide	Chemical	78:103	79:104	3:4	D009336	necrosis|necrosis	Disease	147:218	148:219	6:7	not_include	L2R	CROSS	103-104	211-212	D003520	Cyclophosphamide|Cyclophosphamide	Chemical	78:103	79:104	3:4	D004617	embolism	Disease	211	212	7	1:NR:2	L2R	CROSS	103-104	229-231	D003520	Cyclophosphamide|Cyclophosphamide	Chemical	78:103	79:104	3:4	D010386	pelvic tumor	Disease	229	231	8	1:NR:2	L2R	CROSS	80-83	123-125	D003609	Actomycin - D	Chemical	80	83	3	D011655	pulmonary obstruction	Disease	123	125	5	1:NR:2	L2R	CROSS	80-83	146-147	D003609	Actomycin - D	Chemical	80	83	3	D009369	tumor|tumor|tumor|tumor	Disease	146:167:176:190	147:168:177:191	6:6:6:6	1:NR:2	L2R	CROSS	80-83	147-148	D003609	Actomycin - D	Chemical	80	83	3	D009336	necrosis|necrosis	Disease	147:218	148:219	6:7	1:NR:2	L2R	CROSS	80-83	211-212	D003609	Actomycin - D	Chemical	80	83	3	D004617	embolism	Disease	211	212	7	1:NR:2	L2R	CROSS	80-83	229-231	D003609	Actomycin - D	Chemical	80	83	3	D010386	pelvic tumor	Disease	229	231	8	1:NR:2	L2R	CROSS	85-86	123-125	D002945	Cisplatin	Chemical	85	86	3	D011655	pulmonary obstruction	Disease	123	125	5	1:NR:2	L2R	CROSS	85-86	146-147	D002945	Cisplatin	Chemical	85	86	3	D009369	tumor|tumor|tumor|tumor	Disease	146:167:176:190	147:168:177:191	6:6:6:6	1:NR:2	L2R	CROSS	85-86	147-148	D002945	Cisplatin	Chemical	85	86	3	D009336	necrosis|necrosis	Disease	147:218	148:219	6:7	1:NR:2	L2R	CROSS	85-86	211-212	D002945	Cisplatin	Chemical	85	86	3	D004617	embolism	Disease	211	212	7	1:NR:2	L2R	CROSS	85-86	229-231	D002945	Cisplatin	Chemical	85	86	3	D010386	pelvic tumor	Disease	229	231	8
3409645	Sexual dysfunction among patients with arthritis .|The relationship of arthritis and sexual dysfunction was investigated among 169 patients with rheumatoid arthritis , osteoarthritis and spondyloarthropathy , 130 of whom were pair - matched to controls .|Assessments of marital happiness and depressed mood were also made using the CES - D and the Azrin Marital Happiness Scale ( AMHS ) .|Sexual dysfunctions were found to be common among patients and controls , the majority in both groups reporting one or more dysfunctions .|Impotence was more common among male patients than controls and was found to be associated with co - morbidity and the taking of methotrexate .|Depressed mood was more common among patients and was associated with certain sexual difficulties , but not with impotence .|Marital unhappiness , as indicated by AMHS scores , was not associated with arthritis but was associated with sexual dysfunction , sexual dissatisfaction and being female .	1:CID:2	R2L	NON-CROSS	128-129	108-109	D008727	methotrexate	Chemical	108	109	4	D007172	Impotence|impotence	Disease	85:128	86:129	4:5	not_include	R2L	CROSS	148-150	108-109	D008727	methotrexate	Chemical	108	109	4	D012735	Sexual dysfunction|sexual dysfunction|Sexual dysfunctions|sexual dysfunction	Disease	0:12:62:148	2:14:64:150	0:1:3:6	1:NR:2	R2L	CROSS	143-144	108-109	D008727	methotrexate	Chemical	108	109	4	D001168	arthritis|arthritis|arthritis	Disease	5:10:143	6:11:144	0:1:6	1:NR:2	R2L	CROSS	108-109	20-22	D008727	methotrexate	Chemical	108	109	4	D001172	rheumatoid arthritis	Disease	20	22	1	1:NR:2	R2L	CROSS	108-109	23-24	D008727	methotrexate	Chemical	108	109	4	D010003	osteoarthritis	Disease	23	24	1	1:NR:2	R2L	CROSS	108-109	25-26	D008727	methotrexate	Chemical	108	109	4	D025242	spondyloarthropathy	Disease	25	26	1	1:NR:2	R2L	CROSS	110-112	108-109	D008727	methotrexate	Chemical	108	109	4	D003866	depressed mood|Depressed mood	Disease	42:110	44:112	2:5
3412544	Does paracetamol cause urothelial cancer or renal papillary necrosis ?|The risk of developing renal papillary necrosis or cancer of the renal pelvis , ureter or bladder associated with consumption of either phenacetin or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls .|The risk of renal papillary necrosis was increased nearly 20 - fold by consumption of phenacetin , which also increased the risk for cancer of the renal pelvis and bladder but not for ureteric cancer .|By contrast , we were unable to substantiate an increased risk from paracetamol consumption for renal papillary necrosis or any of these cancers although there was a suggestion of an association with cancer of the ureter .	1:CID:2	R2L	NON-CROSS	64-65	52-55	D010615	phenacetin|phenacetin	Chemical	32:64	33:65	1:2	D007681	renal papillary necrosis|renal papillary necrosis|renal papillary necrosis|renal papillary necrosis	Disease	6:14:52:100	9:17:55:103	0:1:2:3	1:CID:2	R2L	NON-CROSS	32-33	18-27	D010615	phenacetin|phenacetin	Chemical	32:64	33:65	1:2	D007680	cancer of the renal pelvis , ureter or bladder|cancer of the renal pelvis and bladder	Disease	18:72	27:79	1:2	1:CID:2	R2L	NON-CROSS	32-33	18-27	D010615	phenacetin|phenacetin	Chemical	32:64	33:65	1:2	D001749	cancer of the renal pelvis , ureter or bladder|cancer of the renal pelvis and bladder	Disease	18:72	27:79	1:2	1:NR:2	L2R	NON-CROSS	1-2	3-5	D000082	paracetamol|paracetamol|paracetamol	Chemical	1:34:97	2:35:98	0:1:3	D014523	urothelial cancer	Disease	3	5	0	1:NR:2	L2R	NON-CROSS	97-98	100-103	D000082	paracetamol|paracetamol|paracetamol	Chemical	1:34:97	2:35:98	0:1:3	D007681	renal papillary necrosis|renal papillary necrosis|renal papillary necrosis|renal papillary necrosis	Disease	6:14:52:100	9:17:55:103	0:1:2:3	1:NR:2	L2R	NON-CROSS	18-27	34-35	D000082	paracetamol|paracetamol|paracetamol	Chemical	1:34:97	2:35:98	0:1:3	D007680	cancer of the renal pelvis , ureter or bladder|cancer of the renal pelvis and bladder	Disease	18:72	27:79	1:2	1:NR:2	L2R	NON-CROSS	82-84	97-98	D000082	paracetamol|paracetamol|paracetamol	Chemical	1:34:97	2:35:98	0:1:3	D014516	cancer of the renal pelvis , ureter or bladder|ureteric cancer|cancer of the ureter	Disease	18:82:117	27:84:121	1:2:3	1:NR:2	L2R	NON-CROSS	18-27	34-35	D000082	paracetamol|paracetamol|paracetamol	Chemical	1:34:97	2:35:98	0:1:3	D001749	cancer of the renal pelvis , ureter or bladder|cancer of the renal pelvis and bladder	Disease	18:72	27:79	1:2	1:NR:2	L2R	NON-CROSS	97-98	107-108	D000082	paracetamol|paracetamol|paracetamol	Chemical	1:34:97	2:35:98	0:1:3	D009369	cancers	Disease	107	108	3	1:NR:2	R2L	CROSS	32-33	3-5	D010615	phenacetin|phenacetin	Chemical	32:64	33:65	1:2	D014523	urothelial cancer	Disease	3	5	0	1:NR:2	R2L	NON-CROSS	32-33	18-27	D010615	phenacetin|phenacetin	Chemical	32:64	33:65	1:2	D014516	cancer of the renal pelvis , ureter or bladder|ureteric cancer|cancer of the ureter	Disease	18:82:117	27:84:121	1:2:3	not_include	L2R	CROSS	64-65	107-108	D010615	phenacetin|phenacetin	Chemical	32:64	33:65	1:2	D009369	cancers	Disease	107	108	3
3425586	Dapsone - associated Heinz body hemolytic anemia in a Cambodian woman with hemoglobin E trait .|A Cambodian woman with hemoglobin E trait ( AE ) and leprosy developed a Heinz body hemolytic anemia while taking a dose of dapsone ( 50 mg / day ) not usually associated with clinical hemolysis .|Her red blood cells ( RBCs ) had increased incubated Heinz body formation , decreased reduced glutathione ( GSH ) , and decreased GSH stability .|The pentose phosphate shunt activity of the dapsone - exposed AE RBCs was increased compared to normal RBCs .|Although the AE RBCs from an individual not taking dapsone had increased incubated Heinz body formation , the GSH content and GSH stability were normal .|The pentose phosphate shunt activity of the non - dapsone - exposed AE RBCs was decreased compared to normal RBCs .|Thus , AE RBCs appear to have an increased sensitivity to oxidant stress both in vitro and in vivo , since dapsone does not cause hemolytic anemia at this dose in hematologically normal individuals .|Given the influx of Southeast Asians into the United States , oxidant medications should be used with caution , especially if an infection is present , in individuals of ethnic backgrounds that have an increased prevalence of hemoglobin E .	1:CID:2	L2R	NON-CROSS	166-167	170-172	D003622	Dapsone|dapsone|dapsone|dapsone|dapsone|dapsone	Chemical	0:39:86:107:133:166	1:40:87:108:134:167	0:1:3:4:5:6	D000743	hemolytic anemia|hemolytic anemia|hemolytic anemia	Disease	5:32:170	7:34:172	0:1:6	1:NR:2	L2R	NON-CROSS	27-28	39-40	D003622	Dapsone|dapsone|dapsone|dapsone|dapsone|dapsone	Chemical	0:39:86:107:133:166	1:40:87:108:134:167	0:1:3:4:5:6	D007918	leprosy	Disease	27	28	1	1:NR:2	L2R	NON-CROSS	39-40	51-52	D003622	Dapsone|dapsone|dapsone|dapsone|dapsone|dapsone	Chemical	0:39:86:107:133:166	1:40:87:108:134:167	0:1:3:4:5:6	D006461	hemolysis	Disease	51	52	1	1:NR:2	L2R	CROSS	166-167	202-203	D003622	Dapsone|dapsone|dapsone|dapsone|dapsone|dapsone	Chemical	0:39:86:107:133:166	1:40:87:108:134:167	0:1:3:4:5:6	D007239	infection	Disease	202	203	7	1:NR:2	R2L	CROSS	69-70	32-34	D005978	glutathione|GSH|GSH|GSH|GSH	Chemical	69:71:76:116:119	70:72:77:117:120	2:2:2:4:4	D000743	hemolytic anemia|hemolytic anemia|hemolytic anemia	Disease	5:32:170	7:34:172	0:1:6	1:NR:2	R2L	CROSS	170-172	125-127	D010428	pentose phosphate|pentose phosphate	Chemical	80:125	82:127	3:5	D000743	hemolytic anemia|hemolytic anemia|hemolytic anemia	Disease	5:32:170	7:34:172	0:1:6	1:NR:2	R2L	CROSS	69-70	27-28	D005978	glutathione|GSH|GSH|GSH|GSH	Chemical	69:71:76:116:119	70:72:77:117:120	2:2:2:4:4	D007918	leprosy	Disease	27	28	1	1:NR:2	R2L	CROSS	80-82	27-28	D010428	pentose phosphate|pentose phosphate	Chemical	80:125	82:127	3:5	D007918	leprosy	Disease	27	28	1	1:NR:2	R2L	CROSS	69-70	51-52	D005978	glutathione|GSH|GSH|GSH|GSH	Chemical	69:71:76:116:119	70:72:77:117:120	2:2:2:4:4	D006461	hemolysis	Disease	51	52	1	1:NR:2	R2L	CROSS	80-82	51-52	D010428	pentose phosphate|pentose phosphate	Chemical	80:125	82:127	3:5	D006461	hemolysis	Disease	51	52	1	1:NR:2	L2R	CROSS	119-120	202-203	D005978	glutathione|GSH|GSH|GSH|GSH	Chemical	69:71:76:116:119	70:72:77:117:120	2:2:2:4:4	D007239	infection	Disease	202	203	7	1:NR:2	L2R	CROSS	125-127	202-203	D010428	pentose phosphate|pentose phosphate	Chemical	80:125	82:127	3:5	D007239	infection	Disease	202	203	7
3437726	Severe complications of antianginal drug therapy in a patient identified as a poor metabolizer of metoprolol , propafenone , diltiazem , and sparteine .|A 47 - year - old patient suffering from coronary artery disease was admitted to the CCU in shock with III .|AV block , severe hypotension , and impairment of ventricular function .|One week prior to admission a therapy with standard doses of metoprolol ( 100 mg t . i . d .|and then 100 mg b . i . d . ) had been initiated .|Two days before admission diltiazem ( 60 mg b . i . d . ) was prescribed in addition .|Analyses of a blood sample revealed unusually high plasma concentrations of metoprolol ( greater than 3000 ng / ml ) and diltiazem ( 526 ng / ml ) .|The patient recovered within 1 week following discontinuation of antianginal therapy .|Three months later the patient was exposed to a single dose of metoprolol , diltiazem , propafenone ( since he had received this drug in the past ) , and sparteine ( as a probe for the debrisoquine / sparteine type polymorphism of oxidative drug metabolism ) .|It was found that he was a poor metabolizer of all four drugs , indicating that their metabolism is under the same genetic control .|Therefore , patients belonging to the poor - metabolizer phenotype of sparteine / debrisoquine polymorphism in drug metabolism , which constitutes 6 . 4 % of the German population , may experience adverse drug reactions when treated with standard doses of one of these drugs alone .|Moreover , the coadministration of these frequently used drugs is expected to be especially harmful in this subgroup of patients .	1:CID:2	L2R	CROSS	46-48	69-70	D008790	metoprolol|metoprolol|metoprolol|metoprolol	Chemical	15:69:125:167	16:70:126:168	0:3:6:8	D054537	AV block	Disease	46	48	2	1:CID:2	L2R	CROSS	50-51	69-70	D008790	metoprolol|metoprolol|metoprolol|metoprolol	Chemical	15:69:125:167	16:70:126:168	0:3:6:8	D007022	hypotension	Disease	50	51	2	1:CID:2	L2R	CROSS	53-57	69-70	D008790	metoprolol|metoprolol|metoprolol|metoprolol	Chemical	15:69:125:167	16:70:126:168	0:3:6:8	D018754	impairment of ventricular function	Disease	53	57	2	1:CID:2	L2R	CROSS	19-20	46-48	D004110	diltiazem|diltiazem|diltiazem|diltiazem	Chemical	19:98:135:169	20:99:136:170	0:5:6:8	D054537	AV block	Disease	46	48	2	1:CID:2	L2R	CROSS	19-20	50-51	D004110	diltiazem|diltiazem|diltiazem|diltiazem	Chemical	19:98:135:169	20:99:136:170	0:5:6:8	D007022	hypotension	Disease	50	51	2	1:CID:2	L2R	CROSS	19-20	53-57	D004110	diltiazem|diltiazem|diltiazem|diltiazem	Chemical	19:98:135:169	20:99:136:170	0:5:6:8	D018754	impairment of ventricular function	Disease	53	57	2	1:NR:2	L2R	CROSS	15-16	33-36	D008790	metoprolol|metoprolol|metoprolol|metoprolol	Chemical	15:69:125:167	16:70:126:168	0:3:6:8	D003324	coronary artery disease	Disease	33	36	1	1:NR:2	L2R	CROSS	15-16	42-43	D008790	metoprolol|metoprolol|metoprolol|metoprolol	Chemical	15:69:125:167	16:70:126:168	0:3:6:8	D012769	shock	Disease	42	43	1	1:NR:2	L2R	CROSS	167-168	260-263	D008790	metoprolol|metoprolol|metoprolol|metoprolol	Chemical	15:69:125:167	16:70:126:168	0:3:6:8	D064420	adverse drug reactions	Disease	260	263	10	1:NR:2	L2R	CROSS	17-18	33-36	D011405	propafenone|propafenone	Chemical	17:171	18:172	0:8	D003324	coronary artery disease	Disease	33	36	1	1:NR:2	L2R	CROSS	17-18	42-43	D011405	propafenone|propafenone	Chemical	17:171	18:172	0:8	D012769	shock	Disease	42	43	1	1:NR:2	L2R	CROSS	17-18	46-48	D011405	propafenone|propafenone	Chemical	17:171	18:172	0:8	D054537	AV block	Disease	46	48	2	1:NR:2	L2R	CROSS	17-18	50-51	D011405	propafenone|propafenone	Chemical	17:171	18:172	0:8	D007022	hypotension	Disease	50	51	2	1:NR:2	L2R	CROSS	17-18	53-57	D011405	propafenone|propafenone	Chemical	17:171	18:172	0:8	D018754	impairment of ventricular function	Disease	53	57	2	1:NR:2	L2R	CROSS	171-172	260-263	D011405	propafenone|propafenone	Chemical	17:171	18:172	0:8	D064420	adverse drug reactions	Disease	260	263	10	1:NR:2	L2R	CROSS	19-20	33-36	D004110	diltiazem|diltiazem|diltiazem|diltiazem	Chemical	19:98:135:169	20:99:136:170	0:5:6:8	D003324	coronary artery disease	Disease	33	36	1	1:NR:2	L2R	CROSS	19-20	42-43	D004110	diltiazem|diltiazem|diltiazem|diltiazem	Chemical	19:98:135:169	20:99:136:170	0:5:6:8	D012769	shock	Disease	42	43	1	1:NR:2	L2R	CROSS	169-170	260-263	D004110	diltiazem|diltiazem|diltiazem|diltiazem	Chemical	19:98:135:169	20:99:136:170	0:5:6:8	D064420	adverse drug reactions	Disease	260	263	10	1:NR:2	L2R	CROSS	22-23	33-36	D013034	sparteine|sparteine|sparteine|sparteine	Chemical	22:185:194:239	23:186:195:240	0:8:8:10	D003324	coronary artery disease	Disease	33	36	1	1:NR:2	L2R	CROSS	22-23	42-43	D013034	sparteine|sparteine|sparteine|sparteine	Chemical	22:185:194:239	23:186:195:240	0:8:8:10	D012769	shock	Disease	42	43	1	1:NR:2	L2R	CROSS	22-23	46-48	D013034	sparteine|sparteine|sparteine|sparteine	Chemical	22:185:194:239	23:186:195:240	0:8:8:10	D054537	AV block	Disease	46	48	2	1:NR:2	L2R	CROSS	22-23	50-51	D013034	sparteine|sparteine|sparteine|sparteine	Chemical	22:185:194:239	23:186:195:240	0:8:8:10	D007022	hypotension	Disease	50	51	2	1:NR:2	L2R	CROSS	22-23	53-57	D013034	sparteine|sparteine|sparteine|sparteine	Chemical	22:185:194:239	23:186:195:240	0:8:8:10	D018754	impairment of ventricular function	Disease	53	57	2	1:NR:2	L2R	NON-CROSS	239-240	260-263	D013034	sparteine|sparteine|sparteine|sparteine	Chemical	22:185:194:239	23:186:195:240	0:8:8:10	D064420	adverse drug reactions	Disease	260	263	10	1:NR:2	R2L	CROSS	192-193	33-36	D003647	debrisoquine|debrisoquine	Chemical	192:241	193:242	8:10	D003324	coronary artery disease	Disease	33	36	1	1:NR:2	R2L	CROSS	192-193	42-43	D003647	debrisoquine|debrisoquine	Chemical	192:241	193:242	8:10	D012769	shock	Disease	42	43	1	1:NR:2	R2L	CROSS	192-193	46-48	D003647	debrisoquine|debrisoquine	Chemical	192:241	193:242	8:10	D054537	AV block	Disease	46	48	2	1:NR:2	R2L	CROSS	192-193	50-51	D003647	debrisoquine|debrisoquine	Chemical	192:241	193:242	8:10	D007022	hypotension	Disease	50	51	2	1:NR:2	R2L	CROSS	192-193	53-57	D003647	debrisoquine|debrisoquine	Chemical	192:241	193:242	8:10	D018754	impairment of ventricular function	Disease	53	57	2	1:NR:2	L2R	NON-CROSS	241-242	260-263	D003647	debrisoquine|debrisoquine	Chemical	192:241	193:242	8:10	D064420	adverse drug reactions	Disease	260	263	10
3693336	Triazolam - induced brief episodes of secondary mania in a depressed patient .|Large doses of triazolam repeatedly induced brief episodes of mania in a depressed elderly woman .|Features of organic mental disorder ( delirium ) were not present .|Manic excitement was coincident with the duration of action of triazolam .|The possible contribution of the triazolo group to changes in affective status is discussed .	1:CID:2	L2R	NON-CROSS	16-17	22-23	D014229	Triazolam|triazolam|triazolam|triazolo	Chemical	0:16:51:58	1:17:52:59	0:1:3:4	D001714	mania|mania|Manic	Disease	7:22:41	8:23:42	0:1:3	1:NR:2	L2R	NON-CROSS	10-11	16-17	D014229	Triazolam|triazolam|triazolam|triazolo	Chemical	0:16:51:58	1:17:52:59	0:1:3:4	D003866	depressed|depressed	Disease	10:25	11:26	0:1	1:NR:2	L2R	CROSS	16-17	31-34	D014229	Triazolam|triazolam|triazolam|triazolo	Chemical	0:16:51:58	1:17:52:59	0:1:3:4	D019965	organic mental disorder	Disease	31	34	2	1:NR:2	L2R	CROSS	35-36	51-52	D014229	Triazolam|triazolam|triazolam|triazolo	Chemical	0:16:51:58	1:17:52:59	0:1:3:4	D003693	delirium	Disease	35	36	2
3780846	On the mechanisms of the development of tolerance to the muscular rigidity produced by morphine in rats .|The development of tolerance to the muscular rigidity produced by morphine was studied in rats .|Saline - pretreated controls given a test dose of morphine ( 20 mg / kg i . p . ) showed a pronounced rigidity recorded as tonic activity in the electromyogram .|Rats treated for 11 days with morphine and withdrawn for 36 - 40 h showed differences in the development of tolerance : about half of the animals showed a rigidity after the test dose of morphine that was not significantly less than in the controls and were akinetic ( A group ) .|The other rats showed a strong decrease in the rigidity and the occurrence of stereotyped ( S ) licking and / or gnawing in presence of akinetic or hyperkinetic ( K ) behaviour ( AS / KS group ) , suggesting signs of dopaminergic activation .|The rigidity was considerably decreased in both groups after 20 days ' treatment .|In a further series of experiments , haloperidol ( 0 . 2 mg / kg i . p . ) was used in order to block the dopaminergic activation and to estimate the real degree of the tolerance to the rigidity without any dopaminergic interference .|Haloperidol enhanced the rigidity in the A group .|However , the level in the AS / KS group remained considerably lower than in the A group .|The results suggest that rigidity , which is assumed to be due to an action of morphine in the striatum , can be antagonized by another process leading to dopaminergic activation in the striatum .|Nevertheless , there occurs some real tolerance to this effect .|The rapid alternations of rigidity and the signs of dopaminergic activation observed in the animals of the AS / KS group might be due to rapid shifts in the predominance of various DA - innervated structures .	1:CID:2	R2L	NON-CROSS	14-15	10-12	D009020	morphine|morphine|morphine|morphine|morphine|morphine	Chemical	14:28:43:72:101:269	15:29:44:73:102:270	0:1:2:3:3:9	D009127	muscular rigidity|muscular rigidity|rigidity|rigidity|rigidity|rigidity|rigidity|rigidity|rigidity|rigidity	Disease	10:24:57:95:128:166:219:228:257:303	12:26:58:96:129:167:220:229:258:304	0:1:2:3:4:5:6:7:9:11	1:CID:2	R2L	NON-CROSS	228-229	225-226	D006220	haloperidol|Haloperidol	Chemical	186:225	187:226	6:7	D009127	muscular rigidity|muscular rigidity|rigidity|rigidity|rigidity|rigidity|rigidity|rigidity|rigidity|rigidity	Disease	10:24:57:95:128:166:219:228:257:303	12:26:58:96:129:167:220:229:258:304	0:1:2:3:4:5:6:7:9:11	1:CID:2	L2R	NON-CROSS	101-102	113-114	D009020	morphine|morphine|morphine|morphine|morphine|morphine	Chemical	14:28:43:72:101:269	15:29:44:73:102:270	0:1:2:3:3:9	D018476	akinetic|akinetic	Disease	113:145	114:146	3:4	1:CID:2	L2R	CROSS	101-102	147-148	D009020	morphine|morphine|morphine|morphine|morphine|morphine	Chemical	14:28:43:72:101:269	15:29:44:73:102:270	0:1:2:3:3:9	D006948	hyperkinetic	Disease	147	148	4	1:NR:2	R2L	CROSS	186-187	145-146	D006220	haloperidol|Haloperidol	Chemical	186:225	187:226	6:7	D018476	akinetic|akinetic	Disease	113:145	114:146	3:4	1:NR:2	R2L	CROSS	186-187	147-148	D006220	haloperidol|Haloperidol	Chemical	186:225	187:226	6:7	D006948	hyperkinetic	Disease	147	148	4
3800626	Compression neuropathy of the radial nerve due to pentazocine - induced fibrous myopathy .|Fibrous myopathy is a common , well - known side effect of repeated pentazocine injection .|However , compression neuropathy due to fibrotic muscle affected by pentazocine - induced myopathy has not previously been reported .|In a 37 - year - old woman with documented pentazocine - induced fibrous myopathy of triceps and deltoid muscles bilaterally and a three - week history of right wrist drop , electrodiagnostic examination showed a severe but partial lesion of the right radial nerve distal to the branches to the triceps , in addition to the fibrous myopathy .|Surgery revealed the right radial nerve to be severely compressed by the densely fibrotic lateral head of the triceps .|Decompression and neurolysis were performed with good subsequent recovery of function .	1:CID:2	R2L	NON-CROSS	8-9	0-6	D010423	pentazocine|pentazocine|pentazocine|pentazocine	Chemical	8:27:40:60	9:28:41:61	0:1:2:3	D009408	Compression neuropathy of the radial nerve|compression neuropathy	Disease	0:32	6:34	0:2	1:CID:2	R2L	NON-CROSS	8-9	0-6	D010423	pentazocine|pentazocine|pentazocine|pentazocine	Chemical	8:27:40:60	9:28:41:61	0:1:2:3	D020425	Compression neuropathy of the radial nerve	Disease	0	6	0	1:CID:2	L2R	NON-CROSS	8-9	11-13	D010423	pentazocine|pentazocine|pentazocine|pentazocine	Chemical	8:27:40:60	9:28:41:61	0:1:2:3	D005355	fibrous myopathy|Fibrous myopathy|fibrous myopathy|fibrous myopathy	Disease	11:14:63:107	13:16:65:109	0:1:3:3	1:CID:2	L2R	NON-CROSS	8-9	11-13	D010423	pentazocine|pentazocine|pentazocine|pentazocine	Chemical	8:27:40:60	9:28:41:61	0:1:2:3	D009135	fibrous myopathy|Fibrous myopathy|myopathy|fibrous myopathy|fibrous myopathy	Disease	11:14:43:63:107	13:16:44:65:109	0:1:2:3:3
3827439	Recurrent reversible acute renal failure from amphotericin .|A patient with cryptogenic cirrhosis and disseminated sporotrichosis developed acute renal failure immediately following the administration of amphotericin B on four separate occasions .|The abruptness of the renal failure and its reversibility within days suggests that there was a functional component to the renal dysfunction .|We propose that amphotericin , in the setting of reduced effective arterial volume , may activate tubuloglomerular feedback , thereby contributing to acute renal failure .	1:CID:2	R2L	NON-CROSS	6-7	2-5	D000666	amphotericin|amphotericin B|amphotericin	Chemical	6:25:58	7:27:59	0:1:3	D058186	acute renal failure|acute renal failure|acute renal failure	Disease	2:17:77	5:20:80	0:1:3	1:NR:2	L2R	NON-CROSS	6-7	12-13	D000666	amphotericin|amphotericin B|amphotericin	Chemical	6:25:58	7:27:59	0:1:3	D005355	cirrhosis	Disease	12	13	1	1:NR:2	L2R	NON-CROSS	6-7	15-16	D000666	amphotericin|amphotericin B|amphotericin	Chemical	6:25:58	7:27:59	0:1:3	D013174	sporotrichosis	Disease	15	16	1	not_include	L2R	CROSS	25-27	36-38	D000666	amphotericin|amphotericin B|amphotericin	Chemical	6:25:58	7:27:59	0:1:3	D051437	renal failure	Disease	36	38	2	not_include	L2R	CROSS	52-54	58-59	D000666	amphotericin|amphotericin B|amphotericin	Chemical	6:25:58	7:27:59	0:1:3	D007674	renal dysfunction	Disease	52	54	2
3997294	Pneumonitis with pleural and pericardial effusion and neuropathy during amiodarone therapy .|A patient with sinuatrial disease and implanted pacemaker was treated with amiodarone ( maximum dose 1000 mg , maintenance dose 800 mg daily ) for 10 months , for control of supraventricular tachyarrhythmias .|He developed pneumonitis , pleural and pericardial effusions , and a predominantly proximal motor neuropathy .|Immediate but gradual improvement followed withdrawal of amiodarone and treatment with prednisolone .|Review of this and previously reported cases indicates the need for early diagnosis of amiodarone pneumonitis , immediate withdrawal of amiodarone , and prompt but continued steroid therapy to ensure full recovery .	1:CID:2	R2L	NON-CROSS	9-10	2-6	D000638	amiodarone|amiodarone|amiodarone|amiodarone|amiodarone	Chemical	9:23:69:89:95	10:24:70:90:96	0:1:3:4:4	D010996	pleural and pericardial effusion|pleural and pericardial effusions	Disease	2:50	6:54	0:2	1:CID:2	R2L	NON-CROSS	9-10	2-6	D000638	amiodarone|amiodarone|amiodarone|amiodarone|amiodarone	Chemical	9:23:69:89:95	10:24:70:90:96	0:1:3:4:4	D010490	pleural and pericardial effusion|pleural and pericardial effusions	Disease	2:50	6:54	0:2	1:CID:2	L2R	NON-CROSS	89-90	90-91	D000638	amiodarone|amiodarone|amiodarone|amiodarone|amiodarone	Chemical	9:23:69:89:95	10:24:70:90:96	0:1:3:4:4	D011014	pneumonitis|pneumonitis	Disease	48:90	49:91	2:4	1:CID:2	L2R	CROSS	58-61	69-70	D000638	amiodarone|amiodarone|amiodarone|amiodarone|amiodarone	Chemical	9:23:69:89:95	10:24:70:90:96	0:1:3:4:4	D009468	proximal motor neuropathy	Disease	58	61	2	1:NR:2	R2L	CROSS	73-74	50-54	D011239	prednisolone	Chemical	73	74	3	D010996	pleural and pericardial effusion|pleural and pericardial effusions	Disease	2:50	6:54	0:2	1:NR:2	R2L	CROSS	101-102	50-54	D013256	steroid	Chemical	101	102	4	D010996	pleural and pericardial effusion|pleural and pericardial effusions	Disease	2:50	6:54	0:2	1:NR:2	R2L	CROSS	73-74	50-54	D011239	prednisolone	Chemical	73	74	3	D010490	pleural and pericardial effusion|pleural and pericardial effusions	Disease	2:50	6:54	0:2	1:NR:2	R2L	CROSS	101-102	50-54	D013256	steroid	Chemical	101	102	4	D010490	pleural and pericardial effusion|pleural and pericardial effusions	Disease	2:50	6:54	0:2	not_include	R2L	NON-CROSS	9-10	7-8	D000638	amiodarone|amiodarone|amiodarone|amiodarone|amiodarone	Chemical	9:23:69:89:95	10:24:70:90:96	0:1:3:4:4	D009422	neuropathy	Disease	7	8	0	1:NR:2	R2L	CROSS	73-74	7-8	D011239	prednisolone	Chemical	73	74	3	D009422	neuropathy	Disease	7	8	0	1:NR:2	R2L	CROSS	101-102	7-8	D013256	steroid	Chemical	101	102	4	D009422	neuropathy	Disease	7	8	0	not_include	L2R	NON-CROSS	9-10	15-17	D000638	amiodarone|amiodarone|amiodarone|amiodarone|amiodarone	Chemical	9:23:69:89:95	10:24:70:90:96	0:1:3:4:4	D002318	sinuatrial disease	Disease	15	17	1	1:NR:2	L2R	NON-CROSS	23-24	43-45	D000638	amiodarone|amiodarone|amiodarone|amiodarone|amiodarone	Chemical	9:23:69:89:95	10:24:70:90:96	0:1:3:4:4	D013617	supraventricular tachyarrhythmias	Disease	43	45	1	1:NR:2	R2L	CROSS	73-74	15-17	D011239	prednisolone	Chemical	73	74	3	D002318	sinuatrial disease	Disease	15	17	1	1:NR:2	R2L	CROSS	101-102	15-17	D013256	steroid	Chemical	101	102	4	D002318	sinuatrial disease	Disease	15	17	1	1:NR:2	R2L	CROSS	73-74	43-45	D011239	prednisolone	Chemical	73	74	3	D013617	supraventricular tachyarrhythmias	Disease	43	45	1	1:NR:2	R2L	CROSS	101-102	43-45	D013256	steroid	Chemical	101	102	4	D013617	supraventricular tachyarrhythmias	Disease	43	45	1	1:NR:2	R2L	CROSS	90-91	73-74	D011239	prednisolone	Chemical	73	74	3	D011014	pneumonitis|pneumonitis	Disease	48:90	49:91	2:4	1:NR:2	R2L	NON-CROSS	101-102	90-91	D013256	steroid	Chemical	101	102	4	D011014	pneumonitis|pneumonitis	Disease	48:90	49:91	2:4	1:NR:2	R2L	CROSS	73-74	58-61	D011239	prednisolone	Chemical	73	74	3	D009468	proximal motor neuropathy	Disease	58	61	2	1:NR:2	R2L	CROSS	101-102	58-61	D013256	steroid	Chemical	101	102	4	D009468	proximal motor neuropathy	Disease	58	61	2
4071154	Indomethacin - induced renal insufficiency : recurrence on rechallenge .|We have reported a case of acute oliguric renal failure with hyperkalemia in a patient with cirrhosis , ascites , and cor pulmonale after indomethacin therapy .|Prompt restoration of renal function followed drug withdrawal , while re - exposure to a single dose of indomethacin caused recurrence of acute reversible oliguria .|Our case supports the hypothesis that endogenous renal prostaglandins play a role in the maintenance of renal blood flow when circulating plasma volume is diminished .|Since nonsteroidal anti - inflammatory agents interfere with this compensatory mechanism and may cause acute renal failure , they should be used with caution in such patients .	1:CID:2	L2R	NON-CROSS	21-22	34-35	D007213	Indomethacin|indomethacin|indomethacin	Chemical	0:34:55	1:35:56	0:1:2	D006947	hyperkalemia	Disease	21	22	1	1:CID:2	L2R	NON-CROSS	26-27	34-35	D007213	Indomethacin|indomethacin|indomethacin	Chemical	0:34:55	1:35:56	0:1:2	D005355	cirrhosis	Disease	26	27	1	1:CID:2	L2R	NON-CROSS	28-29	34-35	D007213	Indomethacin|indomethacin|indomethacin	Chemical	0:34:55	1:35:56	0:1:2	D001201	ascites	Disease	28	29	1	1:CID:2	L2R	NON-CROSS	31-33	34-35	D007213	Indomethacin|indomethacin|indomethacin	Chemical	0:34:55	1:35:56	0:1:2	D011660	cor pulmonale	Disease	31	33	1	1:CID:2	L2R	NON-CROSS	55-56	61-62	D007213	Indomethacin|indomethacin|indomethacin	Chemical	0:34:55	1:35:56	0:1:2	D009846	oliguria	Disease	61	62	2	1:CID:2	L2R	CROSS	55-56	103-106	D007213	Indomethacin|indomethacin|indomethacin	Chemical	0:34:55	1:35:56	0:1:2	D058186	acute renal failure	Disease	103	106	4	not_include	L2R	NON-CROSS	0-1	3-5	D007213	Indomethacin|indomethacin|indomethacin	Chemical	0:34:55	1:35:56	0:1:2	D051437	renal insufficiency|renal failure	Disease	3:18	5:20	0:1	1:NR:2	R2L	CROSS	71-72	18-20	D011453	prostaglandins	Chemical	71	72	3	D051437	renal insufficiency|renal failure	Disease	3:18	5:20	0:1	1:NR:2	R2L	CROSS	71-72	21-22	D011453	prostaglandins	Chemical	71	72	3	D006947	hyperkalemia	Disease	21	22	1	1:NR:2	R2L	CROSS	71-72	26-27	D011453	prostaglandins	Chemical	71	72	3	D005355	cirrhosis	Disease	26	27	1	1:NR:2	R2L	CROSS	71-72	28-29	D011453	prostaglandins	Chemical	71	72	3	D001201	ascites	Disease	28	29	1	1:NR:2	R2L	CROSS	71-72	31-33	D011453	prostaglandins	Chemical	71	72	3	D011660	cor pulmonale	Disease	31	33	1	1:NR:2	R2L	CROSS	71-72	61-62	D011453	prostaglandins	Chemical	71	72	3	D009846	oliguria	Disease	61	62	2	1:NR:2	L2R	CROSS	71-72	103-106	D011453	prostaglandins	Chemical	71	72	3	D058186	acute renal failure	Disease	103	106	4
6103707	Comparison of the subjective effects and plasma concentrations following oral and i . m .|administration of flunitrazepam in volunteers .|Flunitrazepam 0 . 5 , 1 . 0 or 2 . 0 mg was given by the oral or i . m .|routes to groups of volunteers and its effects compared .|Plasma concentrations of the drug were estimated by gas - liquid chromatography , in a smaller number of the subjects .|The most striking effect was sedation which increased with the dose , 2 mg producing deep sleep although the subjects could still be aroused .|The effects of i . m .|administration were apparent earlier and sometimes lasted longer than those following oral administration .|Dizziness was less marked than sedation , but increased with the dose .|There was pain on i . m .|injection of flunitrazepam significantly more often than with isotonic saline .|Plasma concentrations varied with dose and route and corresponded qualitatively with the subjective effects .|The drug was still present in measurable quantities after 24 h even with the smallest dose .	1:CID:2	L2R	CROSS	121-122	144-145	D005445	flunitrazepam|Flunitrazepam|flunitrazepam	Chemical	17:21:144	18:22:145	1:2:10	D004244	Dizziness	Disease	121	122	8	1:CID:2	L2R	CROSS	136-137	144-145	D005445	flunitrazepam|Flunitrazepam|flunitrazepam	Chemical	17:21:144	18:22:145	1:2:10	D010146	pain	Disease	136	137	9
6229975	Changes in heart size during long - term timolol treatment after myocardial infarction .|The effect of long - term timolol treatment on heart size after myocardial infarction was evaluated by X - ray in a double - blind study including 241 patients ( placebo 126 , timolol 115 ) .|The follow - up period was 12 months .|The timolol - treated patients showed a small but significant increase in heart size from baseline in contrast to a decrease in the placebo group .|These differences may be caused by timolol - induced bradycardia and a compensatory increase in end - diastolic volume .|The timolol - related increase in heart size was observed only in patients with normal and borderline heart size .|In patients with cardiomegaly , the increase in heart size was similar in both groups .|After re - infarction , heart size increased in the placebo group and remained unchanged in the timolol group .	1:CID:2	L2R	CROSS	107-108	129-130	D013999	timolol|timolol|timolol|timolol|timolol|timolol|timolol	Chemical	8:20:47:61:92:107:159	9:21:48:62:93:108:160	0:1:1:3:4:5:7	D006332	cardiomegaly	Disease	129	130	6	1:NR:2	L2R	NON-CROSS	8-9	11-13	D013999	timolol|timolol|timolol|timolol|timolol|timolol|timolol	Chemical	8:20:47:61:92:107:159	9:21:48:62:93:108:160	0:1:1:3:4:5:7	D009203	myocardial infarction|myocardial infarction	Disease	11:26	13:28	0:1	1:NR:2	L2R	NON-CROSS	92-93	95-96	D013999	timolol|timolol|timolol|timolol|timolol|timolol|timolol	Chemical	8:20:47:61:92:107:159	9:21:48:62:93:108:160	0:1:1:3:4:5:7	D001919	bradycardia	Disease	95	96	4	1:NR:2	L2R	NON-CROSS	145-146	159-160	D013999	timolol|timolol|timolol|timolol|timolol|timolol|timolol	Chemical	8:20:47:61:92:107:159	9:21:48:62:93:108:160	0:1:1:3:4:5:7	D007238	infarction	Disease	145	146	7
6286738	Vitamin D3 toxicity in dairy cows .|Large parenteral doses of vitamin D3 ( 15 to 17 . 5 x 10 ( 6 ) IU vitamin D3 ) were associated with prolonged hypercalcemia , hyperphosphatemia , and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows .|Calcium concentrations 1 day postpartum were higher in cows treated with vitamin D3 about 32 days prepartum ( 8 . 8 mg / 100 ml ) than in control cows ( 5 . 5 mg / 100 ml ) .|None of the cows treated with vitamin D3 showed signs of milk fever during the peripartal period ; however , 22 % of the control cows developed clinical signs of milk fever during this period .|Signs of vitamin D3 toxicity were not observed in nonlactating nonpregnant cows ; however , pregnant cows commonly developed severe signs of vitamin D3 toxicity and 10 of 17 cows died .|There was widespread metastatic calcification in the cows that died .|Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever , we concluded that vitamin D3 can not be used practically to prevent milk fever when injected several weeks prepartum .	1:CID:2	L2R	NON-CROSS	25-27	32-33	D002762	Vitamin D3|vitamin D3|vitamin D3|vitamin D3|vitamin D3|vitamin D3|vitamin D3|vitamin D3|vitamin D3|vitamin D3|vitamin D3	Chemical	0:11:25:40:68:103:135:155:182:197:213	2:13:27:42:70:105:137:157:184:199:215	0:1:1:1:2:3:4:4:6:6:6	D006934	hypercalcemia	Disease	32	33	1	1:CID:2	L2R	NON-CROSS	34-35	40-42	D002762	Vitamin D3|vitamin D3|vitamin D3|vitamin D3|vitamin D3|vitamin D3|vitamin D3|vitamin D3|vitamin D3|vitamin D3|vitamin D3	Chemical	0:11:25:40:68:103:135:155:182:197:213	2:13:27:42:70:105:137:157:184:199:215	0:1:1:1:2:3:4:4:6:6:6	D054559	hyperphosphatemia	Disease	34	35	1	1:NR:2	L2R	NON-CROSS	0-2	2-3	D002762	Vitamin D3|vitamin D3|vitamin D3|vitamin D3|vitamin D3|vitamin D3|vitamin D3|vitamin D3|vitamin D3|vitamin D3|vitamin D3	Chemical	0:11:25:40:68:103:135:155:182:197:213	2:13:27:42:70:105:137:157:184:199:215	0:1:1:1:2:3:4:4:6:6:6	D064420	toxicity|toxicity|toxicity|toxicity	Disease	2:137:157:180	3:138:158:181	0:4:4:6	1:NR:2	L2R	NON-CROSS	197-199	201-203	D002762	Vitamin D3|vitamin D3|vitamin D3|vitamin D3|vitamin D3|vitamin D3|vitamin D3|vitamin D3|vitamin D3|vitamin D3|vitamin D3	Chemical	0:11:25:40:68:103:135:155:182:197:213	2:13:27:42:70:105:137:157:184:199:215	0:1:1:1:2:3:4:4:6:6:6	D010319	milk fever|milk fever|milk fever|milk fever|milk fever	Disease	108:127:201:207:222	110:129:203:209:224	3:3:6:6:6	1:NR:2	R2L	CROSS	57-58	2-3	D002118	Calcium	Chemical	57	58	2	D064420	toxicity|toxicity|toxicity|toxicity	Disease	2:137:157:180	3:138:158:181	0:4:4:6	1:NR:2	R2L	CROSS	57-58	32-33	D002118	Calcium	Chemical	57	58	2	D006934	hypercalcemia	Disease	32	33	1	1:NR:2	R2L	CROSS	57-58	34-35	D002118	Calcium	Chemical	57	58	2	D054559	hyperphosphatemia	Disease	34	35	1	1:NR:2	L2R	CROSS	57-58	108-110	D002118	Calcium	Chemical	57	58	2	D010319	milk fever|milk fever|milk fever|milk fever|milk fever	Disease	108:127:201:207:222	110:129:203:209:224	3:3:6:6:6
6287825	Diseases of peripheral nerves as seen in the Nigerian African .|The anatomical and aetiological diagnoses of peripheral nerve disease excluding its primary benign and malignant disorders , as seen in 358 Nigerians are presented .|There is a male preponderance and the peak incidence is in the fourth decade .|Sensori - motor neuropathy was the commonest presentation ( 50 % ) .|Guillain - Barr syndrome was the commonest identifiable cause ( 15 . 6 % ) , accounting for half of the cases with motor neuropathy .|Peripheral neuropathy due to nutritional deficiency of thiamine and riboflavin was common ( 10 . 1 % ) and presented mainly as sensory and sensori - motor neuropathy .|Diabetes mellitus was the major cause of autonomic neuropathy .|Isoniazid was the most frequent agent in drug - induced neuropathy .|Migraine ( 20 % ) was not an uncommon cause of cranial neuropathy although malignancies arising from the reticuloendothelial system or related structures of the head and neck were more frequent ( 26 % ) .|In 26 . 5 % of all the cases , the aetiology of the neuropathy was undetermined .|Heredofamilial and connective tissue disorders were rare .|Some of the factors related to the clinical presentation and pathogenesis of the neuropathies are briefly discussed .	1:CID:2	R2L	NON-CROSS	97-98	90-92	D013831	thiamine	Chemical	97	98	5	D010523	Diseases of peripheral nerves|peripheral nerve disease|Sensori - motor neuropathy|motor neuropathy|Peripheral neuropathy|sensori - motor neuropathy	Disease	0:17:51:87:90:114	4:20:55:89:92:118	0:1:3:4:5:5	1:CID:2	R2L	NON-CROSS	99-100	90-92	D012256	riboflavin	Chemical	99	100	5	D010523	Diseases of peripheral nerves|peripheral nerve disease|Sensori - motor neuropathy|motor neuropathy|Peripheral neuropathy|sensori - motor neuropathy	Disease	0:17:51:87:90:114	4:20:55:89:92:118	0:1:3:4:5:5	1:CID:2	R2L	CROSS	129-130	114-118	D007538	Isoniazid	Chemical	129	130	7	D010523	Diseases of peripheral nerves|peripheral nerve disease|Sensori - motor neuropathy|motor neuropathy|Peripheral neuropathy|sensori - motor neuropathy	Disease	0:17:51:87:90:114	4:20:55:89:92:118	0:1:3:4:5:5	1:NR:2	R2L	CROSS	97-98	64-68	D013831	thiamine	Chemical	97	98	5	D020275	Guillain - Barr syndrome	Disease	64	68	4	1:NR:2	R2L	CROSS	99-100	64-68	D012256	riboflavin	Chemical	99	100	5	D020275	Guillain - Barr syndrome	Disease	64	68	4	1:NR:2	R2L	CROSS	129-130	64-68	D007538	Isoniazid	Chemical	129	130	7	D020275	Guillain - Barr syndrome	Disease	64	68	4	1:NR:2	R2L	NON-CROSS	97-98	94-96	D013831	thiamine	Chemical	97	98	5	D044342	nutritional deficiency	Disease	94	96	5	1:NR:2	R2L	NON-CROSS	99-100	94-96	D012256	riboflavin	Chemical	99	100	5	D044342	nutritional deficiency	Disease	94	96	5	1:NR:2	R2L	CROSS	129-130	94-96	D007538	Isoniazid	Chemical	129	130	7	D044342	nutritional deficiency	Disease	94	96	5	1:NR:2	L2R	CROSS	97-98	119-121	D013831	thiamine	Chemical	97	98	5	D003920	Diabetes mellitus	Disease	119	121	6	not_include	L2R	CROSS	97-98	126-128	D013831	thiamine	Chemical	97	98	5	D009422	autonomic neuropathy|neuropathy|neuropathy|neuropathies	Disease	126:139:191:216	128:140:192:217	6:7:9:11	1:NR:2	L2R	CROSS	97-98	141-142	D013831	thiamine	Chemical	97	98	5	D008881	Migraine	Disease	141	142	8	1:NR:2	L2R	CROSS	97-98	152-154	D013831	thiamine	Chemical	97	98	5	D003389	cranial neuropathy	Disease	152	154	8	1:NR:2	L2R	CROSS	97-98	155-156	D013831	thiamine	Chemical	97	98	5	D009369	malignancies	Disease	155	156	8	1:NR:2	L2R	CROSS	97-98	197-200	D013831	thiamine	Chemical	97	98	5	D003240	connective tissue disorders	Disease	197	200	10	1:NR:2	L2R	CROSS	99-100	119-121	D012256	riboflavin	Chemical	99	100	5	D003920	Diabetes mellitus	Disease	119	121	6	not_include	L2R	CROSS	99-100	126-128	D012256	riboflavin	Chemical	99	100	5	D009422	autonomic neuropathy|neuropathy|neuropathy|neuropathies	Disease	126:139:191:216	128:140:192:217	6:7:9:11	1:NR:2	L2R	CROSS	99-100	141-142	D012256	riboflavin	Chemical	99	100	5	D008881	Migraine	Disease	141	142	8	1:NR:2	L2R	CROSS	99-100	152-154	D012256	riboflavin	Chemical	99	100	5	D003389	cranial neuropathy	Disease	152	154	8	1:NR:2	L2R	CROSS	99-100	155-156	D012256	riboflavin	Chemical	99	100	5	D009369	malignancies	Disease	155	156	8	1:NR:2	L2R	CROSS	99-100	197-200	D012256	riboflavin	Chemical	99	100	5	D003240	connective tissue disorders	Disease	197	200	10	1:NR:2	R2L	CROSS	129-130	119-121	D007538	Isoniazid	Chemical	129	130	7	D003920	Diabetes mellitus	Disease	119	121	6	not_include	R2L	NON-CROSS	129-130	126-128	D007538	Isoniazid	Chemical	129	130	7	D009422	autonomic neuropathy|neuropathy|neuropathy|neuropathies	Disease	126:139:191:216	128:140:192:217	6:7:9:11	1:NR:2	L2R	CROSS	129-130	141-142	D007538	Isoniazid	Chemical	129	130	7	D008881	Migraine	Disease	141	142	8	1:NR:2	L2R	CROSS	129-130	152-154	D007538	Isoniazid	Chemical	129	130	7	D003389	cranial neuropathy	Disease	152	154	8	1:NR:2	L2R	CROSS	129-130	155-156	D007538	Isoniazid	Chemical	129	130	7	D009369	malignancies	Disease	155	156	8	1:NR:2	L2R	CROSS	129-130	197-200	D007538	Isoniazid	Chemical	129	130	7	D003240	connective tissue disorders	Disease	197	200	10
6386793	A double - blind study of the efficacy and safety of dothiepin hydrochloride in the treatment of major depressive disorder .|In a 6 - week double - blind parallel treatment study , dothiepin and amitriptyline were compared to placebo in the treatment of 33 depressed outpatients .|Dothiepin and amitriptyline were equally effective in alleviating the symptoms of depressive illness , and both were significantly superior to placebo .|The overall incidence of side effects and the frequency and severity of blurred vision , dry mouth , and drowsiness were significantly less with dothiepin than with amitriptyline .|Dothiepin also produced fewer CNS and cardiovascular effects .|There were no clinically important changes in laboratory parameters .|Dothiepin thus was found to be an effective antidepressant drug associated with fewer side effects than amitriptyline in the treatment of depressed outpatients .	1:CID:2	L2R	NON-CROSS	82-84	97-98	D000639	amitriptyline|amitriptyline|amitriptyline|amitriptyline	Chemical	35:50:97:134	36:51:98:135	1:2:3:6	D014786	blurred vision	Disease	82	84	3	1:CID:2	L2R	NON-CROSS	85-87	97-98	D000639	amitriptyline|amitriptyline|amitriptyline|amitriptyline	Chemical	35:50:97:134	36:51:98:135	1:2:3:6	D014987	dry mouth	Disease	85	87	3	1:NR:2	L2R	NON-CROSS	45-46	48-49	D004308	dothiepin hydrochloride|dothiepin|Dothiepin|dothiepin|Dothiepin|Dothiepin	Chemical	11:33:48:94:99:118	13:34:49:95:100:119	0:1:2:3:4:6	D003866	depressive disorder|depressed|depressive illness|depressed	Disease	18:45:59:139	20:46:61:140	0:1:2:6	1:NR:2	L2R	NON-CROSS	82-84	94-95	D004308	dothiepin hydrochloride|dothiepin|Dothiepin|dothiepin|Dothiepin|Dothiepin	Chemical	11:33:48:94:99:118	13:34:49:95:100:119	0:1:2:3:4:6	D014786	blurred vision	Disease	82	84	3	1:NR:2	L2R	NON-CROSS	85-87	94-95	D004308	dothiepin hydrochloride|dothiepin|Dothiepin|dothiepin|Dothiepin|Dothiepin	Chemical	11:33:48:94:99:118	13:34:49:95:100:119	0:1:2:3:4:6	D014987	dry mouth	Disease	85	87	3	1:NR:2	R2L	NON-CROSS	50-51	45-46	D000639	amitriptyline|amitriptyline|amitriptyline|amitriptyline	Chemical	35:50:97:134	36:51:98:135	1:2:3:6	D003866	depressive disorder|depressed|depressive illness|depressed	Disease	18:45:59:139	20:46:61:140	0:1:2:6	1:NR:2	R2L	NON-CROSS	139-140	126-127	D000928	antidepressant	Chemical	126	127	6	D003866	depressive disorder|depressed|depressive illness|depressed	Disease	18:45:59:139	20:46:61:140	0:1:2:6	1:NR:2	R2L	CROSS	126-127	82-84	D000928	antidepressant	Chemical	126	127	6	D014786	blurred vision	Disease	82	84	3	1:NR:2	R2L	CROSS	126-127	85-87	D000928	antidepressant	Chemical	126	127	6	D014987	dry mouth	Disease	85	87	3
6387529	Behavioral effects of diazepam and propranolol in patients with panic disorder and agoraphobia .|The effects of oral doses of diazepam ( single dose of 10 mg and a median dose of 30 mg / day for 2 weeks ) and propranolol ( single dose of 80 mg and a median dose of 240 mg / day for 2 weeks ) on psychological performance of patients with panic disorders and agoraphobia were investigated in a double - blind , randomized and crossover design .|Both drugs impaired immediate free recall but the decrease was greater for diazepam than propranolol .|Delayed free recall was also impaired but the two drugs did not differ .|Patients tapped faster after propranolol than diazepam and they were more sedated after diazepam than propranolol .|After 2 weeks of treatment , patients tested 5 - 8 h after the last dose of medication did not show any decrement of performance .|These results are similar to those previously found in healthy subjects .|Accumulation of drugs was not reflected in prolonged behavioral impairment .	1:CID:2	L2R	NON-CROSS	96-97	100-106	D003975	diazepam|diazepam|diazepam|diazepam|diazepam	Chemical	3:20:96:120:127	4:21:97:121:128	0:1:2:4:4	D008569	impaired immediate free recall|Delayed free recall was also impaired	Disease	86:100	90:106	2:3	1:CID:2	L2R	NON-CROSS	98-99	100-106	D011433	propranolol|propranolol|propranolol|propranolol|propranolol	Chemical	5:41:98:118:129	6:42:99:119:130	0:1:2:4:4	D008569	impaired immediate free recall|Delayed free recall was also impaired	Disease	86:100	90:106	2:3	1:NR:2	L2R	NON-CROSS	3-4	9-11	D003975	diazepam|diazepam|diazepam|diazepam|diazepam	Chemical	3:20:96:120:127	4:21:97:121:128	0:1:2:4:4	D016584	panic disorder|panic disorders	Disease	9:67	11:69	0:1	1:NR:2	L2R	NON-CROSS	12-13	20-21	D003975	diazepam|diazepam|diazepam|diazepam|diazepam	Chemical	3:20:96:120:127	4:21:97:121:128	0:1:2:4:4	D000379	agoraphobia|agoraphobia	Disease	12:70	13:71	0:1	1:NR:2	L2R	CROSS	127-128	177-179	D003975	diazepam|diazepam|diazepam|diazepam|diazepam	Chemical	3:20:96:120:127	4:21:97:121:128	0:1:2:4:4	D001523	behavioral impairment	Disease	177	179	7	1:NR:2	L2R	NON-CROSS	5-6	9-11	D011433	propranolol|propranolol|propranolol|propranolol|propranolol	Chemical	5:41:98:118:129	6:42:99:119:130	0:1:2:4:4	D016584	panic disorder|panic disorders	Disease	9:67	11:69	0:1	1:NR:2	L2R	NON-CROSS	5-6	12-13	D011433	propranolol|propranolol|propranolol|propranolol|propranolol	Chemical	5:41:98:118:129	6:42:99:119:130	0:1:2:4:4	D000379	agoraphobia|agoraphobia	Disease	12:70	13:71	0:1	1:NR:2	L2R	CROSS	129-130	177-179	D011433	propranolol|propranolol|propranolol|propranolol|propranolol	Chemical	5:41:98:118:129	6:42:99:119:130	0:1:2:4:4	D001523	behavioral impairment	Disease	177	179	7
6692345	Effect of aspirin on N - [ 4 - ( 5 - nitro - 2 - furyl ) - 2 - thiazolyl ] - formamide - induced epithelial proliferation in the urinary bladder and forestomach of the rat .|The co - administration of aspirin with N - [ 4 - ( 5 - nitro - 2 - furyl ) - 2 - thiazolyl ] - formamide ( FANFT ) to rats resulted in a reduced incidence of FANFT - induced bladder carcinomas but a concomitant induction of forestomach tumors .|An autoradiographic study was performed on male F - 344 rats fed diet containing FANFT at a level of 0 . 2 % and / or aspirin at a level of 0 . 5 % to evaluate the effect of aspirin on the increased cell proliferation induced by FANFT in the forestomach and bladder .|FANFT - induced cell proliferation in the bladder was significantly suppressed by aspirin co - administration after 4 weeks but not after 12 weeks .|In the forestomach , and also in the liver , aspirin did not affect the FANFT - induced increase in labeling index .|The present results are consistent with the carcinogenicity experiment suggesting that different mechanisms are involved in FANFT carcinogenesis in the bladder and forestomach , and that aspirin 's effect on FANFT in the forestomach is not due to an irritant effect associated with increased cell proliferation .|Also , there appears to be an adaptation by the rats to the chronic ingestion of aspirin .	1:CID:2	L2R	NON-CROSS	78-79	81-83	D005200	N - [ 4 - ( 5 - nitro - 2 - furyl ) - 2 - thiazolyl ] - formamide|N - [ 4 - ( 5 - nitro - 2 - furyl ) - 2 - thiazolyl ] - formamide|FANFT|FANFT|FANFT|FANFT|FANFT|FANFT|FANFT|FANFT	Chemical	4:46:68:78:105:139:146:186:210:224	25:67:69:79:106:140:147:187:211:225	0:1:1:1:2:2:3:4:5:5	D001749	bladder carcinomas	Disease	81	83	1	1:CID:2	L2R	NON-CROSS	78-79	88-90	D005200	N - [ 4 - ( 5 - nitro - 2 - furyl ) - 2 - thiazolyl ] - formamide|N - [ 4 - ( 5 - nitro - 2 - furyl ) - 2 - thiazolyl ] - formamide|FANFT|FANFT|FANFT|FANFT|FANFT|FANFT|FANFT|FANFT	Chemical	4:46:68:78:105:139:146:186:210:224	25:67:69:79:106:140:147:187:211:225	0:1:1:1:2:2:3:4:5:5	D013274	forestomach tumors	Disease	88	90	1	1:NR:2	L2R	NON-CROSS	81-83	117-118	D001241	aspirin|aspirin|aspirin|aspirin|aspirin|aspirin|aspirin|aspirin	Chemical	2:44:117:131:158:181:220:257	3:45:118:132:159:182:221:258	0:1:2:2:3:4:5:6	D001749	bladder carcinomas	Disease	81	83	1	1:NR:2	L2R	NON-CROSS	88-90	117-118	D001241	aspirin|aspirin|aspirin|aspirin|aspirin|aspirin|aspirin|aspirin	Chemical	2:44:117:131:158:181:220:257	3:45:118:132:159:182:221:258	0:1:2:2:3:4:5:6	D013274	forestomach tumors	Disease	88	90	1	1:NR:2	L2R	NON-CROSS	211-212	220-221	D001241	aspirin|aspirin|aspirin|aspirin|aspirin|aspirin|aspirin|aspirin	Chemical	2:44:117:131:158:181:220:257	3:45:118:132:159:182:221:258	0:1:2:2:3:4:5:6	D063646	carcinogenesis	Disease	211	212	5	1:NR:2	L2R	NON-CROSS	210-211	211-212	D005200	N - [ 4 - ( 5 - nitro - 2 - furyl ) - 2 - thiazolyl ] - formamide|N - [ 4 - ( 5 - nitro - 2 - furyl ) - 2 - thiazolyl ] - formamide|FANFT|FANFT|FANFT|FANFT|FANFT|FANFT|FANFT|FANFT	Chemical	4:46:68:78:105:139:146:186:210:224	25:67:69:79:106:140:147:187:211:225	0:1:1:1:2:2:3:4:5:5	D063646	carcinogenesis	Disease	211	212	5
6773726	Provocation of postural hypotension by nitroglycerin in diabetic autonomic neuropathy ?|The effect of nitroglycerin on heart rate and systolic blood pressure was compared in 5 normal subjects , 12 diabetic subjects without autonomic neuropathy , and 5 diabetic subjects with autonomic neuropathy .|The magnitude and time course of the increase in heart rate and the decrease in systolic blood pressure after nitroglycerin were similar in the normal and diabetic subjects without autonomic neuropathy , whereas a lesser increase in heart rate and a greater decrease in systolic blood pressure occurred in the diabetic subjects with autonomic neuropathy .|It is therefore suggested that caution should be exercised when prescribing vasodilator drugs in diabetic patients , particularly those with autonomic neuropathy .	1:CID:2	R2L	NON-CROSS	5-6	3-4	D005996	nitroglycerin|nitroglycerin|nitroglycerin	Chemical	5:14:63	6:15:64	0:1:2	D007022	hypotension	Disease	3	4	0	1:NR:2	L2R	NON-CROSS	5-6	7-10	D005996	nitroglycerin|nitroglycerin|nitroglycerin	Chemical	5:14:63	6:15:64	0:1:2	D003929	diabetic autonomic neuropathy	Disease	7	10	0	1:NR:2	L2R	NON-CROSS	63-64	70-71	D005996	nitroglycerin|nitroglycerin|nitroglycerin	Chemical	5:14:63	6:15:64	0:1:2	D003920	diabetic|diabetic|diabetic|diabetic|diabetic	Disease	30:38:70:94:114	31:39:71:95:115	1:1:2:2:3	1:NR:2	L2R	NON-CROSS	63-64	73-75	D005996	nitroglycerin|nitroglycerin|nitroglycerin	Chemical	5:14:63	6:15:64	0:1:2	D009422	autonomic neuropathy|autonomic neuropathy|autonomic neuropathy|autonomic neuropathy|autonomic neuropathy	Disease	33:41:73:97:120	35:43:75:99:122	1:1:2:2:3
6888657	Characterization of estrogen - induced adenohypophyseal tumors in the Fischer 344 rat .|Pituitary tumors were induced in F344 female rats by chronic treatment with diethylstilbestrol ( DES , 8 - 10 mg ) implanted subcutaneously in silastic capsules .|Over a range of 1 - 150 days of DES treatment , pairs of control and DES - treated rats were sacrificed , and their pituitaries dissociated enzymatically into single - cell preparations .|The cell populations were examined regarding total cell recovery correlated with gland weight , intracellular prolactin ( PRL ) content and subsequent release in primary culture , immunocytochemical PRL staining , density and / or size alterations via separation on Ficoll - Hypaque and by unit gravity sedimentation , and cell cycle analysis , after acriflavine DNA staining , by laser flow cytometry .|Total cell yields from DES - treated pituitaries increased from 1 . 3 times control yields at 8 days of treatment to 58 . 9 times control values by day 150 .|Intracellular PRL content ranged from 1 . 9 to 9 . 4 times control levels , and PRL release in vitro was significantly and consistently higher than controls , after at least 8 days of DES exposure .|Beyond 8 days of DES exposure , the immunochemically PRL - positive proportion of cells increased to over 50 % of the total population .|Increased density and / or size and PRL content were indicated for the majority of the PRL cell population in both types of separation protocols .|All these effects of DES were more pronounced among previously ovariectomized animals .|The data extend the findings of other investigators , further establishing the DES - induced tumor as a model for study of PRL cellular control mechanisms .	1:CID:2	R2L	NON-CROSS	25-26	13-15	D004054	diethylstilbestrol|DES|DES|DES|DES|DES|DES|DES|DES	Chemical	25:27:49:56:142:205:212:263:284	26:28:50:57:143:206:213:264:285	1:1:2:2:4:5:6:8:9	D010911	adenohypophyseal tumors|Pituitary tumors	Disease	5:13	7:15	0:1	1:NR:2	L2R	NON-CROSS	2-3	5-7	D004967	estrogen	Chemical	2	3	0	D010911	adenohypophyseal tumors|Pituitary tumors	Disease	5:13	7:15	0:1	1:NR:2	L2R	CROSS	2-3	287-288	D004967	estrogen	Chemical	2	3	0	D009369	tumor	Disease	287	288	9	1:NR:2	R2L	CROSS	129-130	13-15	D000167	acriflavine	Chemical	129	130	3	D010911	adenohypophyseal tumors|Pituitary tumors	Disease	5:13	7:15	0:1	not_include	L2R	NON-CROSS	284-285	287-288	D004054	diethylstilbestrol|DES|DES|DES|DES|DES|DES|DES|DES	Chemical	25:27:49:56:142:205:212:263:284	26:28:50:57:143:206:213:264:285	1:1:2:2:4:5:6:8:9	D009369	tumor	Disease	287	288	9	1:NR:2	L2R	CROSS	129-130	287-288	D000167	acriflavine	Chemical	129	130	3	D009369	tumor	Disease	287	288	9
7265370	Triamterene nephrolithiasis complicating dyazide therapy .|A case of triamterene nephrolithiasis is reported in a man after 4 years of hydrochlorothiazide - triamterene therapy for hypertension .|The stone passed spontaneously and was found to contain a triamterene metabolite admixed with uric acid salts .|Factors affecting triamterene nephrolithiasis are discussed and 2 previously reported cases are reviewed .	1:CID:2	L2R	NON-CROSS	0-1	1-2	D014223	Triamterene|triamterene|triamterene|triamterene	Chemical	0:9:37:47	1:10:38:48	0:1:2:3	D053040	nephrolithiasis|nephrolithiasis|nephrolithiasis	Disease	1:10:48	2:11:49	0:1:3	1:NR:2	L2R	NON-CROSS	25-26	37-38	D014223	Triamterene|triamterene|triamterene|triamterene	Chemical	0:9:37:47	1:10:38:48	0:1:2:3	D006973	hypertension	Disease	25	26	1	1:NR:2	R2L	NON-CROSS	3-4	1-2	C020743	dyazide|hydrochlorothiazide - triamterene	Chemical	3:20	4:23	0:1	D053040	nephrolithiasis|nephrolithiasis|nephrolithiasis	Disease	1:10:48	2:11:49	0:1:3	1:NR:2	R2L	CROSS	48-49	41-44	D014527	uric acid salts	Chemical	41	44	2	D053040	nephrolithiasis|nephrolithiasis|nephrolithiasis	Disease	1:10:48	2:11:49	0:1:3	1:NR:2	R2L	CROSS	48-49	41-44	D012492	uric acid salts	Chemical	41	44	2	D053040	nephrolithiasis|nephrolithiasis|nephrolithiasis	Disease	1:10:48	2:11:49	0:1:3	1:NR:2	L2R	NON-CROSS	20-23	25-26	C020743	dyazide|hydrochlorothiazide - triamterene	Chemical	3:20	4:23	0:1	D006973	hypertension	Disease	25	26	1	1:NR:2	R2L	CROSS	41-44	25-26	D014527	uric acid salts	Chemical	41	44	2	D006973	hypertension	Disease	25	26	1	1:NR:2	R2L	CROSS	41-44	25-26	D012492	uric acid salts	Chemical	41	44	2	D006973	hypertension	Disease	25	26	1
7423039	Metabolic involvement in adriamycin cardiotoxicity .|The cardiotoxic effects of adriamycin were studied in mammalian myocardial cells in culture as a model system .|Adriamycin inhibited cell growth and the rhythmic contractions characteristic of myocardial cells in culture .|A possible involvement of energy metabolism was suggested previously , and in this study the adenylate energy charge and phosphorylcreatine mole fraction were determined in the adriamycin - treated cells .|The adenylate energy charge was found to be significantly decreased , while the phophorylcreatine mole fraction was unchanged .|Such disparity suggests an inhibition of creatine phosphokinase .|The addition of 1 mM adenosine to the myocardial cell cultures markedly increases the ATP concentration through a pathway reportedly leading to a compartmentalized ATP pool .|In the adriamycin - treated cells , the addition of adenosine increased the adenylate charge and , concomitant with this inrcease , the cells ' functional integrity , in terms of percentage of beating cells and rate of contractions , was maintained .	1:CID:2	L2R	NON-CROSS	3-4	4-5	D004317	adriamycin|adriamycin|Adriamycin|adriamycin|adriamycin	Chemical	3:10:24:65:127	4:11:25:66:128	0:1:2:3:7	D066126	cardiotoxicity|cardiotoxic	Disease	4:7	5:8	0:1	1:NR:2	R2L	CROSS	58-59	7-8	D010725	phosphorylcreatine|phophorylcreatine	Chemical	58:83	59:84	3:4	D066126	cardiotoxicity|cardiotoxic	Disease	4:7	5:8	0:1	1:NR:2	R2L	CROSS	95-96	7-8	D003401	creatine	Chemical	95	96	5	D066126	cardiotoxicity|cardiotoxic	Disease	4:7	5:8	0:1	1:NR:2	R2L	CROSS	103-104	7-8	D000241	adenosine|adenosine	Chemical	103:135	104:136	6:7	D066126	cardiotoxicity|cardiotoxic	Disease	4:7	5:8	0:1	1:NR:2	R2L	CROSS	112-113	7-8	D000255	ATP|ATP	Chemical	112:122	113:123	6:6	D066126	cardiotoxicity|cardiotoxic	Disease	4:7	5:8	0:1
7444978	Age - dependent sensitivity of the rat to neurotoxic effects of streptomycin .|Streptomycin sulfate ( 300 mg / kg s . c . ) was injected for various periods into preweanling rats and for 3 weeks into weanling rats .|Beginning at 8 days of age , body movement and hearing were examined for 6 and up to 17 weeks , respectively .|Abnormal movements and deafness occurred only in rats treated during the preweaning period ; within this period the greatest sensitivities for these abnormalities occurred from 2 to 11 - 17 and 5 to 11 days of age , respectively , indicating that the cochlea is more sensitive to streptomycin than the site ( vestibular or central ) responsible for the dyskinesias .	1:CID:2	L2R	NON-CROSS	112-113	124-125	D013307	streptomycin|Streptomycin|streptomycin	Chemical	11:13:112	12:14:113	0:1:3	D004409	Abnormal movements|dyskinesias	Disease	64:124	66:125	3:3	1:CID:2	L2R	NON-CROSS	67-68	112-113	D013307	streptomycin|Streptomycin|streptomycin	Chemical	11:13:112	12:14:113	0:1:3	D003638	deafness	Disease	67	68	3	not_include	R2L	NON-CROSS	11-12	8-9	D013307	streptomycin|Streptomycin|streptomycin	Chemical	11:13:112	12:14:113	0:1:3	D020258	neurotoxic	Disease	8	9	0
7834920	Crescentic fibrillary glomerulonephritis associated with intermittent rifampin therapy for pulmonary tuberculosis .|This case study reveals an unusual finding of rapidly proliferative crescentic glomerulonephritis in a patient treated with rifampin who had no other identifiable causes for developing this disease .|This patient underwent a 10 - month regimen of rifampin and isoniazid for pulmonary tuberculosis and was discovered to have developed signs of severe renal failure five weeks after completion of therapy .|Renal biopsy revealed severe glomerulonephritis with crescents , electron dense fibrillar deposits and moderate lymphocytic interstitial infiltrate .|Other possible causes of rapidly progressive glomerulonephritis were investigated and ruled out .|This report documents the unusual occurrence of rapidly progressive glomerulonephritis with crescents and fibrillar glomerulonephritis in a patient treated with rifampin .	1:CID:2	R2L	NON-CROSS	6-7	2-3	D012293	rifampin|rifampin|rifampin|rifampin	Chemical	6:29:50:125	7:30:51:126	0:1:2:5	D005921	glomerulonephritis|glomerulonephritis|glomerulonephritis|glomerulonephritis|glomerulonephritis|glomerulonephritis	Disease	2:23:78:98:114:119	3:24:79:99:115:120	0:1:3:4:5:5	1:CID:2	L2R	NON-CROSS	50-51	65-67	D012293	rifampin|rifampin|rifampin|rifampin	Chemical	6:29:50:125	7:30:51:126	0:1:2:5	D051437	renal failure	Disease	65	67	2	1:NR:2	R2L	CROSS	78-79	52-53	D007538	isoniazid	Chemical	52	53	2	D005921	glomerulonephritis|glomerulonephritis|glomerulonephritis|glomerulonephritis|glomerulonephritis|glomerulonephritis	Disease	2:23:78:98:114:119	3:24:79:99:115:120	0:1:3:4:5:5	1:NR:2	L2R	NON-CROSS	6-7	9-11	D012293	rifampin|rifampin|rifampin|rifampin	Chemical	6:29:50:125	7:30:51:126	0:1:2:5	D014397	pulmonary tuberculosis|pulmonary tuberculosis	Disease	9:54	11:56	0:2	1:NR:2	R2L	NON-CROSS	54-56	52-53	D007538	isoniazid	Chemical	52	53	2	D014397	pulmonary tuberculosis|pulmonary tuberculosis	Disease	9:54	11:56	0:2	1:NR:2	L2R	NON-CROSS	52-53	65-67	D007538	isoniazid	Chemical	52	53	2	D051437	renal failure	Disease	65	67	2
7881871	Time course of lipid peroxidation in puromycin aminonucleoside - induced nephropathy .|Reactive oxygen species have been implicated in the pathogenesis of acute puromycin aminonucleoside ( PAN ) - induced nephropathy , with antioxidants significantly reducing the proteinuria .|The temporal relationship between lipid peroxidation in the kidney and proteinuria was examined in this study .|Rats were treated with a single IV injection of puromycin aminonucleoside , ( PAN , 7 . 5 mg / kg ) and 24 hour urine samples were obtained prior to sacrifice on days 3 , 5 , 7 , 10 , 17 , 27 , 41 ( N = 5 - 10 per group ) .|The kidneys were removed , flushed with ice cold TRIS buffer .|Kidney cortices from each animal were used to prepare homogenates .|Tissue lipid peroxidation was measured in whole homogenates as well as in lipid extracts from homogenates as thiobarbituric acid reactive substances .|Proteinuria was evident at day 5 , peaked at day 7 and persisted to day 27 .|Lipid peroxidation in homogenates was maximal at day 3 and declined rapidly to control levels by day 17 .|This study supports the role of lipid peroxidation in mediating the proteinuric injury in PAN nephropathy .	1:CID:2	L2R	NON-CROSS	208-209	209-210	D011692	puromycin aminonucleoside|puromycin aminonucleoside|PAN|puromycin aminonucleoside|PAN|PAN	Chemical	6:23:26:65:69:208	8:25:27:67:70:209	0:1:1:3:3:9	D007674	nephropathy|nephropathy|nephropathy	Disease	10:30:209	11:31:210	0:1:9	1:CID:2	L2R	NON-CROSS	205-207	208-209	D011692	puromycin aminonucleoside|puromycin aminonucleoside|PAN|puromycin aminonucleoside|PAN|PAN	Chemical	6:23:26:65:69:208	8:25:27:67:70:209	0:1:1:3:3:9	D011507	proteinuria|proteinuria|Proteinuria|proteinuric injury	Disease	37:49:158:205	38:50:159:207	1:2:7:9	1:NR:2	R2L	NON-CROSS	13-14	10-11	D010100	oxygen	Chemical	13	14	1	D007674	nephropathy|nephropathy|nephropathy	Disease	10:30:209	11:31:210	0:1:9	1:NR:2	R2L	CROSS	209-210	153-155	C029684	thiobarbituric acid	Chemical	153	155	6	D007674	nephropathy|nephropathy|nephropathy	Disease	10:30:209	11:31:210	0:1:9	1:NR:2	L2R	NON-CROSS	13-14	37-38	D010100	oxygen	Chemical	13	14	1	D011507	proteinuria|proteinuria|Proteinuria|proteinuric injury	Disease	37:49:158:205	38:50:159:207	1:2:7:9	1:NR:2	R2L	CROSS	158-159	153-155	C029684	thiobarbituric acid	Chemical	153	155	6	D011507	proteinuria|proteinuria|Proteinuria|proteinuric injury	Disease	37:49:158:205	38:50:159:207	1:2:7:9
7930386	Clomipramine - induced sleep disturbance does not impair its prolactin - releasing action .|The present study was undertaken to examine the role of sleep disturbance , induced by clomipramine administration , on the secretory rate of prolactin ( PRL ) in addition to the direct drug effect .|Two groups of supine subjects were studied under placebo - controlled conditions , one during the night , when sleeping ( n = 7 ) and the other at daytime , when awake ( n = 6 ) .|Each subject received a single 50 mg dose of clomipramine given orally 2 hours before blood collection .|Plasma PRL concentrations were analysed at 10 min intervals and underlying secretory rates calculated by a deconvolution procedure .|For both experiments the drug intake led to significant increases in PRL secretion , acting preferentially on tonic secretion as pulse amplitude and frequency did not differ significantly from corresponding control values .|During the night clomipramine ingestion altered the complete sleep architecture in that it suppressed REM sleep and the sleep cycles and induced increased wakefulness .|As the relative increase in PRL secretion expressed as a percentage of the mean did not significantly differ between the night and day time studies ( 46 + / - 19 % vs 34 + / - 10 % ) , it can be concluded that the observed sleep disturbance did not interfere with the drug action per se .|The presence of REM sleep was shown not to be a determining factor either for secretory pulse amplitude and frequency , as , for both , mean nocturnal values were similar with and without prior clomipramine ingestion .	1:CID:2	L2R	NON-CROSS	0-1	3-5	D002997	Clomipramine|clomipramine|clomipramine|clomipramine|clomipramine	Chemical	0:29:97:161:278	1:30:98:162:279	0:1:3:6:8	D012893	sleep disturbance|sleep disturbance|sleep disturbance	Disease	3:24:231	5:26:233	0:1:7
7988234	Angioedema following the intravenous administration of metoprolol .|A 72 - year - old woman was admitted to the hospital with " flash " pulmonary edema , preceded by chest pain , requiring intubation .|Her medical history included coronary artery disease with previous myocardial infarctions , hypertension , and diabetes mellitus .|A history of angioedema secondary to lisinopril therapy was elicited .|Current medications did not include angiotensin - converting enzyme inhibitors or beta - blockers .|She had no previous beta - blocking drug exposure .|During the first day of hospitalization ( while intubated ) , intravenous metoprolol was given , resulting in severe angioedema .|The angioedema resolved after therapy with intravenous steroids and diphenhydramine hydrochloride .	1:CID:2	R2L	NON-CROSS	6-7	0-1	D008790	metoprolol|metoprolol	Chemical	6:101	7:102	0:6	D000799	Angioedema|angioedema|angioedema|angioedema	Disease	0:56:108:111	1:57:109:112	0:3:6:7	1:CID:2	R2L	NON-CROSS	59-60	56-57	D017706	lisinopril	Chemical	59	60	3	D000799	Angioedema|angioedema|angioedema|angioedema	Disease	0:56:108:111	1:57:109:112	0:3:6:7	1:NR:2	R2L	CROSS	69-70	56-57	D000809	angiotensin	Chemical	69	70	4	D000799	Angioedema|angioedema|angioedema|angioedema	Disease	0:56:108:111	1:57:109:112	0:3:6:7	1:NR:2	R2L	NON-CROSS	117-118	111-112	D013256	steroids	Chemical	117	118	7	D000799	Angioedema|angioedema|angioedema|angioedema	Disease	0:56:108:111	1:57:109:112	0:3:6:7	1:NR:2	R2L	NON-CROSS	119-120	111-112	D004155	diphenhydramine	Chemical	119	120	7	D000799	Angioedema|angioedema|angioedema|angioedema	Disease	0:56:108:111	1:57:109:112	0:3:6:7	1:NR:2	L2R	CROSS	6-7	24-26	D008790	metoprolol|metoprolol	Chemical	6:101	7:102	0:6	D011654	pulmonary edema	Disease	24	26	1	1:NR:2	L2R	CROSS	6-7	29-31	D008790	metoprolol|metoprolol	Chemical	6:101	7:102	0:6	D002637	chest pain	Disease	29	31	1	1:NR:2	L2R	CROSS	6-7	39-42	D008790	metoprolol|metoprolol	Chemical	6:101	7:102	0:6	D003324	coronary artery disease	Disease	39	42	2	1:NR:2	L2R	CROSS	6-7	44-46	D008790	metoprolol|metoprolol	Chemical	6:101	7:102	0:6	D009203	myocardial infarctions	Disease	44	46	2	1:NR:2	L2R	CROSS	6-7	47-48	D008790	metoprolol|metoprolol	Chemical	6:101	7:102	0:6	D006973	hypertension	Disease	47	48	2	1:NR:2	L2R	CROSS	6-7	50-52	D008790	metoprolol|metoprolol	Chemical	6:101	7:102	0:6	D003920	diabetes mellitus	Disease	50	52	2	1:NR:2	R2L	CROSS	59-60	24-26	D017706	lisinopril	Chemical	59	60	3	D011654	pulmonary edema	Disease	24	26	1	1:NR:2	R2L	CROSS	69-70	24-26	D000809	angiotensin	Chemical	69	70	4	D011654	pulmonary edema	Disease	24	26	1	1:NR:2	R2L	CROSS	117-118	24-26	D013256	steroids	Chemical	117	118	7	D011654	pulmonary edema	Disease	24	26	1	1:NR:2	R2L	CROSS	119-120	24-26	D004155	diphenhydramine	Chemical	119	120	7	D011654	pulmonary edema	Disease	24	26	1	1:NR:2	R2L	CROSS	59-60	29-31	D017706	lisinopril	Chemical	59	60	3	D002637	chest pain	Disease	29	31	1	1:NR:2	R2L	CROSS	69-70	29-31	D000809	angiotensin	Chemical	69	70	4	D002637	chest pain	Disease	29	31	1	1:NR:2	R2L	CROSS	117-118	29-31	D013256	steroids	Chemical	117	118	7	D002637	chest pain	Disease	29	31	1	1:NR:2	R2L	CROSS	119-120	29-31	D004155	diphenhydramine	Chemical	119	120	7	D002637	chest pain	Disease	29	31	1	1:NR:2	R2L	CROSS	59-60	39-42	D017706	lisinopril	Chemical	59	60	3	D003324	coronary artery disease	Disease	39	42	2	1:NR:2	R2L	CROSS	69-70	39-42	D000809	angiotensin	Chemical	69	70	4	D003324	coronary artery disease	Disease	39	42	2	1:NR:2	R2L	CROSS	117-118	39-42	D013256	steroids	Chemical	117	118	7	D003324	coronary artery disease	Disease	39	42	2	1:NR:2	R2L	CROSS	119-120	39-42	D004155	diphenhydramine	Chemical	119	120	7	D003324	coronary artery disease	Disease	39	42	2	1:NR:2	R2L	CROSS	59-60	44-46	D017706	lisinopril	Chemical	59	60	3	D009203	myocardial infarctions	Disease	44	46	2	1:NR:2	R2L	CROSS	69-70	44-46	D000809	angiotensin	Chemical	69	70	4	D009203	myocardial infarctions	Disease	44	46	2	1:NR:2	R2L	CROSS	117-118	44-46	D013256	steroids	Chemical	117	118	7	D009203	myocardial infarctions	Disease	44	46	2	1:NR:2	R2L	CROSS	119-120	44-46	D004155	diphenhydramine	Chemical	119	120	7	D009203	myocardial infarctions	Disease	44	46	2	1:NR:2	R2L	CROSS	59-60	47-48	D017706	lisinopril	Chemical	59	60	3	D006973	hypertension	Disease	47	48	2	1:NR:2	R2L	CROSS	69-70	47-48	D000809	angiotensin	Chemical	69	70	4	D006973	hypertension	Disease	47	48	2	1:NR:2	R2L	CROSS	117-118	47-48	D013256	steroids	Chemical	117	118	7	D006973	hypertension	Disease	47	48	2	1:NR:2	R2L	CROSS	119-120	47-48	D004155	diphenhydramine	Chemical	119	120	7	D006973	hypertension	Disease	47	48	2	1:NR:2	R2L	CROSS	59-60	50-52	D017706	lisinopril	Chemical	59	60	3	D003920	diabetes mellitus	Disease	50	52	2	1:NR:2	R2L	CROSS	69-70	50-52	D000809	angiotensin	Chemical	69	70	4	D003920	diabetes mellitus	Disease	50	52	2	1:NR:2	R2L	CROSS	117-118	50-52	D013256	steroids	Chemical	117	118	7	D003920	diabetes mellitus	Disease	50	52	2	1:NR:2	R2L	CROSS	119-120	50-52	D004155	diphenhydramine	Chemical	119	120	7	D003920	diabetes mellitus	Disease	50	52	2
8073369	Effect of coniine on the developing chick embryo .|Coniine , an alkaloid from Conium maculatum ( poison hemlock ) , has been shown to be teratogenic in livestock .|The major teratogenic outcome is arthrogryposis , presumably due to nicotinic receptor blockade .|However , coniine has failed to produce arthrogryposis in rats or mice and is only weakly teratogenic in rabbits .|The purpose of this study was to evaluate and compare the effects of coniine and nicotine in the developing chick .|Concentrations of coniine and nicotine sulfate were 0 . 015 % , 0 . 03 % , 0 . 075 % , 0 . 15 % , 0 . 75 % , 1 . 5 % , 3 % , and 6 % and 1 % , 5 % , and 10 % , respectively .|Both compounds caused deformations and lethality in a dose - dependent manner .|All concentrations of nicotine sulfate caused some lethality but a no effect level for coniine lethality was 0 . 75 % .|The deformations caused by both coniine and nicotine sulfate were excessive flexion or extension of one or more toes .|No histopathological alterations or differences in bone formation were seen in the limbs or toes of any chicks from any group ; however , extensive cranial hemorrhage occurred in all nicotine sulfate - treated chicks .|There was a statistically significant ( P < or = 0 . 01 ) decrease in movement in coniine and nicotine sulfate treated chicks as determined by ultrasound .|Control chicks were in motion an average of 33 . 67 % of the time , while coniine - treated chicks were only moving 8 . 95 % of a 5 - min interval , and no movement was observed for nicotine sulfate treated chicks .|In summary , the chick embryo provides a reliable and simple experimental animal model of coniine - induced arthrogryposis .|Data from this model support a mechanism involving nicotinic receptor blockade with subsequent decreased fetal movement .	1:CID:2	L2R	NON-CROSS	322-323	325-326	C007112	coniine|Coniine|coniine|coniine|coniine|coniine|coniine|coniine|coniine|coniine	Chemical	2:9:46:77:87:168:181:250:278:322	3:10:47:78:88:169:182:251:279:323	0:1:3:4:5:7:8:10:11:12	D001176	arthrogryposis|arthrogryposis|arthrogryposis	Disease	35:51:325	36:52:326	2:3:12	1:CID:2	R2L	CROSS	325-326	302-303	D009538	nicotine|nicotine|nicotine|nicotine|nicotine|nicotine|nicotine	Chemical	79:89:157:183:226:252:302	80:90:158:184:227:253:303	4:5:7:8:9:10:11	D001176	arthrogryposis|arthrogryposis|arthrogryposis	Disease	35:51:325	36:52:326	2:3:12	1:CID:2	L2R	NON-CROSS	221-223	226-227	D009538	nicotine|nicotine|nicotine|nicotine|nicotine|nicotine|nicotine	Chemical	79:89:157:183:226:252:302	80:90:158:184:227:253:303	4:5:7:8:9:10:11	D002543	cranial hemorrhage	Disease	221	223	9	not_include	L2R	NON-CROSS	177-178	181-182	C007112	coniine|Coniine|coniine|coniine|coniine|coniine|coniine|coniine|coniine|coniine	Chemical	2:9:46:77:87:168:181:250:278:322	3:10:47:78:88:169:182:251:279:323	0:1:3:4:5:7:8:10:11:12	D009140	deformations|deformations|excessive flexion or extension of one or more toes	Disease	144:177:186	145:178:195	6:8:8	1:NR:2	L2R	CROSS	221-223	250-251	C007112	coniine|Coniine|coniine|coniine|coniine|coniine|coniine|coniine|coniine|coniine	Chemical	2:9:46:77:87:168:181:250:278:322	3:10:47:78:88:169:182:251:279:323	0:1:3:4:5:7:8:10:11:12	D002543	cranial hemorrhage	Disease	221	223	9	not_include	L2R	NON-CROSS	183-184	186-195	D009538	nicotine|nicotine|nicotine|nicotine|nicotine|nicotine|nicotine	Chemical	79:89:157:183:226:252:302	80:90:158:184:227:253:303	4:5:7:8:9:10:11	D009140	deformations|deformations|excessive flexion or extension of one or more toes	Disease	144:177:186	145:178:195	6:8:8
8302922	Epidural blood flow during prostaglandin E1 or trimethaphan induced hypotension .|To evaluate the effect of prostaglandin E1 ( PGE1 ) or trimethaphan ( TMP ) induced hypotension on epidural blood flow ( EBF ) during spinal surgery , EBF was measured using the heat clearance method in 30 patients who underwent postero - lateral interbody fusion under isoflurane anaesthesia .|An initial dose of 0 . 1 microgram . kg - 1 . min - 1 of PGE1 ( 15 patients ) , or 10 micrograms . kg - 1 . min - 1 of TMP ( 15 patients ) was administered intravenously after the dural opening and the dose was adjusted to maintain the mean arterial blood pressure ( MAP ) at about 60 mmHg .|The hypotensive drug was discontinued at the completion of the operative procedure .|After starting PGE1 or TMP , MAP and rate pressure product ( RPP ) decreased significantly compared with preinfusion values ( P < 0 . 01 ) , and the degree of hypotension due to PGE1 remained constant until 60 min after its discontinuation .|Heart rate ( HR ) did not change in either group .|EBFF did not change during PGE1 infusion whereas in the TMP group , EBF decreased significantly at 30 and 60 min after the start of TMP ( preinfusion : 45 . 9 + / - 13 . 9 ml / 100g / min .|30 min : 32 . 3 + / - 9 . 9 ml / 100 g / min ( P < 0 . 05 ) .|60 min : 30 + / - 7 . 5 ml / 100 g / min ( P < 0 . 05 ) ) .|These results suggest that PGE1 may be preferable to TMP for hypotensive anaesthesia in spinal surgery because TMP decreased EBF .	1:CID:2	L2R	NON-CROSS	173-174	176-177	D000527	prostaglandin E1|prostaglandin E1|PGE1|PGE1|PGE1|PGE1|PGE1|PGE1	Chemical	4:16:19:78:143:176:203:297	6:18:20:79:144:177:204:298	0:1:1:2:4:4:6:9	D007022	hypotension|hypotension|hypotensive|hypotension|hypotensive	Disease	9:27:129:173:304	10:28:130:174:305	0:1:3:4:9	1:CID:2	L2R	NON-CROSS	7-8	9-10	D014294	trimethaphan|trimethaphan|TMP|TMP|TMP|TMP|TMP|TMP|TMP	Chemical	7:22:24:96:145:208:223:302:310	8:23:25:97:146:209:224:303:311	0:1:1:2:4:6:6:9:9	D007022	hypotension|hypotension|hypotensive|hypotension|hypotensive	Disease	9:27:129:173:304	10:28:130:174:305	0:1:3:4:9	1:NR:2	R2L	NON-CROSS	58-59	27-28	D007530	isoflurane	Chemical	58	59	1	D007022	hypotension|hypotension|hypotensive|hypotension|hypotensive	Disease	9:27:129:173:304	10:28:130:174:305	0:1:3:4:9
8410052	Immunohistochemical studies with antibodies to neurofilament proteins on axonal damage in experimental focal lesions in rat .|Immunohistochemistry with monoclonal antibodies against neurofilament ( NF ) proteins of middle and high molecular weight class , NF - M and NF - H , was used to study axonal injury in the borderzone of focal lesions in rats .|Focal injury in the cortex was produced by infusion of lactate at acid pH or by stab caused by needle insertion .|Infarcts in substantia nigra pars reticulata were evoked by prolonged pilocarpine - induced status epilepticus .|Immunohistochemical staining for NFs showed characteristic terminal clubs of axons in the borderzone of lesions .|Differences in the labelling pattern occurred with different antibodies which apparently depended on molecular weight class of NFs and phosphorylation state .|These immunohistochemical changes of NFs can serve as a marker for axonal damage in various experimental traumatic or ischemic lesions .	1:CID:2	R2L	CROSS	90-91	59-63	D010862	pilocarpine	Chemical	90	91	3	D001480	axonal damage|axonal injury|injury in the cortex|axonal damage	Disease	8:47:59:145	10:49:63:147	0:1:2:6	1:CID:2	R2L	NON-CROSS	90-91	80-86	D010862	pilocarpine	Chemical	90	91	3	D002544	Infarcts in substantia nigra pars reticulata	Disease	80	86	3	1:CID:2	L2R	NON-CROSS	90-91	93-95	D010862	pilocarpine	Chemical	90	91	3	D013226	status epilepticus	Disease	93	95	3	1:NR:2	R2L	NON-CROSS	68-69	59-63	D019344	lactate	Chemical	68	69	2	D001480	axonal damage|axonal injury|injury in the cortex|axonal damage	Disease	8:47:59:145	10:49:63:147	0:1:2:6	1:NR:2	L2R	CROSS	68-69	80-86	D019344	lactate	Chemical	68	69	2	D002544	Infarcts in substantia nigra pars reticulata	Disease	80	86	3	1:NR:2	L2R	CROSS	68-69	93-95	D019344	lactate	Chemical	68	69	2	D013226	status epilepticus	Disease	93	95	3	1:NR:2	L2R	CROSS	68-69	150-151	D019344	lactate	Chemical	68	69	2	D014947	traumatic	Disease	150	151	6	1:NR:2	L2R	CROSS	90-91	150-151	D010862	pilocarpine	Chemical	90	91	3	D014947	traumatic	Disease	150	151	6
8423889	Increase of Parkinson disability after fluoxetine medication .|Depression is a major clinical feature of Parkinson 's disease .|We report the increased amount of motor disability in four patients with idiopathic Parkinson 's disease after exposure to the antidepressant fluoxetine .|The possibility of a clinically relevant dopamine - antagonistic capacity of fluoxetine in Parkinson 's disease patients must be considered .	1:CID:2	R2L	NON-CROSS	5-6	2-4	D005473	fluoxetine|fluoxetine|fluoxetine	Chemical	5:40:53	6:41:54	0:2:3	D009069	Parkinson disability|motor disability	Disease	2:25	4:27	0:2	1:NR:2	R2L	NON-CROSS	39-40	25-27	D000928	antidepressant	Chemical	39	40	2	D009069	Parkinson disability|motor disability	Disease	2:25	4:27	0:2	1:NR:2	R2L	CROSS	48-49	25-27	D004298	dopamine	Chemical	48	49	3	D009069	Parkinson disability|motor disability	Disease	2:25	4:27	0:2	1:NR:2	L2R	CROSS	5-6	8-9	D005473	fluoxetine|fluoxetine|fluoxetine	Chemical	5:40:53	6:41:54	0:2:3	D003866	Depression	Disease	8	9	1	1:NR:2	L2R	NON-CROSS	53-54	55-58	D005473	fluoxetine|fluoxetine|fluoxetine	Chemical	5:40:53	6:41:54	0:2:3	D010300	Parkinson 's disease|idiopathic Parkinson 's disease|Parkinson 's disease	Disease	15:31:55	18:35:58	1:2:3	1:NR:2	R2L	CROSS	39-40	8-9	D000928	antidepressant	Chemical	39	40	2	D003866	Depression	Disease	8	9	1	1:NR:2	R2L	CROSS	48-49	8-9	D004298	dopamine	Chemical	48	49	3	D003866	Depression	Disease	8	9	1	1:NR:2	R2L	NON-CROSS	39-40	31-35	D000928	antidepressant	Chemical	39	40	2	D010300	Parkinson 's disease|idiopathic Parkinson 's disease|Parkinson 's disease	Disease	15:31:55	18:35:58	1:2:3	1:NR:2	R2L	NON-CROSS	55-58	48-49	D004298	dopamine	Chemical	48	49	3	D010300	Parkinson 's disease|idiopathic Parkinson 's disease|Parkinson 's disease	Disease	15:31:55	18:35:58	1:2:3
8682684	Acetaminophen - induced hypotension .|Through 30 years of widespread use , acetaminophen has been shown to be a remarkably safe medication in therapeutic dosages .|The potential for acetaminophen to produce cardiovascular toxicities is very low .|However , acetaminophen has been demonstrated to produce symptoms of anaphylaxis , including hypotension , in sensitive individuals .|This article describes two critically ill patients in whom transient episodes of hypotension reproducibly developed after administration of acetaminophen .|Other symptoms of allergic reactions were not clinically detectable .|The hypotensive episodes were severe enough to require vasopressor administration .|The reports illustrate the need for clinicians to consider acetaminophen in patients with hypotension of unknown origin .	1:CID:2	L2R	NON-CROSS	0-1	3-4	D000082	Acetaminophen|acetaminophen|acetaminophen|acetaminophen|acetaminophen|acetaminophen	Chemical	0:12:29:40:75:107	1:13:30:41:76:108	0:1:2:3:4:7	D007022	hypotension|hypotension|hypotension|hypotensive|hypotension	Disease	3:51:69:88:111	4:52:70:89:112	0:3:4:6:7	not_include	L2R	NON-CROSS	29-30	32-34	D000082	Acetaminophen|acetaminophen|acetaminophen|acetaminophen|acetaminophen|acetaminophen	Chemical	0:12:29:40:75:107	1:13:30:41:76:108	0:1:2:3:4:7	D002318	cardiovascular toxicities	Disease	32	34	2	1:NR:2	L2R	NON-CROSS	40-41	48-49	D000082	Acetaminophen|acetaminophen|acetaminophen|acetaminophen|acetaminophen|acetaminophen	Chemical	0:12:29:40:75:107	1:13:30:41:76:108	0:1:2:3:4:7	D000707	anaphylaxis	Disease	48	49	3	1:NR:2	L2R	NON-CROSS	61-63	75-76	D000082	Acetaminophen|acetaminophen|acetaminophen|acetaminophen|acetaminophen|acetaminophen	Chemical	0:12:29:40:75:107	1:13:30:41:76:108	0:1:2:3:4:7	D016638	critically ill	Disease	61	63	4	1:NR:2	L2R	CROSS	75-76	80-82	D000082	Acetaminophen|acetaminophen|acetaminophen|acetaminophen|acetaminophen|acetaminophen	Chemical	0:12:29:40:75:107	1:13:30:41:76:108	0:1:2:3:4:7	D004342	allergic reactions	Disease	80	82	5
9625142	Acute hepatitis , autoimmune hemolytic anemia , and erythroblastocytopenia induced by ceftriaxone .|An 80 - yr - old man developed acute hepatitis shortly after ingesting oral ceftriaxone .|Although the transaminases gradually returned to baseline after withholding the beta lactam antibiotic , there was a gradual increase in serum bilirubin and a decrease in hemoglobin concentration caused by an autoimmune hemolytic anemia and erythroblastocytopenia .|These responded to systemic steroids and immunoglobulins .|Despite the widespread use of these agents this triad of side effects has not previously been reported in connection with beta lactam antibiotics .	1:CID:2	R2L	NON-CROSS	27-28	22-23	D002443	ceftriaxone|ceftriaxone	Chemical	11:27	12:28	0:1	D056486	hepatitis|hepatitis	Disease	1:22	2:23	0:1	1:CID:2	R2L	NON-CROSS	11-12	3-6	D002443	ceftriaxone|ceftriaxone	Chemical	11:27	12:28	0:1	D000744	autoimmune hemolytic anemia|autoimmune hemolytic anemia	Disease	3:60	6:63	0:2	1:NR:2	R2L	CROSS	39-41	22-23	D047090	beta lactam|beta lactam	Chemical	39:94	41:96	2:4	D056486	hepatitis|hepatitis	Disease	1:22	2:23	0:1	1:NR:2	R2L	CROSS	50-51	22-23	D001663	bilirubin	Chemical	50	51	2	D056486	hepatitis|hepatitis	Disease	1:22	2:23	0:1	1:NR:2	R2L	CROSS	70-71	22-23	D013256	steroids	Chemical	70	71	3	D056486	hepatitis|hepatitis	Disease	1:22	2:23	0:1	1:NR:2	R2L	NON-CROSS	60-63	39-41	D047090	beta lactam|beta lactam	Chemical	39:94	41:96	2:4	D000744	autoimmune hemolytic anemia|autoimmune hemolytic anemia	Disease	3:60	6:63	0:2	1:NR:2	R2L	NON-CROSS	60-63	50-51	D001663	bilirubin	Chemical	50	51	2	D000744	autoimmune hemolytic anemia|autoimmune hemolytic anemia	Disease	3:60	6:63	0:2	1:NR:2	R2L	CROSS	70-71	60-63	D013256	steroids	Chemical	70	71	3	D000744	autoimmune hemolytic anemia|autoimmune hemolytic anemia	Disease	3:60	6:63	0:2
9766615	Adverse effects of the atypical antipsychotics .|Collaborative Working Group on Clinical Trial Evaluations .|Adverse effects of antipsychotics often lead to noncompliance .|Thus , clinicians should address patients ' concerns about adverse effects and attempt to choose medications that will improve their patients ' quality of life as well as overall health .|The side effect profiles of the atypical antipsychotics are more advantageous than those of the conventional neuroleptics .|Conventional agents are associated with unwanted central nervous system effects , including extrapyramidal symptoms ( EPS ) , tardive dyskinesia , sedation , and possible impairment of some cognitive measures , as well as cardiac effects , orthostatic hypotension , hepatic changes , anticholinergic side effects , sexual dysfunction , and weight gain .|The newer atypical agents have a lower risk of EPS , but are associated in varying degrees with sedation , cardiovascular effects , anticholinergic effects , weight gain , sexual dysfunction , hepatic effects , lowered seizure threshold ( primarily clozapine ) , and agranulocytosis ( clozapine only ) .|Since the incidence and severity of specific adverse effects differ among the various atypicals , the clinician should carefully consider which side effects are most likely to lead to the individual 's dissatisfaction and noncompliance before choosing an antipsychotic for a particular patient .	1:CID:2	L2R	NON-CROSS	171-172	173-174	D003024	clozapine|clozapine	Chemical	167:173	168:174	6:6	D000380	agranulocytosis	Disease	171	172	6	1:NR:2	R2L	NON-CROSS	167-168	136-137	D003024	clozapine|clozapine	Chemical	167:173	168:174	6:6	D001480	extrapyramidal symptoms|EPS|EPS	Disease	85:88:136	87:89:137	5:5:6	1:NR:2	R2L	CROSS	167-168	91-93	D003024	clozapine|clozapine	Chemical	167:173	168:174	6:6	D004409	tardive dyskinesia	Disease	91	93	5	1:NR:2	R2L	CROSS	167-168	110-112	D003024	clozapine|clozapine	Chemical	167:173	168:174	6:6	D007024	orthostatic hypotension	Disease	110	112	5	1:NR:2	R2L	NON-CROSS	167-168	156-158	D003024	clozapine|clozapine	Chemical	167:173	168:174	6:6	D012735	sexual dysfunction|sexual dysfunction	Disease	120:156	122:158	5:6	1:NR:2	R2L	NON-CROSS	167-168	153-155	D003024	clozapine|clozapine	Chemical	167:173	168:174	6:6	D015430	weight gain|weight gain	Disease	124:153	126:155	5:6	1:NR:2	R2L	NON-CROSS	167-168	163-164	D003024	clozapine|clozapine	Chemical	167:173	168:174	6:6	D012640	seizure	Disease	163	164	6
10193204	Effects of tetrandrine and fangchinoline on experimental thrombosis in mice and human platelet aggregation .|Tetrandrine ( TET ) and fangchinoline ( FAN ) are two naturally occurring analogues with a bisbenzylisoquinoline structure .|The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine ( EP ) in mice , and platelet aggregation and blood coagulation in vitro .|In the in vivo study , the administration ( 50 mg / kg , i . p . ) of TET and FAN in mice showed the inhibition of thrombosis by 55 % and 35 % , respectively , while acetylsalicylic acid ( ASA , 50 mg / kg , i . p . ) , a positive control , showed only 30 % inhibition .|In the vitro human platelet aggregations induced by the agonists used in tests , TET and FAN showed the inhibitions dose dependently .|In addition , neither TET nor FAN showed any anticoagulation activities in the measurement of the activated partial thromboplastin time ( APTT ) , prothrombin time ( PT ) and thrombin time ( TT ) using human - citrated plasma .|These results suggest that antithrombosis of TET and FAN in mice may be mainly related to the antiplatelet aggregation activities .	1:CID:2	R2L	NON-CROSS	55-56	50-51	D004837	epinephrine|EP	Chemical	55:57	56:58	2:2	D013927	thrombosis|thrombosis|thrombosis	Disease	7:50:100	8:51:101	0:2:3	1:NR:2	L2R	NON-CROSS	2-3	7-8	C009438	tetrandrine|Tetrandrine|TET|TET|TET|TET|TET|TET	Chemical	2:15:17:44:91:151:164:207	3:16:18:45:92:152:165:208	0:1:1:2:3:4:5:6	D013927	thrombosis|thrombosis|thrombosis	Disease	7:50:100	8:51:101	0:2:3	1:NR:2	L2R	NON-CROSS	12-14	15-16	C009438	tetrandrine|Tetrandrine|TET|TET|TET|TET|TET|TET	Chemical	2:15:17:44:91:151:164:207	3:16:18:45:92:152:165:208	0:1:1:2:3:4:5:6	D001791	platelet aggregation|platelet aggregation|platelet aggregations	Disease	12:63:141	14:65:143	0:2:4	1:NR:2	L2R	NON-CROSS	44-45	66-68	C009438	tetrandrine|Tetrandrine|TET|TET|TET|TET|TET|TET	Chemical	2:15:17:44:91:151:164:207	3:16:18:45:92:152:165:208	0:1:1:2:3:4:5:6	D001778	blood coagulation	Disease	66	68	2	1:NR:2	L2R	NON-CROSS	4-5	7-8	C060802	fangchinoline|fangchinoline|FAN|FAN|FAN|FAN|FAN|FAN	Chemical	4:20:22:46:93:153:166:209	5:21:23:47:94:154:167:210	0:1:1:2:3:4:5:6	D013927	thrombosis|thrombosis|thrombosis	Disease	7:50:100	8:51:101	0:2:3	1:NR:2	L2R	NON-CROSS	12-14	20-21	C060802	fangchinoline|fangchinoline|FAN|FAN|FAN|FAN|FAN|FAN	Chemical	4:20:22:46:93:153:166:209	5:21:23:47:94:154:167:210	0:1:1:2:3:4:5:6	D001791	platelet aggregation|platelet aggregation|platelet aggregations	Disease	12:63:141	14:65:143	0:2:4	1:NR:2	L2R	NON-CROSS	46-47	66-68	C060802	fangchinoline|fangchinoline|FAN|FAN|FAN|FAN|FAN|FAN	Chemical	4:20:22:46:93:153:166:209	5:21:23:47:94:154:167:210	0:1:1:2:3:4:5:6	D001778	blood coagulation	Disease	66	68	2	1:NR:2	R2L	CROSS	50-51	31-32	D044182	bisbenzylisoquinoline	Chemical	31	32	1	D013927	thrombosis|thrombosis|thrombosis	Disease	7:50:100	8:51:101	0:2:3	1:NR:2	R2L	NON-CROSS	111-113	100-101	D001241	acetylsalicylic acid|ASA	Chemical	111:114	113:115	3:3	D013927	thrombosis|thrombosis|thrombosis	Disease	7:50:100	8:51:101	0:2:3	1:NR:2	R2L	CROSS	31-32	12-14	D044182	bisbenzylisoquinoline	Chemical	31	32	1	D001791	platelet aggregation|platelet aggregation|platelet aggregations	Disease	12:63:141	14:65:143	0:2:4	1:NR:2	R2L	NON-CROSS	63-65	57-58	D004837	epinephrine|EP	Chemical	55:57	56:58	2:2	D001791	platelet aggregation|platelet aggregation|platelet aggregations	Disease	12:63:141	14:65:143	0:2:4	1:NR:2	R2L	CROSS	141-143	114-115	D001241	acetylsalicylic acid|ASA	Chemical	111:114	113:115	3:3	D001791	platelet aggregation|platelet aggregation|platelet aggregations	Disease	12:63:141	14:65:143	0:2:4	1:NR:2	L2R	CROSS	31-32	66-68	D044182	bisbenzylisoquinoline	Chemical	31	32	1	D001778	blood coagulation	Disease	66	68	2	1:NR:2	L2R	NON-CROSS	57-58	66-68	D004837	epinephrine|EP	Chemical	55:57	56:58	2:2	D001778	blood coagulation	Disease	66	68	2	1:NR:2	R2L	CROSS	111-113	66-68	D001241	acetylsalicylic acid|ASA	Chemical	111:114	113:115	3:3	D001778	blood coagulation	Disease	66	68	2
10526274	Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who can not receive cisplatin .|Oncopaz Cooperative Group .|BACKGROUND : Although the prevalence of nonsmall cell lung carcinoma ( NSCLC ) is high among elderly patients , few data are available regarding the efficacy and toxicity of chemotherapy in this group of patients .|Recent reports indicate that single agent therapy with vinorelbine ( VNB ) or gemcitabine ( GEM ) may obtain a response rate of 20 - 30 % in elderly patients , with acceptable toxicity and improvement in symptoms and quality of life .|In the current study the efficacy and toxicity of the combination of GEM and VNB in elderly patients with advanced NSCLC or those with some contraindication to receiving cisplatin were assessed .|METHODS : Forty - nine patients with advanced NSCLC were included , 38 of whom were age > / = 70 years and 11 were age < 70 years but who had some contraindication to receiving cisplatin .|All patients were evaluable for response and toxicity .|Treatment was comprised of VNB , 25 mg / m ( 2 ) , plus GEM , 1000 mg / m ( 2 ) , both on Days 1 , 8 , and 15 every 28 days .|Patients received a minimum of three courses unless progressive disease was detected .|RESULTS : One hundred sixty - five courses were administered , with a median of 3 .|6 courses per patient .|The overall response rate was 26 % ( 95 % confidence interval , 15 - 41 % ) .|Two patients attained a complete response ( 4 % ) and 11 patients ( 22 % ) achieved a partial response .|Eastern Cooperative Oncology Group performance status improved in 35 % of those patients with an initial value > 0 , whereas relief of at least 1 symptom without worsening of other symptoms was noted in 27 patients ( 55 % ) .|The median time to progression was 16 weeks and the 1 - year survival rate was 33 % .|Toxicity was mild .|Six patients ( 12 % ) had World Health Organization Grade 3 - 4 neutropenia , 2 patients ( 4 % ) had Grade 3 - 4 thrombocytopenia , and 2 patients ( 4 % ) had Grade 3 neurotoxicity .|Three patients with severe neutropenia ( 6 % ) died of sepsis .|The median age of those patients developing Grade 3 - 4 neutropenia was significantly higher than that of the remaining patients ( 75 years vs . 72 years ; P = 0 . 047 ) .|CONCLUSIONS : The combination of GEM and VNB is moderately active and well tolerated except in patients age > / = 75 years .|This age group had an increased risk of myelosuppression .|Therefore the prophylactic use of granulocyte - colony stimulating factor should be considered with this treatment .|New chemotherapy combinations with higher activity and lower toxicity are needed for elderly patients with advanced NSCLC .	1:CID:2	L2R	CROSS	428-429	458-459	C056507	Gemcitabine|gemcitabine|GEM|GEM|GEM|GEM	Chemical	0:75:77:117:199:458	1:76:78:118:200:459	0:3:3:4:7:19	D009503	neutropenia|neutropenia|neutropenia	Disease	377:408:428	378:409:429	16:17:18	1:CID:2	L2R	CROSS	390-391	458-459	C056507	Gemcitabine|gemcitabine|GEM|GEM|GEM|GEM	Chemical	0:75:77:117:199:458	1:76:78:118:200:459	0:3:3:4:7:19	D013921	thrombocytopenia	Disease	390	391	16	1:CID:2	L2R	CROSS	402-403	458-459	C056507	Gemcitabine|gemcitabine|GEM|GEM|GEM|GEM	Chemical	0:75:77:117:199:458	1:76:78:118:200:459	0:3:3:4:7:19	D020258	neurotoxicity	Disease	402	403	16	1:CID:2	L2R	CROSS	428-429	460-461	C030852	vinorelbine|vinorelbine|VNB|VNB|VNB|VNB	Chemical	2:70:72:119:188:460	3:71:73:120:189:461	0:3:3:4:7:19	D009503	neutropenia|neutropenia|neutropenia	Disease	377:408:428	378:409:429	16:17:18	1:CID:2	L2R	CROSS	390-391	460-461	C030852	vinorelbine|vinorelbine|VNB|VNB|VNB|VNB	Chemical	2:70:72:119:188:460	3:71:73:120:189:461	0:3:3:4:7:19	D013921	thrombocytopenia	Disease	390	391	16	1:CID:2	L2R	CROSS	402-403	460-461	C030852	vinorelbine|vinorelbine|VNB|VNB|VNB|VNB	Chemical	2:70:72:119:188:460	3:71:73:120:189:461	0:3:3:4:7:19	D020258	neurotoxicity	Disease	402	403	16	1:NR:2	L2R	NON-CROSS	0-1	4-8	C056507	Gemcitabine|gemcitabine|GEM|GEM|GEM|GEM	Chemical	0:75:77:117:199:458	1:76:78:118:200:459	0:3:3:4:7:19	D002289	nonsmall cell lung carcinoma|nonsmall cell lung carcinoma|NSCLC|NSCLC|NSCLC|NSCLC	Disease	4:32:37:125:145:520	8:36:38:126:146:521	0:2:2:4:5:22	1:NR:2	L2R	NON-CROSS	112-113	117-118	C056507	Gemcitabine|gemcitabine|GEM|GEM|GEM|GEM	Chemical	0:75:77:117:199:458	1:76:78:118:200:459	0:3:3:4:7:19	D064420	toxicity|toxicity|toxicity|toxicity|Toxicity|toxicity	Disease	53:95:112:182:359:512	54:96:113:183:360:513	2:3:4:6:15:22	1:NR:2	L2R	CROSS	415-416	458-459	C056507	Gemcitabine|gemcitabine|GEM|GEM|GEM|GEM	Chemical	0:75:77:117:199:458	1:76:78:118:200:459	0:3:3:4:7:19	D018805	sepsis	Disease	415	416	17	1:NR:2	L2R	CROSS	458-459	485-486	C056507	Gemcitabine|gemcitabine|GEM|GEM|GEM|GEM	Chemical	0:75:77:117:199:458	1:76:78:118:200:459	0:3:3:4:7:19	D001855	myelosuppression	Disease	485	486	20	1:NR:2	L2R	NON-CROSS	2-3	4-8	C030852	vinorelbine|vinorelbine|VNB|VNB|VNB|VNB	Chemical	2:70:72:119:188:460	3:71:73:120:189:461	0:3:3:4:7:19	D002289	nonsmall cell lung carcinoma|nonsmall cell lung carcinoma|NSCLC|NSCLC|NSCLC|NSCLC	Disease	4:32:37:125:145:520	8:36:38:126:146:521	0:2:2:4:5:22	1:NR:2	L2R	NON-CROSS	182-183	188-189	C030852	vinorelbine|vinorelbine|VNB|VNB|VNB|VNB	Chemical	2:70:72:119:188:460	3:71:73:120:189:461	0:3:3:4:7:19	D064420	toxicity|toxicity|toxicity|toxicity|Toxicity|toxicity	Disease	53:95:112:182:359:512	54:96:113:183:360:513	2:3:4:6:15:22	1:NR:2	L2R	CROSS	415-416	460-461	C030852	vinorelbine|vinorelbine|VNB|VNB|VNB|VNB	Chemical	2:70:72:119:188:460	3:71:73:120:189:461	0:3:3:4:7:19	D018805	sepsis	Disease	415	416	17	1:NR:2	L2R	CROSS	460-461	485-486	C030852	vinorelbine|vinorelbine|VNB|VNB|VNB|VNB	Chemical	2:70:72:119:188:460	3:71:73:120:189:461	0:3:3:4:7:19	D001855	myelosuppression	Disease	485	486	20	1:NR:2	R2L	NON-CROSS	133-134	125-126	D002945	cisplatin|cisplatin|cisplatin	Chemical	20:133:173	21:134:174	0:4:5	D002289	nonsmall cell lung carcinoma|nonsmall cell lung carcinoma|NSCLC|NSCLC|NSCLC|NSCLC	Disease	4:32:37:125:145:520	8:36:38:126:146:521	0:2:2:4:5:22	1:NR:2	L2R	NON-CROSS	173-174	182-183	D002945	cisplatin|cisplatin|cisplatin	Chemical	20:133:173	21:134:174	0:4:5	D064420	toxicity|toxicity|toxicity|toxicity|Toxicity|toxicity	Disease	53:95:112:182:359:512	54:96:113:183:360:513	2:3:4:6:15:22	1:NR:2	L2R	CROSS	173-174	377-378	D002945	cisplatin|cisplatin|cisplatin	Chemical	20:133:173	21:134:174	0:4:5	D009503	neutropenia|neutropenia|neutropenia	Disease	377:408:428	378:409:429	16:17:18	1:NR:2	L2R	CROSS	173-174	390-391	D002945	cisplatin|cisplatin|cisplatin	Chemical	20:133:173	21:134:174	0:4:5	D013921	thrombocytopenia	Disease	390	391	16	1:NR:2	L2R	CROSS	173-174	402-403	D002945	cisplatin|cisplatin|cisplatin	Chemical	20:133:173	21:134:174	0:4:5	D020258	neurotoxicity	Disease	402	403	16	1:NR:2	L2R	CROSS	173-174	415-416	D002945	cisplatin|cisplatin|cisplatin	Chemical	20:133:173	21:134:174	0:4:5	D018805	sepsis	Disease	415	416	17	1:NR:2	L2R	CROSS	173-174	485-486	D002945	cisplatin|cisplatin|cisplatin	Chemical	20:133:173	21:134:174	0:4:5	D001855	myelosuppression	Disease	485	486	20
10669626	Warfarin - induced artery calcification is accelerated by growth and vitamin D .|The present studies demonstrate that growth and vitamin D treatment enhance the extent of artery calcification in rats given sufficient doses of Warfarin to inhibit gamma - carboxylation of matrix Gla protein , a calcification inhibitor known to be expressed by smooth muscle cells and macrophages in the artery wall .|The first series of experiments examined the influence of age and growth status on artery calcification in Warfarin - treated rats .|Treatment for 2 weeks with Warfarin caused massive focal calcification of the artery media in 20 - day - old rats and less extensive focal calcification in 42 - day - old rats .|In contrast , no artery calcification could be detected in 10 - month - old adult rats even after 4 weeks of Warfarin treatment .|To directly examine the importance of growth to Warfarin - induced artery calcification in animals of the same age , 20 - day - old rats were fed for 2 weeks either an ad libitum diet or a 6 - g / d restricted diet that maintains weight but prevents growth .|Concurrent treatment of both dietary groups with Warfarin produced massive focal calcification of the artery media in the ad libitum - fed rats but no detectable artery calcification in the restricted - diet , growth - inhibited group .|Although the explanation for the association between artery calcification and growth status can not be determined from the present study , there was a relationship between higher serum phosphate and susceptibility to artery calcification , with 30 % higher levels of serum phosphate in young , ad libitum - fed rats compared with either of the groups that was resistant to Warfarin - induced artery calcification , ie , the 10 - month - old rats and the restricted - diet , growth - inhibited young rats .|This observation suggests that increased susceptibility to Warfarin - induced artery calcification could be related to higher serum phosphate levels .|The second set of experiments examined the possible synergy between vitamin D and Warfarin in artery calcification .|High doses of vitamin D are known to cause calcification of the artery media in as little as 3 to 4 days .|High doses of the vitamin K antagonist Warfarin are also known to cause calcification of the artery media , but at treatment times of 2 weeks or longer yet not at 1 week .|In the current study , we investigated the synergy between these 2 treatments and found that concurrent Warfarin administration dramatically increased the extent of calcification in the media of vitamin D - treated rats at 3 and 4 days .|There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium , which suggests that vitamin D may induce artery calcification through its effect on serum calcium .|Because Warfarin treatment had no effect on the elevation in serum calcium produced by vitamin D , the synergy between Warfarin and vitamin D is probably best explained by the hypothesis that Warfarin inhibits the activity of matrix Gla protein as a calcification inhibitor .|High levels of matrix Gla protein are found at sites of artery calcification in rats treated with vitamin D plus Warfarin , and chemical analysis showed that the protein that accumulated was indeed not gamma - carboxylated .|These observations indicate that although the gamma - carboxyglutamate residues of matrix Gla protein are apparently required for its function as a calcification inhibitor , they are not required for its accumulation at calcification sites .	1:CID:2	L2R	NON-CROSS	358-359	360-362	D014859	Warfarin|Warfarin|Warfarin|Warfarin|Warfarin|Warfarin|Warfarin|Warfarin|Warfarin|Warfarin|Warfarin|Warfarin|Warfarin|Warfarin|Warfarin|Warfarin	Chemical	0:35:81:91:142:153:204:297:331:358:393:437:506:525:537:570	1:36:82:92:143:154:205:298:332:359:394:438:507:526:538:571	0:1:2:3:4:5:6:7:8:9:11:12:14:14:14:15	D061205	artery calcification|artery calcification|artery calcification|calcification of the artery|artery calcification|artery calcification|calcification of the artery|artery calcification|artery calcification|artery calcification|artery calcification|artery calcification|artery calcification|calcification of the artery|calcification of the artery|artery calcification|artery calcification|artery calcification	Disease	3:27:78:95:124:156:208:223:243:268:300:334:360:372:399:473:496:561	5:29:80:99:126:158:212:225:245:270:302:336:362:376:403:475:498:563	0:1:2:3:4:5:6:6:7:7:7:8:9:10:11:13:13:15	not_include	L2R	NON-CROSS	437-438	444-445	D014859	Warfarin|Warfarin|Warfarin|Warfarin|Warfarin|Warfarin|Warfarin|Warfarin|Warfarin|Warfarin|Warfarin|Warfarin|Warfarin|Warfarin|Warfarin|Warfarin	Chemical	0:35:81:91:142:153:204:297:331:358:393:437:506:525:537:570	1:36:82:92:143:154:205:298:332:359:394:438:507:526:538:571	0:1:2:3:4:5:6:7:8:9:11:12:14:14:14:15	D002114	calcification|calcification|calcification|calcification|calcification|calcification	Disease	47:111:444:547:610:621	48:112:445:548:611:622	1:3:12:14:16:16	1:NR:2	R2L	NON-CROSS	496-498	492-494	D014807	vitamin D|vitamin D|vitamin D|vitamin D|vitamin D|vitamin D|vitamin D|vitamin D|vitamin D|vitamin D|vitamin D	Chemical	10:20:355:366:449:469:479:492:519:527:567	12:22:357:368:451:471:481:494:521:529:569	0:1:9:10:12:13:13:13:14:14:15	D061205	artery calcification|artery calcification|artery calcification|calcification of the artery|artery calcification|artery calcification|calcification of the artery|artery calcification|artery calcification|artery calcification|artery calcification|artery calcification|artery calcification|calcification of the artery|calcification of the artery|artery calcification|artery calcification|artery calcification	Disease	3:27:78:95:124:156:208:223:243:268:300:334:360:372:399:473:496:561	5:29:80:99:126:158:212:225:245:270:302:336:362:376:403:475:498:563	0:1:2:3:4:5:6:6:7:7:7:8:9:10:11:13:13:15	1:NR:2	R2L	NON-CROSS	268-270	264-265	D010710	phosphate|phosphate|phosphate	Chemical	264:278:342	265:279:343	7:7:8	D061205	artery calcification|artery calcification|artery calcification|calcification of the artery|artery calcification|artery calcification|calcification of the artery|artery calcification|artery calcification|artery calcification|artery calcification|artery calcification|artery calcification|calcification of the artery|calcification of the artery|artery calcification|artery calcification|artery calcification	Disease	3:27:78:95:124:156:208:223:243:268:300:334:360:372:399:473:496:561	5:29:80:99:126:158:212:225:245:270:302:336:362:376:403:475:498:563	0:1:2:3:4:5:6:6:7:7:7:8:9:10:11:13:13:15	1:NR:2	R2L	NON-CROSS	399-403	390-392	D014812	vitamin K	Chemical	390	392	11	D061205	artery calcification|artery calcification|artery calcification|calcification of the artery|artery calcification|artery calcification|calcification of the artery|artery calcification|artery calcification|artery calcification|artery calcification|artery calcification|artery calcification|calcification of the artery|calcification of the artery|artery calcification|artery calcification|artery calcification	Disease	3:27:78:95:124:156:208:223:243:268:300:334:360:372:399:473:496:561	5:29:80:99:126:158:212:225:245:270:302:336:362:376:403:475:498:563	0:1:2:3:4:5:6:6:7:7:7:8:9:10:11:13:13:15	1:NR:2	R2L	NON-CROSS	503-504	496-498	D002118	calcium|calcium|calcium	Chemical	487:503:516	488:504:517	13:13:14	D061205	artery calcification|artery calcification|artery calcification|calcification of the artery|artery calcification|artery calcification|calcification of the artery|artery calcification|artery calcification|artery calcification|artery calcification|artery calcification|artery calcification|calcification of the artery|calcification of the artery|artery calcification|artery calcification|artery calcification	Disease	3:27:78:95:124:156:208:223:243:268:300:334:360:372:399:473:496:561	5:29:80:99:126:158:212:225:245:270:302:336:362:376:403:475:498:563	0:1:2:3:4:5:6:6:7:7:7:8:9:10:11:13:13:15	1:NR:2	R2L	NON-CROSS	584-587	561-563	D015055	gamma - carboxylated|gamma - carboxyglutamate	Chemical	584:594	587:597	15:16	D061205	artery calcification|artery calcification|artery calcification|calcification of the artery|artery calcification|artery calcification|calcification of the artery|artery calcification|artery calcification|artery calcification|artery calcification|artery calcification|artery calcification|calcification of the artery|calcification of the artery|artery calcification|artery calcification|artery calcification	Disease	3:27:78:95:124:156:208:223:243:268:300:334:360:372:399:473:496:561	5:29:80:99:126:158:212:225:245:270:302:336:362:376:403:475:498:563	0:1:2:3:4:5:6:6:7:7:7:8:9:10:11:13:13:15	1:NR:2	L2R	NON-CROSS	444-445	449-451	D014807	vitamin D|vitamin D|vitamin D|vitamin D|vitamin D|vitamin D|vitamin D|vitamin D|vitamin D|vitamin D|vitamin D	Chemical	10:20:355:366:449:469:479:492:519:527:567	12:22:357:368:451:471:481:494:521:529:569	0:1:9:10:12:13:13:13:14:14:15	D002114	calcification|calcification|calcification|calcification|calcification|calcification	Disease	47:111:444:547:610:621	48:112:445:548:611:622	1:3:12:14:16:16	1:NR:2	R2L	CROSS	444-445	342-343	D010710	phosphate|phosphate|phosphate	Chemical	264:278:342	265:279:343	7:7:8	D002114	calcification|calcification|calcification|calcification|calcification|calcification	Disease	47:111:444:547:610:621	48:112:445:548:611:622	1:3:12:14:16:16	1:NR:2	R2L	CROSS	444-445	390-392	D014812	vitamin K	Chemical	390	392	11	D002114	calcification|calcification|calcification|calcification|calcification|calcification	Disease	47:111:444:547:610:621	48:112:445:548:611:622	1:3:12:14:16:16	1:NR:2	R2L	NON-CROSS	547-548	516-517	D002118	calcium|calcium|calcium	Chemical	487:503:516	488:504:517	13:13:14	D002114	calcification|calcification|calcification|calcification|calcification|calcification	Disease	47:111:444:547:610:621	48:112:445:548:611:622	1:3:12:14:16:16	1:NR:2	R2L	NON-CROSS	610-611	594-597	D015055	gamma - carboxylated|gamma - carboxyglutamate	Chemical	584:594	587:597	15:16	D002114	calcification|calcification|calcification|calcification|calcification|calcification	Disease	47:111:444:547:610:621	48:112:445:548:611:622	1:3:12:14:16:16
11379838	Antidepressant - induced mania in bipolar patients : identification of risk factors .|BACKGROUND : Concerns about possible risks of switching to mania associated with antidepressants continue to interfere with the establishment of an optimal treatment paradigm for bipolar depression .|METHOD : The response of 44 patients meeting DSM - IV criteria for bipolar disorder to naturalistic treatment was assessed for at least 6 weeks using the Montgomery - Asberg Depression Rating Scale and the Bech - Rafaelson Mania Rating Scale .|Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age , sex , diagnosis ( DSM - IV bipolar I vs . bipolar II ) , number of previous manic episodes , type of antidepressant therapy used ( electroconvulsive therapy vs . antidepressant drugs and , more particularly , selective serotonin reuptake inhibitors [ SSRIs ] ) , use and type of mood stabilizers ( lithium vs . anticonvulsants ) , and temperament of the patient , assessed during a normothymic period using the hyperthymia component of the Semi - structured Affective Temperament Interview .|RESULTS : Switches to hypomania or mania occurred in 27 % of all patients ( N = 12 ) ( and in 24 % of the subgroup of patients treated with SSRIs [ 8 / 33 ] ) ; 16 % ( N = 7 ) experienced manic episodes , and 11 % ( N = 5 ) experienced hypomanic episodes .|Sex , age , diagnosis ( bipolar I vs . bipolar II ) , and additional treatment did not affect the risk of switching .|The incidence of mood switches seemed not to differ between patients receiving an anticonvulsant and those receiving no mood stabilizer .|In contrast , mood switches were less frequent in patients receiving lithium ( 15 % , 4 / 26 ) than in patients not treated with lithium ( 44 % , 8 / 18 ; p = . 04 ) .|The number of previous manic episodes did not affect the probability of switching , whereas a high score on the hyperthymia component of the Semistructured Affective Temperament Interview was associated with a greater risk of switching ( p = . 008 ) .|CONCLUSION : The frequency of mood switching associated with acute antidepressant therapy may be reduced by lithium treatment .|Particular attention should be paid to patients with a hyperthymic temperament , who have a greater risk of mood switches .	1:CID:2	L2R	NON-CROSS	0-1	3-4	D000928	Antidepressant|antidepressants|antidepressant|antidepressant|antidepressant	Chemical	0:25:127:135:390	1:26:128:136:391	0:1:3:3:9	D001714	mania|bipolar|mania|bipolar depression|bipolar disorder|manic|hypomanic|DSM - IV bipolar I|bipolar II|manic|hypomania|mania|manic|hypomanic|bipolar I|bipolar II|manic	Disease	3:5:22:38:54:87:89:108:115:122:192:194:235:247:256:260:341	4:6:23:40:56:88:90:113:117:123:193:195:236:248:258:262:342	0:0:1:1:2:3:3:3:3:3:4:4:4:4:5:5:8	1:CID:2	R2L	NON-CROSS	235-236	219-220	D017367	serotonin reuptake inhibitors|SSRIs|SSRIs	Chemical	143:147:219	146:148:220	3:3:4	D001714	mania|bipolar|mania|bipolar depression|bipolar disorder|manic|hypomanic|DSM - IV bipolar I|bipolar II|manic|hypomania|mania|manic|hypomanic|bipolar I|bipolar II|manic	Disease	3:5:22:38:54:87:89:108:115:122:192:194:235:247:256:260:341	4:6:23:40:56:88:90:113:117:123:193:195:236:248:258:262:342	0:0:1:1:2:3:3:3:3:3:4:4:4:4:5:5:8	1:NR:2	R2L	NON-CROSS	341-342	322-323	D008094	lithium|lithium|lithium|lithium	Chemical	158:307:322:396	159:308:323:397	3:7:7:9	D001714	mania|bipolar|mania|bipolar depression|bipolar disorder|manic|hypomanic|DSM - IV bipolar I|bipolar II|manic|hypomania|mania|manic|hypomanic|bipolar I|bipolar II|manic	Disease	3:5:22:38:54:87:89:108:115:122:192:194:235:247:256:260:341	4:6:23:40:56:88:90:113:117:123:193:195:236:248:258:262:342	0:0:1:1:2:3:3:3:3:3:4:4:4:4:5:5:8
11419773	Caffeine - induced cardiac arrhythmia : an unrecognised danger of healthfood products .|We describe a 25 - year - old woman with pre - existing mitral valve prolapse who developed intractable ventricular fibrillation after consuming a " natural energy " guarana health drink containing a high concentration of caffeine .|This case highlights the need for adequate labelling and regulation of such products .	1:CID:2	L2R	NON-CROSS	32-34	49-50	D002110	Caffeine|caffeine	Chemical	0:49	1:50	0:1	D014693	ventricular fibrillation	Disease	32	34	1	not_include	L2R	NON-CROSS	0-1	3-5	D002110	Caffeine|caffeine	Chemical	0:49	1:50	0:1	D001145	cardiac arrhythmia	Disease	3	5	0	1:NR:2	L2R	NON-CROSS	26-29	49-50	D002110	Caffeine|caffeine	Chemical	0:49	1:50	0:1	D008945	mitral valve prolapse	Disease	26	29	1
11581460	Bladder retention of urine as a result of continuous intravenous infusion of fentanyl : 2 case reports .|Sedation has been commonly used in the neonate to decrease the stress and pain from the noxious stimuli and invasive procedures in the neonatal intensive care unit , as well as to facilitate synchrony between ventilator and spontaneous breaths .|Fentanyl , an opioid analgesic , is frequently used in the neonatal intensive care unit setting for these very purposes .|Various reported side effects of fentanyl administration include chest wall rigidity , hypotension , respiratory depression , and bradycardia .|Here , 2 cases of urinary bladder retention leading to renal pelvocalyceal dilatation mimicking hydronephrosis as a result of continuous infusion of fentanyl are reported .	1:CID:2	R2L	NON-CROSS	12-13	1-4	D005283	fentanyl|Fentanyl|fentanyl|fentanyl	Chemical	12:58:84:121	13:59:85:122	0:2:3:4	D016055	retention of urine	Disease	1	4	0	1:CID:2	L2R	NON-CROSS	84-85	91-92	D005283	fentanyl|Fentanyl|fentanyl|fentanyl	Chemical	12:58:84:121	13:59:85:122	0:2:3:4	D007022	hypotension	Disease	91	92	3	1:CID:2	L2R	NON-CROSS	84-85	93-95	D005283	fentanyl|Fentanyl|fentanyl|fentanyl	Chemical	12:58:84:121	13:59:85:122	0:2:3:4	D012131	respiratory depression	Disease	93	95	3	1:CID:2	L2R	NON-CROSS	84-85	97-98	D005283	fentanyl|Fentanyl|fentanyl|fentanyl	Chemical	12:58:84:121	13:59:85:122	0:2:3:4	D001919	bradycardia	Disease	97	98	3	1:CID:2	L2R	NON-CROSS	104-107	121-122	D005283	fentanyl|Fentanyl|fentanyl|fentanyl	Chemical	12:58:84:121	13:59:85:122	0:2:3:4	D001745	urinary bladder retention	Disease	104	107	4	1:NR:2	L2R	CROSS	12-13	31-32	D005283	fentanyl|Fentanyl|fentanyl|fentanyl	Chemical	12:58:84:121	13:59:85:122	0:2:3:4	D010146	pain	Disease	31	32	1	1:NR:2	L2R	NON-CROSS	84-85	87-90	D005283	fentanyl|Fentanyl|fentanyl|fentanyl	Chemical	12:58:84:121	13:59:85:122	0:2:3:4	D009127	chest wall rigidity	Disease	87	90	3	1:NR:2	L2R	NON-CROSS	113-114	121-122	D005283	fentanyl|Fentanyl|fentanyl|fentanyl	Chemical	12:58:84:121	13:59:85:122	0:2:3:4	D006869	hydronephrosis	Disease	113	114	4
11706060	Combined antiretroviral therapy causes cardiomyopathy and elevates plasma lactate in transgenic AIDS mice .|Highly active antiretroviral therapy ( HAART ) is implicated in cardiomyopathy ( CM ) and in elevated plasma lactate ( LA ) in AIDS through mechanisms of mitochondrial dysfunction .|To determine mitochondrial events from HAART in vivo , 8 - week - old hemizygous transgenic AIDS mice ( NL4 - 3Delta gag / pol ; TG ) and wild - type FVB / n littermates were treated with the HAART combination of zidovudine , lamivudine , and indinavir or vehicle control for 10 days or 35 days .|At termination of the experiments , mice underwent echocardiography , quantitation of abundance of molecular markers of CM ( ventricular mRNA encoding atrial natriuretic factor [ ANF ] and sarcoplasmic calcium ATPase [ SERCA2 ] ) , and determination of plasma LA .|Myocardial histologic features were analyzed semiquantitatively and results were confirmed by transmission electron microscopy .|After 35 days in the TG + HAART cohort , left ventricular mass increased 160 % by echocardiography .|Molecularly , ANF mRNA increased 250 % and SERCA2 mRNA decreased 57 % .|Biochemically , LA was elevated ( 8 . 5 + / - 2 . 0 mM ) .|Pathologically , granular cytoplasmic changes were found in cardiac myocytes , indicating enlarged , damaged mitochondria .|Findings were confirmed ultrastructurally .|No changes were found in other cohorts .|After 10 days , only ANF was elevated , and only in the TG + HAART cohort .|Results show that cumulative HAART caused mitochondrial CM with elevated LA in AIDS transgenic mice .	1:CID:2	R2L	CROSS	120-121	87-88	D015215	zidovudine	Chemical	87	88	2	D009202	cardiomyopathy|cardiomyopathy|CM|CM|CM	Disease	4:24:26:120:267	5:25:27:121:268	0:1:1:3:12	1:CID:2	R2L	CROSS	120-121	89-90	D019259	lamivudine	Chemical	89	90	2	D009202	cardiomyopathy|cardiomyopathy|CM|CM|CM	Disease	4:24:26:120:267	5:25:27:121:268	0:1:1:3:12	1:CID:2	R2L	CROSS	120-121	92-93	D019469	indinavir	Chemical	92	93	2	D009202	cardiomyopathy|cardiomyopathy|CM|CM|CM	Disease	4:24:26:120:267	5:25:27:121:268	0:1:1:3:12	1:NR:2	R2L	NON-CROSS	270-271	267-268	D019344	lactate|lactate|LA|LA|LA|LA	Chemical	8:32:34:144:196:270	9:33:35:145:197:271	0:1:1:3:7:12	D009202	cardiomyopathy|cardiomyopathy|CM|CM|CM	Disease	4:24:26:120:267	5:25:27:121:268	0:1:1:3:12	1:NR:2	R2L	NON-CROSS	133-134	120-121	D002118	calcium	Chemical	133	134	3	D009202	cardiomyopathy|cardiomyopathy|CM|CM|CM	Disease	4:24:26:120:267	5:25:27:121:268	0:1:1:3:12	1:NR:2	L2R	NON-CROSS	270-271	272-273	D019344	lactate|lactate|LA|LA|LA|LA	Chemical	8:32:34:144:196:270	9:33:35:145:197:271	0:1:1:3:7:12	D000163	AIDS|AIDS|AIDS|AIDS	Disease	11:37:60:272	12:38:61:273	0:1:2:12	1:NR:2	L2R	NON-CROSS	34-35	41-43	D019344	lactate|lactate|LA|LA|LA|LA	Chemical	8:32:34:144:196:270	9:33:35:145:197:271	0:1:1:3:7:12	D028361	mitochondrial dysfunction	Disease	41	43	1	1:NR:2	R2L	NON-CROSS	87-88	60-61	D015215	zidovudine	Chemical	87	88	2	D000163	AIDS|AIDS|AIDS|AIDS	Disease	11:37:60:272	12:38:61:273	0:1:2:12	1:NR:2	R2L	NON-CROSS	89-90	60-61	D019259	lamivudine	Chemical	89	90	2	D000163	AIDS|AIDS|AIDS|AIDS	Disease	11:37:60:272	12:38:61:273	0:1:2:12	1:NR:2	R2L	NON-CROSS	92-93	60-61	D019469	indinavir	Chemical	92	93	2	D000163	AIDS|AIDS|AIDS|AIDS	Disease	11:37:60:272	12:38:61:273	0:1:2:12	1:NR:2	R2L	CROSS	133-134	60-61	D002118	calcium	Chemical	133	134	3	D000163	AIDS|AIDS|AIDS|AIDS	Disease	11:37:60:272	12:38:61:273	0:1:2:12	1:NR:2	R2L	CROSS	87-88	41-43	D015215	zidovudine	Chemical	87	88	2	D028361	mitochondrial dysfunction	Disease	41	43	1	1:NR:2	R2L	CROSS	89-90	41-43	D019259	lamivudine	Chemical	89	90	2	D028361	mitochondrial dysfunction	Disease	41	43	1	1:NR:2	R2L	CROSS	92-93	41-43	D019469	indinavir	Chemical	92	93	2	D028361	mitochondrial dysfunction	Disease	41	43	1	1:NR:2	R2L	CROSS	133-134	41-43	D002118	calcium	Chemical	133	134	3	D028361	mitochondrial dysfunction	Disease	41	43	1
11752354	Oral contraceptives and the risk of myocardial infarction .|BACKGROUND : An association between the use of oral contraceptives and the risk of myocardial infarction has been found in some , but not all , studies .|We investigated this association , according to the type of progestagen included in third - generation ( i . e . , desogestrel or gestodene ) and second - generation ( i . e . , levonorgestrel ) oral contraceptives , the dose of estrogen , and the presence or absence of prothrombotic mutations METHODS : In a nationwide , population - based , case - control study , we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age , calendar year of the index event , and area of residence .|Subjects supplied information on oral - contraceptive use and major cardiovascular risk factors .|An analysis for factor V Leiden and the G20210A mutation in the prothrombin gene was conducted in 217 patients and 763 controls RESULTS : The odds ratio for myocardial infarction among women who used any type of combined oral contraceptive , as compared with nonusers , was 2 . 0 ( 95 percent confidence interval , 1 . 5 to 2 . 8 ) .|The adjusted odds ratio was 2 . 5 ( 95 percent confidence interval , 1 . 5 to 4 . 1 ) among women who used second - generation oral contraceptives and 1 . 3 ( 95 percent confidence interval , 0 . 7 to 2 . 5 ) among those who used third - generation oral contraceptives .|Among women who used oral contraceptives , the odds ratio was 2 . 1 ( 95 percent confidence interval , 1 . 5 to 3 . 0 ) for those without a prothrombotic mutation and 1 . 9 ( 95 percent confidence interval , 0 . 6 to 5 . 5 ) for those with a mutation CONCLUSIONS : The risk of myocardial infarction was increased among women who used second - generation oral contraceptives .|The results with respect to the use of third - generation oral contraceptives were inconclusive but suggested that the risk was lower than the risk associated with second - generation oral contraceptives .|The risk of myocardial infarction was similar among women who used oral contraceptives whether or not they had a prothrombotic mutation .	1:CID:2	L2R	NON-CROSS	0-2	6-8	D003276	Oral contraceptives|oral contraceptives|oral contraceptives|oral - contraceptive|oral contraceptive|oral contraceptives|oral contraceptives|oral contraceptives|oral contraceptives|oral contraceptives|oral contraceptives|oral contraceptives	Chemical	0:17:75:163:211:267:294:301:370:384:403:417	2:19:77:166:213:269:296:303:372:386:405:419	0:1:2:3:4:5:5:6:6:7:7:8	D009203	myocardial infarction|myocardial infarction|myocardial infarction|myocardial infarction|myocardial infarction|myocardial infarction|myocardial infarction	Disease	6:23:123:138:201:359:409	8:25:125:140:203:361:411	0:1:2:2:4:6:8	1:NR:2	R2L	NON-CROSS	47-48	23-25	D011372	progestagen	Chemical	47	48	2	D009203	myocardial infarction|myocardial infarction|myocardial infarction|myocardial infarction|myocardial infarction|myocardial infarction|myocardial infarction	Disease	6:23:123:138:201:359:409	8:25:125:140:203:361:411	0:1:2:2:4:6:8	1:NR:2	R2L	NON-CROSS	59-60	23-25	D017135	desogestrel	Chemical	59	60	2	D009203	myocardial infarction|myocardial infarction|myocardial infarction|myocardial infarction|myocardial infarction|myocardial infarction|myocardial infarction	Disease	6:23:123:138:201:359:409	8:25:125:140:203:361:411	0:1:2:2:4:6:8	1:NR:2	R2L	NON-CROSS	61-62	23-25	C033273	gestodene	Chemical	61	62	2	D009203	myocardial infarction|myocardial infarction|myocardial infarction|myocardial infarction|myocardial infarction|myocardial infarction|myocardial infarction	Disease	6:23:123:138:201:359:409	8:25:125:140:203:361:411	0:1:2:2:4:6:8	1:NR:2	R2L	NON-CROSS	73-74	23-25	D016912	levonorgestrel	Chemical	73	74	2	D009203	myocardial infarction|myocardial infarction|myocardial infarction|myocardial infarction|myocardial infarction|myocardial infarction|myocardial infarction	Disease	6:23:123:138:201:359:409	8:25:125:140:203:361:411	0:1:2:2:4:6:8	1:NR:2	R2L	NON-CROSS	123-125	81-82	D004967	estrogen	Chemical	81	82	2	D009203	myocardial infarction|myocardial infarction|myocardial infarction|myocardial infarction|myocardial infarction|myocardial infarction|myocardial infarction	Disease	6:23:123:138:201:359:409	8:25:125:140:203:361:411	0:1:2:2:4:6:8
12369736	Effects of 5 - HT1B receptor ligands microinjected into the accumbal shell or core on the cocaine - induced locomotor hyperactivity in rats .|The present study was designed to examine the effect of 5 - HT1B receptor ligands microinjected into the subregions of the nucleus accumbens ( the shell and the core ) on the locomotor hyperactivity induced by cocaine in rats .|Male Wistar rats were implanted bilaterally with cannulae into the accumbens shell or core , and then were locally injected with GR 55562 ( an antagonist of 5 - HT1B receptors ) or CP 93129 ( an agonist of 5 - HT1B receptors ) .|Given alone to any accumbal subregion , GR 55562 ( 0 . 1 - 10 microg / side ) or CP 93129 ( 0 . 1 - 10 microg / side ) did not change basal locomotor activity .|Systemic cocaine ( 10 mg / kg ) significantly increased the locomotor activity of rats .|GR 55562 ( 0 . 1 - 10 microg / side ) , administered intra - accumbens shell prior to cocaine , dose - dependently attenuated the psychostimulant - induced locomotor hyperactivity .|Such attenuation was not found in animals which had been injected with GR 55562 into the accumbens core .|When injected into the accumbens shell ( but not the core ) before cocaine , CP 93129 ( 0 . 1 - 10 microg / side ) enhanced the locomotor response to cocaine ; the maximum effect being observed after 10 microg / side of the agonist .|The later enhancement was attenuated after intra - accumbens shell treatment with GR 55562 ( 1 microg / side ) .|Our findings indicate that cocaine induced hyperlocomotion is modified by 5 - HT1B receptor ligands microinjected into the accumbens shell , but not core , this modification consisting in inhibitory and facilitatory effects of the 5 - HT1B receptor antagonist ( GR 55562 ) and agonist ( CP 93129 ) , respectively .|In other words , the present results suggest that the accumbal shell 5 - HT1B receptors play a permissive role in the behavioural response to the psychostimulant .	1:CID:2	L2R	NON-CROSS	289-290	291-292	D003042	cocaine|cocaine|cocaine|cocaine|cocaine|cocaine|cocaine	Chemical	16:60:149:184:229:248:289	17:61:150:185:230:249:290	0:1:4:5:7:7:9	D009069	locomotor hyperactivity|locomotor hyperactivity|locomotor hyperactivity|hyperlocomotion	Disease	19:56:194:291	21:58:196:292	0:1:5:9	1:CID:2	R2L	NON-CROSS	231-233	194-196	C065046	CP 93129|CP 93129|CP 93129|CP 93129	Chemical	97:129:231:332	99:131:233:334	2:3:7:9	D009069	locomotor hyperactivity|locomotor hyperactivity|locomotor hyperactivity|hyperlocomotion	Disease	19:56:194:291	21:58:196:292	0:1:5:9	1:NR:2	R2L	NON-CROSS	209-211	194-196	C103477	GR 55562|GR 55562|GR 55562|GR 55562|GR 55562|GR 55562	Chemical	85:116:164:209:276:326	87:118:166:211:278:328	2:3:5:6:8:9	D009069	locomotor hyperactivity|locomotor hyperactivity|locomotor hyperactivity|hyperlocomotion	Disease	19:56:194:291	21:58:196:292	0:1:5:9
12639165	Ticlopidine - induced cholestatic hepatitis .|OBJECTIVE : To report 2 cases of ticlopidine - induced cholestatic hepatitis , investigate its mechanism , and compare the observed main characteristics with those of the published cases .|CASE SUMMARIES : Two patients developed prolonged cholestatic hepatitis after receiving ticlopidine following percutaneous coronary angioplasty , with complete remission during the follow - up period .|T - cell stimulation by therapeutic concentration of ticlopidine was demonstrated in vitro in the patients , but not in healthy controls .|DISCUSSION : Cholestatic hepatitis is a rare complication of the antiplatelet agent ticlopidine ; several cases have been reported but few in the English literature .|Our patients developed jaundice following treatment with ticlopidine and showed the clinical and laboratory characteristics of cholestatic hepatitis , which resolved after discontinuation of the drug .|Hepatitis may develop weeks after discontinuation of the drug and may run a prolonged course , but complete remission was observed in all reported cases .|An objective causality assessment revealed that the adverse drug event was probably related to the use of ticlopidine .|The mechanisms of this ticlopidine - induced cholestasis are unclear .|Immune mechanisms may be involved in the drug 's hepatotoxicity , as suggested by the T - cell stimulation study reported here .|CONCLUSIONS : Cholestatic hepatitis is a rare adverse effect of ticlopidine that may be immune mediated .|Patients receiving the drug should be monitored with liver function tests along with complete blood cell counts .|This complication will be observed even less often in the future as ticlopidine is being replaced by the newer antiplatelet agent clopidogrel .	1:CID:2	L2R	NON-CROSS	0-1	3-5	D013988	Ticlopidine|ticlopidine|ticlopidine|ticlopidine|ticlopidine|ticlopidine|ticlopidine|ticlopidine|ticlopidine|ticlopidine	Chemical	0:13:47:71:98:119:182:188:228:265	1:14:48:72:99:120:183:189:229:266	0:1:2:3:4:5:7:8:10:12	D002779	cholestatic hepatitis|cholestatic hepatitis|cholestatic hepatitis|Cholestatic hepatitis|cholestatic hepatitis|cholestasis|Cholestatic hepatitis	Disease	3:16:43:88:128:191:220	5:18:45:90:130:192:222	0:1:2:4:5:8:10	1:CID:2	L2R	NON-CROSS	0-1	3-5	D013988	Ticlopidine|ticlopidine|ticlopidine|ticlopidine|ticlopidine|ticlopidine|ticlopidine|ticlopidine|ticlopidine|ticlopidine	Chemical	0:13:47:71:98:119:182:188:228:265	1:14:48:72:99:120:183:189:229:266	0:1:2:3:4:5:7:8:10:12	D056486	cholestatic hepatitis|cholestatic hepatitis|cholestatic hepatitis|Cholestatic hepatitis|cholestatic hepatitis|Hepatitis|hepatotoxicity|Cholestatic hepatitis	Disease	3:16:43:88:128:139:204:220	5:18:45:90:130:140:205:222	0:1:2:4:5:6:9:10	1:CID:2	L2R	NON-CROSS	115-116	119-120	D013988	Ticlopidine|ticlopidine|ticlopidine|ticlopidine|ticlopidine|ticlopidine|ticlopidine|ticlopidine|ticlopidine|ticlopidine	Chemical	0:13:47:71:98:119:182:188:228:265	1:14:48:72:99:120:183:189:229:266	0:1:2:3:4:5:7:8:10:12	D007565	jaundice	Disease	115	116	5	1:NR:2	R2L	CROSS	274-275	220-222	C055162	clopidogrel	Chemical	274	275	12	D002779	cholestatic hepatitis|cholestatic hepatitis|cholestatic hepatitis|Cholestatic hepatitis|cholestatic hepatitis|cholestasis|Cholestatic hepatitis	Disease	3:16:43:88:128:191:220	5:18:45:90:130:192:222	0:1:2:4:5:8:10	1:NR:2	R2L	CROSS	274-275	220-222	C055162	clopidogrel	Chemical	274	275	12	D056486	cholestatic hepatitis|cholestatic hepatitis|cholestatic hepatitis|Cholestatic hepatitis|cholestatic hepatitis|Hepatitis|hepatotoxicity|Cholestatic hepatitis	Disease	3:16:43:88:128:139:204:220	5:18:45:90:130:140:205:222	0:1:2:4:5:6:9:10	1:NR:2	R2L	CROSS	274-275	115-116	C055162	clopidogrel	Chemical	274	275	12	D007565	jaundice	Disease	115	116	5
12653683	Epithelial sodium channel ( ENaC ) subunit mRNA and protein expression in rats with puromycin aminonucleoside - induced nephrotic syndrome .|In experimental nephrotic syndrome , urinary sodium excretion is decreased during the early phase of the disease .|The molecular mechanism ( s ) leading to salt retention has not been completely elucidated .|The rate - limiting constituent of collecting duct sodium transport is the epithelial sodium channel ( ENaC ) .|We examined the abundance of ENaC subunit mRNAs and proteins in puromycin aminonucleoside ( PAN ) - induced nephrotic syndrome .|The time courses of urinary sodium excretion , plasma aldosterone concentration and proteinuria were studied in male Sprague - Dawley rats treated with a single dose of either PAN or vehicle .|The relative amounts of alphaENaC , betaENaC and gammaENaC mRNAs were determined in kidneys from these rats by real - time quantitative TaqMan PCR , and the amounts of proteins by Western blot .|The kinetics of urinary sodium excretion and the appearance of proteinuria were comparable with those reported previously .|Sodium retention occurred on days 2 , 3 and 6 after PAN injection .|A significant up - regulation of alphaENaC and betaENaC mRNA abundance on days 1 and 2 preceded sodium retention on days 2 and 3 .|Conversely , down - regulation of alphaENaC , betaENaC and gammaENaC mRNA expression on day 3 occurred in the presence of high aldosterone concentrations , and was followed by a return of sodium excretion to control values .|The amounts of alphaENaC , betaENaC and gammaENaC proteins were not increased during PAN - induced sodium retention .|In conclusion , ENaC mRNA expression , especially alphaENaC , is increased in the very early phase of the experimental model of PAN - induced nephrotic syndrome in rats , but appears to escape from the regulation by aldosterone after day 3 .	1:CID:2	L2R	NON-CROSS	14-16	18-20	D011692	puromycin aminonucleoside|puromycin aminonucleoside|PAN|PAN|PAN|PAN|PAN	Chemical	14:85:88:123:190:269:297	16:87:89:124:191:270:298	0:4:4:5:8:11:12	D009404	nephrotic syndrome|nephrotic syndrome|nephrotic syndrome|nephrotic syndrome	Disease	18:23:92:300	20:25:94:302	0:1:4:12	1:CID:2	L2R	NON-CROSS	107-108	123-124	D011692	puromycin aminonucleoside|puromycin aminonucleoside|PAN|PAN|PAN|PAN|PAN	Chemical	14:85:88:123:190:269:297	16:87:89:124:191:270:298	0:4:4:5:8:11:12	D011507	proteinuria|proteinuria	Disease	107:171	108:172	5:7	1:NR:2	L2R	NON-CROSS	23-25	27-28	D012964	sodium|sodium|sodium|sodium|sodium|sodium|Sodium|sodium|sodium|sodium	Chemical	1:27:63:68:100:165:179:210:250:272	2:28:64:69:101:166:180:211:251:273	0:1:3:3:5:7:8:9:10:11	D009404	nephrotic syndrome|nephrotic syndrome|nephrotic syndrome|nephrotic syndrome	Disease	18:23:92:300	20:25:94:302	0:1:4:12	1:NR:2	L2R	NON-CROSS	165-166	171-172	D012964	sodium|sodium|sodium|sodium|sodium|sodium|Sodium|sodium|sodium|sodium	Chemical	1:27:63:68:100:165:179:210:250:272	2:28:64:69:101:166:180:211:251:273	0:1:3:3:5:7:8:9:10:11	D011507	proteinuria|proteinuria	Disease	107:171	108:172	5:7	1:NR:2	R2L	NON-CROSS	104-105	92-94	D000450	aldosterone|aldosterone|aldosterone	Chemical	104:240:313	105:241:314	5:10:12	D009404	nephrotic syndrome|nephrotic syndrome|nephrotic syndrome|nephrotic syndrome	Disease	18:23:92:300	20:25:94:302	0:1:4:12	1:NR:2	L2R	NON-CROSS	104-105	107-108	D000450	aldosterone|aldosterone|aldosterone	Chemical	104:240:313	105:241:314	5:10:12	D011507	proteinuria|proteinuria	Disease	107:171	108:172	5:7
14659530	NO - induced migraine attack : strong increase in plasma calcitonin gene - related peptide ( CGRP ) concentration and negative correlation with platelet serotonin release .|The aim of the present study was to investigate changes in the plasma calcitonin gene - related peptide ( CGRP ) concentration and platelet serotonin ( 5 - hydroxytriptamine , 5 - HT ) content during the immediate headache and the delayed genuine migraine attack provoked by nitroglycerin .|Fifteen female migraineurs ( without aura ) and eight controls participated in the study .|Sublingual nitroglycerin ( 0 . 5 mg ) was administered .|Blood was collected from the antecubital vein four times : 60 min before and after the nitroglycerin application , and 60 and 120 min after the beginning of the migraine attack ( mean 344 and 404 min ; 12 subjects ) .|In those subjects who had no migraine attack ( 11 subjects ) a similar time schedule was used .|Plasma CGRP concentration increased significantly ( P < 0 . 01 ) during the migraine attack and returned to baseline after the cessation of the migraine .|In addition , both change and peak , showed significant positive correlations with migraine headache intensity ( P < 0 . 001 ) .|However , plasma CGRP concentrations failed to change during immediate headache and in the subjects with no migraine attack .|Basal CGRP concentration was significantly higher and platelet 5 - HT content tended to be lower in subjects who experienced a migraine attack .|Platelet serotonin content decreased significantly ( P < 0 . 01 ) after nitroglycerin in subjects with no migraine attack but no consistent change was observed in patients with migraine attack .|In conclusion , the fact that plasma CGRP concentration correlates with the timing and severity of a migraine headache suggests a direct relationship between CGRP and migraine .|In contrast , serotonin release from platelets does not provoke migraine , it may even counteract the headache and the concomitant CGRP release in this model .	1:CID:2	L2R	CROSS	0-1	78-83	D009569	NO	Chemical	0	1	0	D020326	migraineurs ( without aura )	Disease	78	83	2	1:CID:2	L2R	CROSS	74-75	78-83	D005996	nitroglycerin|nitroglycerin|nitroglycerin|nitroglycerin	Chemical	74:92:118:271	75:93:119:272	1:3:4:10	D020326	migraineurs ( without aura )	Disease	78	83	2	not_include	L2R	NON-CROSS	0-1	3-4	D009569	NO	Chemical	0	1	0	D008881	migraine|migraine|migraine|migraine|migraine|migraine|migraine|migraine|migraine|migraine|migraine|migraine|migraine|migraine	Disease	3:70:131:150:177:188:203:231:255:276:287:307:316:328	4:71:132:151:178:189:204:232:256:277:288:308:317:329	0:1:4:5:6:6:7:8:9:10:10:11:11:12	1:NR:2	L2R	CROSS	0-1	65-66	D009569	NO	Chemical	0	1	0	D006261	headache|headache|headache|headache|headache	Disease	65:204:224:308:335	66:205:225:309:336	1:7:8:11:12	1:NR:2	R2L	NON-CROSS	316-317	314-315	D015740	calcitonin gene - related peptide|CGRP|calcitonin gene - related peptide|CGRP|CGRP|CGRP|CGRP|CGRP|CGRP|CGRP	Chemical	10:16:40:46:164:217:235:297:314:339	15:17:45:47:165:218:236:298:315:340	0:0:1:1:6:8:9:11:11:12	D008881	migraine|migraine|migraine|migraine|migraine|migraine|migraine|migraine|migraine|migraine|migraine|migraine|migraine|migraine	Disease	3:70:131:150:177:188:203:231:255:276:287:307:316:328	4:71:132:151:178:189:204:232:256:277:288:308:317:329	0:1:4:5:6:6:7:8:9:10:10:11:11:12	1:NR:2	R2L	NON-CROSS	259-260	255-256	D012701	serotonin|serotonin|5 - hydroxytriptamine|5 - HT|5 - HT|serotonin|serotonin	Chemical	24:51:53:57:242:259:321	25:52:56:60:245:260:322	0:1:1:1:9:10:12	D008881	migraine|migraine|migraine|migraine|migraine|migraine|migraine|migraine|migraine|migraine|migraine|migraine|migraine|migraine	Disease	3:70:131:150:177:188:203:231:255:276:287:307:316:328	4:71:132:151:178:189:204:232:256:277:288:308:317:329	0:1:4:5:6:6:7:8:9:10:10:11:11:12	not_include	R2L	NON-CROSS	74-75	70-71	D005996	nitroglycerin|nitroglycerin|nitroglycerin|nitroglycerin	Chemical	74:92:118:271	75:93:119:272	1:3:4:10	D008881	migraine|migraine|migraine|migraine|migraine|migraine|migraine|migraine|migraine|migraine|migraine|migraine|migraine|migraine	Disease	3:70:131:150:177:188:203:231:255:276:287:307:316:328	4:71:132:151:178:189:204:232:256:277:288:308:317:329	0:1:4:5:6:6:7:8:9:10:10:11:11:12	1:NR:2	L2R	NON-CROSS	335-336	339-340	D015740	calcitonin gene - related peptide|CGRP|calcitonin gene - related peptide|CGRP|CGRP|CGRP|CGRP|CGRP|CGRP|CGRP	Chemical	10:16:40:46:164:217:235:297:314:339	15:17:45:47:165:218:236:298:315:340	0:0:1:1:6:8:9:11:11:12	D006261	headache|headache|headache|headache|headache	Disease	65:204:224:308:335	66:205:225:309:336	1:7:8:11:12	1:NR:2	L2R	CROSS	46-47	78-83	D015740	calcitonin gene - related peptide|CGRP|calcitonin gene - related peptide|CGRP|CGRP|CGRP|CGRP|CGRP|CGRP|CGRP	Chemical	10:16:40:46:164:217:235:297:314:339	15:17:45:47:165:218:236:298:315:340	0:0:1:1:6:8:9:11:11:12	D020326	migraineurs ( without aura )	Disease	78	83	2	1:NR:2	L2R	NON-CROSS	57-60	65-66	D012701	serotonin|serotonin|5 - hydroxytriptamine|5 - HT|5 - HT|serotonin|serotonin	Chemical	24:51:53:57:242:259:321	25:52:56:60:245:260:322	0:1:1:1:9:10:12	D006261	headache|headache|headache|headache|headache	Disease	65:204:224:308:335	66:205:225:309:336	1:7:8:11:12	1:NR:2	L2R	CROSS	57-60	78-83	D012701	serotonin|serotonin|5 - hydroxytriptamine|5 - HT|5 - HT|serotonin|serotonin	Chemical	24:51:53:57:242:259:321	25:52:56:60:245:260:322	0:1:1:1:9:10:12	D020326	migraineurs ( without aura )	Disease	78	83	2	1:NR:2	R2L	NON-CROSS	74-75	65-66	D005996	nitroglycerin|nitroglycerin|nitroglycerin|nitroglycerin	Chemical	74:92:118:271	75:93:119:272	1:3:4:10	D006261	headache|headache|headache|headache|headache	Disease	65:204:224:308:335	66:205:225:309:336	1:7:8:11:12
15804801	Coronary aneurysm after implantation of a paclitaxel - eluting stent .|Formation of coronary aneurysm is a rare complication of stenting with bare metal stents , but based on experimental studies drug - eluting stents may induce toxic effects on the vessel wall with incomplete stent apposition , aneurysm formation and with the potential of stent thrombosis or vessel rupture .|We present a 43 - year - old man who developed a coronary aneurysm in the right coronary artery 6 months after receiving a paclitaxel - eluting stent .|The patient was asymptomatic and the aneurysm was detected in a routine control .|Angiography and intracoronary ultrasound demonstrated lack of contact between stent and vessel wall in a 15 - mm long segment with maximal aneurysm diameter of 6 . 0 mm .|The patient was successfully treated with a graft stent .	1:CID:2	R2L	NON-CROSS	6-7	0-2	D017239	paclitaxel|paclitaxel	Chemical	6:85	7:86	0:2	D003323	Coronary aneurysm|coronary aneurysm|coronary aneurysm	Disease	0:13:73	2:15:75	0:1:2	not_include	L2R	CROSS	85-86	96-97	D017239	paclitaxel|paclitaxel	Chemical	6:85	7:86	0:2	D000783	aneurysm|aneurysm|aneurysm	Disease	48:96:126	49:97:127	1:3:4	1:NR:2	L2R	CROSS	56-57	85-86	D017239	paclitaxel|paclitaxel	Chemical	6:85	7:86	0:2	D013927	thrombosis	Disease	56	57	1
16160878	Behavioral effects of urotensin - II centrally administered in mice .|Urotensin - II ( U - II ) receptors are widely distributed in the central nervous system .|Intracerebroventricular ( i . c . v . ) injection of U - II causes hypertension and bradycardia and stimulates prolactin and thyrotropin secretion .|However , the behavioral effects of centrally administered U - II have received little attention .|In the present study , we tested the effects of i . c . v .|injections of U - II on behavioral , metabolic , and endocrine responses in mice .|Administration of graded doses of U - II ( 1 - 10 , 000 ng / mouse ) provoked : ( 1 ) a dose - dependent reduction in the number of head dips in the hole - board test ; ( 2 ) a dose - dependent reduction in the number of entries in the white chamber in the black - and - white compartment test , and in the number of entries in the central platform and open arms in the plus - maze test ; and ( 3 ) a dose - dependent increase in the duration of immobility in the forced - swimming test and tail suspension test .|Intracerebroventricular injection of U - II also caused an increase in : food intake at doses of 100 and 1 , 000 ng / mouse , water intake at doses of 100 - 10 , 000 ng / mouse , and horizontal locomotion activity at a dose of 10 , 000 ng / mouse .|Whatever was the dose , the central administration of U - II had no effect on body temperature , nociception , apomorphine - induced penile erection and climbing behavior , and stress - induced plasma corticosterone level .|Taken together , the present study demonstrates that the central injection of U - II at doses of 1 - 10 , 000 ng / mouse induces anxiogenic - and depressant - like effects in mouse .|These data suggest that U - II may be involved in some aspects of psychiatric disorders .	1:CID:2	L2R	NON-CROSS	291-292	294-296	D001058	apomorphine	Chemical	291	292	8	D010409	penile erection	Disease	294	296	8	1:NR:2	L2R	NON-CROSS	40-43	44-45	D014579	urotensin - II|Urotensin - II|U - II|U - II|U - II|U - II|U - II|U - II|U - II|U - II|U - II	Chemical	3:11:15:40:62:88:107:218:279:320:349	6:14:18:43:65:91:110:221:282:323:352	0:1:1:2:3:5:6:7:8:9:10	D006973	hypertension	Disease	44	45	2	1:NR:2	L2R	NON-CROSS	40-43	46-47	D014579	urotensin - II|Urotensin - II|U - II|U - II|U - II|U - II|U - II|U - II|U - II|U - II|U - II	Chemical	3:11:15:40:62:88:107:218:279:320:349	6:14:18:43:65:91:110:221:282:323:352	0:1:1:2:3:5:6:7:8:9:10	D001919	bradycardia	Disease	46	47	2	1:NR:2	L2R	NON-CROSS	279-282	294-296	D014579	urotensin - II|Urotensin - II|U - II|U - II|U - II|U - II|U - II|U - II|U - II|U - II|U - II	Chemical	3:11:15:40:62:88:107:218:279:320:349	6:14:18:43:65:91:110:221:282:323:352	0:1:1:2:3:5:6:7:8:9:10	D010409	penile erection	Disease	294	296	8	1:NR:2	L2R	NON-CROSS	349-352	359-361	D014579	urotensin - II|Urotensin - II|U - II|U - II|U - II|U - II|U - II|U - II|U - II|U - II|U - II	Chemical	3:11:15:40:62:88:107:218:279:320:349	6:14:18:43:65:91:110:221:282:323:352	0:1:1:2:3:5:6:7:8:9:10	D001523	psychiatric disorders	Disease	359	361	10	1:NR:2	R2L	CROSS	291-292	44-45	D001058	apomorphine	Chemical	291	292	8	D006973	hypertension	Disease	44	45	2	1:NR:2	R2L	CROSS	305-306	44-45	D003345	corticosterone	Chemical	305	306	8	D006973	hypertension	Disease	44	45	2	1:NR:2	R2L	CROSS	291-292	46-47	D001058	apomorphine	Chemical	291	292	8	D001919	bradycardia	Disease	46	47	2	1:NR:2	R2L	CROSS	305-306	46-47	D003345	corticosterone	Chemical	305	306	8	D001919	bradycardia	Disease	46	47	2	1:NR:2	L2R	CROSS	291-292	359-361	D001058	apomorphine	Chemical	291	292	8	D001523	psychiatric disorders	Disease	359	361	10	1:NR:2	R2L	NON-CROSS	305-306	294-296	D003345	corticosterone	Chemical	305	306	8	D010409	penile erection	Disease	294	296	8	1:NR:2	L2R	CROSS	305-306	359-361	D003345	corticosterone	Chemical	305	306	8	D001523	psychiatric disorders	Disease	359	361	10
16274958	Recurrent dysphonia and acitretin .|We report the case of a woman complaining of dysphonia while she was treated by acitretin .|Her symptoms totally regressed after drug withdrawal and reappeared when acitretin was reintroduced .|To our knowledge , this is the first case of acitretin - induced dysphonia .|This effect may be related to the pharmacological effect of this drug on mucous membranes .	1:CID:2	R2L	NON-CROSS	3-4	1-2	D017255	acitretin|acitretin|acitretin|acitretin	Chemical	3:20:32:46	4:21:33:47	0:1:2:3	D055154	dysphonia|dysphonia|dysphonia	Disease	1:14:49	2:15:50	0:1:3
16330766	Pharmacological modulation of pain - related brain activity during normal and central sensitization states in humans .|Abnormal processing of somatosensory inputs in the central nervous system ( central sensitization ) is the mechanism accounting for the enhanced pain sensitivity in the skin surrounding tissue injury ( secondary hyperalgesia ) .|Secondary hyperalgesia shares clinical characteristics with neurogenic hyperalgesia in patients with neuropathic pain .|Abnormal brain responses to somatosensory stimuli have been found in patients with hyperalgesia as well as in normal subjects during experimental central sensitization .|The aim of this study was to assess the effects of gabapentin , a drug effective in neuropathic pain patients , on brain processing of nociceptive information in normal and central sensitization states .|Using functional magnetic resonance imaging ( fMRI ) in normal volunteers , we studied the gabapentin - induced modulation of brain activity in response to nociceptive mechanical stimulation of normal skin and capsaicin - induced secondary hyperalgesia .|The dose of gabapentin was 1 , 800 mg per os , in a single administration .|We found that ( i ) gabapentin reduced the activations in the bilateral operculoinsular cortex , independently of the presence of central sensitization ; ( ii ) gabapentin reduced the activation in the brainstem , only during central sensitization ; ( iii ) gabapentin suppressed stimulus - induced deactivations , only during central sensitization ; this effect was more robust than the effect on brain activation .|The observed drug - induced effects were not due to changes in the baseline fMRI signal .|These findings indicate that gabapentin has a measurable antinociceptive effect and a stronger antihyperalgesic effect most evident in the brain areas undergoing deactivation , thus supporting the concept that gabapentin is more effective in modulating nociceptive transmission when central sensitization is present .	1:CID:2	R2L	NON-CROSS	158-160	155-156	D002211	capsaicin	Chemical	155	156	5	D006930	secondary hyperalgesia|Secondary hyperalgesia|neurogenic hyperalgesia|hyperalgesia|secondary hyperalgesia	Disease	47:51:57:77:158	49:53:59:78:160	1:2:2:3:5	1:NR:2	R2L	CROSS	100-101	38-39	C040029	gabapentin|gabapentin|gabapentin|gabapentin|gabapentin|gabapentin|gabapentin|gabapentin	Chemical	100:138:164:184:205:221:266:291	101:139:165:185:206:222:267:292	4:5:6:7:7:7:9:9	D010146	pain|pain	Disease	3:38	4:39	0:1	1:NR:2	R2L	CROSS	155-156	38-39	D002211	capsaicin	Chemical	155	156	5	D010146	pain|pain	Disease	3:38	4:39	0:1	1:NR:2	R2L	CROSS	100-101	44-46	C040029	gabapentin|gabapentin|gabapentin|gabapentin|gabapentin|gabapentin|gabapentin|gabapentin	Chemical	100:138:164:184:205:221:266:291	101:139:165:185:206:222:267:292	4:5:6:7:7:7:9:9	D017695	tissue injury	Disease	44	46	1	1:NR:2	R2L	CROSS	155-156	44-46	D002211	capsaicin	Chemical	155	156	5	D017695	tissue injury	Disease	44	46	1	1:NR:2	R2L	NON-CROSS	164-165	158-160	C040029	gabapentin|gabapentin|gabapentin|gabapentin|gabapentin|gabapentin|gabapentin|gabapentin	Chemical	100:138:164:184:205:221:266:291	101:139:165:185:206:222:267:292	4:5:6:7:7:7:9:9	D006930	secondary hyperalgesia|Secondary hyperalgesia|neurogenic hyperalgesia|hyperalgesia|secondary hyperalgesia	Disease	47:51:57:77:158	49:53:59:78:160	1:2:2:3:5	1:NR:2	R2L	NON-CROSS	106-108	100-101	C040029	gabapentin|gabapentin|gabapentin|gabapentin|gabapentin|gabapentin|gabapentin|gabapentin	Chemical	100:138:164:184:205:221:266:291	101:139:165:185:206:222:267:292	4:5:6:7:7:7:9:9	D009437	neuropathic pain|neuropathic pain	Disease	62:106	64:108	2:4	1:NR:2	R2L	CROSS	155-156	106-108	D002211	capsaicin	Chemical	155	156	5	D009437	neuropathic pain|neuropathic pain	Disease	62:106	64:108	2:4
16574712	MDMA polydrug users show process - specific central executive impairments coupled with impaired social and emotional judgement processes .|In recent years working memory deficits have been reported in users of MDMA ( 3 , 4 - methylenedioxymethamphetamine , ecstasy ) .|The current study aimed to assess the impact of MDMA use on three separate central executive processes ( set shifting , inhibition and memory updating ) and also on " prefrontal " mediated social and emotional judgement processes .|Fifteen polydrug ecstasy users and 15 polydrug non - ecstasy user controls completed a general drug use questionnaire , the Brixton Spatial Anticipation task ( set shifting ) , Backward Digit Span procedure ( memory updating ) , Inhibition of Return ( inhibition ) , an emotional intelligence scale , the Tromso Social Intelligence Scale and the Dysexecutive Questionnaire ( DEX ) .|Compared with MDMA - free polydrug controls , MDMA polydrug users showed impairments in set shifting and memory updating , and also in social and emotional judgement processes .|The latter two deficits remained significant after controlling for other drug use .|These data lend further support to the proposal that cognitive processes mediated by the prefrontal cortex may be impaired by recreational ecstasy use .	1:CID:2	L2R	NON-CROSS	0-1	12-18	D018817	MDMA|MDMA|3 , 4 - methylenedioxymethamphetamine|ecstasy|MDMA|ecstasy|ecstasy|MDMA|MDMA|ecstasy	Chemical	0:31:33:39:51:83:90:146:152:207	1:32:38:40:52:84:91:147:153:208	0:1:1:1:2:3:3:4:4:6	D003072	impaired social and emotional judgement processes	Disease	12	18	0	1:NR:2	L2R	NON-CROSS	23-25	31-32	D018817	MDMA|MDMA|3 , 4 - methylenedioxymethamphetamine|ecstasy|MDMA|ecstasy|ecstasy|MDMA|MDMA|ecstasy	Chemical	0:31:33:39:51:83:90:146:152:207	1:32:38:40:52:84:91:147:153:208	0:1:1:1:2:3:3:4:4:6	D008569	memory deficits	Disease	23	25	1
17111419	Severe citrate toxicity complicating volunteer apheresis platelet donation .|We report a case of severe citrate toxicity during volunteer donor apheresis platelet collection .|The donor was a 40 - year - old female , first - time apheresis platelet donor .|Past medical history was remarkable for hypertension , hyperlipidemia , and depression .|Reported medications included bumetanide , pravastatin , and paroxetine .|Thirty minutes from the start of the procedure , the donor noted tingling around the mouth , hands , and feet .|She then very rapidly developed acute onset of severe facial and extremity tetany .|Empirical treatment with intravenous calcium gluconate was initiated , and muscle contractions slowly subsided over approximately 10 to 15 minutes .|The events are consistent with a severe reaction to calcium chelation by sodium citrate anticoagulant resulting in symptomatic systemic hypocalcemia .|Upon additional retrospective analysis , it was noted that bumetanide is a loop diuretic that may cause significant hypocalcemia .|We conclude that careful screening for medications and underlying conditions predisposing to hypocalcemia is recommended to help prevent severe reactions due to citrate toxicity .|Laboratory measurement of pre - procedure serum calcium levels in selected donors may identify cases requiring heightened vigilance .|The case also illustrates the importance of maintaining preparedness for managing rare but serious reactions in volunteer apheresis blood donors .	1:CID:2	L2R	NON-CROSS	134-136	141-142	C102006	citrate|citrate|sodium citrate|citrate	Chemical	1:15:134:185	2:16:136:186	0:1:8:10	D006996	hypocalcemia|hypocalcemia|hypocalcemia	Disease	141:161:175	142:162:176	8:9:10	1:NR:2	L2R	NON-CROSS	1-2	2-3	C102006	citrate|citrate|sodium citrate|citrate	Chemical	1:15:134:185	2:16:136:186	0:1:8:10	D064420	toxicity|toxicity|toxicity	Disease	2:16:186	3:17:187	0:1:10	1:NR:2	L2R	CROSS	15-16	48-49	C102006	citrate|citrate|sodium citrate|citrate	Chemical	1:15:134:185	2:16:136:186	0:1:8:10	D006973	hypertension	Disease	48	49	3	1:NR:2	L2R	CROSS	15-16	50-51	C102006	citrate|citrate|sodium citrate|citrate	Chemical	1:15:134:185	2:16:136:186	0:1:8:10	D006949	hyperlipidemia	Disease	50	51	3	1:NR:2	L2R	CROSS	15-16	53-54	C102006	citrate|citrate|sodium citrate|citrate	Chemical	1:15:134:185	2:16:136:186	0:1:8:10	D003866	depression	Disease	53	54	3	1:NR:2	L2R	CROSS	99-100	134-136	C102006	citrate|citrate|sodium citrate|citrate	Chemical	1:15:134:185	2:16:136:186	0:1:8:10	D013746	tetany	Disease	99	100	6	1:NR:2	L2R	CROSS	111-113	134-136	C102006	citrate|citrate|sodium citrate|citrate	Chemical	1:15:134:185	2:16:136:186	0:1:8:10	C536214	muscle contractions	Disease	111	113	7	1:NR:2	R2L	CROSS	186-187	152-153	D002034	bumetanide|bumetanide	Chemical	58:152	59:153	4:9	D064420	toxicity|toxicity|toxicity	Disease	2:16:186	3:17:187	0:1:10	1:NR:2	R2L	CROSS	60-61	16-17	D017035	pravastatin	Chemical	60	61	4	D064420	toxicity|toxicity|toxicity	Disease	2:16:186	3:17:187	0:1:10	1:NR:2	R2L	CROSS	63-64	16-17	D017374	paroxetine	Chemical	63	64	4	D064420	toxicity|toxicity|toxicity	Disease	2:16:186	3:17:187	0:1:10	1:NR:2	R2L	CROSS	186-187	105-107	D002125	calcium gluconate	Chemical	105	107	7	D064420	toxicity|toxicity|toxicity	Disease	2:16:186	3:17:187	0:1:10	1:NR:2	R2L	CROSS	195-196	186-187	D002118	calcium|calcium	Chemical	131:195	132:196	8:11	D064420	toxicity|toxicity|toxicity	Disease	2:16:186	3:17:187	0:1:10	1:NR:2	R2L	CROSS	186-187	155-157	D049994	loop diuretic	Chemical	155	157	9	D064420	toxicity|toxicity|toxicity	Disease	2:16:186	3:17:187	0:1:10	1:NR:2	R2L	CROSS	58-59	48-49	D002034	bumetanide|bumetanide	Chemical	58:152	59:153	4:9	D006973	hypertension	Disease	48	49	3	1:NR:2	R2L	CROSS	60-61	48-49	D017035	pravastatin	Chemical	60	61	4	D006973	hypertension	Disease	48	49	3	1:NR:2	R2L	CROSS	63-64	48-49	D017374	paroxetine	Chemical	63	64	4	D006973	hypertension	Disease	48	49	3	1:NR:2	R2L	CROSS	105-107	48-49	D002125	calcium gluconate	Chemical	105	107	7	D006973	hypertension	Disease	48	49	3	1:NR:2	R2L	CROSS	131-132	48-49	D002118	calcium|calcium	Chemical	131:195	132:196	8:11	D006973	hypertension	Disease	48	49	3	1:NR:2	R2L	CROSS	155-157	48-49	D049994	loop diuretic	Chemical	155	157	9	D006973	hypertension	Disease	48	49	3	1:NR:2	R2L	CROSS	58-59	50-51	D002034	bumetanide|bumetanide	Chemical	58:152	59:153	4:9	D006949	hyperlipidemia	Disease	50	51	3	1:NR:2	R2L	CROSS	60-61	50-51	D017035	pravastatin	Chemical	60	61	4	D006949	hyperlipidemia	Disease	50	51	3	1:NR:2	R2L	CROSS	63-64	50-51	D017374	paroxetine	Chemical	63	64	4	D006949	hyperlipidemia	Disease	50	51	3	1:NR:2	R2L	CROSS	105-107	50-51	D002125	calcium gluconate	Chemical	105	107	7	D006949	hyperlipidemia	Disease	50	51	3	1:NR:2	R2L	CROSS	131-132	50-51	D002118	calcium|calcium	Chemical	131:195	132:196	8:11	D006949	hyperlipidemia	Disease	50	51	3	1:NR:2	R2L	CROSS	155-157	50-51	D049994	loop diuretic	Chemical	155	157	9	D006949	hyperlipidemia	Disease	50	51	3	1:NR:2	R2L	CROSS	58-59	53-54	D002034	bumetanide|bumetanide	Chemical	58:152	59:153	4:9	D003866	depression	Disease	53	54	3	1:NR:2	R2L	CROSS	60-61	53-54	D017035	pravastatin	Chemical	60	61	4	D003866	depression	Disease	53	54	3	1:NR:2	R2L	CROSS	63-64	53-54	D017374	paroxetine	Chemical	63	64	4	D003866	depression	Disease	53	54	3	1:NR:2	R2L	CROSS	105-107	53-54	D002125	calcium gluconate	Chemical	105	107	7	D003866	depression	Disease	53	54	3	1:NR:2	R2L	CROSS	131-132	53-54	D002118	calcium|calcium	Chemical	131:195	132:196	8:11	D003866	depression	Disease	53	54	3	1:NR:2	R2L	CROSS	155-157	53-54	D049994	loop diuretic	Chemical	155	157	9	D003866	depression	Disease	53	54	3	1:NR:2	L2R	CROSS	58-59	99-100	D002034	bumetanide|bumetanide	Chemical	58:152	59:153	4:9	D013746	tetany	Disease	99	100	6	1:NR:2	L2R	CROSS	111-113	152-153	D002034	bumetanide|bumetanide	Chemical	58:152	59:153	4:9	C536214	muscle contractions	Disease	111	113	7	1:NR:2	L2R	NON-CROSS	152-153	161-162	D002034	bumetanide|bumetanide	Chemical	58:152	59:153	4:9	D006996	hypocalcemia|hypocalcemia|hypocalcemia	Disease	141:161:175	142:162:176	8:9:10	1:NR:2	L2R	CROSS	60-61	99-100	D017035	pravastatin	Chemical	60	61	4	D013746	tetany	Disease	99	100	6	1:NR:2	L2R	CROSS	60-61	111-113	D017035	pravastatin	Chemical	60	61	4	C536214	muscle contractions	Disease	111	113	7	1:NR:2	L2R	CROSS	60-61	141-142	D017035	pravastatin	Chemical	60	61	4	D006996	hypocalcemia|hypocalcemia|hypocalcemia	Disease	141:161:175	142:162:176	8:9:10	1:NR:2	L2R	CROSS	63-64	99-100	D017374	paroxetine	Chemical	63	64	4	D013746	tetany	Disease	99	100	6	1:NR:2	L2R	CROSS	63-64	111-113	D017374	paroxetine	Chemical	63	64	4	C536214	muscle contractions	Disease	111	113	7	1:NR:2	L2R	CROSS	63-64	141-142	D017374	paroxetine	Chemical	63	64	4	D006996	hypocalcemia|hypocalcemia|hypocalcemia	Disease	141:161:175	142:162:176	8:9:10	1:NR:2	R2L	CROSS	105-107	99-100	D002125	calcium gluconate	Chemical	105	107	7	D013746	tetany	Disease	99	100	6	1:NR:2	R2L	CROSS	131-132	99-100	D002118	calcium|calcium	Chemical	131:195	132:196	8:11	D013746	tetany	Disease	99	100	6	1:NR:2	R2L	CROSS	155-157	99-100	D049994	loop diuretic	Chemical	155	157	9	D013746	tetany	Disease	99	100	6	1:NR:2	L2R	NON-CROSS	105-107	111-113	D002125	calcium gluconate	Chemical	105	107	7	C536214	muscle contractions	Disease	111	113	7	1:NR:2	L2R	CROSS	105-107	141-142	D002125	calcium gluconate	Chemical	105	107	7	D006996	hypocalcemia|hypocalcemia|hypocalcemia	Disease	141:161:175	142:162:176	8:9:10	1:NR:2	R2L	CROSS	131-132	111-113	D002118	calcium|calcium	Chemical	131:195	132:196	8:11	C536214	muscle contractions	Disease	111	113	7	1:NR:2	R2L	CROSS	155-157	111-113	D049994	loop diuretic	Chemical	155	157	9	C536214	muscle contractions	Disease	111	113	7	1:NR:2	L2R	NON-CROSS	131-132	141-142	D002118	calcium|calcium	Chemical	131:195	132:196	8:11	D006996	hypocalcemia|hypocalcemia|hypocalcemia	Disease	141:161:175	142:162:176	8:9:10	1:NR:2	R2L	NON-CROSS	161-162	155-157	D049994	loop diuretic	Chemical	155	157	9	D006996	hypocalcemia|hypocalcemia|hypocalcemia	Disease	141:161:175	142:162:176	8:9:10
17175308	Proteinuria after conversion to sirolimus in renal transplant recipients .|Sirolimus ( SRL ) is a new , potent immunosuppressive agent .|More recently , proteinuria has been reported as a consequence of sirolimus therapy , although the mechanism has remained unclear .|We retrospectively examined the records of 25 renal transplant patients , who developed or displayed increased proteinuria after SRL conversion .|The patient cohort ( 14 men , 11 women ) was treated with SRL as conversion therapy , due to chronic allograft nephropathy ( CAN ) ( n = 15 ) neoplasia ( n = 8 ) ; Kaposi 's sarcoma , Four skin cancers , One intestinal tumors , One renal cell carsinom ) or BK virus nephropathy ( n = 2 ) .|SRL was started at a mean of 78 + / - 42 ( 15 to 163 ) months after transplantation .|Mean follow - up on SRL therapy was 20 + / - 12 ( 6 to 43 ) months .|Proteinuria increased from 0 . 445 ( 0 to 1 . 5 ) g / d before conversion to 3 . 2 g / dL ( 0 . 2 to 12 ) after conversion ( P = 0 . 001 ) .|Before conversion 8 ( 32 % ) patients had no proteinuria , whereas afterwards all patients had proteinuria .|In 28 % of patients proteinuria remained unchanged , whereas it increased in 68 % of patients .|In 40 % it increased by more than 100 % .|Twenty - eight percent of patients showed increased proteinuria to the nephrotic range .|Biopsies performed in five patients revealed new pathological changes : One membranoproliferative glomerulopathy and interstitial nephritis .|These patients showed persistently good graft function .|Serum creatinine values did not change significantly : 1 . 98 + / - 0 . 8 mg / dL before SRL therapy and 2 . 53 + / - 1 . 9 mg / dL at last follow - up ( P = . 14 ) .|Five grafts were lost and the patients returned to dialysis .|Five patients displayed CAN and Kaposi 's sarcoma .|Mean urinary protein of patients who returned to dialysis was 1 . 26 ( 0 . 5 to 3 . 5 ) g / d before and 4 . 7 ( 3 to 12 ) g / d after conversion ( P = . 01 ) .|Mean serum creatinine level before conversion was 2 . 21 mg / dL and thereafter , 4 . 93 mg / dL ( P = . 02 ) .|Heavy proteinuria was common after the use of SRL as rescue therapy for renal transplantation .|Therefore , conversion should be considered for patients who have not developed advanced CAN and proteinuria .|The possibility of de novo glomerular pathology under SRL treatment requires further investigation by renal biopsy .	1:CID:2	R2L	NON-CROSS	61-62	59-60	D020123	sirolimus|Sirolimus|SRL|sirolimus|SRL|SRL|SRL|SRL|SRL|SRL|SRL	Chemical	4:10:12:33:61:77:129:155:320:451:484	5:11:13:34:62:78:130:156:321:452:485	0:1:1:2:3:4:5:6:14:19:21	D011507	Proteinuria|proteinuria|proteinuria|Proteinuria|proteinuria|proteinuria|proteinuria|proteinuria|proteinuria|proteinuria	Disease	0:25:59:170:222:229:236:268:444:474	1:26:60:171:223:230:237:269:445:475	0:2:3:7:8:8:9:11:19:20	1:NR:2	R2L	CROSS	444-445	416-417	D003404	creatinine|creatinine	Chemical	300:416	301:417	14:18	D011507	Proteinuria|proteinuria|proteinuria|Proteinuria|proteinuria|proteinuria|proteinuria|proteinuria|proteinuria|proteinuria	Disease	0:25:59:170:222:229:236:268:444:474	1:26:60:171:223:230:237:269:445:475	0:2:3:7:8:8:9:11:19:20	1:NR:2	L2R	NON-CROSS	77-78	84-87	D020123	sirolimus|Sirolimus|SRL|sirolimus|SRL|SRL|SRL|SRL|SRL|SRL|SRL	Chemical	4:10:12:33:61:77:129:155:320:451:484	5:11:13:34:62:78:130:156:321:452:485	0:1:1:2:3:4:5:6:14:19:21	D051436	chronic allograft nephropathy	Disease	84	87	4	1:NR:2	L2R	NON-CROSS	122-123	129-130	D020123	sirolimus|Sirolimus|SRL|sirolimus|SRL|SRL|SRL|SRL|SRL|SRL|SRL	Chemical	4:10:12:33:61:77:129:155:320:451:484	5:11:13:34:62:78:130:156:321:452:485	0:1:1:2:3:4:5:6:14:19:21	D007674	CAN|nephropathy|CAN|CAN	Disease	88:122:361:472	89:123:362:473	4:4:16:20	1:NR:2	L2R	NON-CROSS	77-78	95-96	D020123	sirolimus|Sirolimus|SRL|sirolimus|SRL|SRL|SRL|SRL|SRL|SRL|SRL	Chemical	4:10:12:33:61:77:129:155:320:451:484	5:11:13:34:62:78:130:156:321:452:485	0:1:1:2:3:4:5:6:14:19:21	D009369	neoplasia	Disease	95	96	4	1:NR:2	L2R	NON-CROSS	77-78	102-105	D020123	sirolimus|Sirolimus|SRL|sirolimus|SRL|SRL|SRL|SRL|SRL|SRL|SRL	Chemical	4:10:12:33:61:77:129:155:320:451:484	5:11:13:34:62:78:130:156:321:452:485	0:1:1:2:3:4:5:6:14:19:21	D012514	Kaposi 's sarcoma|Kaposi 's sarcoma	Disease	102:363	105:366	4:16	1:NR:2	L2R	NON-CROSS	107-109	129-130	D020123	sirolimus|Sirolimus|SRL|sirolimus|SRL|SRL|SRL|SRL|SRL|SRL|SRL	Chemical	4:10:12:33:61:77:129:155:320:451:484	5:11:13:34:62:78:130:156:321:452:485	0:1:1:2:3:4:5:6:14:19:21	D012878	skin cancers	Disease	107	109	4	1:NR:2	L2R	NON-CROSS	111-113	129-130	D020123	sirolimus|Sirolimus|SRL|sirolimus|SRL|SRL|SRL|SRL|SRL|SRL|SRL	Chemical	4:10:12:33:61:77:129:155:320:451:484	5:11:13:34:62:78:130:156:321:452:485	0:1:1:2:3:4:5:6:14:19:21	D007414	intestinal tumors	Disease	111	113	4	1:NR:2	L2R	NON-CROSS	115-118	129-130	D020123	sirolimus|Sirolimus|SRL|sirolimus|SRL|SRL|SRL|SRL|SRL|SRL|SRL	Chemical	4:10:12:33:61:77:129:155:320:451:484	5:11:13:34:62:78:130:156:321:452:485	0:1:1:2:3:4:5:6:14:19:21	D002292	renal cell carsinom	Disease	115	118	4	1:NR:2	L2R	CROSS	271-272	320-321	D020123	sirolimus|Sirolimus|SRL|sirolimus|SRL|SRL|SRL|SRL|SRL|SRL|SRL	Chemical	4:10:12:33:61:77:129:155:320:451:484	5:11:13:34:62:78:130:156:321:452:485	0:1:1:2:3:4:5:6:14:19:21	D009404	nephrotic	Disease	271	272	11	1:NR:2	L2R	CROSS	285-287	320-321	D020123	sirolimus|Sirolimus|SRL|sirolimus|SRL|SRL|SRL|SRL|SRL|SRL|SRL	Chemical	4:10:12:33:61:77:129:155:320:451:484	5:11:13:34:62:78:130:156:321:452:485	0:1:1:2:3:4:5:6:14:19:21	D015433	membranoproliferative glomerulopathy	Disease	285	287	12	1:NR:2	L2R	CROSS	288-290	320-321	D020123	sirolimus|Sirolimus|SRL|sirolimus|SRL|SRL|SRL|SRL|SRL|SRL|SRL	Chemical	4:10:12:33:61:77:129:155:320:451:484	5:11:13:34:62:78:130:156:321:452:485	0:1:1:2:3:4:5:6:14:19:21	D009395	interstitial nephritis	Disease	288	290	12	1:NR:2	R2L	CROSS	300-301	84-87	D003404	creatinine|creatinine	Chemical	300:416	301:417	14:18	D051436	chronic allograft nephropathy	Disease	84	87	4	1:NR:2	R2L	CROSS	416-417	361-362	D003404	creatinine|creatinine	Chemical	300:416	301:417	14:18	D007674	CAN|nephropathy|CAN|CAN	Disease	88:122:361:472	89:123:362:473	4:4:16:20	1:NR:2	R2L	CROSS	300-301	95-96	D003404	creatinine|creatinine	Chemical	300:416	301:417	14:18	D009369	neoplasia	Disease	95	96	4	1:NR:2	R2L	CROSS	416-417	363-366	D003404	creatinine|creatinine	Chemical	300:416	301:417	14:18	D012514	Kaposi 's sarcoma|Kaposi 's sarcoma	Disease	102:363	105:366	4:16	1:NR:2	R2L	CROSS	300-301	107-109	D003404	creatinine|creatinine	Chemical	300:416	301:417	14:18	D012878	skin cancers	Disease	107	109	4	1:NR:2	R2L	CROSS	300-301	111-113	D003404	creatinine|creatinine	Chemical	300:416	301:417	14:18	D007414	intestinal tumors	Disease	111	113	4	1:NR:2	R2L	CROSS	300-301	115-118	D003404	creatinine|creatinine	Chemical	300:416	301:417	14:18	D002292	renal cell carsinom	Disease	115	118	4	1:NR:2	R2L	CROSS	300-301	271-272	D003404	creatinine|creatinine	Chemical	300:416	301:417	14:18	D009404	nephrotic	Disease	271	272	11	1:NR:2	R2L	CROSS	300-301	285-287	D003404	creatinine|creatinine	Chemical	300:416	301:417	14:18	D015433	membranoproliferative glomerulopathy	Disease	285	287	12	1:NR:2	R2L	CROSS	300-301	288-290	D003404	creatinine|creatinine	Chemical	300:416	301:417	14:18	D009395	interstitial nephritis	Disease	288	290	12
17244258	In vitro characterization of parasympathetic and sympathetic responses in cyclophosphamide - induced cystitis in the rat .|In cyclophosphamide - induced cystitis in the rat , detrusor function is impaired and the expression and effects of muscarinic receptors altered .|Whether or not the neuronal transmission may be affected by cystitis was presently investigated .|Responses of urinary strip preparations from control and cyclophosphamide - pretreated rats to electrical field stimulation and to agonists were assessed in the absence and presence of muscarinic , adrenergic and purinergic receptor antagonists .|Generally , atropine reduced contractions , but in contrast to controls , it also reduced responses to low electrical field stimulation intensity ( 1 - 5 Hz ) in inflamed preparations .|In both types , purinoceptor desensitization with alpha , beta - methylene adenosine - 5 ' - triphosphate ( alpha , beta - meATP ) caused further reductions at low frequencies ( < 10 Hz ) .|The muscarinic receptor antagonists atropine , 4 - diphenylacetoxy - N - methylpiperidine ( 4 - DAMP ) ( ' M ( 1 ) / M ( 3 ) / M ( 5 ) - selective ' ) , methoctramine ( ' M ( 2 ) - selective ' ) and pirenzepine ( ' M ( 1 ) - selective ' ) antagonized the tonic component of the electrical field stimulation - evoked contractile response more potently than the phasic component .|4 - DAMP inhibited the tonic contractions in controls more potently than methoctramine and pirenzepine .|In inflamed preparations , the muscarinic receptor antagonism on the phasic component of the electrical field stimulation - evoked contraction was decreased and the pirenzepine and 4 - DAMP antagonism on the tonic component was much less efficient than in controls .|In contrast to controls , methoctramine increased - - instead of decreased - - the tonic responses at high frequencies .|While contractions to carbachol and ATP were the same in inflamed and in control strips when related to a reference potassium response , isoprenaline - induced relaxations were smaller in inflamed strips .|Thus , in cystitis substantial changes of the efferent functional responses occur .|While postjunctional beta - adrenoceptor - mediated relaxations are reduced , effects by prejunctional inhibitory muscarinic receptors may be increased .	1:CID:2	L2R	NON-CROSS	9-10	12-13	D003520	cyclophosphamide|cyclophosphamide|cyclophosphamide	Chemical	9:18:63	10:19:64	0:1:3	D003556	cystitis|cystitis|cystitis|cystitis	Disease	12:21:50:356	13:22:51:357	0:1:2:11	1:NR:2	R2L	CROSS	92-93	50-51	D001285	atropine|atropine	Chemical	92:163	93:164	4:6	D003556	cystitis|cystitis|cystitis|cystitis	Disease	12:21:50:356	13:22:51:357	0:1:2:11	1:NR:2	R2L	CROSS	129-140	50-51	C002630	alpha , beta - methylene adenosine - 5 ' - triphosphate|alpha , beta - meATP	Chemical	129:141	140:146	5:5	D003556	cystitis|cystitis|cystitis|cystitis	Disease	12:21:50:356	13:22:51:357	0:1:2:11	1:NR:2	R2L	CROSS	356-357	283-286	C042375	4 - diphenylacetoxy - N - methylpiperidine|4 - DAMP|4 - DAMP|4 - DAMP	Chemical	165:173:241:283	172:176:244:286	6:6:7:8	D003556	cystitis|cystitis|cystitis|cystitis	Disease	12:21:50:356	13:22:51:357	0:1:2:11	1:NR:2	R2L	CROSS	356-357	304-305	C054938	methoctramine|methoctramine|methoctramine	Chemical	198:253:304	199:254:305	6:7:9	D003556	cystitis|cystitis|cystitis|cystitis	Disease	12:21:50:356	13:22:51:357	0:1:2:11	1:NR:2	R2L	CROSS	356-357	281-282	D010890	pirenzepine|pirenzepine|pirenzepine	Chemical	210:255:281	211:256:282	6:7:8	D003556	cystitis|cystitis|cystitis|cystitis	Disease	12:21:50:356	13:22:51:357	0:1:2:11	1:NR:2	R2L	CROSS	356-357	323-324	D002217	carbachol	Chemical	323	324	10	D003556	cystitis|cystitis|cystitis|cystitis	Disease	12:21:50:356	13:22:51:357	0:1:2:11	1:NR:2	R2L	CROSS	356-357	325-326	D000255	ATP	Chemical	325	326	10	D003556	cystitis|cystitis|cystitis|cystitis	Disease	12:21:50:356	13:22:51:357	0:1:2:11	1:NR:2	R2L	CROSS	356-357	340-341	D011188	potassium	Chemical	340	341	10	D003556	cystitis|cystitis|cystitis|cystitis	Disease	12:21:50:356	13:22:51:357	0:1:2:11	1:NR:2	R2L	CROSS	356-357	343-344	D007545	isoprenaline	Chemical	343	344	10	D003556	cystitis|cystitis|cystitis|cystitis	Disease	12:21:50:356	13:22:51:357	0:1:2:11
18020536	Associations between use of benzodiazepines or related drugs and health , physical abilities and cognitive function : a non - randomised clinical study in the elderly .|OBJECTIVE : To describe associations between the use of benzodiazepines or related drugs ( BZDs / RDs ) and health , functional abilities and cognitive function in the elderly .|METHODS : A non - randomised clinical study of patients aged > or = 65 years admitted to acute hospital wards during 1 month .|164 patients ( mean age + / - standard deviation [ SD ] 81 . 6 + / - 6 . 8 years ) were admitted .|Of these , nearly half ( n = 78 ) had used BZDs / RDs before admission , and the remainder ( n = 86 ) were non - users .|Cognitive ability was assessed by the Mini - Mental State Examination ( MMSE ) .|Patients scoring > or = 20 MMSE sum points were interviewed ( n = 79 ) and questioned regarding symptoms and functional abilities during the week prior to admission .|Data on use of BZDs / RDs before admission , current medications and discharge diagnoses were collected from medical records .|Health , physical abilities and cognitive function were compared between BZD / RD users and non - users , and adjustments were made for confounding variables .|The residual serum concentrations of oxazepam , temazepam and zopiclone were analysed .|RESULTS : The mean + / - SD duration of BZD / RD use was 7 + / - 7 years ( range 1 - 31 ) .|Two or three BZDs / RDs were concomitantly taken by 26 % of users ( n = 20 ) .|Long - term use of these drugs was associated with female sex and use of a higher number of drugs with effects on the CNS , which tended to be related to diagnosed dementia .|After adjustment for these variables as confounders , use of BZDs / RDs was not associated with cognitive function as measured by the MMSE .|However , use of BZDs / RDs was associated with dizziness , inability to sleep after awaking at night and tiredness in the mornings during the week prior to admission and with stronger depressive symptoms measured at the beginning of the hospital stay .|Use of BZDs / RDs tended to be associated with a reduced ability to walk and shorter night - time sleep during the week prior to admission .|A higher residual serum concentration of temazepam correlated with a lower MMSE sum score after adjustment for confounding variables .|CONCLUSIONS : Long - term use and concomitant use of more than one BZD / RD were common in elderly patients hospitalised because of acute illnesses .|Long - term use was associated with daytime and night - time symptoms indicative of poorer health and potentially caused by the adverse effects of these drugs .	1:CID:2	L2R	NON-CROSS	358-359	364-365	D001569	benzodiazepines|benzodiazepines|BZDs|BZDs|BZDs|BZDs|BZDs|BZDs|BZDs	Chemical	4:36:41:121:189:277:339:358:400	5:37:42:122:190:278:340:359:401	0:1:1:4:7:11:13:14:15	D004244	dizziness	Disease	364	365	14	1:CID:2	L2R	NON-CROSS	358-359	366-369	D001569	benzodiazepines|benzodiazepines|BZDs|BZDs|BZDs|BZDs|BZDs|BZDs|BZDs	Chemical	4:36:41:121:189:277:339:358:400	5:37:42:122:190:278:340:359:401	0:1:1:4:7:11:13:14:15	D007319	inability to sleep	Disease	366	369	14	1:CID:2	L2R	NON-CROSS	358-359	374-375	D001569	benzodiazepines|benzodiazepines|BZDs|BZDs|BZDs|BZDs|BZDs|BZDs|BZDs	Chemical	4:36:41:121:189:277:339:358:400	5:37:42:122:190:278:340:359:401	0:1:1:4:7:11:13:14:15	D005221	tiredness	Disease	374	375	14	1:CID:2	L2R	NON-CROSS	387-389	400-401	D001569	benzodiazepines|benzodiazepines|BZDs|BZDs|BZDs|BZDs|BZDs|BZDs|BZDs	Chemical	4:36:41:121:189:277:339:358:400	5:37:42:122:190:278:340:359:401	0:1:1:4:7:11:13:14:15	D003866	depressive symptoms	Disease	387	389	14	1:NR:2	L2R	CROSS	327-328	339-340	D001569	benzodiazepines|benzodiazepines|BZDs|BZDs|BZDs|BZDs|BZDs|BZDs|BZDs	Chemical	4:36:41:121:189:277:339:358:400	5:37:42:122:190:278:340:359:401	0:1:1:4:7:11:13:14:15	D003704	dementia	Disease	327	328	12	1:NR:2	L2R	CROSS	238-239	327-328	D010076	oxazepam	Chemical	238	239	9	D003704	dementia	Disease	327	328	12	1:NR:2	L2R	CROSS	238-239	364-365	D010076	oxazepam	Chemical	238	239	9	D004244	dizziness	Disease	364	365	14	1:NR:2	L2R	CROSS	238-239	366-369	D010076	oxazepam	Chemical	238	239	9	D007319	inability to sleep	Disease	366	369	14	1:NR:2	L2R	CROSS	238-239	374-375	D010076	oxazepam	Chemical	238	239	9	D005221	tiredness	Disease	374	375	14	1:NR:2	L2R	CROSS	238-239	387-389	D010076	oxazepam	Chemical	238	239	9	D003866	depressive symptoms	Disease	387	389	14	1:NR:2	L2R	CROSS	240-241	327-328	D013693	temazepam|temazepam	Chemical	240:432	241:433	9:16	D003704	dementia	Disease	327	328	12	1:NR:2	L2R	CROSS	364-365	432-433	D013693	temazepam|temazepam	Chemical	240:432	241:433	9:16	D004244	dizziness	Disease	364	365	14	1:NR:2	L2R	CROSS	366-369	432-433	D013693	temazepam|temazepam	Chemical	240:432	241:433	9:16	D007319	inability to sleep	Disease	366	369	14	1:NR:2	L2R	CROSS	374-375	432-433	D013693	temazepam|temazepam	Chemical	240:432	241:433	9:16	D005221	tiredness	Disease	374	375	14	1:NR:2	L2R	CROSS	387-389	432-433	D013693	temazepam|temazepam	Chemical	240:432	241:433	9:16	D003866	depressive symptoms	Disease	387	389	14	1:NR:2	L2R	CROSS	242-243	327-328	C515050	zopiclone	Chemical	242	243	9	D003704	dementia	Disease	327	328	12	1:NR:2	L2R	CROSS	242-243	364-365	C515050	zopiclone	Chemical	242	243	9	D004244	dizziness	Disease	364	365	14	1:NR:2	L2R	CROSS	242-243	366-369	C515050	zopiclone	Chemical	242	243	9	D007319	inability to sleep	Disease	366	369	14	1:NR:2	L2R	CROSS	242-243	374-375	C515050	zopiclone	Chemical	242	243	9	D005221	tiredness	Disease	374	375	14	1:NR:2	L2R	CROSS	242-243	387-389	C515050	zopiclone	Chemical	242	243	9	D003866	depressive symptoms	Disease	387	389	14
18023325	Acute vocal fold palsy after acute disulfiram intoxication .|Acute peripheral neuropathy caused by a disulfiram overdose is very rare and there is no report of it leading to vocal fold palsy .|A 49 - year - old woman was transferred to our department because of quadriparesis , lancinating pain , sensory loss , and paresthesia of the distal limbs .|One month previously , she had taken a single high dose of disulfiram ( 130 tablets of ALCOHOL STOP TAB , Shin - Poong Pharm .|Co . , Ansan , Korea ) in a suicide attempt .|She was not an alcoholic .|For the first few days after ingestion , she was in a confused state and had mild to moderate ataxia and giddiness .|She noticed hoarseness and distally accentuated motor and sensory dysfunction after she had recovered from this state .|A nerve conduction study was consistent with severe sensorimotor axonal polyneuropathy .|Laryngeal electromyography ( thyroarytenoid muscle ) showed ample denervation potentials .|Laryngoscopy revealed asymmetric vocal fold movements during phonation .|Her vocal change and weakness began to improve spontaneously about 3 weeks after transfer .|This was a case of acute palsy of the recurrent laryngeal nerve and superimposed severe acute sensorimotor axonal polyneuropathy caused by high - dose disulfiram intoxication .	1:CID:2	R2L	NON-CROSS	6-7	1-4	D004221	disulfiram|disulfiram|disulfiram|disulfiram	Chemical	6:15:74:218	7:16:75:219	0:1:3:12	D014826	vocal fold palsy|vocal fold palsy	Disease	1:29	4:32	0:1	1:CID:2	L2R	NON-CROSS	6-7	10-12	D004221	disulfiram|disulfiram|disulfiram|disulfiram	Chemical	6:15:74:218	7:16:75:219	0:1:3:12	D010523	peripheral neuropathy	Disease	10	12	1	1:CID:2	L2R	CROSS	47-48	74-75	D004221	disulfiram|disulfiram|disulfiram|disulfiram	Chemical	6:15:74:218	7:16:75:219	0:1:3:12	D011782	quadriparesis	Disease	47	48	2	1:CID:2	L2R	CROSS	50-51	74-75	D004221	disulfiram|disulfiram|disulfiram|disulfiram	Chemical	6:15:74:218	7:16:75:219	0:1:3:12	D010146	pain	Disease	50	51	2	1:CID:2	L2R	CROSS	56-57	74-75	D004221	disulfiram|disulfiram|disulfiram|disulfiram	Chemical	6:15:74:218	7:16:75:219	0:1:3:12	D010292	paresthesia	Disease	56	57	2	1:CID:2	L2R	CROSS	74-75	125-126	D004221	disulfiram|disulfiram|disulfiram|disulfiram	Chemical	6:15:74:218	7:16:75:219	0:1:3:12	D001259	ataxia	Disease	125	126	6	1:NR:2	R2L	CROSS	79-80	29-32	D000431	ALCOHOL	Chemical	79	80	3	D014826	vocal fold palsy|vocal fold palsy	Disease	1:29	4:32	0:1	1:NR:2	L2R	NON-CROSS	15-16	16-17	D004221	disulfiram|disulfiram|disulfiram|disulfiram	Chemical	6:15:74:218	7:16:75:219	0:1:3:12	D062787	overdose	Disease	16	17	1	1:NR:2	L2R	CROSS	52-54	74-75	D004221	disulfiram|disulfiram|disulfiram|disulfiram	Chemical	6:15:74:218	7:16:75:219	0:1:3:12	C580162	sensory loss	Disease	52	54	2	1:NR:2	L2R	CROSS	74-75	127-128	D004221	disulfiram|disulfiram|disulfiram|disulfiram	Chemical	6:15:74:218	7:16:75:219	0:1:3:12	D004244	giddiness	Disease	127	128	6	1:NR:2	L2R	CROSS	74-75	131-132	D004221	disulfiram|disulfiram|disulfiram|disulfiram	Chemical	6:15:74:218	7:16:75:219	0:1:3:12	D006685	hoarseness	Disease	131	132	7	1:NR:2	L2R	NON-CROSS	212-213	218-219	D004221	disulfiram|disulfiram|disulfiram|disulfiram	Chemical	6:15:74:218	7:16:75:219	0:1:3:12	D011115	polyneuropathy|polyneuropathy	Disease	157:212	158:213	8:12	not_include	L2R	NON-CROSS	200-201	218-219	D004221	disulfiram|disulfiram|disulfiram|disulfiram	Chemical	6:15:74:218	7:16:75:219	0:1:3:12	D010243	palsy	Disease	200	201	12	1:NR:2	R2L	CROSS	79-80	10-12	D000431	ALCOHOL	Chemical	79	80	3	D010523	peripheral neuropathy	Disease	10	12	1	1:NR:2	R2L	CROSS	79-80	16-17	D000431	ALCOHOL	Chemical	79	80	3	D062787	overdose	Disease	16	17	1	1:NR:2	R2L	CROSS	79-80	47-48	D000431	ALCOHOL	Chemical	79	80	3	D011782	quadriparesis	Disease	47	48	2	1:NR:2	R2L	CROSS	79-80	50-51	D000431	ALCOHOL	Chemical	79	80	3	D010146	pain	Disease	50	51	2	1:NR:2	R2L	CROSS	79-80	52-54	D000431	ALCOHOL	Chemical	79	80	3	C580162	sensory loss	Disease	52	54	2	1:NR:2	R2L	CROSS	79-80	56-57	D000431	ALCOHOL	Chemical	79	80	3	D010292	paresthesia	Disease	56	57	2	1:NR:2	L2R	CROSS	79-80	125-126	D000431	ALCOHOL	Chemical	79	80	3	D001259	ataxia	Disease	125	126	6	1:NR:2	L2R	CROSS	79-80	127-128	D000431	ALCOHOL	Chemical	79	80	3	D004244	giddiness	Disease	127	128	6	1:NR:2	L2R	CROSS	79-80	131-132	D000431	ALCOHOL	Chemical	79	80	3	D006685	hoarseness	Disease	131	132	7	1:NR:2	L2R	CROSS	79-80	157-158	D000431	ALCOHOL	Chemical	79	80	3	D011115	polyneuropathy|polyneuropathy	Disease	157:212	158:213	8:12	1:NR:2	L2R	CROSS	79-80	200-201	D000431	ALCOHOL	Chemical	79	80	3	D010243	palsy	Disease	200	201	12
18208574	Higher optical density of an antigen assay predicts thrombosis in patients with heparin - induced thrombocytopenia .|OBJECTIVES : To correlate optical density and percent inhibition of a two - step heparin - induced thrombocytopenia ( HIT ) antigen assay with thrombosis ; the assay utilizes reaction inhibition characteristics of a high heparin concentration .|PATIENTS AND METHODS : Patients with more than 50 % decrease in platelet count or thrombocytopenia ( < 150 x 10 ( 9 ) / L ) after exposure to heparin , who had a positive two - step antigen assay [ optical density ( OD ) > 0 . 4 and > 50 inhibition with high concentration of heparin ] were included in the study .|RESULTS : Forty of 94 HIT patients had thrombosis at diagnosis ; 54 / 94 had isolated - HIT without thrombosis .|Eight of the isolated - HIT patients developed thrombosis within the next 30 d ; thus , a total of 48 patients had thrombosis at day 30 .|At diagnosis there was no significant difference in OD between HIT patients with thrombosis and those with isolated - HIT .|However , OD was significantly higher in all patients with thrombosis ( n = 48 , 1 . 34 + / - 0 . 89 ) , including isolated - HIT patients who later developed thrombosis within 30 d ( n = 8 , 1 . 84 + / - 0 . 64 ) as compared to isolated - HIT patients who did not develop thrombosis ( 0 . 96 + / - 0 . 75 ; P = 0 . 011 and P = 0 . 008 ) .|The Receiver Operative Characteristic Curve showed that OD > 1 . 27 in the isolated - HIT group had a significantly higher chance of developing thrombosis by day 30 .|None of these groups showed significant difference in percent inhibition .|Multivariate analysis showed a 2 . 8 - fold increased risk of thrombosis in females .|Similarly , thrombotic risk increased with age and OD values .|CONCLUSION : Higher OD is associated with significant risk of subsequent thrombosis in patients with isolated - HIT ; percent inhibition , however , was not predictive .	1:CID:2	R2L	NON-CROSS	12-13	8-9	D006493	heparin|heparin|heparin|heparin|heparin	Chemical	12:31:52:85:114	13:32:53:86:115	0:1:1:2:2	D013927	thrombosis|thrombosis|thrombosis|thrombosis|thrombosis|thrombosis|thrombosis|thrombosis|thrombosis|thrombosis|thrombosis|thrombosis|thrombotic|thrombosis	Disease	8:41:130:142:152:167:185:203:228:258:308:336:342:362	9:42:131:143:153:168:186:204:229:259:309:337:343:363	0:1:3:3:4:4:5:6:6:6:7:9:10:11	1:CID:2	L2R	NON-CROSS	12-13	15-16	D006493	heparin|heparin|heparin|heparin|heparin	Chemical	12:31:52:85:114	13:32:53:86:115	0:1:1:2:2	D013921	thrombocytopenia|thrombocytopenia|HIT|thrombocytopenia|HIT|HIT|HIT|HIT|HIT|HIT|HIT|HIT|HIT	Disease	15:34:36:70:127:140:149:182:191:223:252:299:368	16:35:37:71:128:141:150:183:192:224:253:300:369	0:1:1:2:3:3:4:5:5:6:6:7:11
18343374	Central retinal vein occlusion associated with clomiphene - induced ovulation .|OBJECTIVE : To report a case of central retinal vein occlusion associated with clomiphene citrate ( CC ) .|DESIGN : Case study .|SETTING : Ophthalmology clinic of an academic hospital .|PATIENT ( S ) : A 36 - year - old woman referred from the infertility clinic for blurred vision .|INTERVENTION ( S ) : Ophthalmic examination after CC therapy .|MAIN OUTCOME MEASURE ( S ) : Central retinal vein occlusion after ovulation induction with CC .|RESULT ( S ) : A 36 - year - old Chinese woman developed central retinal vein occlusion after eight courses of CC .|A search of the literature on the thromboembolic complications of CC does not include this severe ophthalmic complication , although mild visual disturbance after CC intake is not uncommon .|CONCLUSION ( S ) : This is the first reported case of central retinal vein occlusion after treatment with CC .|Extra caution is warranted in treating infertility patients with CC , and patients should be well informed of this side effect before commencement of therapy .	1:CID:2	R2L	NON-CROSS	6-7	1-4	D002996	clomiphene|clomiphene citrate|CC|CC|CC|CC|CC|CC|CC|CC	Chemical	6:24:27:73:91:115:127:141:166:177	7:26:28:74:92:116:128:142:167:178	0:1:1:5:6:7:8:8:9:10	D012170	retinal vein occlusion|retinal vein occlusion|retinal vein occlusion|retinal vein occlusion|retinal vein occlusion	Disease	1:19:84:108:160	4:22:87:111:163	0:1:6:7:9	1:CID:2	L2R	NON-CROSS	138-140	141-142	D002996	clomiphene|clomiphene citrate|CC|CC|CC|CC|CC|CC|CC|CC	Chemical	6:24:27:73:91:115:127:141:166:177	7:26:28:74:92:116:128:142:167:178	0:1:1:5:6:7:8:8:9:10	D014786	blurred vision|visual disturbance	Disease	62:138	64:140	4:8	1:NR:2	L2R	NON-CROSS	174-175	177-178	D002996	clomiphene|clomiphene citrate|CC|CC|CC|CC|CC|CC|CC|CC	Chemical	6:24:27:73:91:115:127:141:166:177	7:26:28:74:92:116:128:142:167:178	0:1:1:5:6:7:8:8:9:10	D007247	infertility|infertility	Disease	59:174	60:175	4:10	1:NR:2	L2R	NON-CROSS	124-125	127-128	D002996	clomiphene|clomiphene citrate|CC|CC|CC|CC|CC|CC|CC|CC	Chemical	6:24:27:73:91:115:127:141:166:177	7:26:28:74:92:116:128:142:167:178	0:1:1:5:6:7:8:8:9:10	D013923	thromboembolic	Disease	124	125	8
18417364	Nicotine - induced nystagmus correlates with midpontine activation .|The pathomechanism of nicotine - induced nystagmus ( NIN ) is unknown .|The aim of this study was to delineate brain structures that are involved in NIN generation .|Eight healthy volunteers inhaled nicotine in darkness during a functional magnetic resonance imaging ( fMRI ) experiment ; eye movements were registered using video - oculography .|NIN correlated with blood oxygen level - dependent ( BOLD ) activity levels in a midpontine site in the posterior basis pontis .|NIN - induced midpontine activation may correspond to activation of the dorsomedial pontine nuclei and the nucleus reticularis tegmenti pontis , structures known to participate in the generation of multidirectional saccades and smooth pursuit eye movements .	1:CID:2	L2R	NON-CROSS	0-1	3-4	D009538	Nicotine|nicotine|nicotine	Chemical	0:12:43	1:13:44	0:1:3	D009759	nystagmus|nystagmus|NIN|NIN|NIN|NIN	Disease	3:15:17:36:66:89	4:16:18:37:67:90	0:1:1:2:4:5	1:NR:2	R2L	NON-CROSS	70-71	66-67	D010100	oxygen	Chemical	70	71	4	D009759	nystagmus|nystagmus|NIN|NIN|NIN|NIN	Disease	3:15:17:36:66:89	4:16:18:37:67:90	0:1:1:2:4:5
18442015	Protective effect of verapamil on gastric hemorrhagic ulcers in severe atherosclerotic rats .|Studies concerning with pathogenesis of gastric hemorrhage and mucosal ulceration produced in atherosclerotic rats are lacking .|The aim of this study is to examine the role of gastric acid back - diffusion , mast cell histamine release , lipid peroxide ( LPO ) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol .|Additionally , the protective effect of verapamil on this ulcer model was evaluated .|Male Wistar rats were challenged intragastrically once daily for 9 days with 1 . 0 ml / kg of corn oil containing vitamin D2 and cholesterol to induce atherosclerosis .|Control rats received corn oil only .|After gastric surgery , rat stomachs were irrigated for 3 h with either simulated gastric juice or normal saline .|Gastric acid back - diffusion , mucosal LPO generation , histamine concentration , microvascular permeability , luminal hemoglobin content and ulcer areas were determined .|Elevated atherosclerotic parameters , such as serum calcium , total cholesterol and low - density lipoprotein concentration were obtained in atherosclerotic rats .|Severe gastric ulcers accompanied with increased ulcerogenic factors , including gastric acid back - diffusion , histamine release , LPO generation and luminal hemoglobin content were also observed in these rats .|Moreover , a positive correlation of histamine to gastric hemorrhage and to ulcer was found in those atherosclerotic rats .|This hemorrhagic ulcer and various ulcerogenic parameters were dose - dependently ameliorated by daily intragastric verapamil .|Atherosclerosis could produce gastric hemorrhagic ulcer via aggravation of gastric acid back - diffusion , LPO generation , histamine release and microvascular permeability that could be ameliorated by verapamil in rats .	1:CID:2	R2L	NON-CROSS	76-78	64-66	D004872	vitamin D2|vitamin D2	Chemical	76:117	78:119	2:4	D006471	gastric hemorrhagic|gastric hemorrhage|gastric hemorrhage|gastric hemorrhage|hemorrhagic|gastric hemorrhagic	Disease	5:18:64:240:253:272	7:20:66:242:254:274	0:1:2:10:11:12	1:CID:2	R2L	NON-CROSS	79-80	64-66	D002784	cholesterol|cholesterol|cholesterol	Chemical	79:120:187	80:121:188	2:4:8	D006471	gastric hemorrhagic|gastric hemorrhage|gastric hemorrhage|gastric hemorrhage|hemorrhagic|gastric hemorrhagic	Disease	5:18:64:240:253:272	7:20:66:242:254:274	0:1:2:10:11:12	1:CID:2	R2L	NON-CROSS	76-78	67-68	D004872	vitamin D2|vitamin D2	Chemical	76:117	78:119	2:4	D014456	ulcers|ulcer|ulcer|ulcer|ulcers|ulcer|ulcer|ulcer	Disease	7:67:90:172:202:244:254:274	8:68:91:173:203:245:255:275	0:2:3:7:9:10:11:12	1:CID:2	R2L	NON-CROSS	90-91	79-80	D002784	cholesterol|cholesterol|cholesterol	Chemical	79:120:187	80:121:188	2:4:8	D014456	ulcers|ulcer|ulcer|ulcer|ulcers|ulcer|ulcer|ulcer	Disease	7:67:90:172:202:244:254:274	8:68:91:173:203:245:255:275	0:2:3:7:9:10:11:12	1:CID:2	R2L	NON-CROSS	76-78	71-72	D004872	vitamin D2|vitamin D2	Chemical	76:117	78:119	2:4	D050197	atherosclerotic|atherosclerotic|atherosclerosis|atherosclerosis|atherosclerotic|atherosclerotic|atherosclerotic|Atherosclerosis	Disease	10:25:71:123:178:197:249:269	11:26:72:124:179:198:250:270	0:1:2:4:8:8:10:12	1:CID:2	R2L	NON-CROSS	123-124	120-121	D002784	cholesterol|cholesterol|cholesterol	Chemical	79:120:187	80:121:188	2:4:8	D050197	atherosclerotic|atherosclerotic|atherosclerosis|atherosclerosis|atherosclerotic|atherosclerotic|atherosclerotic|Atherosclerosis	Disease	10:25:71:123:178:197:249:269	11:26:72:124:179:198:250:270	0:1:2:4:8:8:10:12	1:NR:2	L2R	NON-CROSS	3-4	5-7	D014700	verapamil|verapamil|verapamil|verapamil	Chemical	3:87:267:297	4:88:268:298	0:3:11:12	D006471	gastric hemorrhagic|gastric hemorrhage|gastric hemorrhage|gastric hemorrhage|hemorrhagic|gastric hemorrhagic	Disease	5:18:64:240:253:272	7:20:66:242:254:274	0:1:2:10:11:12	1:NR:2	L2R	NON-CROSS	87-88	90-91	D014700	verapamil|verapamil|verapamil|verapamil	Chemical	3:87:267:297	4:88:268:298	0:3:11:12	D014456	ulcers|ulcer|ulcer|ulcer|ulcers|ulcer|ulcer|ulcer	Disease	7:67:90:172:202:244:254:274	8:68:91:173:203:245:255:275	0:2:3:7:9:10:11:12	1:NR:2	L2R	NON-CROSS	267-268	269-270	D014700	verapamil|verapamil|verapamil|verapamil	Chemical	3:87:267:297	4:88:268:298	0:3:11:12	D050197	atherosclerotic|atherosclerotic|atherosclerosis|atherosclerosis|atherosclerotic|atherosclerotic|atherosclerotic|Atherosclerosis	Disease	10:25:71:123:178:197:249:269	11:26:72:124:179:198:250:270	0:1:2:4:8:8:10:12	1:NR:2	R2L	NON-CROSS	240-242	238-239	D006632	histamine|histamine|histamine|histamine|histamine	Chemical	49:162:216:238:287	50:163:217:239:288	2:7:9:10:12	D006471	gastric hemorrhagic|gastric hemorrhage|gastric hemorrhage|gastric hemorrhage|hemorrhagic|gastric hemorrhagic	Disease	5:18:64:240:253:272	7:20:66:242:254:274	0:1:2:10:11:12	1:NR:2	R2L	CROSS	240-242	222-223	D010634	luminal|luminal	Chemical	168:222	169:223	7:9	D006471	gastric hemorrhagic|gastric hemorrhage|gastric hemorrhage|gastric hemorrhage|hemorrhagic|gastric hemorrhagic	Disease	5:18:64:240:253:272	7:20:66:242:254:274	0:1:2:10:11:12	1:NR:2	R2L	CROSS	240-242	184-185	D002118	calcium	Chemical	184	185	8	D006471	gastric hemorrhagic|gastric hemorrhage|gastric hemorrhage|gastric hemorrhage|hemorrhagic|gastric hemorrhagic	Disease	5:18:64:240:253:272	7:20:66:242:254:274	0:1:2:10:11:12	1:NR:2	R2L	NON-CROSS	244-245	238-239	D006632	histamine|histamine|histamine|histamine|histamine	Chemical	49:162:216:238:287	50:163:217:239:288	2:7:9:10:12	D014456	ulcers|ulcer|ulcer|ulcer|ulcers|ulcer|ulcer|ulcer	Disease	7:67:90:172:202:244:254:274	8:68:91:173:203:245:255:275	0:2:3:7:9:10:11:12	1:NR:2	R2L	NON-CROSS	172-173	168-169	D010634	luminal|luminal	Chemical	168:222	169:223	7:9	D014456	ulcers|ulcer|ulcer|ulcer|ulcers|ulcer|ulcer|ulcer	Disease	7:67:90:172:202:244:254:274	8:68:91:173:203:245:255:275	0:2:3:7:9:10:11:12	1:NR:2	R2L	CROSS	184-185	172-173	D002118	calcium	Chemical	184	185	8	D014456	ulcers|ulcer|ulcer|ulcer|ulcers|ulcer|ulcer|ulcer	Disease	7:67:90:172:202:244:254:274	8:68:91:173:203:245:255:275	0:2:3:7:9:10:11:12	1:NR:2	R2L	NON-CROSS	249-250	238-239	D006632	histamine|histamine|histamine|histamine|histamine	Chemical	49:162:216:238:287	50:163:217:239:288	2:7:9:10:12	D050197	atherosclerotic|atherosclerotic|atherosclerosis|atherosclerosis|atherosclerotic|atherosclerotic|atherosclerotic|Atherosclerosis	Disease	10:25:71:123:178:197:249:269	11:26:72:124:179:198:250:270	0:1:2:4:8:8:10:12	1:NR:2	R2L	CROSS	178-179	168-169	D010634	luminal|luminal	Chemical	168:222	169:223	7:9	D050197	atherosclerotic|atherosclerotic|atherosclerosis|atherosclerosis|atherosclerotic|atherosclerotic|atherosclerotic|Atherosclerosis	Disease	10:25:71:123:178:197:249:269	11:26:72:124:179:198:250:270	0:1:2:4:8:8:10:12	1:NR:2	R2L	NON-CROSS	184-185	178-179	D002118	calcium	Chemical	184	185	8	D050197	atherosclerotic|atherosclerotic|atherosclerosis|atherosclerosis|atherosclerotic|atherosclerotic|atherosclerotic|Atherosclerosis	Disease	10:25:71:123:178:197:249:269	11:26:72:124:179:198:250:270	0:1:2:4:8:8:10:12
18619688	Adriamycin - induced autophagic cardiomyocyte death plays a pathogenic role in a rat model of heart failure .|BACKGROUND : The mechanisms underlying heart failure induced by adriamycin are very complicated and still unclear .|The aim of this study was to investigate whether autophagy was involved in the progression of heart failure induced by adriamycin , so that we can develop a novel treatment strategy for heart failure .|METHODS : 3 - methyladenine ( 3MA ) , a specific inhibitor on autophagy was used in a heart failure model of rats induced by adriamycin .|Neonatal cardiomyocytes were isolated from Sprague - Dawley rat hearts and randomly divided into controls , an adriamycin - treated group , and a 3MA plus adriamycin - treated group .|We then examined the morphology , expression of beclin 1 gene , mitochondrial permeability transition ( MPT ) , and Na + - K + ATPase activity in vivo .|We also assessed cell viability , mitochondrial membrane potential changes and counted autophagic vacuoles in cultured cardiomyocytes .|In addition , we analyzed the expression of autophagy associated gene , beclin 1 using RT - PCR and Western blotting in an animal model .|RESULTS : 3MA significantly improved cardiac function and reduced mitochondrial injury .|Furthermore , adriamycin induced the formation of autophagic vacuoles , and 3MA strongly downregulated the expression of beclin 1 in adriamycin - induced failing heart and inhibited the formation of autophagic vacuoles .|CONCLUSION : Autophagic cardiomyocyte death plays an important role in the pathogenesis of heart failure in rats induced by adriamycin .|Mitochondrial injury may be involved in the progression of heart failure caused by adriamycin via the autophagy pathway .	1:CID:2	L2R	NON-CROSS	277-279	281-282	D004317	Adriamycin|adriamycin|adriamycin|adriamycin|adriamycin|adriamycin|adriamycin|adriamycin|adriamycin|adriamycin	Chemical	0:27:55:95:114:123:216:234:266:281	1:28:56:96:115:124:217:235:267:282	0:1:2:3:4:4:9:9:10:11	D006333	heart failure|heart failure|heart failure|heart failure|heart failure|heart failure|heart failure	Disease	15:23:51:67:88:260:277	17:25:53:69:90:262:279	0:1:2:2:3:10:11	1:NR:2	L2R	NON-CROSS	0-1	5-6	D004317	Adriamycin|adriamycin|adriamycin|adriamycin|adriamycin|adriamycin|adriamycin|adriamycin|adriamycin|adriamycin	Chemical	0:27:55:95:114:123:216:234:266:281	1:28:56:96:115:124:217:235:267:282	0:1:2:3:4:4:9:9:10:11	D003643	death|death	Disease	5:251	6:252	0:10	1:NR:2	R2L	CROSS	251-252	225-226	C025946	3 - methyladenine|3MA|3MA|3MA|3MA	Chemical	72:76:121:204:225	75:77:122:205:226	3:3:4:8:9	D003643	death|death	Disease	5:251	6:252	0:10	1:NR:2	R2L	CROSS	251-252	151-152	D011188	K	Chemical	151	152	5	D003643	death|death	Disease	5:251	6:252	0:10	1:NR:2	R2L	NON-CROSS	72-75	67-69	C025946	3 - methyladenine|3MA|3MA|3MA|3MA	Chemical	72:76:121:204:225	75:77:122:205:226	3:3:4:8:9	D006333	heart failure|heart failure|heart failure|heart failure|heart failure|heart failure|heart failure	Disease	15:23:51:67:88:260:277	17:25:53:69:90:262:279	0:1:2:2:3:10:11	1:NR:2	R2L	CROSS	151-152	88-90	D011188	K	Chemical	151	152	5	D006333	heart failure|heart failure|heart failure|heart failure|heart failure|heart failure|heart failure	Disease	15:23:51:67:88:260:277	17:25:53:69:90:262:279	0:1:2:2:3:10:11
19308880	Confusion , a rather serious adverse drug reaction with valproic acid : a review of the French Pharmacovigilance database .|INTRODUCTION : Confusion is an adverse drug reaction frequently observed with valproic acid .|Some case reports are published in the literature but no systematic study from a sample of patients has been published .|We performed this study in order to describe the main characteristics of this adverse drug reaction .|METHODS : Using the French Pharmacovigilance database , we selected the cases of confusion reported since 1985 with valproic acid .|RESULTS : 272 cases of confusion were reported with valproic acid : 153 women and 119 men .|Confusion mostly occurred during the two first weeks following valproic acid exposure ( 39 . 7 % ) .|It was " serious " for almost 2 / 3 of the patients ( 62 . 5 % ) and its outcome favourable in most of the cases ( 82 % ) .|The occurrence of this ADR was more frequent in patients aged between 61 and 80 years .|CONCLUSION : This work shows that confusion with valproic acid is a serious , rather frequent but reversible adverse drug reaction .|It occurs especially in older patients and during the first two weeks of treatment .	1:CID:2	R2L	NON-CROSS	188-190	186-187	D014635	valproic acid|valproic acid|valproic acid|valproic acid|valproic acid|valproic acid	Chemical	9:31:90:102:120:188	11:33:92:104:122:190	0:1:4:5:6:9	D003221	Confusion|Confusion|confusion|confusion|Confusion|confusion	Disease	0:22:85:98:111:186	1:23:86:99:112:187	0:1:4:5:6:9
19631624	Learning and memory deficits in ecstasy users and their neural correlates during a face - learning task .|It has been consistently shown that ecstasy users display impairments in learning and memory performance .|In addition , working memory processing in ecstasy users has been shown to be associated with neural alterations in hippocampal and / or cortical regions as measured by functional magnetic resonance imaging ( fMRI ) .|Using functional imaging and a face - learning task , we investigated neural correlates of encoding and recalling face - name associations in 20 recreational drug users whose predominant drug use was ecstasy and 20 controls .|To address the potential confounding effects of the cannabis use of the ecstasy using group , a second analysis included 14 previously tested cannabis users ( Nestor , L . , Roberts , G . , Garavan , H . , Hester , R . , 2008 .|Deficits in learning and memory : parahippocampal hyperactivity and frontocortical hypoactivity in cannabis users .|Neuroimage 40 , 1328 - 1339 ) .|Ecstasy users performed significantly worse in learning and memory compared to controls and cannabis users .|A conjunction analysis of the encode and recall phases of the task revealed ecstasy - specific hyperactivity in bilateral frontal regions , left temporal , right parietal , bilateral temporal , and bilateral occipital brain regions .|Ecstasy - specific hypoactivity was evident in the right dorsal anterior cingulated cortex ( ACC ) and left posterior cingulated cortex .|In both ecstasy and cannabis groups brain activation was decreased in the right medial frontal gyrus , left parahippocampal gyrus , left dorsal cingulate gyrus , and left caudate .|These results elucidated ecstasy - related deficits , only some of which might be attributed to cannabis use .|These ecstasy - specific effects may be related to the vulnerability of isocortical and allocortical regions to the neurotoxic effects of ecstasy .	1:CID:2	R2L	NON-CROSS	5-6	0-4	D018817	ecstasy|ecstasy|ecstasy|ecstasy|ecstasy|Ecstasy|ecstasy|Ecstasy|ecstasy|ecstasy|ecstasy|ecstasy	Chemical	5:24:41:102:119:178:207:231:255:286:303:323	6:25:42:103:120:179:208:232:256:287:304:324	0:1:2:3:4:7:8:9:10:11:12:12	D007859	Learning and memory deficits|impairments in learning and memory|Deficits in learning and memory	Disease	0:27:155	4:32:160	0:1:5	1:CID:2	R2L	NON-CROSS	5-6	0-4	D018817	ecstasy|ecstasy|ecstasy|ecstasy|ecstasy|Ecstasy|ecstasy|Ecstasy|ecstasy|ecstasy|ecstasy|ecstasy	Chemical	5:24:41:102:119:178:207:231:255:286:303:323	6:25:42:103:120:179:208:232:256:287:304:324	0:1:2:3:4:7:8:9:10:11:12:12	D008569	Learning and memory deficits|impairments in learning and memory|Deficits in learning and memory	Disease	0:27:155	4:32:160	0:1:5	1:NR:2	R2L	NON-CROSS	167-168	155-160	D002188	cannabis|cannabis|cannabis|cannabis|cannabis|cannabis	Chemical	115:130:167:191:257:299	116:131:168:192:258:300	4:4:5:7:10:11	D007859	Learning and memory deficits|impairments in learning and memory|Deficits in learning and memory	Disease	0:27:155	4:32:160	0:1:5	1:NR:2	R2L	NON-CROSS	167-168	155-160	D002188	cannabis|cannabis|cannabis|cannabis|cannabis|cannabis	Chemical	115:130:167:191:257:299	116:131:168:192:258:300	4:4:5:7:10:11	D008569	Learning and memory deficits|impairments in learning and memory|Deficits in learning and memory	Disease	0:27:155	4:32:160	0:1:5	1:NR:2	L2R	NON-CROSS	207-208	210-211	D018817	ecstasy|ecstasy|ecstasy|ecstasy|ecstasy|Ecstasy|ecstasy|Ecstasy|ecstasy|ecstasy|ecstasy|ecstasy	Chemical	5:24:41:102:119:178:207:231:255:286:303:323	6:25:42:103:120:179:208:232:256:287:304:324	0:1:2:3:4:7:8:9:10:11:12:12	D006948	hyperactivity|hyperactivity	Disease	162:210	163:211	5:8	1:NR:2	L2R	NON-CROSS	320-321	323-324	D018817	ecstasy|ecstasy|ecstasy|ecstasy|ecstasy|Ecstasy|ecstasy|Ecstasy|ecstasy|ecstasy|ecstasy|ecstasy	Chemical	5:24:41:102:119:178:207:231:255:286:303:323	6:25:42:103:120:179:208:232:256:287:304:324	0:1:2:3:4:7:8:9:10:11:12:12	D020258	neurotoxic	Disease	320	321	12	1:NR:2	L2R	NON-CROSS	162-163	167-168	D002188	cannabis|cannabis|cannabis|cannabis|cannabis|cannabis	Chemical	115:130:167:191:257:299	116:131:168:192:258:300	4:4:5:7:10:11	D006948	hyperactivity|hyperactivity	Disease	162:210	163:211	5:8	1:NR:2	L2R	CROSS	299-300	320-321	D002188	cannabis|cannabis|cannabis|cannabis|cannabis|cannabis	Chemical	115:130:167:191:257:299	116:131:168:192:258:300	4:4:5:7:10:11	D020258	neurotoxic	Disease	320	321	12
20003049	Prolonged elevation of plasma argatroban in a cardiac transplant patient with a suspected history of heparin - induced thrombocytopenia with thrombosis .|BACKGROUND : Direct thrombin inhibitors ( DTIs ) provide an alternative method of anticoagulation for patients with a history of heparin - induced thrombocytopenia ( HIT ) or HIT with thrombosis ( HITT ) undergoing cardiopulmonary bypass ( CPB ) .|In the following report , a 65 - year - old critically ill patient with a suspected history of HITT was administered argatroban for anticoagulation on bypass during heart transplantation .|The patient required massive transfusion support ( 55 units of red blood cells , 42 units of fresh - frozen plasma , 40 units of cryoprecipitate , 40 units of platelets , and three doses of recombinant Factor VIIa ) for severe intraoperative and postoperative bleeding .|STUDY DESIGN AND METHODS : Plasma samples from before and after CPB were analyzed postoperatively for argatroban concentration using a modified ecarin clotting time ( ECT ) assay .|RESULTS : Unexpectedly high concentrations of argatroban were measured in these samples ( range , 0 - 32 microg / mL ) , and a prolonged plasma argatroban half life ( t ( 1 / 2 ) ) of 514 minutes was observed ( published elimination t ( 1 / 2 ) is 39 - 51 minutes [ < or = 181 minutes with hepatic impairment ] ) .|CONCLUSIONS : Correlation of plasma argatroban concentration versus the patient 's coagulation variables and clinical course suggest that prolonged elevated levels of plasma argatroban may have contributed to the patient 's extended coagulopathy .|Because DTIs do not have reversal agents , surgical teams and transfusion services should remain aware of the possibility of massive transfusion events during anticoagulation with these agents .|This is the first report to measure plasma argatroban concentration in the context of CPB and extended coagulopathy .	1:CID:2	L2R	CROSS	136-140	157-158	C031942	argatroban|argatroban|argatroban|argatroban|argatroban|argatroban|argatroban|argatroban	Chemical	4:85:157:176:197:244:262:310	5:86:158:177:198:245:263:311	0:2:4:5:5:6:6:8	D016063	intraoperative and postoperative bleeding	Disease	136	140	3	1:CID:2	L2R	CROSS	136-140	157-158	C031942	argatroban|argatroban|argatroban|argatroban|argatroban|argatroban|argatroban|argatroban	Chemical	4:85:157:176:197:244:262:310	5:86:158:177:198:245:263:311	0:2:4:5:5:6:6:8	D019106	intraoperative and postoperative bleeding	Disease	136	140	3	1:NR:2	L2R	NON-CROSS	82-83	85-86	C031942	argatroban|argatroban|argatroban|argatroban|argatroban|argatroban|argatroban|argatroban	Chemical	4:85:157:176:197:244:262:310	5:86:158:177:198:245:263:311	0:2:4:5:5:6:6:8	D013921	thrombocytopenia|thrombocytopenia|HIT|HIT|HITT|HITT	Disease	18:45:47:50:54:82	19:46:48:51:55:83	0:1:1:1:1:2	1:NR:2	L2R	NON-CROSS	82-83	85-86	C031942	argatroban|argatroban|argatroban|argatroban|argatroban|argatroban|argatroban|argatroban	Chemical	4:85:157:176:197:244:262:310	5:86:158:177:198:245:263:311	0:2:4:5:5:6:6:8	D013927	thrombosis|thrombosis|HITT|HITT	Disease	20:52:54:82	21:53:55:83	0:1:1:2	1:NR:2	L2R	NON-CROSS	74-76	85-86	C031942	argatroban|argatroban|argatroban|argatroban|argatroban|argatroban|argatroban|argatroban	Chemical	4:85:157:176:197:244:262:310	5:86:158:177:198:245:263:311	0:2:4:5:5:6:6:8	D016638	critically ill	Disease	74	76	2	1:NR:2	L2R	NON-CROSS	234-236	244-245	C031942	argatroban|argatroban|argatroban|argatroban|argatroban|argatroban|argatroban|argatroban	Chemical	4:85:157:176:197:244:262:310	5:86:158:177:198:245:263:311	0:2:4:5:5:6:6:8	D008107	hepatic impairment	Disease	234	236	5	1:NR:2	L2R	NON-CROSS	262-263	271-272	C031942	argatroban|argatroban|argatroban|argatroban|argatroban|argatroban|argatroban|argatroban	Chemical	4:85:157:176:197:244:262:310	5:86:158:177:198:245:263:311	0:2:4:5:5:6:6:8	D001778	coagulopathy|coagulopathy	Disease	271:319	272:320	6:8	1:NR:2	L2R	NON-CROSS	15-16	18-19	D006493	heparin|heparin	Chemical	15:42	16:43	0:1	D013921	thrombocytopenia|thrombocytopenia|HIT|HIT|HITT|HITT	Disease	18:45:47:50:54:82	19:46:48:51:55:83	0:1:1:1:1:2	1:NR:2	L2R	NON-CROSS	15-16	20-21	D006493	heparin|heparin	Chemical	15:42	16:43	0:1	D013927	thrombosis|thrombosis|HITT|HITT	Disease	20:52:54:82	21:53:55:83	0:1:1:2	1:NR:2	L2R	CROSS	42-43	74-76	D006493	heparin|heparin	Chemical	15:42	16:43	0:1	D016638	critically ill	Disease	74	76	2	1:NR:2	L2R	CROSS	42-43	136-140	D006493	heparin|heparin	Chemical	15:42	16:43	0:1	D016063	intraoperative and postoperative bleeding	Disease	136	140	3	1:NR:2	L2R	CROSS	42-43	136-140	D006493	heparin|heparin	Chemical	15:42	16:43	0:1	D019106	intraoperative and postoperative bleeding	Disease	136	140	3	1:NR:2	L2R	CROSS	42-43	234-236	D006493	heparin|heparin	Chemical	15:42	16:43	0:1	D008107	hepatic impairment	Disease	234	236	5	1:NR:2	L2R	CROSS	42-43	271-272	D006493	heparin|heparin	Chemical	15:42	16:43	0:1	D001778	coagulopathy|coagulopathy	Disease	271:319	272:320	6:8
20196116	Antituberculosis therapy - induced acute liver failure : magnitude , profile , prognosis , and predictors of outcome .|Antituberculosis therapy ( ATT ) - associated acute liver failure ( ATT - ALF ) is the commonest drug - induced ALF in South Asia .|Prospective studies on ATT - ALF are lacking .|The current study prospectively evaluated the magnitude , clinical course , outcome , and prognostic factors in ATT - ALF .|From January 1986 to January 2009 , 1223 consecutive ALF patients were evaluated : ATT alone was the cause in 70 ( 5 . 7 % ) patients .|Another 15 ( 1 . 2 % ) had ATT and simultaneous hepatitis virus infection .|In 44 ( 62 . 8 % ) patients , ATT was prescribed empirically without definitive evidence of tuberculosis .|ATT - ALF patients were younger ( 32 . 87 [ + / - 15 . 8 ] years ) , and 49 ( 70 % ) of them were women .|Most had hyperacute presentation ; the median icterus encephalopathy interval was 4 . 5 ( 0 - 30 ) days .|The median duration of ATT before ALF was 30 ( 7 - 350 ) days .|At presentation , advanced encephalopathy and cerebral edema were present in 51 ( 76 % ) and 29 ( 41 . 4 % ) patients , respectively .|Gastrointestinal bleed , seizures , infection , and acute renal failure were documented in seven ( 10 % ) , five ( 7 . 1 % ) , 26 ( 37 . 1 % ) , and seven ( 10 % ) patients , respectively .|Compared with hepatitis E virus ( HEV ) and non - A non - E - induced ALF , ATT - ALF patients had nearly similar presentations except for older age and less elevation of liver enzymes .|The mortality rate among patients with ATT - ALF was high ( 67 . 1 % , n = 47 ) , and only 23 ( 32 . 9 % ) patients recovered with medical treatment .|In multivariate analysis , three factors independently predicted mortality : serum bilirubin ( > or = 10 . 8 mg / dL ) , prothrombin time ( PT ) prolongation ( > or = 26 seconds ) , and grade III / IV encephalopathy at presentation .|CONCLUSION : ATT - ALF constituted 5 . 7 % of ALF at our center and had a high mortality rate .|Because the mortality rate is so high , determining which factors are predictors is less important .|A high proportion of patients had consumed ATT empirically , which could have been prevented .	1:CID:2	L2R	NON-CROSS	0-1	4-7	D000995	Antituberculosis|Antituberculosis	Chemical	0:19	1:20	0:1	D017114	acute liver failure|acute liver failure|ALF|ALF|ALF|ALF|ALF|ALF|ALF|ALF|ALF|ALF|ALF|ALF	Disease	4:26:32:40:50:73:84:142:199:300:304:329:409:416	7:29:33:41:51:74:85:143:200:301:305:330:410:417	0:1:1:1:2:3:4:7:9:12:12:13:15:15	1:NR:2	L2R	CROSS	19-20	116-119	D000995	Antituberculosis|Antituberculosis	Chemical	0:19	1:20	0:1	D006525	hepatitis virus infection	Disease	116	119	5	1:NR:2	L2R	CROSS	19-20	138-139	D000995	Antituberculosis|Antituberculosis	Chemical	0:19	1:20	0:1	D014376	tuberculosis	Disease	138	139	6	1:NR:2	L2R	CROSS	19-20	179-180	D000995	Antituberculosis|Antituberculosis	Chemical	0:19	1:20	0:1	D007565	icterus	Disease	179	180	8	1:NR:2	L2R	CROSS	19-20	180-181	D000995	Antituberculosis|Antituberculosis	Chemical	0:19	1:20	0:1	D001927	encephalopathy|encephalopathy|encephalopathy	Disease	180:213:401	181:214:402	8:10:14	1:NR:2	L2R	CROSS	19-20	215-217	D000995	Antituberculosis|Antituberculosis	Chemical	0:19	1:20	0:1	D001929	cerebral edema	Disease	215	217	10	1:NR:2	L2R	CROSS	19-20	237-239	D000995	Antituberculosis|Antituberculosis	Chemical	0:19	1:20	0:1	D006471	Gastrointestinal bleed	Disease	237	239	11	1:NR:2	L2R	CROSS	19-20	240-241	D000995	Antituberculosis|Antituberculosis	Chemical	0:19	1:20	0:1	D012640	seizures	Disease	240	241	11	1:NR:2	L2R	CROSS	19-20	242-243	D000995	Antituberculosis|Antituberculosis	Chemical	0:19	1:20	0:1	D007239	infection	Disease	242	243	11	1:NR:2	L2R	CROSS	19-20	245-248	D000995	Antituberculosis|Antituberculosis	Chemical	0:19	1:20	0:1	D058186	acute renal failure	Disease	245	248	11	1:NR:2	L2R	CROSS	19-20	285-287	D000995	Antituberculosis|Antituberculosis	Chemical	0:19	1:20	0:1	D016751	hepatitis E	Disease	285	287	12	1:NR:2	R2L	CROSS	369-370	329-330	D001663	bilirubin	Chemical	369	370	14	D017114	acute liver failure|acute liver failure|ALF|ALF|ALF|ALF|ALF|ALF|ALF|ALF|ALF|ALF|ALF|ALF	Disease	4:26:32:40:50:73:84:142:199:300:304:329:409:416	7:29:33:41:51:74:85:143:200:301:305:330:410:417	0:1:1:1:2:3:4:7:9:12:12:13:15:15	1:NR:2	R2L	CROSS	369-370	116-119	D001663	bilirubin	Chemical	369	370	14	D006525	hepatitis virus infection	Disease	116	119	5	1:NR:2	R2L	CROSS	369-370	138-139	D001663	bilirubin	Chemical	369	370	14	D014376	tuberculosis	Disease	138	139	6	1:NR:2	R2L	CROSS	369-370	179-180	D001663	bilirubin	Chemical	369	370	14	D007565	icterus	Disease	179	180	8	1:NR:2	R2L	NON-CROSS	401-402	369-370	D001663	bilirubin	Chemical	369	370	14	D001927	encephalopathy|encephalopathy|encephalopathy	Disease	180:213:401	181:214:402	8:10:14	1:NR:2	R2L	CROSS	369-370	215-217	D001663	bilirubin	Chemical	369	370	14	D001929	cerebral edema	Disease	215	217	10	1:NR:2	R2L	CROSS	369-370	237-239	D001663	bilirubin	Chemical	369	370	14	D006471	Gastrointestinal bleed	Disease	237	239	11	1:NR:2	R2L	CROSS	369-370	240-241	D001663	bilirubin	Chemical	369	370	14	D012640	seizures	Disease	240	241	11	1:NR:2	R2L	CROSS	369-370	242-243	D001663	bilirubin	Chemical	369	370	14	D007239	infection	Disease	242	243	11	1:NR:2	R2L	CROSS	369-370	245-248	D001663	bilirubin	Chemical	369	370	14	D058186	acute renal failure	Disease	245	248	11	1:NR:2	R2L	CROSS	369-370	285-287	D001663	bilirubin	Chemical	369	370	14	D016751	hepatitis E	Disease	285	287	12
20470218	Central nervous system complications during treatment of acute lymphoblastic leukemia in a single pediatric institution .|Central nervous system ( CNS ) complications during treatment of childhood acute lymphoblastic leukemia ( ALL ) remain a challenging clinical problem .|Outcome improvement with more intensive chemotherapy has significantly increased the incidence and severity of adverse events .|This study analyzed the incidence of neurological complications during ALL treatment in a single pediatric institution , focusing on clinical , radiological , and electrophysiological findings .|Exclusion criteria included CNS leukemic infiltration at diagnosis , therapy - related peripheral neuropathy , late - onset encephalopathy , or long - term neurocognitive defects .|During a 9 - year period , we retrospectively collected 27 neurological events ( 11 % ) in as many patients , from 253 children enrolled in the ALL front - line protocol .|CNS complications included posterior reversible leukoencephalopathy syndrome ( n = 10 ) , stroke ( n = 5 ) , temporal lobe epilepsy ( n = 2 ) , high - dose methotrexate toxicity ( n = 2 ) , syndrome of inappropriate antidiuretic hormone secretion ( n = 1 ) , and other unclassified events ( n = 7 ) .|In conclusion , CNS complications are frequent events during ALL therapy , and require rapid detection and prompt treatment to limit permanent damage .	1:CID:2	R2L	CROSS	176-177	107-109	D008727	methotrexate	Chemical	176	177	6	D002493	Central nervous system complications|Central nervous system ( CNS ) complications|neurological complications|neurocognitive defects	Disease	0:16:62:107	4:23:64:109	0:1:3:4	1:NR:2	R2L	CROSS	176-177	138-139	D008727	methotrexate	Chemical	176	177	6	D054198	acute lymphoblastic leukemia|acute lymphoblastic leukemia|ALL|ALL|ALL|ALL	Disease	7:27:31:65:138:215	10:30:32:66:139:216	0:1:1:3:5:7	1:NR:2	R2L	CROSS	176-177	87-89	D008727	methotrexate	Chemical	176	177	6	D017254	leukemic infiltration	Disease	87	89	4	1:NR:2	R2L	CROSS	176-177	95-97	D008727	methotrexate	Chemical	176	177	6	D010523	peripheral neuropathy	Disease	95	97	4	1:NR:2	R2L	CROSS	176-177	101-102	D008727	methotrexate	Chemical	176	177	6	D001927	encephalopathy	Disease	101	102	4	1:NR:2	R2L	NON-CROSS	176-177	149-150	D008727	methotrexate	Chemical	176	177	6	D056784	leukoencephalopathy	Disease	149	150	6	1:NR:2	R2L	NON-CROSS	176-177	157-158	D008727	methotrexate	Chemical	176	177	6	D020521	stroke	Disease	157	158	6	1:NR:2	R2L	NON-CROSS	176-177	164-167	D008727	methotrexate	Chemical	176	177	6	D004833	temporal lobe epilepsy	Disease	164	167	6	1:NR:2	L2R	NON-CROSS	176-177	177-178	D008727	methotrexate	Chemical	176	177	6	D064420	toxicity	Disease	177	178	6	1:NR:2	L2R	NON-CROSS	176-177	186-190	D008727	methotrexate	Chemical	176	177	6	D007177	inappropriate antidiuretic hormone secretion	Disease	186	190	6
20722491	Safety of capecitabine : a review .|IMPORTANCE OF THE FIELD : Fluoropyrimidines , in particular 5 - fluorouracil ( 5 - FU ) , have been the mainstay of treatment for several solid tumors , including colorectal , breast and head and neck cancers , for > 40 years .|AREAS COVERED IN THIS REVIEW : This article reviews the pharmacology and efficacy of capecitabine with a special emphasis on its safety .|WHAT THE READER WILL GAIN : The reader will gain better insight into the safety of capecitabine in special populations such as patients with advanced age , renal and kidney disease .|We also explore different dosing and schedules of capecitabine administration .|TAKE HOME MESSAGE : Capecitabine is an oral prodrug of 5 - FU and was developed to fulfill the need for a more convenient therapy and provide an improved safety / efficacy profile .|It has shown promising results alone or in combination with other chemotherapeutic agents in colorectal , breast , pancreaticobiliary , gastric , renal cell and head and neck cancers .|The most commonly reported toxic effects of capecitabine are diarrhea , nausea , vomiting , stomatitis and hand - foot syndrome .|Capecitabine has a well - established safety profile and can be given safely to patients with advanced age , hepatic and renal dysfunctions .	1:CID:2	L2R	NON-CROSS	188-189	190-191	C110904	capecitabine|capecitabine|capecitabine|capecitabine|Capecitabine|capecitabine|Capecitabine	Chemical	2:65:90:114:121:188:203	3:66:91:115:122:189:204	0:2:3:4:5:7:8	D003967	diarrhea	Disease	190	191	7	1:CID:2	L2R	NON-CROSS	188-189	192-193	C110904	capecitabine|capecitabine|capecitabine|capecitabine|Capecitabine|capecitabine|Capecitabine	Chemical	2:65:90:114:121:188:203	3:66:91:115:122:189:204	0:2:3:4:5:7:8	D009325	nausea	Disease	192	193	7	1:CID:2	L2R	NON-CROSS	188-189	194-195	C110904	capecitabine|capecitabine|capecitabine|capecitabine|Capecitabine|capecitabine|Capecitabine	Chemical	2:65:90:114:121:188:203	3:66:91:115:122:189:204	0:2:3:4:5:7:8	D014839	vomiting	Disease	194	195	7	1:CID:2	L2R	NON-CROSS	196-197	203-204	C110904	capecitabine|capecitabine|capecitabine|capecitabine|Capecitabine|capecitabine|Capecitabine	Chemical	2:65:90:114:121:188:203	3:66:91:115:122:189:204	0:2:3:4:5:7:8	D013280	stomatitis	Disease	196	197	7	1:CID:2	L2R	NON-CROSS	198-202	203-204	C110904	capecitabine|capecitabine|capecitabine|capecitabine|Capecitabine|capecitabine|Capecitabine	Chemical	2:65:90:114:121:188:203	3:66:91:115:122:189:204	0:2:3:4:5:7:8	D060831	hand - foot syndrome	Disease	198	202	7	1:NR:2	L2R	CROSS	34-35	65-66	C110904	capecitabine|capecitabine|capecitabine|capecitabine|Capecitabine|capecitabine|Capecitabine	Chemical	2:65:90:114:121:188:203	3:66:91:115:122:189:204	0:2:3:4:5:7:8	D009369	tumors	Disease	34	35	1	1:NR:2	L2R	CROSS	165-180	188-189	C110904	capecitabine|capecitabine|capecitabine|capecitabine|Capecitabine|capecitabine|Capecitabine	Chemical	2:65:90:114:121:188:203	3:66:91:115:122:189:204	0:2:3:4:5:7:8	D015179	colorectal , breast and head and neck cancers|colorectal , breast , pancreaticobiliary , gastric , renal cell and head and neck cancers	Disease	37:165	45:180	1:6	1:NR:2	L2R	CROSS	165-180	188-189	C110904	capecitabine|capecitabine|capecitabine|capecitabine|Capecitabine|capecitabine|Capecitabine	Chemical	2:65:90:114:121:188:203	3:66:91:115:122:189:204	0:2:3:4:5:7:8	D001943	colorectal , breast and head and neck cancers|colorectal , breast , pancreaticobiliary , gastric , renal cell and head and neck cancers	Disease	37:165	45:180	1:6	1:NR:2	L2R	CROSS	165-180	188-189	C110904	capecitabine|capecitabine|capecitabine|capecitabine|Capecitabine|capecitabine|Capecitabine	Chemical	2:65:90:114:121:188:203	3:66:91:115:122:189:204	0:2:3:4:5:7:8	D006258	colorectal , breast and head and neck cancers|colorectal , breast , pancreaticobiliary , gastric , renal cell and head and neck cancers	Disease	37:165	45:180	1:6	1:NR:2	L2R	NON-CROSS	101-105	114-115	C110904	capecitabine|capecitabine|capecitabine|capecitabine|Capecitabine|capecitabine|Capecitabine	Chemical	2:65:90:114:121:188:203	3:66:91:115:122:189:204	0:2:3:4:5:7:8	D007674	renal and kidney disease|hepatic and renal dysfunctions	Disease	101:222	105:226	3:8	1:NR:2	L2R	CROSS	165-180	188-189	C110904	capecitabine|capecitabine|capecitabine|capecitabine|Capecitabine|capecitabine|Capecitabine	Chemical	2:65:90:114:121:188:203	3:66:91:115:122:189:204	0:2:3:4:5:7:8	D010190	colorectal , breast , pancreaticobiliary , gastric , renal cell and head and neck cancers	Disease	165	180	6	1:NR:2	L2R	CROSS	165-180	188-189	C110904	capecitabine|capecitabine|capecitabine|capecitabine|Capecitabine|capecitabine|Capecitabine	Chemical	2:65:90:114:121:188:203	3:66:91:115:122:189:204	0:2:3:4:5:7:8	D013274	colorectal , breast , pancreaticobiliary , gastric , renal cell and head and neck cancers	Disease	165	180	6	1:NR:2	L2R	CROSS	165-180	188-189	C110904	capecitabine|capecitabine|capecitabine|capecitabine|Capecitabine|capecitabine|Capecitabine	Chemical	2:65:90:114:121:188:203	3:66:91:115:122:189:204	0:2:3:4:5:7:8	D002292	colorectal , breast , pancreaticobiliary , gastric , renal cell and head and neck cancers	Disease	165	180	6	1:NR:2	L2R	NON-CROSS	203-204	222-226	C110904	capecitabine|capecitabine|capecitabine|capecitabine|Capecitabine|capecitabine|Capecitabine	Chemical	2:65:90:114:121:188:203	3:66:91:115:122:189:204	0:2:3:4:5:7:8	D008107	hepatic and renal dysfunctions	Disease	222	226	8	1:NR:2	L2R	NON-CROSS	20-23	34-35	D005472	5 - fluorouracil|5 - FU|5 - FU	Chemical	16:20:127	19:23:130	1:1:5	D009369	tumors	Disease	34	35	1	1:NR:2	L2R	NON-CROSS	20-23	37-45	D005472	5 - fluorouracil|5 - FU|5 - FU	Chemical	16:20:127	19:23:130	1:1:5	D015179	colorectal , breast and head and neck cancers|colorectal , breast , pancreaticobiliary , gastric , renal cell and head and neck cancers	Disease	37:165	45:180	1:6	1:NR:2	L2R	NON-CROSS	20-23	37-45	D005472	5 - fluorouracil|5 - FU|5 - FU	Chemical	16:20:127	19:23:130	1:1:5	D001943	colorectal , breast and head and neck cancers|colorectal , breast , pancreaticobiliary , gastric , renal cell and head and neck cancers	Disease	37:165	45:180	1:6	1:NR:2	L2R	NON-CROSS	20-23	37-45	D005472	5 - fluorouracil|5 - FU|5 - FU	Chemical	16:20:127	19:23:130	1:1:5	D006258	colorectal , breast and head and neck cancers|colorectal , breast , pancreaticobiliary , gastric , renal cell and head and neck cancers	Disease	37:165	45:180	1:6	1:NR:2	L2R	CROSS	101-105	127-130	D005472	5 - fluorouracil|5 - FU|5 - FU	Chemical	16:20:127	19:23:130	1:1:5	D007674	renal and kidney disease|hepatic and renal dysfunctions	Disease	101:222	105:226	3:8	1:NR:2	L2R	CROSS	127-130	165-180	D005472	5 - fluorouracil|5 - FU|5 - FU	Chemical	16:20:127	19:23:130	1:1:5	D010190	colorectal , breast , pancreaticobiliary , gastric , renal cell and head and neck cancers	Disease	165	180	6	1:NR:2	L2R	CROSS	127-130	165-180	D005472	5 - fluorouracil|5 - FU|5 - FU	Chemical	16:20:127	19:23:130	1:1:5	D013274	colorectal , breast , pancreaticobiliary , gastric , renal cell and head and neck cancers	Disease	165	180	6	1:NR:2	L2R	CROSS	127-130	165-180	D005472	5 - fluorouracil|5 - FU|5 - FU	Chemical	16:20:127	19:23:130	1:1:5	D002292	colorectal , breast , pancreaticobiliary , gastric , renal cell and head and neck cancers	Disease	165	180	6	1:NR:2	L2R	CROSS	127-130	190-191	D005472	5 - fluorouracil|5 - FU|5 - FU	Chemical	16:20:127	19:23:130	1:1:5	D003967	diarrhea	Disease	190	191	7	1:NR:2	L2R	CROSS	127-130	192-193	D005472	5 - fluorouracil|5 - FU|5 - FU	Chemical	16:20:127	19:23:130	1:1:5	D009325	nausea	Disease	192	193	7	1:NR:2	L2R	CROSS	127-130	194-195	D005472	5 - fluorouracil|5 - FU|5 - FU	Chemical	16:20:127	19:23:130	1:1:5	D014839	vomiting	Disease	194	195	7	1:NR:2	L2R	CROSS	127-130	196-197	D005472	5 - fluorouracil|5 - FU|5 - FU	Chemical	16:20:127	19:23:130	1:1:5	D013280	stomatitis	Disease	196	197	7	1:NR:2	L2R	CROSS	127-130	198-202	D005472	5 - fluorouracil|5 - FU|5 - FU	Chemical	16:20:127	19:23:130	1:1:5	D060831	hand - foot syndrome	Disease	198	202	7	1:NR:2	L2R	CROSS	127-130	222-226	D005472	5 - fluorouracil|5 - FU|5 - FU	Chemical	16:20:127	19:23:130	1:1:5	D008107	hepatic and renal dysfunctions	Disease	222	226	8
20882060	Effects of pallidal neurotensin on haloperidol - induced parkinsonian catalepsy : behavioral and electrophysiological studies .|OBJECTIVE : The globus pallidus plays a critical role in movement regulation .|Previous studies have indicated that the globus pallidus receives neurotensinergic innervation from the striatum , and systemic administration of a neurotensin analog could produce antiparkinsonian effects .|The present study aimed to investigate the effects of pallidal neurotensin on haloperidol - induced parkinsonian symptoms .|METHODS : Behavioral experiments and electrophysiological recordings were performed in the present study .|RESULTS : Bilateral infusions of neurotensin into the globus pallidus reversed haloperidol - induced parkinsonian catalepsy in rats .|Electrophysiological recordings showed that microinjection of neurotensin induced excitation of pallidal neurons in the presence of systemic haloperidol administration .|The neurotensin type - 1 receptor antagonist SR48692 blocked both the behavioral and the electrophysiological effects induced by neurotensin .|CONCLUSION : Activation of pallidal neurotensin receptors may be involved in neurotensin - induced antiparkinsonian effects .	1:CID:2	L2R	NON-CROSS	5-6	8-10	D006220	haloperidol|haloperidol|haloperidol|haloperidol	Chemical	5:68:99:124	6:69:100:125	0:3:5:6	D002375	parkinsonian catalepsy|parkinsonian catalepsy	Disease	8:102	10:104	0:5	1:NR:2	L2R	NON-CROSS	3-4	8-10	D009496	neurotensin|neurotensin|neurotensin|neurotensin|neurotensin|neurotensin|neurotensin|neurotensin	Chemical	3:49:66:93:113:145:152:158	4:50:67:94:114:146:153:159	0:2:3:5:6:7:8:8	D002375	parkinsonian catalepsy|parkinsonian catalepsy	Disease	8:102	10:104	0:5	1:NR:2	L2R	NON-CROSS	66-67	71-73	D009496	neurotensin|neurotensin|neurotensin|neurotensin|neurotensin|neurotensin|neurotensin|neurotensin	Chemical	3:49:66:93:113:145:152:158	4:50:67:94:114:146:153:159	0:2:3:5:6:7:8:8	D010302	parkinsonian symptoms	Disease	71	73	3	1:NR:2	L2R	NON-CROSS	68-69	71-73	D006220	haloperidol|haloperidol|haloperidol|haloperidol	Chemical	5:68:99:124	6:69:100:125	0:3:5:6	D010302	parkinsonian symptoms	Disease	71	73	3	1:NR:2	R2L	CROSS	128-134	102-104	C079087	neurotensin type - 1 receptor antagonist|SR48692	Chemical	128:134	134:135	7:7	D002375	parkinsonian catalepsy|parkinsonian catalepsy	Disease	8:102	10:104	0:5	1:NR:2	R2L	CROSS	128-134	71-73	C079087	neurotensin type - 1 receptor antagonist|SR48692	Chemical	128:134	134:135	7:7	D010302	parkinsonian symptoms	Disease	71	73	3
26094	Antihypertensive drugs and depression : a reappraisal .|Eighty - nine new referral hypertensive out - patients and 46 new referral non - hypertensive chronically physically ill out - patients completed a mood rating scale at regular intervals for one year .|The results showed a high prevalence of depression in both groups of patients , with no preponderance in the hypertensive group .|Hypertensive patients with psychiatric histories had a higher prevalence of depression than the comparison patients .|This was accounted for by a significant number of depressions occurring in methyl dopa treated patients with psychiatric histories .	1:CID:2	R2L	NON-CROSS	92-94	89-90	D008750	methyl dopa	Chemical	92	94	4	D003866	depression|depression|depression|depressions	Disease	3:49:74:89	4:50:75:90	0:2:3:4	1:NR:2	R2L	CROSS	92-94	64-65	D008750	methyl dopa	Chemical	92	94	4	D006973	hypertensive|hypertensive|hypertensive|Hypertensive	Disease	13:23:61:64	14:24:62:65	1:1:2:3	not_include	R2L	NON-CROSS	97-98	92-94	D008750	methyl dopa	Chemical	92	94	4	D001523	psychiatric|psychiatric	Disease	67:97	68:98	3:4
322550	Pulmonary shunt and cardiovascular responses to CPAP during nitroprusside - induced hypotension .|The effects of continuous positive airway pressure ( CPAP ) on cardiovascular dynamics and pulmonary shunt ( QS / QT ) were investigated in 12 dogs before and during sodium nitroprusside infusion that decreased mean arterial blood pressure 40 - 50 per cent .|Before nitroprusside infusion , 5 cm H2O CPAP significantly , P less than . 05 , decreased arterial blood pressure , but did not significantly alter heart rate , cardiac output , systemic vascular resistance , or QS / QT .|Ten cm H2O CPAP before nitroprusside infusion produced a further decrease in arterial blood pressure and significantly increased heart rate and decreased cardiac output and QS / QT .|Nitroprusside caused significant decreases in arterial blood pressure and systemic vascular resistance and increases in heart rate , but did not change cardiac output or QS / QT .|Five cm H2O CPAP during nitroprusside did not further alter any of the above - mentioned variables .|However , 10 cm H2O CPAP decreased arterial blood pressure , cardiac output , and QS / QT .|These data indicate that nitroprusside infusion rates that decrease mean arterial blood pressure by 40 - 50 per cent do not change cardiac output or QS / QT .|During nitroprusside infusion low levels of CPAP do not markedly alter cardiovascular dynamics , but high levels of CPAP ( 10 cm H2O ) , while decreasing QS / QT , produce marked decreases in arterial blood pressure and cardiac output .	1:CID:2	L2R	NON-CROSS	8-9	11-12	D009599	nitroprusside|sodium nitroprusside|nitroprusside|nitroprusside|Nitroprusside|nitroprusside|nitroprusside|nitroprusside	Chemical	8:42:58:103:127:161:197:223	9:44:59:104:128:162:198:224	0:1:2:3:4:5:7:8	D007022	hypotension|decrease in arterial blood pressure|decreases in arterial blood pressure|decreases in arterial blood pressure and cardiac output	Disease	11:108:130:255	12:113:135:263	0:3:4:8	1:NR:2	L2R	NON-CROSS	119-122	127-128	D009599	nitroprusside|sodium nitroprusside|nitroprusside|nitroprusside|Nitroprusside|nitroprusside|nitroprusside|nitroprusside	Chemical	8:42:58:103:127:161:197:223	9:44:59:104:128:162:198:224	0:1:2:3:4:5:7:8	D002303	decreased cardiac output|decreases in arterial blood pressure and cardiac output	Disease	119:255	122:263	3:8	1:NR:2	R2L	NON-CROSS	255-263	244-245	D014867	H2O|H2O|H2O|H2O|H2O	Chemical	63:100:158:178:244	64:101:159:179:245	2:3:5:6:8	D007022	hypotension|decrease in arterial blood pressure|decreases in arterial blood pressure|decreases in arterial blood pressure and cardiac output	Disease	11:108:130:255	12:113:135:263	0:3:4:8	1:NR:2	L2R	NON-CROSS	244-245	255-263	D014867	H2O|H2O|H2O|H2O|H2O	Chemical	63:100:158:178:244	64:101:159:179:245	2:3:5:6:8	D002303	decreased cardiac output|decreases in arterial blood pressure and cardiac output	Disease	119:255	122:263	3:8
869641	Mediation of enhanced reflex vagal bradycardia by L - dopa via central dopamine formation in dogs .|L - Dopa ( 5 mg / kg i . v . ) decreased blood pressure and heart rate after extracerebral decarboxylase inhibition with MK - 486 ( 25 mg / kg i . v . ) in anesthetize MAO - inhibited dogs .|In addition , reflex bradycardia caused by injected norepinephrine was significantly enhanced by L - dopa , DL - Threo - dihydroxyphenylserine had no effect on blood pressure , heart rate or reflex responses to norepinephrine .|FLA - 63 , a dopamine - beta - oxidase inhibitor , did not have any effect on the hypotension , bradycardia or reflex - enhancing effect of L - dopa .|Pimozide did not affect the actions of L - dopa on blood pressure and heart rate but completely blocked the enhancement of reflexes .|Removal of the carotid sinuses caused an elevation blood pressure and heart rate and abolished the negative chronotropic effect of norepinephrine .|However , L - dopa restored the bradycardia caused by norepinephrine in addition to decreasing blood pressure and heart rate .|5 - HTP ( 5 mg / kg i . v . ) decreased blood pressure and heart rate and decreased the reflex bradycardia to norepinephrine .|It is concluded that L - dopa enhances reflex bradycardia through central alpha - receptor stimulation .|Furthermore , the effects are mediated through dopamine rather than norepinephrine and do not require the carotid sinus baroreceptors .	1:CID:2	R2L	NON-CROSS	222-223	220-221	D009638	norepinephrine|norepinephrine|norepinephrine|norepinephrine|norepinephrine|norepinephrine	Chemical	69:96:174:186:222:251	70:97:175:187:223:252	2:2:5:6:7:9	D001919	bradycardia|bradycardia|bradycardia|bradycardia|bradycardia|bradycardia	Disease	5:65:119:183:220:233	6:66:120:184:221:234	0:2:3:6:7:8	1:NR:2	R2L	NON-CROSS	7-10	5-6	D007980	L - dopa|L - Dopa|L - dopa|L - dopa|L - dopa|L - dopa|L - dopa	Chemical	7:17:74:126:137:178:228	10:20:77:129:140:181:231	0:1:2:3:4:6:8	D001919	bradycardia|bradycardia|bradycardia|bradycardia|bradycardia|bradycardia	Disease	5:65:119:183:220:233	6:66:120:184:221:234	0:2:3:6:7:8	1:NR:2	R2L	NON-CROSS	12-13	5-6	D004298	dopamine|dopamine|dopamine	Chemical	12:103:248	13:104:249	0:3:9	D001919	bradycardia|bradycardia|bradycardia|bradycardia|bradycardia|bradycardia	Disease	5:65:119:183:220:233	6:66:120:184:221:234	0:2:3:6:7:8	1:NR:2	R2L	CROSS	65-66	41-44	D002230	MK - 486	Chemical	41	44	1	D001919	bradycardia|bradycardia|bradycardia|bradycardia|bradycardia|bradycardia	Disease	5:65:119:183:220:233	6:66:120:184:221:234	0:2:3:6:7:8	1:NR:2	R2L	CROSS	65-66	56-57	D008995	MAO	Chemical	56	57	1	D001919	bradycardia|bradycardia|bradycardia|bradycardia|bradycardia|bradycardia	Disease	5:65:119:183:220:233	6:66:120:184:221:234	0:2:3:6:7:8	1:NR:2	R2L	NON-CROSS	78-83	65-66	D015103	DL - Threo - dihydroxyphenylserine	Chemical	78	83	2	D001919	bradycardia|bradycardia|bradycardia|bradycardia|bradycardia|bradycardia	Disease	5:65:119:183:220:233	6:66:120:184:221:234	0:2:3:6:7:8	1:NR:2	R2L	NON-CROSS	119-120	98-101	D005406	FLA - 63	Chemical	98	101	3	D001919	bradycardia|bradycardia|bradycardia|bradycardia|bradycardia|bradycardia	Disease	5:65:119:183:220:233	6:66:120:184:221:234	0:2:3:6:7:8	1:NR:2	R2L	CROSS	130-131	119-120	D010868	Pimozide	Chemical	130	131	4	D001919	bradycardia|bradycardia|bradycardia|bradycardia|bradycardia|bradycardia	Disease	5:65:119:183:220:233	6:66:120:184:221:234	0:2:3:6:7:8	1:NR:2	R2L	NON-CROSS	197-200	183-184	D006916	5 - HTP	Chemical	197	200	7	D001919	bradycardia|bradycardia|bradycardia|bradycardia|bradycardia|bradycardia	Disease	5:65:119:183:220:233	6:66:120:184:221:234	0:2:3:6:7:8	1:NR:2	L2R	NON-CROSS	117-118	126-129	D007980	L - dopa|L - Dopa|L - dopa|L - dopa|L - dopa|L - dopa|L - dopa	Chemical	7:17:74:126:137:178:228	10:20:77:129:140:181:231	0:1:2:3:4:6:8	D007022	hypotension	Disease	117	118	3	1:NR:2	L2R	NON-CROSS	103-104	117-118	D004298	dopamine|dopamine|dopamine	Chemical	12:103:248	13:104:249	0:3:9	D007022	hypotension	Disease	117	118	3	1:NR:2	L2R	CROSS	41-44	117-118	D002230	MK - 486	Chemical	41	44	1	D007022	hypotension	Disease	117	118	3	1:NR:2	L2R	CROSS	56-57	117-118	D008995	MAO	Chemical	56	57	1	D007022	hypotension	Disease	117	118	3	1:NR:2	L2R	CROSS	96-97	117-118	D009638	norepinephrine|norepinephrine|norepinephrine|norepinephrine|norepinephrine|norepinephrine	Chemical	69:96:174:186:222:251	70:97:175:187:223:252	2:2:5:6:7:9	D007022	hypotension	Disease	117	118	3	1:NR:2	L2R	CROSS	78-83	117-118	D015103	DL - Threo - dihydroxyphenylserine	Chemical	78	83	2	D007022	hypotension	Disease	117	118	3	1:NR:2	L2R	NON-CROSS	98-101	117-118	D005406	FLA - 63	Chemical	98	101	3	D007022	hypotension	Disease	117	118	3	1:NR:2	R2L	CROSS	130-131	117-118	D010868	Pimozide	Chemical	130	131	4	D007022	hypotension	Disease	117	118	3	1:NR:2	R2L	CROSS	197-200	117-118	D006916	5 - HTP	Chemical	197	200	7	D007022	hypotension	Disease	117	118	3
1749407	Cocaine - induced myocardial infarction : clinical observations and pathogenetic considerations .|Clinical and experimental data published to date suggest several possible mechanisms by which cocaine may result in acute myocardial infarction .|In individuals with preexisting , high - grade coronary arterial narrowing , acute myocardial infarction may result from an increase in myocardial oxygen demand associated with cocaine - induced increase in rate - pressure product .|In other individuals with no underlying atherosclerotic obstruction , coronary occlusion may be due to spasm , thrombus , or both .|With regard to spasm , the clinical findings are largely circumstantial , and the locus of cocaine - induced vasoconstriction remains speculative .|Although certain clinical and experimental findings support the hypothesis that spasm involves the epicardial , medium - size vessels , other data suggest intramural vasoconstriction .|Diffuse intramural vasoconstriction is not consistent with reports of segmental , discrete infarction .|Whereas certain in vivo data suggest that these effects are alpha - mediated , other in vitro data suggest the opposite .|The finding of cocaine - induced vasoconstriction in segments of ( noninnervated ) human umbilical artery suggests that the presence or absence of intact innervation is not sufficient to explain the discrepant data involving the possibility of alpha - mediated effects .|Finally , the contribution of a primary , thrombotic effect of cocaine has not been excluded .	1:CID:2	L2R	NON-CROSS	0-1	3-5	D003042	Cocaine|cocaine|cocaine|cocaine|cocaine|cocaine	Chemical	0:25:59:107:179:229	1:26:60:108:180:230	0:1:2:4:8:9	D009203	myocardial infarction|acute myocardial infarction|acute myocardial infarction	Disease	3:29:45	5:32:48	0:1:2	1:NR:2	L2R	CROSS	59-60	75-77	D003042	Cocaine|cocaine|cocaine|cocaine|cocaine|cocaine	Chemical	0:25:59:107:179:229	1:26:60:108:180:230	0:1:2:4:8:9	D050197	atherosclerotic obstruction	Disease	75	77	3	1:NR:2	L2R	CROSS	59-60	78-80	D003042	Cocaine|cocaine|cocaine|cocaine|cocaine|cocaine	Chemical	0:25:59:107:179:229	1:26:60:108:180:230	0:1:2:4:8:9	D054059	coronary occlusion	Disease	78	80	3	1:NR:2	L2R	NON-CROSS	94-95	107-108	D003042	Cocaine|cocaine|cocaine|cocaine|cocaine|cocaine	Chemical	0:25:59:107:179:229	1:26:60:108:180:230	0:1:2:4:8:9	D013035	spasm|spasm|spasm	Disease	84:94:124	85:95:125	3:4:5	1:NR:2	L2R	NON-CROSS	226-227	229-230	D003042	Cocaine|cocaine|cocaine|cocaine|cocaine|cocaine	Chemical	0:25:59:107:179:229	1:26:60:108:180:230	0:1:2:4:8:9	D013927	thrombus|thrombotic	Disease	86:226	87:227	3:9	1:NR:2	L2R	CROSS	152-153	179-180	D003042	Cocaine|cocaine|cocaine|cocaine|cocaine|cocaine	Chemical	0:25:59:107:179:229	1:26:60:108:180:230	0:1:2:4:8:9	D007238	infarction	Disease	152	153	6	1:NR:2	R2L	NON-CROSS	55-56	45-48	D010100	oxygen	Chemical	55	56	2	D009203	myocardial infarction|acute myocardial infarction|acute myocardial infarction	Disease	3:29:45	5:32:48	0:1:2	1:NR:2	L2R	CROSS	55-56	75-77	D010100	oxygen	Chemical	55	56	2	D050197	atherosclerotic obstruction	Disease	75	77	3	1:NR:2	L2R	CROSS	55-56	78-80	D010100	oxygen	Chemical	55	56	2	D054059	coronary occlusion	Disease	78	80	3	1:NR:2	L2R	CROSS	55-56	84-85	D010100	oxygen	Chemical	55	56	2	D013035	spasm|spasm|spasm	Disease	84:94:124	85:95:125	3:4:5	1:NR:2	L2R	CROSS	55-56	86-87	D010100	oxygen	Chemical	55	56	2	D013927	thrombus|thrombotic	Disease	86:226	87:227	3:9	1:NR:2	L2R	CROSS	55-56	152-153	D010100	oxygen	Chemical	55	56	2	D007238	infarction	Disease	152	153	6
1786266	Rabbit syndrome , antidepressant use , and cerebral perfusion SPECT scan findings .|The rabbit syndrome is an extrapyramidal side effect associated with chronic neuroleptic therapy .|Its occurrence in a patient being treated with imipramine is described , representing the first reported case of this syndrome in conjunction with antidepressants .|Repeated cerebral perfusion SPECT scans revealed decreased basal ganglia perfusion while the movement disorder was present , and a return to normal perfusion when the rabbit syndrome resolved .	1:CID:2	R2L	CROSS	35-36	14-16	D007099	imipramine	Chemical	35	36	2	D001480	Rabbit syndrome|rabbit syndrome|decreased basal ganglia perfusion|rabbit syndrome	Disease	0:14:58:77	2:16:62:79	0:1:3:3	1:NR:2	R2L	NON-CROSS	3-4	0-2	D000928	antidepressant|antidepressants	Chemical	3:50	4:51	0:2	D001480	Rabbit syndrome|rabbit syndrome|decreased basal ganglia perfusion|rabbit syndrome	Disease	0:14:58:77	2:16:62:79	0:1:3:3	1:NR:2	L2R	CROSS	50-51	64-66	D000928	antidepressant|antidepressants	Chemical	3:50	4:51	0:2	D009069	movement disorder	Disease	64	66	3	1:NR:2	L2R	CROSS	35-36	64-66	D007099	imipramine	Chemical	35	36	2	D009069	movement disorder	Disease	64	66	3
1835291	Acute bronchodilating effects of ipratropium bromide and theophylline in chronic obstructive pulmonary disease .|The bronchodilator effects of a single dose of ipratropium bromide aerosol ( 36 micrograms ) and short - acting theophylline tablets ( dose titrated to produce serum levels of 10 - 20 micrograms / mL ) were compared in a double - blind , placebo - controlled crossover study in 21 patients with stable , chronic obstructive pulmonary disease .|Mean peak forced expiratory volume in 1 second ( FEV1 ) increases over baseline and the proportion of patients attaining at least a 15 % increase in the FEV1 ( responders ) were 31 % and 90 % , respectively , for ipratropium and 17 % and 50 % , respectively , for theophylline .|The average FEV1 increases during the 6 - hour observation period were 18 % for ipratropium and 8 % for theophylline .|The mean duration of action was 3 . 8 hours with ipratropium and 2 . 4 hours with theophylline .|While side effects were rare , those experienced after theophylline use did involve the cardiovascular and gastrointestinal systems .|These results show that ipratropium is a more potent bronchodilator than oral theophylline in patients with chronic airflow obstruction .	1:CID:2	L2R	NON-CROSS	180-181	185-189	D013806	theophylline|theophylline|theophylline|theophylline|theophylline|theophylline|theophylline	Chemical	7:33:127:149:169:180:202	8:34:128:150:170:181:203	0:1:2:3:4:5:6	D002318	cardiovascular and gastrointestinal systems	Disease	185	189	5	1:CID:2	L2R	NON-CROSS	180-181	185-189	D013806	theophylline|theophylline|theophylline|theophylline|theophylline|theophylline|theophylline	Chemical	7:33:127:149:169:180:202	8:34:128:150:170:181:203	0:1:2:3:4:5:6	D005767	cardiovascular and gastrointestinal systems	Disease	185	189	5	1:NR:2	L2R	NON-CROSS	4-6	9-13	D009241	ipratropium bromide|ipratropium bromide|ipratropium|ipratropium|ipratropium|ipratropium	Chemical	4:22:116:144:162:194	6:24:117:145:163:195	0:1:2:3:4:6	D029424	chronic obstructive pulmonary disease|chronic obstructive pulmonary disease|chronic airflow obstruction	Disease	9:69:206	13:73:209	0:1:6	1:NR:2	L2R	CROSS	185-189	194-195	D009241	ipratropium bromide|ipratropium bromide|ipratropium|ipratropium|ipratropium|ipratropium	Chemical	4:22:116:144:162:194	6:24:117:145:163:195	0:1:2:3:4:6	D002318	cardiovascular and gastrointestinal systems	Disease	185	189	5	1:NR:2	L2R	CROSS	185-189	194-195	D009241	ipratropium bromide|ipratropium bromide|ipratropium|ipratropium|ipratropium|ipratropium	Chemical	4:22:116:144:162:194	6:24:117:145:163:195	0:1:2:3:4:6	D005767	cardiovascular and gastrointestinal systems	Disease	185	189	5	1:NR:2	L2R	NON-CROSS	7-8	9-13	D013806	theophylline|theophylline|theophylline|theophylline|theophylline|theophylline|theophylline	Chemical	7:33:127:149:169:180:202	8:34:128:150:170:181:203	0:1:2:3:4:5:6	D029424	chronic obstructive pulmonary disease|chronic obstructive pulmonary disease|chronic airflow obstruction	Disease	9:69:206	13:73:209	0:1:6
1919871	Irreversible damage to the medullary interstitium in experimental analgesic nephropathy in F344 rats .|Renal papillary necrosis ( RPN ) and a decreased urinary concentrating ability developed during continuous long - term treatment with aspirin and paracetamol in female Fischer 344 rats .|Renal structure and concentrating ability were examined after a recovery period of up to 18 weeks , when no analgesics were given , to investigate whether the analgesic - induced changes were reversible .|There was no evidence of repair to the damaged medullary interstitial matrix , or proliferation of remaining undamaged type 1 medullary interstitial cells after the recovery period following analgesic treatment .|The recovery of urinary concentrating ability was related to the length of analgesic treatment and the extent of the resulting inner medullary structural damage .|During the early stages of analgesic treatment , the changes in urinary concentrating ability were reversible , but after prolonged analgesic treatment , maximum urinary concentrating ability failed to recover .|This study shows that prolonged analgesic treatment in Fischer 344 rats causes progressive and irreversible damage to the interstitial matrix and type 1 interstitial cells leading to RPN .|The associated urinary concentrating defect is reversible only during the early stages of structural damage to the inner medulla .	1:CID:2	R2L	NON-CROSS	34-35	18-19	D001241	aspirin	Chemical	34	35	1	D007681	Renal papillary necrosis|RPN|RPN	Disease	14:18:191	17:19:192	1:1:6	1:CID:2	R2L	NON-CROSS	36-37	18-19	D000082	paracetamol	Chemical	36	37	1	D007681	Renal papillary necrosis|RPN|RPN	Disease	14:18:191	17:19:192	1:1:6	not_include	R2L	CROSS	34-35	9-10	D001241	aspirin	Chemical	34	35	1	D007674	nephropathy	Disease	9	10	0	not_include	R2L	CROSS	36-37	9-10	D000082	paracetamol	Chemical	36	37	1	D007674	nephropathy	Disease	9	10	0
1987816	Less frequent lithium administration and lower urine volume .|OBJECTIVE : This study was designed to determine whether patients maintained on a regimen of lithium on a once - per - day schedule have lower urine volumes than do patients receiving multiple doses per day .|METHOD : This was a cross - sectional study of 85 patients from a lithium clinic who received different dose schedules .|Patients were admitted to the hospital for measurement of lithium level , creatinine clearance , urine volume , and maximum osmolality .|RESULTS : Multiple daily doses of lithium were associated with higher urine volumes .|The dosing schedule , duration of lithium treatment , and daily dose of lithium did not affect maximum osmolality or creatinine clearance .|CONCLUSIONS : Urine volume can be reduced by giving lithium once daily and / or by lowering the total daily dose .|Lithium - induced polyuria seems to be related to extrarenal as well as to renal effects .	1:CID:2	L2R	NON-CROSS	149-150	152-153	D008094	lithium|lithium|lithium|lithium|lithium|lithium|lithium|lithium|Lithium	Chemical	2:24:60:77:96:110:117:136:149	3:25:61:78:97:111:118:137:150	0:1:2:3:4:5:5:6:7	D011141	polyuria	Disease	152	153	7	1:NR:2	L2R	CROSS	124-125	152-153	D003404	creatinine|creatinine	Chemical	80:124	81:125	3:5	D011141	polyuria	Disease	152	153	7
2054792	Effect of adriamycin combined with whole body hyperthermia on tumor and normal tissues .|Thermal enhancement of Adriamycin - mediated antitumor activity and normal tissue toxicities by whole body hyperthermia were compared using a F344 rat model .|Antitumor activity was studied using a tumor growth delay assay .|Acute normal tissue toxicities ( i . e . , leukopenia and thrombocytopenia ) and late normal tissue toxicities ( i . e . , myocardial and kidney injury ) were evaluated by functional / physiological assays and by morphological techniques .|Whole body hyperthermia ( 120 min at 41 . 5 degrees C ) enhanced both Adriamycin - mediated antitumor activity and toxic side effects .|The thermal enhancement ratio calculated for antitumor activity was 1 . 6 .|Thermal enhancement ratios estimated for " acute " hematological changes were 1 . 3 , whereas those estimated for " late " damage ( based on morphological cardiac and renal lesions ) varied between 2 . 4 and 4 . 3 .|Thus , while whole body hyperthermia enhances Adriamycin - mediated antitumor effect , normal tissue toxicity is also increased , and the potential therapeutic gain of the combined modality treatment is eroded .	1:CID:2	L2R	CROSS	156-160	178-179	D004317	adriamycin|Adriamycin|Adriamycin|Adriamycin	Chemical	2:17:106:178	3:18:107:179	0:1:4:7	D006331	myocardial and kidney injury|cardiac and renal lesions	Disease	74:156	78:160	3:6	1:NR:2	L2R	NON-CROSS	176-177	178-179	D004317	adriamycin|Adriamycin|Adriamycin|Adriamycin	Chemical	2:17:106:178	3:18:107:179	0:1:4:7	D005334	hyperthermia|hyperthermia|hyperthermia|hyperthermia	Disease	7:29:93:176	8:30:94:177	0:1:4:7	1:NR:2	L2R	NON-CROSS	2-3	9-10	D004317	adriamycin|Adriamycin|Adriamycin|Adriamycin	Chemical	2:17:106:178	3:18:107:179	0:1:4:7	D009369	tumor|tumor	Disease	9:44	10:45	0:2	1:NR:2	L2R	NON-CROSS	17-18	25-26	D004317	adriamycin|Adriamycin|Adriamycin|Adriamycin	Chemical	2:17:106:178	3:18:107:179	0:1:4:7	D064420	toxicities|toxicities|toxicities|toxicity	Disease	25:52:67:186	26:53:68:187	1:3:3:7	1:NR:2	L2R	CROSS	17-18	59-60	D004317	adriamycin|Adriamycin|Adriamycin|Adriamycin	Chemical	2:17:106:178	3:18:107:179	0:1:4:7	D007970	leukopenia	Disease	59	60	3	1:NR:2	L2R	CROSS	17-18	61-62	D004317	adriamycin|Adriamycin|Adriamycin|Adriamycin	Chemical	2:17:106:178	3:18:107:179	0:1:4:7	D013921	thrombocytopenia	Disease	61	62	3	1:NR:2	L2R	CROSS	156-160	178-179	D004317	adriamycin|Adriamycin|Adriamycin|Adriamycin	Chemical	2:17:106:178	3:18:107:179	0:1:4:7	D007674	myocardial and kidney injury|cardiac and renal lesions	Disease	74:156	78:160	3:6
2304736	Prazosin - induced stress incontinence .|A case of genuine stress incontinence due to prazosin , a common antihypertensive drug , is presented .|Prazosin exerts its antihypertensive effects through vasodilatation caused by selective blockade of postsynaptic alpha - 1 adrenergic receptors .|As an alpha - blocker , it also exerts a significant relaxant effect on the bladder neck and urethra .|The patient 's clinical course is described and correlated with initial urodynamic studies while on prazosin and subsequent studies while taking verapamil .|Her incontinence resolved with the change of medication .|The restoration of continence was accompanied by a substantial rise in maximum urethral pressure , maximum urethral closure pressure , and functional urethral length .|Patients who present with stress incontinence while taking prazosin should change their antihypertensive medication before considering surgery , because their incontinence may resolve spontaneously with a change in drug therapy .	1:CID:2	L2R	NON-CROSS	0-1	3-5	D011224	Prazosin|prazosin|Prazosin|prazosin|prazosin	Chemical	0:14:24:78:128	1:15:25:79:129	0:1:2:4:7	D014550	stress incontinence|stress incontinence|stress incontinence	Disease	3:10:124	5:12:126	0:1:7	not_include	L2R	NON-CROSS	78-79	87-88	D011224	Prazosin|prazosin|Prazosin|prazosin|prazosin	Chemical	0:14:24:78:128	1:15:25:79:129	0:1:2:4:7	D014549	incontinence|incontinence	Disease	87:140	88:141	5:7	1:NR:2	R2L	CROSS	124-126	84-85	D014700	verapamil	Chemical	84	85	4	D014550	stress incontinence|stress incontinence|stress incontinence	Disease	3:10:124	5:12:126	0:1:7	1:NR:2	L2R	CROSS	84-85	87-88	D014700	verapamil	Chemical	84	85	4	D014549	incontinence|incontinence	Disease	87:140	88:141	5:7
2312209	Myocardial infarction following sublingual administration of isosorbide dinitrate .|A 78 - year - old with healed septal necrosis suffered a recurrent myocardial infarction of the anterior wall following the administration of isosorbide dinitrate 5 mg sublingually .|After detailing the course of events , we discuss the role of paradoxical coronary spasm and hypotension - mediated myocardial ischemia occurring downstream to significant coronary arterial stenosis in the pathophysiology of acute coronary insufficiency .	1:CID:2	R2L	NON-CROSS	6-8	0-2	D007548	isosorbide dinitrate|isosorbide dinitrate	Chemical	6:32	8:34	0:1	D009203	Myocardial infarction|myocardial infarction	Disease	0:22	2:24	0:1	1:NR:2	L2R	NON-CROSS	6-8	18-19	D007548	isosorbide dinitrate|isosorbide dinitrate	Chemical	6:32	8:34	0:1	D009336	necrosis	Disease	18	19	1	1:NR:2	L2R	CROSS	32-34	52-53	D007548	isosorbide dinitrate|isosorbide dinitrate	Chemical	6:32	8:34	0:1	D013035	spasm	Disease	52	53	2	1:NR:2	L2R	CROSS	32-34	54-55	D007548	isosorbide dinitrate|isosorbide dinitrate	Chemical	6:32	8:34	0:1	D007022	hypotension	Disease	54	55	2	not_include	L2R	CROSS	32-34	57-59	D007548	isosorbide dinitrate|isosorbide dinitrate	Chemical	6:32	8:34	0:1	D017202	myocardial ischemia	Disease	57	59	2	1:NR:2	L2R	CROSS	32-34	63-66	D007548	isosorbide dinitrate|isosorbide dinitrate	Chemical	6:32	8:34	0:1	D023921	coronary arterial stenosis	Disease	63	66	2	1:NR:2	L2R	CROSS	32-34	70-73	D007548	isosorbide dinitrate|isosorbide dinitrate	Chemical	6:32	8:34	0:1	D054058	acute coronary insufficiency	Disease	70	73	2
2549018	Fluoxetine - induced akathisia : clinical and theoretical implications .|Five patients receiving fluoxetine for the treatment of obsessive compulsive disorder or major depression developed akathisia .|The typical fluoxetine - induced symptoms of restlessness , constant pacing , purposeless movements of the feet and legs , and marked anxiety were indistinguishable from those of neuroleptic - induced akathisia .|Three patients who had experienced neuroleptic - induced akathisia in the past reported that the symptoms of fluoxetine - induced akathisia were identical , although somewhat milder .|Akathisia appeared to be a common side effect of fluoxetine and generally responded well to treatment with the beta - adrenergic antagonist propranolol , dose reduction , or both .|The authors suggest that fluoxetine - induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine - induced akathisia and tricyclic antidepressant - induced " jitteriness " may be identical .	1:CID:2	L2R	NON-CROSS	0-1	3-4	D005473	Fluoxetine|fluoxetine|fluoxetine|fluoxetine|fluoxetine|fluoxetine|fluoxetine	Chemical	0:13:29:77:97:122:141	1:14:30:78:98:123:142	0:1:2:3:4:5:5	D017109	akathisia|akathisia|akathisia|akathisia|akathisia|Akathisia|akathisia|akathisia	Disease	3:25:58:68:80:88:125:144	4:26:59:69:81:89:126:145	0:1:2:3:3:4:5:5	1:NR:2	L2R	NON-CROSS	13-14	18-21	D005473	Fluoxetine|fluoxetine|fluoxetine|fluoxetine|fluoxetine|fluoxetine|fluoxetine	Chemical	0:13:29:77:97:122:141	1:14:30:78:98:123:142	0:1:2:3:4:5:5	D009771	obsessive compulsive disorder	Disease	18	21	1	1:NR:2	L2R	NON-CROSS	22-24	29-30	D005473	Fluoxetine|fluoxetine|fluoxetine|fluoxetine|fluoxetine|fluoxetine|fluoxetine	Chemical	0:13:29:77:97:122:141	1:14:30:78:98:123:142	0:1:2:3:4:5:5	D003865	major depression	Disease	22	24	1	1:NR:2	L2R	NON-CROSS	29-30	49-50	D005473	Fluoxetine|fluoxetine|fluoxetine|fluoxetine|fluoxetine|fluoxetine|fluoxetine	Chemical	0:13:29:77:97:122:141	1:14:30:78:98:123:142	0:1:2:3:4:5:5	D001008	anxiety	Disease	49	50	2	1:NR:2	R2L	NON-CROSS	125-126	110-111	D011433	propranolol	Chemical	110	111	4	D017109	akathisia|akathisia|akathisia|akathisia|akathisia|Akathisia|akathisia|akathisia	Disease	3:25:58:68:80:88:125:144	4:26:59:69:81:89:126:145	0:1:2:3:3:4:5:5	1:NR:2	R2L	NON-CROSS	147-148	144-145	D000928	antidepressant	Chemical	147	148	5	D017109	akathisia|akathisia|akathisia|akathisia|akathisia|Akathisia|akathisia|akathisia	Disease	3:25:58:68:80:88:125:144	4:26:59:69:81:89:126:145	0:1:2:3:3:4:5:5	1:NR:2	R2L	CROSS	110-111	18-21	D011433	propranolol	Chemical	110	111	4	D009771	obsessive compulsive disorder	Disease	18	21	1	1:NR:2	R2L	CROSS	147-148	18-21	D000928	antidepressant	Chemical	147	148	5	D009771	obsessive compulsive disorder	Disease	18	21	1	1:NR:2	R2L	CROSS	110-111	22-24	D011433	propranolol	Chemical	110	111	4	D003865	major depression	Disease	22	24	1	1:NR:2	R2L	CROSS	147-148	22-24	D000928	antidepressant	Chemical	147	148	5	D003865	major depression	Disease	22	24	1	1:NR:2	R2L	CROSS	110-111	49-50	D011433	propranolol	Chemical	110	111	4	D001008	anxiety	Disease	49	50	2	1:NR:2	R2L	CROSS	147-148	49-50	D000928	antidepressant	Chemical	147	148	5	D001008	anxiety	Disease	49	50	2
2611118	Chronic active hepatitis associated with diclofenac sodium therapy .|Diclofenac sodium ( Voltarol , Geigy Pharmaceuticals ) is a non - steroidal anti - inflammatory derivative of phenylacetic acid .|Although generally well - tolerated , asymptomatic abnormalities of liver function have been recorded and , less commonly , severe hepatitis induced by diclofenac .|The patient described developed chronic active hepatitis after six months therapy with diclofenac sodium which progressed despite the withdrawal of the drug , a finding not previously reported .	1:CID:2	L2R	NON-CROSS	50-51	53-54	D004008	diclofenac sodium|Diclofenac sodium|Voltarol|diclofenac|diclofenac sodium	Chemical	5:9:12:53:67	7:11:13:54:69	0:1:1:2:3	D056486	abnormalities of liver function|hepatitis	Disease	37:50	41:51	2:2	1:NR:2	R2L	NON-CROSS	5-7	0-3	D004008	diclofenac sodium|Diclofenac sodium|Voltarol|diclofenac|diclofenac sodium	Chemical	5:9:12:53:67	7:11:13:54:69	0:1:1:2:3	D006521	Chronic active hepatitis|chronic active hepatitis	Disease	0:59	3:62	0:3	1:NR:2	R2L	CROSS	27-29	0-3	C025136	phenylacetic acid	Chemical	27	29	1	D006521	Chronic active hepatitis|chronic active hepatitis	Disease	0:59	3:62	0:3	1:NR:2	L2R	CROSS	27-29	37-41	C025136	phenylacetic acid	Chemical	27	29	1	D056486	abnormalities of liver function|hepatitis	Disease	37:50	41:51	2:2
2673163	Stroke associated with cocaine use .|We describe eight patients in whom cocaine use was related to stroke and review 39 cases from the literature .|Among these 47 patients the mean ( + / - SD ) age was 32 . 5 + / - 12 . 1 years ; 76 % ( 34 / 45 ) were men .|Stroke followed cocaine use by inhalation , intranasal , intravenous , and intramuscular routes .|Intracranial aneurysms or arteriovenous malformations were present in 17 of 32 patients studied angiographically or at autopsy ; cerebral vasculitis was present in two patients .|Cerebral infarction occurred in 10 patients ( 22 % ) , intracerebral hemorrhage in 22 ( 49 % ) , and subarachnoid hemorrhage in 13 ( 29 % ) .|These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) cocaine - associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in cocaine - associated stroke , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .	1:CID:2	L2R	NON-CROSS	198-199	211-213	D003042	cocaine|cocaine|cocaine|cocaine|cocaine|cocaine|cocaine|cocaine	Chemical	3:12:63:146:154:173:181:198	4:13:64:147:155:174:182:199	0:1:3:6:6:6:6:6	D002544	Cerebral infarction|cerebral infarction	Disease	102:211	104:213	5:6	1:CID:2	L2R	CROSS	113-115	146-147	D003042	cocaine|cocaine|cocaine|cocaine|cocaine|cocaine|cocaine|cocaine	Chemical	3:12:63:146:154:173:181:198	4:13:64:147:155:174:182:199	0:1:3:6:6:6:6:6	D002543	intracerebral hemorrhage	Disease	113	115	5	1:CID:2	L2R	CROSS	123-125	146-147	D003042	cocaine|cocaine|cocaine|cocaine|cocaine|cocaine|cocaine|cocaine	Chemical	3:12:63:146:154:173:181:198	4:13:64:147:155:174:182:199	0:1:3:6:6:6:6:6	D013345	subarachnoid hemorrhage	Disease	123	125	5	not_include	R2L	NON-CROSS	63-64	61-62	D003042	cocaine|cocaine|cocaine|cocaine|cocaine|cocaine|cocaine|cocaine	Chemical	3:12:63:146:154:173:181:198	4:13:64:147:155:174:182:199	0:1:3:6:6:6:6:6	D020521	Stroke|stroke|Stroke|stroke|stroke|stroke|stroke|stroke	Disease	0:17:61:143:157:167:179:201	1:18:62:144:158:168:180:202	0:1:3:6:6:6:6:6	1:NR:2	L2R	NON-CROSS	181-182	187-189	D003042	cocaine|cocaine|cocaine|cocaine|cocaine|cocaine|cocaine|cocaine	Chemical	3:12:63:146:154:173:181:198	4:13:64:147:155:174:182:199	0:1:3:6:6:6:6:6	D002532	Intracranial aneurysms|intracranial aneurysms	Disease	76:187	78:189	4:6	1:NR:2	L2R	NON-CROSS	190-192	198-199	D003042	cocaine|cocaine|cocaine|cocaine|cocaine|cocaine|cocaine|cocaine	Chemical	3:12:63:146:154:173:181:198	4:13:64:147:155:174:182:199	0:1:3:6:6:6:6:6	D001165	arteriovenous malformations|arteriovenous malformations	Disease	79:190	81:192	4:6	1:NR:2	L2R	CROSS	63-64	94-96	D003042	cocaine|cocaine|cocaine|cocaine|cocaine|cocaine|cocaine|cocaine	Chemical	3:12:63:146:154:173:181:198	4:13:64:147:155:174:182:199	0:1:3:6:6:6:6:6	D020293	cerebral vasculitis	Disease	94	96	4	not_include	L2R	NON-CROSS	198-199	206-208	D003042	cocaine|cocaine|cocaine|cocaine|cocaine|cocaine|cocaine|cocaine	Chemical	3:12:63:146:154:173:181:198	4:13:64:147:155:174:182:199	0:1:3:6:6:6:6:6	D020300	intracranial hemorrhage	Disease	206	208	6
3107448	Glyburide - induced hepatitis .|Drug - induced hepatotoxicity , although common , has been reported only infrequently with sulfonylureas .|For glyburide , a second - generation sulfonylurea , only two brief reports of hepatotoxicity exist .|Two patients with type II diabetes mellitus developed an acute hepatitis - like syndrome soon after initiation of glyburide therapy .|There was no serologic evidence of viral infection , and a liver biopsy sample showed a histologic pattern consistent with drug - induced hepatitis .|Both patients recovered quickly after stopping glyburide therapy and have remained well for a follow - up period of 1 year .|Glyburide can produce an acute hepatitis - like illness in some persons .	1:CID:2	L2R	NON-CROSS	0-1	3-4	D005905	Glyburide|glyburide|glyburide|glyburide|Glyburide	Chemical	0:22:56:90:106	1:23:57:91:107	0:2:3:5:6	D056486	hepatitis|hepatotoxicity|hepatotoxicity|acute hepatitis - like syndrome|drug - induced hepatitis|acute hepatitis - like illness	Disease	3:8:35:47:79:110	4:9:36:52:83:115	0:1:2:3:4:6	1:NR:2	L2R	NON-CROSS	41-45	56-57	D005905	Glyburide|glyburide|glyburide|glyburide|Glyburide	Chemical	0:22:56:90:106	1:23:57:91:107	0:2:3:5:6	D003924	type II diabetes mellitus	Disease	41	45	3	1:NR:2	L2R	CROSS	56-57	65-67	D005905	Glyburide|glyburide|glyburide|glyburide|Glyburide	Chemical	0:22:56:90:106	1:23:57:91:107	0:2:3:5:6	D014777	viral infection	Disease	65	67	4	1:NR:2	R2L	NON-CROSS	35-36	28-29	D013453	sulfonylureas|sulfonylurea	Chemical	19:28	20:29	1:2	D056486	hepatitis|hepatotoxicity|hepatotoxicity|acute hepatitis - like syndrome|drug - induced hepatitis|acute hepatitis - like illness	Disease	3:8:35:47:79:110	4:9:36:52:83:115	0:1:2:3:4:6	1:NR:2	L2R	CROSS	28-29	41-45	D013453	sulfonylureas|sulfonylurea	Chemical	19:28	20:29	1:2	D003924	type II diabetes mellitus	Disease	41	45	3	1:NR:2	L2R	CROSS	28-29	65-67	D013453	sulfonylureas|sulfonylurea	Chemical	19:28	20:29	1:2	D014777	viral infection	Disease	65	67	4
3341566	Systolic pressure variation is greater during hemorrhage than during sodium nitroprusside - induced hypotension in ventilated dogs .|The systolic pressure variation ( SPV ) , which is the difference between the maximal and minimal values of the systolic blood pressure ( SBP ) after one positive - pressure breath , was studied in ventilated dogs subjected to hypotension .|Mean arterial pressure was decreased to 50 mm Hg for 30 minutes either by hemorrhage ( HEM , n = 7 ) or by continuous infusion of sodium nitroprusside ( SNP , n = 7 ) .|During HEM - induced hypotension the cardiac output was significantly lower and systemic vascular resistance higher compared with that in the SNP group .|The systemic , central venous , pulmonary capillary wedge pressures , and heart rates , were similar in the two groups .|Analysis of the respiratory changes in the arterial pressure waveform enabled differentiation between the two groups .|The SPV during hypotension was 15 . 7 + / - 6 . 7 mm Hg in the HEM group , compared with 9 . 1 + / - 2 . 0 mm Hg in the SNP group ( P less than 0 . 02 ) .|The delta down , which is the measure of decrease of SBP after a mechanical breath , was 20 . 3 + / - 8 . 4 and 10 . 1 + / - 3 . 8 mm Hg in the HEM and SNP groups , respectively , during hypotension ( P less than 0 . 02 ) .|It is concluded that increases in the SPV and the delta down are characteristic of a hypotensive state due to a predominant decrease in preload .|They are thus more important during absolute hypovolemia than during deliberate hypotension .	1:CID:2	L2R	NON-CROSS	9-11	13-14	D009599	sodium nitroprusside|sodium nitroprusside|SNP|SNP|SNP|SNP	Chemical	9:87:90:118:196:250	11:89:91:119:197:251	0:2:2:3:6:7	D007022	hypotension|hypotension|hypotension|hypotension|hypotension|hypotensive|hypotension	Disease	13:58:101:163:256:282:303	14:59:102:164:257:283:304	0:1:3:6:7:8:9	1:NR:2	R2L	NON-CROSS	250-251	248-249	D009599	sodium nitroprusside|sodium nitroprusside|SNP|SNP|SNP|SNP	Chemical	9:87:90:118:196:250	11:89:91:119:197:251	0:2:2:3:6:7	D006470	hemorrhage|hemorrhage|HEM|HEM|HEM|HEM	Disease	6:74:76:98:178:248	7:75:77:99:179:249	0:2:2:3:6:7	1:NR:2	L2R	CROSS	250-251	299-300	D009599	sodium nitroprusside|sodium nitroprusside|SNP|SNP|SNP|SNP	Chemical	9:87:90:118:196:250	11:89:91:119:197:251	0:2:2:3:6:7	D020896	hypovolemia	Disease	299	300	9
3564823	Drug - induced arterial spasm relieved by lidocaine .|Case report .|Following major intracranial surgery in a 35 - year - old man , sodium pentothal was intravenously infused to minimize cerebral ischaemia .|Intense vasospasm with threatened gangrene arose in the arm used for the infusion .|Since the cranial condition precluded use of more usual methods , lidocaine was given intra - arterially , with careful cardiovascular monitoring , to counteract the vasospasm .|The treatment was rapidly successful .	1:CID:2	R2L	CROSS	25-27	4-5	D013874	sodium pentothal	Chemical	25	27	2	D013035	spasm	Disease	4	5	0	1:NR:2	R2L	NON-CROSS	7-8	4-5	D008012	lidocaine|lidocaine	Chemical	7:60	8:61	0:4	D013035	spasm	Disease	4	5	0	1:NR:2	L2R	CROSS	7-8	32-34	D008012	lidocaine|lidocaine	Chemical	7:60	8:61	0:4	D002545	cerebral ischaemia	Disease	32	34	2	1:NR:2	L2R	NON-CROSS	60-61	75-76	D008012	lidocaine|lidocaine	Chemical	7:60	8:61	0:4	D020301	vasospasm|vasospasm	Disease	36:75	37:76	3:4	1:NR:2	L2R	CROSS	39-40	60-61	D008012	lidocaine|lidocaine	Chemical	7:60	8:61	0:4	D005734	gangrene	Disease	39	40	3	1:NR:2	L2R	NON-CROSS	25-27	32-34	D013874	sodium pentothal	Chemical	25	27	2	D002545	cerebral ischaemia	Disease	32	34	2	1:NR:2	L2R	CROSS	25-27	36-37	D013874	sodium pentothal	Chemical	25	27	2	D020301	vasospasm|vasospasm	Disease	36:75	37:76	3:4	1:NR:2	L2R	CROSS	25-27	39-40	D013874	sodium pentothal	Chemical	25	27	2	D005734	gangrene	Disease	39	40	3
3676049	Cerebral blood flow and metabolism during isoflurane - induced hypotension in patients subjected to surgery for cerebral aneurysms .|Cerebral blood flow and cerebral metabolic rate for oxygen were measured during isoflurane - induced hypotension in 10 patients subjected to craniotomy for clipping of a cerebral aneurysm .|Flow and metabolism were measured 5 - 13 days after the subarachnoid haemorrhage by a modification of the classical Kety - Schmidt technique using xenon - 133 i . v .|Anaesthesia was maintained with an inspired isoflurane concentration of 0 . 75 % ( plus 67 % nitrous oxide in oxygen ) , during which CBF and CMRO2 were 34 . 3 + / - 2 . 1 ml / 100 g min - 1 and 2 . 32 + / - 0 . 16 ml / 100 g min - 1 at PaCO2 4 . 1 + / - 0 . 1 kPa ( mean + / - SEM ) .|Controlled hypotension to an average MAP of 50 - 55 mm Hg was induced by increasing the dose of isoflurane , and maintained at an inspired concentration of 2 . 2 + / - 0 . 2 % .|This resulted in a significant decrease in CMRO2 ( to 1 . 73 + / - 0 . 16 ml / 100 g min - 1 ) , while CBF was unchanged .|After the clipping of the aneurysm the isoflurane concentration was reduced to 0 . 75 % .|There was a significant increase in CBF , although CMRO2 was unchanged , compared with pre - hypotensive values .|These changes might offer protection to brain tissue during periods of induced hypotension .	1:CID:2	L2R	NON-CROSS	6-7	9-10	D007530	isoflurane|isoflurane|isoflurane|isoflurane|isoflurane	Chemical	6:31:85:180:240	7:32:86:181:241	0:1:3:4:6	D007022	hypotension|hypotension|hypotension|hypotensive|hypotension	Disease	9:34:162:267:282	10:35:163:268:283	0:1:4:7:8	1:NR:2	L2R	NON-CROSS	6-7	16-18	D007530	isoflurane|isoflurane|isoflurane|isoflurane|isoflurane	Chemical	6:31:85:180:240	7:32:86:181:241	0:1:3:4:6	D002532	cerebral aneurysms|cerebral aneurysm	Disease	16:45	18:47	0:1	1:NR:2	L2R	CROSS	59-61	85-86	D007530	isoflurane|isoflurane|isoflurane|isoflurane|isoflurane	Chemical	6:31:85:180:240	7:32:86:181:241	0:1:3:4:6	D013345	subarachnoid haemorrhage	Disease	59	61	2	1:NR:2	L2R	NON-CROSS	238-239	240-241	D007530	isoflurane|isoflurane|isoflurane|isoflurane|isoflurane	Chemical	6:31:85:180:240	7:32:86:181:241	0:1:3:4:6	D000783	aneurysm	Disease	238	239	6	1:NR:2	R2L	NON-CROSS	34-35	27-28	D010100	oxygen|oxygen	Chemical	27:99	28:100	1:3	D007022	hypotension|hypotension|hypotension|hypotensive|hypotension	Disease	9:34:162:267:282	10:35:163:268:283	0:1:4:7:8	1:NR:2	R2L	CROSS	72-73	34-35	D014978	xenon	Chemical	72	73	2	D007022	hypotension|hypotension|hypotension|hypotensive|hypotension	Disease	9:34:162:267:282	10:35:163:268:283	0:1:4:7:8	1:NR:2	R2L	CROSS	96-98	34-35	D009609	nitrous oxide	Chemical	96	98	3	D007022	hypotension|hypotension|hypotension|hypotensive|hypotension	Disease	9:34:162:267:282	10:35:163:268:283	0:1:4:7:8	1:NR:2	R2L	NON-CROSS	172-173	162-163	D008628	Hg	Chemical	172	173	4	D007022	hypotension|hypotension|hypotension|hypotensive|hypotension	Disease	9:34:162:267:282	10:35:163:268:283	0:1:4:7:8	1:NR:2	R2L	NON-CROSS	27-28	16-18	D010100	oxygen|oxygen	Chemical	27:99	28:100	1:3	D002532	cerebral aneurysms|cerebral aneurysm	Disease	16:45	18:47	0:1	1:NR:2	R2L	CROSS	72-73	45-47	D014978	xenon	Chemical	72	73	2	D002532	cerebral aneurysms|cerebral aneurysm	Disease	16:45	18:47	0:1	1:NR:2	R2L	CROSS	96-98	45-47	D009609	nitrous oxide	Chemical	96	98	3	D002532	cerebral aneurysms|cerebral aneurysm	Disease	16:45	18:47	0:1	1:NR:2	R2L	CROSS	172-173	45-47	D008628	Hg	Chemical	172	173	4	D002532	cerebral aneurysms|cerebral aneurysm	Disease	16:45	18:47	0:1	1:NR:2	L2R	CROSS	27-28	59-61	D010100	oxygen|oxygen	Chemical	27:99	28:100	1:3	D013345	subarachnoid haemorrhage	Disease	59	61	2	1:NR:2	L2R	CROSS	99-100	238-239	D010100	oxygen|oxygen	Chemical	27:99	28:100	1:3	D000783	aneurysm	Disease	238	239	6	1:NR:2	R2L	NON-CROSS	72-73	59-61	D014978	xenon	Chemical	72	73	2	D013345	subarachnoid haemorrhage	Disease	59	61	2	1:NR:2	R2L	CROSS	96-98	59-61	D009609	nitrous oxide	Chemical	96	98	3	D013345	subarachnoid haemorrhage	Disease	59	61	2	1:NR:2	R2L	CROSS	172-173	59-61	D008628	Hg	Chemical	172	173	4	D013345	subarachnoid haemorrhage	Disease	59	61	2	1:NR:2	L2R	CROSS	72-73	238-239	D014978	xenon	Chemical	72	73	2	D000783	aneurysm	Disease	238	239	6	1:NR:2	L2R	CROSS	96-98	238-239	D009609	nitrous oxide	Chemical	96	98	3	D000783	aneurysm	Disease	238	239	6	1:NR:2	L2R	CROSS	172-173	238-239	D008628	Hg	Chemical	172	173	4	D000783	aneurysm	Disease	238	239	6
3719553	Allergic reaction to 5 - fluorouracil infusion .|An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5 - fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity , cirrhosis , and cisplatin - induced impaired renal function .|This reaction occurred during the sixth and seventh courses of infusional chemotherapy .|Oral diphenhydramine and prednisone were ineffective in preventing the recurrence of the allergic reaction .|Discontinuance of effective chemotherapy in this patient during partial remission resulted in fatal disease progression .	1:CID:2	L2R	NON-CROSS	13-15	19-22	D005472	5 - fluorouracil|5 - fluorouracil	Chemical	3:19	6:22	0:1	D000799	angioneurotic edema	Disease	13	15	1	1:NR:2	R2L	NON-CROSS	3-6	0-2	D005472	5 - fluorouracil|5 - fluorouracil	Chemical	3:19	6:22	0:1	D004342	Allergic reaction|allergic reaction|allergic reaction	Disease	0:9:69	2:11:71	0:1:3	1:NR:2	R2L	NON-CROSS	37-38	9-11	D002945	cisplatin	Chemical	37	38	1	D004342	Allergic reaction|allergic reaction|allergic reaction	Disease	0:9:69	2:11:71	0:1:3	1:NR:2	R2L	NON-CROSS	69-71	58-59	D004155	diphenhydramine	Chemical	58	59	3	D004342	Allergic reaction|allergic reaction|allergic reaction	Disease	0:9:69	2:11:71	0:1:3	1:NR:2	R2L	NON-CROSS	69-71	60-61	D011241	prednisone	Chemical	60	61	3	D004342	Allergic reaction|allergic reaction|allergic reaction	Disease	0:9:69	2:11:71	0:1:3	1:NR:2	L2R	NON-CROSS	19-22	28-33	D005472	5 - fluorouracil|5 - fluorouracil	Chemical	3:19	6:22	0:1	D009062	carcinoma of the oral cavity	Disease	28	33	1	1:NR:2	L2R	NON-CROSS	19-22	34-35	D005472	5 - fluorouracil|5 - fluorouracil	Chemical	3:19	6:22	0:1	D005355	cirrhosis	Disease	34	35	1	1:NR:2	L2R	NON-CROSS	19-22	40-43	D005472	5 - fluorouracil|5 - fluorouracil	Chemical	3:19	6:22	0:1	D007674	impaired renal function	Disease	40	43	1	1:NR:2	R2L	NON-CROSS	37-38	13-15	D002945	cisplatin	Chemical	37	38	1	D000799	angioneurotic edema	Disease	13	15	1	1:NR:2	R2L	CROSS	58-59	13-15	D004155	diphenhydramine	Chemical	58	59	3	D000799	angioneurotic edema	Disease	13	15	1	1:NR:2	R2L	CROSS	60-61	13-15	D011241	prednisone	Chemical	60	61	3	D000799	angioneurotic edema	Disease	13	15	1	1:NR:2	R2L	NON-CROSS	37-38	28-33	D002945	cisplatin	Chemical	37	38	1	D009062	carcinoma of the oral cavity	Disease	28	33	1	1:NR:2	R2L	CROSS	58-59	28-33	D004155	diphenhydramine	Chemical	58	59	3	D009062	carcinoma of the oral cavity	Disease	28	33	1	1:NR:2	R2L	CROSS	60-61	28-33	D011241	prednisone	Chemical	60	61	3	D009062	carcinoma of the oral cavity	Disease	28	33	1	1:NR:2	R2L	NON-CROSS	37-38	34-35	D002945	cisplatin	Chemical	37	38	1	D005355	cirrhosis	Disease	34	35	1	1:NR:2	R2L	CROSS	58-59	34-35	D004155	diphenhydramine	Chemical	58	59	3	D005355	cirrhosis	Disease	34	35	1	1:NR:2	R2L	CROSS	60-61	34-35	D011241	prednisone	Chemical	60	61	3	D005355	cirrhosis	Disease	34	35	1	1:NR:2	L2R	NON-CROSS	37-38	40-43	D002945	cisplatin	Chemical	37	38	1	D007674	impaired renal function	Disease	40	43	1	1:NR:2	R2L	CROSS	58-59	40-43	D004155	diphenhydramine	Chemical	58	59	3	D007674	impaired renal function	Disease	40	43	1	1:NR:2	R2L	CROSS	60-61	40-43	D011241	prednisone	Chemical	60	61	3	D007674	impaired renal function	Disease	40	43	1
4008111	Amiodarone - induced sinoatrial block .|We observed sinoatrial block due to chronic amiodarone administration in a 5 - year - old boy with primary cardiomyopathy , Wolff - Parkinson - White syndrome and supraventricular tachycardia .|Reduction in the dosage of amiodarone resulted in the disappearance of the sinoatrial block and the persistence of asymptomatic sinus bradycardia .	1:CID:2	L2R	NON-CROSS	0-1	3-5	D000638	Amiodarone|amiodarone|amiodarone	Chemical	0:13:42	1:14:43	0:1:2	D012848	sinoatrial block|sinoatrial block|sinoatrial block	Disease	3:8:49	5:10:51	0:1:2	1:NR:2	L2R	NON-CROSS	13-14	24-26	D000638	Amiodarone|amiodarone|amiodarone	Chemical	0:13:42	1:14:43	0:1:2	D009202	primary cardiomyopathy	Disease	24	26	1	1:NR:2	L2R	NON-CROSS	27-33	42-43	D000638	Amiodarone|amiodarone|amiodarone	Chemical	0:13:42	1:14:43	0:1:2	D014927	Wolff - Parkinson - White syndrome	Disease	27	33	1	1:NR:2	L2R	NON-CROSS	34-36	42-43	D000638	Amiodarone|amiodarone|amiodarone	Chemical	0:13:42	1:14:43	0:1:2	D013617	supraventricular tachycardia	Disease	34	36	1	1:NR:2	L2R	NON-CROSS	42-43	56-58	D000638	Amiodarone|amiodarone|amiodarone	Chemical	0:13:42	1:14:43	0:1:2	D012804	sinus bradycardia	Disease	56	58	2
6133211	Possible teratogenicity of sulphasalazine .|Three infants , born of two mothers with inflammatory bowel disease who received treatment with sulphasalazine throughout pregnancy , were found to have major congenital anomalies .|In the singleton pregnancy , the mother had ulcerative colitis , and the infant , a male , had coarctation of the aorta and a ventricular septal defect .|In the twin pregnancy , the mother had Crohn 's disease .|The first twin , a female , had a left Potter - type IIa polycystic kidney and a rudimentary left uterine cornu .|The second twin , a male , had some features of Potter 's facies , hypoplastic lungs , absent kidneys and ureters , and talipes equinovarus .|Despite reports to the contrary , it is suggested that sulphasalazine may be teratogenic .	1:CID:2	L2R	CROSS	20-21	51-55	D012460	sulphasalazine|sulphasalazine|sulphasalazine	Chemical	3:20:133	4:21:134	0:1:6	D001017	coarctation of the aorta	Disease	51	55	2	1:CID:2	L2R	CROSS	20-21	57-60	D012460	sulphasalazine|sulphasalazine|sulphasalazine	Chemical	3:20:133	4:21:134	0:1:6	D006345	ventricular septal defect	Disease	57	60	2	1:CID:2	L2R	CROSS	83-89	133-134	D012460	sulphasalazine|sulphasalazine|sulphasalazine	Chemical	3:20:133	4:21:134	0:1:6	D007690	Potter - type IIa polycystic kidney	Disease	83	89	4	1:CID:2	L2R	CROSS	120-122	133-134	D012460	sulphasalazine|sulphasalazine|sulphasalazine	Chemical	3:20:133	4:21:134	0:1:6	D003025	talipes equinovarus	Disease	120	122	5	1:NR:2	L2R	NON-CROSS	13-16	20-21	D012460	sulphasalazine|sulphasalazine|sulphasalazine	Chemical	3:20:133	4:21:134	0:1:6	D015212	inflammatory bowel disease	Disease	13	16	1	not_include	L2R	NON-CROSS	20-21	29-31	D012460	sulphasalazine|sulphasalazine|sulphasalazine	Chemical	3:20:133	4:21:134	0:1:6	D000013	congenital anomalies	Disease	29	31	1	1:NR:2	L2R	CROSS	20-21	40-42	D012460	sulphasalazine|sulphasalazine|sulphasalazine	Chemical	3:20:133	4:21:134	0:1:6	D003093	ulcerative colitis	Disease	40	42	2	1:NR:2	L2R	CROSS	20-21	69-72	D012460	sulphasalazine|sulphasalazine|sulphasalazine	Chemical	3:20:133	4:21:134	0:1:6	D003424	Crohn 's disease	Disease	69	72	3
6503301	Veno - occlusive liver disease after dacarbazine therapy ( DTIC ) for melanoma .|A case of veno - occlusive disease of the liver with fatal outcome after dacarbazine ( DTIC ) therapy for melanoma is reported .|There was a fulminant clinical course from start of symptoms until death .|At autopsy the liver was enlarged and firm with signs of venous congestion .|Small - and medium - sized hepatic veins were blocked by thrombosis .|Eosinophilic infiltrations were found around the vessels .|Published cases from the literature are reviewed and pertinent features discussed .	1:CID:2	R2L	NON-CROSS	6-7	0-5	D003606	dacarbazine|DTIC|dacarbazine|DTIC	Chemical	6:9:28:30	7:10:29:31	0:0:1:1	D006504	Veno - occlusive liver disease|veno - occlusive disease of the liver	Disease	0:17	5:24	0:1	1:NR:2	L2R	NON-CROSS	9-10	12-13	D003606	dacarbazine|DTIC|dacarbazine|DTIC	Chemical	6:9:28:30	7:10:29:31	0:0:1:1	D008545	melanoma|melanoma	Disease	12:34	13:35	0:1	1:NR:2	L2R	CROSS	30-31	49-50	D003606	dacarbazine|DTIC|dacarbazine|DTIC	Chemical	6:9:28:30	7:10:29:31	0:0:1:1	D003643	death	Disease	49	50	2	1:NR:2	L2R	CROSS	30-31	62-64	D003606	dacarbazine|DTIC|dacarbazine|DTIC	Chemical	6:9:28:30	7:10:29:31	0:0:1:1	D006940	venous congestion	Disease	62	64	3	1:NR:2	L2R	CROSS	30-31	76-77	D003606	dacarbazine|DTIC|dacarbazine|DTIC	Chemical	6:9:28:30	7:10:29:31	0:0:1:1	D013927	thrombosis	Disease	76	77	4
6727060	A case of tardive dyskinesia caused by metoclopramide .|Abnormal involuntary movements appeared in the mouth , tongue , neck and abdomen of a 64 - year - old male patient after he took metoclopramide for gastrointestinal disorder in a regimen of 30 mg per day for a total of about 260 days .|The symptoms exacerbated to a maximum in a month .|When the metoclopramide administration was discontinued , the abnormal movements gradually improved to a considerable extent .|Attention to the possible induction of specific tardive dyskinesia is called for in the use of this drug .	1:CID:2	R2L	NON-CROSS	9-12	7-8	D008787	metoclopramide|metoclopramide|metoclopramide	Chemical	7:34:66	8:35:67	0:1:3	D004409	tardive dyskinesia|Abnormal involuntary movements|abnormal movements|tardive dyskinesia	Disease	3:9:72:88	5:12:74:90	0:1:3:4	1:NR:2	L2R	NON-CROSS	34-35	36-38	D008787	metoclopramide|metoclopramide|metoclopramide	Chemical	7:34:66	8:35:67	0:1:3	D005767	gastrointestinal disorder	Disease	36	38	1
7083920	Further observations on the electrophysiologic effects of oral amiodarone therapy .|A case is presented of a reversible intra - Hisian block occurring under amiodarone treatment for atrial tachycardia in a patient without clear intraventricular conduction abnormalities .|His bundle recordings showed an atrial tachycardia with intermittent exit block and greatly prolonged BH and HV intervals ( 40 and 100 msec , respectively ) .|Thirty days after amiodarone discontinuation , His bundle electrograms showed atrial flutter without intra - Hisian or infra - Hisian delay .|Amiodarone should be used with caution during long - term oral therapy in patients with or without clear intraventricular conduction defects .	1:CID:2	L2R	NON-CROSS	18-22	24-25	D000638	amiodarone|amiodarone|amiodarone|Amiodarone	Chemical	8:24:68:87	9:25:69:88	0:1:3:4	D006327	intra - Hisian block	Disease	18	22	1	1:NR:2	L2R	NON-CROSS	24-25	27-29	D000638	amiodarone|amiodarone|amiodarone|Amiodarone	Chemical	8:24:68:87	9:25:69:88	0:1:3:4	D013617	atrial tachycardia|atrial tachycardia	Disease	27:43	29:45	1:2	1:NR:2	L2R	NON-CROSS	24-25	34-37	D000638	amiodarone|amiodarone|amiodarone|Amiodarone	Chemical	8:24:68:87	9:25:69:88	0:1:3:4	D006345	intraventricular conduction abnormalities	Disease	34	37	1	1:NR:2	L2R	NON-CROSS	68-69	75-77	D000638	amiodarone|amiodarone|amiodarone|Amiodarone	Chemical	8:24:68:87	9:25:69:88	0:1:3:4	D001282	atrial flutter	Disease	75	77	3
7269015	Busulfan - induced hemorrhagic cystitis .|A case of a busulfan - induced hemorrhage cystitis is reported .|Spontaneous resolution occurred following cessation of the drug .|The similarity between the histologic appearances of busulfan cystitis and both radiation and cyclophosphamide - induced cystitis is discussed and the world literature reviewed .|In view of the known tendency of busulfan to induce cellular atypia and carcinoma in other sites , periodic urinary cytology is suggested in patients on long - term therapy .	1:CID:2	L2R	NON-CROSS	0-1	3-5	D002066	Busulfan|busulfan|busulfan|busulfan	Chemical	0:10:34:59	1:11:35:60	0:1:3:4	D006470	hemorrhagic cystitis|hemorrhage cystitis	Disease	3:13	5:15	0:1	1:CID:2	L2R	NON-CROSS	34-35	35-36	D002066	Busulfan|busulfan|busulfan|busulfan	Chemical	0:10:34:59	1:11:35:60	0:1:3:4	D003556	hemorrhagic cystitis|hemorrhage cystitis|cystitis|cystitis	Disease	3:13:35:43	5:15:36:44	0:1:3:3	1:NR:2	L2R	NON-CROSS	59-60	65-66	D002066	Busulfan|busulfan|busulfan|busulfan	Chemical	0:10:34:59	1:11:35:60	0:1:3:4	D002277	carcinoma	Disease	65	66	4	1:NR:2	R2L	CROSS	40-41	13-15	D003520	cyclophosphamide	Chemical	40	41	3	D006470	hemorrhagic cystitis|hemorrhage cystitis	Disease	3:13	5:15	0:1	1:NR:2	R2L	NON-CROSS	43-44	40-41	D003520	cyclophosphamide	Chemical	40	41	3	D003556	hemorrhagic cystitis|hemorrhage cystitis|cystitis|cystitis	Disease	3:13:35:43	5:15:36:44	0:1:3:3	1:NR:2	L2R	CROSS	40-41	65-66	D003520	cyclophosphamide	Chemical	40	41	3	D002277	carcinoma	Disease	65	66	4
7352670	Rebound hypertensive after sodium nitroprusside prevented by saralasin in rats .|The role of the renin - - angiotensin system in the maintenance of blood pressure during halothane anesthesia and sodium nitroprusside ( SNP ) - induced hypotension was evaluated .|Control rats received halothane anesthesia ( 1 MAC ) for one hour , followed by SNP infusion , 40 microgram / kg / min , for 30 min , followed by a 30 - min recovery period .|A second group of rats was treated identically and , in addition , received an infusion of saralasin ( a competitive inhibitor of angiotensin II ) throughout the experimental period .|In each group , SNP infusion resulted in an initial decrease in blood pressure from 86 torr and 83 torr , respectively , to 48 torr .|During the SNP infusion the control animals demonstrated a progressive increase in blood pressure to 61 torr , whereas the saralasin - treated animals showed no change .|Following discontinuation of SNP , blood pressure in the control animals rebounded to 94 torr , as compared with 78 torr in the saralasin - treated rats .|This study indicates that with stable halothane anesthesia , the partial recovery of blood pressure during SNP infusion and the post - SNP rebound of blood pressure can be completely blocked by saralasin .|This demonstrates the participation of the renin - - angiotensin system in antagonizing the combined hypotensive effects of halothane and SNP .	1:CID:2	L2R	NON-CROSS	33-34	37-38	D009599	sodium nitroprusside|sodium nitroprusside|SNP|SNP|SNP|SNP|SNP|SNP|SNP|SNP	Chemical	3:30:33:56:114:139:168:209:215:247	5:32:34:57:115:140:169:210:216:248	0:1:1:2:4:5:6:7:7:8	D007022	hypotension|hypotensive	Disease	37:242	38:243	1:8	1:CID:2	L2R	NON-CROSS	242-243	245-246	D006221	halothane|halothane|halothane|halothane	Chemical	27:44:199:245	28:45:200:246	1:2:7:8	D007022	hypotension|hypotensive	Disease	37:242	38:243	1:8	1:NR:2	R2L	NON-CROSS	3-5	1-2	D009599	sodium nitroprusside|sodium nitroprusside|SNP|SNP|SNP|SNP|SNP|SNP|SNP|SNP	Chemical	3:30:33:56:114:139:168:209:215:247	5:32:34:57:115:140:169:210:216:248	0:1:1:2:4:5:6:7:7:8	D006973	hypertensive|increase in blood pressure	Disease	1:147	2:151	0:5	1:NR:2	R2L	NON-CROSS	7-8	1-2	D012504	saralasin|saralasin|saralasin|saralasin|saralasin	Chemical	7:96:157:188:225	8:97:158:189:226	0:3:5:6:7	D006973	hypertensive|increase in blood pressure	Disease	1:147	2:151	0:5	1:NR:2	R2L	CROSS	18-19	1-2	D000809	angiotensin|angiotensin	Chemical	18:236	19:237	1:8	D006973	hypertensive|increase in blood pressure	Disease	1:147	2:151	0:5	1:NR:2	R2L	CROSS	27-28	1-2	D006221	halothane|halothane|halothane|halothane	Chemical	27:44:199:245	28:45:200:246	1:2:7:8	D006973	hypertensive|increase in blood pressure	Disease	1:147	2:151	0:5	1:NR:2	R2L	CROSS	147-151	102-104	D000804	angiotensin II	Chemical	102	104	3	D006973	hypertensive|increase in blood pressure	Disease	1:147	2:151	0:5	1:NR:2	L2R	CROSS	225-226	242-243	D012504	saralasin|saralasin|saralasin|saralasin|saralasin	Chemical	7:96:157:188:225	8:97:158:189:226	0:3:5:6:7	D007022	hypotension|hypotensive	Disease	37:242	38:243	1:8	1:NR:2	L2R	NON-CROSS	236-237	242-243	D000809	angiotensin|angiotensin	Chemical	18:236	19:237	1:8	D007022	hypotension|hypotensive	Disease	37:242	38:243	1:8	1:NR:2	R2L	CROSS	102-104	37-38	D000804	angiotensin II	Chemical	102	104	3	D007022	hypotension|hypotensive	Disease	37:242	38:243	1:8
7504976	Toxic hepatitis induced by antithyroid drugs : four cases including one with cross - reactivity between carbimazole and benzylthiouracil .|OBJECTIVE : This study was conducted to assess the occurrence of hepatic adverse effects encountered with antithyroid drugs .|METHODS : Retrospective review of medical records of 236 patients with hyperthyroidism admitted in our department ( in - or out - patients ) from 1986 to 1992 .|RESULTS : Four patients ( 1 . 7 % ) were identified with toxic hepatitis which could reasonably be attributed to the use of antithyroid agent .|Two patients had a cholestatic hepatitis induced by carbimazole ( N omercazole ) .|Two others had a mixed ( cholestatic and cytolytic ) hepatitis following carbimazole .|One of the latter two patients further experienced a cytolytic hepatitis which appeared after Benzylthiouracil ( Basd ne ) had replaced carbimazole .|Biological features of hepatitis disappeared in all cases after cessation of the incriminated drug , while biliary , viral and immunological searches were negative .|Only 2 patients of our retrospective study experienced a mild or severe neutropenia .|CONCLUSION : Toxic hepatitis is a potential adverse effect of antithyroid drugs which warrants , as for haematological disturbances , a pre - therapeutic determination and a careful follow - up of relevant biological markers .|Moreover , hepatotoxicity may not be restricted to one class of antithyroid agents .	1:CID:2	R2L	NON-CROSS	121-122	119-120	D002231	carbimazole|carbimazole|N omercazole|carbimazole|carbimazole	Chemical	16:103:105:121:144	17:104:107:122:145	0:4:4:5:6	D056486	Toxic hepatitis|hepatic adverse effects|toxic hepatitis|cholestatic hepatitis|hepatitis|hepatitis|hepatitis|Toxic hepatitis|hepatotoxicity	Disease	0:31:81:99:119:133:149:187:223	2:34:83:101:120:134:150:189:224	0:1:3:4:5:6:7:9:10	1:CID:2	L2R	NON-CROSS	99-101	103-104	D002231	carbimazole|carbimazole|N omercazole|carbimazole|carbimazole	Chemical	16:103:105:121:144	17:104:107:122:145	0:4:4:5:6	D002779	cholestatic hepatitis|cholestatic	Disease	99:115	101:116	4:5	1:NR:2	R2L	NON-CROSS	137-138	133-134	C019269	benzylthiouracil|Benzylthiouracil|Basd ne	Chemical	18:137:139	19:138:141	0:6:6	D056486	Toxic hepatitis|hepatic adverse effects|toxic hepatitis|cholestatic hepatitis|hepatitis|hepatitis|hepatitis|Toxic hepatitis|hepatotoxicity	Disease	0:31:81:99:119:133:149:187:223	2:34:83:101:120:134:150:189:224	0:1:3:4:5:6:7:9:10	1:NR:2	L2R	CROSS	16-17	50-51	D002231	carbimazole|carbimazole|N omercazole|carbimazole|carbimazole	Chemical	16:103:105:121:144	17:104:107:122:145	0:4:4:5:6	D006980	hyperthyroidism	Disease	50	51	2	1:NR:2	L2R	CROSS	144-145	183-184	D002231	carbimazole|carbimazole|N omercazole|carbimazole|carbimazole	Chemical	16:103:105:121:144	17:104:107:122:145	0:4:4:5:6	D009503	neutropenia	Disease	183	184	8	1:NR:2	L2R	CROSS	18-19	50-51	C019269	benzylthiouracil|Benzylthiouracil|Basd ne	Chemical	18:137:139	19:138:141	0:6:6	D006980	hyperthyroidism	Disease	50	51	2	1:NR:2	L2R	CROSS	115-116	137-138	C019269	benzylthiouracil|Benzylthiouracil|Basd ne	Chemical	18:137:139	19:138:141	0:6:6	D002779	cholestatic hepatitis|cholestatic	Disease	99:115	101:116	4:5	1:NR:2	L2R	CROSS	139-141	183-184	C019269	benzylthiouracil|Benzylthiouracil|Basd ne	Chemical	18:137:139	19:138:141	0:6:6	D009503	neutropenia	Disease	183	184	8
7628595	Study of the role of vitamin B12 and folinic acid supplementation in preventing hematologic toxicity of zidovudine .|A prospective , randomized study was conducted to evaluate the role of vitamin B12 and folinic acid supplementation in preventing zidovudine ( ZDV ) - induced bone marrow suppression .|Seventy - five human immunodeficiency virus ( HIV ) - infected patients with CD4 + cell counts < 500 / mm3 were randomized to receive either ZDV ( 500 mg daily ) alone ( group I , n = 38 ) or in combination with folinic acid ( 15 mg daily ) and intramascular vitamin B12 ( 1000 micrograms monthly ) ( group II , n = 37 ) .|Finally , 15 patients were excluded from the study ( noncompliance 14 , death 1 ) ; thus , 60 patients ( 31 in group I and 29 in group II ) were eligible for analysis .|No significant differences between groups were found at enrollment .|During the study , vitamin B12 and folate levels were significantly higher in group II patients ; however , no differences in hemoglobin , hematocrit , mean corpuscular volume , and white - cell , neutrophil and platelet counts were observed between groups at 3 , 6 , 9 and 12 months .|Severe hematologic toxicity ( neutrophil count < 1000 / mm3 and / or hemoglobin < 8 g / dl ) occurred in 4 patients assigned to group I and 7 assigned to group II .|There was no correlation between vitamin B12 or folate levels and development of myelosuppression .|Vitamin B12 and folinic acid supplementation of ZDV therapy does not seem useful in preventing or reducing ZDV - induced myelotoxicity in the overall treated population , although a beneficial effect in certain subgroups of patients can not be excluded .	1:CID:2	L2R	NON-CROSS	285-286	288-289	D015215	zidovudine|zidovudine|ZDV|ZDV|ZDV|ZDV	Chemical	16:38:40:74:275:285	17:39:41:75:276:286	0:1:1:2:8:8	D001855	bone marrow suppression|myelosuppression|myelotoxicity	Disease	44:266:288	47:267:289	1:7:8	1:NR:2	L2R	NON-CROSS	5-7	14-15	D014805	vitamin B12|vitamin B12|vitamin B12|vitamin B12|vitamin B12|Vitamin B12	Chemical	5:30:102:169:258:268	7:32:104:171:260:270	0:1:2:5:7:8	D064420	toxicity|toxicity	Disease	14:220	15:221	0:6	1:NR:2	L2R	NON-CROSS	266-267	268-270	D014805	vitamin B12|vitamin B12|vitamin B12|vitamin B12|vitamin B12|Vitamin B12	Chemical	5:30:102:169:258:268	7:32:104:171:260:270	0:1:2:5:7:8	D001855	bone marrow suppression|myelosuppression|myelotoxicity	Disease	44:266:288	47:267:289	1:7:8	1:NR:2	L2R	NON-CROSS	30-32	51-59	D014805	vitamin B12|vitamin B12|vitamin B12|vitamin B12|vitamin B12|Vitamin B12	Chemical	5:30:102:169:258:268	7:32:104:171:260:270	0:1:2:5:7:8	D015658	human immunodeficiency virus ( HIV ) - infected	Disease	51	59	2	1:NR:2	L2R	CROSS	102-104	131-132	D014805	vitamin B12|vitamin B12|vitamin B12|vitamin B12|vitamin B12|Vitamin B12	Chemical	5:30:102:169:258:268	7:32:104:171:260:270	0:1:2:5:7:8	D003643	death	Disease	131	132	3	1:NR:2	L2R	NON-CROSS	8-10	14-15	D002955	folinic acid|folinic acid|folinic acid|folinic acid	Chemical	8:33:93:271	10:35:95:273	0:1:2:8	D064420	toxicity|toxicity	Disease	14:220	15:221	0:6	1:NR:2	L2R	NON-CROSS	266-267	271-273	D002955	folinic acid|folinic acid|folinic acid|folinic acid	Chemical	8:33:93:271	10:35:95:273	0:1:2:8	D001855	bone marrow suppression|myelosuppression|myelotoxicity	Disease	44:266:288	47:267:289	1:7:8	1:NR:2	L2R	NON-CROSS	33-35	51-59	D002955	folinic acid|folinic acid|folinic acid|folinic acid	Chemical	8:33:93:271	10:35:95:273	0:1:2:8	D015658	human immunodeficiency virus ( HIV ) - infected	Disease	51	59	2	1:NR:2	L2R	CROSS	93-95	131-132	D002955	folinic acid|folinic acid|folinic acid|folinic acid	Chemical	8:33:93:271	10:35:95:273	0:1:2:8	D003643	death	Disease	131	132	3	1:NR:2	R2L	NON-CROSS	16-17	14-15	D015215	zidovudine|zidovudine|ZDV|ZDV|ZDV|ZDV	Chemical	16:38:40:74:275:285	17:39:41:75:276:286	0:1:1:2:8:8	D064420	toxicity|toxicity	Disease	14:220	15:221	0:6	1:NR:2	R2L	CROSS	261-262	220-221	D005492	folate|folate	Chemical	172:261	173:262	5:7	D064420	toxicity|toxicity	Disease	14:220	15:221	0:6	1:NR:2	L2R	NON-CROSS	40-41	51-59	D015215	zidovudine|zidovudine|ZDV|ZDV|ZDV|ZDV	Chemical	16:38:40:74:275:285	17:39:41:75:276:286	0:1:1:2:8:8	D015658	human immunodeficiency virus ( HIV ) - infected	Disease	51	59	2	1:NR:2	L2R	CROSS	74-75	131-132	D015215	zidovudine|zidovudine|ZDV|ZDV|ZDV|ZDV	Chemical	16:38:40:74:275:285	17:39:41:75:276:286	0:1:1:2:8:8	D003643	death	Disease	131	132	3	1:NR:2	R2L	NON-CROSS	266-267	261-262	D005492	folate|folate	Chemical	172:261	173:262	5:7	D001855	bone marrow suppression|myelosuppression|myelotoxicity	Disease	44:266:288	47:267:289	1:7:8	1:NR:2	R2L	CROSS	172-173	51-59	D005492	folate|folate	Chemical	172:261	173:262	5:7	D015658	human immunodeficiency virus ( HIV ) - infected	Disease	51	59	2	1:NR:2	R2L	CROSS	172-173	131-132	D005492	folate|folate	Chemical	172:261	173:262	5:7	D003643	death	Disease	131	132	3
7858459	Acute confusion induced by a high - dose infusion of 5 - fluorouracil and folinic acid .|A 61 - year - old man was treated with combination chemotherapy incorporating cisplatinum , etoposide , high - dose 5 - fluorouracil ( 2 , 250 mg / m2 / 24 hours ) and folinic acid for an inoperable gastric adenocarcinoma .|He developed acute neurologic symptoms of mental confusion , disorientation and irritability , and then lapsed into a deep coma , lasting for approximately 40 hours during the first dose ( day 2 ) of 5 - fluorouracil and folinic acid infusion .|This complication reappeared on day 25 during the second dose of 5 - fluorouracil and folinic acid , which were then the only drugs given .|Because folinic acid was unlikely to be associated with this condition , neurotoxicity due to high - dose 5 - fluorouracil was highly suspected .|The pathogenesis of 5 - fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate , thiamine deficiency , or dihydrouracil dehydrogenase deficiency .|High - dose 5 - fluorouracil / folinic acid infusion therapy has recently become a popular regimen for various cancers .|It is necessary that both oncologists and neurologists be fully aware of this unusual complication .	1:CID:2	R2L	NON-CROSS	10-13	1-2	D005472	5 - fluorouracil|5 - fluorouracil|5 - fluorouracil|5 - fluorouracil|5 - fluorouracil|5 - fluorouracil|5 - fluorouracil	Chemical	10:37:95:114:147:157:185	13:40:98:117:150:160:188	0:1:2:3:4:5:6	D003221	confusion|confusion|disorientation	Disease	1:67:69	2:68:70	0:2:2	1:CID:2	R2L	NON-CROSS	14-16	1-2	D002955	folinic acid|folinic acid|folinic acid|folinic acid|folinic acid|folinic acid	Chemical	14:52:99:118:130:189	16:54:101:120:132:191	0:1:2:3:4:6	D003221	confusion|confusion|disorientation	Disease	1:67:69	2:68:70	0:2:2	1:CID:2	L2R	NON-CROSS	79-80	95-98	D005472	5 - fluorouracil|5 - fluorouracil|5 - fluorouracil|5 - fluorouracil|5 - fluorouracil|5 - fluorouracil|5 - fluorouracil	Chemical	10:37:95:114:147:157:185	13:40:98:117:150:160:188	0:1:2:3:4:5:6	D003128	coma	Disease	79	80	2	1:CID:2	L2R	NON-CROSS	79-80	99-101	D002955	folinic acid|folinic acid|folinic acid|folinic acid|folinic acid|folinic acid	Chemical	14:52:99:118:130:189	16:54:101:120:132:191	0:1:2:3:4:6	D003128	coma	Disease	79	80	2	1:NR:2	R2L	CROSS	30-31	1-2	D002945	cisplatinum	Chemical	30	31	1	D003221	confusion|confusion|disorientation	Disease	1:67:69	2:68:70	0:2:2	1:NR:2	R2L	CROSS	32-33	1-2	D005047	etoposide	Chemical	32	33	1	D003221	confusion|confusion|disorientation	Disease	1:67:69	2:68:70	0:2:2	1:NR:2	R2L	CROSS	170-171	69-70	D005463	fluoroacetate	Chemical	170	171	5	D003221	confusion|confusion|disorientation	Disease	1:67:69	2:68:70	0:2:2	1:NR:2	R2L	CROSS	172-173	69-70	C007744	fluorocitrate	Chemical	172	173	5	D003221	confusion|confusion|disorientation	Disease	1:67:69	2:68:70	0:2:2	1:NR:2	R2L	CROSS	174-175	69-70	D013831	thiamine	Chemical	174	175	5	D003221	confusion|confusion|disorientation	Disease	1:67:69	2:68:70	0:2:2	1:NR:2	R2L	CROSS	178-179	69-70	C007419	dihydrouracil	Chemical	178	179	5	D003221	confusion|confusion|disorientation	Disease	1:67:69	2:68:70	0:2:2	1:NR:2	L2R	NON-CROSS	37-40	57-59	D005472	5 - fluorouracil|5 - fluorouracil|5 - fluorouracil|5 - fluorouracil|5 - fluorouracil|5 - fluorouracil|5 - fluorouracil	Chemical	10:37:95:114:147:157:185	13:40:98:117:150:160:188	0:1:2:3:4:5:6	D013274	gastric adenocarcinoma	Disease	57	59	1	1:NR:2	L2R	NON-CROSS	71-72	95-98	D005472	5 - fluorouracil|5 - fluorouracil|5 - fluorouracil|5 - fluorouracil|5 - fluorouracil|5 - fluorouracil|5 - fluorouracil	Chemical	10:37:95:114:147:157:185	13:40:98:117:150:160:188	0:1:2:3:4:5:6	D001523	irritability	Disease	71	72	2	1:NR:2	L2R	NON-CROSS	157-160	160-161	D005472	5 - fluorouracil|5 - fluorouracil|5 - fluorouracil|5 - fluorouracil|5 - fluorouracil|5 - fluorouracil|5 - fluorouracil	Chemical	10:37:95:114:147:157:185	13:40:98:117:150:160:188	0:1:2:3:4:5:6	D020258	neurotoxicity|neurotoxicity	Disease	141:160	142:161	4:5	1:NR:2	L2R	NON-CROSS	185-188	201-202	D005472	5 - fluorouracil|5 - fluorouracil|5 - fluorouracil|5 - fluorouracil|5 - fluorouracil|5 - fluorouracil|5 - fluorouracil	Chemical	10:37:95:114:147:157:185	13:40:98:117:150:160:188	0:1:2:3:4:5:6	D009369	cancers	Disease	201	202	6	1:NR:2	L2R	NON-CROSS	52-54	57-59	D002955	folinic acid|folinic acid|folinic acid|folinic acid|folinic acid|folinic acid	Chemical	14:52:99:118:130:189	16:54:101:120:132:191	0:1:2:3:4:6	D013274	gastric adenocarcinoma	Disease	57	59	1	1:NR:2	L2R	NON-CROSS	52-54	71-72	D002955	folinic acid|folinic acid|folinic acid|folinic acid|folinic acid|folinic acid	Chemical	14:52:99:118:130:189	16:54:101:120:132:191	0:1:2:3:4:6	D001523	irritability	Disease	71	72	2	1:NR:2	L2R	NON-CROSS	130-132	141-142	D002955	folinic acid|folinic acid|folinic acid|folinic acid|folinic acid|folinic acid	Chemical	14:52:99:118:130:189	16:54:101:120:132:191	0:1:2:3:4:6	D020258	neurotoxicity|neurotoxicity	Disease	141:160	142:161	4:5	1:NR:2	L2R	NON-CROSS	189-191	201-202	D002955	folinic acid|folinic acid|folinic acid|folinic acid|folinic acid|folinic acid	Chemical	14:52:99:118:130:189	16:54:101:120:132:191	0:1:2:3:4:6	D009369	cancers	Disease	201	202	6	1:NR:2	L2R	NON-CROSS	30-31	57-59	D002945	cisplatinum	Chemical	30	31	1	D013274	gastric adenocarcinoma	Disease	57	59	1	1:NR:2	L2R	CROSS	30-31	71-72	D002945	cisplatinum	Chemical	30	31	1	D001523	irritability	Disease	71	72	2	1:NR:2	L2R	CROSS	30-31	79-80	D002945	cisplatinum	Chemical	30	31	1	D003128	coma	Disease	79	80	2	1:NR:2	L2R	CROSS	30-31	141-142	D002945	cisplatinum	Chemical	30	31	1	D020258	neurotoxicity|neurotoxicity	Disease	141:160	142:161	4:5	1:NR:2	L2R	CROSS	30-31	201-202	D002945	cisplatinum	Chemical	30	31	1	D009369	cancers	Disease	201	202	6	1:NR:2	L2R	NON-CROSS	32-33	57-59	D005047	etoposide	Chemical	32	33	1	D013274	gastric adenocarcinoma	Disease	57	59	1	1:NR:2	L2R	CROSS	32-33	71-72	D005047	etoposide	Chemical	32	33	1	D001523	irritability	Disease	71	72	2	1:NR:2	L2R	CROSS	32-33	79-80	D005047	etoposide	Chemical	32	33	1	D003128	coma	Disease	79	80	2	1:NR:2	L2R	CROSS	32-33	141-142	D005047	etoposide	Chemical	32	33	1	D020258	neurotoxicity|neurotoxicity	Disease	141:160	142:161	4:5	1:NR:2	L2R	CROSS	32-33	201-202	D005047	etoposide	Chemical	32	33	1	D009369	cancers	Disease	201	202	6	1:NR:2	R2L	CROSS	170-171	57-59	D005463	fluoroacetate	Chemical	170	171	5	D013274	gastric adenocarcinoma	Disease	57	59	1	1:NR:2	R2L	CROSS	172-173	57-59	C007744	fluorocitrate	Chemical	172	173	5	D013274	gastric adenocarcinoma	Disease	57	59	1	1:NR:2	R2L	CROSS	174-175	57-59	D013831	thiamine	Chemical	174	175	5	D013274	gastric adenocarcinoma	Disease	57	59	1	1:NR:2	R2L	CROSS	178-179	57-59	C007419	dihydrouracil	Chemical	178	179	5	D013274	gastric adenocarcinoma	Disease	57	59	1	1:NR:2	R2L	CROSS	170-171	71-72	D005463	fluoroacetate	Chemical	170	171	5	D001523	irritability	Disease	71	72	2	1:NR:2	R2L	CROSS	172-173	71-72	C007744	fluorocitrate	Chemical	172	173	5	D001523	irritability	Disease	71	72	2	1:NR:2	R2L	CROSS	174-175	71-72	D013831	thiamine	Chemical	174	175	5	D001523	irritability	Disease	71	72	2	1:NR:2	R2L	CROSS	178-179	71-72	C007419	dihydrouracil	Chemical	178	179	5	D001523	irritability	Disease	71	72	2	1:NR:2	R2L	CROSS	170-171	79-80	D005463	fluoroacetate	Chemical	170	171	5	D003128	coma	Disease	79	80	2	1:NR:2	R2L	CROSS	172-173	79-80	C007744	fluorocitrate	Chemical	172	173	5	D003128	coma	Disease	79	80	2	1:NR:2	R2L	CROSS	174-175	79-80	D013831	thiamine	Chemical	174	175	5	D003128	coma	Disease	79	80	2	1:NR:2	R2L	CROSS	178-179	79-80	C007419	dihydrouracil	Chemical	178	179	5	D003128	coma	Disease	79	80	2	1:NR:2	R2L	NON-CROSS	170-171	160-161	D005463	fluoroacetate	Chemical	170	171	5	D020258	neurotoxicity|neurotoxicity	Disease	141:160	142:161	4:5	1:NR:2	R2L	NON-CROSS	172-173	160-161	C007744	fluorocitrate	Chemical	172	173	5	D020258	neurotoxicity|neurotoxicity	Disease	141:160	142:161	4:5	1:NR:2	R2L	NON-CROSS	174-175	160-161	D013831	thiamine	Chemical	174	175	5	D020258	neurotoxicity|neurotoxicity	Disease	141:160	142:161	4:5	1:NR:2	R2L	NON-CROSS	178-179	160-161	C007419	dihydrouracil	Chemical	178	179	5	D020258	neurotoxicity|neurotoxicity	Disease	141:160	142:161	4:5	1:NR:2	L2R	CROSS	170-171	201-202	D005463	fluoroacetate	Chemical	170	171	5	D009369	cancers	Disease	201	202	6	1:NR:2	L2R	CROSS	172-173	201-202	C007744	fluorocitrate	Chemical	172	173	5	D009369	cancers	Disease	201	202	6	1:NR:2	L2R	CROSS	174-175	201-202	D013831	thiamine	Chemical	174	175	5	D009369	cancers	Disease	201	202	6	1:NR:2	L2R	CROSS	178-179	201-202	C007419	dihydrouracil	Chemical	178	179	5	D009369	cancers	Disease	201	202	6
7862923	Effect of switching carbamazepine to oxcarbazepine on the plasma levels of neuroleptics .|A case report .|Carbamazepine was switched to its 10 - keto analogue oxcarbazepine among six difficult - to - treat schizophrenic or organic psychotic patients using concomitantly haloperidol , chlorpromazine or clozapine .|This change resulted within 2 - 4 weeks in the 50 - 200 % increase in the plasma levels of these neuroleptics and the appearance of extrapyramidal symptoms .|None of the patients showed any clinical deteriotation during the following 3 - 6 months .|The results of this case report support the idea that in contrast with carbamazepine oxcarbazepine does not induce the hepatic microsomal enzyme systems regulating the inactivation of antipsychotic drugs .	1:CID:2	L2R	CROSS	73-75	106-107	C036006	oxcarbazepine|oxcarbazepine|oxcarbazepine	Chemical	5:26:106	6:27:107	0:2:5	D001480	extrapyramidal symptoms	Disease	73	75	3	1:CID:2	L2R	CROSS	41-42	73-75	D006220	haloperidol	Chemical	41	42	2	D001480	extrapyramidal symptoms	Disease	73	75	3	1:CID:2	L2R	CROSS	43-44	73-75	D002746	chlorpromazine	Chemical	43	44	2	D001480	extrapyramidal symptoms	Disease	73	75	3	1:CID:2	L2R	CROSS	45-46	73-75	D003024	clozapine	Chemical	45	46	2	D001480	extrapyramidal symptoms	Disease	73	75	3	1:NR:2	L2R	NON-CROSS	17-18	34-35	D002220	carbamazepine|Carbamazepine|carbamazepine	Chemical	3:17:105	4:18:106	0:2:5	D012559	schizophrenic	Disease	34	35	2	1:NR:2	L2R	NON-CROSS	17-18	36-38	D002220	carbamazepine|Carbamazepine|carbamazepine	Chemical	3:17:105	4:18:106	0:2:5	D019965	organic psychotic	Disease	36	38	2	1:NR:2	L2R	CROSS	73-75	105-106	D002220	carbamazepine|Carbamazepine|carbamazepine	Chemical	3:17:105	4:18:106	0:2:5	D001480	extrapyramidal symptoms	Disease	73	75	3	1:NR:2	L2R	NON-CROSS	26-27	34-35	C036006	oxcarbazepine|oxcarbazepine|oxcarbazepine	Chemical	5:26:106	6:27:107	0:2:5	D012559	schizophrenic	Disease	34	35	2	1:NR:2	L2R	NON-CROSS	26-27	36-38	C036006	oxcarbazepine|oxcarbazepine|oxcarbazepine	Chemical	5:26:106	6:27:107	0:2:5	D019965	organic psychotic	Disease	36	38	2	1:NR:2	R2L	NON-CROSS	41-42	34-35	D006220	haloperidol	Chemical	41	42	2	D012559	schizophrenic	Disease	34	35	2	1:NR:2	R2L	NON-CROSS	43-44	34-35	D002746	chlorpromazine	Chemical	43	44	2	D012559	schizophrenic	Disease	34	35	2	1:NR:2	R2L	NON-CROSS	45-46	34-35	D003024	clozapine	Chemical	45	46	2	D012559	schizophrenic	Disease	34	35	2	1:NR:2	R2L	NON-CROSS	41-42	36-38	D006220	haloperidol	Chemical	41	42	2	D019965	organic psychotic	Disease	36	38	2	1:NR:2	R2L	NON-CROSS	43-44	36-38	D002746	chlorpromazine	Chemical	43	44	2	D019965	organic psychotic	Disease	36	38	2	1:NR:2	R2L	NON-CROSS	45-46	36-38	D003024	clozapine	Chemical	45	46	2	D019965	organic psychotic	Disease	36	38	2
7919560	Erythema multiforme and hypersensitivity myocarditis caused by ampicillin .|OBJECTIVE : To report a case of erythema multiforme and hypersensitivity myocarditis caused by ampicillin .|CASE SUMMARY : A 13 - year - old boy was treated with ampicillin and gentamicin because of suspected septicemia .|Medications were discontinued when erythema multiforme and congestive heart failure caused by myocarditis occurred .|The patient was treated with methylprednisolone and gradually improved .|Macrophage - migration inhibition ( MIF ) test with ampicillin was positive .|DISCUSSION : After most infections causing erythema multiforme and myocarditis were ruled out , a drug - induced allergic reaction was suspected .|Positive MIF test for ampicillin showed sensitization of the patient 's lymphocytes to ampicillin .|CONCLUSIONS : Hypersensitivity myocarditis is a rare and dangerous manifestation of allergy to penicillins .	1:CID:2	R2L	NON-CROSS	7-8	0-2	D000667	ampicillin|ampicillin|ampicillin|ampicillin|ampicillin|ampicillin	Chemical	7:23:38:80:111:120	8:24:39:81:112:121	0:1:2:5:7:7	D004892	Erythema multiforme|erythema multiforme|erythema multiforme|erythema multiforme	Disease	0:16:50:90	2:18:52:92	0:1:3:6	1:CID:2	R2L	NON-CROSS	7-8	3-5	D000667	ampicillin|ampicillin|ampicillin|ampicillin|ampicillin|ampicillin	Chemical	7:23:38:80:111:120	8:24:39:81:112:121	0:1:2:5:7:7	D009205	hypersensitivity myocarditis|hypersensitivity myocarditis|myocarditis|myocarditis|Hypersensitivity myocarditis	Disease	3:19:58:93:124	5:21:59:94:126	0:1:3:6:8	1:CID:2	L2R	CROSS	99-104	111-112	D000667	ampicillin|ampicillin|ampicillin|ampicillin|ampicillin|ampicillin	Chemical	7:23:38:80:111:120	8:24:39:81:112:121	0:1:2:5:7:7	D004342	drug - induced allergic reaction|allergy	Disease	99:133	104:134	6:8	1:NR:2	R2L	CROSS	50-52	40-41	D005839	gentamicin	Chemical	40	41	2	D004892	Erythema multiforme|erythema multiforme|erythema multiforme|erythema multiforme	Disease	0:16:50:90	2:18:52:92	0:1:3:6	1:NR:2	R2L	CROSS	66-67	50-52	D008775	methylprednisolone	Chemical	66	67	4	D004892	Erythema multiforme|erythema multiforme|erythema multiforme|erythema multiforme	Disease	0:16:50:90	2:18:52:92	0:1:3:6	1:NR:2	R2L	CROSS	135-136	90-92	D010406	penicillins	Chemical	135	136	8	D004892	Erythema multiforme|erythema multiforme|erythema multiforme|erythema multiforme	Disease	0:16:50:90	2:18:52:92	0:1:3:6	1:NR:2	R2L	CROSS	58-59	40-41	D005839	gentamicin	Chemical	40	41	2	D009205	hypersensitivity myocarditis|hypersensitivity myocarditis|myocarditis|myocarditis|Hypersensitivity myocarditis	Disease	3:19:58:93:124	5:21:59:94:126	0:1:3:6:8	1:NR:2	R2L	CROSS	66-67	58-59	D008775	methylprednisolone	Chemical	66	67	4	D009205	hypersensitivity myocarditis|hypersensitivity myocarditis|myocarditis|myocarditis|Hypersensitivity myocarditis	Disease	3:19:58:93:124	5:21:59:94:126	0:1:3:6:8	1:NR:2	R2L	NON-CROSS	135-136	124-126	D010406	penicillins	Chemical	135	136	8	D009205	hypersensitivity myocarditis|hypersensitivity myocarditis|myocarditis|myocarditis|Hypersensitivity myocarditis	Disease	3:19:58:93:124	5:21:59:94:126	0:1:3:6:8	1:NR:2	L2R	NON-CROSS	38-39	44-45	D000667	ampicillin|ampicillin|ampicillin|ampicillin|ampicillin|ampicillin	Chemical	7:23:38:80:111:120	8:24:39:81:112:121	0:1:2:5:7:7	D018805	septicemia	Disease	44	45	2	1:NR:2	L2R	CROSS	38-39	53-56	D000667	ampicillin|ampicillin|ampicillin|ampicillin|ampicillin|ampicillin	Chemical	7:23:38:80:111:120	8:24:39:81:112:121	0:1:2:5:7:7	D006333	congestive heart failure	Disease	53	56	3	1:NR:2	L2R	CROSS	80-81	88-89	D000667	ampicillin|ampicillin|ampicillin|ampicillin|ampicillin|ampicillin	Chemical	7:23:38:80:111:120	8:24:39:81:112:121	0:1:2:5:7:7	D007239	infections	Disease	88	89	6	1:NR:2	L2R	NON-CROSS	40-41	44-45	D005839	gentamicin	Chemical	40	41	2	D018805	septicemia	Disease	44	45	2	1:NR:2	L2R	CROSS	40-41	53-56	D005839	gentamicin	Chemical	40	41	2	D006333	congestive heart failure	Disease	53	56	3	1:NR:2	L2R	CROSS	40-41	88-89	D005839	gentamicin	Chemical	40	41	2	D007239	infections	Disease	88	89	6	1:NR:2	L2R	CROSS	40-41	99-104	D005839	gentamicin	Chemical	40	41	2	D004342	drug - induced allergic reaction|allergy	Disease	99:133	104:134	6:8	1:NR:2	R2L	CROSS	66-67	44-45	D008775	methylprednisolone	Chemical	66	67	4	D018805	septicemia	Disease	44	45	2	1:NR:2	R2L	CROSS	135-136	44-45	D010406	penicillins	Chemical	135	136	8	D018805	septicemia	Disease	44	45	2	1:NR:2	R2L	CROSS	66-67	53-56	D008775	methylprednisolone	Chemical	66	67	4	D006333	congestive heart failure	Disease	53	56	3	1:NR:2	R2L	CROSS	135-136	53-56	D010406	penicillins	Chemical	135	136	8	D006333	congestive heart failure	Disease	53	56	3	1:NR:2	L2R	CROSS	66-67	88-89	D008775	methylprednisolone	Chemical	66	67	4	D007239	infections	Disease	88	89	6	1:NR:2	L2R	CROSS	66-67	99-104	D008775	methylprednisolone	Chemical	66	67	4	D004342	drug - induced allergic reaction|allergy	Disease	99:133	104:134	6:8	1:NR:2	R2L	CROSS	135-136	88-89	D010406	penicillins	Chemical	135	136	8	D007239	infections	Disease	88	89	6	1:NR:2	R2L	NON-CROSS	135-136	133-134	D010406	penicillins	Chemical	135	136	8	D004342	drug - induced allergic reaction|allergy	Disease	99:133	104:134	6:8
8092427	Immediate allergic reactions to amoxicillin .|A large group of patients with suspected allergic reactions to beta - lactam antibiotics was evaluated .|A detailed clinical history , together with skin tests , RAST ( radioallergosorbent test ) , and controlled challenge tests , was used to establish whether patients allergic to beta - lactam antibiotics had selective immediate allergic responses to amoxicillin ( AX ) or were cross - reacting with other penicillin derivatives .|Skin tests were performed with benzylpenicilloyl - poly - L - lysine ( BPO - PLL ) , benzylpenicilloate , benzylpenicillin ( PG ) , ampicillin ( AMP ) , and AX .|RAST for BPO - PLL and AX - PLL was done .|When both skin test and RAST for BPO were negative , single - blind , placebo - controlled challenge tests were done to ensure tolerance of PG or sensitivity to AX .|A total of 177 patients were diagnosed as allergic to beta - lactam antibiotics .|We selected the 54 ( 30 . 5 % ) cases of immediate AX allergy with good tolerance of PG .|Anaphylaxis was seen in 37 patients ( 69 % ) , the other 17 ( 31 % ) having urticaria and / or angioedema .|All the patients were skin test negative to BPO ; 49 of 51 ( 96 % ) were also negative to MDM , and 44 of 46 ( 96 % ) to PG .|Skin tests with AX were positive in 34 ( 63 % ) patients .|RAST was positive for AX in 22 patients ( 41 % ) and to BPO in just 5 ( 9 % ) .|None of the sera with negative RAST for AX were positive to BPO .|Challenge tests with AX were performed in 23 subjects ( 43 % ) to establish the diagnosis of immediate allergic reaction to AX , and in 15 cases ( 28 % ) both skin test and RAST for AX were negative .|PG was well tolerated by all 54 patients .|We describe the largest group of AX - allergic patients who have tolerated PG reported so far .|Diagnosis of these patients can be achieved only if specific AX - related reagents are employed .|Further studies are necessary to determine the exact extent of this problem and to improve the efficacy of diagnostic methods .	1:CID:2	R2L	NON-CROSS	182-183	181-182	D000658	amoxicillin|amoxicillin|AX|AX|AX|AX|AX|AX|AX|AX|AX|AX|AX|AX|AX	Chemical	4:62:64:107:115:151:181:251:266:293:302:321:337:356:378	5:63:65:108:116:152:182:252:267:294:303:322:338:357:379	0:2:2:3:4:5:7:10:11:12:13:13:13:15:16	D004342	allergic reactions|allergic reactions|allergic|allergic|allergic|allergy|allergic reaction|allergic	Disease	1:13:50:59:161:182:318:358	3:15:51:60:162:183:320:359	0:1:2:2:6:7:13:15	1:CID:2	L2R	CROSS	181-182	189-190	D000658	amoxicillin|amoxicillin|AX|AX|AX|AX|AX|AX|AX|AX|AX|AX|AX|AX|AX	Chemical	4:62:64:107:115:151:181:251:266:293:302:321:337:356:378	5:63:65:108:116:152:182:252:267:294:303:322:338:357:379	0:2:2:3:4:5:7:10:11:12:13:13:13:15:16	D000707	Anaphylaxis	Disease	189	190	8	1:CID:2	L2R	CROSS	181-182	212-213	D000658	amoxicillin|amoxicillin|AX|AX|AX|AX|AX|AX|AX|AX|AX|AX|AX|AX|AX	Chemical	4:62:64:107:115:151:181:251:266:293:302:321:337:356:378	5:63:65:108:116:152:182:252:267:294:303:322:338:357:379	0:2:2:3:4:5:7:10:11:12:13:13:13:15:16	D000799	angioedema	Disease	212	213	8	1:NR:2	R2L	NON-CROSS	16-19	13-15	D047090	beta - lactam|beta - lactam|beta - lactam	Chemical	16:52:163	19:55:166	1:2:6	D004342	allergic reactions|allergic reactions|allergic|allergic|allergic|allergy|allergic reaction|allergic	Disease	1:13:50:59:161:182:318:358	3:15:51:60:162:183:320:359	0:1:2:2:6:7:13:15	1:NR:2	R2L	NON-CROSS	73-74	59-60	D010406	penicillin	Chemical	73	74	2	D004342	allergic reactions|allergic reactions|allergic|allergic|allergic|allergy|allergic reaction|allergic	Disease	1:13:50:59:161:182:318:358	3:15:51:60:162:183:320:359	0:1:2:2:6:7:13:15	1:NR:2	R2L	NON-CROSS	187-188	182-183	D010400	benzylpenicillin|PG|PG|PG|PG|PG|PG	Chemical	96:98:147:187:246:341:363	97:99:148:188:247:342:364	3:3:5:7:9:14:15	D004342	allergic reactions|allergic reactions|allergic|allergic|allergic|allergy|allergic reaction|allergic	Disease	1:13:50:59:161:182:318:358	3:15:51:60:162:183:320:359	0:1:2:2:6:7:13:15	1:NR:2	R2L	CROSS	101-102	59-60	D000667	ampicillin|AMP	Chemical	101:103	102:104	3:3	D004342	allergic reactions|allergic reactions|allergic|allergic|allergic|allergy|allergic reaction|allergic	Disease	1:13:50:59:161:182:318:358	3:15:51:60:162:183:320:359	0:1:2:2:6:7:13:15	not_include	L2R	CROSS	181-182	208-209	D000658	amoxicillin|amoxicillin|AX|AX|AX|AX|AX|AX|AX|AX|AX|AX|AX|AX|AX	Chemical	4:62:64:107:115:151:181:251:266:293:302:321:337:356:378	5:63:65:108:116:152:182:252:267:294:303:322:338:357:379	0:2:2:3:4:5:7:10:11:12:13:13:13:15:16	D014581	urticaria	Disease	208	209	8	1:NR:2	L2R	CROSS	235-236	251-252	D000658	amoxicillin|amoxicillin|AX|AX|AX|AX|AX|AX|AX|AX|AX|AX|AX|AX|AX	Chemical	4:62:64:107:115:151:181:251:266:293:302:321:337:356:378	5:63:65:108:116:152:182:252:267:294:303:322:338:357:379	0:2:2:3:4:5:7:10:11:12:13:13:13:15:16	D007645	MDM	Disease	235	236	9	1:NR:2	L2R	CROSS	163-166	189-190	D047090	beta - lactam|beta - lactam|beta - lactam	Chemical	16:52:163	19:55:166	1:2:6	D000707	Anaphylaxis	Disease	189	190	8	1:NR:2	L2R	CROSS	163-166	208-209	D047090	beta - lactam|beta - lactam|beta - lactam	Chemical	16:52:163	19:55:166	1:2:6	D014581	urticaria	Disease	208	209	8	1:NR:2	L2R	CROSS	163-166	212-213	D047090	beta - lactam|beta - lactam|beta - lactam	Chemical	16:52:163	19:55:166	1:2:6	D000799	angioedema	Disease	212	213	8	1:NR:2	L2R	CROSS	163-166	235-236	D047090	beta - lactam|beta - lactam|beta - lactam	Chemical	16:52:163	19:55:166	1:2:6	D007645	MDM	Disease	235	236	9	1:NR:2	L2R	CROSS	73-74	189-190	D010406	penicillin	Chemical	73	74	2	D000707	Anaphylaxis	Disease	189	190	8	1:NR:2	L2R	CROSS	73-74	208-209	D010406	penicillin	Chemical	73	74	2	D014581	urticaria	Disease	208	209	8	1:NR:2	L2R	CROSS	73-74	212-213	D010406	penicillin	Chemical	73	74	2	D000799	angioedema	Disease	212	213	8	1:NR:2	L2R	CROSS	73-74	235-236	D010406	penicillin	Chemical	73	74	2	D007645	MDM	Disease	235	236	9	1:NR:2	L2R	CROSS	187-188	189-190	D010400	benzylpenicillin|PG|PG|PG|PG|PG|PG	Chemical	96:98:147:187:246:341:363	97:99:148:188:247:342:364	3:3:5:7:9:14:15	D000707	Anaphylaxis	Disease	189	190	8	1:NR:2	L2R	CROSS	187-188	208-209	D010400	benzylpenicillin|PG|PG|PG|PG|PG|PG	Chemical	96:98:147:187:246:341:363	97:99:148:188:247:342:364	3:3:5:7:9:14:15	D014581	urticaria	Disease	208	209	8	1:NR:2	L2R	CROSS	187-188	212-213	D010400	benzylpenicillin|PG|PG|PG|PG|PG|PG	Chemical	96:98:147:187:246:341:363	97:99:148:188:247:342:364	3:3:5:7:9:14:15	D000799	angioedema	Disease	212	213	8	1:NR:2	L2R	NON-CROSS	235-236	246-247	D010400	benzylpenicillin|PG|PG|PG|PG|PG|PG	Chemical	96:98:147:187:246:341:363	97:99:148:188:247:342:364	3:3:5:7:9:14:15	D007645	MDM	Disease	235	236	9	1:NR:2	L2R	CROSS	103-104	189-190	D000667	ampicillin|AMP	Chemical	101:103	102:104	3:3	D000707	Anaphylaxis	Disease	189	190	8	1:NR:2	L2R	CROSS	103-104	208-209	D000667	ampicillin|AMP	Chemical	101:103	102:104	3:3	D014581	urticaria	Disease	208	209	8	1:NR:2	L2R	CROSS	103-104	212-213	D000667	ampicillin|AMP	Chemical	101:103	102:104	3:3	D000799	angioedema	Disease	212	213	8	1:NR:2	L2R	CROSS	103-104	235-236	D000667	ampicillin|AMP	Chemical	101:103	102:104	3:3	D007645	MDM	Disease	235	236	9
8638206	Persistent paralysis after prolonged use of atracurium in the absence of corticosteroids .|Neuromuscular blocking agents ( NMBAs ) are often used for patients requiring prolonged mechanical ventilation .|Reports of persistent paralysis after the discontinuance of these drugs have most often involved aminosteroid - based NMBAs such as vecuronium bromide , especially when used in conjunction with corticosteroids .|Atracurium besylate , a short - acting benzylisoquinolinium NMBA that is eliminated independently of renal or hepatic function , has also been associated with persistent paralysis , but only when used with corticosteroids .|We report a case of atracurium - related paralysis persisting for approximately 50 hours in a patient who was not treated with corticosteroids .	1:CID:2	R2L	NON-CROSS	102-103	99-100	D001279	atracurium|Atracurium besylate|atracurium	Chemical	6:60:99	7:62:100	0:3:4	D010243	paralysis|paralysis|paralysis|paralysis	Disease	1:32:85:102	2:33:86:103	0:2:3:4	1:CID:2	R2L	NON-CROSS	49-51	32-33	D014673	vecuronium bromide	Chemical	49	51	2	D010243	paralysis|paralysis|paralysis|paralysis	Disease	1:32:85:102	2:33:86:103	0:2:3:4
8669433	Habitual use of acetaminophen as a risk factor for chronic renal failure : a comparison with phenacetin .|Six epidemiologic studies in the United States and Europe indicate that habitual use of phenacetin is associated with the development of chronic renal failure and end - stage renal disease ( ESRD ) , with a relative risk in the range of 4 to 19 .|As a result of these and other studies , phenacetin has now been withdrawn from the market in most countries .|However , three case control studies , one each in North Carolina , northern Maryland , and West Berlin , Germany , showed that habitual use of acetaminophen is also associated with chronic renal failure and ESRD , with a relative risk in the range of 2 to 4 .|These studies suggest that both phenacetin and acetaminophen may contribute to the burden of ESRD , with the risk of the latter being somewhat less than that of the former .|This apparent difference in risk may not be due to differences in nephrotoxic potential of the drugs themselves .|A lower relative risk would be expected for acetaminophen if the risk of both drugs in combination with other analgesics was higher than the risk of either agent alone .|Thus , acetaminophen has been used both as a single agent and in combination with other analgesics , whereas phenacetin was available only in combinations .|The possibility that habitual use of acetaminophen alone increases the risk of ESRD has not been clearly demonstrated , but can not be dismissed .	1:CID:2	R2L	NON-CROSS	16-17	9-12	D010615	phenacetin|phenacetin|phenacetin|phenacetin|phenacetin	Chemical	16:32:73:140:234	17:33:74:141:235	0:1:2:4:7	D007676	chronic renal failure|chronic renal failure|end - stage renal disease|ESRD|chronic renal failure|ESRD|ESRD|ESRD	Disease	9:39:43:49:117:121:149:253	12:42:48:50:120:122:150:254	0:1:1:1:3:3:4:8	1:NR:2	L2R	NON-CROSS	112-113	117-120	D000082	acetaminophen|acetaminophen|acetaminophen|acetaminophen|acetaminophen|acetaminophen	Chemical	3:112:142:193:217:247	4:113:143:194:218:248	0:3:4:6:7:8	D007676	chronic renal failure|chronic renal failure|end - stage renal disease|ESRD|chronic renal failure|ESRD|ESRD|ESRD	Disease	9:39:43:49:117:121:149:253	12:42:48:50:120:122:150:254	0:1:1:1:3:3:4:8	1:NR:2	L2R	CROSS	178-179	193-194	D000082	acetaminophen|acetaminophen|acetaminophen|acetaminophen|acetaminophen|acetaminophen	Chemical	3:112:142:193:217:247	4:113:143:194:218:248	0:3:4:6:7:8	D007674	nephrotoxic	Disease	178	179	5	not_include	L2R	CROSS	140-141	178-179	D010615	phenacetin|phenacetin|phenacetin|phenacetin|phenacetin	Chemical	16:32:73:140:234	17:33:74:141:235	0:1:2:4:7	D007674	nephrotoxic	Disease	178	179	5
8690168	Reduction of heparan sulphate - associated anionic sites in the glomerular basement membrane of rats with streptozotocin - induced diabetic nephropathy .|Heparan sulphate - associated anionic sites in the glomerular basement membrane were studied in rats 8 months after induction of diabetes by streptozotocin and in age - adn sex - matched control rats , employing the cationic dye cuprolinic blue .|Morphometric analysis at the ultrastructural level was performed using a computerized image processor .|The heparan sulphate specificity of the cuprolinic blue staining was demonstrated by glycosaminoglycan - degrading enzymes , showing that pretreatment of the sections with heparitinase abolished all staining , whereas chondroitinase ABC had no effect .|The majority of anionic sites ( 74 % in diabetic and 81 % in control rats ) were found within the lamina rara externa of the glomerular basement membrane .|A minority of anionic sites were scattered throughout the lamina densa and lamina rara interna , and were significantly smaller than those in the lamina rara externa of the glomerular basement membrane ( p < 0 . 001 and p < 0 . 01 for diabetic and control rats , respectively ) .|Diabetic rats progressively developed albuminuria reaching 40 . 3 ( 32 . 2 - 62 . 0 ) mg / 24 h after 8 months in contrast to the control animals ( 0 . 8 ( 0 . 2 - 0 . 9 ) mg / 24 h , p < 0 . 002 ) .|At the same time , the number of heparan sulphate anionic sites and the total anionic site surface ( number of anionic sites x mean anionic site surface ) in the lamina rara externa of the glomerular basement membrane was reduced by 19 % ( p < 0 . 021 ) and by 26 % ( p < 0 . 02 ) , respectively .|Number and total anionic site surface in the remaining part of the glomerular basement membrane ( lamina densa and lamina rara interna ) were not significantly changed .|We conclude that in streptozotocin - diabetic rats with an increased urinary albumin excretion , a reduced heparan sulphate charge barrier / density is found at the lamina rara externa of the glomerular basement membrane .	1:CID:2	L2R	NON-CROSS	16-17	19-21	D013311	streptozotocin|streptozotocin|streptozotocin	Chemical	16:44:349	17:45:350	0:1:9	D003928	diabetic nephropathy	Disease	19	21	0	1:NR:2	L2R	NON-CROSS	19-21	22-24	D006497	heparan sulphate|Heparan sulphate|heparan sulphate|heparan sulphate|heparan sulphate	Chemical	2:22:78:260:362	4:24:80:262:364	0:1:3:7:9	D003928	diabetic nephropathy	Disease	19	21	0	1:NR:2	L2R	NON-CROSS	351-352	362-364	D006497	heparan sulphate|Heparan sulphate|heparan sulphate|heparan sulphate|heparan sulphate	Chemical	2:22:78:260:362	4:24:80:262:364	0:1:3:7:9	D003920	diabetes|diabetic|diabetic|Diabetic|diabetic	Disease	42:122:188:196:351	43:123:189:197:352	1:4:5:6:9	1:NR:2	L2R	CROSS	200-201	260-262	D006497	heparan sulphate|Heparan sulphate|heparan sulphate|heparan sulphate|heparan sulphate	Chemical	2:22:78:260:362	4:24:80:262:364	0:1:3:7:9	D000419	albuminuria	Disease	200	201	6	not_include	L2R	NON-CROSS	42-43	44-45	D013311	streptozotocin|streptozotocin|streptozotocin	Chemical	16:44:349	17:45:350	0:1:9	D003920	diabetes|diabetic|diabetic|Diabetic|diabetic	Disease	42:122:188:196:351	43:123:189:197:352	1:4:5:6:9	1:NR:2	L2R	CROSS	200-201	349-350	D013311	streptozotocin|streptozotocin|streptozotocin	Chemical	16:44:349	17:45:350	0:1:9	D000419	albuminuria	Disease	200	201	6	1:NR:2	R2L	CROSS	60-62	19-21	C015445	cuprolinic blue|cuprolinic blue	Chemical	60:83	62:85	1:3	D003928	diabetic nephropathy	Disease	19	21	0	1:NR:2	R2L	CROSS	89-90	19-21	D006025	glycosaminoglycan	Chemical	89	90	3	D003928	diabetic nephropathy	Disease	19	21	0	1:NR:2	R2L	NON-CROSS	60-62	42-43	C015445	cuprolinic blue|cuprolinic blue	Chemical	60:83	62:85	1:3	D003920	diabetes|diabetic|diabetic|Diabetic|diabetic	Disease	42:122:188:196:351	43:123:189:197:352	1:4:5:6:9	1:NR:2	R2L	CROSS	122-123	89-90	D006025	glycosaminoglycan	Chemical	89	90	3	D003920	diabetes|diabetic|diabetic|Diabetic|diabetic	Disease	42:122:188:196:351	43:123:189:197:352	1:4:5:6:9	1:NR:2	L2R	CROSS	83-85	200-201	C015445	cuprolinic blue|cuprolinic blue	Chemical	60:83	62:85	1:3	D000419	albuminuria	Disease	200	201	6	1:NR:2	L2R	CROSS	89-90	200-201	D006025	glycosaminoglycan	Chemical	89	90	3	D000419	albuminuria	Disease	200	201	6
8739323	Effect of some anticancer drugs and combined chemotherapy on renal toxicity .|The nephrotoxic action of anticancer drugs such as nitrogranulogen ( NG ) , methotrexate ( MTX ) , 5 - fluorouracil ( 5 - FU ) and cyclophosphamide ( CY ) administered alone or in combination [ MTX + 5 - FU + CY ( CMF ) ] was evaluated in experiments on Wistar rats .|After drug administration , creatinine concentrations in the plasma and in the urine of the rats were determined , as well as creatinine clearance .|Histopathologic evaluation of the kidneys was also performed .|After MTX administration a significant increase ( p = 0 . 0228 ) in the plasma creatinine concentration and a significant ( p = 0 . 0001 ) decrease in creatinine clearance was noted compared to controls .|After the administration of NG , 5 - FU and CY neither a statistically significant increase in creatinine concentration nor an increase in creatinine clearance was observed compared to the group receiving no cytostatics .|Following polytherapy according to the CMF regimen , a statistically significant decrease ( p = 0 . 0343 ) in creatinine clearance was found , but creatinine concentration did not increase significantly compared to controls .|CY caused hemorrhagic cystitis in 40 % of rats , but it did not cause this complication when combined with 5 - FU and MTX .|Histologic changes were found in rat kidneys after administration of MTX , CY and NG , while no such change was observed after 5 - FU and joint administration of MTX + 5 - FU + CY compared to controls .|Our studies indicate that nephrotoxicity of MTX + 5 - FU + CY administered jointly is lower than in monotherapy .	1:CID:2	L2R	NON-CROSS	211-212	213-215	D003520	cyclophosphamide|CY|CY|CY|CY|CY|CY|CY	Chemical	39:41:55:150:211:249:273:290	40:42:56:151:212:250:274:291	1:1:1:5:7:8:8:9	D006470	hemorrhagic cystitis	Disease	213	215	7	1:CID:2	L2R	NON-CROSS	211-212	213-215	D003520	cyclophosphamide|CY|CY|CY|CY|CY|CY|CY	Chemical	39:41:55:150:211:249:273:290	40:42:56:151:212:250:274:291	1:1:1:5:7:8:8:9	D003556	hemorrhagic cystitis	Disease	213	215	7	1:NR:2	R2L	NON-CROSS	20-21	13-14	D008466	nitrogranulogen|NG|NG|NG	Chemical	20:22:144:251	21:23:145:252	1:1:5:8	D007674	renal toxicity|nephrotoxic|nephrotoxicity	Disease	9:13:282	11:14:283	0:1:9	1:NR:2	R2L	NON-CROSS	284-285	282-283	D008727	methotrexate|MTX|MTX|MTX|MTX|MTX|MTX|MTX	Chemical	25:27:49:103:235:247:267:284	26:28:50:104:236:248:268:285	1:1:1:4:7:8:8:9	D007674	renal toxicity|nephrotoxic|nephrotoxicity	Disease	9:13:282	11:14:283	0:1:9	1:NR:2	R2L	NON-CROSS	286-289	282-283	D005472	5 - fluorouracil|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU	Chemical	30:34:51:146:231:260:269:286	33:37:54:149:234:263:272:289	1:1:1:5:7:8:8:9	D007674	renal toxicity|nephrotoxic|nephrotoxicity	Disease	9:13:282	11:14:283	0:1:9	1:NR:2	R2L	NON-CROSS	290-291	282-283	D003520	cyclophosphamide|CY|CY|CY|CY|CY|CY|CY	Chemical	39:41:55:150:211:249:273:290	40:42:56:151:212:250:274:291	1:1:1:5:7:8:8:9	D007674	renal toxicity|nephrotoxic|nephrotoxicity	Disease	9:13:282	11:14:283	0:1:9	1:NR:2	R2L	CROSS	72-73	13-14	D003404	creatinine|creatinine|creatinine|creatinine|creatinine|creatinine|creatinine|creatinine	Chemical	72:90:118:132:157:163:195:201	73:91:119:133:158:164:196:202	2:2:4:4:5:5:6:6	D007674	renal toxicity|nephrotoxic|nephrotoxicity	Disease	9:13:282	11:14:283	0:1:9	1:NR:2	L2R	CROSS	213-215	251-252	D008466	nitrogranulogen|NG|NG|NG	Chemical	20:22:144:251	21:23:145:252	1:1:5:8	D006470	hemorrhagic cystitis	Disease	213	215	7	1:NR:2	L2R	CROSS	213-215	251-252	D008466	nitrogranulogen|NG|NG|NG	Chemical	20:22:144:251	21:23:145:252	1:1:5:8	D003556	hemorrhagic cystitis	Disease	213	215	7	1:NR:2	L2R	NON-CROSS	213-215	235-236	D008727	methotrexate|MTX|MTX|MTX|MTX|MTX|MTX|MTX	Chemical	25:27:49:103:235:247:267:284	26:28:50:104:236:248:268:285	1:1:1:4:7:8:8:9	D006470	hemorrhagic cystitis	Disease	213	215	7	1:NR:2	L2R	NON-CROSS	213-215	235-236	D008727	methotrexate|MTX|MTX|MTX|MTX|MTX|MTX|MTX	Chemical	25:27:49:103:235:247:267:284	26:28:50:104:236:248:268:285	1:1:1:4:7:8:8:9	D003556	hemorrhagic cystitis	Disease	213	215	7	1:NR:2	L2R	NON-CROSS	213-215	231-234	D005472	5 - fluorouracil|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU	Chemical	30:34:51:146:231:260:269:286	33:37:54:149:234:263:272:289	1:1:1:5:7:8:8:9	D006470	hemorrhagic cystitis	Disease	213	215	7	1:NR:2	L2R	NON-CROSS	213-215	231-234	D005472	5 - fluorouracil|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU	Chemical	30:34:51:146:231:260:269:286	33:37:54:149:234:263:272:289	1:1:1:5:7:8:8:9	D003556	hemorrhagic cystitis	Disease	213	215	7	1:NR:2	L2R	CROSS	201-202	213-215	D003404	creatinine|creatinine|creatinine|creatinine|creatinine|creatinine|creatinine|creatinine	Chemical	72:90:118:132:157:163:195:201	73:91:119:133:158:164:196:202	2:2:4:4:5:5:6:6	D006470	hemorrhagic cystitis	Disease	213	215	7	1:NR:2	L2R	CROSS	201-202	213-215	D003404	creatinine|creatinine|creatinine|creatinine|creatinine|creatinine|creatinine|creatinine	Chemical	72:90:118:132:157:163:195:201	73:91:119:133:158:164:196:202	2:2:4:4:5:5:6:6	D003556	hemorrhagic cystitis	Disease	213	215	7
8752018	Lithium - associated cognitive and functional deficits reduced by a switch to divalproex sodium : a case series .|BACKGROUND : Lithium remains a first - line treatment for the acute and maintenance treatment of bipolar disorder .|Although much has been written about the management of the more common adverse effects of lithium , such as polyuria and tremor , more subtle lithium side effects such as cognitive deficits , loss of creativity , and functional impairments remain understudied .|This report summarizes our experience in switching bipolar patients from lithium to divalproex sodium to alleviate such cognitive and functional impairments .|METHOD : Open , case series design .|RESULTS : We report seven cases where substitution of lithium , either fully or partially , with divalproex sodium was extremely helpful in reducing the cognitive , motivational , or creative deficits attributed to lithium in our bipolar patients .|CONCLUSION : In this preliminary report , divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits , loss of creativity , and functional impairments .	1:CID:2	L2R	NON-CROSS	0-1	3-7	D008094	Lithium|Lithium|lithium|lithium|lithium|lithium|lithium|lithium	Chemical	0:21:53:63:91:120:145:165	1:22:54:64:92:121:146:166	0:1:2:2:3:5:5:6	D003072	cognitive and functional deficits|cognitive deficits|loss of creativity|functional impairments|cognitive and functional impairments|cognitive , motivational , or creative deficits|cognitive deficits|loss of creativity|functional impairments	Disease	3:68:71:76:98:136:170:173:178	7:70:74:78:102:143:172:176:180	0:2:2:2:3:5:6:6:6	1:NR:2	L2R	NON-CROSS	165-166	167-168	D008094	Lithium|Lithium|lithium|lithium|lithium|lithium|lithium|lithium	Chemical	0:21:53:63:91:120:145:165	1:22:54:64:92:121:146:166	0:1:2:2:3:5:5:6	D001714	bipolar disorder|bipolar|bipolar|bipolar	Disease	35:88:148:167	37:89:149:168	1:3:5:6	1:NR:2	L2R	NON-CROSS	53-54	57-58	D008094	Lithium|Lithium|lithium|lithium|lithium|lithium|lithium|lithium	Chemical	0:21:53:63:91:120:145:165	1:22:54:64:92:121:146:166	0:1:2:2:3:5:5:6	D011141	polyuria	Disease	57	58	2	1:NR:2	L2R	NON-CROSS	59-60	63-64	D008094	Lithium|Lithium|lithium|lithium|lithium|lithium|lithium|lithium	Chemical	0:21:53:63:91:120:145:165	1:22:54:64:92:121:146:166	0:1:2:2:3:5:5:6	D014202	tremor	Disease	59	60	2	1:NR:2	R2L	NON-CROSS	170-172	158-160	D014635	divalproex sodium|divalproex sodium|divalproex sodium|divalproex sodium	Chemical	12:93:128:158	14:95:130:160	0:3:5:6	D003072	cognitive and functional deficits|cognitive deficits|loss of creativity|functional impairments|cognitive and functional impairments|cognitive , motivational , or creative deficits|cognitive deficits|loss of creativity|functional impairments	Disease	3:68:71:76:98:136:170:173:178	7:70:74:78:102:143:172:176:180	0:2:2:2:3:5:6:6:6	1:NR:2	L2R	NON-CROSS	88-89	93-95	D014635	divalproex sodium|divalproex sodium|divalproex sodium|divalproex sodium	Chemical	12:93:128:158	14:95:130:160	0:3:5:6	D001714	bipolar disorder|bipolar|bipolar|bipolar	Disease	35:88:148:167	37:89:149:168	1:3:5:6	1:NR:2	L2R	CROSS	57-58	93-95	D014635	divalproex sodium|divalproex sodium|divalproex sodium|divalproex sodium	Chemical	12:93:128:158	14:95:130:160	0:3:5:6	D011141	polyuria	Disease	57	58	2	1:NR:2	L2R	CROSS	59-60	93-95	D014635	divalproex sodium|divalproex sodium|divalproex sodium|divalproex sodium	Chemical	12:93:128:158	14:95:130:160	0:3:5:6	D014202	tremor	Disease	59	60	2
9390208	Treatment of previously treated metastatic breast cancer by mitoxantrone and 48 - hour continuous infusion of high - dose 5 - FU and leucovorin ( MFL ) : low palliative benefit and high treatment - related toxicity .|For previously treated advanced breast cancer , there is no standard second - line therapy .|Combination chemotherapy with mitoxantrone , high - dose 5 - fluorouracil ( 5 - FU ) and leucovorin ( MFL regimen ) had been reported as an effective and well tolerated regimen .|From October 1993 to November 1995 , we treated 13 patients with previously chemotherapy - treated metastatic breast cancer by mitoxantrone , 12 mg / m2 , on day 1 and continuous infusion of 5 - FU , 3000 mg / m2 , together with leucovorin , 300 mg / m2 , for 48 h from day 1 to 2 .|Each course of chemotherapy was given every 4 weeks .|Most of these patients had more than two metastatic sites , with lung metastasis predominant .|Seven patients had been treated with anthracycline .|Seven patients had previously received radiotherapy and seven had received hormone therapy .|Median number of courses of MFL regimen given was six and the median cumulative dose of mitoxantrone was 68 . 35 mg / m2 .|One patient had complete response , seven had stable disease , none had partial response and five had progressive disease .|The overall objective response rate was 7 . 6 % .|The median follow - up period was 14 months .|Median survival was 16 months .|Median progression - free survival was 5 months .|A complete responder had relapse - free survival up to 17 months .|Major toxicities were cardiotoxicity and leukopenia .|Eight patients were dead in the last follow - up ; two of them died of treatment - related toxicity .|The MFL regimen achieves little palliative benefit and induces severe toxicity at a fairly high rate .|Administration of this regimen to breast cancer patients who have been treated by chemotherapy and those with impaired heart function requires careful attention .	1:CID:2	L2R	CROSS	295-296	319-321	C085788	MFL|MFL regimen|MFL regimen|MFL regimen	Chemical	25:73:200:319	26:75:202:321	0:2:8:17	D007970	leukopenia	Disease	295	296	15	1:CID:2	L2R	CROSS	319-321	352-355	C085788	MFL|MFL regimen|MFL regimen|MFL regimen	Chemical	25:73:200:319	26:75:202:321	0:2:8:17	D006331	impaired heart function	Disease	352	355	18	1:NR:2	R2L	NON-CROSS	8-9	5-7	D008942	mitoxantrone|mitoxantrone|mitoxantrone|mitoxantrone	Chemical	8:57:107:211	9:58:108:212	0:2:3:8	D001943	breast cancer|breast cancer|breast cancer|breast cancer	Disease	5:42:104:340	7:44:106:342	0:1:3:18	1:NR:2	R2L	NON-CROSS	19-22	5-7	D005472	5 - FU|5 - fluorouracil|5 - FU|5 - FU	Chemical	19:62:66:121	22:65:69:124	0:2:2:3	D001943	breast cancer|breast cancer|breast cancer|breast cancer	Disease	5:42:104:340	7:44:106:342	0:1:3:18	1:NR:2	R2L	NON-CROSS	23-24	5-7	D002955	leucovorin|leucovorin|leucovorin	Chemical	23:71:132	24:72:133	0:2:3	D001943	breast cancer|breast cancer|breast cancer|breast cancer	Disease	5:42:104:340	7:44:106:342	0:1:3:18	1:NR:2	R2L	NON-CROSS	42-44	25-26	C085788	MFL|MFL regimen|MFL regimen|MFL regimen	Chemical	25:73:200:319	26:75:202:321	0:2:8:17	D001943	breast cancer|breast cancer|breast cancer|breast cancer	Disease	5:42:104:340	7:44:106:342	0:1:3:18	1:NR:2	R2L	CROSS	180-181	104-106	D018943	anthracycline	Chemical	180	181	6	D001943	breast cancer|breast cancer|breast cancer|breast cancer	Disease	5:42:104:340	7:44:106:342	0:1:3:18	1:NR:2	L2R	NON-CROSS	36-37	57-58	D008942	mitoxantrone|mitoxantrone|mitoxantrone|mitoxantrone	Chemical	8:57:107:211	9:58:108:212	0:2:3:8	D064420	toxicity|toxicities|toxicity|toxicity	Disease	36:291:316:328	37:292:317:329	0:15:16:17	1:NR:2	L2R	CROSS	211-212	293-294	D008942	mitoxantrone|mitoxantrone|mitoxantrone|mitoxantrone	Chemical	8:57:107:211	9:58:108:212	0:2:3:8	D066126	cardiotoxicity	Disease	293	294	15	1:NR:2	L2R	CROSS	211-212	295-296	D008942	mitoxantrone|mitoxantrone|mitoxantrone|mitoxantrone	Chemical	8:57:107:211	9:58:108:212	0:2:3:8	D007970	leukopenia	Disease	295	296	15	1:NR:2	L2R	CROSS	211-212	352-355	D008942	mitoxantrone|mitoxantrone|mitoxantrone|mitoxantrone	Chemical	8:57:107:211	9:58:108:212	0:2:3:8	D006331	impaired heart function	Disease	352	355	18	1:NR:2	L2R	NON-CROSS	19-22	36-37	D005472	5 - FU|5 - fluorouracil|5 - FU|5 - FU	Chemical	19:62:66:121	22:65:69:124	0:2:2:3	D064420	toxicity|toxicities|toxicity|toxicity	Disease	36:291:316:328	37:292:317:329	0:15:16:17	1:NR:2	L2R	CROSS	121-124	293-294	D005472	5 - FU|5 - fluorouracil|5 - FU|5 - FU	Chemical	19:62:66:121	22:65:69:124	0:2:2:3	D066126	cardiotoxicity	Disease	293	294	15	1:NR:2	L2R	CROSS	121-124	295-296	D005472	5 - FU|5 - fluorouracil|5 - FU|5 - FU	Chemical	19:62:66:121	22:65:69:124	0:2:2:3	D007970	leukopenia	Disease	295	296	15	1:NR:2	L2R	CROSS	121-124	352-355	D005472	5 - FU|5 - fluorouracil|5 - FU|5 - FU	Chemical	19:62:66:121	22:65:69:124	0:2:2:3	D006331	impaired heart function	Disease	352	355	18	1:NR:2	L2R	NON-CROSS	23-24	36-37	D002955	leucovorin|leucovorin|leucovorin	Chemical	23:71:132	24:72:133	0:2:3	D064420	toxicity|toxicities|toxicity|toxicity	Disease	36:291:316:328	37:292:317:329	0:15:16:17	1:NR:2	L2R	CROSS	132-133	293-294	D002955	leucovorin|leucovorin|leucovorin	Chemical	23:71:132	24:72:133	0:2:3	D066126	cardiotoxicity	Disease	293	294	15	1:NR:2	L2R	CROSS	132-133	295-296	D002955	leucovorin|leucovorin|leucovorin	Chemical	23:71:132	24:72:133	0:2:3	D007970	leukopenia	Disease	295	296	15	1:NR:2	L2R	CROSS	132-133	352-355	D002955	leucovorin|leucovorin|leucovorin	Chemical	23:71:132	24:72:133	0:2:3	D006331	impaired heart function	Disease	352	355	18	1:NR:2	L2R	NON-CROSS	316-317	319-321	C085788	MFL|MFL regimen|MFL regimen|MFL regimen	Chemical	25:73:200:319	26:75:202:321	0:2:8:17	D064420	toxicity|toxicities|toxicity|toxicity	Disease	36:291:316:328	37:292:317:329	0:15:16:17	1:NR:2	L2R	CROSS	293-294	319-321	C085788	MFL|MFL regimen|MFL regimen|MFL regimen	Chemical	25:73:200:319	26:75:202:321	0:2:8:17	D066126	cardiotoxicity	Disease	293	294	15	1:NR:2	R2L	CROSS	291-292	180-181	D018943	anthracycline	Chemical	180	181	6	D064420	toxicity|toxicities|toxicity|toxicity	Disease	36:291:316:328	37:292:317:329	0:15:16:17	1:NR:2	L2R	CROSS	180-181	293-294	D018943	anthracycline	Chemical	180	181	6	D066126	cardiotoxicity	Disease	293	294	15	1:NR:2	L2R	CROSS	180-181	295-296	D018943	anthracycline	Chemical	180	181	6	D007970	leukopenia	Disease	295	296	15	1:NR:2	L2R	CROSS	180-181	352-355	D018943	anthracycline	Chemical	180	181	6	D006331	impaired heart function	Disease	352	355	18
9406968	Upregulation of the expression of vasopressin gene in the paraventricular and supraoptic nuclei of the lithium - induced diabetes insipidus rat .|The expression of arginine vasopressin ( AVP ) gene in the paraventricular ( PVN ) and supraoptic nuclei ( SON ) was investigated in rats with lithium ( Li ) - induced polyuria , using in situ hybridization histochemistry and radioimmunoassay .|The male Wistar rats consuming a diet that contained LiCl ( 60 mmol / kg ) for 4 weeks developed marked polyuria .|The Li - treated rats produced a large volume of hypotonic urine with low ionic concentrations .|Plasma sodium concentrations were found to be slightly increased in the Li - treated rats compared with those in controls .|Plasma concentration of AVP and transcripts of AVP gene in the PVN and SON were significantly increased in the Li - treated rats compared with controls .|These results suggest that dehydration and / or the activation of visceral afferent inputs may contribute to the elevation of plasma AVP and the upregulation of AVP gene expression in the PVN and the SON of the Li - induced diabetes insipidus rat .	1:CID:2	R2L	NON-CROSS	85-86	73-74	D018021	LiCl	Chemical	73	74	2	D011141	polyuria|polyuria	Disease	54:85	55:86	1:2	1:NR:2	L2R	NON-CROSS	5-6	18-20	D014667	vasopressin	Chemical	5	6	0	D003919	diabetes insipidus|diabetes insipidus	Disease	18:192	20:194	0:6	1:NR:2	L2R	CROSS	5-6	54-55	D014667	vasopressin	Chemical	5	6	0	D011141	polyuria|polyuria	Disease	54:85	55:86	1:2	1:NR:2	L2R	CROSS	5-6	156-157	D014667	vasopressin	Chemical	5	6	0	D003681	dehydration	Disease	156	157	6	1:NR:2	L2R	NON-CROSS	15-16	18-20	D008094	lithium|lithium|Li|Li|Li|Li|Li	Chemical	15:48:50:88:115:144:189	16:49:51:89:116:145:190	0:1:1:3:4:5:6	D003919	diabetes insipidus|diabetes insipidus	Disease	18:192	20:194	0:6	1:NR:2	L2R	NON-CROSS	85-86	88-89	D008094	lithium|lithium|Li|Li|Li|Li|Li	Chemical	15:48:50:88:115:144:189	16:49:51:89:116:145:190	0:1:1:3:4:5:6	D011141	polyuria|polyuria	Disease	54:85	55:86	1:2	1:NR:2	L2R	NON-CROSS	144-145	156-157	D008094	lithium|lithium|Li|Li|Li|Li|Li	Chemical	15:48:50:88:115:144:189	16:49:51:89:116:145:190	0:1:1:3:4:5:6	D003681	dehydration	Disease	156	157	6	1:NR:2	R2L	NON-CROSS	25-27	18-20	D001127	arginine vasopressin|AVP|AVP|AVP|AVP|AVP	Chemical	25:28:128:132:173:178	27:29:129:133:174:179	1:1:5:5:6:6	D003919	diabetes insipidus|diabetes insipidus	Disease	18:192	20:194	0:6	1:NR:2	R2L	CROSS	73-74	18-20	D018021	LiCl	Chemical	73	74	2	D003919	diabetes insipidus|diabetes insipidus	Disease	18:192	20:194	0:6	1:NR:2	R2L	CROSS	105-106	18-20	D012964	sodium	Chemical	105	106	4	D003919	diabetes insipidus|diabetes insipidus	Disease	18:192	20:194	0:6	1:NR:2	L2R	NON-CROSS	28-29	54-55	D001127	arginine vasopressin|AVP|AVP|AVP|AVP|AVP	Chemical	25:28:128:132:173:178	27:29:129:133:174:179	1:1:5:5:6:6	D011141	polyuria|polyuria	Disease	54:85	55:86	1:2	1:NR:2	L2R	NON-CROSS	156-157	173-174	D001127	arginine vasopressin|AVP|AVP|AVP|AVP|AVP	Chemical	25:28:128:132:173:178	27:29:129:133:174:179	1:1:5:5:6:6	D003681	dehydration	Disease	156	157	6	1:NR:2	R2L	CROSS	105-106	85-86	D012964	sodium	Chemical	105	106	4	D011141	polyuria|polyuria	Disease	54:85	55:86	1:2	1:NR:2	L2R	CROSS	73-74	156-157	D018021	LiCl	Chemical	73	74	2	D003681	dehydration	Disease	156	157	6	1:NR:2	L2R	CROSS	105-106	156-157	D012964	sodium	Chemical	105	106	4	D003681	dehydration	Disease	156	157	6
9587734	Suxamethonium - induced cardiac arrest and death following 5 days of immobilization .|The present report describes a case of cardiac arrest and subsequent death as a result of hyperkalaemia following the use of suxamethonium in a 23 - year - old Malawian woman .|Five days after the onset of the symptoms of meningitis , the patient aspirated stomach contents and needed endotracheal intubation .|Forty seconds after injection of suxamethonium , bradycardia and cardiac arrest occurred .|Attempts to resuscitate the patient were not successful .|The serum level of potassium was observed to be 8 . 4 mequiv L - 1 .|Apart from the reduction in the patient 's level of consciousness , there were no signs of motor neurone damage or of any of the other known predisposing conditions for hyperkalaemia following the administration of suxamethonium .|It is postulated that her death was caused by hypersensitivity to suxamethonium , associated with her 5 - day immobilization .	1:CID:2	L2R	NON-CROSS	0-1	3-5	D013390	Suxamethonium|suxamethonium|suxamethonium|suxamethonium|suxamethonium	Chemical	0:34:71:140:153	1:35:72:141:154	0:1:3:6:7	D006323	cardiac arrest|cardiac arrest|cardiac arrest	Disease	3:20:75	5:22:77	0:1:3	1:CID:2	L2R	NON-CROSS	29-30	34-35	D013390	Suxamethonium|suxamethonium|suxamethonium|suxamethonium|suxamethonium	Chemical	0:34:71:140:153	1:35:72:141:154	0:1:3:6:7	D006947	hyperkalaemia|hyperkalaemia	Disease	29:135	30:136	1:6	1:CID:2	L2R	NON-CROSS	71-72	73-74	D013390	Suxamethonium|suxamethonium|suxamethonium|suxamethonium|suxamethonium	Chemical	0:34:71:140:153	1:35:72:141:154	0:1:3:6:7	D001919	bradycardia	Disease	73	74	3	1:CID:2	L2R	NON-CROSS	151-152	153-154	D013390	Suxamethonium|suxamethonium|suxamethonium|suxamethonium|suxamethonium	Chemical	0:34:71:140:153	1:35:72:141:154	0:1:3:6:7	D004342	hypersensitivity	Disease	151	152	7	1:NR:2	L2R	NON-CROSS	0-1	6-7	D013390	Suxamethonium|suxamethonium|suxamethonium|suxamethonium|suxamethonium	Chemical	0:34:71:140:153	1:35:72:141:154	0:1:3:6:7	D003643	death|death|death	Disease	6:24:147	7:25:148	0:1:7	1:NR:2	L2R	CROSS	54-55	71-72	D013390	Suxamethonium|suxamethonium|suxamethonium|suxamethonium|suxamethonium	Chemical	0:34:71:140:153	1:35:72:141:154	0:1:3:6:7	D008581	meningitis	Disease	54	55	2	1:NR:2	R2L	CROSS	92-93	75-77	D011188	potassium	Chemical	92	93	5	D006323	cardiac arrest|cardiac arrest|cardiac arrest	Disease	3:20:75	5:22:77	0:1:3	1:NR:2	R2L	CROSS	147-148	92-93	D011188	potassium	Chemical	92	93	5	D003643	death|death|death	Disease	6:24:147	7:25:148	0:1:7	1:NR:2	R2L	CROSS	135-136	92-93	D011188	potassium	Chemical	92	93	5	D006947	hyperkalaemia|hyperkalaemia	Disease	29:135	30:136	1:6	1:NR:2	R2L	CROSS	92-93	54-55	D011188	potassium	Chemical	92	93	5	D008581	meningitis	Disease	54	55	2	1:NR:2	R2L	CROSS	92-93	73-74	D011188	potassium	Chemical	92	93	5	D001919	bradycardia	Disease	73	74	3	1:NR:2	L2R	CROSS	92-93	151-152	D011188	potassium	Chemical	92	93	5	D004342	hypersensitivity	Disease	151	152	7
9698967	An unusual toxic reaction to axillary block by mepivacaine with adrenaline .|An increase in blood pressure , accompanied by atrial fibrillation , agitation , incomprehensible shouts and loss of consciousness , was observed in an elderly , ASA classification group II , cardiovascularly medicated male , 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0 . 225 mg , for correction of Dupuytren 's contracture .|After intravenous administration of labetalol , metoprolol and midazolam the patient 's condition improved , and 15 min later he woke up .|The block was successful and surgery was conducted as scheduled despite persisting atrial fibrillation .|Postoperatively , the patient refused DC cardioversion and was treated medically .|Both the temporal relationship of events and the response to treatment suggest that a rapid systemic absorption of mepivacaine with adrenaline and / or interaction of these drugs with the patient 's cardiovascular medications were responsible for the perioperative complications .	1:CID:2	L2R	NON-CROSS	8-9	13-17	D008619	mepivacaine|mepivacaine|mepivacaine	Chemical	8:55:140	9:56:141	0:1:5	D006973	increase in blood pressure	Disease	13	17	1	1:CID:2	L2R	NON-CROSS	8-9	20-22	D008619	mepivacaine|mepivacaine|mepivacaine	Chemical	8:55:140	9:56:141	0:1:5	D001281	atrial fibrillation|atrial fibrillation	Disease	20:107	22:109	1:3	1:CID:2	L2R	NON-CROSS	10-11	13-17	D004837	adrenaline|adrenaline|adrenaline	Chemical	10:59:142	11:60:143	0:1:5	D006973	increase in blood pressure	Disease	13	17	1	1:CID:2	L2R	NON-CROSS	10-11	20-22	D004837	adrenaline|adrenaline|adrenaline	Chemical	10:59:142	11:60:143	0:1:5	D001281	atrial fibrillation|atrial fibrillation	Disease	20:107	22:109	1:3	1:NR:2	L2R	NON-CROSS	8-9	23-24	D008619	mepivacaine|mepivacaine|mepivacaine	Chemical	8:55:140	9:56:141	0:1:5	D011595	agitation	Disease	23	24	1	1:NR:2	L2R	NON-CROSS	8-9	25-27	D008619	mepivacaine|mepivacaine|mepivacaine	Chemical	8:55:140	9:56:141	0:1:5	D019954	incomprehensible shouts	Disease	25	27	1	1:NR:2	L2R	NON-CROSS	8-9	28-31	D008619	mepivacaine|mepivacaine|mepivacaine	Chemical	8:55:140	9:56:141	0:1:5	D014474	loss of consciousness	Disease	28	31	1	1:NR:2	L2R	NON-CROSS	55-56	68-71	D008619	mepivacaine|mepivacaine|mepivacaine	Chemical	8:55:140	9:56:141	0:1:5	D004387	Dupuytren 's contracture	Disease	68	71	1	1:NR:2	L2R	NON-CROSS	10-11	23-24	D004837	adrenaline|adrenaline|adrenaline	Chemical	10:59:142	11:60:143	0:1:5	D011595	agitation	Disease	23	24	1	1:NR:2	L2R	NON-CROSS	10-11	25-27	D004837	adrenaline|adrenaline|adrenaline	Chemical	10:59:142	11:60:143	0:1:5	D019954	incomprehensible shouts	Disease	25	27	1	1:NR:2	L2R	NON-CROSS	10-11	28-31	D004837	adrenaline|adrenaline|adrenaline	Chemical	10:59:142	11:60:143	0:1:5	D014474	loss of consciousness	Disease	28	31	1	1:NR:2	L2R	NON-CROSS	59-60	68-71	D004837	adrenaline|adrenaline|adrenaline	Chemical	10:59:142	11:60:143	0:1:5	D004387	Dupuytren 's contracture	Disease	68	71	1	1:NR:2	R2L	CROSS	76-77	13-17	D007741	labetalol	Chemical	76	77	2	D006973	increase in blood pressure	Disease	13	17	1	1:NR:2	R2L	CROSS	78-79	13-17	D008790	metoprolol	Chemical	78	79	2	D006973	increase in blood pressure	Disease	13	17	1	1:NR:2	R2L	CROSS	80-81	13-17	D008874	midazolam	Chemical	80	81	2	D006973	increase in blood pressure	Disease	13	17	1	1:NR:2	R2L	CROSS	107-109	76-77	D007741	labetalol	Chemical	76	77	2	D001281	atrial fibrillation|atrial fibrillation	Disease	20:107	22:109	1:3	1:NR:2	R2L	CROSS	107-109	78-79	D008790	metoprolol	Chemical	78	79	2	D001281	atrial fibrillation|atrial fibrillation	Disease	20:107	22:109	1:3	1:NR:2	R2L	CROSS	107-109	80-81	D008874	midazolam	Chemical	80	81	2	D001281	atrial fibrillation|atrial fibrillation	Disease	20:107	22:109	1:3	1:NR:2	R2L	CROSS	76-77	23-24	D007741	labetalol	Chemical	76	77	2	D011595	agitation	Disease	23	24	1	1:NR:2	R2L	CROSS	78-79	23-24	D008790	metoprolol	Chemical	78	79	2	D011595	agitation	Disease	23	24	1	1:NR:2	R2L	CROSS	80-81	23-24	D008874	midazolam	Chemical	80	81	2	D011595	agitation	Disease	23	24	1	1:NR:2	R2L	CROSS	76-77	25-27	D007741	labetalol	Chemical	76	77	2	D019954	incomprehensible shouts	Disease	25	27	1	1:NR:2	R2L	CROSS	78-79	25-27	D008790	metoprolol	Chemical	78	79	2	D019954	incomprehensible shouts	Disease	25	27	1	1:NR:2	R2L	CROSS	80-81	25-27	D008874	midazolam	Chemical	80	81	2	D019954	incomprehensible shouts	Disease	25	27	1	1:NR:2	R2L	CROSS	76-77	28-31	D007741	labetalol	Chemical	76	77	2	D014474	loss of consciousness	Disease	28	31	1	1:NR:2	R2L	CROSS	78-79	28-31	D008790	metoprolol	Chemical	78	79	2	D014474	loss of consciousness	Disease	28	31	1	1:NR:2	R2L	CROSS	80-81	28-31	D008874	midazolam	Chemical	80	81	2	D014474	loss of consciousness	Disease	28	31	1	1:NR:2	R2L	CROSS	76-77	68-71	D007741	labetalol	Chemical	76	77	2	D004387	Dupuytren 's contracture	Disease	68	71	1	1:NR:2	R2L	CROSS	78-79	68-71	D008790	metoprolol	Chemical	78	79	2	D004387	Dupuytren 's contracture	Disease	68	71	1	1:NR:2	R2L	CROSS	80-81	68-71	D008874	midazolam	Chemical	80	81	2	D004387	Dupuytren 's contracture	Disease	68	71	1
9855119	Clinical and histopathologic examination of renal allografts treated with tacrolimus ( FK506 ) for at least one year .|BACKGROUND : We clinically and pathologically analyzed renal allografts from 1 9 renal transplant patients treated with tacrolimus ( FK506 ) for more than 1 year .|METHODS : Twenty - six renal allograft biopsy specimens from 1 9 renal transplant patients who underwent transplantations between 1991 and 1993 were evaluated .|Thirteen biopsies were performed from stable functioning renal allografts with informed consent ( nonepisode biopsy ) and the other 13 were from dysfunctional renal allografts with a clinical indication for biopsy ( episode biopsy ) .|RESULTS : The main pathologic diagnoses ( some overlap ) were acute rejection ( AR ; n = 4 ) , chronic rejection ( CR ; n = 5 ) , AR + CR ( n = 4 ) , recurrent IgA nephropathy ( n = 5 ) , normal findings ( n = 2 ) , minimal - type chronic FK506 nephropathy ( n = 9 ) , and mild - type FK506 nephropathy ( n = 11 ) .|Of the nonepisode biopsies , 7 and 4 biopsies showed minimal - type and mild - type chronic FK506 nephropathy , respectively .|Chronic FK506 nephropathy consisted of rough and foamy tubular vacuolization ( 5 biopsies ) , arteriolopathy ( angiodegeneration of the arteriolar wall ; 20 biopsies ) , focal segmental glomerulosclerosis ( 4 biopsies ) and the striped form of interstitial fibrosis ( 11 biopsies ) .|The serum creatinine levels of patients in the mild - type chronic FK506 nephropathy group , which included 7 episode biopsies , were statistically higher than those in the minimum - type chronic FK506 - nephropathy group ( P < 0 . 001 ) .|CONCLUSIONS : This study demonstrates that chronic FK506 nephropathy consists primarily of arteriolopathy manifesting as insudative hyalinosis of the arteriolar wall , and suggests that mild - type chronic FK506 nephropathy is a condition which may lead to deterioration of renal allograft function .	1:CID:2	L2R	NON-CROSS	212-213	238-241	D016559	tacrolimus|FK506|tacrolimus|FK506|FK506|FK506|FK506|FK506|FK506|FK506|FK506|FK506	Chemical	9:11:36:38:168:180:206:212:269:290:309:331	10:12:37:39:169:181:207:213:270:291:310:332	0:0:1:1:4:4:5:6:7:7:8:8	D005923	focal segmental glomerulosclerosis	Disease	238	241	6	1:NR:2	L2R	NON-CROSS	148-150	168-169	D016559	tacrolimus|FK506|tacrolimus|FK506|FK506|FK506|FK506|FK506|FK506|FK506|FK506|FK506	Chemical	9:11:36:38:168:180:206:212:269:290:309:331	10:12:37:39:169:181:207:213:270:291:310:332	0:0:1:1:4:4:5:6:7:7:8:8	D005922	IgA nephropathy	Disease	148	150	4	not_include	L2R	NON-CROSS	168-169	169-170	D016559	tacrolimus|FK506|tacrolimus|FK506|FK506|FK506|FK506|FK506|FK506|FK506|FK506|FK506	Chemical	9:11:36:38:168:180:206:212:269:290:309:331	10:12:37:39:169:181:207:213:270:291:310:332	0:0:1:1:4:4:5:6:7:7:8:8	D007674	nephropathy|nephropathy|nephropathy|nephropathy|nephropathy|nephropathy|nephropathy|nephropathy	Disease	169:181:207:213:270:292:310:332	170:182:208:214:271:293:311:333	4:4:5:6:7:7:8:8	1:NR:2	L2R	NON-CROSS	250-252	269-270	D016559	tacrolimus|FK506|tacrolimus|FK506|FK506|FK506|FK506|FK506|FK506|FK506|FK506|FK506	Chemical	9:11:36:38:168:180:206:212:269:290:309:331	10:12:37:39:169:181:207:213:270:291:310:332	0:0:1:1:4:4:5:6:7:7:8:8	D005355	interstitial fibrosis	Disease	250	252	6	1:NR:2	R2L	CROSS	259-260	148-150	D003404	creatinine	Chemical	259	260	7	D005922	IgA nephropathy	Disease	148	150	4	1:NR:2	R2L	NON-CROSS	270-271	259-260	D003404	creatinine	Chemical	259	260	7	D007674	nephropathy|nephropathy|nephropathy|nephropathy|nephropathy|nephropathy|nephropathy|nephropathy	Disease	169:181:207:213:270:292:310:332	170:182:208:214:271:293:311:333	4:4:5:6:7:7:8:8	1:NR:2	R2L	CROSS	259-260	238-241	D003404	creatinine	Chemical	259	260	7	D005923	focal segmental glomerulosclerosis	Disease	238	241	6	1:NR:2	R2L	CROSS	259-260	250-252	D003404	creatinine	Chemical	259	260	7	D005355	interstitial fibrosis	Disease	250	252	6
9869257	Memory facilitation and stimulation of endogenous nerve growth factor synthesis by the acetylcholine releaser PG - 9 .|The effects of PG - 9 ( 3alpha - tropyl 2 - ( p - bromophenyl ) propionate ) , the acetylcholine releaser , on memory processes and nerve growth factor ( NGF ) synthesis were evaluated .|In the mouse passive - avoidance test , PG - 9 ( 10 - 30 mg / kg , i . p . ) , administered 20 min before the training session , prevented amnesia induced by both the non selective antimuscarinic drug scopolamine and the M1 - selective antagonist S - ( - ) - ET - 126 .|In the same experimental conditions , PG - 9 ( 5 - 20 microg per mouse , i . c . v . ) was also able to prevent antimuscarine - induced amnesia , demonstrating a central localization of the activity .|At the highest effective doses , PG - 9 did not produce any collateral symptoms as revealed by the Irwin test , and it did not modify spontaneous motility and inspection activity , as revealed by the hole - board test .|PG - 9 was also able to increase the amount of NGF secreted in vitro by astrocytes in a dose - dependent manner .|The maximal NGF contents obtained by PG - 9 were 17 . 6 - fold of the control value .|During culture , no morphological changes were found at effective concentrations of PG - 9 .|The current work indicates the ability of PG - 9 to induce beneficial effects on cognitive processes and stimulate activity of NGF synthesis in astroglial cells .|Therefore , PG - 9 could represent a potential useful drug able to improve the function of impaired cognitive processes .	1:CID:2	R2L	NON-CROSS	99-100	90-91	D012601	scopolamine	Chemical	99	100	2	D000647	amnesia|amnesia	Disease	90:148	91:149	2:3	1:CID:2	R2L	NON-CROSS	106-115	90-91	C098725	S - ( - ) - ET - 126	Chemical	106	115	2	D000647	amnesia|amnesia	Disease	90:148	91:149	2:3	1:NR:2	L2R	CROSS	39-40	90-91	D000109	acetylcholine|acetylcholine	Chemical	12:39	13:40	0:1	D000647	amnesia|amnesia	Disease	90:148	91:149	2:3	1:NR:2	L2R	NON-CROSS	148-149	164-167	C087567	PG - 9|PG - 9|3alpha - tropyl 2 - ( p - bromophenyl ) propionate|PG - 9|PG - 9|PG - 9|PG - 9|PG - 9|PG - 9|PG - 9|PG - 9	Chemical	14:21:25:64:122:164:200:230:256:267:289	17:24:36:67:125:167:203:233:259:270:292	0:1:1:2:3:4:5:6:7:8:9	D000647	amnesia|amnesia	Disease	90:148	91:149	2:3
10342929	Angioedema due to ACE inhibitors : common and inadequately diagnosed .|The estimated incidence of angioedema during angiotensin - converting enzyme ( ACE ) inhibitor treatment is between 1 and 7 per thousand patients .|This potentially serious adverse effect is often preceded by minor manifestations that may serve as a warning .	1:CID:2	R2L	NON-CROSS	17-25	15-16	D000806	ACE inhibitors|angiotensin - converting enzyme ( ACE ) inhibitor	Chemical	3:17	5:25	0:1	D000799	Angioedema|angioedema	Disease	0:15	1:16	0:1
10457883	Recurarization in the recovery room .|A case of recurarization in the recovery room is reported .|Accumulation of atracurium in the intravenous line led to recurarization after flushing the line in the recovery room .|A respiratory arrest with severe desaturation and bradycardia occurred .|Circumstances leading to this event and the mechanisms enabling a neuromuscular blockade to occur , following the administration of a small dose of relaxant , are discussed .	1:CID:2	L2R	CROSS	19-20	37-39	D001279	atracurium	Chemical	19	20	2	D012131	respiratory arrest	Disease	37	39	3	1:CID:2	L2R	CROSS	19-20	41-42	D001279	atracurium	Chemical	19	20	2	D001049	desaturation	Disease	41	42	3	1:CID:2	L2R	CROSS	19-20	43-44	D001279	atracurium	Chemical	19	20	2	D001919	bradycardia	Disease	43	44	3	1:NR:2	L2R	CROSS	19-20	56-58	D001279	atracurium	Chemical	19	20	2	D020879	neuromuscular blockade	Disease	56	58	4
10739826	Recurrent use of newer oral contraceptives and the risk of venous thromboembolism .|The epidemiological studies that assessed the risk of venous thromboembolism ( VTE ) associated with newer oral contraceptives ( OC ) did not distinguish between patterns of OC use , namely first - time users , repeaters and switchers .|Data from a Transnational case - control study were used to assess the risk of VTE for the latter patterns of use , while accounting for duration of use .|Over the period 1993 - 1996 , 551 cases of VTE were identified in Germany and the UK along with 2066 controls .|Totals of 128 cases and 650 controls were analysed for repeat use and 135 cases and 622 controls for switching patterns .|The adjusted rate ratio of VTE for repeat users of third generation OC was 0 . 6 ( 95 % CI : 0 . 3 - 1 . 2 ) relative to repeat users of second generation pills , whereas it was 1 . 3 ( 95 % CI : 0 . 7 - 2 . 4 ) for switchers from second to third generation pills relative to switchers from third to second generation pills .|We conclude that second and third generation agents are associated with equivalent risks of VTE when the same agent is used repeatedly after interruption periods or when users are switched between the two generations of pills .|These analyses suggest that the higher risk observed for the newer OC in other studies may be the result of inadequate comparisons of pill users with different patterns of pill use .	1:CID:2	L2R	NON-CROSS	4-6	10-12	D003276	oral contraceptives|oral contraceptives|OC|OC|OC|OC	Chemical	4:29:32:40:140:252	6:31:33:41:141:253	0:1:1:1:5:7	D054556	venous thromboembolism|venous thromboembolism|VTE|VTE|VTE|VTE|VTE	Disease	10:21:24:68:93:133:218	12:23:25:69:94:134:219	0:1:1:2:3:5:6
10791295	Development of apomorphine - induced aggressive behavior : comparison of adult male and female Wistar rats .|The development of apomorphine - induced ( 1 . 0 mg / kg s . c .|once daily ) aggressive behavior of adult male and female Wistar rats obtained from the same breeder was studied in two consecutive sets .|In male animals , repeated apomorphine treatment induced a gradual development of aggressive behavior as evidenced by the increased intensity of aggressiveness and shortened latency before the first attack toward the opponent .|In female rats , only a weak tendency toward aggressiveness was found .|In conclusion , the present study demonstrates gender differences in the development of the apomorphine - induced aggressive behavior and indicates that the female rats do not fill the validation criteria for use in this method .	1:CID:2	L2R	NON-CROSS	2-3	5-7	D001058	apomorphine|apomorphine|apomorphine|apomorphine	Chemical	2:20:63:118	3:21:64:119	0:1:3:5	D010554	aggressive behavior|aggressive behavior|aggressive behavior|aggressiveness|aggressiveness|aggressive behavior	Disease	5:37:70:79:100:121	7:39:72:80:101:123	0:2:3:3:4:5
11147747	Serotonergic antidepressants and urinary incontinence .|Many new serotonergic antidepressants have been introduced over the past decade .|Although urinary incontinence is listed as one side effect of these drugs in their package inserts there is only one report in the literature .|This concerns 2 male patients who experienced incontinence while taking venlafaxine .|In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline , as well as a third who developed this side effect on venlafaxine .|In 2 of the 3 cases the patients were also taking lithium carbonate and beta - blockers , both of which could have contributed to the incontinence .|Animal studies suggest that incontinence secondary to serotonergic antidepressants could be mediated by the 5HT4 receptors found on the bladder .|Further research is needed to delineate the frequency of this troubling side effect and how best to treat it .	1:CID:2	L2R	NON-CROSS	0-2	3-5	D018490	Serotonergic antidepressants|serotonergic antidepressants|serotonergic antidepressants	Chemical	0:8:127	2:10:129	0:1:6	D014549	urinary incontinence|urinary incontinence|incontinence|incontinence|incontinence|incontinence	Disease	3:19:50:67:118:124	5:21:51:68:119:125	0:2:3:4:5:6	1:CID:2	R2L	NON-CROSS	53-54	50-51	C047426	venlafaxine|venlafaxine	Chemical	53:90	54:91	3:4	D014549	urinary incontinence|urinary incontinence|incontinence|incontinence|incontinence|incontinence	Disease	3:19:50:67:118:124	5:21:51:68:119:125	0:2:3:4:5:6	1:CID:2	R2L	NON-CROSS	75-76	67-68	D017374	paroxetine	Chemical	75	76	4	D014549	urinary incontinence|urinary incontinence|incontinence|incontinence|incontinence|incontinence	Disease	3:19:50:67:118:124	5:21:51:68:119:125	0:2:3:4:5:6	1:CID:2	R2L	NON-CROSS	77-78	67-68	D020280	sertraline	Chemical	77	78	4	D014549	urinary incontinence|urinary incontinence|incontinence|incontinence|incontinence|incontinence	Disease	3:19:50:67:118:124	5:21:51:68:119:125	0:2:3:4:5:6	1:CID:2	R2L	NON-CROSS	118-119	103-105	D016651	lithium carbonate	Chemical	103	105	5	D014549	urinary incontinence|urinary incontinence|incontinence|incontinence|incontinence|incontinence	Disease	3:19:50:67:118:124	5:21:51:68:119:125	0:2:3:4:5:6	1:NR:2	R2L	NON-CROSS	72-73	67-68	D012701	serotonin	Chemical	72	73	4	D014549	urinary incontinence|urinary incontinence|incontinence|incontinence|incontinence|incontinence	Disease	3:19:50:67:118:124	5:21:51:68:119:125	0:2:3:4:5:6
11198499	Hypotension following the initiation of tizanidine in a patient treated with an angiotensin converting enzyme inhibitor for chronic hypertension .|Centrally acting alpha - 2 adrenergic agonists are one of several pharmacologic agents used in the treatment of spasticity related to disorders of the central nervous system .|In addition to their effects on spasticity , certain adverse cardiorespiratory effects have been reported .|Adults chronically treated with angiotensin converting enzyme inhibitors may have a limited ability to respond to hypotension when the sympathetic response is simultaneously blocked .|The authors present a 10 - year - old boy chronically treated with lisinopril , an angiotensin converting enzyme inhibitor , to control hypertension who developed hypotension following the addition of tizanidine , an alpha - 2 agonist , for the treatment of spasticity .|The possible interaction of tizanidine and other antihypertensive agents should be kept in mind when prescribing therapy to treat either hypertension or spasticity in such patients .	1:CID:2	R2L	NON-CROSS	5-6	0-1	C023754	tizanidine|tizanidine|tizanidine	Chemical	5:120:138	6:121:139	0:4:5	D007022	Hypotension|hypotension|hypotension	Disease	0:80:115	1:81:116	0:3:4	1:CID:2	R2L	NON-CROSS	115-116	102-103	D017706	lisinopril	Chemical	102	103	4	D007022	Hypotension|hypotension|hypotension	Disease	0:80:115	1:81:116	0:3:4	1:NR:2	R2L	NON-CROSS	115-116	105-106	D000809	angiotensin|angiotensin|angiotensin	Chemical	12:68:105	13:69:106	0:3:4	D007022	Hypotension|hypotension|hypotension	Disease	0:80:115	1:81:116	0:3:4	1:NR:2	L2R	NON-CROSS	112-113	120-121	C023754	tizanidine|tizanidine|tizanidine	Chemical	5:120:138	6:121:139	0:4:5	D006973	hypertension|hypertension|hypertension	Disease	18:112:154	19:113:155	0:4:5	1:NR:2	L2R	NON-CROSS	132-133	138-139	C023754	tizanidine|tizanidine|tizanidine	Chemical	5:120:138	6:121:139	0:4:5	D009128	spasticity|spasticity|spasticity|spasticity	Disease	38:54:132:156	39:55:133:157	1:2:4:5	1:NR:2	L2R	CROSS	5-6	41-47	C023754	tizanidine|tizanidine|tizanidine	Chemical	5:120:138	6:121:139	0:4:5	D002493	disorders of the central nervous system	Disease	41	47	1	1:NR:2	L2R	NON-CROSS	12-13	18-19	D000809	angiotensin|angiotensin|angiotensin	Chemical	12:68:105	13:69:106	0:3:4	D006973	hypertension|hypertension|hypertension	Disease	18:112:154	19:113:155	0:4:5	1:NR:2	L2R	NON-CROSS	54-55	68-69	D000809	angiotensin|angiotensin|angiotensin	Chemical	12:68:105	13:69:106	0:3:4	D009128	spasticity|spasticity|spasticity|spasticity	Disease	38:54:132:156	39:55:133:157	1:2:4:5	1:NR:2	L2R	CROSS	41-47	68-69	D000809	angiotensin|angiotensin|angiotensin	Chemical	12:68:105	13:69:106	0:3:4	D002493	disorders of the central nervous system	Disease	41	47	1	1:NR:2	R2L	NON-CROSS	112-113	102-103	D017706	lisinopril	Chemical	102	103	4	D006973	hypertension|hypertension|hypertension	Disease	18:112:154	19:113:155	0:4:5	1:NR:2	R2L	NON-CROSS	132-133	102-103	D017706	lisinopril	Chemical	102	103	4	D009128	spasticity|spasticity|spasticity|spasticity	Disease	38:54:132:156	39:55:133:157	1:2:4:5	1:NR:2	R2L	CROSS	102-103	41-47	D017706	lisinopril	Chemical	102	103	4	D002493	disorders of the central nervous system	Disease	41	47	1
11391224	Peritubular capillary basement membrane reduplication in allografts and native kidney disease : a clinicopathologic study of 278 consecutive renal specimens .|BACKGROUND : An association has been found between transplant glomerulopathy ( TG ) and reduplication of peritubular capillary basement membranes ( PTCR ) .|Although such an association is of practical and theoretical importance , only one prospective study has tried to confirm it .|METHODS : We examined 278 consecutive renal specimens ( from 135 transplants and 143 native kidneys ) for ultrastructural evidence of PTCR .|In addition to renal allografts with TG , we also examined grafts with acute rejection , recurrent glomerulonephritis , chronic allograft nephropathy and stable grafts ( " protocol biopsies " ) .|Native kidney specimens included a wide range of glomerulopathies as well as cases of thrombotic microangiopathy , malignant hypertension , acute interstitial nephritis , and acute tubular necrosis .|RESULTS : We found PTCR in 14 of 15 cases of TG , in 7 transplant biopsy specimens without TG , and in 13 of 143 native kidney biopsy specimens .|These 13 included cases of malignant hypertension , thrombotic microangiopathy , lupus nephritis , Henoch - Schonlein nephritis , crescentic glomerulonephritis , and cocaine - related acute renal failure .|Mild PTCR in allografts without TG did not predict renal failure or significant proteinuria after follow - up periods of between 3 months and 1 year .|CONCLUSIONS : We conclude that in transplants , there is a strong association between well - developed PTCR and TG , while the significance of mild PTCR and its predictive value in the absence of TG is unclear .|PTCR also occurs in certain native kidney diseases , though the association is not as strong as that for TG .|We suggest that repeated endothelial injury , including immunologic injury , may be the cause of this lesion both in allografts and native kidneys .	1:CID:2	L2R	NON-CROSS	204-205	207-210	D003042	cocaine	Chemical	204	205	7	D058186	acute renal failure	Disease	207	210	7	not_include	R2L	CROSS	216-217	204-205	D003042	cocaine	Chemical	204	205	7	D007674	kidney disease|transplant glomerulopathy|TG|TG|glomerulopathies|TG|TG|TG|TG|TG|kidney diseases|TG	Disease	9:29:32:95:129:161:169:216:257:273:283:296	11:31:33:96:130:162:170:217:258:274:285:297	0:1:1:4:5:6:6:8:9:9:10:10	1:NR:2	R2L	NON-CROSS	204-205	201-202	D003042	cocaine	Chemical	204	205	7	D005921	glomerulonephritis|glomerulonephritis	Disease	106:201	107:202	4:7	1:NR:2	R2L	CROSS	204-205	108-111	D003042	cocaine	Chemical	204	205	7	D051436	chronic allograft nephropathy	Disease	108	111	4	1:NR:2	R2L	NON-CROSS	204-205	189-191	D003042	cocaine	Chemical	204	205	7	D057049	thrombotic microangiopathy|thrombotic microangiopathy	Disease	135:189	137:191	5:7	1:NR:2	R2L	NON-CROSS	204-205	186-188	D003042	cocaine	Chemical	204	205	7	D006974	malignant hypertension|malignant hypertension	Disease	138:186	140:188	5:7	1:NR:2	R2L	CROSS	204-205	142-144	D003042	cocaine	Chemical	204	205	7	D009395	interstitial nephritis	Disease	142	144	5	1:NR:2	R2L	CROSS	204-205	146-149	D003042	cocaine	Chemical	204	205	7	D007683	acute tubular necrosis	Disease	146	149	5	1:NR:2	R2L	NON-CROSS	204-205	192-194	D003042	cocaine	Chemical	204	205	7	D008181	lupus nephritis	Disease	192	194	7	1:NR:2	R2L	NON-CROSS	204-205	195-199	D003042	cocaine	Chemical	204	205	7	D011695	Henoch - Schonlein nephritis	Disease	195	199	7	not_include	L2R	CROSS	204-205	220-222	D003042	cocaine	Chemical	204	205	7	D051437	renal failure	Disease	220	222	8	1:NR:2	L2R	CROSS	204-205	224-225	D003042	cocaine	Chemical	204	205	7	D011507	proteinuria	Disease	224	225	8	1:NR:2	L2R	CROSS	204-205	302-304	D003042	cocaine	Chemical	204	205	7	D014947	endothelial injury	Disease	302	304	11	1:NR:2	L2R	CROSS	204-205	306-308	D003042	cocaine	Chemical	204	205	7	D007154	immunologic injury	Disease	306	308	11
11426838	Conformationally restricted analogs of BD1008 and an antisense oligodeoxynucleotide targeting sigma1 receptors produce anti - cocaine effects in mice .|Cocaine 's ability to interact with sigma receptors suggests that these proteins mediate some of its behavioral effects .|Therefore , three novel sigma receptor ligands with antagonist activity were evaluated in Swiss Webster mice : BD1018 ( 3S - 1 - [ 2 - ( 3 , 4 - dichlorophenyl ) ethyl ] - 1 , 4 - diazabicyclo [ 4 . 3 . 0 ] nonane ) , BD1063 ( 1 - [ 2 - ( 3 , 4 - dichlorophenyl ) ethyl ] - 4 - methylpiperazine ) , and LR132 ( 1R , 2S - ( + ) - cis - N - [ 2 - ( 3 , 4 - dichlorophenyl ) ethyl ] - 2 - ( 1 - pyrrolidinyl ) cyclohexylamine ) .|Competition binding assays demonstrated that all three compounds have high affinities for sigma1 receptors .|The three compounds vary in their affinities for sigma2 receptors and exhibit negligible affinities for dopamine , opioid , GABA ( A ) and NMDA receptors .|In behavioral studies , pre - treatment of mice with BD1018 , BD1063 , or LR132 significantly attenuated cocaine - induced convulsions and lethality .|Moreover , post - treatment with LR132 prevented cocaine - induced lethality in a significant proportion of animals .|In contrast to the protection provided by the putative antagonists , the well - characterized sigma receptor agonist di - o - tolylguanidine ( DTG ) and the novel sigma receptor agonist BD1031 ( 3R - 1 - [ 2 - ( 3 , 4 - dichlorophenyl ) ethyl ] - 1 , 4 - diazabicyclo [ 4 . 3 . 0 ] nonane ) each worsened the behavioral toxicity of cocaine .|At doses where alone , they produced no significant effects on locomotion , BD1018 , BD1063 and LR132 significantly attenuated the locomotor stimulatory effects of cocaine .|To further validate the hypothesis that the anti - cocaine effects of the novel ligands involved antagonism of sigma receptors , an antisense oligodeoxynucleotide against sigma1 receptors was also shown to significantly attenuate the convulsive and locomotor stimulatory effects of cocaine .|Together , the data suggests that functional antagonism of sigma receptors is capable of attenuating a number of cocaine - induced behaviors .	1:CID:2	L2R	NON-CROSS	210-211	213-214	D003042	cocaine|Cocaine|cocaine|cocaine|cocaine|cocaine|cocaine|cocaine|cocaine	Chemical	15:20:210:225:307:334:345:376:396	16:21:211:226:308:335:346:377:397	0:1:5:6:7:8:9:9:10	D012640	convulsions|convulsive	Disease	213:370	214:371	5:9	1:NR:2	L2R	CROSS	4-5	213-214	C085527	BD1008	Chemical	4	5	0	D012640	convulsions|convulsive	Disease	213:370	214:371	5:9	1:NR:2	L2R	CROSS	4-5	305-306	C085527	BD1008	Chemical	4	5	0	D064420	toxicity	Disease	305	306	7	1:NR:2	L2R	NON-CROSS	359-360	370-371	D009838	oligodeoxynucleotide|oligodeoxynucleotide	Chemical	8:359	9:360	0:9	D012640	convulsions|convulsive	Disease	213:370	214:371	5:9	1:NR:2	L2R	CROSS	305-306	359-360	D009838	oligodeoxynucleotide|oligodeoxynucleotide	Chemical	8:359	9:360	0:9	D064420	toxicity	Disease	305	306	7	1:NR:2	L2R	NON-CROSS	305-306	307-308	D003042	cocaine|Cocaine|cocaine|cocaine|cocaine|cocaine|cocaine|cocaine|cocaine	Chemical	15:20:210:225:307:334:345:376:396	16:21:211:226:308:335:346:377:397	0:1:5:6:7:8:9:9:10	D064420	toxicity	Disease	305	306	7	1:NR:2	L2R	NON-CROSS	204-205	213-214	C093337	BD1063|1 - [ 2 - ( 3 , 4 - dichlorophenyl ) ethyl ] - 4 - methylpiperazine|BD1063|BD1063	Chemical	90:92:204:324	91:110:205:325	2:2:5:8	D012640	convulsions|convulsive	Disease	213:370	214:371	5:9	1:NR:2	L2R	CROSS	305-306	324-325	C093337	BD1063|1 - [ 2 - ( 3 , 4 - dichlorophenyl ) ethyl ] - 4 - methylpiperazine|BD1063|BD1063	Chemical	90:92:204:324	91:110:205:325	2:2:5:8	D064420	toxicity	Disease	305	306	7	1:NR:2	L2R	CROSS	180-181	213-214	D004298	dopamine	Chemical	180	181	4	D012640	convulsions|convulsive	Disease	213:370	214:371	5:9	1:NR:2	L2R	CROSS	180-181	305-306	D004298	dopamine	Chemical	180	181	4	D064420	toxicity	Disease	305	306	7	1:NR:2	L2R	CROSS	184-185	213-214	D005680	GABA	Chemical	184	185	4	D012640	convulsions|convulsive	Disease	213:370	214:371	5:9	1:NR:2	L2R	CROSS	184-185	305-306	D005680	GABA	Chemical	184	185	4	D064420	toxicity	Disease	305	306	7	1:NR:2	L2R	CROSS	189-190	213-214	D016202	NMDA	Chemical	189	190	4	D012640	convulsions|convulsive	Disease	213:370	214:371	5:9	1:NR:2	L2R	CROSS	189-190	305-306	D016202	NMDA	Chemical	189	190	4	D064420	toxicity	Disease	305	306	7	1:NR:2	R2L	CROSS	254-259	213-214	C050232	di - o - tolylguanidine|DTG	Chemical	254:260	259:261	7:7	D012640	convulsions|convulsive	Disease	213:370	214:371	5:9	1:NR:2	L2R	NON-CROSS	260-261	305-306	C050232	di - o - tolylguanidine|DTG	Chemical	254:260	259:261	7:7	D064420	toxicity	Disease	305	306	7
11569530	Pharmacokinetic / pharmacodynamic assessment of the effects of E4031 , cisapride , terfenadine and terodiline on monophasic action potential duration in dog .|1 . Torsades de pointes ( TDP ) is a potentially fatal ventricular tachycardia associated with increases in QT interval and monophasic action potential duration ( MAPD ) .|TDP is a side - effect that has led to withdrawal of several drugs from the market ( e . g . terfenadine and terodiline ) .|2 .|The potential of compounds to cause TDP was evaluated by monitoring their effects on MAPD in dog .|Four compounds known to increase QT interval and cause TDP were investigated : terfenadine , terodiline , cisapride and E4031 .|On the basis that only free drug in the systemic circulation will elicit a pharmacological response target , free concentrations in plasma were selected to mimic the free drug exposures in man .|Infusion regimens were designed that rapidly achieved and maintained target - free concentrations of these drugs in plasma and data on the relationship between free concentration and changes in MAPD were obtained for these compounds .|3 .|These data indicate that the free ED50 in plasma for terfenadine ( 1 . 9 nM ) , terodiline ( 76 nM ) , cisapride ( 11 nM ) and E4031 ( 1 . 9 nM ) closely correlate with the free concentration in man causing QT effects .|For compounds that have shown TDP in the clinic ( terfenadine , terodiline , cisapride ) there is little differentiation between the dog ED50 and the efficacious free plasma concentrations in man ( < 10 - fold ) reflecting their limited safety margins .|These data underline the need to maximize the therapeutic ratio with respect to TDP in potential development candidates and the importance of using free drug concentrations in pharmacokinetic / pharmacodynamic studies .	1:CID:2	L2R	NON-CROSS	108-109	116-117	D020117	cisapride|cisapride|cisapride|cisapride	Chemical	10:116:215:254	11:117:216:255	0:5:9:10	D016171	Torsades de pointes|TDP|TDP|TDP|TDP|TDP|TDP	Disease	25:29:52:87:108:245:297	28:30:53:88:109:246:298	1:1:2:4:5:10:11	1:CID:2	L2R	NON-CROSS	108-109	112-113	D016593	terfenadine|terfenadine|terfenadine|terfenadine|terfenadine	Chemical	12:74:112:201:250	13:75:113:202:251	0:2:5:9:10	D016171	Torsades de pointes|TDP|TDP|TDP|TDP|TDP|TDP	Disease	25:29:52:87:108:245:297	28:30:53:88:109:246:298	1:1:2:4:5:10:11	1:CID:2	L2R	NON-CROSS	108-109	114-115	C010637	terodiline|terodiline|terodiline|terodiline|terodiline	Chemical	14:76:114:209:252	15:77:115:210:253	0:2:5:9:10	D016171	Torsades de pointes|TDP|TDP|TDP|TDP|TDP|TDP	Disease	25:29:52:87:108:245:297	28:30:53:88:109:246:298	1:1:2:4:5:10:11	1:NR:2	L2R	NON-CROSS	108-109	118-119	C063968	E4031|E4031|E4031	Chemical	8:118:221	9:119:222	0:5:9	D016171	Torsades de pointes|TDP|TDP|TDP|TDP|TDP|TDP	Disease	25:29:52:87:108:245:297	28:30:53:88:109:246:298	1:1:2:4:5:10:11	1:NR:2	L2R	CROSS	8-9	35-37	C063968	E4031|E4031|E4031	Chemical	8:118:221	9:119:222	0:5:9	D017180	ventricular tachycardia	Disease	35	37	1	not_include	L2R	CROSS	10-11	35-37	D020117	cisapride|cisapride|cisapride|cisapride	Chemical	10:116:215:254	11:117:216:255	0:5:9:10	D017180	ventricular tachycardia	Disease	35	37	1	not_include	L2R	CROSS	12-13	35-37	D016593	terfenadine|terfenadine|terfenadine|terfenadine|terfenadine	Chemical	12:74:112:201:250	13:75:113:202:251	0:2:5:9:10	D017180	ventricular tachycardia	Disease	35	37	1	not_include	L2R	CROSS	14-15	35-37	C010637	terodiline|terodiline|terodiline|terodiline|terodiline	Chemical	14:76:114:209:252	15:77:115:210:253	0:2:5:9:10	D017180	ventricular tachycardia	Disease	35	37	1
11587867	Fatal myeloencephalopathy due to accidental intrathecal vincristin administration : a report of two cases .|We report on two fatal cases of accidental intrathecal vincristine instillation in a 5 - year old girl with recurrent acute lymphoblastic leucemia and a 57 - year old man with lymphoblastic lymphoma .|The girl died seven days , the man four weeks after intrathecal injection of vincristine .|Clinically , the onset was characterized by the signs of opistothonus , sensory and motor dysfunction and ascending paralysis .|Histological and immunohistochemical investigations ( HE - LFB , CD - 68 , Neurofilament ) revealed degeneration of myelin and axons as well as pseudocystic transformation in areas exposed to vincristine , accompanied by secondary changes with numerous prominent macrophages .|The clinical course and histopathological results of the two cases are presented .|A review of all reported cases in the literature is given .|A better controlled regimen for administering vincristine and intrathecal chemotherapy is recommended .	1:CID:2	L2R	CROSS	63-64	75-81	D014750	vincristin|vincristine|vincristine|vincristine|vincristine	Chemical	6:24:63:115:157	7:25:64:116:158	0:1:2:4:7	D020258	opistothonus , sensory and motor dysfunction|opistothonus , sensory and motor dysfunction|opistothonus , sensory and motor dysfunction	Disease	75:75:75	81:81:81	3:3:3	1:CID:2	L2R	NON-CROSS	101-106	115-116	D014750	vincristin|vincristine|vincristine|vincristine|vincristine	Chemical	6:24:63:115:157	7:25:64:116:158	0:1:2:4:7	D003711	degeneration of myelin and axons	Disease	101	106	4	1:CID:2	L2R	NON-CROSS	101-106	115-116	D014750	vincristin|vincristine|vincristine|vincristine|vincristine	Chemical	6:24:63:115:157	7:25:64:116:158	0:1:2:4:7	D009410	degeneration of myelin and axons	Disease	101	106	4	1:NR:2	R2L	NON-CROSS	6-7	1-2	D014750	vincristin|vincristine|vincristine|vincristine|vincristine	Chemical	6:24:63:115:157	7:25:64:116:158	0:1:2:4:7	D001927	myeloencephalopathy	Disease	1	2	0	1:NR:2	L2R	NON-CROSS	24-25	35-38	D014750	vincristin|vincristine|vincristine|vincristine|vincristine	Chemical	6:24:63:115:157	7:25:64:116:158	0:1:2:4:7	D054198	acute lymphoblastic leucemia|lymphoblastic lymphoma	Disease	35:46	38:48	1:1	1:NR:2	L2R	CROSS	63-64	83-84	D014750	vincristin|vincristine|vincristine|vincristine|vincristine	Chemical	6:24:63:115:157	7:25:64:116:158	0:1:2:4:7	D010243	paralysis	Disease	83	84	3
11679859	Intravenous administration of prochlorperazine by 15 - minute infusion versus 2 - minute bolus does not affect the incidence of akathisia : a prospective , randomized , controlled trial .|STUDY OBJECTIVE : We sought to compare the rate of akathisia after administration of intravenous prochlorperazine as a 2 - minute bolus or 15 - minute infusion .|METHODS : We conducted a prospective , randomized , double - blind study in the emergency department of a central - city teaching hospital .|Patients aged 18 years or older treated with prochlorperazine for headache , nausea , or vomiting were eligible for inclusion .|Study participants were randomized to receive 10 mg of prochlorperazine administered intravenously by means of 2 - minute push ( bolus group ) or 10 mg diluted in 50 mL of normal saline solution administered by means of intravenous infusion during a 15 - minute period ( infusion group ) .|The main outcome was the number of study participants experiencing akathisia within 60 minutes of administration .|Akathisia was defined as either a spontaneous report of restlessness or agitation or a change of 2 or more in the patient - reported akathisia rating scale and a change of at least 1 in the investigator - observed akathisia rating scale .|The intensity of headache and nausea was measured with a 100 - mm visual analog scale .|RESULTS : One hundred patients were enrolled .|One study participant was excluded after protocol violation .|Seventy - three percent ( 73 / 99 ) of the study participants were treated for headache and 70 % ( 70 / 99 ) for nausea .|In the bolus group , 26 . 0 % ( 13 / 50 ) had akathisia compared with 32 . 7 % ( 16 / 49 ) in the infusion group ( Delta = - 6 . 7 % ; 95 % confidence interval [ CI ] - 24 . 6 % to 11 . 2 % ) .|The difference between the bolus and infusion groups in the percentage of participants who saw a 50 % reduction in their headache intensity within 30 minutes was 11 . 8 % ( 95 % CI - 9 . 6 % to 33 . 3 % ) .|The difference in the percentage of patients with a 50 % reduction in their nausea was 12 . 6 % ( 95 % CI - 4 . 6 % to 29 . 8 % ) .|CONCLUSION : A 50 % reduction in the incidence of akathisia when prochlorperazine was administered by means of 15 - minute intravenous infusion versus a 2 - minute intravenous push was not detected .|The efficacy of prochlorperazine in the treatment of headache and nausea likewise did not appear to be affected by the rate of administration , although no formal statistical comparisons were made .	1:CID:2	L2R	NON-CROSS	429-430	431-432	D011346	prochlorperazine|prochlorperazine|prochlorperazine|prochlorperazine|prochlorperazine|prochlorperazine	Chemical	3:45:91:113:431:456	4:46:92:114:432:457	0:1:3:4:14:15	D017109	akathisia|akathisia|akathisia|akathisia|akathisia|akathisia|akathisia	Disease	20:40:165:196:211:292:429	21:41:166:197:212:293:430	0:1:5:6:6:11:14	1:NR:2	L2R	NON-CROSS	91-92	93-94	D011346	prochlorperazine|prochlorperazine|prochlorperazine|prochlorperazine|prochlorperazine|prochlorperazine	Chemical	3:45:91:113:431:456	4:46:92:114:432:457	0:1:3:4:14:15	D006261	headache|headache|headache|headache|headache	Disease	93:218:265:357:461	94:219:266:358:462	3:7:10:12:15	1:NR:2	L2R	NON-CROSS	91-92	95-96	D011346	prochlorperazine|prochlorperazine|prochlorperazine|prochlorperazine|prochlorperazine|prochlorperazine	Chemical	3:45:91:113:431:456	4:46:92:114:432:457	0:1:3:4:14:15	D009325	nausea|nausea|nausea|nausea|nausea	Disease	95:220:275:397:463	96:221:276:398:464	3:7:10:13:15	1:NR:2	L2R	NON-CROSS	91-92	98-99	D011346	prochlorperazine|prochlorperazine|prochlorperazine|prochlorperazine|prochlorperazine|prochlorperazine	Chemical	3:45:91:113:431:456	4:46:92:114:432:457	0:1:3:4:14:15	D014839	vomiting	Disease	98	99	3	not_include	L2R	CROSS	113-114	183-184	D011346	prochlorperazine|prochlorperazine|prochlorperazine|prochlorperazine|prochlorperazine|prochlorperazine	Chemical	3:45:91:113:431:456	4:46:92:114:432:457	0:1:3:4:14:15	D011595	agitation	Disease	183	184	6
12041669	Antithymocyte globulin in the treatment of D - penicillamine - induced aplastic anemia .|A patient who received antithymocyte globulin therapy for aplastic anemia due to D - penicillamine therapy is described .|Bone marrow recovery and peripheral blood recovery were complete 1 month and 3 months , respectively , after treatment , and blood transfusion or other therapies were not necessary in a follow - up period of more than 2 years .|Use of antithymocyte globulin may be the optimal treatment of D - penicillamine - induced aplastic anemia .	1:CID:2	L2R	NON-CROSS	6-9	11-13	D010396	D - penicillamine|D - penicillamine|D - penicillamine	Chemical	6:26:84	9:29:87	0:1:3	D000741	aplastic anemia|aplastic anemia|aplastic anemia	Disease	11:22:89	13:24:91	0:1:3	1:NR:2	L2R	NON-CROSS	18-20	22-24	D000961	Antithymocyte globulin|antithymocyte globulin|antithymocyte globulin	Chemical	0:18:76	2:20:78	0:1:3	D000741	aplastic anemia|aplastic anemia|aplastic anemia	Disease	11:22:89	13:24:91	0:1:3
12198388	The relationship between hippocampal acetylcholine release and cholinergic convulsant sensitivity in withdrawal seizure - prone and withdrawal seizure - resistant selected mouse lines .|BACKGROUND : The septo - hippocampal cholinergic pathway has been implicated in epileptogenesis , and genetic factors influence the response to cholinergic agents , but limited data are available on cholinergic involvement in alcohol withdrawal severity .|Thus , the relationship between cholinergic activity and responsiveness and alcohol withdrawal was investigated in a genetic animal model of ethanol withdrawal severity .|METHODS : Cholinergic convulsant sensitivity was examined in alcohol - na ve Withdrawal Seizure - Prone ( WSP ) and - Resistant ( WSR ) mice .|Animals were administered nicotine , carbachol , or neostigmine via timed tail vein infusion , and the latencies to onset of tremor and clonus were recorded and converted to threshold dose .|We also used microdialysis to measure basal and potassium - stimulated acetylcholine ( ACh ) release in the CA1 region of the hippocampus .|Potassium was applied by reverse dialysis twice , separated by 75 min .|Hippocampal ACh also was measured during testing for handling - induced convulsions .|RESULTS : Sensitivity to several convulsion endpoints induced by nicotine , carbachol , and neostigmine were significantly greater in WSR versus WSP mice .|In microdialysis experiments , the lines did not differ in basal release of ACh , and 50 mM KCl increased ACh output in both lines of mice .|However , the increase in release of ACh produced by the first application of KCl was 2 - fold higher in WSP versus WSR mice .|When hippocampal ACh was measured during testing for handling - induced convulsions , extracellular ACh was significantly elevated ( 192 % ) in WSP mice , but was nonsignificantly elevated ( 59 % ) in WSR mice .|CONCLUSIONS : These results suggest that differences in cholinergic activity and postsynaptic sensitivity to cholinergic convulsants may be associated with ethanol withdrawal severity and implicate cholinergic mechanisms in alcohol withdrawal .|Specifically , WSP mice may have lower sensitivity to cholinergic convulsants compared with WSR because of postsynaptic receptor desensitization brought on by higher activity of cholinergic neurons .	1:CID:2	R2L	NON-CROSS	203-204	199-200	D009538	nicotine|nicotine	Chemical	115:203	116:204	4:8	D012640	seizure|seizure|Seizure|convulsions|convulsion|convulsions|convulsants|convulsants	Disease	12:17:98:192:199:283:325:351	13:18:99:193:200:284:326:352	0:0:3:7:8:11:12:13	1:CID:2	R2L	NON-CROSS	205-206	199-200	D002217	carbachol|carbachol	Chemical	117:205	118:206	4:8	D012640	seizure|seizure|Seizure|convulsions|convulsion|convulsions|convulsants|convulsants	Disease	12:17:98:192:199:283:325:351	13:18:99:193:200:284:326:352	0:0:3:7:8:11:12:13	1:CID:2	R2L	NON-CROSS	208-209	199-200	D009388	neostigmine|neostigmine	Chemical	120:208	121:209	4:8	D012640	seizure|seizure|Seizure|convulsions|convulsion|convulsions|convulsants|convulsants	Disease	12:17:98:192:199:283:325:351	13:18:99:193:200:284:326:352	0:0:3:7:8:11:12:13	1:NR:2	L2R	NON-CROSS	283-284	286-287	D000109	acetylcholine|acetylcholine|ACh|ACh|ACh|ACh|ACh|ACh|ACh	Chemical	4:155:157:182:231:238:253:274:286	5:156:158:183:232:239:254:275:287	0:5:5:7:9:9:10:11:11	D012640	seizure|seizure|Seizure|convulsions|convulsion|convulsions|convulsants|convulsants	Disease	12:17:98:192:199:283:325:351	13:18:99:193:200:284:326:352	0:0:3:7:8:11:12:13	1:NR:2	L2R	CROSS	133-134	155-156	D000109	acetylcholine|acetylcholine|ACh|ACh|ACh|ACh|ACh|ACh|ACh	Chemical	4:155:157:182:231:238:253:274:286	5:156:158:183:232:239:254:275:287	0:5:5:7:9:9:10:11:11	D014202	tremor	Disease	133	134	4	1:NR:2	R2L	NON-CROSS	98-99	93-94	D000431	alcohol|alcohol|ethanol|alcohol|ethanol|alcohol	Chemical	57:71:81:93:330:338	58:72:82:94:331:339	1:2:2:3:12:12	D012640	seizure|seizure|Seizure|convulsions|convulsion|convulsions|convulsants|convulsants	Disease	12:17:98:192:199:283:325:351	13:18:99:193:200:284:326:352	0:0:3:7:8:11:12:13	1:NR:2	R2L	CROSS	192-193	168-169	D011188	potassium|Potassium	Chemical	152:168	153:169	5:6	D012640	seizure|seizure|Seizure|convulsions|convulsion|convulsions|convulsants|convulsants	Disease	12:17:98:192:199:283:325:351	13:18:99:193:200:284:326:352	0:0:3:7:8:11:12:13	1:NR:2	R2L	CROSS	283-284	260-261	C522374	KCl|KCl	Chemical	236:260	237:261	9:10	D012640	seizure|seizure|Seizure|convulsions|convulsion|convulsions|convulsants|convulsants	Disease	12:17:98:192:199:283:325:351	13:18:99:193:200:284:326:352	0:0:3:7:8:11:12:13	1:NR:2	L2R	CROSS	93-94	133-134	D000431	alcohol|alcohol|ethanol|alcohol|ethanol|alcohol	Chemical	57:71:81:93:330:338	58:72:82:94:331:339	1:2:2:3:12:12	D014202	tremor	Disease	133	134	4	1:NR:2	L2R	NON-CROSS	115-116	133-134	D009538	nicotine|nicotine	Chemical	115:203	116:204	4:8	D014202	tremor	Disease	133	134	4	1:NR:2	L2R	NON-CROSS	117-118	133-134	D002217	carbachol|carbachol	Chemical	117:205	118:206	4:8	D014202	tremor	Disease	133	134	4	1:NR:2	L2R	NON-CROSS	120-121	133-134	D009388	neostigmine|neostigmine	Chemical	120:208	121:209	4:8	D014202	tremor	Disease	133	134	4	1:NR:2	R2L	CROSS	152-153	133-134	D011188	potassium|Potassium	Chemical	152:168	153:169	5:6	D014202	tremor	Disease	133	134	4	1:NR:2	R2L	CROSS	236-237	133-134	C522374	KCl|KCl	Chemical	236:260	237:261	9:10	D014202	tremor	Disease	133	134	4
12574103	Prenatal dexamethasone programs hypertension and renal injury in the rat .|Dexamethasone is frequently administered to the developing fetus to accelerate pulmonary development .|The purpose of the present study was to determine if prenatal dexamethasone programmed a progressive increase in blood pressure and renal injury in rats .|Pregnant rats were given either vehicle or 2 daily intraperitoneal injections of dexamethasone ( 0 . 2 mg / kg body weight ) on gestational days 11 and 12 , 13 and 14 , 15 and 16 , 17 and 18 , or 19 and 20 .|Offspring of rats administered dexamethasone on days 15 and 16 gestation had a 20 % reduction in glomerular number compared with control at 6 to 9 months of age ( 22 527 + / - 509 versus 28 050 + / - 561 , P < 0 . 05 ) , which was comparable to the percent reduction in glomeruli measured at 3 weeks of age .|Six - to 9 - month old rats receiving prenatal dexamethasone on days 17 and 18 of gestation had a 17 % reduction in glomeruli ( 23 380 + / - 587 ) compared with control rats ( P < 0 . 05 ) .|Male rats that received prenatal dexamethasone on days 15 and 16 , 17 and 18 , and 13 and 14 of gestation had elevated blood pressures at 6 months of age ; the latter group did not have a reduction in glomerular number .|Adult rats given dexamethasone on days 15 and 16 of gestation had more glomeruli with glomerulosclerosis than control rats .|This study shows that prenatal dexamethasone in rats results in a reduction in glomerular number , glomerulosclerosis , and hypertension when administered at specific points during gestation .|Hypertension was observed in animals that had a reduction in glomeruli as well as in a group that did not have a reduction in glomerular number , suggesting that a reduction in glomerular number is not the sole cause for the development of hypertension .	1:CID:2	L2R	NON-CROSS	1-2	3-4	D003907	dexamethasone|dexamethasone|dexamethasone|dexamethasone|dexamethasone|dexamethasone|dexamethasone|dexamethasone	Chemical	1:35:61:100:173:213:255:277	2:36:62:101:174:214:256:278	0:2:3:4:5:6:7:8	D006973	hypertension|increase in blood pressure|elevated blood pressures|hypertension|Hypertension|hypertension	Disease	3:39:231:291:300:343	4:43:234:292:301:344	0:2:6:8:9:9	1:CID:2	L2R	NON-CROSS	1-2	5-7	D003907	dexamethasone|dexamethasone|dexamethasone|dexamethasone|dexamethasone|dexamethasone|dexamethasone|dexamethasone	Chemical	1:35:61:100:173:213:255:277	2:36:62:101:174:214:256:278	0:2:3:4:5:6:7:8	D007674	renal injury|renal injury|reduction in glomerular number|reduction in glomerular number|reduction in glomerular number|reduction in glomerular number|reduction in glomerular number	Disease	5:44:111:247:283:322:330	7:46:115:251:287:326:334	0:2:4:6:8:9:9	1:NR:2	L2R	NON-CROSS	267-268	277-278	D003907	dexamethasone|dexamethasone|dexamethasone|dexamethasone|dexamethasone|dexamethasone|dexamethasone|dexamethasone	Chemical	1:35:61:100:173:213:255:277	2:36:62:101:174:214:256:278	0:2:3:4:5:6:7:8	D005921	glomerulosclerosis|glomerulosclerosis	Disease	267:288	268:289	7:8
12615818	The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with ethinyl estradiol : a nested cohort analysis and case - control study .|BACKGROUND : Cyproterone acetate combined with ethinyl estradiol ( CPA / EE ) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome ( PCOS ) .|Previous studies have demonstrated an increased risk of venous thromboembolism ( VTE ) associated with CPA / EE compared with conventional combined oral contraceptives ( COCs ) .|We believe the results of those studies may have been affected by residual confounding .|METHODS : Using the General Practice Research Database we conducted a cohort analysis and case - control study nested within a population of women aged between 15 and 39 years with acne , hirsutism or PCOS to estimate the risk of VTE associated with CPA / EE .|RESULTS : The age - adjusted incidence rate ratio for CPA / EE versus conventional COCs was 2 . 20 [ 95 % confidence interval ( CI ) 1 . 35 - 3 . 58 ] .|Using as the reference group women who were not using oral contraception , had no recent pregnancy or menopausal symptoms , the case - control analysis gave an adjusted odds ratio ( OR ( adj ) ) of 7 . 44 ( 95 % CI 3 . 67 - 15 . 08 ) for CPA / EE use compared with an OR ( adj ) of 2 . 58 ( 95 % CI 1 . 60 - 4 . 18 ) for use of conventional COCs .|CONCLUSIONS : We have demonstrated an increased risk of VTE associated with the use of CPA / EE in women with acne , hirsutism or PCOS although residual confounding by indication can not be excluded .	1:CID:2	R2L	NON-CROSS	154-155	151-152	D017373	cyproterone acetate|Cyproterone acetate|CPA|CPA|CPA|CPA|CPA|CPA	Chemical	8:28:35:82:154:168:249:297	10:30:36:83:155:169:250:298	0:1:1:2:4:5:6:7	D054556	venous thromboembolism|venous thromboembolism|VTE|VTE|VTE	Disease	3:75:78:151:291	5:77:79:152:292	0:2:2:4:7	1:CID:2	R2L	NON-CROSS	156-157	151-152	D004997	ethinyl estradiol|ethinyl estradiol|EE|EE|EE|EE|EE|EE	Chemical	13:32:37:84:156:170:251:299	15:34:38:85:157:171:252:300	0:1:1:2:4:5:6:7	D054556	venous thromboembolism|venous thromboembolism|VTE|VTE|VTE	Disease	3:75:78:151:291	5:77:79:152:292	0:2:2:4:7	1:NR:2	R2L	NON-CROSS	89-91	78-79	D003276	oral contraceptives	Chemical	89	91	2	D054556	venous thromboembolism|venous thromboembolism|VTE|VTE|VTE	Disease	3:75:78:151:291	5:77:79:152:292	0:2:2:4:7	1:NR:2	L2R	NON-CROSS	297-298	303-304	D017373	cyproterone acetate|Cyproterone acetate|CPA|CPA|CPA|CPA|CPA|CPA	Chemical	8:28:35:82:154:168:249:297	10:30:36:83:155:169:250:298	0:1:1:2:4:5:6:7	D000152	acne|acne|acne	Disease	50:141:303	51:142:304	1:4:7	1:NR:2	L2R	NON-CROSS	297-298	305-306	D017373	cyproterone acetate|Cyproterone acetate|CPA|CPA|CPA|CPA|CPA|CPA	Chemical	8:28:35:82:154:168:249:297	10:30:36:83:155:169:250:298	0:1:1:2:4:5:6:7	D006628	hirsutism|hirsutism|hirsutism	Disease	52:143:305	53:144:306	1:4:7	1:NR:2	L2R	NON-CROSS	145-146	154-155	D017373	cyproterone acetate|Cyproterone acetate|CPA|CPA|CPA|CPA|CPA|CPA	Chemical	8:28:35:82:154:168:249:297	10:30:36:83:155:169:250:298	0:1:1:2:4:5:6:7	D011085	polycystic ovary syndrome|PCOS|PCOS|PCOS	Disease	60:64:145:307	63:65:146:308	1:1:4:7	1:NR:2	L2R	NON-CROSS	299-300	303-304	D004997	ethinyl estradiol|ethinyl estradiol|EE|EE|EE|EE|EE|EE	Chemical	13:32:37:84:156:170:251:299	15:34:38:85:157:171:252:300	0:1:1:2:4:5:6:7	D000152	acne|acne|acne	Disease	50:141:303	51:142:304	1:4:7	1:NR:2	L2R	NON-CROSS	299-300	305-306	D004997	ethinyl estradiol|ethinyl estradiol|EE|EE|EE|EE|EE|EE	Chemical	13:32:37:84:156:170:251:299	15:34:38:85:157:171:252:300	0:1:1:2:4:5:6:7	D006628	hirsutism|hirsutism|hirsutism	Disease	52:143:305	53:144:306	1:4:7	1:NR:2	L2R	NON-CROSS	299-300	307-308	D004997	ethinyl estradiol|ethinyl estradiol|EE|EE|EE|EE|EE|EE	Chemical	13:32:37:84:156:170:251:299	15:34:38:85:157:171:252:300	0:1:1:2:4:5:6:7	D011085	polycystic ovary syndrome|PCOS|PCOS|PCOS	Disease	60:64:145:307	63:65:146:308	1:1:4:7	1:NR:2	R2L	CROSS	89-91	50-51	D003276	oral contraceptives	Chemical	89	91	2	D000152	acne|acne|acne	Disease	50:141:303	51:142:304	1:4:7	1:NR:2	R2L	CROSS	89-91	52-53	D003276	oral contraceptives	Chemical	89	91	2	D006628	hirsutism|hirsutism|hirsutism	Disease	52:143:305	53:144:306	1:4:7	1:NR:2	R2L	CROSS	89-91	64-65	D003276	oral contraceptives	Chemical	89	91	2	D011085	polycystic ovary syndrome|PCOS|PCOS|PCOS	Disease	60:64:145:307	63:65:146:308	1:1:4:7
12789195	Pseudoacromegaly induced by the long - term use of minoxidil .|Acromegaly is an endocrine disorder caused by chronic excessive growth hormone secretion from the anterior pituitary gland .|Significant disfiguring changes occur as a result of bone , cartilage , and soft tissue hypertrophy , including the thickening of the skin , coarsening of facial features , and cutis verticis gyrata .|Pseudoacromegaly , on the other hand , is the presence of similar acromegaloid features in the absence of elevated growth hormone or insulin - like growth factor levels .|We present a patient with pseudoacromegaly that resulted from the long - term use of minoxidil at an unusually high dose .|This is the first case report of pseudoacromegaly as a side effect of minoxidil use .	1:CID:2	L2R	CROSS	9-10	11-12	D008914	minoxidil|minoxidil|minoxidil	Chemical	9:107:127	10:108:128	0:4:5	D000172	Acromegaly	Disease	11	12	1	1:NR:2	R2L	NON-CROSS	127-128	121-122	D008914	minoxidil|minoxidil|minoxidil	Chemical	9:107:127	10:108:128	0:4:5	D004194	Pseudoacromegaly|Pseudoacromegaly|pseudoacromegaly|pseudoacromegaly	Disease	0:63:97:121	1:64:98:122	0:3:4:5	not_include	L2R	CROSS	9-10	14-16	D008914	minoxidil|minoxidil|minoxidil	Chemical	9:107:127	10:108:128	0:4:5	D004700	endocrine disorder	Disease	14	16	1	1:NR:2	L2R	CROSS	9-10	44-45	D008914	minoxidil|minoxidil|minoxidil	Chemical	9:107:127	10:108:128	0:4:5	D006984	hypertrophy	Disease	44	45	2	1:NR:2	L2R	CROSS	59-62	107-108	D008914	minoxidil|minoxidil|minoxidil	Chemical	9:107:127	10:108:128	0:4:5	C535610	cutis verticis gyrata	Disease	59	62	2
12820454	Combined androgen blockade - induced anemia in prostate cancer patients without bone involvement .|BACKGROUND : To determine the onset and extent of combined androgen blockade ( CAB ) - induced anemia in prostate cancer patients without bone involvement .|PATIENTS AND METHODS : Forty - two patients with biopsy - proven prostatic adenocarcinoma [ 26 with stage C ( T3N0M0 ) and 16 with stage D1 ( T3N1M0 ) ] were included in this study .|All patients received CAB [ leuprolide acetate ( LHRH - A ) 3 . 75 mg , intramuscularly , every 28 days plus 250 mg flutamide , tid , per Os ] and were evaluated for anemia by physical examination and laboratory tests at baseline and 4 subsequent intervals ( 1 , 2 , 3 and 6 months post - CAB ) .|Hb , PSA and Testosterone measurements were recorded .|Patients with stage D2 - 3 disease , abnormal hemoglobin level or renal and liver function tests that were higher than the upper limits were excluded from the study .|The duration of the study was six months .|RESULTS : The mean hemoglobin ( Hb ) levels were significantly declined in all patients from baseline of 14 . 2 g / dl to 14 . 0 g / dl , 13 . 5 g / dl , 13 . 2 g / dl and 12 . 7 g / dl at 1 , 2 , 3 and 6 months post - CAB , respectively .|Severe and clinically evident anemia of Hb < 11 g / dl with clinical symptoms was detected in 6 patients ( 14 . 3 % ) .|This CAB - induced anemia was normochromic and normocytic .|At six months post - CAB , patients with severe anemia had a Hb mean value of 10 . 2 + / - 0 . 1 g / dl ( X + / - SE ) , whereas the other patients had mild anemia with Hb mean value of 13 . 2 + / - 0 . 17 ( X + / - SE ) .|The development of severe anemia at 6 months post - CAB was predictable by the reduction of Hb baseline value of more than 2 . 5 g / dl after 3 months of CAB ( p = 0 . 01 ) .|The development of severe CAB - induced anemia in prostate cancer patients did not correlate with T baseline values ( T < 3 ng / ml versus T > or = 3 ng / ml ) , with age ( < 76 yrs versus > or = 76 yrs ) , and clinical stage ( stage C versus stage D1 ) .|Severe and clinically evident anemia was easily corrected by subcutaneous injections ( 3 times / week for 1 month ) of recombinant erythropoietin ( rHuEPO - beta ) .|CONCLUSION : Our data suggest that rHuEPO - beta correctable CAB - induced anemia occurs in 14 . 3 % of prostate cancer patients after 6 months of therapy .	1:CID:2	R2L	NON-CROSS	113-114	85-88	D016729	leuprolide acetate|LHRH - A	Chemical	82:85	84:88	3:3	D000740	anemia|anemia|anemia|anemia|anemia|anemia|anemia|anemia|anemia|anemia|anemia	Disease	5:31:113:259:286:302:335:362:407:466:504	6:32:114:260:287:303:336:363:408:467:505	0:1:3:8:9:10:10:11:12:13:14	1:CID:2	R2L	NON-CROSS	113-114	102-103	D005485	flutamide	Chemical	102	103	3	D000740	anemia|anemia|anemia|anemia|anemia|anemia|anemia|anemia|anemia|anemia|anemia	Disease	5:31:113:259:286:302:335:362:407:466:504	6:32:114:260:287:303:336:363:408:467:505	0:1:3:8:9:10:10:11:12:13:14	1:NR:2	R2L	CROSS	144-145	113-114	D013739	Testosterone	Chemical	144	145	4	D000740	anemia|anemia|anemia|anemia|anemia|anemia|anemia|anemia|anemia|anemia|anemia	Disease	5:31:113:259:286:302:335:362:407:466:504	6:32:114:260:287:303:336:363:408:467:505	0:1:3:8:9:10:10:11:12:13:14	1:NR:2	R2L	CROSS	82-84	33-35	D016729	leuprolide acetate|LHRH - A	Chemical	82:85	84:88	3:3	D011471	prostate cancer|prostate cancer|prostate cancer|prostate cancer	Disease	7:33:409:512	9:35:411:514	0:1:12:14	1:NR:2	R2L	CROSS	102-103	33-35	D005485	flutamide	Chemical	102	103	3	D011471	prostate cancer|prostate cancer|prostate cancer|prostate cancer	Disease	7:33:409:512	9:35:411:514	0:1:12:14	1:NR:2	R2L	CROSS	144-145	33-35	D013739	Testosterone	Chemical	144	145	4	D011471	prostate cancer|prostate cancer|prostate cancer|prostate cancer	Disease	7:33:409:512	9:35:411:514	0:1:12:14	1:NR:2	R2L	CROSS	82-84	52-54	D016729	leuprolide acetate|LHRH - A	Chemical	82:85	84:88	3:3	D000230	prostatic adenocarcinoma	Disease	52	54	2	1:NR:2	R2L	CROSS	102-103	52-54	D005485	flutamide	Chemical	102	103	3	D000230	prostatic adenocarcinoma	Disease	52	54	2	1:NR:2	R2L	CROSS	144-145	52-54	D013739	Testosterone	Chemical	144	145	4	D000230	prostatic adenocarcinoma	Disease	52	54	2
14657095	Reversible dilated cardiomyopathy related to amphotericin B therapy .|We describe a patient who developed dilated cardiomyopathy and clinical congestive heart failure after 2 months of therapy with amphotericin B ( AmB ) for disseminated coccidioidomycosis .|His echocardiographic abnormalities and heart failure resolved after posaconazole was substituted for AmB .|It is important to recognize the rare and potentially reversible toxicity of AmB .	1:CID:2	R2L	NON-CROSS	5-7	1-3	D000666	amphotericin B|amphotericin B|AmB|AmB|AmB	Chemical	5:28:31:49:63	7:30:32:50:64	0:1:1:2:3	D002311	dilated cardiomyopathy|dilated cardiomyopathy	Disease	1:15	3:17	0:1	1:CID:2	L2R	NON-CROSS	41-43	49-50	D000666	amphotericin B|amphotericin B|AmB|AmB|AmB	Chemical	5:28:31:49:63	7:30:32:50:64	0:1:1:2:3	D006333	heart failure|heart failure	Disease	20:41	22:43	1:2	1:NR:2	R2L	CROSS	45-46	15-17	C101425	posaconazole	Chemical	45	46	2	D002311	dilated cardiomyopathy|dilated cardiomyopathy	Disease	1:15	3:17	0:1	1:NR:2	L2R	NON-CROSS	31-32	35-36	D000666	amphotericin B|amphotericin B|AmB|AmB|AmB	Chemical	5:28:31:49:63	7:30:32:50:64	0:1:1:2:3	D003047	coccidioidomycosis	Disease	35	36	1	1:NR:2	L2R	NON-CROSS	61-62	63-64	D000666	amphotericin B|amphotericin B|AmB|AmB|AmB	Chemical	5:28:31:49:63	7:30:32:50:64	0:1:1:2:3	D064420	toxicity	Disease	61	62	3	1:NR:2	R2L	NON-CROSS	45-46	41-43	C101425	posaconazole	Chemical	45	46	2	D006333	heart failure|heart failure	Disease	20:41	22:43	1:2	1:NR:2	R2L	CROSS	45-46	35-36	C101425	posaconazole	Chemical	45	46	2	D003047	coccidioidomycosis	Disease	35	36	1	1:NR:2	L2R	CROSS	45-46	61-62	C101425	posaconazole	Chemical	45	46	2	D064420	toxicity	Disease	61	62	3
14765563	Risks of the consumption of beverages containing quinine .|Although the United States Food and Drug Administration banned its use for nocturnal leg cramps due to lack of safety and efficacy , quinine is widely available in beverages including tonic water and bitter lemon .|Numerous anecdotal reports suggest that products containing quinine may produce neurological complications , including confusion , altered mental status , seizures , and coma , particularly in older women .|Psychologists need to inquire about consumption of quinine - containing beverages as part of an evaluation process .	1:CID:2	L2R	NON-CROSS	52-53	59-60	D011803	quinine|quinine|quinine|quinine	Chemical	7:32:52:82	8:33:53:83	0:1:2:3	D003221	confusion	Disease	59	60	2	1:CID:2	L2R	NON-CROSS	52-53	65-66	D011803	quinine|quinine|quinine|quinine	Chemical	7:32:52:82	8:33:53:83	0:1:2:3	D012640	seizures	Disease	65	66	2	1:CID:2	L2R	NON-CROSS	68-69	82-83	D011803	quinine|quinine|quinine|quinine	Chemical	7:32:52:82	8:33:53:83	0:1:2:3	D003128	coma	Disease	68	69	2	1:NR:2	L2R	NON-CROSS	21-24	32-33	D011803	quinine|quinine|quinine|quinine	Chemical	7:32:52:82	8:33:53:83	0:1:2:3	D020922	nocturnal leg cramps	Disease	21	24	1	not_include	L2R	NON-CROSS	52-53	55-57	D011803	quinine|quinine|quinine|quinine	Chemical	7:32:52:82	8:33:53:83	0:1:2:3	D002493	neurological complications	Disease	55	57	2
15036754	Organophosphate - induced convulsions and prevention of neuropathological damages .|Such organophosphorus ( OP ) compounds as diisopropylfluorophosphate ( DFP ) , sarin and soman are potent inhibitors of acetylcholinesterases ( AChEs ) and butyrylcholinesterases ( BChEs ) .|The acute toxicity of OPs is the result of their irreversible binding with AChEs in the central nervous system ( CNS ) , which elevates acetylcholine ( ACh ) levels .|The protective action of subcutaneously ( SC ) administered antidotes or their combinations in DFP ( 2 . 0 mg / kg BW ) intoxication was studied in 9 - 10 - weeks - old Han - Wistar male rats .|The rats received AChE reactivator pralidoxime - 2 - chloride ( 2PAM ) ( 30 . 0 mg / kg BW ) , anticonvulsant diazepam ( 2 . 0 mg / kg BW ) , A ( 1 ) - adenosine receptor agonist N ( 6 ) - cyclopentyl adenosine ( CPA ) ( 2 . 0 mg / kg BW ) , NMDA - receptor antagonist dizocilpine maleate ( + - MK801 hydrogen maleate ) ( 2 . 0 mg / kg BW ) or their combinations with cholinolytic drug atropine sulfate ( 50 . 0 mg / kg BW ) immediately or 30 min after the single SC injection of DFP .|The control rats received atropine sulfate , but also saline and olive oil instead of other antidotes and DFP , respectively .|All rats were terminated either 24 h or 3 weeks after the DFP injection .|The rats treated with DFP - atropine showed severe typical OP - induced toxicity signs .|When CPA , diazepam or 2PAM was given immediately after DFP - atropine , these treatments prevented , delayed or shortened the occurrence of serious signs of poisoning .|Atropine - MK801 did not offer any additional protection against DFP toxicity .|In conclusion , CPA , diazepam and 2PAM in combination with atropine prevented the occurrence of serious signs of poisoning and thus reduced the toxicity of DFP in rat .	1:CID:2	R2L	CROSS	17-18	3-4	D007531	diisopropylfluorophosphate|DFP|DFP|DFP|DFP|DFP|DFP|DFP|DFP|DFP	Chemical	17:19:84:223:243:259:266:288:317:346	18:20:85:224:244:260:267:289:318:347	1:1:3:4:5:6:7:8:9:10	D012640	convulsions	Disease	3	4	0	1:NR:2	L2R	NON-CROSS	0-1	3-4	D010755	Organophosphate|organophosphorus|OP|OPs|OP	Chemical	0:11:13:43:272	1:12:14:44:273	0:1:1:2:7	D012640	convulsions	Disease	3	4	0	1:NR:2	L2R	NON-CROSS	7-9	11-12	D010755	Organophosphate|organophosphorus|OP|OPs|OP	Chemical	0:11:13:43:272	1:12:14:44:273	0:1:1:2:7	D004194	neuropathological damages	Disease	7	9	0	1:NR:2	L2R	NON-CROSS	41-42	43-44	D010755	Organophosphate|organophosphorus|OP|OPs|OP	Chemical	0:11:13:43:272	1:12:14:44:273	0:1:1:2:7	D064420	toxicity|toxicity|toxicity|toxicity	Disease	41:275:318:344	42:276:319:345	2:7:9:10	1:NR:2	L2R	CROSS	272-273	305-306	D010755	Organophosphate|organophosphorus|OP|OPs|OP	Chemical	0:11:13:43:272	1:12:14:44:273	0:1:1:2:7	D011041	poisoning|poisoning	Disease	305:339	306:340	8:10	1:NR:2	R2L	CROSS	22-23	3-4	D012524	sarin	Chemical	22	23	1	D012640	convulsions	Disease	3	4	0	1:NR:2	R2L	CROSS	24-25	3-4	D012999	soman	Chemical	24	25	1	D012640	convulsions	Disease	3	4	0	1:NR:2	R2L	CROSS	64-65	3-4	D000109	acetylcholine|ACh	Chemical	64:66	65:67	2:2	D012640	convulsions	Disease	3	4	0	1:NR:2	R2L	CROSS	116-121	3-4	D011220	pralidoxime - 2 - chloride|2PAM|2PAM|2PAM	Chemical	116:122:283:327	121:123:284:328	4:4:8:10	D012640	convulsions	Disease	3	4	0	1:NR:2	R2L	CROSS	135-136	3-4	D003975	diazepam|diazepam|diazepam	Chemical	135:281:325	136:282:326	4:8:10	D012640	convulsions	Disease	3	4	0	1:NR:2	R2L	CROSS	151-152	3-4	D000241	adenosine	Chemical	151	152	4	D012640	convulsions	Disease	3	4	0	1:NR:2	R2L	CROSS	154-161	3-4	C048599	N ( 6 ) - cyclopentyl adenosine|CPA|CPA|CPA	Chemical	154:162:279:323	161:163:280:324	4:4:8:10	D012640	convulsions	Disease	3	4	0	1:NR:2	R2L	CROSS	174-175	3-4	D016202	NMDA	Chemical	174	175	4	D012640	convulsions	Disease	3	4	0	1:NR:2	R2L	CROSS	178-180	3-4	D016291	dizocilpine maleate|MK801	Chemical	178:309	180:310	4:9	D012640	convulsions	Disease	3	4	0	1:NR:2	R2L	CROSS	202-204	3-4	D001285	atropine sulfate|atropine sulfate|atropine|atropine|Atropine|atropine	Chemical	202:229:268:290:307:331	204:231:269:291:308:332	4:5:7:8:9:10	D012640	convulsions	Disease	3	4	0	1:NR:2	R2L	CROSS	17-18	7-9	D007531	diisopropylfluorophosphate|DFP|DFP|DFP|DFP|DFP|DFP|DFP|DFP|DFP	Chemical	17:19:84:223:243:259:266:288:317:346	18:20:85:224:244:260:267:289:318:347	1:1:3:4:5:6:7:8:9:10	D004194	neuropathological damages	Disease	7	9	0	1:NR:2	R2L	CROSS	22-23	7-9	D012524	sarin	Chemical	22	23	1	D004194	neuropathological damages	Disease	7	9	0	1:NR:2	R2L	CROSS	24-25	7-9	D012999	soman	Chemical	24	25	1	D004194	neuropathological damages	Disease	7	9	0	1:NR:2	R2L	CROSS	64-65	7-9	D000109	acetylcholine|ACh	Chemical	64:66	65:67	2:2	D004194	neuropathological damages	Disease	7	9	0	1:NR:2	R2L	CROSS	116-121	7-9	D011220	pralidoxime - 2 - chloride|2PAM|2PAM|2PAM	Chemical	116:122:283:327	121:123:284:328	4:4:8:10	D004194	neuropathological damages	Disease	7	9	0	1:NR:2	R2L	CROSS	135-136	7-9	D003975	diazepam|diazepam|diazepam	Chemical	135:281:325	136:282:326	4:8:10	D004194	neuropathological damages	Disease	7	9	0	1:NR:2	R2L	CROSS	151-152	7-9	D000241	adenosine	Chemical	151	152	4	D004194	neuropathological damages	Disease	7	9	0	1:NR:2	R2L	CROSS	154-161	7-9	C048599	N ( 6 ) - cyclopentyl adenosine|CPA|CPA|CPA	Chemical	154:162:279:323	161:163:280:324	4:4:8:10	D004194	neuropathological damages	Disease	7	9	0	1:NR:2	R2L	CROSS	174-175	7-9	D016202	NMDA	Chemical	174	175	4	D004194	neuropathological damages	Disease	7	9	0	1:NR:2	R2L	CROSS	178-180	7-9	D016291	dizocilpine maleate|MK801	Chemical	178:309	180:310	4:9	D004194	neuropathological damages	Disease	7	9	0	1:NR:2	R2L	CROSS	202-204	7-9	D001285	atropine sulfate|atropine sulfate|atropine|atropine|Atropine|atropine	Chemical	202:229:268:290:307:331	204:231:269:291:308:332	4:5:7:8:9:10	D004194	neuropathological damages	Disease	7	9	0	1:NR:2	L2R	NON-CROSS	317-318	318-319	D007531	diisopropylfluorophosphate|DFP|DFP|DFP|DFP|DFP|DFP|DFP|DFP|DFP	Chemical	17:19:84:223:243:259:266:288:317:346	18:20:85:224:244:260:267:289:318:347	1:1:3:4:5:6:7:8:9:10	D064420	toxicity|toxicity|toxicity|toxicity	Disease	41:275:318:344	42:276:319:345	2:7:9:10	1:NR:2	L2R	NON-CROSS	339-340	346-347	D007531	diisopropylfluorophosphate|DFP|DFP|DFP|DFP|DFP|DFP|DFP|DFP|DFP	Chemical	17:19:84:223:243:259:266:288:317:346	18:20:85:224:244:260:267:289:318:347	1:1:3:4:5:6:7:8:9:10	D011041	poisoning|poisoning	Disease	305:339	306:340	8:10	1:NR:2	L2R	CROSS	22-23	41-42	D012524	sarin	Chemical	22	23	1	D064420	toxicity|toxicity|toxicity|toxicity	Disease	41:275:318:344	42:276:319:345	2:7:9:10	1:NR:2	L2R	CROSS	22-23	305-306	D012524	sarin	Chemical	22	23	1	D011041	poisoning|poisoning	Disease	305:339	306:340	8:10	1:NR:2	L2R	CROSS	24-25	41-42	D012999	soman	Chemical	24	25	1	D064420	toxicity|toxicity|toxicity|toxicity	Disease	41:275:318:344	42:276:319:345	2:7:9:10	1:NR:2	L2R	CROSS	24-25	305-306	D012999	soman	Chemical	24	25	1	D011041	poisoning|poisoning	Disease	305:339	306:340	8:10	1:NR:2	R2L	NON-CROSS	64-65	41-42	D000109	acetylcholine|ACh	Chemical	64:66	65:67	2:2	D064420	toxicity|toxicity|toxicity|toxicity	Disease	41:275:318:344	42:276:319:345	2:7:9:10	1:NR:2	R2L	NON-CROSS	283-284	275-276	D011220	pralidoxime - 2 - chloride|2PAM|2PAM|2PAM	Chemical	116:122:283:327	121:123:284:328	4:4:8:10	D064420	toxicity|toxicity|toxicity|toxicity	Disease	41:275:318:344	42:276:319:345	2:7:9:10	1:NR:2	R2L	NON-CROSS	281-282	275-276	D003975	diazepam|diazepam|diazepam	Chemical	135:281:325	136:282:326	4:8:10	D064420	toxicity|toxicity|toxicity|toxicity	Disease	41:275:318:344	42:276:319:345	2:7:9:10	1:NR:2	R2L	CROSS	151-152	41-42	D000241	adenosine	Chemical	151	152	4	D064420	toxicity|toxicity|toxicity|toxicity	Disease	41:275:318:344	42:276:319:345	2:7:9:10	1:NR:2	R2L	NON-CROSS	279-280	275-276	C048599	N ( 6 ) - cyclopentyl adenosine|CPA|CPA|CPA	Chemical	154:162:279:323	161:163:280:324	4:4:8:10	D064420	toxicity|toxicity|toxicity|toxicity	Disease	41:275:318:344	42:276:319:345	2:7:9:10	1:NR:2	R2L	CROSS	275-276	174-175	D016202	NMDA	Chemical	174	175	4	D064420	toxicity|toxicity|toxicity|toxicity	Disease	41:275:318:344	42:276:319:345	2:7:9:10	1:NR:2	R2L	NON-CROSS	318-319	309-310	D016291	dizocilpine maleate|MK801	Chemical	178:309	180:310	4:9	D064420	toxicity|toxicity|toxicity|toxicity	Disease	41:275:318:344	42:276:319:345	2:7:9:10	1:NR:2	R2L	NON-CROSS	275-276	268-269	D001285	atropine sulfate|atropine sulfate|atropine|atropine|Atropine|atropine	Chemical	202:229:268:290:307:331	204:231:269:291:308:332	4:5:7:8:9:10	D064420	toxicity|toxicity|toxicity|toxicity	Disease	41:275:318:344	42:276:319:345	2:7:9:10	1:NR:2	L2R	CROSS	66-67	305-306	D000109	acetylcholine|ACh	Chemical	64:66	65:67	2:2	D011041	poisoning|poisoning	Disease	305:339	306:340	8:10	1:NR:2	L2R	NON-CROSS	327-328	339-340	D011220	pralidoxime - 2 - chloride|2PAM|2PAM|2PAM	Chemical	116:122:283:327	121:123:284:328	4:4:8:10	D011041	poisoning|poisoning	Disease	305:339	306:340	8:10	1:NR:2	L2R	NON-CROSS	325-326	339-340	D003975	diazepam|diazepam|diazepam	Chemical	135:281:325	136:282:326	4:8:10	D011041	poisoning|poisoning	Disease	305:339	306:340	8:10	1:NR:2	L2R	CROSS	151-152	305-306	D000241	adenosine	Chemical	151	152	4	D011041	poisoning|poisoning	Disease	305:339	306:340	8:10	1:NR:2	L2R	NON-CROSS	323-324	339-340	C048599	N ( 6 ) - cyclopentyl adenosine|CPA|CPA|CPA	Chemical	154:162:279:323	161:163:280:324	4:4:8:10	D011041	poisoning|poisoning	Disease	305:339	306:340	8:10	1:NR:2	L2R	CROSS	174-175	305-306	D016202	NMDA	Chemical	174	175	4	D011041	poisoning|poisoning	Disease	305:339	306:340	8:10	1:NR:2	L2R	CROSS	305-306	309-310	D016291	dizocilpine maleate|MK801	Chemical	178:309	180:310	4:9	D011041	poisoning|poisoning	Disease	305:339	306:340	8:10	1:NR:2	L2R	NON-CROSS	305-306	307-308	D001285	atropine sulfate|atropine sulfate|atropine|atropine|Atropine|atropine	Chemical	202:229:268:290:307:331	204:231:269:291:308:332	4:5:7:8:9:10	D011041	poisoning|poisoning	Disease	305:339	306:340	8:10
15145918	Differential modulation by estrogen of alpha2 - adrenergic and I1 - imidazoline receptor - mediated hypotension in female rats .|We have recently shown that estrogen negatively modulates the hypotensive effect of clonidine ( mixed alpha2 - / I1 - receptor agonist ) in female rats and implicates the cardiovascular autonomic control in this interaction .|The present study investigated whether this effect of estrogen involves interaction with alpha2 - and / or I1 - receptors .|Changes evoked by a single intraperitoneal injection of rilmenidine ( 600 microg / kg ) or alpha - methyldopa ( 100 mg / kg ) , selective I1 - and alpha2 - receptor agonists , respectively , in blood pressure , hemodynamic variability , and locomotor activity were assessed in radiotelemetered sham - operated and ovariectomized ( Ovx ) Sprague - Dawley female rats with or without 12 - wk estrogen replacement .|Three time domain indexes of hemodynamic variability were employed : the standard deviation of mean arterial pressure as a measure of blood pressure variability and the standard deviation of beat - to - beat intervals ( SDRR ) and the root mean square of successive differences in R - wave - to - R - wave intervals as measures of heart rate variability .|In sham - operated rats , rilmenidine or alpha - methyldopa elicited similar hypotension that lasted at least 5 h and was associated with reductions in standard deviation of mean arterial pressure .|SDRR was reduced only by alpha - methyldopa .|Ovx significantly enhanced the hypotensive response to alpha - methyldopa , in contrast to no effect on rilmenidine hypotension .|The enhanced alpha - methyldopa hypotension in Ovx rats was paralleled with further reduction in SDRR and a reduced locomotor activity .|Estrogen replacement ( 17beta - estradiol subcutaneous pellet , 14 . 2 microg / day , 12 wk ) of Ovx rats restored the hemodynamic and locomotor effects of alpha - methyldopa to sham - operated levels .|These findings suggest that estrogen downregulates alpha2 - but not I1 - receptor - mediated hypotension and highlight a role for the cardiac autonomic control in alpha - methyldopa - estrogen interaction .	1:CID:2	R2L	NON-CROSS	274-275	273-274	C032302	rilmenidine|rilmenidine|rilmenidine	Chemical	85:220:273	86:221:274	3:5:7	D007022	hypotension|hypotensive|hypotension|hypotensive|hypotension|hypotension|hypotension	Disease	15:29:227:260:274:281:351	16:30:228:261:275:282:352	0:1:5:7:7:8:10	1:CID:2	R2L	NON-CROSS	281-282	278-281	D008750	alpha - methyldopa|alpha - methyldopa|alpha - methyldopa|alpha - methyldopa|alpha - methyldopa|alpha - methyldopa|alpha - methyldopa	Chemical	93:222:252:263:278:327:362	96:225:255:266:281:330:365	3:5:6:7:8:9:10	D007022	hypotension|hypotensive|hypotension|hypotensive|hypotension|hypotension|hypotension	Disease	15:29:227:260:274:281:351	16:30:228:261:275:282:352	0:1:5:7:7:8:10	1:NR:2	L2R	NON-CROSS	25-26	29-30	D004967	estrogen|estrogen|estrogen|estrogen|estrogen|estrogen	Chemical	3:25:64:147:340:366	4:26:65:148:341:367	0:1:2:3:10:10	D007022	hypotension|hypotensive|hypotension|hypotensive|hypotension|hypotension|hypotension	Disease	15:29:227:260:274:281:351	16:30:228:261:275:282:352	0:1:5:7:7:8:10	1:NR:2	L2R	CROSS	293-297	340-341	D004967	estrogen|estrogen|estrogen|estrogen|estrogen|estrogen	Chemical	3:25:64:147:340:366	4:26:65:148:341:367	0:1:2:3:10:10	D001523	a reduced locomotor activity	Disease	293	297	8	1:NR:2	L2R	NON-CROSS	11-12	15-16	D048288	imidazoline	Chemical	11	12	0	D007022	hypotension|hypotensive|hypotension|hypotensive|hypotension|hypotension|hypotension	Disease	15:29:227:260:274:281:351	16:30:228:261:275:282:352	0:1:5:7:7:8:10	1:NR:2	L2R	CROSS	11-12	293-297	D048288	imidazoline	Chemical	11	12	0	D001523	a reduced locomotor activity	Disease	293	297	8	1:NR:2	R2L	NON-CROSS	32-33	29-30	D003000	clonidine	Chemical	32	33	1	D007022	hypotension|hypotensive|hypotension|hypotensive|hypotension|hypotension|hypotension	Disease	15:29:227:260:274:281:351	16:30:228:261:275:282:352	0:1:5:7:7:8:10	1:NR:2	R2L	CROSS	301-304	281-282	D004958	17beta - estradiol	Chemical	301	304	9	D007022	hypotension|hypotensive|hypotension|hypotensive|hypotension|hypotension|hypotension	Disease	15:29:227:260:274:281:351	16:30:228:261:275:282:352	0:1:5:7:7:8:10	1:NR:2	L2R	CROSS	32-33	293-297	D003000	clonidine	Chemical	32	33	1	D001523	a reduced locomotor activity	Disease	293	297	8	1:NR:2	L2R	CROSS	273-274	293-297	C032302	rilmenidine|rilmenidine|rilmenidine	Chemical	85:220:273	86:221:274	3:5:7	D001523	a reduced locomotor activity	Disease	293	297	8	1:NR:2	L2R	NON-CROSS	278-281	293-297	D008750	alpha - methyldopa|alpha - methyldopa|alpha - methyldopa|alpha - methyldopa|alpha - methyldopa|alpha - methyldopa|alpha - methyldopa	Chemical	93:222:252:263:278:327:362	96:225:255:266:281:330:365	3:5:6:7:8:9:10	D001523	a reduced locomotor activity	Disease	293	297	8	1:NR:2	R2L	CROSS	301-304	293-297	D004958	17beta - estradiol	Chemical	301	304	9	D001523	a reduced locomotor activity	Disease	293	297	8
15233872	Cardioprotective effect of tincture of Crataegus on isoproterenol - induced myocardial infarction in rats .|Tincture of Crataegus ( TCR ) , an alcoholic extract of the berries of hawthorn ( Crataegus oxycantha ) , is used in herbal and homeopathic medicine .|The present study was done to investigate the protective effect of TCR on experimentally induced myocardial infarction in rats .|Pretreatment of TCR , at a dose of 0 . 5 mL / 100 g bodyweight per day , orally for 30 days , prevented the increase in lipid peroxidation and activity of marker enzymes observed in isoproterenol - induced rats ( 85 mg kg ( - 1 ) s .|c .|for 2 days at an interval of 24 h ) .|TCR prevented the isoproterenol - induced decrease in antioxidant enzymes in the heart and increased the rate of ADP - stimulated oxygen uptake and respiratory coupling ratio .|TCR protected against pathological changes induced by isoproterenol in rat heart .|The results show that pretreatment with TCR may be useful in preventing the damage induced by isoproterenol in rat heart .	1:CID:2	L2R	NON-CROSS	7-8	10-12	D007545	isoproterenol|isoproterenol|isoproterenol|isoproterenol|isoproterenol	Chemical	7:100:130:162:183	8:101:131:163:184	0:3:6:7:8	D009203	myocardial infarction|myocardial infarction	Disease	10:58	12:60	0:2	1:NR:2	L2R	NON-CROSS	54-55	58-60	C007145	tincture of Crataegus|Tincture of Crataegus|TCR|alcoholic extract of the berries of hawthorn|Crataegus oxycantha|TCR|TCR|TCR|TCR|TCR	Chemical	3:15:19:23:31:54:65:127:155:173	6:18:20:30:33:55:66:128:156:174	0:1:1:1:1:2:3:6:7:8	D009203	myocardial infarction|myocardial infarction	Disease	10:58	12:60	0:2	1:NR:2	R2L	CROSS	145-146	58-60	D000244	ADP	Chemical	145	146	6	D009203	myocardial infarction|myocardial infarction	Disease	10:58	12:60	0:2	1:NR:2	R2L	CROSS	148-149	58-60	D010100	oxygen	Chemical	148	149	6	D009203	myocardial infarction|myocardial infarction	Disease	10:58	12:60	0:2
15458908	Safety and adverse effects associated with raloxifene : multiple outcomes of raloxifene evaluation .|OBJECTIVE : To examine the effect of raloxifene on major adverse events that occur with postmenopausal estrogen therapy or tamoxifen .|METHODS : The Multiple Outcomes of Raloxifene Evaluation , a multicenter , randomized , double - blind trial , enrolled 7 , 705 postmenopausal women with osteoporosis .|Women were randomly assigned to raloxifene 60 mg / d or 120 mg / d or placebo .|Outcomes included venous thromboembolism , cataracts , gallbladder disease , and endometrial hyperplasia or cancer .|RESULTS : During a mean follow - up of 3 . 3 years , raloxifene was associated with an increased risk for venous thromboembolism ( relative risk [ RR ] 2 . 1 ; 95 % confidence interval [ CI ] 1 . 2 - 3 . 8 ) .|The excess event rate was 1 . 8 per 1 , 000 woman - years ( 95 % CI - 0 . 5 - 4 . 1 ) , and the number needed to treat to cause 1 event was 170 ( 95 % CI 100 - 582 ) over 3 . 3 years .|Risk in the raloxifene group was higher than in the placebo group for the first 2 years , but decreased to about the same rate as in the placebo group thereafter .|Raloxifene did not increase risk for cataracts ( RR 0 . 9 ; 95 % CI 0 . 8 - 1 . 1 ) , gallbladder disease ( RR 1 . 0 ; 95 % CI 0 . 7 - 1 . 3 ) , endometrial hyperplasia ( RR 1 . 3 ; 95 % CI 0 . 4 - 5 . 1 ) , or endometrial cancer ( RR 0 . 9 ; 95 % CI 0 . 3 - 2 . 7 ) .|CONCLUSION : Raloxifene was associated with an increased risk for venous thromboembolism , but there was no increased risk for cataracts , gallbladder disease , endometrial hyperplasia , or endometrial cancer .|LEVEL OF EVIDENCE : I	1:CID:2	L2R	NON-CROSS	111-112	119-121	D020849	raloxifene|raloxifene|raloxifene|Raloxifene|raloxifene|raloxifene|raloxifene|Raloxifene|Raloxifene	Chemical	6:11:21:41:68:111:205:234:322	7:12:22:42:69:112:206:235:323	0:0:1:2:3:5:7:8:9	D054556	venous thromboembolism|venous thromboembolism|venous thromboembolism	Disease	83:119:330	85:121:332	4:5:9	1:NR:2	L2R	NON-CROSS	61-62	68-69	D020849	raloxifene|raloxifene|raloxifene|Raloxifene|raloxifene|raloxifene|raloxifene|Raloxifene|Raloxifene	Chemical	6:11:21:41:68:111:205:234:322	7:12:22:42:69:112:206:235:323	0:0:1:2:3:5:7:8:9	D010024	osteoporosis	Disease	61	62	2	1:NR:2	L2R	NON-CROSS	234-235	240-241	D020849	raloxifene|raloxifene|raloxifene|Raloxifene|raloxifene|raloxifene|raloxifene|Raloxifene|Raloxifene	Chemical	6:11:21:41:68:111:205:234:322	7:12:22:42:69:112:206:235:323	0:0:1:2:3:5:7:8:9	D002386	cataracts|cataracts|cataracts	Disease	86:240:340	87:241:341	4:8:9	1:NR:2	L2R	NON-CROSS	68-69	88-90	D020849	raloxifene|raloxifene|raloxifene|Raloxifene|raloxifene|raloxifene|raloxifene|Raloxifene|Raloxifene	Chemical	6:11:21:41:68:111:205:234:322	7:12:22:42:69:112:206:235:323	0:0:1:2:3:5:7:8:9	D005705	gallbladder disease|gallbladder disease|gallbladder disease	Disease	88:259:342	90:261:344	4:8:9	1:NR:2	L2R	NON-CROSS	92-96	111-112	D020849	raloxifene|raloxifene|raloxifene|Raloxifene|raloxifene|raloxifene|raloxifene|Raloxifene|Raloxifene	Chemical	6:11:21:41:68:111:205:234:322	7:12:22:42:69:112:206:235:323	0:0:1:2:3:5:7:8:9	D004714	endometrial hyperplasia or cancer|endometrial hyperplasia|endometrial hyperplasia	Disease	92:279:345	96:281:347	4:8:9	1:NR:2	L2R	NON-CROSS	92-96	111-112	D020849	raloxifene|raloxifene|raloxifene|Raloxifene|raloxifene|raloxifene|raloxifene|Raloxifene|Raloxifene	Chemical	6:11:21:41:68:111:205:234:322	7:12:22:42:69:112:206:235:323	0:0:1:2:3:5:7:8:9	D016889	endometrial hyperplasia or cancer|endometrial cancer|endometrial cancer	Disease	92:300:349	96:302:351	4:8:9	1:NR:2	L2R	CROSS	30-31	61-62	D004967	estrogen	Chemical	30	31	1	D010024	osteoporosis	Disease	61	62	2	1:NR:2	L2R	CROSS	30-31	83-85	D004967	estrogen	Chemical	30	31	1	D054556	venous thromboembolism|venous thromboembolism|venous thromboembolism	Disease	83:119:330	85:121:332	4:5:9	1:NR:2	L2R	CROSS	30-31	86-87	D004967	estrogen	Chemical	30	31	1	D002386	cataracts|cataracts|cataracts	Disease	86:240:340	87:241:341	4:8:9	1:NR:2	L2R	CROSS	30-31	88-90	D004967	estrogen	Chemical	30	31	1	D005705	gallbladder disease|gallbladder disease|gallbladder disease	Disease	88:259:342	90:261:344	4:8:9	1:NR:2	L2R	CROSS	30-31	92-96	D004967	estrogen	Chemical	30	31	1	D004714	endometrial hyperplasia or cancer|endometrial hyperplasia|endometrial hyperplasia	Disease	92:279:345	96:281:347	4:8:9	1:NR:2	L2R	CROSS	30-31	92-96	D004967	estrogen	Chemical	30	31	1	D016889	endometrial hyperplasia or cancer|endometrial cancer|endometrial cancer	Disease	92:300:349	96:302:351	4:8:9	1:NR:2	L2R	CROSS	33-34	61-62	D013629	tamoxifen	Chemical	33	34	1	D010024	osteoporosis	Disease	61	62	2	1:NR:2	L2R	CROSS	33-34	83-85	D013629	tamoxifen	Chemical	33	34	1	D054556	venous thromboembolism|venous thromboembolism|venous thromboembolism	Disease	83:119:330	85:121:332	4:5:9	1:NR:2	L2R	CROSS	33-34	86-87	D013629	tamoxifen	Chemical	33	34	1	D002386	cataracts|cataracts|cataracts	Disease	86:240:340	87:241:341	4:8:9	1:NR:2	L2R	CROSS	33-34	88-90	D013629	tamoxifen	Chemical	33	34	1	D005705	gallbladder disease|gallbladder disease|gallbladder disease	Disease	88:259:342	90:261:344	4:8:9	1:NR:2	L2R	CROSS	33-34	92-96	D013629	tamoxifen	Chemical	33	34	1	D004714	endometrial hyperplasia or cancer|endometrial hyperplasia|endometrial hyperplasia	Disease	92:279:345	96:281:347	4:8:9	1:NR:2	L2R	CROSS	33-34	92-96	D013629	tamoxifen	Chemical	33	34	1	D016889	endometrial hyperplasia or cancer|endometrial cancer|endometrial cancer	Disease	92:300:349	96:302:351	4:8:9
15737522	Ceftriaxone - associated biliary pseudolithiasis in paediatric surgical patients .|It is well known that ceftriaxone leads to pseudolithiasis in some patients .|Clinical and experimental studies also suggest that situations causing gallbladder dysfunction , such as fasting , may have a role for the development of pseudolithiasis .|In this study , we prospectively evaluated the incidence and clinical importance of pseudolithiasis in paediatric surgical patients receiving ceftriaxone treatment , who often had to fast in the post - operative period .|Fifty children who were given ceftriaxone were evaluated by serial abdominal sonograms .|Of those , 13 ( 26 % ) developed biliary pathology .|Comparison of the patients with or without pseudolithiasis revealed no significant difference with respect to age , sex , duration of the treatment and starvation variables .|After cessation of the treatment , pseudolithiasis resolved spontaneously within a short period .|The incidence of pseudolithiasis is not affected by fasting .	1:CID:2	L2R	NON-CROSS	0-1	3-5	D002443	Ceftriaxone|ceftriaxone|ceftriaxone|ceftriaxone	Chemical	0:15:68:88	1:16:69:89	0:1:3:4	D001660	biliary pseudolithiasis|pseudolithiasis|pseudolithiasis|pseudolithiasis|pseudolithiasis|pseudolithiasis|pseudolithiasis	Disease	3:18:47:62:115:141:152	5:19:48:63:116:142:153	0:1:2:3:6:7:8	1:NR:2	L2R	CROSS	15-16	32-34	D002443	Ceftriaxone|ceftriaxone|ceftriaxone|ceftriaxone	Chemical	0:15:68:88	1:16:69:89	0:1:3:4	D005705	gallbladder dysfunction	Disease	32	34	2
16005948	Evaluation of the anticocaine monoclonal antibody GNC92H2 as an immunotherapy for cocaine overdose .|The illicit use of cocaine continues in epidemic proportions and treatment for cocaine overdose remains elusive .|Current protein - based technology offers a new therapeutic venue by which antibodies bind the drug in the blood stream , inactivating its toxic effects .|The therapeutic potential of the anticocaine antibody GNC92H2 was examined using a model of cocaine overdose .|Swiss albino mice prepared with intrajugular catheters were tested in photocell cages after administration of 93 mg / kg ( LD50 ) of cocaine and GNC92H2 infusions ranging from 30 to 190 mg / kg .|GNC92H2 was delivered 30 min before , concomitantly or 3 min after cocaine treatment .|Significant blockade of cocaine toxicity was observed with the higher dose of GNC92H2 ( 190 mg / kg ) , where premorbid behaviors were reduced up to 40 % , seizures up to 77 % and death by 72 % .|Importantly , GNC92H2 prevented death even post - cocaine injection .|The results support the important potential of GNC92H2 as a therapeutic tool against cocaine overdose .	1:CID:2	L2R	NON-CROSS	155-156	174-175	D003042	cocaine|cocaine|cocaine|cocaine|cocaine	Chemical	18:97:122:128:174	19:98:123:129:175	1:4:5:6:7	D012640	seizures	Disease	155	156	6	1:NR:2	R2L	NON-CROSS	18-19	11-13	D003042	cocaine|cocaine|cocaine|cocaine|cocaine	Chemical	18:97:122:128:174	19:98:123:129:175	1:4:5:6:7	D062787	cocaine overdose|cocaine overdose|cocaine overdose|cocaine overdose	Disease	11:26:71:190	13:28:73:192	0:1:3:8	1:NR:2	L2R	NON-CROSS	128-129	129-130	D003042	cocaine|cocaine|cocaine|cocaine|cocaine	Chemical	18:97:122:128:174	19:98:123:129:175	1:4:5:6:7	D064420	toxicity	Disease	129	130	6	1:NR:2	L2R	NON-CROSS	170-171	174-175	D003042	cocaine|cocaine|cocaine|cocaine|cocaine	Chemical	18:97:122:128:174	19:98:123:129:175	1:4:5:6:7	D003643	death|death	Disease	161:170	162:171	6:7
16167916	The effects of short - term raloxifene therapy on fibrinolysis markers : TAFI , tPA , and PAI - 1 .|BACKGROUND : Markers of fibrinolysis , thrombin - activatable fibrinolysis inhibitor ( TAFI ) , tissue - type plasminogen activator ( tPA ) , and plasminogen activator inhibitor - 1 ( PAI - 1 ) levels were studied for the evaluation of short - term effects of raloxifene administration in postmenopausal women .|METHODS : Thirty - nine postmenopausal women with osteopenia or osteoporosis were included in this prospective , controlled clinical study .|Twenty - five women were given raloxifene hydrochloride ( 60 mg / day ) plus calcium ( 500 mg / day ) .|Age - matched controls ( n = 14 ) were given only calcium .|Plasma TAFI , tPA , and PAI - 1 antigen levels were measured at baseline and after 3 months of treatment by commercially available ELISA kits .|Variations of individuals were assessed by Wilcoxon 's test .|Relationship between those markers and demographic characteristics were investigated .|RESULTS : Three months of raloxifene treatment was associated with a significant decrease in the plasma TAFI antigen concentrations ( 16 % change , P < 0 . 01 ) , and a significant increase in tPA antigen concentrations ( 25 % change , P < 0 . 05 ) .|A significant correlation was found between baseline TAFI antigen concentrations and the duration of amenorrhea ( P < 0 . 05 ; r = 0 . 33 ) .|CONCLUSION : We suggest that the increased risk of venous thromboembolism due to raloxifene treatment may be related to increased tPA levels , but not TAFI levels .	1:CID:2	L2R	NON-CROSS	268-270	272-273	D020849	raloxifene|raloxifene|raloxifene hydrochloride|raloxifene|raloxifene	Chemical	6:68:101:184:272	7:69:103:185:273	0:1:3:8:10	D054556	venous thromboembolism	Disease	268	270	10	1:NR:2	L2R	CROSS	68-69	82-83	D020849	raloxifene|raloxifene|raloxifene hydrochloride|raloxifene|raloxifene	Chemical	6:68:101:184:272	7:69:103:185:273	0:1:3:8:10	D001851	osteopenia	Disease	82	83	2	1:NR:2	L2R	CROSS	68-69	84-85	D020849	raloxifene|raloxifene|raloxifene hydrochloride|raloxifene|raloxifene	Chemical	6:68:101:184:272	7:69:103:185:273	0:1:3:8:10	D010024	osteoporosis	Disease	84	85	2	1:NR:2	L2R	CROSS	244-245	272-273	D020849	raloxifene|raloxifene|raloxifene hydrochloride|raloxifene|raloxifene	Chemical	6:68:101:184:272	7:69:103:185:273	0:1:3:8:10	D000568	amenorrhea	Disease	244	245	9	1:NR:2	R2L	CROSS	110-111	82-83	D002118	calcium|calcium	Chemical	110:130	111:131	3:4	D001851	osteopenia	Disease	82	83	2	1:NR:2	R2L	CROSS	110-111	84-85	D002118	calcium|calcium	Chemical	110:130	111:131	3:4	D010024	osteoporosis	Disease	84	85	2	1:NR:2	L2R	CROSS	130-131	244-245	D002118	calcium|calcium	Chemical	110:130	111:131	3:4	D000568	amenorrhea	Disease	244	245	9	1:NR:2	L2R	CROSS	130-131	268-270	D002118	calcium|calcium	Chemical	110:130	111:131	3:4	D054556	venous thromboembolism	Disease	268	270	10
16403073	Ketoconazole induced torsades de pointes without concomitant use of QT interval - prolonging drug .|Ketoconazole is not known to be proarrhythmic without concomitant use of QT interval - prolonging drugs .|We report a woman with coronary artery disease who developed a markedly prolonged QT interval and torsades de pointes ( TdP ) after taking ketoconazole for treatment of fungal infection .|Her QT interval returned to normal upon withdrawal of ketoconazole .|Genetic study did not find any mutation in her genes that encode cardiac IKr channel proteins .|We postulate that by virtue of its direct blocking action on IKr , ketoconazole alone may prolong QT interval and induce TdP .|This calls for attention when ketoconazole is administered to patients with risk factors for acquired long QT syndrome .	1:CID:2	L2R	NON-CROSS	0-1	2-5	D007654	Ketoconazole|Ketoconazole|ketoconazole|ketoconazole|ketoconazole|ketoconazole	Chemical	0:15:56:72:104:119	1:16:57:73:105:120	0:1:2:3:5:6	D016171	torsades de pointes|torsades de pointes|TdP|TdP	Disease	2:48:52:112	5:51:53:113	0:2:2:5	1:CID:2	L2R	NON-CROSS	119-120	129-132	D007654	Ketoconazole|Ketoconazole|ketoconazole|ketoconazole|ketoconazole|ketoconazole	Chemical	0:15:56:72:104:119	1:16:57:73:105:120	0:1:2:3:5:6	D008133	prolonged QT interval|long QT syndrome	Disease	44:129	47:132	2:6	1:NR:2	L2R	NON-CROSS	37-40	56-57	D007654	Ketoconazole|Ketoconazole|ketoconazole|ketoconazole|ketoconazole|ketoconazole	Chemical	0:15:56:72:104:119	1:16:57:73:105:120	0:1:2:3:5:6	D003324	coronary artery disease	Disease	37	40	2	1:NR:2	L2R	NON-CROSS	56-57	60-62	D007654	Ketoconazole|Ketoconazole|ketoconazole|ketoconazole|ketoconazole|ketoconazole	Chemical	0:15:56:72:104:119	1:16:57:73:105:120	0:1:2:3:5:6	D009181	fungal infection	Disease	60	62	2
16755009	Pharmacological evidence for the potential of Daucus carota in the management of cognitive dysfunctions .|The present study was aimed at investigating the effects of Daucus carota seeds on cognitive functions , total serum cholesterol levels and brain cholinesterase activity in mice .|The ethanolic extract of Daucus carota seeds ( DCE ) was administered orally in three doses ( 100 , 200 , 400 mg / kg ) for seven successive days to different groups of young and aged mice .|Elevated plus maze and passive avoidance apparatus served as the exteroceptive behavioral models for testing memory .|Diazepam - , scopolamine - and ageing - induced amnesia served as the interoceptive behavioral models .|DCE ( 200 , 400 mg / kg , p . o . ) showed significant improvement in memory scores of young and aged mice .|The extent of memory improvement evoked by DCE was 23 % at the dose of 200 mg / kg and 35 % at the dose of 400 mg / kg in young mice using elevated plus maze .|Similarly , significant improvements in memory scores were observed using passive avoidance apparatus and aged mice .|Furthermore , DCE reversed the amnesia induced by scopolamine ( 0 . 4 mg / kg , i . p . ) and diazepam ( 1 mg / kg , i . p . ) .|Daucus carota extract ( 200 , 400 mg / kg , p . o . ) reduced significantly the brain acetylcholinesterase activity and cholesterol levels in young and aged mice .|The extent of inhibition of brain cholinesterase activity evoked by DCE at the dose of 400 mg / kg was 22 % in young and 19 % in aged mice .|There was a remarkable reduction in total cholesterol level as well , to the extent of 23 % in young and 21 % in aged animals with this dose of DCE .|Therefore , DCE may prove to be a useful remedy for the management of cognitive dysfunctions on account of its multifarious beneficial effects such as , memory improving property , cholesterol lowering property and anticholinesterase activity .	1:CID:2	L2R	NON-CROSS	99-100	108-109	D003975	Diazepam|diazepam	Chemical	99:220	100:221	4:8	D000647	amnesia|amnesia	Disease	108:202	109:203	4:8	1:CID:2	L2R	NON-CROSS	202-203	205-206	D012601	scopolamine|scopolamine	Chemical	102:205	103:206	4:8	D000647	amnesia|amnesia	Disease	108:202	109:203	4:8	1:NR:2	R2L	NON-CROSS	357-358	341-343	D002784	cholesterol|cholesterol|cholesterol|cholesterol	Chemical	34:256:302:357	35:257:303:358	1:9:11:12	D003072	cognitive dysfunctions|cognitive dysfunctions	Disease	12:341	14:343	0:12	1:NR:2	R2L	NON-CROSS	341-343	329-330	D010936	extract of Daucus carota seeds|DCE|DCE|DCE|DCE|Daucus carota extract|DCE|DCE|DCE	Chemical	45:51:116:149:199:233:274:325:329	50:52:117:150:200:236:275:326:330	2:2:5:6:8:9:10:11:12	D003072	cognitive dysfunctions|cognitive dysfunctions	Disease	12:341	14:343	0:12	1:NR:2	R2L	CROSS	99-100	12-14	D003975	Diazepam|diazepam	Chemical	99:220	100:221	4:8	D003072	cognitive dysfunctions|cognitive dysfunctions	Disease	12:341	14:343	0:12	1:NR:2	R2L	CROSS	102-103	12-14	D012601	scopolamine|scopolamine	Chemical	102:205	103:206	4:8	D003072	cognitive dysfunctions|cognitive dysfunctions	Disease	12:341	14:343	0:12	1:NR:2	L2R	CROSS	202-203	256-257	D002784	cholesterol|cholesterol|cholesterol|cholesterol	Chemical	34:256:302:357	35:257:303:358	1:9:11:12	D000647	amnesia|amnesia	Disease	108:202	109:203	4:8	1:NR:2	L2R	NON-CROSS	199-200	202-203	D010936	extract of Daucus carota seeds|DCE|DCE|DCE|DCE|Daucus carota extract|DCE|DCE|DCE	Chemical	45:51:116:149:199:233:274:325:329	50:52:117:150:200:236:275:326:330	2:2:5:6:8:9:10:11:12	D000647	amnesia|amnesia	Disease	108:202	109:203	4:8
16904497	Cauda equina syndrome after epidural steroid injection : a case report .|OBJECTIVE : Conventional treatment methods of lumbusacral radiculopathy are physical therapy , epidural steroid injections , oral medications , and spinal manipulative therapy .|Cauda equina syndrome is a rare complication of epidural anesthesia .|The following case is a report of cauda equina syndrome possibly caused by epidural injection of triamcinolone and bupivacaine .|CLINICAL FEATURES : A 50 - year - old woman with low back and right leg pain was scheduled for epidural steroid injection .|INTERVENTION AND OUTCOME : An 18 - gauge Touhy needle was inserted until loss of resistance occurred at the L4 - 5 level .|Spread of the contrast medium within the epidural space was determined by radiographic imaging .|After verifying the epidural space , bupivacaine and triamcinolone diacetate were injected .|After the injection , there was a reduction in radicular symptoms .|Three hours later , she complained of perineal numbness and lower extremity weakness .|The neurologic evaluation revealed loss of sensation in the saddle area and medial aspect of her right leg .|There was a decrease in the perception of pinprick test .|Deep - tendon reflexes were decreased especially in the right leg .|She was unable to urinate .|The patient 's symptoms improved slightly over the next few hours .|She had a gradual return of motor function and ability of feeling Foley catheter .|All of the symptoms were completely resolved over the next 8 hours .|CONCLUSION : Complications associated with epidural steroid injections are rare .|Clinical examination and continued vigilance for neurologic deterioration after epidural steroid injections is important .	1:CID:2	R2L	NON-CROSS	65-66	54-57	D002045	bupivacaine|bupivacaine	Chemical	65:136	66:137	3:7	D011128	Cauda equina syndrome|Cauda equina syndrome|cauda equina syndrome	Disease	0:36:54	3:39:57	0:2:3	1:CID:2	R2L	CROSS	138-140	54-57	C030262	triamcinolone diacetate	Chemical	138	140	7	D011128	Cauda equina syndrome|Cauda equina syndrome|cauda equina syndrome	Disease	0:36:54	3:39:57	0:2:3	1:NR:2	R2L	NON-CROSS	5-6	0-3	D013256	steroid|steroid|steroid|steroid|steroid	Chemical	5:25:88:263:278	6:26:89:264:279	0:1:4:17:18	D011128	Cauda equina syndrome|Cauda equina syndrome|cauda equina syndrome	Disease	0:36:54	3:39:57	0:2:3	1:NR:2	R2L	NON-CROSS	63-64	54-57	D014221	triamcinolone	Chemical	63	64	3	D011128	Cauda equina syndrome|Cauda equina syndrome|cauda equina syndrome	Disease	0:36:54	3:39:57	0:2:3	1:NR:2	L2R	NON-CROSS	19-20	25-26	D013256	steroid|steroid|steroid|steroid|steroid	Chemical	5:25:88:263:278	6:26:89:264:279	0:1:4:17:18	D011843	radiculopathy	Disease	19	20	1	1:NR:2	L2R	NON-CROSS	78-84	88-89	D013256	steroid|steroid|steroid|steroid|steroid	Chemical	5:25:88:263:278	6:26:89:264:279	0:1:4:17:18	D017116	low back and right leg pain	Disease	78	84	4	1:NR:2	L2R	NON-CROSS	78-84	88-89	D013256	steroid|steroid|steroid|steroid|steroid	Chemical	5:25:88:263:278	6:26:89:264:279	0:1:4:17:18	D010146	low back and right leg pain	Disease	78	84	4	1:NR:2	L2R	CROSS	88-89	163-164	D013256	steroid|steroid|steroid|steroid|steroid	Chemical	5:25:88:263:278	6:26:89:264:279	0:1:4:17:18	D006987	numbness|loss of sensation	Disease	163:173	164:176	9:10	1:NR:2	L2R	CROSS	88-89	165-168	D013256	steroid|steroid|steroid|steroid|steroid	Chemical	5:25:88:263:278	6:26:89:264:279	0:1:4:17:18	D020335	lower extremity weakness	Disease	165	168	9	1:NR:2	L2R	NON-CROSS	274-276	278-279	D013256	steroid|steroid|steroid|steroid|steroid	Chemical	5:25:88:263:278	6:26:89:264:279	0:1:4:17:18	D009422	neurologic deterioration	Disease	274	276	18	1:NR:2	R2L	CROSS	63-64	19-20	D014221	triamcinolone	Chemical	63	64	3	D011843	radiculopathy	Disease	19	20	1	1:NR:2	R2L	CROSS	65-66	19-20	D002045	bupivacaine|bupivacaine	Chemical	65:136	66:137	3:7	D011843	radiculopathy	Disease	19	20	1	1:NR:2	R2L	CROSS	138-140	19-20	C030262	triamcinolone diacetate	Chemical	138	140	7	D011843	radiculopathy	Disease	19	20	1	1:NR:2	L2R	CROSS	63-64	78-84	D014221	triamcinolone	Chemical	63	64	3	D017116	low back and right leg pain	Disease	78	84	4	1:NR:2	L2R	CROSS	63-64	78-84	D014221	triamcinolone	Chemical	63	64	3	D010146	low back and right leg pain	Disease	78	84	4	1:NR:2	L2R	CROSS	63-64	163-164	D014221	triamcinolone	Chemical	63	64	3	D006987	numbness|loss of sensation	Disease	163:173	164:176	9:10	1:NR:2	L2R	CROSS	63-64	165-168	D014221	triamcinolone	Chemical	63	64	3	D020335	lower extremity weakness	Disease	165	168	9	1:NR:2	L2R	CROSS	63-64	274-276	D014221	triamcinolone	Chemical	63	64	3	D009422	neurologic deterioration	Disease	274	276	18	1:NR:2	L2R	CROSS	65-66	78-84	D002045	bupivacaine|bupivacaine	Chemical	65:136	66:137	3:7	D017116	low back and right leg pain	Disease	78	84	4	1:NR:2	L2R	CROSS	65-66	78-84	D002045	bupivacaine|bupivacaine	Chemical	65:136	66:137	3:7	D010146	low back and right leg pain	Disease	78	84	4	1:NR:2	L2R	CROSS	136-137	163-164	D002045	bupivacaine|bupivacaine	Chemical	65:136	66:137	3:7	D006987	numbness|loss of sensation	Disease	163:173	164:176	9:10	1:NR:2	L2R	CROSS	136-137	165-168	D002045	bupivacaine|bupivacaine	Chemical	65:136	66:137	3:7	D020335	lower extremity weakness	Disease	165	168	9	not_include	L2R	CROSS	136-137	274-276	D002045	bupivacaine|bupivacaine	Chemical	65:136	66:137	3:7	D009422	neurologic deterioration	Disease	274	276	18	1:NR:2	R2L	CROSS	138-140	78-84	C030262	triamcinolone diacetate	Chemical	138	140	7	D017116	low back and right leg pain	Disease	78	84	4	1:NR:2	R2L	CROSS	138-140	78-84	C030262	triamcinolone diacetate	Chemical	138	140	7	D010146	low back and right leg pain	Disease	78	84	4	1:NR:2	L2R	CROSS	138-140	163-164	C030262	triamcinolone diacetate	Chemical	138	140	7	D006987	numbness|loss of sensation	Disease	163:173	164:176	9:10	1:NR:2	L2R	CROSS	138-140	165-168	C030262	triamcinolone diacetate	Chemical	138	140	7	D020335	lower extremity weakness	Disease	165	168	9	not_include	L2R	CROSS	138-140	274-276	C030262	triamcinolone diacetate	Chemical	138	140	7	D009422	neurologic deterioration	Disease	274	276	18
16938416	High - dose testosterone is associated with atherosclerosis in postmenopausal women .|OBJECTIVES : To study the long - term effects of androgen treatment on atherosclerosis in postmenopausal women .|METHODS : In a population - based study in 513 naturally postmenopausal women aged 54 - 67 years , we studied the association between self - reported intramuscularly administered high - dose estrogen - testosterone therapy ( estradiol - and testosterone esters ) and aortic atherosclerosis .|Aortic atherosclerosis was diagnosed by radiographic detection of calcified deposits in the abdominal aorta , which have been shown to reflect intima atherosclerosis .|Hormone therapy users were compared with never users .|RESULTS : Intramuscular hormone therapy use for 1 year or longer was reported by 25 women .|In almost half of these women severe atherosclerosis of the aorta was present ( n = 11 ) , while in women without hormone use severe atherosclerosis of the aorta was present in less than 20 % ( OR 3 . 1 ; 95 % CI , 1 . 1 - 8 . 5 , adjusted for age , years since menopause , smoking , and body mass index ) .|The association remained after additional adjustment for diabetes , cholesterol level , systolic blood pressure , or alcohol use .|No association was found for hormone use less than 1 year .|CONCLUSION : Our results suggest that high - dose testosterone therapy may adversely affect atherosclerosis in postmenopausal women and indicate that androgen replacement in these women may not be harmless .	1:CID:2	L2R	NON-CROSS	3-4	7-8	D013739	testosterone|testosterone|testosterone	Chemical	3:64:239	4:65:240	0:2:9	D050197	atherosclerosis|atherosclerosis|atherosclerosis|atherosclerosis|atherosclerosis|atherosclerosis|atherosclerosis|atherosclerosis	Disease	7:25:75:78:99:134:153:244	8:26:76:79:100:135:154:245	0:1:2:3:3:6:6:9	1:NR:2	L2R	CROSS	205-206	239-240	D013739	testosterone|testosterone|testosterone	Chemical	3:64:239	4:65:240	0:2:9	D003920	diabetes	Disease	205	206	7	1:NR:2	R2L	NON-CROSS	75-76	62-63	D004967	estrogen	Chemical	62	63	2	D050197	atherosclerosis|atherosclerosis|atherosclerosis|atherosclerosis|atherosclerosis|atherosclerosis|atherosclerosis|atherosclerosis	Disease	7:25:75:78:99:134:153:244	8:26:76:79:100:135:154:245	0:1:2:3:3:6:6:9	1:NR:2	R2L	NON-CROSS	78-79	67-72	C032109	estradiol - and testosterone esters	Chemical	67	72	2	D050197	atherosclerosis|atherosclerosis|atherosclerosis|atherosclerosis|atherosclerosis|atherosclerosis|atherosclerosis|atherosclerosis	Disease	7:25:75:78:99:134:153:244	8:26:76:79:100:135:154:245	0:1:2:3:3:6:6:9	1:NR:2	R2L	CROSS	244-245	207-208	D002784	cholesterol	Chemical	207	208	7	D050197	atherosclerosis|atherosclerosis|atherosclerosis|atherosclerosis|atherosclerosis|atherosclerosis|atherosclerosis|atherosclerosis	Disease	7:25:75:78:99:134:153:244	8:26:76:79:100:135:154:245	0:1:2:3:3:6:6:9	1:NR:2	R2L	CROSS	244-245	215-216	D000431	alcohol	Chemical	215	216	7	D050197	atherosclerosis|atherosclerosis|atherosclerosis|atherosclerosis|atherosclerosis|atherosclerosis|atherosclerosis|atherosclerosis	Disease	7:25:75:78:99:134:153:244	8:26:76:79:100:135:154:245	0:1:2:3:3:6:6:9	1:NR:2	L2R	CROSS	62-63	205-206	D004967	estrogen	Chemical	62	63	2	D003920	diabetes	Disease	205	206	7	1:NR:2	L2R	CROSS	67-72	205-206	C032109	estradiol - and testosterone esters	Chemical	67	72	2	D003920	diabetes	Disease	205	206	7	1:NR:2	R2L	NON-CROSS	207-208	205-206	D002784	cholesterol	Chemical	207	208	7	D003920	diabetes	Disease	205	206	7	1:NR:2	R2L	NON-CROSS	215-216	205-206	D000431	alcohol	Chemical	215	216	7	D003920	diabetes	Disease	205	206	7
17147461	Sirolimus - associated proteinuria and renal dysfunction .|Sirolimus is a novel immunosuppressant with potent antiproliferative actions through its ability to inhibit the raptor - containing mammalian target of rapamycin protein kinase .|Sirolimus represents a major therapeutic advance in the prevention of acute renal allograft rejection and chronic allograft nephropathy .|Its role in the therapy of glomerulonephritis , autoimmunity , cystic renal diseases and renal cancer is under investigation .|Because sirolimus does not share the vasomotor renal adverse effects exhibited by calcineurin inhibitors , it has been designated a ' non - nephrotoxic drug ' .|However , clinical reports suggest that , under some circumstances , sirolimus is associated with proteinuria and acute renal dysfunction .|A common risk factor appears to be presence of pre - existing chronic renal damage .|The mechanisms of sirolimus - associated proteinuria are multifactorial and may be due to an increase in glomerular capillary pressure following calcineurin inhibitor withdrawal .|It has also been suggested that sirolimus directly causes increased glomerular permeability / injury , but evidence for this mechanism is currently inconclusive .|The acute renal dysfunction associated with sirolimus ( such as in delayed graft function ) may be due to suppression of compensatory renal cell proliferation and survival / repair processes .|Although these adverse effects occur in some patients , their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney , the use of sirolimus in appropriate patient populations , close monitoring of proteinuria and renal function , use of angiotensin - converting enzyme inhibitors or angiotensin II receptor blockers if proteinuria occurs and withdrawal if needed .|Further long - term analysis of renal allograft studies using sirolimus as de novo immunosuppression along with clinical and laboratory studies will refine these issues in the future .	1:CID:2	L2R	NON-CROSS	0-1	3-4	D020123	Sirolimus|Sirolimus|rapamycin|Sirolimus|sirolimus|sirolimus|sirolimus|sirolimus|sirolimus|sirolimus|sirolimus|sirolimus	Chemical	0:8:29:33:73:110:139:167:191:237:245:289	1:9:30:34:74:111:140:168:192:238:246:290	0:1:1:2:4:5:7:8:9:10:10:11	D011507	proteinuria|proteinuria|proteinuria|proteinuria|proteinuria	Disease	3:114:142:254:272	4:115:143:255:273	0:5:7:10:10	1:CID:2	L2R	NON-CROSS	5-7	8-9	D020123	Sirolimus|Sirolimus|rapamycin|Sirolimus|sirolimus|sirolimus|sirolimus|sirolimus|sirolimus|sirolimus|sirolimus|sirolimus	Chemical	0:8:29:33:73:110:139:167:191:237:245:289	1:9:30:34:74:111:140:168:192:238:246:290	0:1:1:2:4:5:7:8:9:10:10:11	D007674	renal dysfunction|nephropathy|nephrotoxic	Disease	5:50:95	7:51:96	0:2:4	1:NR:2	L2R	CROSS	58-59	73-74	D020123	Sirolimus|Sirolimus|rapamycin|Sirolimus|sirolimus|sirolimus|sirolimus|sirolimus|sirolimus|sirolimus|sirolimus|sirolimus	Chemical	0:8:29:33:73:110:139:167:191:237:245:289	1:9:30:34:74:111:140:168:192:238:246:290	0:1:1:2:4:5:7:8:9:10:10:11	D005921	glomerulonephritis	Disease	58	59	3	1:NR:2	L2R	CROSS	60-61	73-74	D020123	Sirolimus|Sirolimus|rapamycin|Sirolimus|sirolimus|sirolimus|sirolimus|sirolimus|sirolimus|sirolimus|sirolimus|sirolimus	Chemical	0:8:29:33:73:110:139:167:191:237:245:289	1:9:30:34:74:111:140:168:192:238:246:290	0:1:1:2:4:5:7:8:9:10:10:11	D001327	autoimmunity	Disease	60	61	3	1:NR:2	L2R	CROSS	62-65	73-74	D020123	Sirolimus|Sirolimus|rapamycin|Sirolimus|sirolimus|sirolimus|sirolimus|sirolimus|sirolimus|sirolimus|sirolimus|sirolimus	Chemical	0:8:29:33:73:110:139:167:191:237:245:289	1:9:30:34:74:111:140:168:192:238:246:290	0:1:1:2:4:5:7:8:9:10:10:11	D052177	cystic renal diseases	Disease	62	65	3	1:NR:2	L2R	CROSS	66-68	73-74	D020123	Sirolimus|Sirolimus|rapamycin|Sirolimus|sirolimus|sirolimus|sirolimus|sirolimus|sirolimus|sirolimus|sirolimus|sirolimus	Chemical	0:8:29:33:73:110:139:167:191:237:245:289	1:9:30:34:74:111:140:168:192:238:246:290	0:1:1:2:4:5:7:8:9:10:10:11	D007680	renal cancer	Disease	66	68	3	1:NR:2	L2R	NON-CROSS	186-189	191-192	D020123	Sirolimus|Sirolimus|rapamycin|Sirolimus|sirolimus|sirolimus|sirolimus|sirolimus|sirolimus|sirolimus|sirolimus|sirolimus	Chemical	0:8:29:33:73:110:139:167:191:237:245:289	1:9:30:34:74:111:140:168:192:238:246:290	0:1:1:2:4:5:7:8:9:10:10:11	D058186	acute renal dysfunction|acute renal dysfunction	Disease	116:186	119:189	5:9	1:NR:2	L2R	CROSS	132-135	139-140	D020123	Sirolimus|Sirolimus|rapamycin|Sirolimus|sirolimus|sirolimus|sirolimus|sirolimus|sirolimus|sirolimus|sirolimus|sirolimus	Chemical	0:8:29:33:73:110:139:167:191:237:245:289	1:9:30:34:74:111:140:168:192:238:246:290	0:1:1:2:4:5:7:8:9:10:10:11	D051436	chronic renal damage	Disease	132	135	6	1:NR:2	R2L	NON-CROSS	261-262	254-255	D000809	angiotensin	Chemical	261	262	10	D011507	proteinuria|proteinuria|proteinuria|proteinuria|proteinuria	Disease	3:114:142:254:272	4:115:143:255:273	0:5:7:10:10	1:NR:2	R2L	NON-CROSS	272-273	267-269	D000804	angiotensin II	Chemical	267	269	10	D011507	proteinuria|proteinuria|proteinuria|proteinuria|proteinuria	Disease	3:114:142:254:272	4:115:143:255:273	0:5:7:10:10	1:NR:2	R2L	CROSS	261-262	95-96	D000809	angiotensin	Chemical	261	262	10	D007674	renal dysfunction|nephropathy|nephrotoxic	Disease	5:50:95	7:51:96	0:2:4	1:NR:2	R2L	CROSS	267-269	95-96	D000804	angiotensin II	Chemical	267	269	10	D007674	renal dysfunction|nephropathy|nephrotoxic	Disease	5:50:95	7:51:96	0:2:4	1:NR:2	R2L	CROSS	261-262	58-59	D000809	angiotensin	Chemical	261	262	10	D005921	glomerulonephritis	Disease	58	59	3	1:NR:2	R2L	CROSS	267-269	58-59	D000804	angiotensin II	Chemical	267	269	10	D005921	glomerulonephritis	Disease	58	59	3	1:NR:2	R2L	CROSS	261-262	60-61	D000809	angiotensin	Chemical	261	262	10	D001327	autoimmunity	Disease	60	61	3	1:NR:2	R2L	CROSS	267-269	60-61	D000804	angiotensin II	Chemical	267	269	10	D001327	autoimmunity	Disease	60	61	3	1:NR:2	R2L	CROSS	261-262	62-65	D000809	angiotensin	Chemical	261	262	10	D052177	cystic renal diseases	Disease	62	65	3	1:NR:2	R2L	CROSS	267-269	62-65	D000804	angiotensin II	Chemical	267	269	10	D052177	cystic renal diseases	Disease	62	65	3	1:NR:2	R2L	CROSS	261-262	66-68	D000809	angiotensin	Chemical	261	262	10	D007680	renal cancer	Disease	66	68	3	1:NR:2	R2L	CROSS	267-269	66-68	D000804	angiotensin II	Chemical	267	269	10	D007680	renal cancer	Disease	66	68	3	1:NR:2	R2L	CROSS	261-262	186-189	D000809	angiotensin	Chemical	261	262	10	D058186	acute renal dysfunction|acute renal dysfunction	Disease	116:186	119:189	5:9	1:NR:2	R2L	CROSS	267-269	186-189	D000804	angiotensin II	Chemical	267	269	10	D058186	acute renal dysfunction|acute renal dysfunction	Disease	116:186	119:189	5:9	1:NR:2	R2L	CROSS	261-262	132-135	D000809	angiotensin	Chemical	261	262	10	D051436	chronic renal damage	Disease	132	135	6	1:NR:2	R2L	CROSS	267-269	132-135	D000804	angiotensin II	Chemical	267	269	10	D051436	chronic renal damage	Disease	132	135	6
17241784	Progressive myopathy with up - regulation of MHC - I associated with statin therapy .|Statins can cause a necrotizing myopathy and hyperCKaemia which is reversible on cessation of the drug .|What is less well known is a phenomenon whereby statins may induce a myopathy , which persists or may progress after stopping the drug .|We investigated the muscle pathology in 8 such cases .|All had myofibre necrosis but only 3 had an inflammatory infiltrate .|In all cases there was diffuse or multifocal up - regulation of MHC - I expression even in non - necrotic fibres .|Progressive improvement occurred in 7 cases after commencement of prednisolone and methotrexate , and in one case spontaneously .|These observations suggest that statins may initiate an immune - mediated myopathy that persists after withdrawal of the drug and responds to immunosuppressive therapy .|The mechanism of this myopathy is uncertain but may involve the induction by statins of an endoplasmic reticulum stress response with associated up - regulation of MHC - I expression and antigen presentation by muscle fibres .	1:CID:2	R2L	NON-CROSS	45-46	41-42	D019821	statin|Statins|statins|statins|statins	Chemical	12:15:41:125:159	13:16:42:126:160	0:1:2:7:8	D009135	myopathy|myopathy|myopathy|myopathy|myopathy	Disease	1:20:45:132:150	2:21:46:133:151	0:1:2:7:8	1:CID:2	L2R	CROSS	99-100	125-126	D019821	statin|Statins|statins|statins|statins	Chemical	12:15:41:125:159	13:16:42:126:160	0:1:2:7:8	D009336	necrosis|necrotic	Disease	70:99	71:100	4:5	1:NR:2	R2L	CROSS	132-133	111-112	D011239	prednisolone	Chemical	111	112	6	D009135	myopathy|myopathy|myopathy|myopathy|myopathy	Disease	1:20:45:132:150	2:21:46:133:151	0:1:2:7:8	1:NR:2	R2L	CROSS	132-133	113-114	D008727	methotrexate	Chemical	113	114	6	D009135	myopathy|myopathy|myopathy|myopathy|myopathy	Disease	1:20:45:132:150	2:21:46:133:151	0:1:2:7:8	1:NR:2	R2L	CROSS	111-112	99-100	D011239	prednisolone	Chemical	111	112	6	D009336	necrosis|necrotic	Disease	70:99	71:100	4:5	1:NR:2	R2L	CROSS	113-114	99-100	D008727	methotrexate	Chemical	113	114	6	D009336	necrosis|necrotic	Disease	70:99	71:100	4:5
17261653	Direct inhibition of cardiac hyperpolarization - activated cyclic nucleotide - gated pacemaker channels by clonidine .|BACKGROUND : Inhibition of cardiac sympathetic tone represents an important strategy for treatment of cardiovascular disease , including arrhythmia , coronary heart disease , and chronic heart failure .|Activation of presynaptic alpha2 - adrenoceptors is the most widely accepted mechanism of action of the antisympathetic drug clonidine ; however , other target proteins have been postulated to contribute to the in vivo actions of clonidine .|METHODS AND RESULTS : To test whether clonidine elicits pharmacological effects independent of alpha2 - adrenoceptors , we have generated mice with a targeted deletion of all 3 alpha2 - adrenoceptor subtypes ( alpha2ABC - / - ) .|Alpha2ABC - / - mice were completely unresponsive to the analgesic and hypnotic effects of clonidine ; however , clonidine significantly lowered heart rate in alpha2ABC - / - mice by up to 150 bpm .|Clonidine - induced bradycardia in conscious alpha2ABC - / - mice was 32 . 3 % ( 10 microg / kg ) and 26 . 6 % ( 100 microg / kg ) of the effect in wild - type mice .|A similar bradycardic effect of clonidine was observed in isolated spontaneously beating right atria from alpha2ABC - knockout and wild - type mice .|Clonidine inhibited the native pacemaker current ( I ( f ) ) in isolated sinoatrial node pacemaker cells and the I ( f ) - generating hyperpolarization - activated cyclic nucleotide - gated ( HCN ) 2 and HCN4 channels in transfected HEK293 cells .|As a consequence of blocking I ( f ) , clonidine reduced the slope of the diastolic depolarization and the frequency of pacemaker potentials in sinoatrial node cells from wild - type and alpha2ABC - knockout mice .|CONCLUSIONS : Direct inhibition of cardiac HCN pacemaker channels contributes to the bradycardic effects of clonidine gene - targeted mice in vivo , and thus , clonidine - like drugs represent novel structures for future HCN channel inhibitors .	1:CID:2	L2R	NON-CROSS	158-159	161-162	D003000	clonidine|clonidine|clonidine|clonidine|clonidine|clonidine|Clonidine|clonidine|Clonidine|clonidine|clonidine|clonidine	Chemical	14:63:81:90:137:141:158:205:224:279:322:333	15:64:82:91:138:142:159:206:225:280:323:334	0:2:2:3:4:4:5:6:7:8:9:9	D001919	bradycardia	Disease	161	162	5	1:NR:2	L2R	CROSS	7-9	30-32	D009712	cyclic nucleotide|cyclic nucleotide	Chemical	7:253	9:255	0:7	D002318	cardiovascular disease	Disease	30	32	1	1:NR:2	L2R	CROSS	7-9	34-35	D009712	cyclic nucleotide|cyclic nucleotide	Chemical	7:253	9:255	0:7	D001145	arrhythmia	Disease	34	35	1	1:NR:2	L2R	CROSS	7-9	36-39	D009712	cyclic nucleotide|cyclic nucleotide	Chemical	7:253	9:255	0:7	D003327	coronary heart disease	Disease	36	39	1	1:NR:2	L2R	CROSS	7-9	42-44	D009712	cyclic nucleotide|cyclic nucleotide	Chemical	7:253	9:255	0:7	D006333	heart failure	Disease	42	44	1	1:NR:2	L2R	CROSS	161-162	253-255	D009712	cyclic nucleotide|cyclic nucleotide	Chemical	7:253	9:255	0:7	D001919	bradycardia	Disease	161	162	5	not_include	L2R	CROSS	14-15	30-32	D003000	clonidine|clonidine|clonidine|clonidine|clonidine|clonidine|Clonidine|clonidine|Clonidine|clonidine|clonidine|clonidine	Chemical	14:63:81:90:137:141:158:205:224:279:322:333	15:64:82:91:138:142:159:206:225:280:323:334	0:2:2:3:4:4:5:6:7:8:9:9	D002318	cardiovascular disease	Disease	30	32	1	not_include	L2R	CROSS	14-15	34-35	D003000	clonidine|clonidine|clonidine|clonidine|clonidine|clonidine|Clonidine|clonidine|Clonidine|clonidine|clonidine|clonidine	Chemical	14:63:81:90:137:141:158:205:224:279:322:333	15:64:82:91:138:142:159:206:225:280:323:334	0:2:2:3:4:4:5:6:7:8:9:9	D001145	arrhythmia	Disease	34	35	1	1:NR:2	L2R	CROSS	14-15	36-39	D003000	clonidine|clonidine|clonidine|clonidine|clonidine|clonidine|Clonidine|clonidine|Clonidine|clonidine|clonidine|clonidine	Chemical	14:63:81:90:137:141:158:205:224:279:322:333	15:64:82:91:138:142:159:206:225:280:323:334	0:2:2:3:4:4:5:6:7:8:9:9	D003327	coronary heart disease	Disease	36	39	1	1:NR:2	L2R	CROSS	42-44	63-64	D003000	clonidine|clonidine|clonidine|clonidine|clonidine|clonidine|Clonidine|clonidine|Clonidine|clonidine|clonidine|clonidine	Chemical	14:63:81:90:137:141:158:205:224:279:322:333	15:64:82:91:138:142:159:206:225:280:323:334	0:2:2:3:4:4:5:6:7:8:9:9	D006333	heart failure	Disease	42	44	1
17343925	Influence of smoking on developing cochlea .|Does smoking during pregnancy affect the amplitudes of transient evoked otoacoustic emissions in newborns ?|OBJECTIVE : Maternal tobacco smoking has negative effects on fetal growth .|The influence of smoking during pregnancy on the developing cochlea has not been estimated , although smoking has been positively associated with hearing loss in adults .|The objective of this study was to determine the effects of maternal smoking on transient evoked otoacoustic emissions ( TEOAEs ) of healthy neonates .|METHODS : This study was undertaken as part of neonatal screening for hearing impairment and involved both ears of 200 newborns .|Newborns whose mothers reported smoking during pregnancy ( n = 200 ears ) were compared to a control group of newborns ( n = 200 ears ) , whose mothers were non - smokers .|Exposure to tobacco was characterized as low ( < 5 cigarettes per day , n = 88 ears ) , moderate ( 5 < or = cigarettes per day < 10 , n = 76 ) or high ( > or = 10 cigarettes per day , n = 36 ) .|RESULTS : In exposed neonates , TEOAEs mean response ( across frequency ) and mean amplitude at 4000Hz was significantly lower than in non - exposed neonates .|Comparisons between exposed newborns ' subgroups revealed no significant differences .|However , by comparing each subgroup to control group , we found statistically significant decreases of TEOAEs amplitudes at 4000Hz for all three groups .|Mean TEOAEs responses of highly exposed newborns were also significantly lower in comparison to our control group .|CONCLUSION : In utero , exposure to tobacco smoking seems to have a small impact on outer hair cells .|These effects seem to be equally true for all exposed newborns , regardless of the degree of exposure .|Further studies are needed in order to establish a potential negative effect of maternal smoking on the neonate 's hearing acuity .	1:CID:2	L2R	NON-CROSS	50-51	56-58	D012906	smoking|smoking|smoking|smoking|smoking|smoking|smoking|smoking|smoking	Chemical	2:8:26:37:50:73:112:285:330	3:9:27:38:51:74:113:286:331	0:1:2:3:3:4:6:12:14	D034381	hearing loss|hearing impairment	Disease	56:98	58:100	3:5
17400887	Neuroinflammation and behavioral abnormalities after neonatal terbutaline treatment in rats : implications for autism .|Autism is a neurodevelopmental disorder presenting before 3 years of age with deficits in communication and social skills and repetitive behaviors .|In addition to genetic influences , recent studies suggest that prenatal drug or chemical exposures are risk factors for autism .|Terbutaline , a beta2 - adrenoceptor agonist used to arrest preterm labor , has been associated with increased concordance for autism in dizygotic twins .|We studied the effects of terbutaline on microglial activation in different brain regions and behavioral outcomes in developing rats .|Newborn rats were given terbutaline ( 10 mg / kg ) daily on postnatal days ( PN ) 2 to 5 or PN 11 to 14 and examined 24 h after the last dose and at PN 30 .|Immunohistochemical studies showed that administration of terbutaline on PN 2 to 5 produced a robust increase in microglial activation on PN 30 in the cerebral cortex , as well as in cerebellar and cerebrocortical white matter .|None of these effects occurred in animals given terbutaline on PN 11 to 14 .|In behavioral tests , animals treated with terbutaline on PN 2 to 5 showed consistent patterns of hyper - reactivity to novelty and aversive stimuli when assessed in a novel open field , as well as in the acoustic startle response test .|Our findings indicate that beta2 - adrenoceptor overstimulation during an early critical period results in microglial activation associated with innate neuroinflammatory pathways and behavioral abnormalities , similar to those described in autism .|This study provides a useful animal model for understanding the neuropathological processes underlying autism spectrum disorders .	1:CID:2	L2R	NON-CROSS	56-57	58-59	D013726	terbutaline|Terbutaline|terbutaline|terbutaline|terbutaline|terbutaline|terbutaline	Chemical	6:58:88:107:148:187:201	7:59:89:108:149:188:202	0:3:4:5:6:7:8	D001321	autism|Autism|autism|autism|autism	Disease	13:15:56:78:268	14:16:57:79:269	0:1:2:3:9	1:NR:2	R2L	NON-CROSS	6-7	0-1	D013726	terbutaline|Terbutaline|terbutaline|terbutaline|terbutaline|terbutaline|terbutaline	Chemical	6:58:88:107:148:187:201	7:59:89:108:149:188:202	0:3:4:5:6:7:8	D020078	Neuroinflammation	Disease	0	1	0	not_include	R2L	NON-CROSS	6-7	2-4	D013726	terbutaline|Terbutaline|terbutaline|terbutaline|terbutaline|terbutaline|terbutaline	Chemical	6:58:88:107:148:187:201	7:59:89:108:149:188:202	0:3:4:5:6:7:8	D001523	behavioral abnormalities|repetitive behaviors|behavioral abnormalities	Disease	2:34:260	4:36:262	0:1:9	1:NR:2	L2R	CROSS	6-7	18-20	D013726	terbutaline|Terbutaline|terbutaline|terbutaline|terbutaline|terbutaline|terbutaline	Chemical	6:58:88:107:148:187:201	7:59:89:108:149:188:202	0:3:4:5:6:7:8	D002658	neurodevelopmental disorder	Disease	18	20	1	1:NR:2	L2R	CROSS	6-7	27-33	D013726	terbutaline|Terbutaline|terbutaline|terbutaline|terbutaline|terbutaline|terbutaline	Chemical	6:58:88:107:148:187:201	7:59:89:108:149:188:202	0:3:4:5:6:7:8	D003147	deficits in communication and social skills	Disease	27	33	1	1:NR:2	L2R	NON-CROSS	58-59	68-70	D013726	terbutaline|Terbutaline|terbutaline|terbutaline|terbutaline|terbutaline|terbutaline	Chemical	6:58:88:107:148:187:201	7:59:89:108:149:188:202	0:3:4:5:6:7:8	D007752	preterm labor	Disease	68	70	3	not_include	L2R	CROSS	201-202	283-286	D013726	terbutaline|Terbutaline|terbutaline|terbutaline|terbutaline|terbutaline|terbutaline	Chemical	6:58:88:107:148:187:201	7:59:89:108:149:188:202	0:3:4:5:6:7:8	D002659	autism spectrum disorders	Disease	283	286	10
17612891	Acute myocarditis associated with clozapine .|OBJECTIVE : A case of acute myocarditis associated with the commencement of clozapine is described , highlighting the onset , course and possible contributing factors .|There is an urgent need to raise awareness about this potentially fatal complication of clozapine use .|RESULTS : A 20 - year - old male with schizophrenia developed a sudden onset of myocarditis after commencement of clozapine .|The patient recovered with intensive medical support .|The symptoms occurred around 2 weeks after starting clozapine in an inpatient setting .|Possible contributing factors may have been concomitant antidepressant use and unaccustomed physical activity .|CONCLUSIONS : Myocarditis is an increasingly recognized complication associated with the use of clozapine .|It can be fatal if not recognized and treated early .|Considering that clozapine remains the gold standard in treatment of resistant psychosis , there is an urgent need to raise awareness among medical and paramedical staff involved in the care of these patients .|There are also implications for recommendations and regulations regarding the use of clozapine .	1:CID:2	R2L	NON-CROSS	4-5	1-2	D003024	clozapine|clozapine|clozapine|clozapine|clozapine|clozapine|clozapine|clozapine	Chemical	4:18:46:69:87:120:135:179	5:19:47:70:88:121:136:180	0:1:2:3:5:7:9:10	D009205	myocarditis|myocarditis|myocarditis|Myocarditis	Disease	1:12:65:109	2:13:66:110	0:1:3:7	1:CID:2	R2L	CROSS	109-110	100-101	D000928	antidepressant	Chemical	100	101	6	D009205	myocarditis|myocarditis|myocarditis|Myocarditis	Disease	1:12:65:109	2:13:66:110	0:1:3:7	1:NR:2	L2R	NON-CROSS	59-60	69-70	D003024	clozapine|clozapine|clozapine|clozapine|clozapine|clozapine|clozapine|clozapine	Chemical	4:18:46:69:87:120:135:179	5:19:47:70:88:121:136:180	0:1:2:3:5:7:9:10	D012559	schizophrenia	Disease	59	60	3	1:NR:2	L2R	NON-CROSS	135-136	144-145	D003024	clozapine|clozapine|clozapine|clozapine|clozapine|clozapine|clozapine|clozapine	Chemical	4:18:46:69:87:120:135:179	5:19:47:70:88:121:136:180	0:1:2:3:5:7:9:10	D011618	psychosis	Disease	144	145	9	1:NR:2	R2L	CROSS	100-101	59-60	D000928	antidepressant	Chemical	100	101	6	D012559	schizophrenia	Disease	59	60	3	1:NR:2	L2R	CROSS	100-101	144-145	D000928	antidepressant	Chemical	100	101	6	D011618	psychosis	Disease	144	145	9
18081909	Encephalopathy induced by levetiracetam added to valproate .|BACKGROUND : We report on the manifestation of a levetiracetam ( LEV ) - induced encephalopathy .|FINDINGS : A 28 - year - old man suffering from idiopathic epilepsy with generalized seizures was treated with LEV ( 3000 mg ) added to valproate ( VPA ) ( 2000 mg ) .|Frequency of generalized tonic - clonic seizures increased from one per 6 months to two per month .|Neuropsychological testing showed impaired word fluency , psychomotor speed and working memory .|The interictal electroencephalogram ( EEG ) showed a generalized slowing to 5 per second theta rhythms with bilateral generalized high - amplitude discharges .|OUTCOME : Following discontinuation of LEV , EEG and neuropsychological findings improved and seizure frequency decreased .	1:CID:2	R2L	NON-CROSS	3-4	0-1	C026098	levetiracetam|levetiracetam|LEV|LEV|LEV	Chemical	3:17:19:44:120	4:18:20:45:121	0:1:1:2:6	D001927	Encephalopathy|encephalopathy	Disease	0:23	1:24	0:1	1:CID:2	R2L	NON-CROSS	6-7	0-1	D014635	valproate|valproate|VPA	Chemical	6:51:53	7:52:54	0:2:2	D001927	Encephalopathy|encephalopathy	Disease	0:23	1:24	0:1	1:CID:2	L2R	CROSS	44-45	63-67	C026098	levetiracetam|levetiracetam|LEV|LEV|LEV	Chemical	3:17:19:44:120	4:18:20:45:121	0:1:1:2:6	D004830	tonic - clonic seizures	Disease	63	67	3	1:CID:2	L2R	CROSS	81-90	120-121	C026098	levetiracetam|levetiracetam|LEV|LEV|LEV	Chemical	3:17:19:44:120	4:18:20:45:121	0:1:1:2:6	D008569	impaired word fluency , psychomotor speed and working memory	Disease	81	90	4	1:CID:2	L2R	CROSS	53-54	63-67	D014635	valproate|valproate|VPA	Chemical	6:51:53	7:52:54	0:2:2	D004830	tonic - clonic seizures	Disease	63	67	3	1:CID:2	L2R	CROSS	53-54	81-90	D014635	valproate|valproate|VPA	Chemical	6:51:53	7:52:54	0:2:2	D008569	impaired word fluency , psychomotor speed and working memory	Disease	81	90	4	1:NR:2	L2R	NON-CROSS	36-38	44-45	C026098	levetiracetam|levetiracetam|LEV|LEV|LEV	Chemical	3:17:19:44:120	4:18:20:45:121	0:1:1:2:6	C562694	idiopathic epilepsy	Disease	36	38	2	1:NR:2	L2R	NON-CROSS	40-41	44-45	C026098	levetiracetam|levetiracetam|LEV|LEV|LEV	Chemical	3:17:19:44:120	4:18:20:45:121	0:1:1:2:6	D012640	seizures|seizure	Disease	40:128	41:129	2:6	1:NR:2	L2R	NON-CROSS	36-38	51-52	D014635	valproate|valproate|VPA	Chemical	6:51:53	7:52:54	0:2:2	C562694	idiopathic epilepsy	Disease	36	38	2	1:NR:2	L2R	NON-CROSS	40-41	51-52	D014635	valproate|valproate|VPA	Chemical	6:51:53	7:52:54	0:2:2	D012640	seizures|seizure	Disease	40:128	41:129	2:6
18083142	Norepinephrine signaling through beta - adrenergic receptors is critical for expression of cocaine - induced anxiety .|BACKGROUND : Cocaine is a widely abused psychostimulant that has both rewarding and aversive properties .|While the mechanisms underlying cocaine 's rewarding effects have been studied extensively , less attention has been paid to the unpleasant behavioral states induced by cocaine , such as anxiety .|METHODS : In this study , we evaluated the performance of dopamine beta - hydroxylase knockout ( Dbh - / - ) mice , which lack norepinephrine ( NE ) , in the elevated plus maze ( EPM ) to examine the contribution of noradrenergic signaling to cocaine - induced anxiety .|RESULTS : We found that cocaine dose - dependently increased anxiety - like behavior in control ( Dbh + / - ) mice , as measured by a decrease in open arm exploration .|The Dbh - / - mice had normal baseline performance in the EPM but were completely resistant to the anxiogenic effects of cocaine .|Cocaine - induced anxiety was also attenuated in Dbh + / - mice following administration of disulfiram , a dopamine beta - hydroxylase ( DBH ) inhibitor .|In experiments using specific adrenergic antagonists , we found that pretreatment with the beta - adrenergic receptor antagonist propranolol blocked cocaine - induced anxiety - like behavior in Dbh + / - and wild - type C57BL6 / J mice , while the alpha ( 1 ) antagonist prazosin and the alpha ( 2 ) antagonist yohimbine had no effect .|CONCLUSIONS : These results indicate that noradrenergic signaling via beta - adrenergic receptors is required for cocaine - induced anxiety in mice .	1:CID:2	L2R	NON-CROSS	12-13	15-16	D003042	cocaine|Cocaine|cocaine|cocaine|cocaine|cocaine|cocaine|Cocaine|cocaine|cocaine	Chemical	12:19:37:58:111:121:172:174:222:279	13:20:38:59:112:122:173:175:223:280	0:1:2:2:3:4:5:6:7:8	D001008	anxiety|anxiety|anxiety|anxiety|anxiety|anxiety|anxiety	Disease	15:62:114:126:177:225:282	16:63:115:127:178:226:283	0:2:3:4:6:7:8	1:NR:2	L2R	NON-CROSS	0-1	15-16	D009638	Norepinephrine|norepinephrine|NE	Chemical	0:90:92	1:91:93	0:3:3	D001008	anxiety|anxiety|anxiety|anxiety|anxiety|anxiety|anxiety	Disease	15:62:114:126:177:225:282	16:63:115:127:178:226:283	0:2:3:4:6:7:8	1:NR:2	R2L	NON-CROSS	75-76	62-63	D004298	dopamine|dopamine	Chemical	75:193	76:194	3:6	D001008	anxiety|anxiety|anxiety|anxiety|anxiety|anxiety|anxiety	Disease	15:62:114:126:177:225:282	16:63:115:127:178:226:283	0:2:3:4:6:7:8	1:NR:2	R2L	NON-CROSS	190-191	177-178	D004221	disulfiram	Chemical	190	191	6	D001008	anxiety|anxiety|anxiety|anxiety|anxiety|anxiety|anxiety	Disease	15:62:114:126:177:225:282	16:63:115:127:178:226:283	0:2:3:4:6:7:8	1:NR:2	R2L	NON-CROSS	225-226	220-221	D011433	propranolol	Chemical	220	221	7	D001008	anxiety|anxiety|anxiety|anxiety|anxiety|anxiety|anxiety	Disease	15:62:114:126:177:225:282	16:63:115:127:178:226:283	0:2:3:4:6:7:8	1:NR:2	R2L	NON-CROSS	250-251	225-226	D011224	prazosin	Chemical	250	251	7	D001008	anxiety|anxiety|anxiety|anxiety|anxiety|anxiety|anxiety	Disease	15:62:114:126:177:225:282	16:63:115:127:178:226:283	0:2:3:4:6:7:8	1:NR:2	R2L	NON-CROSS	282-283	258-259	D015016	yohimbine	Chemical	258	259	7	D001008	anxiety|anxiety|anxiety|anxiety|anxiety|anxiety|anxiety	Disease	15:62:114:126:177:225:282	16:63:115:127:178:226:283	0:2:3:4:6:7:8
18182964	Clonidine for attention - deficit / hyperactivity disorder : II .|ECG changes and adverse events analysis .|OBJECTIVE : To examine the safety and tolerability of clonidine used alone or with methylphenidate in children with attention - deficit / hyperactivity disorder ( ADHD ) .|METHOD : In a 16 - week multicenter , double - blind trial , 122 children with ADHD were randomly assigned to clonidine ( n = 31 ) , methylphenidate ( n = 29 ) , clonidine and methylphenidate ( n = 32 ) , or placebo ( n = 30 ) .|Doses were flexibly titrated up to 0 . 6 mg / day for clonidine and 60 mg / day for methylphenidate ( both with divided dosing ) .|Groups were compared regarding adverse events and changes from baseline to week 16 in electrocardiograms and vital signs .|RESULTS : There were more incidents of bradycardia in subjects treated with clonidine compared with those not treated with clonidine ( 17 . 5 % versus 3 . 4 % ; p = . 02 ) , but no other significant group differences regarding electrocardiogram and other cardiovascular outcomes .|There were no suggestions of interactions between clonidine and methylphenidate regarding cardiovascular outcomes .|Moderate or severe adverse events were more common in subjects on clonidine ( 79 . 4 % versus 49 . 2 % ; p = . 0006 ) but not associated with higher rates of early study withdrawal .|Drowsiness was common on clonidine , but generally resolved by 6 to 8 weeks .|CONCLUSIONS : Clonidine , used alone or with methylphenidate , appears safe and well tolerated in childhood ADHD .|Physicians prescribing clonidine should monitor for bradycardia and advise patients about the high likelihood of initial drowsiness .	1:CID:2	L2R	NON-CROSS	285-286	289-290	D003000	Clonidine|clonidine|clonidine|clonidine|clonidine|clonidine|clonidine|clonidine|clonidine|clonidine|Clonidine|clonidine	Chemical	0:27:68:82:112:158:165:203:221:253:266:285	1:28:69:83:113:159:166:204:222:254:267:286	0:2:3:3:4:6:6:7:8:9:10:11	D001919	bradycardia|bradycardia	Disease	153:289	154:290	6:11	1:NR:2	L2R	NON-CROSS	0-1	2-8	D003000	Clonidine|clonidine|clonidine|clonidine|clonidine|clonidine|clonidine|clonidine|clonidine|clonidine|Clonidine|clonidine	Chemical	0:27:68:82:112:158:165:203:221:253:266:285	1:28:69:83:113:159:166:204:222:254:267:286	0:2:3:3:4:6:6:7:8:9:10:11	D001289	attention - deficit / hyperactivity disorder|attention - deficit / hyperactivity disorder|ADHD|ADHD|ADHD	Disease	2:36:43:63:281	8:42:44:64:282	0:2:2:3:10	1:NR:2	L2R	NON-CROSS	249-250	253-254	D003000	Clonidine|clonidine|clonidine|clonidine|clonidine|clonidine|clonidine|clonidine|clonidine|clonidine|Clonidine|clonidine	Chemical	0:27:68:82:112:158:165:203:221:253:266:285	1:28:69:83:113:159:166:204:222:254:267:286	0:2:3:3:4:6:6:7:8:9:10:11	D006970	Drowsiness|drowsiness	Disease	249:299	250:300	9:11	1:NR:2	R2L	NON-CROSS	36-42	32-33	D008774	methylphenidate|methylphenidate|methylphenidate|methylphenidate|methylphenidate|methylphenidate	Chemical	32:75:84:119:205:272	33:76:85:120:206:273	2:3:3:4:7:10	D001289	attention - deficit / hyperactivity disorder|attention - deficit / hyperactivity disorder|ADHD|ADHD|ADHD	Disease	2:36:43:63:281	8:42:44:64:282	0:2:2:3:10	1:NR:2	L2R	CROSS	272-273	289-290	D008774	methylphenidate|methylphenidate|methylphenidate|methylphenidate|methylphenidate|methylphenidate	Chemical	32:75:84:119:205:272	33:76:85:120:206:273	2:3:3:4:7:10	D001919	bradycardia|bradycardia	Disease	153:289	154:290	6:11	1:NR:2	L2R	CROSS	249-250	272-273	D008774	methylphenidate|methylphenidate|methylphenidate|methylphenidate|methylphenidate|methylphenidate	Chemical	32:75:84:119:205:272	33:76:85:120:206:273	2:3:3:4:7:10	D006970	Drowsiness|drowsiness	Disease	249:299	250:300	9:11
18217897	Thalidomide has limited single - agent activity in relapsed or refractory indolent non - Hodgkin lymphomas : a phase II trial of the Cancer and Leukemia Group B .|Thalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma , mantle cell lymphoma and lymphoplasmacytic lymphoma .|Its activity is believed to be due modulation of the tumour milieu , including downregulation of angiogenesis and inflammatory cytokines .|Between July 2001 and April 2004 , 24 patients with relapsed / refractory indolent lymphomas received thalidomide 200 mg daily with escalation by 100 mg daily every 1 - 2 weeks as tolerated , up to a maximum of 800 mg daily .|Patients had received a median of 2 ( range , 1 - 4 ) prior regimens .|Of 24 evaluable patients , two achieved a complete remission and one achieved a partial remission for an overall response rate of 12 . 5 % ( 95 % confidence interval : 2 . 6 - 32 . 4 % ) .|Eleven patients progressed during therapy .|Grade 3 - 4 adverse effects included myelosuppression , fatigue , somnolence / depressed mood , neuropathy and dyspnea .|Of concern was the occurrence of four thromboembolic events .|Our results failed to demonstrate an important response rate to single agent thalidomide in indolent lymphomas and contrast with the higher activity level reported with the second generation immunomodulatory agent , lenalidomide .	1:CID:2	L2R	CROSS	204-205	219-220	D013792	Thalidomide|Thalidomide|thalidomide|thalidomide	Chemical	0:29:85:219	1:30:86:220	0:1:3:9	D013923	thromboembolic	Disease	204	205	8	1:NR:2	L2R	NON-CROSS	0-1	12-16	D013792	Thalidomide|Thalidomide|thalidomide|thalidomide	Chemical	0:29:85:219	1:30:86:220	0:1:3:9	D008228	non - Hodgkin lymphomas	Disease	12	16	0	1:NR:2	L2R	NON-CROSS	23-24	29-30	D013792	Thalidomide|Thalidomide|thalidomide|thalidomide	Chemical	0:29:85:219	1:30:86:220	0:1:3:9	D009369	Cancer|tumour	Disease	23:58	24:59	0:2	1:NR:2	L2R	NON-CROSS	25-26	29-30	D013792	Thalidomide|Thalidomide|thalidomide|thalidomide	Chemical	0:29:85:219	1:30:86:220	0:1:3:9	D007938	Leukemia	Disease	25	26	0	1:NR:2	L2R	NON-CROSS	29-30	38-40	D013792	Thalidomide|Thalidomide|thalidomide|thalidomide	Chemical	0:29:85:219	1:30:86:220	0:1:3:9	D009101	multiple myeloma	Disease	38	40	1	1:NR:2	L2R	NON-CROSS	29-30	41-44	D013792	Thalidomide|Thalidomide|thalidomide|thalidomide	Chemical	0:29:85:219	1:30:86:220	0:1:3:9	D020522	mantle cell lymphoma	Disease	41	44	1	1:NR:2	L2R	NON-CROSS	83-84	85-86	D013792	Thalidomide|Thalidomide|thalidomide|thalidomide	Chemical	0:29:85:219	1:30:86:220	0:1:3:9	D008223	lymphoplasmacytic lymphoma|lymphomas|lymphomas	Disease	45:83:222	47:84:223	1:3:9	1:NR:2	L2R	CROSS	184-185	219-220	D013792	Thalidomide|Thalidomide|thalidomide|thalidomide	Chemical	0:29:85:219	1:30:86:220	0:1:3:9	D001855	myelosuppression	Disease	184	185	7	1:NR:2	L2R	CROSS	186-187	219-220	D013792	Thalidomide|Thalidomide|thalidomide|thalidomide	Chemical	0:29:85:219	1:30:86:220	0:1:3:9	D005221	fatigue	Disease	186	187	7	1:NR:2	L2R	CROSS	188-189	219-220	D013792	Thalidomide|Thalidomide|thalidomide|thalidomide	Chemical	0:29:85:219	1:30:86:220	0:1:3:9	D006970	somnolence	Disease	188	189	7	1:NR:2	L2R	CROSS	190-192	219-220	D013792	Thalidomide|Thalidomide|thalidomide|thalidomide	Chemical	0:29:85:219	1:30:86:220	0:1:3:9	D003866	depressed mood	Disease	190	192	7	1:NR:2	L2R	CROSS	193-194	219-220	D013792	Thalidomide|Thalidomide|thalidomide|thalidomide	Chemical	0:29:85:219	1:30:86:220	0:1:3:9	D009422	neuropathy	Disease	193	194	7	1:NR:2	L2R	CROSS	195-196	219-220	D013792	Thalidomide|Thalidomide|thalidomide|thalidomide	Chemical	0:29:85:219	1:30:86:220	0:1:3:9	D004417	dyspnea	Disease	195	196	7	1:NR:2	R2L	CROSS	238-239	12-16	C467567	lenalidomide	Chemical	238	239	9	D008228	non - Hodgkin lymphomas	Disease	12	16	0	1:NR:2	R2L	CROSS	238-239	58-59	C467567	lenalidomide	Chemical	238	239	9	D009369	Cancer|tumour	Disease	23:58	24:59	0:2	1:NR:2	R2L	CROSS	238-239	25-26	C467567	lenalidomide	Chemical	238	239	9	D007938	Leukemia	Disease	25	26	0	1:NR:2	R2L	CROSS	238-239	38-40	C467567	lenalidomide	Chemical	238	239	9	D009101	multiple myeloma	Disease	38	40	1	1:NR:2	R2L	CROSS	238-239	41-44	C467567	lenalidomide	Chemical	238	239	9	D020522	mantle cell lymphoma	Disease	41	44	1	1:NR:2	R2L	NON-CROSS	238-239	222-223	C467567	lenalidomide	Chemical	238	239	9	D008223	lymphoplasmacytic lymphoma|lymphomas|lymphomas	Disease	45:83:222	47:84:223	1:3:9	1:NR:2	R2L	CROSS	238-239	184-185	C467567	lenalidomide	Chemical	238	239	9	D001855	myelosuppression	Disease	184	185	7	1:NR:2	R2L	CROSS	238-239	186-187	C467567	lenalidomide	Chemical	238	239	9	D005221	fatigue	Disease	186	187	7	1:NR:2	R2L	CROSS	238-239	188-189	C467567	lenalidomide	Chemical	238	239	9	D006970	somnolence	Disease	188	189	7	1:NR:2	R2L	CROSS	238-239	190-192	C467567	lenalidomide	Chemical	238	239	9	D003866	depressed mood	Disease	190	192	7	1:NR:2	R2L	CROSS	238-239	193-194	C467567	lenalidomide	Chemical	238	239	9	D009422	neuropathy	Disease	193	194	7	1:NR:2	R2L	CROSS	238-239	195-196	C467567	lenalidomide	Chemical	238	239	9	D004417	dyspnea	Disease	195	196	7	1:NR:2	R2L	CROSS	238-239	204-205	C467567	lenalidomide	Chemical	238	239	9	D013923	thromboembolic	Disease	204	205	8
18996674	Intracavernous epinephrine : a minimally invasive treatment for priapism in the emergency department .|Priapism is the prolonged erection of the penis in the absence of sexual arousal .|A 45 - year - old man , an admitted frequent cocaine user , presented to the Emergency Department ( ED ) on two separate occasions with a history of priapism after cocaine use .|The management options in the ED , as exemplified by four individual case reports , in particular the use of a minimally invasive method of intracorporal epinephrine instillation , are discussed .	1:CID:2	R2L	NON-CROSS	61-62	59-60	D003042	cocaine|cocaine	Chemical	40:61	41:62	2:2	D011317	priapism|Priapism|priapism	Disease	8:14:59	9:15:60	0:1:2	1:NR:2	L2R	NON-CROSS	1-2	8-9	D004837	epinephrine|epinephrine	Chemical	1:90	2:91	0:3	D011317	priapism|Priapism|priapism	Disease	8:14:59	9:15:60	0:1:2
19058010	Effect of green tea and vitamin E combination in isoproterenol induced myocardial infarction in rats .|The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight , body weight , serum marker enzymes , lipid peroxidation , endogenous antioxidants and membrane bound ATPases in isoproterenol ( ISO ) - induced myocardial infarction in rats .|Adult male albino rats , treated with ISO ( 200 mg / kg , s . c . ) for 2 days at an interval of 24 h caused a significant ( P < 0 . 05 ) elevation of heart weight , serum marker enzymes , lipid peroxidation and Ca + 2 ATPase level whereas there was a significant ( P < 0 . 05 ) decrease in body weight , endogenous antioxidants , Na + / K + ATPase and Mg + 2 ATPase levels .|Administration of green tea ( 100 mg / kg / day , p . o . ) and vitamin E ( 100 mg / kg / day , p . o . ) together for 30 consecutive days and challenged with ISO on the day 29th and 30th , showed a significant ( P < 0 . 05 ) decrease in heart weight , serum marker enzymes , lipid peroxidation , Ca + 2 ATPase and a significant increase in the body weight , endogenous antioxidants , Na + / K + ATPase and Mg + 2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups .|These findings indicate the synergistic protective effect of green tea and vitamin E during ISO induced myocardial infarction in rats .	1:CID:2	L2R	NON-CROSS	9-10	11-13	D007545	isoproterenol|isoproterenol|ISO|ISO|ISO|ISO|ISO	Chemical	9:53:55:71:193:253:280	10:54:56:72:194:254:281	0:1:1:2:3:3:4	D009203	myocardial infarction|myocardial infarction|myocardial infarction	Disease	11:59:282	13:61:284	0:1:4	1:NR:2	L2R	NON-CROSS	274-276	282-284	D010936	green tea|green tea|green tea|green tea|green tea	Chemical	2:27:154:257:274	4:29:156:259:276	0:1:3:3:4	D009203	myocardial infarction|myocardial infarction|myocardial infarction	Disease	11:59:282	13:61:284	0:1:4	1:NR:2	L2R	NON-CROSS	277-279	282-284	D014810	vitamin E|vitamin E|vitamin E|vitamin E|vitamin E	Chemical	5:30:170:260:277	7:32:172:262:279	0:1:3:3:4	D009203	myocardial infarction|myocardial infarction|myocardial infarction	Disease	11:59:282	13:61:284	0:1:4	1:NR:2	R2L	CROSS	114-115	59-61	D002118	Ca|Ca	Chemical	114:223	115:224	2:3	D009203	myocardial infarction|myocardial infarction|myocardial infarction	Disease	11:59:282	13:61:284	0:1:4	1:NR:2	R2L	CROSS	282-284	239-240	D012964	Na|Na	Chemical	139:239	140:240	2:3	D009203	myocardial infarction|myocardial infarction|myocardial infarction	Disease	11:59:282	13:61:284	0:1:4	1:NR:2	R2L	CROSS	282-284	242-243	D011188	K|K	Chemical	142:242	143:243	2:3	D009203	myocardial infarction|myocardial infarction|myocardial infarction	Disease	11:59:282	13:61:284	0:1:4	1:NR:2	R2L	CROSS	282-284	246-247	D008274	Mg|Mg	Chemical	146:246	147:247	2:3	D009203	myocardial infarction|myocardial infarction|myocardial infarction	Disease	11:59:282	13:61:284	0:1:4
19581773	Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C .|A 63 - year - old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon ( IFN ) alpha - 2b and ribavirin for chronic hepatitis C ( CHC ) .|Ophthalmologic examinations showed ptosis on the right upper lid and restricted right eye movement without any other neurological signs .|A brain imaging study and repetitive nerve stimulation test indicated no abnormality .|The acetylcholine receptor antibody titer and response to acetylcholinesterase inhibitors were negative , and the results of thyroid function tests were normal .|The patient 's ophthalmological symptoms improved rapidly 3 weeks after discontinuation of pegylated IFN alpha - 2b and ribavirin .|The ocular myasthenia associated with combination therapy of pegylated IFN alpha - 2b and ribavirin for CHC is very rarely reported ; therefore , we present this case with a review of the various eye complications of IFN therapy .	1:CID:2	R2L	NON-CROSS	5-7	2-4	C417083	pegylated interferon|pegylated interferon ( IFN ) alpha - 2b|pegylated IFN alpha - 2b|pegylated IFN alpha - 2b|IFN	Chemical	5:31:117:133:162	7:39:122:138:163	0:1:5:6:6	D009157	ocular myasthenia|ocular myasthenia	Disease	2:126	4:128	0:6	1:CID:2	R2L	NON-CROSS	126-128	123-124	D012254	ribavirin|ribavirin|ribavirin|ribavirin	Chemical	8:40:123:139	9:41:124:140	0:1:5:6	D009157	ocular myasthenia|ocular myasthenia	Disease	2:126	4:128	0:6	1:CID:2	L2R	CROSS	31-39	52-58	C417083	pegylated interferon|pegylated interferon ( IFN ) alpha - 2b|pegylated IFN alpha - 2b|pegylated IFN alpha - 2b|IFN	Chemical	5:31:117:133:162	7:39:122:138:163	0:1:5:6:6	D001763	ptosis on the right upper lid	Disease	52	58	2	1:CID:2	L2R	CROSS	31-39	59-63	C417083	pegylated interferon|pegylated interferon ( IFN ) alpha - 2b|pegylated IFN alpha - 2b|pegylated IFN alpha - 2b|IFN	Chemical	5:31:117:133:162	7:39:122:138:163	0:1:5:6:6	D015835	restricted right eye movement	Disease	59	63	2	1:CID:2	L2R	CROSS	40-41	52-58	D012254	ribavirin|ribavirin|ribavirin|ribavirin	Chemical	8:40:123:139	9:41:124:140	0:1:5:6	D001763	ptosis on the right upper lid	Disease	52	58	2	1:CID:2	L2R	CROSS	40-41	59-63	D012254	ribavirin|ribavirin|ribavirin|ribavirin	Chemical	8:40:123:139	9:41:124:140	0:1:5:6	D015835	restricted right eye movement	Disease	59	63	2	1:NR:2	R2L	CROSS	126-128	83-84	D000109	acetylcholine	Chemical	83	84	4	D009157	ocular myasthenia|ocular myasthenia	Disease	2:126	4:128	0:6	1:NR:2	L2R	NON-CROSS	31-39	42-45	C417083	pegylated interferon|pegylated interferon ( IFN ) alpha - 2b|pegylated IFN alpha - 2b|pegylated IFN alpha - 2b|IFN	Chemical	5:31:117:133:162	7:39:122:138:163	0:1:5:6:6	D019698	chronic hepatitis C|chronic hepatitis C|CHC|CHC	Disease	11:42:46:141	14:45:47:142	0:1:1:6	1:NR:2	L2R	NON-CROSS	24-25	31-39	C417083	pegylated interferon|pegylated interferon ( IFN ) alpha - 2b|pegylated IFN alpha - 2b|pegylated IFN alpha - 2b|IFN	Chemical	5:31:117:133:162	7:39:122:138:163	0:1:5:6:6	D004172	diplopia	Disease	24	25	1	1:NR:2	L2R	NON-CROSS	40-41	42-45	D012254	ribavirin|ribavirin|ribavirin|ribavirin	Chemical	8:40:123:139	9:41:124:140	0:1:5:6	D019698	chronic hepatitis C|chronic hepatitis C|CHC|CHC	Disease	11:42:46:141	14:45:47:142	0:1:1:6	1:NR:2	L2R	NON-CROSS	8-9	24-25	D012254	ribavirin|ribavirin|ribavirin|ribavirin	Chemical	8:40:123:139	9:41:124:140	0:1:5:6	D004172	diplopia	Disease	24	25	1	1:NR:2	R2L	CROSS	83-84	46-47	D000109	acetylcholine	Chemical	83	84	4	D019698	chronic hepatitis C|chronic hepatitis C|CHC|CHC	Disease	11:42:46:141	14:45:47:142	0:1:1:6	1:NR:2	R2L	CROSS	83-84	24-25	D000109	acetylcholine	Chemical	83	84	4	D004172	diplopia	Disease	24	25	1	1:NR:2	R2L	CROSS	83-84	52-58	D000109	acetylcholine	Chemical	83	84	4	D001763	ptosis on the right upper lid	Disease	52	58	2	1:NR:2	R2L	CROSS	83-84	59-63	D000109	acetylcholine	Chemical	83	84	4	D015835	restricted right eye movement	Disease	59	63	2
19759529	The glycine transporter - 1 inhibitor SSR103800 displays a selective and specific antipsychotic - like profile in normal and transgenic mice .|Schizophrenia has been initially associated with dysfunction in dopamine neurotransmission .|However , the observation that antagonists of the glutamate N - methyl - D - aspartate ( NMDA ) receptor produce schizophrenic - like symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its NMDA receptor .|As a result , there is a growing interest in the development of pharmacological agents with potential antipsychotic properties that enhance the activity of the glutamatergic system via a modulation of the NMDA receptor .|Among them are glycine transporter - 1 ( GlyT1 ) inhibitors such as SSR103800 , which indirectly enhance NMDA receptor function by increasing the glycine ( a co - agonist for the NMDA receptor ) levels in the synapse .|This study aimed at investigating the potential antipsychotic - like properties of SSR103800 , with a particular focus on models of hyperactivity , involving either drug challenge ( ie , amphetamine and MK - 801 ) or transgenic mice ( ie , NMDA Nr1 ( neo - / - ) and DAT ( - / - ) ) .|Results showed that SSR103800 ( 10 - 30 mg / kg p . o . ) blocked hyperactivity induced by the non - competitive NMDA receptor antagonist , MK - 801 and partially reversed spontaneous hyperactivity of NMDA Nr1 ( neo - / - ) mice .|In contrast , SSR103800 failed to affect hyperactivity induced by amphetamine or naturally observed in dopamine transporter ( DAT ( - / - ) ) knockout mice ( 10 - 30 mg / kg p . o . ) .|Importantly , both classical ( haloperidol ) and atypical ( olanzapine , clozapine and aripiprazole ) antipsychotics were effective in all these models of hyperactivity .|However , unlike these latter , SSR103800 did not produce catalepsy ( retention on the bar test ) up to 30 mg / kg p . o .|Together these findings show that the GlyT1 inhibitor , SSR103800 , produces antipsychotic - like effects , which differ from those observed with compounds primarily targeting the dopaminergic system , and has a reduced side - effect potential as compared with these latter drugs .	1:CID:2	R2L	NON-CROSS	268-269	265-266	D000661	amphetamine|amphetamine	Chemical	182:268	183:269	5:7	D006948	hyperactivity|hyperactivity|hyperactivity|hyperactivity|hyperactivity	Disease	173:228:246:265:322	174:229:247:266:323	5:6:6:7:8	1:CID:2	R2L	NON-CROSS	246-247	239-242	D016291	MK - 801|MK - 801	Chemical	184:239	187:242	5:6	D006948	hyperactivity|hyperactivity|hyperactivity|hyperactivity|hyperactivity	Disease	173:228:246:265:322	174:229:247:266:323	5:6:6:7:8	1:CID:2	L2R	CROSS	303-304	334-335	D006220	haloperidol	Chemical	303	304	8	D002375	catalepsy	Disease	334	335	9	1:CID:2	L2R	CROSS	308-309	334-335	C076029	olanzapine	Chemical	308	309	8	D002375	catalepsy	Disease	334	335	9	1:CID:2	L2R	CROSS	310-311	334-335	D003024	clozapine	Chemical	310	311	8	D002375	catalepsy	Disease	334	335	9	1:CID:2	L2R	CROSS	312-313	334-335	C094645	aripiprazole	Chemical	312	313	8	D002375	catalepsy	Disease	334	335	9	1:NR:2	L2R	CROSS	1-2	22-23	D005998	glycine|glycine|glycine	Chemical	1:115:136	2:116:137	0:4:4	D012559	Schizophrenia|schizophrenic	Disease	22:54	23:55	1:2	1:NR:2	L2R	CROSS	136-137	173-174	D005998	glycine|glycine|glycine	Chemical	1:115:136	2:116:137	0:4:4	D006948	hyperactivity|hyperactivity|hyperactivity|hyperactivity|hyperactivity	Disease	173:228:246:265:322	174:229:247:266:323	5:6:6:7:8	1:NR:2	L2R	CROSS	136-137	334-335	D005998	glycine|glycine|glycine	Chemical	1:115:136	2:116:137	0:4:4	D002375	catalepsy	Disease	334	335	9	1:NR:2	R2L	NON-CROSS	30-31	22-23	D004298	dopamine|dopamine	Chemical	30:273	31:274	1:7	D012559	Schizophrenia|schizophrenic	Disease	22:54	23:55	1:2	1:NR:2	R2L	NON-CROSS	54-55	41-42	D018698	glutamate	Chemical	41	42	2	D012559	Schizophrenia|schizophrenic	Disease	22:54	23:55	1:2	1:NR:2	R2L	NON-CROSS	54-55	50-51	D016202	N - methyl - D - aspartate|NMDA|NMDA|NMDA|NMDA|NMDA|NMDA|NMDA|NMDA	Chemical	42:50:74:109:130:144:194:235:248	49:51:75:110:131:145:195:236:249	2:2:2:3:4:4:5:6:6	D012559	Schizophrenia|schizophrenic	Disease	22:54	23:55	1:2	1:NR:2	R2L	CROSS	182-183	54-55	D000661	amphetamine|amphetamine	Chemical	182:268	183:269	5:7	D012559	Schizophrenia|schizophrenic	Disease	22:54	23:55	1:2	1:NR:2	R2L	CROSS	184-187	54-55	D016291	MK - 801|MK - 801	Chemical	184:239	187:242	5:6	D012559	Schizophrenia|schizophrenic	Disease	22:54	23:55	1:2	1:NR:2	R2L	CROSS	303-304	54-55	D006220	haloperidol	Chemical	303	304	8	D012559	Schizophrenia|schizophrenic	Disease	22:54	23:55	1:2	1:NR:2	R2L	CROSS	308-309	54-55	C076029	olanzapine	Chemical	308	309	8	D012559	Schizophrenia|schizophrenic	Disease	22:54	23:55	1:2	1:NR:2	R2L	CROSS	310-311	54-55	D003024	clozapine	Chemical	310	311	8	D012559	Schizophrenia|schizophrenic	Disease	22:54	23:55	1:2	1:NR:2	R2L	CROSS	312-313	54-55	C094645	aripiprazole	Chemical	312	313	8	D012559	Schizophrenia|schizophrenic	Disease	22:54	23:55	1:2	1:NR:2	L2R	NON-CROSS	265-266	273-274	D004298	dopamine|dopamine	Chemical	30:273	31:274	1:7	D006948	hyperactivity|hyperactivity|hyperactivity|hyperactivity|hyperactivity	Disease	173:228:246:265:322	174:229:247:266:323	5:6:6:7:8	1:NR:2	L2R	CROSS	273-274	334-335	D004298	dopamine|dopamine	Chemical	30:273	31:274	1:7	D002375	catalepsy	Disease	334	335	9	1:NR:2	L2R	CROSS	41-42	173-174	D018698	glutamate	Chemical	41	42	2	D006948	hyperactivity|hyperactivity|hyperactivity|hyperactivity|hyperactivity	Disease	173:228:246:265:322	174:229:247:266:323	5:6:6:7:8	1:NR:2	L2R	CROSS	41-42	334-335	D018698	glutamate	Chemical	41	42	2	D002375	catalepsy	Disease	334	335	9	1:NR:2	L2R	NON-CROSS	246-247	248-249	D016202	N - methyl - D - aspartate|NMDA|NMDA|NMDA|NMDA|NMDA|NMDA|NMDA|NMDA	Chemical	42:50:74:109:130:144:194:235:248	49:51:75:110:131:145:195:236:249	2:2:2:3:4:4:5:6:6	D006948	hyperactivity|hyperactivity|hyperactivity|hyperactivity|hyperactivity	Disease	173:228:246:265:322	174:229:247:266:323	5:6:6:7:8	1:NR:2	L2R	CROSS	248-249	334-335	D016202	N - methyl - D - aspartate|NMDA|NMDA|NMDA|NMDA|NMDA|NMDA|NMDA|NMDA	Chemical	42:50:74:109:130:144:194:235:248	49:51:75:110:131:145:195:236:249	2:2:2:3:4:4:5:6:6	D002375	catalepsy	Disease	334	335	9	1:NR:2	R2L	NON-CROSS	322-323	303-304	D006220	haloperidol	Chemical	303	304	8	D006948	hyperactivity|hyperactivity|hyperactivity|hyperactivity|hyperactivity	Disease	173:228:246:265:322	174:229:247:266:323	5:6:6:7:8	1:NR:2	R2L	NON-CROSS	322-323	308-309	C076029	olanzapine	Chemical	308	309	8	D006948	hyperactivity|hyperactivity|hyperactivity|hyperactivity|hyperactivity	Disease	173:228:246:265:322	174:229:247:266:323	5:6:6:7:8	1:NR:2	R2L	NON-CROSS	322-323	310-311	D003024	clozapine	Chemical	310	311	8	D006948	hyperactivity|hyperactivity|hyperactivity|hyperactivity|hyperactivity	Disease	173:228:246:265:322	174:229:247:266:323	5:6:6:7:8	1:NR:2	R2L	NON-CROSS	322-323	312-313	C094645	aripiprazole	Chemical	312	313	8	D006948	hyperactivity|hyperactivity|hyperactivity|hyperactivity|hyperactivity	Disease	173:228:246:265:322	174:229:247:266:323	5:6:6:7:8	1:NR:2	L2R	CROSS	268-269	334-335	D000661	amphetamine|amphetamine	Chemical	182:268	183:269	5:7	D002375	catalepsy	Disease	334	335	9	1:NR:2	L2R	CROSS	239-242	334-335	D016291	MK - 801|MK - 801	Chemical	184:239	187:242	5:6	D002375	catalepsy	Disease	334	335	9
19957053	Phenylephrine but not ephedrine reduces frontal lobe oxygenation following anesthesia - induced hypotension .|BACKGROUND : Vasopressor agents are used to correct anesthesia - induced hypotension .|We describe the effect of phenylephrine and ephedrine on frontal lobe oxygenation ( S ( c ) O ( 2 ) ) following anesthesia - induced hypotension .|METHODS : Following induction of anesthesia by fentanyl ( 0 . 15 mg kg ( - 1 ) ) and propofol ( 2 . 0 mg kg ( - 1 ) ) , 13 patients received phenylephrine ( 0 . 1 mg iv ) and 12 patients received ephedrine ( 10 mg iv ) to restore mean arterial pressure ( MAP ) .|Heart rate ( HR ) , MAP , stroke volume ( SV ) , cardiac output ( CO ) , and frontal lobe oxygenation ( S ( c ) O ( 2 ) ) were registered .|RESULTS : Induction of anesthesia was followed by a decrease in MAP , HR , SV , and CO concomitant with an elevation in S ( c ) O ( 2 ) .|After administration of phenylephrine , MAP increased ( 51 + / - 12 to 81 + / - 13 mmHg ; P < 0 . 001 ; mean + / - SD ) .|However , a 14 % ( from 70 + / - 8 % to 60 + / - 7 % ) reduction in S ( c ) O ( 2 ) ( P < 0 . 05 ) followed with no change in CO ( 3 . 7 + / - 1 . 1 to 3 . 4 + / - 0 . 9 l min ( - 1 ) ) .|The administration of ephedrine led to a similar increase in MAP ( 53 + / - 9 to 79 + / - 8 mmHg ; P < 0 . 001 ) , restored CO ( 3 . 2 + / - 1 . 2 to 5 . 0 + / - 1 . 3 l min ( - 1 ) ) , and preserved S ( c ) O ( 2 ) .|CONCLUSIONS : The utilization of phenylephrine to correct hypotension induced by anesthesia has a negative impact on S ( c ) O ( 2 ) while ephedrine maintains frontal lobe oxygenation potentially related to an increase in CO .	1:CID:2	L2R	NON-CROSS	0-1	4-8	D010656	Phenylephrine|phenylephrine|phenylephrine|phenylephrine|phenylephrine	Chemical	0:32:91:191:372	1:33:92:192:373	0:2:3:6:9	D002534	reduces frontal lobe oxygenation	Disease	4	8	0	1:CID:2	R2L	CROSS	62-63	53-54	D005283	fentanyl	Chemical	62	63	3	D007022	hypotension|hypotension|hypotension|a decrease in MAP , HR , SV , and CO|hypotension	Disease	12:25:53:163:375	13:26:54:174:376	0:1:2:5:9	1:CID:2	R2L	CROSS	75-76	53-54	D015742	propofol	Chemical	75	76	3	D007022	hypotension|hypotension|hypotension|a decrease in MAP , HR , SV , and CO|hypotension	Disease	12:25:53:163:375	13:26:54:174:376	0:1:2:5:9	1:CID:2	L2R	CROSS	62-63	163-174	D005283	fentanyl	Chemical	62	63	3	D002303	a decrease in MAP , HR , SV , and CO	Disease	163	174	5	1:CID:2	L2R	CROSS	75-76	163-174	D015742	propofol	Chemical	75	76	3	D002303	a decrease in MAP , HR , SV , and CO	Disease	163	174	5	1:NR:2	L2R	NON-CROSS	372-373	375-376	D010656	Phenylephrine|phenylephrine|phenylephrine|phenylephrine|phenylephrine	Chemical	0:32:91:191:372	1:33:92:192:373	0:2:3:6:9	D007022	hypotension|hypotension|hypotension|a decrease in MAP , HR , SV , and CO|hypotension	Disease	12:25:53:163:375	13:26:54:174:376	0:1:2:5:9	1:NR:2	L2R	CROSS	91-92	126-127	D010656	Phenylephrine|phenylephrine|phenylephrine|phenylephrine|phenylephrine	Chemical	0:32:91:191:372	1:33:92:192:373	0:2:3:6:9	D020521	stroke	Disease	126	127	4	1:NR:2	L2R	CROSS	163-174	191-192	D010656	Phenylephrine|phenylephrine|phenylephrine|phenylephrine|phenylephrine	Chemical	0:32:91:191:372	1:33:92:192:373	0:2:3:6:9	D002303	a decrease in MAP , HR , SV , and CO	Disease	163	174	5	1:NR:2	L2R	NON-CROSS	3-4	4-8	D004809	ephedrine|ephedrine|ephedrine|ephedrine|ephedrine	Chemical	3:34:103:297:393	4:35:104:298:394	0:2:3:8:9	D002534	reduces frontal lobe oxygenation	Disease	4	8	0	1:NR:2	L2R	NON-CROSS	3-4	12-13	D004809	ephedrine|ephedrine|ephedrine|ephedrine|ephedrine	Chemical	3:34:103:297:393	4:35:104:298:394	0:2:3:8:9	D007022	hypotension|hypotension|hypotension|a decrease in MAP , HR , SV , and CO|hypotension	Disease	12:25:53:163:375	13:26:54:174:376	0:1:2:5:9	1:NR:2	L2R	CROSS	103-104	126-127	D004809	ephedrine|ephedrine|ephedrine|ephedrine|ephedrine	Chemical	3:34:103:297:393	4:35:104:298:394	0:2:3:8:9	D020521	stroke	Disease	126	127	4	1:NR:2	L2R	CROSS	103-104	163-174	D004809	ephedrine|ephedrine|ephedrine|ephedrine|ephedrine	Chemical	3:34:103:297:393	4:35:104:298:394	0:2:3:8:9	D002303	a decrease in MAP , HR , SV , and CO	Disease	163	174	5	1:NR:2	R2L	CROSS	62-63	4-8	D005283	fentanyl	Chemical	62	63	3	D002534	reduces frontal lobe oxygenation	Disease	4	8	0	1:NR:2	R2L	CROSS	75-76	4-8	D015742	propofol	Chemical	75	76	3	D002534	reduces frontal lobe oxygenation	Disease	4	8	0	1:NR:2	L2R	CROSS	62-63	126-127	D005283	fentanyl	Chemical	62	63	3	D020521	stroke	Disease	126	127	4	1:NR:2	L2R	CROSS	75-76	126-127	D015742	propofol	Chemical	75	76	3	D020521	stroke	Disease	126	127	4
20619828	A novel , multiple symptom model of obsessive - compulsive - like behaviors in animals .|BACKGROUND : Current animal models of obsessive - compulsive disorder ( OCD ) typically involve acute , drug - induced symptom provocation or a genetic association with stereotypies or anxiety .|None of these current models demonstrate multiple OCD - like behaviors .|METHODS : Neonatal rats were treated with the tricyclic antidepressant clomipramine or vehicle between days 9 and 16 twice daily and behaviorally tested in adulthood .|RESULTS : Clomipramine exposure in immature rats produced significant behavioral and biochemical changes that include enhanced anxiety ( elevated plus maze and marble burying ) , behavioral inflexibility ( perseveration in the spontaneous alternation task and impaired reversal learning ) , working memory impairment ( e . g . , win - shift paradigm ) , hoarding , and corticostriatal dysfunction .|Dopamine D2 receptors were elevated in the striatum , whereas serotonin 2C , but not serotonin 1A , receptors were elevated in the orbital frontal cortex .|CONCLUSIONS : This is the first demonstration of multiple symptoms consistent with an OCD - like profile in animals .|Moreover , these behaviors are accompanied by biochemical changes in brain regions previously identified as relevant to OCD .|This novel model of OCD demonstrates that drug exposure during a sensitive period can program disease - like systems permanently , which could have implications for current and future therapeutic strategies for this and other psychiatric disorders .	1:CID:2	R2L	NON-CROSS	101-102	87-88	D002997	clomipramine|Clomipramine	Chemical	69:87	70:88	3:4	D001008	anxiety|anxiety	Disease	45:101	46:102	1:4	1:CID:2	L2R	NON-CROSS	87-88	127-129	D002997	clomipramine|Clomipramine	Chemical	69:87	70:88	3:4	D008569	memory impairment	Disease	127	129	4	1:CID:2	L2R	NON-CROSS	87-88	141-142	D002997	clomipramine|Clomipramine	Chemical	69:87	70:88	3:4	D060845	hoarding	Disease	141	142	4	1:NR:2	R2L	CROSS	68-69	54-55	D000928	antidepressant	Chemical	68	69	3	D009771	obsessive - compulsive - like behaviors|obsessive - compulsive disorder|OCD|OCD|OCD|OCD|OCD	Disease	7:22:27:54:187:211:217	13:26:28:55:188:212:218	0:1:1:2:6:7:8	1:NR:2	R2L	CROSS	69-70	54-55	D002997	clomipramine|Clomipramine	Chemical	69:87	70:88	3:4	D009771	obsessive - compulsive - like behaviors|obsessive - compulsive disorder|OCD|OCD|OCD|OCD|OCD	Disease	7:22:27:54:187:211:217	13:26:28:55:188:212:218	0:1:1:2:6:7:8	1:NR:2	R2L	CROSS	187-188	147-148	D004298	Dopamine	Chemical	147	148	5	D009771	obsessive - compulsive - like behaviors|obsessive - compulsive disorder|OCD|OCD|OCD|OCD|OCD	Disease	7:22:27:54:187:211:217	13:26:28:55:188:212:218	0:1:1:2:6:7:8	1:NR:2	R2L	CROSS	187-188	162-163	D012701	serotonin|serotonin	Chemical	157:162	158:163	5:5	D009771	obsessive - compulsive - like behaviors|obsessive - compulsive disorder|OCD|OCD|OCD|OCD|OCD	Disease	7:22:27:54:187:211:217	13:26:28:55:188:212:218	0:1:1:2:6:7:8	1:NR:2	R2L	CROSS	68-69	45-46	D000928	antidepressant	Chemical	68	69	3	D001008	anxiety|anxiety	Disease	45:101	46:102	1:4	1:NR:2	R2L	CROSS	147-148	101-102	D004298	Dopamine	Chemical	147	148	5	D001008	anxiety|anxiety	Disease	45:101	46:102	1:4	1:NR:2	R2L	CROSS	157-158	101-102	D012701	serotonin|serotonin	Chemical	157:162	158:163	5:5	D001008	anxiety|anxiety	Disease	45:101	46:102	1:4	1:NR:2	L2R	CROSS	68-69	127-129	D000928	antidepressant	Chemical	68	69	3	D008569	memory impairment	Disease	127	129	4	1:NR:2	L2R	CROSS	68-69	141-142	D000928	antidepressant	Chemical	68	69	3	D060845	hoarding	Disease	141	142	4	1:NR:2	L2R	CROSS	68-69	248-250	D000928	antidepressant	Chemical	68	69	3	D001523	psychiatric disorders	Disease	248	250	8	not_include	L2R	CROSS	87-88	248-250	D002997	clomipramine|Clomipramine	Chemical	69:87	70:88	3:4	D001523	psychiatric disorders	Disease	248	250	8	1:NR:2	R2L	CROSS	147-148	127-129	D004298	Dopamine	Chemical	147	148	5	D008569	memory impairment	Disease	127	129	4	1:NR:2	R2L	CROSS	157-158	127-129	D012701	serotonin|serotonin	Chemical	157:162	158:163	5:5	D008569	memory impairment	Disease	127	129	4	1:NR:2	R2L	CROSS	147-148	141-142	D004298	Dopamine	Chemical	147	148	5	D060845	hoarding	Disease	141	142	4	1:NR:2	R2L	CROSS	157-158	141-142	D012701	serotonin|serotonin	Chemical	157:162	158:163	5:5	D060845	hoarding	Disease	141	142	4	1:NR:2	L2R	CROSS	147-148	248-250	D004298	Dopamine	Chemical	147	148	5	D001523	psychiatric disorders	Disease	248	250	8	1:NR:2	L2R	CROSS	162-163	248-250	D012701	serotonin|serotonin	Chemical	157:162	158:163	5:5	D001523	psychiatric disorders	Disease	248	250	8
891050	Late recovery of renal function in a woman with the hemolytic uremic syndrome .|A case is reported of the hemolytic uremic syndrome ( HUS ) in a woman taking oral contraceptives .|She was treated with heparin , dipyridamole and hemodialysis ; and after more than three months , her urinary output rose above 500 ml ; and six months after the onset of anuria , dialysis treatment was stopped .|This case emphasizes the possibility that HUS in adults is not invariably irreversible and that , despite prolonged oliguria , recovery of renal function can be obtained .|Therefore , in adult patients affected by HUS , dialysis should not be discontinued prematurely ; moreover , bilateral nephrectomy , for treatment of severe hypertension and microangiopathic hemolytic anemia , should be performed with caution .	1:CID:2	R2L	NON-CROSS	30-32	24-25	D003276	oral contraceptives	Chemical	30	32	1	D006463	hemolytic uremic syndrome|hemolytic uremic syndrome|HUS|HUS|HUS	Disease	10:20:24:78:107	13:23:25:79:108	0:1:1:3:4	1:NR:2	R2L	CROSS	37-38	24-25	D006493	heparin	Chemical	37	38	2	D006463	hemolytic uremic syndrome|hemolytic uremic syndrome|HUS|HUS|HUS	Disease	10:20:24:78:107	13:23:25:79:108	0:1:1:3:4	1:NR:2	R2L	CROSS	39-40	24-25	D004176	dipyridamole	Chemical	39	40	2	D006463	hemolytic uremic syndrome|hemolytic uremic syndrome|HUS|HUS|HUS	Disease	10:20:24:78:107	13:23:25:79:108	0:1:1:3:4	1:NR:2	L2R	CROSS	30-32	65-66	D003276	oral contraceptives	Chemical	30	32	1	D001002	anuria	Disease	65	66	2	1:NR:2	L2R	CROSS	30-32	90-91	D003276	oral contraceptives	Chemical	30	32	1	D009846	oliguria	Disease	90	91	3	1:NR:2	L2R	CROSS	30-32	125-126	D003276	oral contraceptives	Chemical	30	32	1	D006973	hypertension	Disease	125	126	4	not_include	L2R	CROSS	30-32	127-130	D003276	oral contraceptives	Chemical	30	32	1	D000743	microangiopathic hemolytic anemia	Disease	127	130	4	1:NR:2	L2R	NON-CROSS	37-38	65-66	D006493	heparin	Chemical	37	38	2	D001002	anuria	Disease	65	66	2	1:NR:2	L2R	CROSS	37-38	90-91	D006493	heparin	Chemical	37	38	2	D009846	oliguria	Disease	90	91	3	1:NR:2	L2R	CROSS	37-38	125-126	D006493	heparin	Chemical	37	38	2	D006973	hypertension	Disease	125	126	4	1:NR:2	L2R	CROSS	37-38	127-130	D006493	heparin	Chemical	37	38	2	D000743	microangiopathic hemolytic anemia	Disease	127	130	4	1:NR:2	L2R	NON-CROSS	39-40	65-66	D004176	dipyridamole	Chemical	39	40	2	D001002	anuria	Disease	65	66	2	1:NR:2	L2R	CROSS	39-40	90-91	D004176	dipyridamole	Chemical	39	40	2	D009846	oliguria	Disease	90	91	3	1:NR:2	L2R	CROSS	39-40	125-126	D004176	dipyridamole	Chemical	39	40	2	D006973	hypertension	Disease	125	126	4	1:NR:2	L2R	CROSS	39-40	127-130	D004176	dipyridamole	Chemical	39	40	2	D000743	microangiopathic hemolytic anemia	Disease	127	130	4
983936	Effects of acetylsalicylic acid , dipyridamole , and hydrocortisone on epinephrine - induced myocardial injury in dogs .|A reproducible model for producing diffuse myocardial injury ( epinephrine infusion ) has been developed to study the cardioprotective effects of agents or maneuvers which might alter the evolution of acute myocardial infarction .|Infusions of epinephrine ( 4 mug per kilogram per minute for 6 hours ) increased radiocalcium uptakes into intact myocardium and each of its subcellular components with the mitochondrial fraction showing the most consistent changes when compared to saline - infused control animals ( 4 , 957 vs . 827 counts per minute per gram of dried tissue or fraction ) .|Myocardial concentrations of calcium also increased significantly ( 12 . 0 vs . 5 . 0 mg . per 100 Gm . of fat - free dry weight ) .|Infusions of calcium chloride sufficient to raise serum calcium concentrations 2 mEq . per liter failed to increase calcium influx into the myocardial cell .|Mitochondrial radiocalcium uptakes were significantly decreased in animals pretreated with acetylsalicylic acid or dipyridamole or when hydrocortisone was added to the epinephrine infusion ( 2 , 682 , 2 , 803 , and 3 , 424 counts per minute per gram of dried fraction , respectively ) .|Myocardial calcium concentrations also were decreased ( 11 . 2 , 8 . 3 , and 8 . 9 mg .|per 100 Gm . of fat - free dry weight , respectively ) in the three treatment groups , being significantly decreased only in the last two .|Evidence of microscopic damage was graded as less severe in the three treatment groups .|Acetylsalicylic acid , dipyridamole , and hydrocortisone all appear to have cardioprotective effects when tested in this model .	1:CID:2	L2R	NON-CROSS	24-26	27-28	D004837	epinephrine|epinephrine|epinephrine|epinephrine	Chemical	10:27:54:190	11:28:55:191	0:1:2:5	D009202	myocardial injury|myocardial injury	Disease	13:24	15:26	0:1	1:NR:2	L2R	NON-CROSS	2-4	13-15	D001241	acetylsalicylic acid|acetylsalicylic acid|Acetylsalicylic acid	Chemical	2:179:281	4:181:283	0:5:9	D009202	myocardial injury|myocardial injury	Disease	13:24	15:26	0:1	1:NR:2	L2R	CROSS	2-4	49-51	D001241	acetylsalicylic acid|acetylsalicylic acid|Acetylsalicylic acid	Chemical	2:179:281	4:181:283	0:5:9	D009203	myocardial infarction	Disease	49	51	1	1:NR:2	L2R	NON-CROSS	5-6	13-15	D004176	dipyridamole|dipyridamole|dipyridamole	Chemical	5:182:284	6:183:285	0:5:9	D009202	myocardial injury|myocardial injury	Disease	13:24	15:26	0:1	1:NR:2	L2R	CROSS	5-6	49-51	D004176	dipyridamole|dipyridamole|dipyridamole	Chemical	5:182:284	6:183:285	0:5:9	D009203	myocardial infarction	Disease	49	51	1	1:NR:2	L2R	NON-CROSS	8-9	13-15	D006854	hydrocortisone|hydrocortisone|hydrocortisone	Chemical	8:185:287	9:186:288	0:5:9	D009202	myocardial injury|myocardial injury	Disease	13:24	15:26	0:1	1:NR:2	L2R	CROSS	8-9	49-51	D006854	hydrocortisone|hydrocortisone|hydrocortisone	Chemical	8:185:287	9:186:288	0:5:9	D009203	myocardial infarction	Disease	49	51	1	1:NR:2	L2R	NON-CROSS	49-51	54-55	D004837	epinephrine|epinephrine|epinephrine|epinephrine	Chemical	10:27:54:190	11:28:55:191	0:1:2:5	D009203	myocardial infarction	Disease	49	51	1	1:NR:2	R2L	CROSS	67-68	24-26	D002132	radiocalcium|radiocalcium	Chemical	67:170	68:171	2:5	D009202	myocardial injury|myocardial injury	Disease	13:24	15:26	0:1	1:NR:2	R2L	CROSS	117-118	24-26	D002118	calcium|calcium|calcium|calcium	Chemical	117:152:162:218	118:153:163:219	3:4:4:6	D009202	myocardial injury|myocardial injury	Disease	13:24	15:26	0:1	1:NR:2	R2L	CROSS	146-148	24-26	D002122	calcium chloride	Chemical	146	148	4	D009202	myocardial injury|myocardial injury	Disease	13:24	15:26	0:1	1:NR:2	R2L	CROSS	67-68	49-51	D002132	radiocalcium|radiocalcium	Chemical	67:170	68:171	2:5	D009203	myocardial infarction	Disease	49	51	1	1:NR:2	R2L	CROSS	117-118	49-51	D002118	calcium|calcium|calcium|calcium	Chemical	117:152:162:218	118:153:163:219	3:4:4:6	D009203	myocardial infarction	Disease	49	51	1	1:NR:2	R2L	CROSS	146-148	49-51	D002122	calcium chloride	Chemical	146	148	4	D009203	myocardial infarction	Disease	49	51	1
1428568	Changes in depressive status associated with topical beta - blockers .|Depression and sexual dysfunction have been related to side effects of topical beta - blockers .|We performed a preliminary study in order to determine any difference between a non selective beta - blocker ( timolol ) and a selective beta - blocker ( betaxolol ) regarding CNS side effects .|Eight glaucomatous patients chronically treated with timolol 0 . 5 % / 12h , suffering from depression diagnosed through DMS - III - R criteria , were included in the study .|During the six - month follow up , depression was quantified through the Beck and Zung - Conde scales every two months .|In a double blind cross - over study with control group , the patients under timolol treatment presented higher depression values measured through the Beck and the Zung - Conde scales ( p < 0 . 001 vs control ) .|These results suggest that betaxolol could be less of a depression - inducer than timolol in predisposed patients .	1:CID:2	R2L	NON-CROSS	136-137	132-133	D013999	timolol|timolol|timolol|timolol	Chemical	46:68:132:172	47:69:133:173	2:3:5:6	D003866	depressive|Depression|depression|depression|depression|depression	Disease	2:11:78:102:136:168	3:12:79:103:137:169	0:1:3:4:5:6	1:NR:2	R2L	NON-CROSS	168-169	162-163	D015784	betaxolol|betaxolol	Chemical	55:162	56:163	2:6	D003866	depressive|Depression|depression|depression|depression|depression	Disease	2:11:78:102:136:168	3:12:79:103:137:169	0:1:3:4:5:6	1:NR:2	R2L	CROSS	46-47	13-15	D013999	timolol|timolol|timolol|timolol	Chemical	46:68:132:172	47:69:133:173	2:3:5:6	D012735	sexual dysfunction	Disease	13	15	1	1:NR:2	R2L	CROSS	55-56	13-15	D015784	betaxolol|betaxolol	Chemical	55:162	56:163	2:6	D012735	sexual dysfunction	Disease	13	15	1	1:NR:2	L2R	NON-CROSS	63-64	68-69	D013999	timolol|timolol|timolol|timolol	Chemical	46:68:132:172	47:69:133:173	2:3:5:6	D005901	glaucomatous	Disease	63	64	3	1:NR:2	L2R	CROSS	55-56	63-64	D015784	betaxolol|betaxolol	Chemical	55:162	56:163	2:6	D005901	glaucomatous	Disease	63	64	3
1720453	Long - term follow - up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors : an International Society of Pediatric Oncology report .|The renal function of 74 children with malignant mesenchymal tumors in complete remission and who have received the same ifosfamide chemotherapy protocol ( International Society of Pediatric Oncology Malignant Mesenchymal Tumor Study 84 [ SIOP MMT 84 ] ) were studied 1 year after the completion of treatment .|Total cumulative doses were 36 or 60 g / m2 of ifosfamide ( six or 10 cycles of ifosfamide , vincristine , and dactinomycin [ IVA ] ) .|None of them had received cisplatin chemotherapy .|Ages ranged from 4 months to 17 years ; 58 patients were males and 42 females .|The most common primary tumor site was the head and neck .|Renal function was investigated by measuring plasma and urinary electrolytes , glucosuria , proteinuria , aminoaciduria , urinary pH , osmolarity , creatinine clearance , phosphate tubular reabsorption , beta 2 microglobulinuria , and lysozymuria .|Fifty - eight patients ( 78 % ) had normal renal tests , whereas 16 patients ( 22 % ) had renal abnormalities .|Two subsets of patients were identified from this latter group : the first included four patients ( 5 % of the total population ) who developed major toxicity resulting in Fanconi 's syndrome ( TDFS ) ; and the second group included five patients with elevated beta 2 microglobulinuria and low phosphate reabsorption .|The remaining seven patients had isolated beta 2 microglobulinuria .|Severe toxicity was correlated with the higher cumulative dose of 60 g / m2 of ifosfamide , a younger age ( less than 2 1 / 2 years old ) , and a predominance of vesicoprostatic tumor involvement .|This low percentage ( 5 % ) of TDFS must be evaluated with respect to the efficacy of ifosfamide in the treatment of mesenchymal tumors in children .	1:CID:2	L2R	NON-CROSS	7-8	8-10	D007069	ifosfamide|ifosfamide|ifosfamide|ifosfamide|ifosfamide	Chemical	7:45:86:280:322	8:46:87:281:323	0:1:2:10:11	D007674	renal toxicity|renal abnormalities	Disease	8:198	10:200	0:7	1:CID:2	L2R	CROSS	235-236	280-281	D007069	ifosfamide|ifosfamide|ifosfamide|ifosfamide|ifosfamide	Chemical	7:45:86:280:322	8:46:87:281:323	0:1:2:10:11	D005198	Fanconi 's syndrome|TDFS	Disease	231:235	234:236	8:8	1:NR:2	L2R	NON-CROSS	322-323	327-329	D007069	ifosfamide|ifosfamide|ifosfamide|ifosfamide|ifosfamide	Chemical	7:45:86:280:322	8:46:87:281:323	0:1:2:10:11	C535700	malignant mesenchymal tumors|malignant mesenchymal tumors|Malignant Mesenchymal Tumor|mesenchymal tumors	Disease	14:33:54:327	17:36:57:329	0:1:1:11	1:NR:2	L2R	NON-CROSS	280-281	301-302	D007069	ifosfamide|ifosfamide|ifosfamide|ifosfamide|ifosfamide	Chemical	7:45:86:280:322	8:46:87:281:323	0:1:2:10:11	D009369	tumor|tumor	Disease	133:301	134:302	5:10	1:NR:2	L2R	CROSS	86-87	152-153	D007069	ifosfamide|ifosfamide|ifosfamide|ifosfamide|ifosfamide	Chemical	7:45:86:280:322	8:46:87:281:323	0:1:2:10:11	D006030	glucosuria	Disease	152	153	6	1:NR:2	L2R	CROSS	86-87	154-155	D007069	ifosfamide|ifosfamide|ifosfamide|ifosfamide|ifosfamide	Chemical	7:45:86:280:322	8:46:87:281:323	0:1:2:10:11	D011507	proteinuria	Disease	154	155	6	1:NR:2	L2R	CROSS	86-87	156-157	D007069	ifosfamide|ifosfamide|ifosfamide|ifosfamide|ifosfamide	Chemical	7:45:86:280:322	8:46:87:281:323	0:1:2:10:11	D000608	aminoaciduria	Disease	156	157	6	1:NR:2	L2R	NON-CROSS	266-267	280-281	D007069	ifosfamide|ifosfamide|ifosfamide|ifosfamide|ifosfamide	Chemical	7:45:86:280:322	8:46:87:281:323	0:1:2:10:11	D064420	toxicity|toxicity	Disease	228:266	229:267	8:10	1:NR:2	R2L	CROSS	93-99	8-10	C064227	ifosfamide , vincristine , and dactinomycin|IVA	Chemical	93:100	99:101	2:2	D007674	renal toxicity|renal abnormalities	Disease	8:198	10:200	0:7	1:NR:2	R2L	CROSS	198-200	109-110	D002945	cisplatin	Chemical	109	110	3	D007674	renal toxicity|renal abnormalities	Disease	8:198	10:200	0:7	1:NR:2	R2L	CROSS	198-200	163-164	D003404	creatinine	Chemical	163	164	6	D007674	renal toxicity|renal abnormalities	Disease	8:198	10:200	0:7	1:NR:2	R2L	CROSS	198-200	166-167	D010710	phosphate|phosphate	Chemical	166:252	167:253	6:8	D007674	renal toxicity|renal abnormalities	Disease	8:198	10:200	0:7	1:NR:2	R2L	CROSS	93-99	54-57	C064227	ifosfamide , vincristine , and dactinomycin|IVA	Chemical	93:100	99:101	2:2	C535700	malignant mesenchymal tumors|malignant mesenchymal tumors|Malignant Mesenchymal Tumor|mesenchymal tumors	Disease	14:33:54:327	17:36:57:329	0:1:1:11	1:NR:2	R2L	CROSS	109-110	54-57	D002945	cisplatin	Chemical	109	110	3	C535700	malignant mesenchymal tumors|malignant mesenchymal tumors|Malignant Mesenchymal Tumor|mesenchymal tumors	Disease	14:33:54:327	17:36:57:329	0:1:1:11	1:NR:2	R2L	CROSS	163-164	54-57	D003404	creatinine	Chemical	163	164	6	C535700	malignant mesenchymal tumors|malignant mesenchymal tumors|Malignant Mesenchymal Tumor|mesenchymal tumors	Disease	14:33:54:327	17:36:57:329	0:1:1:11	1:NR:2	R2L	CROSS	327-329	252-253	D010710	phosphate|phosphate	Chemical	166:252	167:253	6:8	C535700	malignant mesenchymal tumors|malignant mesenchymal tumors|Malignant Mesenchymal Tumor|mesenchymal tumors	Disease	14:33:54:327	17:36:57:329	0:1:1:11	1:NR:2	L2R	CROSS	100-101	133-134	C064227	ifosfamide , vincristine , and dactinomycin|IVA	Chemical	93:100	99:101	2:2	D009369	tumor|tumor	Disease	133:301	134:302	5:10	1:NR:2	L2R	CROSS	100-101	152-153	C064227	ifosfamide , vincristine , and dactinomycin|IVA	Chemical	93:100	99:101	2:2	D006030	glucosuria	Disease	152	153	6	1:NR:2	L2R	CROSS	100-101	154-155	C064227	ifosfamide , vincristine , and dactinomycin|IVA	Chemical	93:100	99:101	2:2	D011507	proteinuria	Disease	154	155	6	1:NR:2	L2R	CROSS	100-101	156-157	C064227	ifosfamide , vincristine , and dactinomycin|IVA	Chemical	93:100	99:101	2:2	D000608	aminoaciduria	Disease	156	157	6	1:NR:2	L2R	CROSS	100-101	228-229	C064227	ifosfamide , vincristine , and dactinomycin|IVA	Chemical	93:100	99:101	2:2	D064420	toxicity|toxicity	Disease	228:266	229:267	8:10	1:NR:2	L2R	CROSS	100-101	231-234	C064227	ifosfamide , vincristine , and dactinomycin|IVA	Chemical	93:100	99:101	2:2	D005198	Fanconi 's syndrome|TDFS	Disease	231:235	234:236	8:8	1:NR:2	L2R	CROSS	109-110	133-134	D002945	cisplatin	Chemical	109	110	3	D009369	tumor|tumor	Disease	133:301	134:302	5:10	1:NR:2	L2R	CROSS	109-110	152-153	D002945	cisplatin	Chemical	109	110	3	D006030	glucosuria	Disease	152	153	6	1:NR:2	L2R	CROSS	109-110	154-155	D002945	cisplatin	Chemical	109	110	3	D011507	proteinuria	Disease	154	155	6	1:NR:2	L2R	CROSS	109-110	156-157	D002945	cisplatin	Chemical	109	110	3	D000608	aminoaciduria	Disease	156	157	6	1:NR:2	L2R	CROSS	109-110	228-229	D002945	cisplatin	Chemical	109	110	3	D064420	toxicity|toxicity	Disease	228:266	229:267	8:10	1:NR:2	L2R	CROSS	109-110	231-234	D002945	cisplatin	Chemical	109	110	3	D005198	Fanconi 's syndrome|TDFS	Disease	231:235	234:236	8:8	1:NR:2	R2L	CROSS	163-164	133-134	D003404	creatinine	Chemical	163	164	6	D009369	tumor|tumor	Disease	133:301	134:302	5:10	1:NR:2	R2L	CROSS	166-167	133-134	D010710	phosphate|phosphate	Chemical	166:252	167:253	6:8	D009369	tumor|tumor	Disease	133:301	134:302	5:10	1:NR:2	R2L	NON-CROSS	163-164	152-153	D003404	creatinine	Chemical	163	164	6	D006030	glucosuria	Disease	152	153	6	1:NR:2	R2L	NON-CROSS	166-167	152-153	D010710	phosphate|phosphate	Chemical	166:252	167:253	6:8	D006030	glucosuria	Disease	152	153	6	1:NR:2	R2L	NON-CROSS	163-164	154-155	D003404	creatinine	Chemical	163	164	6	D011507	proteinuria	Disease	154	155	6	1:NR:2	R2L	NON-CROSS	166-167	154-155	D010710	phosphate|phosphate	Chemical	166:252	167:253	6:8	D011507	proteinuria	Disease	154	155	6	1:NR:2	R2L	NON-CROSS	163-164	156-157	D003404	creatinine	Chemical	163	164	6	D000608	aminoaciduria	Disease	156	157	6	1:NR:2	R2L	NON-CROSS	166-167	156-157	D010710	phosphate|phosphate	Chemical	166:252	167:253	6:8	D000608	aminoaciduria	Disease	156	157	6	1:NR:2	L2R	CROSS	163-164	228-229	D003404	creatinine	Chemical	163	164	6	D064420	toxicity|toxicity	Disease	228:266	229:267	8:10	1:NR:2	L2R	CROSS	163-164	231-234	D003404	creatinine	Chemical	163	164	6	D005198	Fanconi 's syndrome|TDFS	Disease	231:235	234:236	8:8	1:NR:2	L2R	NON-CROSS	252-253	266-267	D010710	phosphate|phosphate	Chemical	166:252	167:253	6:8	D064420	toxicity|toxicity	Disease	228:266	229:267	8:10	1:NR:2	L2R	NON-CROSS	235-236	252-253	D010710	phosphate|phosphate	Chemical	166:252	167:253	6:8	D005198	Fanconi 's syndrome|TDFS	Disease	231:235	234:236	8:8
1833784	Evidence for an involvement of D1 and D2 dopamine receptors in mediating nicotine - induced hyperactivity in rats .|Previous studies have suggested that repeated exposure of rats to the drug or to the experimental environment is necessary to observe nicotine - induced locomotor stimulation .|In the present study the role of habituation to the experimental environment on the stimulant effect of nicotine in rats was examined .|In addition , the role of dopamine receptors in mediating nicotine - induced locomotor stimulation was investigated by examining the effects of selective D1 and D2 dopamine receptor antagonists on activity induced by nicotine .|Locomotor activity was assessed in male Sprague - Dawley rats tested in photocell cages .|Nicotine ( 1 . 0 mg / kg ) caused a significant increase in locomotor activity in rats that were habituated to the test environment , but had only a weak and delayed stimulant action in rats that were unfamiliar with the test environment .|The stimulant action of nicotine was blocked by the central nicotinic antagonist mecamylamine but not by the peripheral nicotinic blocker hexamethonium , indicating that the response is probably mediated by central nicotinic receptors .|Nicotine - induced hyperactivity was blocked by the selective D1 antagonist SCH 23390 , the selective D2 antagonist raclopride and the D1 / D2 antagonist fluphenazine .|Pretreatment with the D2 agonist PHNO enhanced nicotine - induced hyperactivity , whereas the D1 agonist SKF 38393 had no effect .|The results indicate that acute nicotine injection induces a pronounced hyperactivity in rats habituated to the test environment .|The effect appears to be mediated by central nicotine receptors , possibly located on dopaminergic neurons , and also requires the activation of both D1 and D2 dopamine receptors .	1:CID:2	L2R	NON-CROSS	12-13	15-16	D009538	nicotine|nicotine|nicotine|nicotine|nicotine|Nicotine|nicotine|Nicotine|nicotine|nicotine|nicotine	Chemical	12:40:63:79:102:119:168:198:232:252:274	13:41:64:80:103:120:169:199:233:253:275	0:1:2:3:3:5:6:7:8:9:10	D006948	hyperactivity|increase in locomotor activity|hyperactivity|hyperactivity|hyperactivity	Disease	15:131:201:235:257	16:135:202:236:258	0:5:7:8:9	1:NR:2	L2R	NON-CROSS	8-9	15-16	D004298	dopamine|dopamine|dopamine|dopamine	Chemical	8:75:95:293	9:76:96:294	0:3:3:10	D006948	hyperactivity|increase in locomotor activity|hyperactivity|hyperactivity|hyperactivity	Disease	15:131:201:235:257	16:135:202:236:258	0:5:7:8:9	1:NR:2	R2L	CROSS	201-202	176-177	D008464	mecamylamine	Chemical	176	177	6	D006948	hyperactivity|increase in locomotor activity|hyperactivity|hyperactivity|hyperactivity	Disease	15:131:201:235:257	16:135:202:236:258	0:5:7:8:9	1:NR:2	R2L	CROSS	201-202	184-185	D018738	hexamethonium	Chemical	184	185	6	D006948	hyperactivity|increase in locomotor activity|hyperactivity|hyperactivity|hyperactivity	Disease	15:131:201:235:257	16:135:202:236:258	0:5:7:8:9	1:NR:2	R2L	NON-CROSS	209-211	201-202	C534628	SCH 23390	Chemical	209	211	7	D006948	hyperactivity|increase in locomotor activity|hyperactivity|hyperactivity|hyperactivity	Disease	15:131:201:235:257	16:135:202:236:258	0:5:7:8:9	1:NR:2	R2L	NON-CROSS	216-217	201-202	D020891	raclopride	Chemical	216	217	7	D006948	hyperactivity|increase in locomotor activity|hyperactivity|hyperactivity|hyperactivity	Disease	15:131:201:235:257	16:135:202:236:258	0:5:7:8:9	1:NR:2	R2L	NON-CROSS	235-236	223-224	D005476	fluphenazine	Chemical	223	224	7	D006948	hyperactivity|increase in locomotor activity|hyperactivity|hyperactivity|hyperactivity	Disease	15:131:201:235:257	16:135:202:236:258	0:5:7:8:9	1:NR:2	R2L	NON-CROSS	241-243	235-236	D015647	SKF 38393	Chemical	241	243	8	D006948	hyperactivity|increase in locomotor activity|hyperactivity|hyperactivity|hyperactivity	Disease	15:131:201:235:257	16:135:202:236:258	0:5:7:8:9
1867351	Neuropsychiatric side effects after the use of mefloquine .|This study describes neuropsychiatric side effects in patients after treatment with mefloquine .|Reactions consisted mainly of seizures , acute psychoses , anxiety neurosis , and major disturbances of sleep - wake rhythm .|Side effects occurred after both therapeutic and prophylactic intake and were graded from moderate to severe .|In a risk analysis of neuropsychiatric side effects in Germany , it is estimated that one of 8 , 000 mefloquine users suffers from such reactions .|The incidence calculation revealed that one of 215 therapeutic users had reactions , compared with one of 13 , 000 in the prophylaxis group , making the risk of neuropsychiatric reactions after mefloquine treatment 60 times higher than after prophylaxis .|Therefore , certain limitations for malaria prophylaxis and treatment with mefloquine are recommended .	1:CID:2	L2R	CROSS	20-21	26-27	D015767	mefloquine|mefloquine|mefloquine|mefloquine|mefloquine	Chemical	7:20:80:119:138	8:21:81:120:139	0:1:4:5:6	D012640	seizures	Disease	26	27	2	1:CID:2	L2R	CROSS	20-21	29-30	D015767	mefloquine|mefloquine|mefloquine|mefloquine|mefloquine	Chemical	7:20:80:119:138	8:21:81:120:139	0:1:4:5:6	D011605	psychoses	Disease	29	30	2	1:CID:2	L2R	CROSS	20-21	31-33	D015767	mefloquine|mefloquine|mefloquine|mefloquine|mefloquine	Chemical	7:20:80:119:138	8:21:81:120:139	0:1:4:5:6	D001008	anxiety neurosis	Disease	31	33	2	1:CID:2	L2R	CROSS	20-21	36-42	D015767	mefloquine|mefloquine|mefloquine|mefloquine|mefloquine	Chemical	7:20:80:119:138	8:21:81:120:139	0:1:4:5:6	D012893	disturbances of sleep - wake rhythm	Disease	36	42	2	1:NR:2	L2R	NON-CROSS	133-134	138-139	D015767	mefloquine|mefloquine|mefloquine|mefloquine|mefloquine	Chemical	7:20:80:119:138	8:21:81:120:139	0:1:4:5:6	D008288	malaria	Disease	133	134	6
2070391	Reduction in injection pain using buffered lidocaine as a local anesthetic before cardiac catheterization .|Previous reports have suggested that pain associated with the injection of lidocaine is related to the acidic pH of the solution .|To determine if the addition of a buffering solution to adjust the pH of lidocaine into the physiologic range would reduce pain during injection , we performed a blinded randomized study in patients undergoing cardiac catheterization .|Twenty patients were asked to quantify the severity of pain after receiving standard lidocaine in one femoral area and buffered lidocaine in the opposite femoral area .|The mean pain score for buffered lidocaine was significantly lower than the mean score for standard lidocaine ( 2 . 7 + / - 1 . 9 vs . 3 . 8 + / - 2 . 2 , P = 0 . 03 ) .|The pH adjustment of standard lidocaine can be accomplished easily in the catheterization laboratory before injection and results in a reduction of the pain occurring during the infiltration of tissues .	1:CID:2	R2L	NON-CROSS	6-7	3-4	D008012	lidocaine|lidocaine|lidocaine|lidocaine|lidocaine|lidocaine|lidocaine|lidocaine	Chemical	6:26:51:87:94:107:117:152	7:27:52:88:95:108:118:153	0:1:2:3:3:4:4:5	D010146	pain|pain|pain|pain|pain|pain	Disease	3:20:58:83:103:170	4:21:59:84:104:171	0:1:2:3:4:5
2266990	Randomized , double - blind trial of mazindol in Duchenne dystrophy .|There is evidence that growth hormone may be related to the progression of weakness in Duchenne dystrophy .|We conducted a 12 - month controlled trial of mazindol , a putative growth hormone secretion inhibitor , in 83 boys with Duchenne dystrophy .|Muscle strength , contractures , functional ability and pulmonary function were tested at baseline , and 6 and 12 months after treatment with mazindol ( 3 mg / d ) or placebo .|The study was designed to have a power of greater than 0 . 90 to detect a slowing to 25 % of the expected rate of progression of weakness at P less than 0 . 05 .|Mazindol did not benefit strength at any point in the study .|Side effects attributable to mazindol included decreased appetite ( 36 % ) , dry mouth ( 10 % ) , behavioral change ( 22 % ) , and gastrointestinal symptoms ( 18 % ) ; mazindol dosage was reduced in 43 % of patients .|The effect of mazindol on GH secretion was estimated indirectly by comparing the postabsorptive IGF - I levels obtained following 3 , 6 , 9 , and 12 months in the mazindol treated to those in the placebo groups .|Although mazindol - treated patients gained less weight and height than placebo - treated patients , no significant effect on IGF - I levels was observed .|Mazindol doses not slow the progression of weakness in Duchenne dystrophy .	1:CID:2	L2R	NON-CROSS	141-142	143-145	D008454	mazindol|mazindol|mazindol|Mazindol|mazindol|mazindol|mazindol|mazindol|mazindol|Mazindol	Chemical	7:39:78:125:141:172:185:213:223:249	8:40:79:126:142:173:186:214:224:250	0:2:3:5:6:6:7:7:8:9	D001068	decreased appetite	Disease	143	145	6	1:CID:2	L2R	NON-CROSS	141-142	150-152	D008454	mazindol|mazindol|mazindol|Mazindol|mazindol|mazindol|mazindol|mazindol|mazindol|Mazindol	Chemical	7:39:78:125:141:172:185:213:223:249	8:40:79:126:142:173:186:214:224:250	0:2:3:5:6:6:7:7:8:9	D014987	dry mouth	Disease	150	152	6	1:CID:2	L2R	NON-CROSS	165-167	172-173	D008454	mazindol|mazindol|mazindol|Mazindol|mazindol|mazindol|mazindol|mazindol|mazindol|Mazindol	Chemical	7:39:78:125:141:172:185:213:223:249	8:40:79:126:142:173:186:214:224:250	0:2:3:5:6:6:7:7:8:9	D012817	gastrointestinal symptoms	Disease	165	167	6	1:NR:2	L2R	NON-CROSS	7-8	9-11	D008454	mazindol|mazindol|mazindol|Mazindol|mazindol|mazindol|mazindol|mazindol|mazindol|Mazindol	Chemical	7:39:78:125:141:172:185:213:223:249	8:40:79:126:142:173:186:214:224:250	0:2:3:5:6:6:7:7:8:9	D020388	Duchenne dystrophy|Duchenne dystrophy|Duchenne dystrophy|Duchenne dystrophy	Disease	9:27:52:258	11:29:54:260	0:1:2:9	1:NR:2	L2R	NON-CROSS	249-250	256-257	D008454	mazindol|mazindol|mazindol|Mazindol|mazindol|mazindol|mazindol|mazindol|mazindol|Mazindol	Chemical	7:39:78:125:141:172:185:213:223:249	8:40:79:126:142:173:186:214:224:250	0:2:3:5:6:6:7:7:8:9	D018908	weakness|weakness|weakness	Disease	25:116:256	26:117:257	1:4:9
2348231	Pentoxifylline ( Trental ) does not inhibit dipyridamole - induced coronary hyperemia : implications for dipyridamole - thallium - 201 myocardial imaging .|Dipyridamole - thallium - 201 imaging is often performed in patients unable to exercise because of peripheral vascular disease .|Many of these patients are taking pentoxifylline ( Trental ) , a methylxanthine derivative which may improve intermittent claudication .|Whether pentoxifylline inhibits dipyridamole - induced coronary hyperemia like other methylxanthines such as theophylline and should be stopped prior to dipyridamole - thallium - 201 imaging is unknown .|Therefore , we studied the hyperemic response to dipyridamole in seven open - chest anesthetized dogs after pretreatment with either pentoxifylline ( 0 , 7 . 5 , or 15 mg / kg i . v . ) or theophylline ( 3 mg / kg i . v . ) .|Baseline circumflex coronary blood flows did not differ significantly among treatment groups .|Dipyridamole significantly increased coronary blood flow before and after 7 . 5 or 15 mm / kg i . v .|pentoxifylline ( p less than 0 . 002 ) .|Neither dose of pentoxifylline significantly decreased the dipyridamole - induced hyperemia , while peak coronary blood flow was significantly lower after theophylline ( p less than 0 . 01 ) .|We conclude that pentoxyifylline does not inhibit dipyridamole - induced coronary hyperemia even at high doses .	1:CID:2	L2R	NON-CROSS	60-62	64-65	D010431	Pentoxifylline|Trental|pentoxifylline|Trental|pentoxifylline|pentoxifylline|pentoxifylline|pentoxifylline|pentoxyifylline	Chemical	0:2:49:51:64:112:177:190:221	1:3:50:52:65:113:178:191:222	0:0:2:2:3:4:7:8:9	D007383	intermittent claudication	Disease	60	62	2	1:CID:2	L2R	NON-CROSS	194-195	197-198	D004176	dipyridamole|dipyridamole|Dipyridamole|dipyridamole|dipyridamole|dipyridamole|Dipyridamole|dipyridamole|dipyridamole	Chemical	7:15:23:66:83:100:156:194:225	8:16:24:67:84:101:157:195:226	0:0:1:3:3:4:6:8:9	D006940	hyperemia|hyperemia|hyperemia|hyperemia	Disease	11:70:197:229	12:71:198:230	0:3:8:9	1:NR:2	L2R	NON-CROSS	64-65	70-71	D010431	Pentoxifylline|Trental|pentoxifylline|Trental|pentoxifylline|pentoxifylline|pentoxifylline|pentoxifylline|pentoxyifylline	Chemical	0:2:49:51:64:112:177:190:221	1:3:50:52:65:113:178:191:222	0:0:2:2:3:4:7:8:9	D006940	hyperemia|hyperemia|hyperemia|hyperemia	Disease	11:70:197:229	12:71:198:230	0:3:8:9	1:NR:2	L2R	CROSS	39-42	49-50	D010431	Pentoxifylline|Trental|pentoxifylline|Trental|pentoxifylline|pentoxifylline|pentoxifylline|pentoxifylline|pentoxyifylline	Chemical	0:2:49:51:64:112:177:190:221	1:3:50:52:65:113:178:191:222	0:0:2:2:3:4:7:8:9	D016491	peripheral vascular disease	Disease	39	42	1	1:NR:2	L2R	NON-CROSS	23-24	39-42	D004176	dipyridamole|dipyridamole|Dipyridamole|dipyridamole|dipyridamole|dipyridamole|Dipyridamole|dipyridamole|dipyridamole	Chemical	7:15:23:66:83:100:156:194:225	8:16:24:67:84:101:157:195:226	0:0:1:3:3:4:6:8:9	D016491	peripheral vascular disease	Disease	39	42	1	1:NR:2	L2R	CROSS	60-62	66-67	D004176	dipyridamole|dipyridamole|Dipyridamole|dipyridamole|dipyridamole|dipyridamole|Dipyridamole|dipyridamole|dipyridamole	Chemical	7:15:23:66:83:100:156:194:225	8:16:24:67:84:101:157:195:226	0:0:1:3:3:4:6:8:9	D007383	intermittent claudication	Disease	60	62	2	1:NR:2	R2L	NON-CROSS	17-18	11-12	D013793	thallium|thallium|thallium	Chemical	17:25:85	18:26:86	0:1:3	D006940	hyperemia|hyperemia|hyperemia|hyperemia	Disease	11:70:197:229	12:71:198:230	0:3:8:9	1:NR:2	R2L	NON-CROSS	73-74	70-71	C008514	methylxanthine|methylxanthines	Chemical	55:73	56:74	2:3	D006940	hyperemia|hyperemia|hyperemia|hyperemia	Disease	11:70:197:229	12:71:198:230	0:3:8:9	1:NR:2	R2L	NON-CROSS	76-77	70-71	D013806	theophylline|theophylline|theophylline	Chemical	76:131:208	77:132:209	3:4:8	D006940	hyperemia|hyperemia|hyperemia|hyperemia	Disease	11:70:197:229	12:71:198:230	0:3:8:9	1:NR:2	L2R	NON-CROSS	25-26	39-42	D013793	thallium|thallium|thallium	Chemical	17:25:85	18:26:86	0:1:3	D016491	peripheral vascular disease	Disease	39	42	1	1:NR:2	L2R	CROSS	60-62	85-86	D013793	thallium|thallium|thallium	Chemical	17:25:85	18:26:86	0:1:3	D007383	intermittent claudication	Disease	60	62	2	1:NR:2	R2L	CROSS	55-56	39-42	C008514	methylxanthine|methylxanthines	Chemical	55:73	56:74	2:3	D016491	peripheral vascular disease	Disease	39	42	1	1:NR:2	R2L	CROSS	76-77	39-42	D013806	theophylline|theophylline|theophylline	Chemical	76:131:208	77:132:209	3:4:8	D016491	peripheral vascular disease	Disease	39	42	1	1:NR:2	L2R	NON-CROSS	55-56	60-62	C008514	methylxanthine|methylxanthines	Chemical	55:73	56:74	2:3	D007383	intermittent claudication	Disease	60	62	2	1:NR:2	R2L	CROSS	76-77	60-62	D013806	theophylline|theophylline|theophylline	Chemical	76:131:208	77:132:209	3:4:8	D007383	intermittent claudication	Disease	60	62	2
2355241	Cause of death among patients with Parkinson 's disease : a rare mortality due to cerebral haemorrhage .|Causes of death , with special reference to cerebral haemorrhage , among 240 patients with pathologically verified Parkinson 's disease were investigated using the Annuals of the Pathological Autopsy Cases in Japan from 1981 to 1985 .|The leading causes of death were pneumonia and bronchitis ( 44 . 1 % ) , malignant neoplasms ( 11 . 6 % ) , heart diseases ( 4 . 1 % ) , cerebral infarction ( 3 . 7 % ) and septicaemia ( 3 . 3 % ) .|Cerebral haemorrhage was the 11th most frequent cause of death , accounting for only 0 . 8 % of deaths among the patients , whereas it was the 5th most common cause of death among the Japanese general population in 1985 .|The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson 's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain .	1:CID:2	R2L	NON-CROSS	171-172	168-169	D007980	levodopa	Chemical	171	172	4	D007022	hypotensive|hypotensive	Disease	168:174	169:175	4:4	1:NR:2	R2L	NON-CROSS	171-172	158-159	D007980	levodopa	Chemical	171	172	4	D003643	death|death|death|death|deaths|death|death	Disease	2:20:59:115:125:139:158	3:21:60:116:126:140:159	0:1:2:3:3:3:4	1:NR:2	R2L	NON-CROSS	179-180	158-159	D009638	noradrenaline	Chemical	179	180	4	D003643	death|death|death|death|deaths|death|death	Disease	2:20:59:115:125:139:158	3:21:60:116:126:140:159	0:1:2:3:3:3:4	1:NR:2	R2L	NON-CROSS	171-172	162-165	D007980	levodopa	Chemical	171	172	4	D010300	Parkinson 's disease|Parkinson 's disease|Parkinson 's disease|parkinsonian	Disease	6:35:162:183	9:38:165:184	0:1:4:4	1:NR:2	R2L	NON-CROSS	183-184	179-180	D009638	noradrenaline	Chemical	179	180	4	D010300	Parkinson 's disease|Parkinson 's disease|Parkinson 's disease|parkinsonian	Disease	6:35:162:183	9:38:165:184	0:1:4:4	1:NR:2	R2L	NON-CROSS	171-172	152-154	D007980	levodopa	Chemical	171	172	4	D002543	cerebral haemorrhage|cerebral haemorrhage|Cerebral haemorrhage|cerebral haemorrhage	Disease	15:26:106:152	17:28:108:154	0:1:3:4	1:NR:2	R2L	NON-CROSS	179-180	152-154	D009638	noradrenaline	Chemical	179	180	4	D002543	cerebral haemorrhage|cerebral haemorrhage|Cerebral haemorrhage|cerebral haemorrhage	Disease	15:26:106:152	17:28:108:154	0:1:3:4	1:NR:2	R2L	CROSS	171-172	61-62	D007980	levodopa	Chemical	171	172	4	D011014	pneumonia	Disease	61	62	2	1:NR:2	R2L	CROSS	179-180	61-62	D009638	noradrenaline	Chemical	179	180	4	D011014	pneumonia	Disease	61	62	2	1:NR:2	R2L	CROSS	171-172	63-64	D007980	levodopa	Chemical	171	172	4	D001991	bronchitis	Disease	63	64	2	1:NR:2	R2L	CROSS	179-180	63-64	D009638	noradrenaline	Chemical	179	180	4	D001991	bronchitis	Disease	63	64	2	1:NR:2	R2L	CROSS	171-172	72-73	D007980	levodopa	Chemical	171	172	4	D009369	neoplasms	Disease	72	73	2	1:NR:2	R2L	CROSS	179-180	72-73	D009638	noradrenaline	Chemical	179	180	4	D009369	neoplasms	Disease	72	73	2	1:NR:2	R2L	CROSS	171-172	80-82	D007980	levodopa	Chemical	171	172	4	D006331	heart diseases	Disease	80	82	2	1:NR:2	R2L	CROSS	179-180	80-82	D009638	noradrenaline	Chemical	179	180	4	D006331	heart diseases	Disease	80	82	2	1:NR:2	R2L	CROSS	171-172	89-91	D007980	levodopa	Chemical	171	172	4	D002544	cerebral infarction	Disease	89	91	2	1:NR:2	R2L	CROSS	179-180	89-91	D009638	noradrenaline	Chemical	179	180	4	D002544	cerebral infarction	Disease	89	91	2	1:NR:2	R2L	CROSS	171-172	98-99	D007980	levodopa	Chemical	171	172	4	D018805	septicaemia	Disease	98	99	2	1:NR:2	R2L	CROSS	179-180	98-99	D009638	noradrenaline	Chemical	179	180	4	D018805	septicaemia	Disease	98	99	2	1:NR:2	R2L	NON-CROSS	179-180	174-175	D009638	noradrenaline	Chemical	179	180	4	D007022	hypotensive|hypotensive	Disease	168:174	169:175	4:4
2445283	Tolerance and antiviral effect of ribavirin in patients with Argentine hemorrhagic fever .|Tolerance and antiviral effect of ribavirin was studied in 6 patients with Argentine hemorrhagic fever ( AHF ) of more than 8 days of evolution .|Administration of ribavirin resulted in a neutralization of viremia and a drop of endogenous interferon titers .|The average time of death was delayed .|A reversible anemia was the only adverse effect observed .|From these results , we conclude that ribavirin has an antiviral effect in advanced cases of AHF , and that anemia , the only secondary reaction observed , can be easily managed .|The possible beneficial effect of ribavirin during the initial days of AHF is discussed .	1:CID:2	L2R	NON-CROSS	81-82	94-95	D012254	ribavirin|ribavirin|ribavirin|ribavirin|ribavirin	Chemical	5:18:41:81:112	6:19:42:82:113	0:1:2:5:6	D000740	anemia|anemia	Disease	66:94	67:95	4:5	1:NR:2	L2R	NON-CROSS	5-6	9-12	D012254	ribavirin|ribavirin|ribavirin|ribavirin|ribavirin	Chemical	5:18:41:81:112	6:19:42:82:113	0:1:2:5:6	D006478	Argentine hemorrhagic fever|Argentine hemorrhagic fever|AHF|AHF|AHF	Disease	9:25:29:90:118	12:28:30:91:119	0:1:1:5:6	1:NR:2	L2R	NON-CROSS	41-42	47-48	D012254	ribavirin|ribavirin|ribavirin|ribavirin|ribavirin	Chemical	5:18:41:81:112	6:19:42:82:113	0:1:2:5:6	D014766	viremia	Disease	47	48	2	1:NR:2	L2R	CROSS	41-42	60-61	D012254	ribavirin|ribavirin|ribavirin|ribavirin|ribavirin	Chemical	5:18:41:81:112	6:19:42:82:113	0:1:2:5:6	D003643	death	Disease	60	61	3
2950248	Dipyridamole - induced myocardial ischemia .|Angina and ischemic electrocardiographic changes occurred after administration of oral dipyridamole in four patients awaiting urgent myocardial revascularization procedures .|To our knowledge , this has not previously been reported as a side effect of preoperative dipyridamole therapy , although dipyridamole - induced myocardial ischemia has been demonstrated to occur in animals and humans with coronary artery disease .|Epicardial coronary collateral vessels were demonstrated in all four patients ; a coronary " steal " phenomenon may be the mechanism of the dipyridamole - induced ischemia observed .	1:CID:2	L2R	NON-CROSS	0-1	6-7	D004176	Dipyridamole|dipyridamole|dipyridamole|dipyridamole|dipyridamole	Chemical	0:16:42:46:88	1:17:43:47:89	0:1:2:2:3	D000787	Angina	Disease	6	7	1	not_include	L2R	NON-CROSS	0-1	3-5	D004176	Dipyridamole|dipyridamole|dipyridamole|dipyridamole|dipyridamole	Chemical	0:16:42:46:88	1:17:43:47:89	0:1:2:2:3	D017202	myocardial ischemia|myocardial ischemia	Disease	3:49	5:51	0:2	1:NR:2	L2R	NON-CROSS	46-47	61-64	D004176	Dipyridamole|dipyridamole|dipyridamole|dipyridamole|dipyridamole	Chemical	0:16:42:46:88	1:17:43:47:89	0:1:2:2:3	D003324	coronary artery disease	Disease	61	64	2	1:NR:2	L2R	NON-CROSS	88-89	91-92	D004176	Dipyridamole|dipyridamole|dipyridamole|dipyridamole|dipyridamole	Chemical	0:16:42:46:88	1:17:43:47:89	0:1:2:2:3	D007511	ischemia	Disease	91	92	3
3015567	Inhibition of immunoreactive corticotropin - releasing factor secretion into the hypophysial - portal circulation by delayed glucocorticoid feedback .|Nitroprusside - induced hypotension evokes ACTH secretion which is primarily mediated by enhanced secretion of immunoreactive corticotropin - releasing factor ( irCRF ) into the hypophysial - portal circulation .|Portal plasma concentrations of neither arginine vasopressin nor oxytocin are significantly altered in this paradigm .|Application of a delayed feedback signal , in the form of a 2 - h systemic corticosterone infusion in urethane - anesthetized rats with pharmacological blockade of glucocorticoid synthesis , is without effect on the resting secretion of arginine vasopressin and oxytocin at any corticosterone feedback dose tested .|Resting irCRF levels are suppressed only at the highest corticosterone infusion rate , which resulted in systemic corticosterone levels of 40 micrograms / dl .|Suppression of irCRF secretion in response to nitroprusside - induced hypotension is observed and occurs at a plasma corticosterone level between 8 - 12 micrograms / dl .|These studies provide further evidence for a strong central component of the delayed feedback process which is mediated by modulation of irCRF release .	1:CID:2	L2R	NON-CROSS	19-20	22-23	D009599	Nitroprusside|nitroprusside	Chemical	19:146	20:147	1:5	D007022	hypotension|hypotension	Disease	22:149	23:150	1:5	1:NR:2	R2L	CROSS	54-56	22-23	D001127	arginine vasopressin|arginine vasopressin	Chemical	54:103	56:105	2:3	D007022	hypotension|hypotension	Disease	22:149	23:150	1:5	1:NR:2	R2L	CROSS	57-58	22-23	D010121	oxytocin|oxytocin	Chemical	57:106	58:107	2:3	D007022	hypotension|hypotension	Disease	22:149	23:150	1:5	1:NR:2	R2L	NON-CROSS	157-158	149-150	D003345	corticosterone|corticosterone|corticosterone|corticosterone|corticosterone	Chemical	81:109:123:131:157	82:110:124:132:158	3:3:4:4:5	D007022	hypotension|hypotension	Disease	22:149	23:150	1:5	1:NR:2	R2L	CROSS	84-85	22-23	D014520	urethane	Chemical	84	85	3	D007022	hypotension|hypotension	Disease	22:149	23:150	1:5
3031535	Noradrenergic involvement in catalepsy induced by delta 9 - tetrahydrocannabinol .|In order to elucidate the role of the catecholaminergic system in the cataleptogenic effect of delta 9 - tetrahydrocannabinol ( THC ) , the effect of pretreatment with 6 - hydroxydopamine ( 6 - OHDA ) or with desipramine and 6 - OHDA and lesions of the locus coeruleus were investigated in rats .|The cataleptogenic effect of THC was significantly reduced in rats treated with 6 - OHDA and in rats with lesions of the locus coeruleus but not in rats treated with desipramine and 6 - OHDA , as compared with control rats .|On the contrary , the cataleptogenic effect of haloperidol was significantly reduced in rats treated with desipramine and 6 - OHDA but not in rats treated with 6 - OHDA or in rats with lesions of the locus coeruleus .|These results indicate that noradrenergic neurons have an important role in the manifestation of catalepsy induced by THC , whereas dopaminergic neurons are important in catalepsy induced by haloperidol .	1:CID:2	R2L	NON-CROSS	6-10	3-4	D013759	delta 9 - tetrahydrocannabinol|delta 9 - tetrahydrocannabinol|THC|THC|THC	Chemical	6:26:31:69:164	10:30:32:70:165	0:1:1:2:4	D002375	catalepsy|catalepsy|catalepsy	Disease	3:161:172	4:162:173	0:4:4	1:CID:2	R2L	NON-CROSS	175-176	172-173	D006220	haloperidol|haloperidol	Chemical	115:175	116:176	3:4	D002375	catalepsy|catalepsy|catalepsy	Disease	3:161:172	4:162:173	0:4:4	1:NR:2	R2L	CROSS	161-162	134-137	D016627	6 - hydroxydopamine|6 - OHDA|6 - OHDA|6 - OHDA|6 - OHDA|6 - OHDA|6 - OHDA	Chemical	39:43:51:77:97:125:134	42:46:54:80:100:128:137	1:1:1:2:2:3:3	D002375	catalepsy|catalepsy|catalepsy	Disease	3:161:172	4:162:173	0:4:4	1:NR:2	R2L	CROSS	161-162	123-124	D003891	desipramine|desipramine|desipramine	Chemical	49:95:123	50:96:124	1:2:3	D002375	catalepsy|catalepsy|catalepsy	Disease	3:161:172	4:162:173	0:4:4
3125768	Intracranial pressure increases during alfentanil - induced rigidity .|Intracranial pressure ( ICP ) was measured during alfentanil - induced rigidity in rats .|Ten rats had arterial , central venous ( CVP ) , and subdural cannulae inserted under halothane anesthesia .|The animals were mechanically ventilated to achieve normocarbia ( PCO2 = 42 + / - 1 mmHg , mean + / - SE ) .|Following instrumentation , halothane was discontinued and alfentanil ( 125 mu / kg ) administered iv during emergence from halothane anesthesia .|In the five rats that developed somatic rigidity , ICP and CVP increased significantly above baseline ( delta ICP 7 . 5 + / - 1 . 0 mmHg , delta CVP 5 . 9 + / - 1 . 3 mmHg ) .|These variables returned to baseline when rigidity was abolished with metocurine .|In five rats that did not become rigid , ICP and CVP did not change following alfentanil .|These observations suggest that rigidity should be prevented when alfentanil , and , presumably , other opiates , are used in the anesthetic management of patients with ICP problems .	1:CID:2	L2R	NON-CROSS	4-5	7-8	D015760	alfentanil|alfentanil|alfentanil|alfentanil|alfentanil	Chemical	4:17:75:162:173	5:18:76:163:174	0:1:4:7:8	D009127	rigidity|rigidity|somatic rigidity|rigidity|rigidity	Disease	7:20:96:140:168	8:21:98:141:169	0:1:5:6:8	1:NR:2	R2L	CROSS	96-98	87-88	D006221	halothane|halothane|halothane	Chemical	40:71:87	41:72:88	2:4:4	D009127	rigidity|rigidity|somatic rigidity|rigidity|rigidity	Disease	7:20:96:140:168	8:21:98:141:169	0:1:5:6:8	1:NR:2	R2L	NON-CROSS	144-145	140-141	C032943	metocurine	Chemical	144	145	6	D009127	rigidity|rigidity|somatic rigidity|rigidity|rigidity	Disease	7:20:96:140:168	8:21:98:141:169	0:1:5:6:8
3187073	Adverse cardiac effects during induction chemotherapy treatment with cis - platin and 5 - fluorouracil .|Survival for patients with advanced head and neck carcinoma and esophageal carcinoma is poor with radiotherapy and / or surgery .|Obviously , there is a need for effective chemotherapy .|In the present study , cis - platin ( 80 - 120 mg / m2BSA ) and 5 - FU ( 1000 mg / m2BSA daily as a continuous infusion during 5 days ) were given to 76 patients before radiotherapy and surgery .|The aim of the study was to clarify the incidence and severity of adverse cardiac effects to this treatment .|Before treatment all patients had a cardiac evaluation and during treatment serial ECG recordings were performed .|In the pre - treatment evaluation , signs of cardiovascular disease were found in 33 patients ( 43 % ) .|During treatment , adverse cardiac effects were observed in 14 patients ( 18 % ) .|The mean age of these patients was the same as for the entire group , 64 years .|The incidence of cardiotoxicity was not higher in patients with signs of cardiovascular disease than in those without in the pre - treatment evaluation .|The most common signs of cardiotoxicity were chest pain , ST - T wave changes and atrial fibrillation .|This was followed by ventricular fibrillation in one patient and sudden death in another .|It is concluded that patients on 5 - FU treatment should be under close supervision and that the treatment should be discontinued if chest pain or tachyarrhythmia is observed .	1:CID:2	L2R	CROSS	52-55	137-139	D002945	cis - platin|cis - platin	Chemical	8:52	11:55	0:3	D002318	cardiovascular disease|cardiovascular disease	Disease	137:195	139:197	6:9	1:CID:2	L2R	CROSS	52-55	215-217	D002945	cis - platin|cis - platin	Chemical	8:52	11:55	0:3	D002637	chest pain|chest pain	Disease	215:265	217:267	10:12	1:CID:2	L2R	CROSS	52-55	224-226	D002945	cis - platin|cis - platin	Chemical	8:52	11:55	0:3	D001281	atrial fibrillation	Disease	224	226	10	1:CID:2	L2R	CROSS	52-55	231-233	D002945	cis - platin|cis - platin	Chemical	8:52	11:55	0:3	D014693	ventricular fibrillation	Disease	231	233	11	1:CID:2	L2R	CROSS	195-197	248-251	D005472	5 - fluorouracil|5 - FU|5 - FU	Chemical	12:64:248	15:67:251	0:3:12	D002318	cardiovascular disease|cardiovascular disease	Disease	137:195	139:197	6:9	1:CID:2	L2R	NON-CROSS	248-251	265-267	D005472	5 - fluorouracil|5 - FU|5 - FU	Chemical	12:64:248	15:67:251	0:3:12	D002637	chest pain|chest pain	Disease	215:265	217:267	10:12	1:CID:2	L2R	CROSS	224-226	248-251	D005472	5 - fluorouracil|5 - FU|5 - FU	Chemical	12:64:248	15:67:251	0:3:12	D001281	atrial fibrillation	Disease	224	226	10	1:CID:2	L2R	CROSS	231-233	248-251	D005472	5 - fluorouracil|5 - FU|5 - FU	Chemical	12:64:248	15:67:251	0:3:12	D014693	ventricular fibrillation	Disease	231	233	11	1:NR:2	L2R	CROSS	8-11	21-25	D002945	cis - platin|cis - platin	Chemical	8:52	11:55	0:3	D006258	head and neck carcinoma	Disease	21	25	1	1:NR:2	L2R	CROSS	8-11	26-28	D002945	cis - platin|cis - platin	Chemical	8:52	11:55	0:3	D004938	esophageal carcinoma	Disease	26	28	1	1:NR:2	L2R	CROSS	52-55	186-187	D002945	cis - platin|cis - platin	Chemical	8:52	11:55	0:3	D066126	cardiotoxicity|cardiotoxicity	Disease	186:213	187:214	9:10	1:NR:2	L2R	CROSS	52-55	237-239	D002945	cis - platin|cis - platin	Chemical	8:52	11:55	0:3	D003645	sudden death	Disease	237	239	11	1:NR:2	L2R	CROSS	52-55	268-269	D002945	cis - platin|cis - platin	Chemical	8:52	11:55	0:3	D013610	tachyarrhythmia	Disease	268	269	12	1:NR:2	L2R	CROSS	12-15	21-25	D005472	5 - fluorouracil|5 - FU|5 - FU	Chemical	12:64:248	15:67:251	0:3:12	D006258	head and neck carcinoma	Disease	21	25	1	1:NR:2	L2R	CROSS	12-15	26-28	D005472	5 - fluorouracil|5 - FU|5 - FU	Chemical	12:64:248	15:67:251	0:3:12	D004938	esophageal carcinoma	Disease	26	28	1	1:NR:2	L2R	CROSS	213-214	248-251	D005472	5 - fluorouracil|5 - FU|5 - FU	Chemical	12:64:248	15:67:251	0:3:12	D066126	cardiotoxicity|cardiotoxicity	Disease	186:213	187:214	9:10	1:NR:2	L2R	CROSS	237-239	248-251	D005472	5 - fluorouracil|5 - FU|5 - FU	Chemical	12:64:248	15:67:251	0:3:12	D003645	sudden death	Disease	237	239	11	1:NR:2	L2R	NON-CROSS	248-251	268-269	D005472	5 - fluorouracil|5 - FU|5 - FU	Chemical	12:64:248	15:67:251	0:3:12	D013610	tachyarrhythmia	Disease	268	269	12
3371379	Verapamil - induced carbamazepine neurotoxicity .|A report of two cases .|Two patients with signs of carbamazepine neurotoxicity after combined treatment with verapamil showed complete recovery after discontinuation of the calcium entry blocker .|Use of verapamil in combination with carbamazepine should either be avoided or prescribed only with appropriate adjustment of the carbamazepine dose ( usually reduction of the carbamazepine dose by one half ) .	1:CID:2	L2R	NON-CROSS	0-1	4-5	D014700	Verapamil|verapamil|verapamil	Chemical	0:23:37	1:24:38	0:2:3	D020258	neurotoxicity|neurotoxicity	Disease	4:18	5:19	0:2	1:CID:2	L2R	NON-CROSS	3-4	4-5	D002220	carbamazepine|carbamazepine|carbamazepine|carbamazepine|carbamazepine	Chemical	3:17:41:54:61	4:18:42:55:62	0:2:3:3:3	D020258	neurotoxicity|neurotoxicity	Disease	4:18	5:19	0:2	1:NR:2	R2L	NON-CROSS	31-32	18-19	D002118	calcium	Chemical	31	32	2	D020258	neurotoxicity|neurotoxicity	Disease	4:18	5:19	0:2
3503576	Serial studies of auditory neurotoxicity in patients receiving deferoxamine therapy .|Visual and auditory neurotoxicity was previously documented in 42 of 89 patients with transfusion - dependent anemia who were receiving iron chelation therapy with daily subcutaneous deferoxamine .|Twenty - two patients in the affected group had abnormal audiograms with deficits mostly in the high frequency range of 4 , 000 to 8 , 000 Hz and in the hearing threshold levels of 30 to 100 decibels .|When deferoxamine therapy was discontinued and serial studies were performed , audiograms in seven cases reverted to normal or near normal within two to three weeks , and nine of 13 patients with symptoms became asymptomatic .|Audiograms from 15 patients remained abnormal and four patients required hearing aids because of permanent disability .|Since 18 of the 22 patients were initially receiving deferoxamine doses in excess of the commonly recommended 50 mg / kg per dose , therapy was restarted with lower doses , usually 50 mg / kg per dose or less depending on the degree of auditory abnormality , and with the exception of two cases no further toxicity was demonstrated .|Auditory deterioration and improvement , demonstrated serially in individual patients receiving and not receiving deferoxamine , respectively , provided convincing evidence for a cause - and - effect relation between deferoxamine administration and ototoxicity .|Based on these data , a plan of management was developed that allows effective yet safe administration of deferoxamine .|A dose of 50 mg / kg is recommended in those without audiogram abnormalities .|With mild toxicity , a reduction to 30 or 40 mg / kg per dose should result in a reversal of the abnormal results to normal within four weeks .|Moderate abnormalities require a reduction of deferoxamine to 25 mg / kg per dose with careful monitoring .|In those with symptoms of hearing loss , the drug should be stopped for four weeks , and when the audiogram is stable or improved , therapy should be restarted at 10 to 25 mg / kg per dose .|Serial audiograms should be performed every six months in those without problems and more frequently in young patients with normal serum ferritin values and in those with auditory dysfunction .	1:CID:2	L2R	NON-CROSS	8-9	11-15	D003676	deferoxamine|deferoxamine|deferoxamine|deferoxamine|deferoxamine|deferoxamine|deferoxamine|deferoxamine	Chemical	8:37:80:142:208:224:247:300	9:38:81:143:209:225:248:301	0:1:3:5:6:6:7:10	D014786	Visual and auditory neurotoxicity	Disease	11	15	1	1:CID:2	L2R	CROSS	37-38	48-67	D003676	deferoxamine|deferoxamine|deferoxamine|deferoxamine|deferoxamine|deferoxamine|deferoxamine|deferoxamine	Chemical	8:37:80:142:208:224:247:300	9:38:81:143:209:225:248:301	0:1:3:5:6:6:7:10	D006316	abnormal audiograms with deficits mostly in the high frequency range of 4 , 000 to 8 , 000 Hz	Disease	48	67	2	not_include	R2L	NON-CROSS	227-228	224-225	D003676	deferoxamine|deferoxamine|deferoxamine|deferoxamine|deferoxamine|deferoxamine|deferoxamine|deferoxamine	Chemical	8:37:80:142:208:224:247:300	9:38:81:143:209:225:248:301	0:1:3:5:6:6:7:10	D006311	auditory neurotoxicity|Visual and auditory neurotoxicity|auditory abnormality|ototoxicity|auditory dysfunction	Disease	3:11:178:227:379	5:15:180:228:381	0:1:5:6:12	1:NR:2	R2L	NON-CROSS	31-32	11-15	D007501	iron	Chemical	31	32	1	D006311	auditory neurotoxicity|Visual and auditory neurotoxicity|auditory abnormality|ototoxicity|auditory dysfunction	Disease	3:11:178:227:379	5:15:180:228:381	0:1:5:6:12	1:NR:2	L2R	NON-CROSS	27-28	37-38	D003676	deferoxamine|deferoxamine|deferoxamine|deferoxamine|deferoxamine|deferoxamine|deferoxamine|deferoxamine	Chemical	8:37:80:142:208:224:247:300	9:38:81:143:209:225:248:301	0:1:3:5:6:6:7:10	D000740	anemia	Disease	27	28	1	1:NR:2	L2R	CROSS	130-132	142-143	D003676	deferoxamine|deferoxamine|deferoxamine|deferoxamine|deferoxamine|deferoxamine|deferoxamine|deferoxamine	Chemical	8:37:80:142:208:224:247:300	9:38:81:143:209:225:248:301	0:1:3:5:6:6:7:10	D003638	permanent disability	Disease	130	132	4	1:NR:2	L2R	NON-CROSS	190-191	208-209	D003676	deferoxamine|deferoxamine|deferoxamine|deferoxamine|deferoxamine|deferoxamine|deferoxamine|deferoxamine	Chemical	8:37:80:142:208:224:247:300	9:38:81:143:209:225:248:301	0:1:3:5:6:6:7:10	D064420	toxicity|toxicity	Disease	190:266	191:267	5:9	not_include	L2R	CROSS	300-301	317-319	D003676	deferoxamine|deferoxamine|deferoxamine|deferoxamine|deferoxamine|deferoxamine|deferoxamine|deferoxamine	Chemical	8:37:80:142:208:224:247:300	9:38:81:143:209:225:248:301	0:1:3:5:6:6:7:10	D034381	hearing loss	Disease	317	319	11	1:NR:2	R2L	NON-CROSS	31-32	11-15	D007501	iron	Chemical	31	32	1	D014786	Visual and auditory neurotoxicity	Disease	11	15	1	1:NR:2	R2L	NON-CROSS	31-32	27-28	D007501	iron	Chemical	31	32	1	D000740	anemia	Disease	27	28	1	1:NR:2	L2R	CROSS	31-32	48-67	D007501	iron	Chemical	31	32	1	D006316	abnormal audiograms with deficits mostly in the high frequency range of 4 , 000 to 8 , 000 Hz	Disease	48	67	2	1:NR:2	L2R	CROSS	31-32	130-132	D007501	iron	Chemical	31	32	1	D003638	permanent disability	Disease	130	132	4	1:NR:2	L2R	CROSS	31-32	190-191	D007501	iron	Chemical	31	32	1	D064420	toxicity|toxicity	Disease	190:266	191:267	5:9	1:NR:2	L2R	CROSS	31-32	317-319	D007501	iron	Chemical	31	32	1	D034381	hearing loss	Disease	317	319	11
3560095	Flurbiprofen in the treatment of juvenile rheumatoid arthritis .|Thirty - four patients with juvenile rheumatoid arthritis , who were treated with flurbiprofen at a maximum dose of 4 mg / kg / day , had statistically significant decreases from baseline in 6 arthritis indices after 12 weeks of treatment .|Improvements were seen in the number of tender joints , the severity of swelling and tenderness , the time of walk 50 feet , the duration of morning stiffness and the circumference of the left knee .|The most frequently observed side effect was fecal occult blood ( 25 % of patients ) ; however , there was no other evidence of gastrointestinal ( GI ) bleeding in these patients .|One patient was prematurely discontinued from the study for severe headache and abdominal pain .|Most side effects were mild and related to the GI tract .	1:CID:2	L2R	CROSS	22-23	113-118	D005480	Flurbiprofen|flurbiprofen	Chemical	0:22	1:23	0:1	D006471	gastrointestinal ( GI ) bleeding	Disease	113	118	3	1:CID:2	L2R	CROSS	22-23	132-133	D005480	Flurbiprofen|flurbiprofen	Chemical	0:22	1:23	0:1	D006261	headache	Disease	132	133	4	1:CID:2	L2R	CROSS	22-23	134-136	D005480	Flurbiprofen|flurbiprofen	Chemical	0:22	1:23	0:1	D015746	abdominal pain	Disease	134	136	4	1:NR:2	L2R	NON-CROSS	0-1	5-8	D005480	Flurbiprofen|flurbiprofen	Chemical	0:22	1:23	0:1	D001171	juvenile rheumatoid arthritis|juvenile rheumatoid arthritis	Disease	5:14	8:17	0:1	1:NR:2	L2R	NON-CROSS	22-23	43-44	D005480	Flurbiprofen|flurbiprofen	Chemical	0:22	1:23	0:1	D001168	arthritis	Disease	43	44	1	1:NR:2	L2R	CROSS	22-23	64-65	D005480	Flurbiprofen|flurbiprofen	Chemical	0:22	1:23	0:1	D004487	swelling	Disease	64	65	2
3714122	The correlation between neurotoxic esterase inhibition and mipafox - induced neuropathic damage in rats .|The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme ( NTE ) was examined in rats acutely exposed to Mipafox ( N , N ' - diisopropylphosphorodiamidofluoridate ) , a neurotoxic organophosphate .|Brain and spinal cord NTE activities were measured in Long - Evans male rats 1 hr post - exposure to various dosages of Mipafox ( ip , 1 - 15 mg / kg ) .|These data were correlated with histologically scored cervical cord damage in a separate group of similarly dosed rats sampled 14 - 21 days post - exposure .|Those dosages ( greater than or equal to 10 mg / kg ) that inhibited mean NTE activity in the spinal cord greater than or equal to 73 % and brain greater than or equal to 67 % of control values produced severe ( greater than or equal to 3 ) cervical cord pathology in 85 % of the rats .|In contrast , dosages of Mipafox ( less than or equal to 5 mg / kg ) which inhibited mean NTE activity in spinal cord less than or equal to 61 % and brain less than or equal to 60 % produced this degree of cord damage in only 9 % of the animals .|These data indicate that a critical percentage of NTE inhibition in brain and spinal cord sampled shortly after Mipafox exposure can predict neuropathic damage in rats several weeks later .	1:CID:2	L2R	NON-CROSS	76-77	96-98	C005238	mipafox|Mipafox|N , N ' - diisopropylphosphorodiamidofluoridate|Mipafox|Mipafox|Mipafox	Chemical	7:39:41:76:181:249	8:40:47:77:182:250	0:1:1:2:5:6	D013118	cord damage|cord damage	Disease	96:221	98:223	3:5	1:NR:2	R2L	NON-CROSS	7-8	3-4	C005238	mipafox|Mipafox|N , N ' - diisopropylphosphorodiamidofluoridate|Mipafox|Mipafox|Mipafox	Chemical	7:39:41:76:181:249	8:40:47:77:182:250	0:1:1:2:5:6	D020258	neurotoxic|neurotoxic|neurotoxic	Disease	3:23:50	4:24:51	0:1:1	1:NR:2	R2L	NON-CROSS	51-52	50-51	D010755	organophosphate	Chemical	51	52	1	D020258	neurotoxic|neurotoxic|neurotoxic	Disease	3:23:50	4:24:51	0:1:1	not_include	L2R	NON-CROSS	7-8	10-12	C005238	mipafox|Mipafox|N , N ' - diisopropylphosphorodiamidofluoridate|Mipafox|Mipafox|Mipafox	Chemical	7:39:41:76:181:249	8:40:47:77:182:250	0:1:1:2:5:6	D009422	neuropathic damage|neuropathic damage|neuropathy|neuropathic damage	Disease	10:18:26:253	12:20:27:255	0:1:1:6	1:NR:2	R2L	NON-CROSS	51-52	26-27	D010755	organophosphate	Chemical	51	52	1	D009422	neuropathic damage|neuropathic damage|neuropathy|neuropathic damage	Disease	10:18:26:253	12:20:27:255	0:1:1:6	1:NR:2	L2R	CROSS	51-52	96-98	D010755	organophosphate	Chemical	51	52	1	D013118	cord damage|cord damage	Disease	96:221	98:223	3:5
3828020	Cerebral infarction with a single oral dose of phenylpropanolamine .|Phenylpropanolamine ( PPA ) , a synthetic sympathomimetic that is structurally similar to amphetamine , is available over the counter in anorectics , nasal congestants , and cold preparations .|Its prolonged use or overuse has been associated with seizures , intracerebral hemorrhage , neuropsychiatric symptoms , and nonhemorrhagic cerebral infarction .|We report the case of a young woman who suffered a cerebral infarction after taking a single oral dose of PPA .	1:CID:2	R2L	NON-CROSS	8-9	0-2	D010665	phenylpropanolamine|Phenylpropanolamine|PPA|PPA	Chemical	8:10:12:82	9:11:13:83	0:1:1:3	D002544	Cerebral infarction|cerebral infarction|cerebral infarction	Disease	0:59:73	2:61:75	0:2:3	1:CID:2	L2R	CROSS	49-50	82-83	D010665	phenylpropanolamine|Phenylpropanolamine|PPA|PPA	Chemical	8:10:12:82	9:11:13:83	0:1:1:3	D012640	seizures	Disease	49	50	2	1:CID:2	L2R	CROSS	51-53	82-83	D010665	phenylpropanolamine|Phenylpropanolamine|PPA|PPA	Chemical	8:10:12:82	9:11:13:83	0:1:1:3	D002543	intracerebral hemorrhage	Disease	51	53	2	1:CID:2	L2R	CROSS	54-56	82-83	D010665	phenylpropanolamine|Phenylpropanolamine|PPA|PPA	Chemical	8:10:12:82	9:11:13:83	0:1:1:3	D001523	neuropsychiatric symptoms	Disease	54	56	2	1:NR:2	R2L	CROSS	23-24	0-2	D000661	amphetamine	Chemical	23	24	1	D002544	Cerebral infarction|cerebral infarction|cerebral infarction	Disease	0:59:73	2:61:75	0:2:3	1:NR:2	L2R	CROSS	23-24	49-50	D000661	amphetamine	Chemical	23	24	1	D012640	seizures	Disease	49	50	2	1:NR:2	L2R	CROSS	23-24	51-53	D000661	amphetamine	Chemical	23	24	1	D002543	intracerebral hemorrhage	Disease	51	53	2	1:NR:2	L2R	CROSS	23-24	54-56	D000661	amphetamine	Chemical	23	24	1	D001523	neuropsychiatric symptoms	Disease	54	56	2
4812392	Treatment of psoriasis with azathioprine .|Azathioprine treatment benefited 19 ( 66 % ) out of 29 patients suffering from severe psoriasis .|Haematological complications were not troublesome and results of biochemical liver function tests remained normal .|Minimal cholestasis was seen in two cases and portal fibrosis of a reversible degree in eight .|Liver biopsies should be undertaken at regular intervals if azathioprine therapy is continued so that structural liver damage may be detected at an early and reversible stage .	1:CID:2	L2R	CROSS	39-40	64-65	D001379	azathioprine|Azathioprine|azathioprine	Chemical	4:6:64	5:7:65	0:1:4	D002779	cholestasis	Disease	39	40	3	1:CID:2	L2R	CROSS	47-48	64-65	D001379	azathioprine|Azathioprine|azathioprine	Chemical	4:6:64	5:7:65	0:1:4	D005355	fibrosis	Disease	47	48	3	1:NR:2	R2L	NON-CROSS	4-5	2-3	D001379	azathioprine|Azathioprine|azathioprine	Chemical	4:6:64	5:7:65	0:1:4	D011565	psoriasis|psoriasis	Disease	2:21	3:22	0:1	1:NR:2	L2R	NON-CROSS	64-65	71-73	D001379	azathioprine|Azathioprine|azathioprine	Chemical	4:6:64	5:7:65	0:1:4	D056486	liver damage	Disease	71	73	4
6518066	Maternal lithium and neonatal Ebstein 's anomaly : evaluation with cross - sectional echocardiography .|Cross - sectional echocardiography was used to evaluate two neonates whose mothers ingested lithium during pregnancy .|In one infant , Ebstein 's anomaly of the tricuspid valve was identified .|In the other infant cross - sectional echocardiography provided reassurance that the infant did not have Ebstein 's anomaly .|Cross - sectional echocardiographic screening of newborns exposed to lithium during gestation can provide highly accurate , noninvasive assessment of the presence or absence of lithium - induced cardiac malformations .	1:CID:2	L2R	NON-CROSS	1-2	4-7	D008094	lithium|lithium|lithium|lithium	Chemical	1:28:75:91	2:29:76:92	0:1:4:4	D004437	Ebstein 's anomaly|Ebstein 's anomaly|Ebstein 's anomaly	Disease	4:36:62	7:39:65	0:2:3	not_include	L2R	NON-CROSS	91-92	94-96	D008094	lithium|lithium|lithium|lithium	Chemical	1:28:75:91	2:29:76:92	0:1:4:4	D006331	cardiac malformations	Disease	94	96	4
6534871	Effects of training on the extent of experimental myocardial infarction in aging rats .|The effects of exercise on the severity of isoproterenol - induced myocardial infarction were studied in female albino rats of 20 , 40 , 60 and 80 weeks of age .|The rats were trained to swim for a specific duration and for a particular period .|The occurrence of infarcts were confirmed by histological methods .|Elevations in the serum GOT and GPT were maximum in the sedentary - isoproterenols and minimum in the exercise - controls .|These changes in the serum transaminases were associated with corresponding depletions in the cardiac GOT and GPT .|However , age was seen to interfere with the responses exhibited by the young and old rats .|Studies dealing with myocardial infarction are more informative when dealt with age .	1:CID:2	R2L	NON-CROSS	25-27	22-23	D007545	isoproterenol|isoproterenols	Chemical	22:84	23:85	1:4	D009203	myocardial infarction|myocardial infarction|myocardial infarction	Disease	8:25:132	10:27:134	0:1:7	1:NR:2	L2R	CROSS	64-65	84-85	D007545	isoproterenol|isoproterenols	Chemical	22:84	23:85	1:4	D007238	infarcts	Disease	64	65	3
6538499	Effect of polyethylene glycol 400 on adriamycin toxicity in mice .|The effect of a widely used organic solvent , polyethylene glycol 400 ( PEG 400 ) , on the toxic action of an acute or chronic treatment with adriamycin ( ADR ) was evaluated in mice .|PEG 400 impressively decreased both acute high - dose and chronic low - dose - ADR - associated lethality .|Light microscopic analysis showed a significant protection against ADR - induced cardiac morphological alterations .|Such treatment did not diminish the ADR antitumor activity in L1210 leukemia and in Ehrlich ascites tumor .	1:CID:2	L2R	NON-CROSS	76-77	79-82	D004317	adriamycin|adriamycin|ADR|ADR|ADR|ADR	Chemical	6:39:41:63:76:89	7:40:42:64:77:90	0:1:1:2:3:4	D009202	cardiac morphological alterations	Disease	79	82	3	1:NR:2	L2R	NON-CROSS	2-5	7-8	D011092	polyethylene glycol 400|polyethylene glycol 400|PEG 400|PEG 400	Chemical	2:20:24:48	5:23:26:50	0:1:1:2	D064420	toxicity	Disease	7	8	0	1:NR:2	L2R	CROSS	48-50	79-82	D011092	polyethylene glycol 400|polyethylene glycol 400|PEG 400|PEG 400	Chemical	2:20:24:48	5:23:26:50	0:1:1:2	D009202	cardiac morphological alterations	Disease	79	82	3	1:NR:2	L2R	CROSS	48-50	93-95	D011092	polyethylene glycol 400|polyethylene glycol 400|PEG 400|PEG 400	Chemical	2:20:24:48	5:23:26:50	0:1:1:2	D007939	L1210 leukemia	Disease	93	95	4	1:NR:2	L2R	CROSS	48-50	97-100	D011092	polyethylene glycol 400|polyethylene glycol 400|PEG 400|PEG 400	Chemical	2:20:24:48	5:23:26:50	0:1:1:2	D002286	Ehrlich ascites tumor	Disease	97	100	4	1:NR:2	L2R	NON-CROSS	6-7	7-8	D004317	adriamycin|adriamycin|ADR|ADR|ADR|ADR	Chemical	6:39:41:63:76:89	7:40:42:64:77:90	0:1:1:2:3:4	D064420	toxicity	Disease	7	8	0	1:NR:2	L2R	NON-CROSS	89-90	93-95	D004317	adriamycin|adriamycin|ADR|ADR|ADR|ADR	Chemical	6:39:41:63:76:89	7:40:42:64:77:90	0:1:1:2:3:4	D007939	L1210 leukemia	Disease	93	95	4	1:NR:2	L2R	NON-CROSS	89-90	97-100	D004317	adriamycin|adriamycin|ADR|ADR|ADR|ADR	Chemical	6:39:41:63:76:89	7:40:42:64:77:90	0:1:1:2:3:4	D002286	Ehrlich ascites tumor	Disease	97	100	4
6747681	Intra - arterial BCNU chemotherapy for treatment of malignant gliomas of the central nervous system .|Because of the rapid systemic clearance of BCNU ( 1 , 3 - bis - ( 2 - chloroethyl ) - 1 - nitrosourea ) , intra - arterial administration should provide a substantial advantage over intravenous administration for the treatment of malignant gliomas .|Thirty - six patients were treated with BCNU every 6 to 8 weeks , either by transfemoral catheterization of the internal carotid or vertebral artery or through a fully implantable intracarotid drug delivery system , beginning with a dose of 200 mg / sq m body surface area .|Twelve patients with Grade III or IV astrocytomas were treated after partial resection of the tumor without prior radiation therapy .|After two to seven cycles of chemotherapy , nine patients showed a decrease in tumor size and surrounding edema on contrast - enhanced computerized tomography scans .|In the nine responders , median duration of chemotherapy response from the time of operation was 25 weeks ( range 12 to more than 91 weeks ) .|The median duration of survival in the 12 patients was 54 weeks ( range 21 to more than 156 weeks ) , with an 18 - month survival rate of 42 % .|Twenty - four patients with recurrent Grade I to IV astrocytomas , whose resection and irradiation therapy had failed , received two to eight courses of intra - arterial BCNU therapy .|Seventeen of these had a response or were stable for a median of 20 weeks ( range 6 to more than 66 weeks ) .|The catheterization procedure is safe , with no immediate complication in 111 infusions of BCNU .|A delayed complication in nine patients has been unilateral loss of vision secondary to a retinal vasculitis .|The frequency of visual loss decreased after the concentration of the ethanol diluent was lowered .	1:CID:2	L2R	CROSS	290-291	307-309	D002330	BCNU|BCNU|1 , 3 - bis - ( 2 - chloroethyl ) - 1 - nitrosourea|BCNU|BCNU|BCNU	Chemical	3:23:25:68:248:290	4:24:40:69:249:291	0:1:1:2:7:9	D031300	retinal vasculitis	Disease	307	309	10	1:NR:2	L2R	NON-CROSS	3-4	8-10	D002330	BCNU|BCNU|1 , 3 - bis - ( 2 - chloroethyl ) - 1 - nitrosourea|BCNU|BCNU|BCNU	Chemical	3:23:25:68:248:290	4:24:40:69:249:291	0:1:1:2:7:9	D005910	malignant gliomas|malignant gliomas	Disease	8:58	10:60	0:1	1:NR:2	L2R	NON-CROSS	229-230	248-249	D002330	BCNU|BCNU|1 , 3 - bis - ( 2 - chloroethyl ) - 1 - nitrosourea|BCNU|BCNU|BCNU	Chemical	3:23:25:68:248:290	4:24:40:69:249:291	0:1:1:2:7:9	D001254	astrocytomas|astrocytomas	Disease	117:229	118:230	3:7	1:NR:2	L2R	CROSS	68-69	125-126	D002330	BCNU|BCNU|1 , 3 - bis - ( 2 - chloroethyl ) - 1 - nitrosourea|BCNU|BCNU|BCNU	Chemical	3:23:25:68:248:290	4:24:40:69:249:291	0:1:1:2:7:9	D009369	tumor|tumor	Disease	125:145	126:146	3:4	1:NR:2	L2R	CROSS	68-69	149-150	D002330	BCNU|BCNU|1 , 3 - bis - ( 2 - chloroethyl ) - 1 - nitrosourea|BCNU|BCNU|BCNU	Chemical	3:23:25:68:248:290	4:24:40:69:249:291	0:1:1:2:7:9	D004487	edema	Disease	149	150	4	1:NR:2	L2R	CROSS	290-291	301-304	D002330	BCNU|BCNU|1 , 3 - bis - ( 2 - chloroethyl ) - 1 - nitrosourea|BCNU|BCNU|BCNU	Chemical	3:23:25:68:248:290	4:24:40:69:249:291	0:1:1:2:7:9	D014786	loss of vision|visual loss	Disease	301:313	304:315	10:11	1:NR:2	R2L	CROSS	321-322	58-60	D000431	ethanol	Chemical	321	322	11	D005910	malignant gliomas|malignant gliomas	Disease	8:58	10:60	0:1	1:NR:2	R2L	CROSS	321-322	229-230	D000431	ethanol	Chemical	321	322	11	D001254	astrocytomas|astrocytomas	Disease	117:229	118:230	3:7	1:NR:2	R2L	CROSS	321-322	145-146	D000431	ethanol	Chemical	321	322	11	D009369	tumor|tumor	Disease	125:145	126:146	3:4	1:NR:2	R2L	CROSS	321-322	149-150	D000431	ethanol	Chemical	321	322	11	D004487	edema	Disease	149	150	4	1:NR:2	R2L	NON-CROSS	321-322	313-315	D000431	ethanol	Chemical	321	322	11	D014786	loss of vision|visual loss	Disease	301:313	304:315	10:11	1:NR:2	R2L	CROSS	321-322	307-309	D000431	ethanol	Chemical	321	322	11	D031300	retinal vasculitis	Disease	307	309	10
6861444	Blood pressure response to chronic low - dose intrarenal noradrenaline infusion in conscious rats .|Sodium chloride solution ( 0 . 9 % ) or noradrenaline in doses of 4 , 12 and 36 micrograms h - 1 kg - 1 was infused for five consecutive days , either intrarenally ( by a new technique ) or intravenously into rats with one kidney removed .|Intrarenal infusion of noradrenaline caused hypertension at doses which did not do so when infused intravenously .|Intrarenal compared with intravenous infusion of noradrenaline caused higher plasma noradrenaline concentrations and a shift of the plasma noradrenaline concentration - blood pressure effect curve towards lower plasma noradrenaline levels .|These results suggest that hypertension after chronic intrarenal noradrenaline infusion is produced by relatively higher levels of circulating noradrenaline and by triggering of an additional intrarenal pressor mechanism .	1:CID:2	L2R	NON-CROSS	68-69	70-71	D009638	noradrenaline|noradrenaline|noradrenaline|noradrenaline|noradrenaline|noradrenaline|noradrenaline|noradrenaline|noradrenaline	Chemical	9:25:68:88:92:100:110:121:131	10:26:69:89:93:101:111:122:132	0:1:2:3:3:3:3:4:4	D006973	hypertension|hypertension	Disease	70:117	71:118	2:4	1:NR:2	L2R	CROSS	15-17	70-71	D012965	Sodium chloride	Chemical	15	17	1	D006973	hypertension|hypertension	Disease	70:117	71:118	2:4
7053303	Age and renal clearance of cimetidine .|In 35 patients ( ages 20 to 86 yr ) receiving cimetidine therapeutically two serum samples and all urine formed in the interim were collected for analysis of cimetidine by high - pressure liquid chromatography and for creatinine .|Cimetidine clearance decreased with age .|The extrapolated 6 - hr serum concentration of cimetidine per unit dose , after intravenous cimetidine , increased with age of the patients .|The ratio of cimetidine clearance to creatinine clearance ( Rc ) averaged 4 . 8 + / - 2 . 0 , indicating net tubular secretion for cimetidine .|Rc seemed to be independent of age and decreased with increasing serum concentration of cimetidine , suggesting that secretion of cimetidine is a saturable process .|There was only one case of dementia possibly due to cimetidine ( with a drug level of 1 . 9 microgram / ml 6 hr after a dose ) in a group of 13 patients without liver or kidney disease who had cimetidine levels above 1 . 25 microgram / ml .|Thus , high cimetidine levels alone do not always induce dementia .	1:CID:2	L2R	NON-CROSS	137-138	141-142	D002927	cimetidine|cimetidine|cimetidine|Cimetidine|cimetidine|cimetidine|cimetidine|cimetidine|cimetidine|cimetidine|cimetidine|cimetidine|cimetidine	Chemical	5:18:35:46:60:67:79:103:119:125:141:173:186	6:19:36:47:61:68:80:104:120:126:142:174:187	0:1:1:2:3:3:4:4:5:5:6:6:7	D003704	dementia|dementia	Disease	137:193	138:194	6:7	1:NR:2	L2R	NON-CROSS	167-171	173-174	D002927	cimetidine|cimetidine|cimetidine|Cimetidine|cimetidine|cimetidine|cimetidine|cimetidine|cimetidine|cimetidine|cimetidine|cimetidine|cimetidine	Chemical	5:18:35:46:60:67:79:103:119:125:141:173:186	6:19:36:47:61:68:80:104:120:126:142:174:187	0:1:1:2:3:3:4:4:5:5:6:6:7	D008107	liver or kidney disease	Disease	167	171	6	1:NR:2	L2R	NON-CROSS	167-171	173-174	D002927	cimetidine|cimetidine|cimetidine|Cimetidine|cimetidine|cimetidine|cimetidine|cimetidine|cimetidine|cimetidine|cimetidine|cimetidine|cimetidine	Chemical	5:18:35:46:60:67:79:103:119:125:141:173:186	6:19:36:47:61:68:80:104:120:126:142:174:187	0:1:1:2:3:3:4:4:5:5:6:6:7	D007674	liver or kidney disease	Disease	167	171	6	1:NR:2	L2R	CROSS	82-83	137-138	D003404	creatinine|creatinine	Chemical	44:82	45:83	1:4	D003704	dementia|dementia	Disease	137:193	138:194	6:7	1:NR:2	L2R	CROSS	82-83	167-171	D003404	creatinine|creatinine	Chemical	44:82	45:83	1:4	D008107	liver or kidney disease	Disease	167	171	6	1:NR:2	L2R	CROSS	82-83	167-171	D003404	creatinine|creatinine	Chemical	44:82	45:83	1:4	D007674	liver or kidney disease	Disease	167	171	6
7088431	Development of clear cell adenocarcinoma in DES - exposed offspring under observation .|Two cases of clear cell adenocarcinoma of the vagina detected at follow - up in young women exposed in utero to diethylstilbestrol are reported .|One patient , aged 23 , had been followed for 2 years before carcinoma was diagnosed ; the second patient , aged 22 , had been seen on a regular basis for 5 years , 8 months .|In both instances , suspicion of the presence of carcinoma was aroused by the palpation of a small nodule in the vaginal fornix .|Hysterosalpingography was performed on both patients and , in 1 instance , an abnormal x - ray film was reflected by the gross appearance of the uterine cavity found in the surgical specimen .	1:CID:2	R2L	NON-CROSS	6-7	2-5	D004054	DES|diethylstilbestrol	Chemical	6:34	7:35	0:1	D018262	clear cell adenocarcinoma|clear cell adenocarcinoma of the vagina	Disease	2:16	5:22	0:1	1:CID:2	L2R	NON-CROSS	6-7	16-22	D004054	DES|diethylstilbestrol	Chemical	6:34	7:35	0:1	D014625	clear cell adenocarcinoma of the vagina	Disease	16	22	1	not_include	L2R	CROSS	34-35	51-52	D004054	DES|diethylstilbestrol	Chemical	6:34	7:35	0:1	D002277	carcinoma|carcinoma	Disease	51:85	52:86	2:3
7248170	Phenobarbitone - induced enlargement of the liver in the rat : its relationship to carbon tetrachloride - induced cirrhosis .|The yield of severe cirrhosis of the liver ( defined as a shrunken finely nodular liver with micronodular histology , ascites greater than 30 ml , plasma albumin less than 2 . 2 g / dl , splenomegaly 2 - 3 times normal , and testicular atrophy approximately half normal weight ) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone - primed rat was increased from 25 % to 56 % by giving the initial " calibrating " dose of carbon tetrachloride at the peak of the phenobarbitone - induced enlargement of the liver .|At this point it was assumed that the cytochrome P450 / CCl4 toxic state was both maximal and stable .|The optimal rat size to begin phenobarbitone was determined as 100 g , and this size as a group had a mean maximum relative liver weight increase 47 % greater than normal rats of the same body weight .|The optimal time for the initial dose of carbon tetrachloride was after 14 days on phenobarbitone .	1:CID:2	L2R	NON-CROSS	0-1	3-7	D010634	Phenobarbitone|phenobarbitone|phenobarbitone|phenobarbitone|phenobarbitone	Chemical	0:82:110:144:192	1:83:111:145:193	0:1:1:3:4	D006529	enlargement of the liver|enlargement of the liver	Disease	3:113	7:117	0:1	1:CID:2	L2R	NON-CROSS	0-1	24-28	D010634	Phenobarbitone|phenobarbitone|phenobarbitone|phenobarbitone|phenobarbitone	Chemical	0:82:110:144:192	1:83:111:145:193	0:1:1:3:4	D008103	cirrhosis of the liver	Disease	24	28	1	1:CID:2	L2R	NON-CROSS	14-16	24-28	D002251	carbon tetrachloride|carbon tetrachloride|carbon tetrachloride|CCl4|carbon tetrachloride	Chemical	14:76:103:129:185	16:78:105:130:187	0:1:1:2:4	D008103	cirrhosis of the liver	Disease	24	28	1	1:NR:2	L2R	NON-CROSS	0-1	18-19	D010634	Phenobarbitone|phenobarbitone|phenobarbitone|phenobarbitone|phenobarbitone	Chemical	0:82:110:144:192	1:83:111:145:193	0:1:1:3:4	D005355	cirrhosis	Disease	18	19	0	1:NR:2	L2R	NON-CROSS	0-1	40-41	D010634	Phenobarbitone|phenobarbitone|phenobarbitone|phenobarbitone|phenobarbitone	Chemical	0:82:110:144:192	1:83:111:145:193	0:1:1:3:4	D001201	ascites	Disease	40	41	1	1:NR:2	L2R	NON-CROSS	57-58	82-83	D010634	Phenobarbitone|phenobarbitone|phenobarbitone|phenobarbitone|phenobarbitone	Chemical	0:82:110:144:192	1:83:111:145:193	0:1:1:3:4	D013163	splenomegaly	Disease	57	58	1	1:NR:2	L2R	NON-CROSS	66-67	82-83	D010634	Phenobarbitone|phenobarbitone|phenobarbitone|phenobarbitone|phenobarbitone	Chemical	0:82:110:144:192	1:83:111:145:193	0:1:1:3:4	D001284	atrophy	Disease	66	67	1	1:NR:2	R2L	NON-CROSS	14-16	3-7	D002251	carbon tetrachloride|carbon tetrachloride|carbon tetrachloride|CCl4|carbon tetrachloride	Chemical	14:76:103:129:185	16:78:105:130:187	0:1:1:2:4	D006529	enlargement of the liver|enlargement of the liver	Disease	3:113	7:117	0:1	1:NR:2	L2R	NON-CROSS	14-16	18-19	D002251	carbon tetrachloride|carbon tetrachloride|carbon tetrachloride|CCl4|carbon tetrachloride	Chemical	14:76:103:129:185	16:78:105:130:187	0:1:1:2:4	D005355	cirrhosis	Disease	18	19	0	1:NR:2	L2R	NON-CROSS	14-16	40-41	D002251	carbon tetrachloride|carbon tetrachloride|carbon tetrachloride|CCl4|carbon tetrachloride	Chemical	14:76:103:129:185	16:78:105:130:187	0:1:1:2:4	D001201	ascites	Disease	40	41	1	1:NR:2	L2R	NON-CROSS	57-58	76-78	D002251	carbon tetrachloride|carbon tetrachloride|carbon tetrachloride|CCl4|carbon tetrachloride	Chemical	14:76:103:129:185	16:78:105:130:187	0:1:1:2:4	D013163	splenomegaly	Disease	57	58	1	1:NR:2	L2R	NON-CROSS	66-67	76-78	D002251	carbon tetrachloride|carbon tetrachloride|carbon tetrachloride|CCl4|carbon tetrachloride	Chemical	14:76:103:129:185	16:78:105:130:187	0:1:1:2:4	D001284	atrophy	Disease	66	67	1
7453952	Attenuation of the lithium - induced diabetes - insipidus - like syndrome by amiloride in rats .|The effect of amiloride on lithium - induced polydipsia and polyuria and on the lithium concentration in the plasma , brain , kidney , thyroid and red blood cells was investigated in rats , chronically treated with LiCl .|Amiloride reduced the drinking and urine volume of rats in an acute ( 6 or 12 h ) and a subacute ( 3 days ) experiment .|6 h after the administration of amiloride , a reduction was observed in the lithium content of the renal medulla but not in the other organs studied .|At 12 h , all the tissues showed a slight increase in lithium levels .|After 3 days of combined treatment , a marked elevation in plasma and tissue lithium levels accompanied a reduction in water intake .|In all the experiments , the attenuation of the lithium - induced diabetes - insipidus - like syndrome by amiloride was accompanied by a reduction of the ratio between the lithium concentration in the renal medulla and its levels in the blood and an elevation in the plasma potassium level .|It is concluded that acute amiloride administration to lithium - treated patients suffering from polydipsia and polyuria might relieve these patients but prolonged amiloride supplementation would result in elevated lithium levels and might be hazardous .	1:CID:2	L2R	NON-CROSS	3-4	6-12	D008094	lithium|lithium|lithium|lithium|lithium|lithium|lithium|lithium|lithium|lithium	Chemical	3:22:31:97:123:140:158:179:208:229	4:23:32:98:124:141:159:180:209:230	0:1:1:3:4:5:6:6:7:7	D003919	diabetes - insipidus - like syndrome|diabetes - insipidus - like syndrome	Disease	6:161	12:167	0:6	1:NR:2	L2R	NON-CROSS	22-23	25-26	D008094	lithium|lithium|lithium|lithium|lithium|lithium|lithium|lithium|lithium|lithium	Chemical	3:22:31:97:123:140:158:179:208:229	4:23:32:98:124:141:159:180:209:230	0:1:1:3:4:5:6:6:7:7	D059606	polydipsia|polydipsia	Disease	25:214	26:215	1:7	1:NR:2	L2R	NON-CROSS	27-28	31-32	D008094	lithium|lithium|lithium|lithium|lithium|lithium|lithium|lithium|lithium|lithium	Chemical	3:22:31:97:123:140:158:179:208:229	4:23:32:98:124:141:159:180:209:230	0:1:1:3:4:5:6:6:7:7	D011141	polyuria|polyuria	Disease	27:216	28:217	1:7	1:NR:2	R2L	NON-CROSS	13-14	6-12	D000584	amiloride|amiloride|Amiloride|amiloride|amiloride|amiloride|amiloride	Chemical	13:20:56:89:168:205:223	14:21:57:90:169:206:224	0:1:2:3:6:7:7	D003919	diabetes - insipidus - like syndrome|diabetes - insipidus - like syndrome	Disease	6:161	12:167	0:6	1:NR:2	R2L	CROSS	54-55	6-12	D018021	LiCl	Chemical	54	55	1	D003919	diabetes - insipidus - like syndrome|diabetes - insipidus - like syndrome	Disease	6:161	12:167	0:6	1:NR:2	R2L	NON-CROSS	197-198	161-167	D011188	potassium	Chemical	197	198	6	D003919	diabetes - insipidus - like syndrome|diabetes - insipidus - like syndrome	Disease	6:161	12:167	0:6	1:NR:2	L2R	NON-CROSS	20-21	25-26	D000584	amiloride|amiloride|Amiloride|amiloride|amiloride|amiloride|amiloride	Chemical	13:20:56:89:168:205:223	14:21:57:90:169:206:224	0:1:2:3:6:7:7	D059606	polydipsia|polydipsia	Disease	25:214	26:215	1:7	1:NR:2	L2R	NON-CROSS	20-21	27-28	D000584	amiloride|amiloride|Amiloride|amiloride|amiloride|amiloride|amiloride	Chemical	13:20:56:89:168:205:223	14:21:57:90:169:206:224	0:1:2:3:6:7:7	D011141	polyuria|polyuria	Disease	27:216	28:217	1:7	1:NR:2	R2L	NON-CROSS	54-55	25-26	D018021	LiCl	Chemical	54	55	1	D059606	polydipsia|polydipsia	Disease	25:214	26:215	1:7	1:NR:2	R2L	CROSS	214-215	197-198	D011188	potassium	Chemical	197	198	6	D059606	polydipsia|polydipsia	Disease	25:214	26:215	1:7	1:NR:2	R2L	NON-CROSS	54-55	27-28	D018021	LiCl	Chemical	54	55	1	D011141	polyuria|polyuria	Disease	27:216	28:217	1:7	1:NR:2	R2L	CROSS	216-217	197-198	D011188	potassium	Chemical	197	198	6	D011141	polyuria|polyuria	Disease	27:216	28:217	1:7
7802851	Safety and side - effects of alprazolam .|Controlled study in agoraphobia with panic disorder .|BACKGROUND : The widespread use of benzodiazepines has led to increasing recognition of their unwanted effects .|The efficacy of alprazolam and placebo in panic disorder with agoraphobia , and the side - effect and adverse effect profiles of both drug groups were measured .|METHOD : In London and Toronto 154 patients who met DSM - III criteria for panic disorder with agoraphobia were randomised to alprazolam or placebo .|Subjects in each drug group also received either exposure or relaxation .|Treatment was from weeks 0 to 8 and was then tapered from weeks 8 to 16 .|RESULTS : Mean alprazolam dose was 5 mg daily .|Compared with placebo subjects , alprazolam patients developed more adverse reactions ( 21 % v .|0 % ) of depression , enuresis , disinhibition and aggression ; and more side - effects , particularly sedation , irritability , impaired memory , weight loss and ataxia .|Side - effects tended to diminish during treatment but remained significant at week 8 .|Despite this , the drop - out rate was low .|CONCLUSIONS : Alprazolam caused side - effects and adverse effects during treatment but many patients were willing to accept these .	1:CID:2	L2R	CROSS	131-132	146-147	D000525	alprazolam|alprazolam|alprazolam|alprazolam|alprazolam|Alprazolam	Chemical	6:36:83:119:131:201	7:37:84:120:132:202	0:3:4:7:8:12	D003866	depression	Disease	146	147	9	1:CID:2	L2R	CROSS	131-132	148-149	D000525	alprazolam|alprazolam|alprazolam|alprazolam|alprazolam|Alprazolam	Chemical	6:36:83:119:131:201	7:37:84:120:132:202	0:3:4:7:8:12	D004775	enuresis	Disease	148	149	9	1:CID:2	L2R	CROSS	131-132	165-167	D000525	alprazolam|alprazolam|alprazolam|alprazolam|alprazolam|Alprazolam	Chemical	6:36:83:119:131:201	7:37:84:120:132:202	0:3:4:7:8:12	D008569	impaired memory	Disease	165	167	9	1:CID:2	L2R	CROSS	168-170	201-202	D000525	alprazolam|alprazolam|alprazolam|alprazolam|alprazolam|Alprazolam	Chemical	6:36:83:119:131:201	7:37:84:120:132:202	0:3:4:7:8:12	D015431	weight loss	Disease	168	170	9	1:CID:2	L2R	CROSS	171-172	201-202	D000525	alprazolam|alprazolam|alprazolam|alprazolam|alprazolam|Alprazolam	Chemical	6:36:83:119:131:201	7:37:84:120:132:202	0:3:4:7:8:12	D001259	ataxia	Disease	171	172	9	1:NR:2	L2R	NON-CROSS	79-80	83-84	D000525	alprazolam|alprazolam|alprazolam|alprazolam|alprazolam|Alprazolam	Chemical	6:36:83:119:131:201	7:37:84:120:132:202	0:3:4:7:8:12	D000379	agoraphobia|agoraphobia|agoraphobia	Disease	11:43:79	12:44:80	1:3:4	1:NR:2	L2R	NON-CROSS	36-37	40-42	D000525	alprazolam|alprazolam|alprazolam|alprazolam|alprazolam|Alprazolam	Chemical	6:36:83:119:131:201	7:37:84:120:132:202	0:3:4:7:8:12	D016584	panic disorder|panic disorder|panic disorder	Disease	13:40:76	15:42:78	1:3:4	not_include	L2R	CROSS	131-132	152-153	D000525	alprazolam|alprazolam|alprazolam|alprazolam|alprazolam|Alprazolam	Chemical	6:36:83:119:131:201	7:37:84:120:132:202	0:3:4:7:8:12	D001523	aggression|irritability	Disease	152:163	153:164	9:9	1:NR:2	R2L	CROSS	22-23	11-12	D001569	benzodiazepines	Chemical	22	23	2	D000379	agoraphobia|agoraphobia|agoraphobia	Disease	11:43:79	12:44:80	1:3:4	1:NR:2	R2L	CROSS	22-23	13-15	D001569	benzodiazepines	Chemical	22	23	2	D016584	panic disorder|panic disorder|panic disorder	Disease	13:40:76	15:42:78	1:3:4	1:NR:2	L2R	CROSS	22-23	146-147	D001569	benzodiazepines	Chemical	22	23	2	D003866	depression	Disease	146	147	9	1:NR:2	L2R	CROSS	22-23	148-149	D001569	benzodiazepines	Chemical	22	23	2	D004775	enuresis	Disease	148	149	9	1:NR:2	L2R	CROSS	22-23	152-153	D001569	benzodiazepines	Chemical	22	23	2	D001523	aggression|irritability	Disease	152:163	153:164	9:9	1:NR:2	L2R	CROSS	22-23	165-167	D001569	benzodiazepines	Chemical	22	23	2	D008569	impaired memory	Disease	165	167	9	1:NR:2	L2R	CROSS	22-23	168-170	D001569	benzodiazepines	Chemical	22	23	2	D015431	weight loss	Disease	168	170	9	1:NR:2	L2R	CROSS	22-23	171-172	D001569	benzodiazepines	Chemical	22	23	2	D001259	ataxia	Disease	171	172	9
8319760	Dup 753 prevents the development of puromycin aminonucleoside - induced nephrosis .|The appearance of nephrotic syndromes such as proteinuria , hypoalbuminemia , hypercholesterolemia and increase in blood nitrogen urea , induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 ( losartan ) , a novel angiotensin II receptor antagonist , at a dose of 1 or 2 mg / kg per day .|The results suggest a possible involvement of the renin - angiotensin system in the development of puromycin aminonucleoside - induced nephrosis .	1:CID:2	L2R	NON-CROSS	6-8	15-17	D011692	puromycin aminonucleoside|puromycin aminonucleoside|puromycin aminonucleoside	Chemical	6:37:88	8:39:90	0:1:2	D009404	nephrotic syndromes	Disease	15	17	1	1:CID:2	L2R	NON-CROSS	6-8	19-20	D011692	puromycin aminonucleoside|puromycin aminonucleoside|puromycin aminonucleoside	Chemical	6:37:88	8:39:90	0:1:2	D011507	proteinuria	Disease	19	20	1	1:CID:2	L2R	NON-CROSS	6-8	21-22	D011692	puromycin aminonucleoside|puromycin aminonucleoside|puromycin aminonucleoside	Chemical	6:37:88	8:39:90	0:1:2	D034141	hypoalbuminemia	Disease	21	22	1	1:CID:2	L2R	NON-CROSS	23-24	37-39	D011692	puromycin aminonucleoside|puromycin aminonucleoside|puromycin aminonucleoside	Chemical	6:37:88	8:39:90	0:1:2	D006937	hypercholesterolemia	Disease	23	24	1	1:NR:2	L2R	NON-CROSS	0-2	10-11	D019808	Dup 753|Dup 753|losartan	Chemical	0:46:49	2:48:50	0:1:1	D009401	nephrosis|nephrosis	Disease	10:92	11:93	0:2	1:NR:2	L2R	NON-CROSS	0-2	15-17	D019808	Dup 753|Dup 753|losartan	Chemical	0:46:49	2:48:50	0:1:1	D009404	nephrotic syndromes	Disease	15	17	1	1:NR:2	L2R	NON-CROSS	0-2	19-20	D019808	Dup 753|Dup 753|losartan	Chemical	0:46:49	2:48:50	0:1:1	D011507	proteinuria	Disease	19	20	1	1:NR:2	L2R	NON-CROSS	0-2	21-22	D019808	Dup 753|Dup 753|losartan	Chemical	0:46:49	2:48:50	0:1:1	D034141	hypoalbuminemia	Disease	21	22	1	1:NR:2	L2R	NON-CROSS	0-2	23-24	D019808	Dup 753|Dup 753|losartan	Chemical	0:46:49	2:48:50	0:1:1	D006937	hypercholesterolemia	Disease	23	24	1	not_include	L2R	NON-CROSS	6-8	10-11	D011692	puromycin aminonucleoside|puromycin aminonucleoside|puromycin aminonucleoside	Chemical	6:37:88	8:39:90	0:1:2	D009401	nephrosis|nephrosis	Disease	10:92	11:93	0:2	1:NR:2	R2L	CROSS	27-30	10-11	D001806	blood nitrogen urea	Chemical	27	30	1	D009401	nephrosis|nephrosis	Disease	10:92	11:93	0:2	1:NR:2	R2L	CROSS	92-93	54-56	D000804	angiotensin II	Chemical	54	56	1	D009401	nephrosis|nephrosis	Disease	10:92	11:93	0:2	1:NR:2	R2L	NON-CROSS	92-93	82-83	D000809	angiotensin	Chemical	82	83	2	D009401	nephrosis|nephrosis	Disease	10:92	11:93	0:2	1:NR:2	R2L	NON-CROSS	27-30	15-17	D001806	blood nitrogen urea	Chemical	27	30	1	D009404	nephrotic syndromes	Disease	15	17	1	1:NR:2	R2L	NON-CROSS	54-56	15-17	D000804	angiotensin II	Chemical	54	56	1	D009404	nephrotic syndromes	Disease	15	17	1	1:NR:2	R2L	CROSS	82-83	15-17	D000809	angiotensin	Chemical	82	83	2	D009404	nephrotic syndromes	Disease	15	17	1	1:NR:2	R2L	NON-CROSS	27-30	19-20	D001806	blood nitrogen urea	Chemical	27	30	1	D011507	proteinuria	Disease	19	20	1	1:NR:2	R2L	NON-CROSS	54-56	19-20	D000804	angiotensin II	Chemical	54	56	1	D011507	proteinuria	Disease	19	20	1	1:NR:2	R2L	CROSS	82-83	19-20	D000809	angiotensin	Chemical	82	83	2	D011507	proteinuria	Disease	19	20	1	1:NR:2	R2L	NON-CROSS	27-30	21-22	D001806	blood nitrogen urea	Chemical	27	30	1	D034141	hypoalbuminemia	Disease	21	22	1	1:NR:2	R2L	NON-CROSS	54-56	21-22	D000804	angiotensin II	Chemical	54	56	1	D034141	hypoalbuminemia	Disease	21	22	1	1:NR:2	R2L	CROSS	82-83	21-22	D000809	angiotensin	Chemical	82	83	2	D034141	hypoalbuminemia	Disease	21	22	1	1:NR:2	R2L	NON-CROSS	27-30	23-24	D001806	blood nitrogen urea	Chemical	27	30	1	D006937	hypercholesterolemia	Disease	23	24	1	1:NR:2	R2L	NON-CROSS	54-56	23-24	D000804	angiotensin II	Chemical	54	56	1	D006937	hypercholesterolemia	Disease	23	24	1	1:NR:2	R2L	CROSS	82-83	23-24	D000809	angiotensin	Chemical	82	83	2	D006937	hypercholesterolemia	Disease	23	24	1
8386779	Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction .|In an attempt to determine whether penile pain associated with intracorporeal injections could be due to the acidity of the medication , we performed a randomized study comparing the incidence of penile pain following intracorporeal injections with or without the addition of sodium bicarbonate to the intracorporeal medications .|A total of 38 consecutive patients who presented to our clinic with impotence received 0 . 2 ml .|of a combination of 3 drugs : 6 mg .|papaverine , 100 micrograms .|phentolamine and 10 micrograms .|prostaglandin E1 with ( pH 7 . 05 ) or without ( pH 4 . 17 ) the addition of sodium bicarbonate ( 0 . 03 mEq . ) .|Of the 19 patients without sodium bicarbonate added to the medication 11 ( 58 % ) complained of penile pain due to the medication , while only 1 of the 19 men ( 5 % ) who received sodium bicarbonate complained of penile pain .|From these data we conclude that the penile pain following intracorporeal injections is most likely due to the acidity of the medication , which can be overcome by elevating the pH to a neutral level .	1:CID:2	R2L	CROSS	96-97	44-46	D010646	phentolamine	Chemical	96	97	5	D004414	penile pain|penile pain|penile pain|penile pain|penile pain|penile pain	Disease	3:19:44:149:173:183	5:21:46:151:175:185	0:1:1:7:7:8	1:CID:2	R2L	CROSS	149-151	101-103	D000527	prostaglandin E1	Chemical	101	103	6	D004414	penile pain|penile pain|penile pain|penile pain|penile pain|penile pain	Disease	3:19:44:149:173:183	5:21:46:151:175:185	0:1:1:7:7:8	1:NR:2	L2R	NON-CROSS	0-2	3-5	D017693	Sodium bicarbonate|sodium bicarbonate|sodium bicarbonate|sodium bicarbonate|sodium bicarbonate	Chemical	0:55:121:136:169	2:57:123:138:171	0:1:6:7:7	D004414	penile pain|penile pain|penile pain|penile pain|penile pain|penile pain	Disease	3:19:44:149:173:183	5:21:46:151:175:185	0:1:1:7:7:8	1:NR:2	L2R	NON-CROSS	0-2	10-12	D017693	Sodium bicarbonate|sodium bicarbonate|sodium bicarbonate|sodium bicarbonate|sodium bicarbonate	Chemical	0:55:121:136:169	2:57:123:138:171	0:1:6:7:7	D007172	erectile dysfunction|impotence	Disease	10:74	12:75	0:2	1:NR:2	R2L	CROSS	91-92	44-46	D010208	papaverine	Chemical	91	92	4	D004414	penile pain|penile pain|penile pain|penile pain|penile pain|penile pain	Disease	3:19:44:149:173:183	5:21:46:151:175:185	0:1:1:7:7:8	1:NR:2	R2L	CROSS	91-92	74-75	D010208	papaverine	Chemical	91	92	4	D007172	erectile dysfunction|impotence	Disease	10:74	12:75	0:2	1:NR:2	R2L	CROSS	96-97	74-75	D010646	phentolamine	Chemical	96	97	5	D007172	erectile dysfunction|impotence	Disease	10:74	12:75	0:2	1:NR:2	R2L	CROSS	101-103	74-75	D000527	prostaglandin E1	Chemical	101	103	6	D007172	erectile dysfunction|impotence	Disease	10:74	12:75	0:2
8421099	Prospective study of the long - term effects of somatostatin analog ( octreotide ) on gallbladder function and gallstone formation in Chinese acromegalic patients .|This article reports the changes in gallbladder function examined by ultrasonography in 20 Chinese patients with active acromegaly treated with sc injection of the somatostatin analog octreotide in dosages of 300 - 1500 micrograms / day for a mean of 24 . 2 + / - 13 . 9 months .|During treatment with octreotide , 17 patients developed sludge , 10 had gallstones , and 1 developed acute cholecystitis requiring surgery .|In all of 7 patients examined acutely , gallbladder contractility was inhibited after a single 100 - micrograms injection .|In 8 patients followed for 24 weeks , gallbladder contractility remained depressed throughout therapy .|After withdrawal of octreotide in 10 patients without gallstones , 8 patients assessed had return of normal gallbladder contractility within 1 month .|In 8 of the remaining 10 patients who developed gallstones during treatment , gallbladder contractility normalized in 5 patients ( 3 of whom has disappearance of their stones within 3 weeks ) , and remained depressed in 3 ( 2 of whom had stones present at 6 months ) .|Our results suggest that the suppression of gallbladder contractility is the cause of the successive formation of bile sludge , gallstones , and cholecystitis during octreotide therapy in Chinese acromegalic patients .|It is therefore very important to follow the changes of gallbladder function during long - term octreotide therapy of acromegalic patients .	1:CID:2	L2R	NON-CROSS	136-137	141-142	D015282	octreotide|octreotide|octreotide|octreotide|octreotide|octreotide	Chemical	12:51:79:136:231:254	13:52:80:137:232:255	0:1:2:5:7:8	D042882	gallstone|gallstones|gallstones|gallstones|gallstones	Disease	18:88:141:165:226	19:89:142:166:227	0:2:5:6:7	1:CID:2	L2R	NON-CROSS	79-80	93-95	D015282	octreotide|octreotide|octreotide|octreotide|octreotide|octreotide	Chemical	12:51:79:136:231:254	13:52:80:137:232:255	0:1:2:5:7:8	D041881	acute cholecystitis	Disease	93	95	2	1:NR:2	L2R	NON-CROSS	254-255	257-258	D015282	octreotide|octreotide|octreotide|octreotide|octreotide|octreotide	Chemical	12:51:79:136:231:254	13:52:80:137:232:255	0:1:2:5:7:8	D000172	acromegalic|acromegaly|acromegalic|acromegalic	Disease	22:42:235:257	23:43:236:258	0:1:7:8	1:NR:2	L2R	CROSS	129-130	136-137	D015282	octreotide|octreotide|octreotide|octreotide|octreotide|octreotide	Chemical	12:51:79:136:231:254	13:52:80:137:232:255	0:1:2:5:7:8	D003866	depressed|depressed	Disease	129:191	130:192	4:6	not_include	L2R	NON-CROSS	229-230	231-232	D015282	octreotide|octreotide|octreotide|octreotide|octreotide|octreotide	Chemical	12:51:79:136:231:254	13:52:80:137:232:255	0:1:2:5:7:8	D002764	cholecystitis	Disease	229	230	7
8649546	Improvement of levodopa - induced dyskinesia by propranolol in Parkinson 's disease .|Seven patients suffering from Parkinson 's disease ( PD ) with severely disabling dyskinesia received low - dose propranolol as an adjunct to the currently used medical treatment .|There was a significant 40 % improvement in the dyskinesia score without increase of parkinsonian motor disability .|Ballistic and choreic dyskinesia were markedly ameliorated , whereas dystonia was not .|This study suggests that administration of low doses of beta - blockers may improve levodopa - induced ballistic and choreic dyskinesia in PD .	1:CID:2	L2R	NON-CROSS	2-3	5-6	D007980	levodopa|levodopa	Chemical	2:87	3:88	0:4	D004409	dyskinesia|dyskinesia|dyskinesia|dyskinesia|dyskinesia	Disease	5:26:51:63:93	6:27:52:64:94	0:1:2:3:4	1:NR:2	L2R	NON-CROSS	2-3	9-12	D007980	levodopa|levodopa	Chemical	2:87	3:88	0:4	D010300	Parkinson 's disease|Parkinson 's disease|PD|parkinsonian|PD	Disease	9:17:21:56:95	12:20:22:57:96	0:1:1:2:4	not_include	L2R	CROSS	57-59	87-88	D007980	levodopa|levodopa	Chemical	2:87	3:88	0:4	D009069	motor disability	Disease	57	59	2	1:NR:2	L2R	CROSS	69-70	87-88	D007980	levodopa|levodopa	Chemical	2:87	3:88	0:4	D004421	dystonia	Disease	69	70	3	1:NR:2	R2L	NON-CROSS	7-8	5-6	D011433	propranolol|propranolol	Chemical	7:31	8:32	0:1	D004409	dyskinesia|dyskinesia|dyskinesia|dyskinesia|dyskinesia	Disease	5:26:51:63:93	6:27:52:64:94	0:1:2:3:4	1:NR:2	L2R	NON-CROSS	7-8	9-12	D011433	propranolol|propranolol	Chemical	7:31	8:32	0:1	D010300	Parkinson 's disease|Parkinson 's disease|PD|parkinsonian|PD	Disease	9:17:21:56:95	12:20:22:57:96	0:1:1:2:4	1:NR:2	L2R	CROSS	31-32	57-59	D011433	propranolol|propranolol	Chemical	7:31	8:32	0:1	D009069	motor disability	Disease	57	59	2	1:NR:2	L2R	CROSS	31-32	69-70	D011433	propranolol|propranolol	Chemical	7:31	8:32	0:1	D004421	dystonia	Disease	69	70	3
8919272	Morphological features of encephalopathy after chronic administration of the antiepileptic drug valproate to rats .|A transmission electron microscopic study of capillaries in the cerebellar cortex .|Long - term intragastric application of the antiepileptic drug sodium valproate ( Vupral " Polfa " ) at the effective dose of 200 mg / kg b .|w .|once daily to rats for 1 , 3 , 6 , 9 and 12 months revealed neurological disorders indicating cerebellum damage ( " valproate encephalopathy " ) .|The first ultrastructural changes in structural elements of the blood - brain - barrier ( BBB ) in the cerebellar cortex were detectable after 3 months of the experiment .|They became more severe in the later months of the experiment , and were most severe after 12 months , located mainly in the molecular layer of the cerebellar cortex .|Lesions of the capillary included necrosis of endothelial cells .|Organelles of these cells , in particular the mitochondria ( increased number and size , distinct degeneration of their matrix and cristae ) and Golgi apparatus were altered .|Reduced size of capillary lumen and occlusion were caused by swollen endothelial cells which had luminal protrusions and swollen microvilli .|Pressure on the vessel wall was produced by enlarged perivascular astrocytic processes .|Fragments of necrotic endothelial cells were in the vascular lumens and in these there was loosening and breaking of tight cellular junctions .|Damage to the vascular basement lamina was also observed .|Damage to the capillary was accompanied by marked damage to neuroglial cells , mainly to perivascular processes of astrocytes .|The proliferation of astrocytes ( Bergmann 's in particular ) and occasionally of oligodendrocytes was found .|Alterations in the structural elements of the BBB coexisted with marked lesions of neurons of the cerebellum ( Purkinje cells are earliest ) .|In electron micrographs both luminal and antiluminal sides of the BBB of the cerebellar cortex had similar lesions .|The possible influence of the hepatic damage , mainly hyperammonemia , upon the development of valproate encephalopathy is discussed .	1:CID:2	R2L	NON-CROSS	81-82	80-81	D014635	valproate|sodium valproate|valproate|valproate	Chemical	11:36:80:347	12:38:81:348	0:2:4:17	D001927	encephalopathy|encephalopathy|encephalopathy	Disease	3:81:348	4:82:349	0:4:17	1:NR:2	R2L	CROSS	348-349	317-318	D010634	luminal|luminal	Chemical	200:317	201:318	9:16	D001927	encephalopathy|encephalopathy|encephalopathy	Disease	3:81:348	4:82:349	0:4:17	not_include	L2R	NON-CROSS	73-75	80-81	D014635	valproate|sodium valproate|valproate|valproate	Chemical	11:36:80:347	12:38:81:348	0:2:4:17	D009422	neurological disorders	Disease	73	75	4	1:NR:2	L2R	NON-CROSS	76-78	80-81	D014635	valproate|sodium valproate|valproate|valproate	Chemical	11:36:80:347	12:38:81:348	0:2:4:17	D002526	cerebellum damage	Disease	76	78	4	1:NR:2	L2R	CROSS	80-81	151-152	D014635	valproate|sodium valproate|valproate|valproate	Chemical	11:36:80:347	12:38:81:348	0:2:4:17	D009336	necrosis|necrotic	Disease	151:221	152:222	7:11	1:NR:2	L2R	NON-CROSS	337-339	347-348	D014635	valproate|sodium valproate|valproate|valproate	Chemical	11:36:80:347	12:38:81:348	0:2:4:17	D056486	hepatic damage	Disease	337	339	17	1:NR:2	L2R	NON-CROSS	341-342	347-348	D014635	valproate|sodium valproate|valproate|valproate	Chemical	11:36:80:347	12:38:81:348	0:2:4:17	D022124	hyperammonemia	Disease	341	342	17	1:NR:2	R2L	CROSS	200-201	73-75	D010634	luminal|luminal	Chemical	200:317	201:318	9:16	D009422	neurological disorders	Disease	73	75	4	1:NR:2	R2L	CROSS	200-201	76-78	D010634	luminal|luminal	Chemical	200:317	201:318	9:16	D002526	cerebellum damage	Disease	76	78	4	1:NR:2	R2L	CROSS	221-222	200-201	D010634	luminal|luminal	Chemical	200:317	201:318	9:16	D009336	necrosis|necrotic	Disease	151:221	152:222	7:11	1:NR:2	L2R	CROSS	317-318	337-339	D010634	luminal|luminal	Chemical	200:317	201:318	9:16	D056486	hepatic damage	Disease	337	339	17	1:NR:2	L2R	CROSS	317-318	341-342	D010634	luminal|luminal	Chemical	200:317	201:318	9:16	D022124	hyperammonemia	Disease	341	342	17
9199746	Macula toxicity after intravitreal amikacin .|BACKGROUND : Although intravitreal aminoglycosides have substantially improved visual prognosis in endophthalmitis , macular infarction may impair full visual recovery .|METHODS : We present a case of presumed amikacin retinal toxicity following treatment with amikacin and vancomycin for alpha - haemolytic streptococcal endophthalmitis .|RESULTS : Endophthalmitis resolved with improvement in visual acuity to 6 / 24 at three months .|Fundus fluorescein angiography confirmed macular capillary closure and telangiectasis .|CONCLUSIONS : Currently accepted intravitreal antibiotic regimens may cause retinal toxicity and macular ischaemia .|Treatment strategies aimed at avoiding retinal toxicity are discussed .	1:CID:2	L2R	NON-CROSS	35-36	36-38	D000583	amikacin|amikacin|amikacin	Chemical	4:35:41	5:36:42	0:2:2	D012164	retinal toxicity|retinal toxicity|retinal toxicity	Disease	36:87:98	38:89:100	2:5:6	1:CID:2	L2R	CROSS	41-42	91-92	D000583	amikacin|amikacin|amikacin	Chemical	4:35:41	5:36:42	0:2:2	D007511	ischaemia	Disease	91	92	5	1:NR:2	R2L	NON-CROSS	4-5	1-2	D000583	amikacin|amikacin|amikacin	Chemical	4:35:41	5:36:42	0:2:2	D064420	toxicity	Disease	1	2	0	1:NR:2	R2L	CROSS	10-11	1-2	D000617	aminoglycosides	Chemical	10	11	1	D064420	toxicity	Disease	1	2	0	1:NR:2	R2L	CROSS	43-44	1-2	D014640	vancomycin	Chemical	43	44	2	D064420	toxicity	Disease	1	2	0	1:NR:2	R2L	CROSS	69-70	1-2	D019793	fluorescein	Chemical	69	70	4	D064420	toxicity	Disease	1	2	0	1:NR:2	L2R	CROSS	41-42	53-54	D000583	amikacin|amikacin|amikacin	Chemical	4:35:41	5:36:42	0:2:2	D009877	endophthalmitis|Endophthalmitis	Disease	17:53	18:54	1:3	1:NR:2	L2R	CROSS	20-21	35-36	D000583	amikacin|amikacin|amikacin	Chemical	4:35:41	5:36:42	0:2:2	D007238	infarction	Disease	20	21	1	1:NR:2	L2R	NON-CROSS	41-42	48-50	D000583	amikacin|amikacin|amikacin	Chemical	4:35:41	5:36:42	0:2:2	D013290	streptococcal endophthalmitis	Disease	48	50	2	1:NR:2	L2R	CROSS	41-42	76-77	D000583	amikacin|amikacin|amikacin	Chemical	4:35:41	5:36:42	0:2:2	D013684	telangiectasis	Disease	76	77	4	1:NR:2	L2R	NON-CROSS	10-11	17-18	D000617	aminoglycosides	Chemical	10	11	1	D009877	endophthalmitis|Endophthalmitis	Disease	17:53	18:54	1:3	1:NR:2	L2R	NON-CROSS	10-11	20-21	D000617	aminoglycosides	Chemical	10	11	1	D007238	infarction	Disease	20	21	1	1:NR:2	L2R	CROSS	10-11	36-38	D000617	aminoglycosides	Chemical	10	11	1	D012164	retinal toxicity|retinal toxicity|retinal toxicity	Disease	36:87:98	38:89:100	2:5:6	1:NR:2	L2R	CROSS	10-11	48-50	D000617	aminoglycosides	Chemical	10	11	1	D013290	streptococcal endophthalmitis	Disease	48	50	2	1:NR:2	L2R	CROSS	10-11	76-77	D000617	aminoglycosides	Chemical	10	11	1	D013684	telangiectasis	Disease	76	77	4	1:NR:2	L2R	CROSS	10-11	91-92	D000617	aminoglycosides	Chemical	10	11	1	D007511	ischaemia	Disease	91	92	5	1:NR:2	R2L	CROSS	53-54	43-44	D014640	vancomycin	Chemical	43	44	2	D009877	endophthalmitis|Endophthalmitis	Disease	17:53	18:54	1:3	1:NR:2	R2L	CROSS	69-70	53-54	D019793	fluorescein	Chemical	69	70	4	D009877	endophthalmitis|Endophthalmitis	Disease	17:53	18:54	1:3	1:NR:2	R2L	CROSS	43-44	20-21	D014640	vancomycin	Chemical	43	44	2	D007238	infarction	Disease	20	21	1	1:NR:2	R2L	CROSS	69-70	20-21	D019793	fluorescein	Chemical	69	70	4	D007238	infarction	Disease	20	21	1	1:NR:2	R2L	NON-CROSS	43-44	36-38	D014640	vancomycin	Chemical	43	44	2	D012164	retinal toxicity|retinal toxicity|retinal toxicity	Disease	36:87:98	38:89:100	2:5:6	1:NR:2	R2L	CROSS	87-89	69-70	D019793	fluorescein	Chemical	69	70	4	D012164	retinal toxicity|retinal toxicity|retinal toxicity	Disease	36:87:98	38:89:100	2:5:6	1:NR:2	L2R	NON-CROSS	43-44	48-50	D014640	vancomycin	Chemical	43	44	2	D013290	streptococcal endophthalmitis	Disease	48	50	2	1:NR:2	L2R	CROSS	43-44	76-77	D014640	vancomycin	Chemical	43	44	2	D013684	telangiectasis	Disease	76	77	4	1:NR:2	L2R	CROSS	43-44	91-92	D014640	vancomycin	Chemical	43	44	2	D007511	ischaemia	Disease	91	92	5	1:NR:2	R2L	CROSS	69-70	48-50	D019793	fluorescein	Chemical	69	70	4	D013290	streptococcal endophthalmitis	Disease	48	50	2	1:NR:2	L2R	NON-CROSS	69-70	76-77	D019793	fluorescein	Chemical	69	70	4	D013684	telangiectasis	Disease	76	77	4	1:NR:2	L2R	CROSS	69-70	91-92	D019793	fluorescein	Chemical	69	70	4	D007511	ischaemia	Disease	91	92	5
9249847	Iatrogenically induced intractable atrioventricular reentrant tachycardia after verapamil and catheter ablation in a patient with Wolff - Parkinson - White syndrome and idiopathic dilated cardiomyopathy .|In a patient with WPW syndrome and idiopathic dilated cardiomyopathy , intractable atrioventricular reentrant tachycardia ( AVRT ) was iatrogenically induced .|QRS without preexcitation , caused by junctional escape beats after verapamil or unidirectional antegrade block of accessory pathway after catheter ablation , established frequent AVRT attack .	1:CID:2	R2L	NON-CROSS	7-8	3-6	D014700	verapamil|verapamil	Chemical	7:58	8:59	0:2	D013611	atrioventricular reentrant tachycardia|atrioventricular reentrant tachycardia|AVRT|AVRT	Disease	3:38:42:72	6:41:43:73	0:1:1:2	1:NR:2	L2R	NON-CROSS	7-8	15-21	D014700	verapamil|verapamil	Chemical	7:58	8:59	0:2	D014927	Wolff - Parkinson - White syndrome|WPW syndrome	Disease	15:30	21:32	0:1	1:NR:2	L2R	NON-CROSS	7-8	22-25	D014700	verapamil|verapamil	Chemical	7:58	8:59	0:2	D002311	idiopathic dilated cardiomyopathy|idiopathic dilated cardiomyopathy	Disease	22:33	25:36	0:1
9284778	Epidemic of liver disease caused by hydrochlorofluorocarbons used as ozone - sparing substitutes of chlorofluorocarbons .|BACKGROUND : Hydrochlorofluorocarbons ( HCFCs ) are used increasingly in industry as substitutes for ozone - depleting chlorofluorocarbons ( CFCs ) .|Limited studies in animals indicate potential hepatotoxicity of some of these compounds .|We investigated an epidemic of liver disease in nine industrial workers who had had repeated accidental exposure to a mixture of 1 , 1 - dichloro - 2 , 2 , 2 - trifluoroethane ( HCFC 123 ) and 1 - chloro - 1 , 2 , 2 , 2 - tetrafluoroethane ( HCFC 124 ) .|All nine exposed workers were affected to various degrees .|Both compounds are metabolised in the same way as 1 - bromo - 1 - chloro - 2 , 2 , 2 - trifluoroethane ( halothane ) to form reactive trifluoroacetyl halide intermediates , which have been implicated in the hepatotoxicity of halothane .|We aimed to test whether HCFCs 123 and 124 can result in serious liver disease .|METHODS : For one severely affected worker liver biopsy and immunohistochemical stainings for the presence of trifluoroacetyl protein adducts were done .|The serum of six affected workers and five controls was tested for autoantibodies that react with human liver cytochrome - P450 2E1 ( P450 2E1 ) and P58 protein disulphide isomerase isoform ( P58 ) .|FINDINGS : The liver biopsy sample showed hepatocellular necrosis which was prominent in perivenular zone three and extended focally from portal tracts to portal tracts and centrilobular areas ( bridging necrosis ) .|Trifluoroacetyl - adducted proteins were detected in surviving hepatocytes .|Autoantibodies against P450 2E1 or P58 , previously associated with halothane hepatitis , were detected in the serum of five affected workers .|INTERPRETATION : Repeated exposure of human beings to HCFCs 123 and 124 can result in serious liver injury in a large proportion of the exposed population .|Although the exact mechanism of hepatotoxicity of these agents is not known , the results suggest that trifluoroacetyl - altered liver proteins are involved .|In view of the potentially widespread use of these compounds , there is an urgent need to develop safer alternatives .	1:CID:2	R2L	NON-CROSS	175-177	167-171	C067411	1 , 1 - dichloro - 2 , 2 , 2 - trifluoroethane|HCFC 123|HCFCs 123 and 124|HCFCs 123 and 124	Chemical	72:86:167:310	85:88:171:314	3:3:6:12	D008107	liver disease|liver disease|liver disease	Disease	2:56:175	4:58:177	0:3:6	1:CID:2	R2L	NON-CROSS	175-177	167-171	C072959	1 - chloro - 1 , 2 , 2 , 2 - tetrafluoroethane|HCFC 124|HCFCs 123 and 124|HCFCs 123 and 124	Chemical	90:104:167:310	103:106:171:314	3:3:6:12	D008107	liver disease|liver disease|liver disease	Disease	2:56:175	4:58:177	0:3:6	1:NR:2	R2L	NON-CROSS	9-10	2-4	D010126	ozone|ozone	Chemical	9:30	10:31	0:1	D008107	liver disease|liver disease|liver disease	Disease	2:56:175	4:58:177	0:3:6	1:NR:2	R2L	NON-CROSS	14-15	2-4	D017402	chlorofluorocarbons|chlorofluorocarbons|CFCs	Chemical	14:33:35	15:34:36	0:1:1	D008107	liver disease|liver disease|liver disease	Disease	2:56:175	4:58:177	0:3:6	1:NR:2	R2L	CROSS	175-177	160-161	D006221	1 - bromo - 1 - chloro - 2 , 2 , 2 - trifluoroethane|halothane|halothane	Chemical	127:143:160	142:144:161	5:5:5	D008107	liver disease|liver disease|liver disease	Disease	2:56:175	4:58:177	0:3:6	1:NR:2	R2L	CROSS	194-195	175-177	D014269	trifluoroacetyl|trifluoroacetyl|Trifluoroacetyl|trifluoroacetyl	Chemical	148:194:269:346	149:195:270:347	5:7:10:13	D008107	liver disease|liver disease|liver disease	Disease	2:56:175	4:58:177	0:3:6	1:NR:2	L2R	CROSS	30-31	44-45	D010126	ozone|ozone	Chemical	9:30	10:31	0:1	D056486	hepatotoxicity|hepatotoxicity|liver injury|hepatotoxicity	Disease	44:158:318:334	45:159:320:335	2:5:12:13	1:NR:2	L2R	CROSS	30-31	244-245	D010126	ozone|ozone	Chemical	9:30	10:31	0:1	D009336	necrosis|necrosis	Disease	244:266	245:267	9:9	1:NR:2	L2R	CROSS	30-31	289-291	D010126	ozone|ozone	Chemical	9:30	10:31	0:1	C562477	halothane hepatitis	Disease	289	291	11	1:NR:2	L2R	CROSS	35-36	44-45	D017402	chlorofluorocarbons|chlorofluorocarbons|CFCs	Chemical	14:33:35	15:34:36	0:1:1	D056486	hepatotoxicity|hepatotoxicity|liver injury|hepatotoxicity	Disease	44:158:318:334	45:159:320:335	2:5:12:13	1:NR:2	L2R	CROSS	35-36	244-245	D017402	chlorofluorocarbons|chlorofluorocarbons|CFCs	Chemical	14:33:35	15:34:36	0:1:1	D009336	necrosis|necrosis	Disease	244:266	245:267	9:9	1:NR:2	L2R	CROSS	35-36	289-291	D017402	chlorofluorocarbons|chlorofluorocarbons|CFCs	Chemical	14:33:35	15:34:36	0:1:1	C562477	halothane hepatitis	Disease	289	291	11	1:NR:2	R2L	NON-CROSS	318-320	310-314	C067411	1 , 1 - dichloro - 2 , 2 , 2 - trifluoroethane|HCFC 123|HCFCs 123 and 124|HCFCs 123 and 124	Chemical	72:86:167:310	85:88:171:314	3:3:6:12	D056486	hepatotoxicity|hepatotoxicity|liver injury|hepatotoxicity	Disease	44:158:318:334	45:159:320:335	2:5:12:13	1:NR:2	R2L	NON-CROSS	318-320	310-314	C072959	1 - chloro - 1 , 2 , 2 , 2 - tetrafluoroethane|HCFC 124|HCFCs 123 and 124|HCFCs 123 and 124	Chemical	90:104:167:310	103:106:171:314	3:3:6:12	D056486	hepatotoxicity|hepatotoxicity|liver injury|hepatotoxicity	Disease	44:158:318:334	45:159:320:335	2:5:12:13	1:NR:2	R2L	NON-CROSS	160-161	158-159	D006221	1 - bromo - 1 - chloro - 2 , 2 , 2 - trifluoroethane|halothane|halothane	Chemical	127:143:160	142:144:161	5:5:5	D056486	hepatotoxicity|hepatotoxicity|liver injury|hepatotoxicity	Disease	44:158:318:334	45:159:320:335	2:5:12:13	1:NR:2	R2L	NON-CROSS	158-159	148-149	D014269	trifluoroacetyl|trifluoroacetyl|Trifluoroacetyl|trifluoroacetyl	Chemical	148:194:269:346	149:195:270:347	5:7:10:13	D056486	hepatotoxicity|hepatotoxicity|liver injury|hepatotoxicity	Disease	44:158:318:334	45:159:320:335	2:5:12:13	1:NR:2	L2R	CROSS	266-267	310-314	C067411	1 , 1 - dichloro - 2 , 2 , 2 - trifluoroethane|HCFC 123|HCFCs 123 and 124|HCFCs 123 and 124	Chemical	72:86:167:310	85:88:171:314	3:3:6:12	D009336	necrosis|necrosis	Disease	244:266	245:267	9:9	1:NR:2	L2R	CROSS	289-291	310-314	C067411	1 , 1 - dichloro - 2 , 2 , 2 - trifluoroethane|HCFC 123|HCFCs 123 and 124|HCFCs 123 and 124	Chemical	72:86:167:310	85:88:171:314	3:3:6:12	C562477	halothane hepatitis	Disease	289	291	11	1:NR:2	L2R	CROSS	266-267	310-314	C072959	1 - chloro - 1 , 2 , 2 , 2 - tetrafluoroethane|HCFC 124|HCFCs 123 and 124|HCFCs 123 and 124	Chemical	90:104:167:310	103:106:171:314	3:3:6:12	D009336	necrosis|necrosis	Disease	244:266	245:267	9:9	1:NR:2	L2R	CROSS	289-291	310-314	C072959	1 - chloro - 1 , 2 , 2 , 2 - tetrafluoroethane|HCFC 124|HCFCs 123 and 124|HCFCs 123 and 124	Chemical	90:104:167:310	103:106:171:314	3:3:6:12	C562477	halothane hepatitis	Disease	289	291	11	1:NR:2	L2R	CROSS	160-161	244-245	D006221	1 - bromo - 1 - chloro - 2 , 2 , 2 - trifluoroethane|halothane|halothane	Chemical	127:143:160	142:144:161	5:5:5	D009336	necrosis|necrosis	Disease	244:266	245:267	9:9	1:NR:2	L2R	CROSS	160-161	289-291	D006221	1 - bromo - 1 - chloro - 2 , 2 , 2 - trifluoroethane|halothane|halothane	Chemical	127:143:160	142:144:161	5:5:5	C562477	halothane hepatitis	Disease	289	291	11	1:NR:2	L2R	CROSS	266-267	269-270	D014269	trifluoroacetyl|trifluoroacetyl|Trifluoroacetyl|trifluoroacetyl	Chemical	148:194:269:346	149:195:270:347	5:7:10:13	D009336	necrosis|necrosis	Disease	244:266	245:267	9:9	1:NR:2	L2R	CROSS	269-270	289-291	D014269	trifluoroacetyl|trifluoroacetyl|Trifluoroacetyl|trifluoroacetyl	Chemical	148:194:269:346	149:195:270:347	5:7:10:13	C562477	halothane hepatitis	Disease	289	291	11
9522143	The effect of different anaesthetic agents in hearing loss following spinal anaesthesia .|The cause of hearing loss after spinal anaesthesia is unknown .|Up until now , the only factor studied has been the effect of the diameter of the spinal needle on post - operative sensorineural hearing loss .|The aim of this study was to describe this hearing loss and to investigate other factors influencing the degree of hearing loss .|Two groups of 22 similar patients were studied : one group received 6 mL prilocaine 2 % ; and the other received 3 mL bupivacaine 0 . 5 % .|Patients given prilocaine were more likely to develop hearing loss ( 10 out of 22 ) than those given bupivacaine ( 4 out of 22 ) ( P < 0 . 05 ) .|The average hearing loss for speech frequencies was about 10 dB after prilocaine and 15 dB after bupivacaine .|None of the patients complained of subjective hearing loss .|Long - term follow - up of the patients was not possible .	1:CID:2	R2L	NON-CROSS	112-114	106-107	D011318	prilocaine|prilocaine|prilocaine	Chemical	88:106:150	89:107:151	4:5:6	D034381	hearing loss|hearing loss|hearing loss|hearing loss|hearing loss|hearing loss|hearing loss	Disease	7:16:60:71:112:140:164	9:18:62:73:114:142:166	0:1:3:3:5:6:7	1:CID:2	R2L	NON-CROSS	164-166	155-156	D002045	bupivacaine|bupivacaine|bupivacaine	Chemical	98:123:155	99:124:156	4:5:6	D034381	hearing loss|hearing loss|hearing loss|hearing loss|hearing loss|hearing loss|hearing loss	Disease	7:16:60:71:112:140:164	9:18:62:73:114:142:166	0:1:3:3:5:6:7	1:NR:2	R2L	CROSS	88-89	47-50	D011318	prilocaine|prilocaine|prilocaine	Chemical	88:106:150	89:107:151	4:5:6	D006319	sensorineural hearing loss	Disease	47	50	2	1:NR:2	R2L	CROSS	98-99	47-50	D002045	bupivacaine|bupivacaine|bupivacaine	Chemical	98:123:155	99:124:156	4:5:6	D006319	sensorineural hearing loss	Disease	47	50	2
9522152	A transient neurological deficit following intrathecal injection of 1 % hyperbaric bupivacaine for unilateral spinal anaesthesia .|We describe a case of transient neurological deficit that occurred after unilateral spinal anaesthesia with 8 mg of 1 % hyperbaric bupivacaine slowly injected through a 25 - gauge pencil - point spinal needle .|The surgery and anaesthesia were uneventful , but 3 days after surgery , the patient reported an area of hypoaesthesia over L3 - L4 dermatomes of the leg which had been operated on ( loss of pinprick sensation ) without reduction in muscular strength .|Sensation in this area returned to normal over the following 2 weeks .|Prospective multicentre studies with a large population and a long follow - up should be performed in order to evaluate the incidence of this unusual side effect .|However , we suggest that a low solution concentration should be preferred for unilateral spinal anaesthesia with a hyperbaric anaesthetic solution ( if pencil - point needle and slow injection rate are employed ) , in order to minimize the risk of a localized high peak anaesthetic concentration , which might lead to a transient neurological deficit .	1:CID:2	L2R	CROSS	38-39	86-90	D002045	bupivacaine|bupivacaine	Chemical	11:38	12:39	0:1	D012678	loss of pinprick sensation	Disease	86	90	2	not_include	R2L	NON-CROSS	11-12	2-4	D002045	bupivacaine|bupivacaine	Chemical	11:38	12:39	0:1	D009461	neurological deficit|neurological deficit|neurological deficit	Disease	2:23:193	4:25:195	0:1:5
9672936	Pethidine - associated seizure in a healthy adolescent receiving pethidine for postoperative pain control .|A healthy 17 - year - old male received standard intermittent doses of pethidine via a patient - controlled analgesia ( PCA ) pump for management of postoperative pain control .|Twenty - three h postoperatively he developed a brief self - limited seizure .|Both plasma pethidine and norpethidine were elevated in the range associated with clinical manifestations of central nervous system excitation .|No other risk factors for CNS toxicity were identified .|This method allowed frequent self - dosing of pethidine at short time intervals and rapid accumulation of pethidine and norpethidine .|The routine use of pethidine via PCA even for a brief postoperative analgesia should be reconsidered .	1:CID:2	L2R	NON-CROSS	0-1	3-4	D008614	Pethidine|pethidine|pethidine|pethidine|pethidine|pethidine|pethidine	Chemical	0:9:28:62:98:107:115	1:10:29:63:99:108:116	0:0:1:3:5:5:6	D012640	seizure|seizure	Disease	3:58	4:59	0:2	1:NR:2	L2R	NON-CROSS	9-10	11-13	D008614	Pethidine|pethidine|pethidine|pethidine|pethidine|pethidine|pethidine	Chemical	0:9:28:62:98:107:115	1:10:29:63:99:108:116	0:0:1:3:5:5:6	D010149	postoperative pain|postoperative pain	Disease	11:42	13:44	0:1	1:NR:2	L2R	CROSS	86-87	98-99	D008614	Pethidine|pethidine|pethidine|pethidine|pethidine|pethidine|pethidine	Chemical	0:9:28:62:98:107:115	1:10:29:63:99:108:116	0:0:1:3:5:5:6	D064420	toxicity	Disease	86	87	4	1:NR:2	R2L	CROSS	64-65	58-59	C002752	norpethidine|norpethidine	Chemical	64:109	65:110	3:5	D012640	seizure|seizure	Disease	3:58	4:59	0:2	1:NR:2	R2L	CROSS	64-65	42-44	C002752	norpethidine|norpethidine	Chemical	64:109	65:110	3:5	D010149	postoperative pain|postoperative pain	Disease	11:42	13:44	0:1	1:NR:2	L2R	CROSS	64-65	86-87	C002752	norpethidine|norpethidine	Chemical	64:109	65:110	3:5	D064420	toxicity	Disease	86	87	4
9721172	Drug - associated acute - onset vanishing bile duct and Stevens - Johnson syndromes in a child .|Acute vanishing bile duct syndrome is a rare but established cause of progressive cholestasis in adults , is most often drug or toxin related , and is of unknown pathogenesis .|It has not been reported previously in children .|Stevens - Johnson syndrome is a well - recognized immune complex - mediated hypersensitivity reaction that affects all age groups , is drug or infection induced , and has classic systemic , mucosal , and dermatologic manifestations .|A previously healthy child who developed acute , severe , rapidly progressive vanishing bile duct syndrome shortly after Stevens - Johnson syndrome is described ; this was temporally associated with ibuprofen use .|Despite therapy with ursodeoxycholic acid , prednisone , and then tacrolimus , her cholestatic disease was unrelenting , with cirrhosis shown by biopsy 6 months after presentation .|This case documents acute drug - related vanishing bile duct syndrome in the pediatric age group and suggests shared immune mechanisms in the pathogenesis of both Stevens - Johnson syndrome and vanishing bile duct syndrome .	1:CID:2	R2L	NON-CROSS	126-127	114-118	D007052	ibuprofen	Chemical	126	127	4	D013262	Stevens - Johnson syndromes|Stevens - Johnson syndrome|Stevens - Johnson syndrome|Stevens - Johnson syndrome	Disease	10:58:114:183	14:62:118:187	0:3:4:6	1:CID:2	R2L	CROSS	142-144	126-127	D007052	ibuprofen	Chemical	126	127	4	D002779	cholestasis|cholestatic disease	Disease	31:142	32:144	1:5	not_include	R2L	NON-CROSS	126-127	108-112	D007052	ibuprofen	Chemical	126	127	4	D001649	vanishing bile duct|vanishing bile duct|vanishing bile duct syndrome|vanishing bile duct syndrome|vanishing bile duct syndrome	Disease	6:19:108:164:188	9:22:112:168:192	0:1:4:6:6	1:NR:2	R2L	CROSS	132-134	108-112	D014580	ursodeoxycholic acid	Chemical	132	134	5	D001649	vanishing bile duct|vanishing bile duct|vanishing bile duct syndrome|vanishing bile duct syndrome|vanishing bile duct syndrome	Disease	6:19:108:164:188	9:22:112:168:192	0:1:4:6:6	1:NR:2	R2L	CROSS	135-136	108-112	D011241	prednisone	Chemical	135	136	5	D001649	vanishing bile duct|vanishing bile duct|vanishing bile duct syndrome|vanishing bile duct syndrome|vanishing bile duct syndrome	Disease	6:19:108:164:188	9:22:112:168:192	0:1:4:6:6	1:NR:2	R2L	CROSS	164-168	139-140	D016559	tacrolimus	Chemical	139	140	5	D001649	vanishing bile duct|vanishing bile duct|vanishing bile duct syndrome|vanishing bile duct syndrome|vanishing bile duct syndrome	Disease	6:19:108:164:188	9:22:112:168:192	0:1:4:6:6	1:NR:2	R2L	CROSS	132-134	114-118	D014580	ursodeoxycholic acid	Chemical	132	134	5	D013262	Stevens - Johnson syndromes|Stevens - Johnson syndrome|Stevens - Johnson syndrome|Stevens - Johnson syndrome	Disease	10:58:114:183	14:62:118:187	0:3:4:6	1:NR:2	R2L	CROSS	135-136	114-118	D011241	prednisone	Chemical	135	136	5	D013262	Stevens - Johnson syndromes|Stevens - Johnson syndrome|Stevens - Johnson syndrome|Stevens - Johnson syndrome	Disease	10:58:114:183	14:62:118:187	0:3:4:6	1:NR:2	R2L	CROSS	139-140	114-118	D016559	tacrolimus	Chemical	139	140	5	D013262	Stevens - Johnson syndromes|Stevens - Johnson syndrome|Stevens - Johnson syndrome|Stevens - Johnson syndrome	Disease	10:58:114:183	14:62:118:187	0:3:4:6	1:NR:2	R2L	NON-CROSS	142-144	132-134	D014580	ursodeoxycholic acid	Chemical	132	134	5	D002779	cholestasis|cholestatic disease	Disease	31:142	32:144	1:5	1:NR:2	R2L	NON-CROSS	142-144	135-136	D011241	prednisone	Chemical	135	136	5	D002779	cholestasis|cholestatic disease	Disease	31:142	32:144	1:5	1:NR:2	R2L	NON-CROSS	142-144	139-140	D016559	tacrolimus	Chemical	139	140	5	D002779	cholestasis|cholestatic disease	Disease	31:142	32:144	1:5	not_include	R2L	CROSS	126-127	71-72	D007052	ibuprofen	Chemical	126	127	4	D004342	hypersensitivity	Disease	71	72	3	1:NR:2	R2L	CROSS	132-134	71-72	D014580	ursodeoxycholic acid	Chemical	132	134	5	D004342	hypersensitivity	Disease	71	72	3	1:NR:2	R2L	CROSS	135-136	71-72	D011241	prednisone	Chemical	135	136	5	D004342	hypersensitivity	Disease	71	72	3	1:NR:2	R2L	CROSS	139-140	71-72	D016559	tacrolimus	Chemical	139	140	5	D004342	hypersensitivity	Disease	71	72	3	1:NR:2	R2L	CROSS	126-127	82-83	D007052	ibuprofen	Chemical	126	127	4	D007239	infection	Disease	82	83	3	1:NR:2	R2L	CROSS	132-134	82-83	D014580	ursodeoxycholic acid	Chemical	132	134	5	D007239	infection	Disease	82	83	3	1:NR:2	R2L	CROSS	135-136	82-83	D011241	prednisone	Chemical	135	136	5	D007239	infection	Disease	82	83	3	1:NR:2	R2L	CROSS	139-140	82-83	D016559	tacrolimus	Chemical	139	140	5	D007239	infection	Disease	82	83	3	1:NR:2	L2R	CROSS	126-127	148-149	D007052	ibuprofen	Chemical	126	127	4	D005355	cirrhosis	Disease	148	149	5	1:NR:2	L2R	NON-CROSS	132-134	148-149	D014580	ursodeoxycholic acid	Chemical	132	134	5	D005355	cirrhosis	Disease	148	149	5	1:NR:2	L2R	NON-CROSS	135-136	148-149	D011241	prednisone	Chemical	135	136	5	D005355	cirrhosis	Disease	148	149	5	1:NR:2	L2R	NON-CROSS	139-140	148-149	D016559	tacrolimus	Chemical	139	140	5	D005355	cirrhosis	Disease	148	149	5
9727773	High incidence of primary pulmonary hypertension associated with appetite suppressants in Belgium .|Primary pulmonary hypertension is a rare , progressive and incurable disease , which has been associated with the intake of appetite suppressant drugs .|The importance of this association was evaluated in Belgium while this country still had no restriction on the prescription of appetite suppressants .|Thirty - five patients with primary pulmonary hypertension and 85 matched controls were recruited over 32 months ( 1992 - 1994 ) in Belgium .|Exposure to appetite - suppressants was assessed on the basis of hospital records and standardized interview .|Twenty - three of the patients had previously taken appetite suppressants , mainly fenfluramines , as compared with only 5 of the controls ( 66 versus 6 % , p < 0 . 0001 ) .|Five patients died before the interview , all of them had taken appetite suppressants .|In 8 patients the diagnosis of primary pulmonary hypertension was uncertain , 5 of them had taken appetite suppressants .|The patients who had been exposed to appetite suppressants tended to be on average more severely ill , and to have a shorter median delay between onset of symptoms and diagnosis .|A policy of unrestricted prescription of appetite suppressants may lead to a high incidence of associated primary pulmonary hypertension .|Intake of appetite suppressants may accelerate the progression of the disease .	1:CID:2	R2L	NON-CROSS	8-10	3-6	D001067	appetite suppressants|appetite suppressant|appetite suppressants|appetite - suppressants|appetite suppressants|appetite suppressants|appetite suppressants|appetite suppressants|appetite suppressants|appetite suppressants	Chemical	8:33:57:87:111:150:170:180:211:227	10:35:59:90:113:152:172:182:213:229	0:1:2:4:5:6:7:8:9:10	D006976	primary pulmonary hypertension|Primary pulmonary hypertension|primary pulmonary hypertension|primary pulmonary hypertension|primary pulmonary hypertension	Disease	3:13:65:159:221	6:16:68:162:224	0:1:3:7:9	1:CID:2	R2L	CROSS	159-162	115-116	D005277	fenfluramines	Chemical	115	116	5	D006976	primary pulmonary hypertension|Primary pulmonary hypertension|primary pulmonary hypertension|primary pulmonary hypertension|primary pulmonary hypertension	Disease	3:13:65:159:221	6:16:68:162:224	0:1:3:7:9
9754849	Choreoathetoid movements associated with rapid adjustment to methadone .|Choreatiform hyperkinesias are known to be occasional movement abnormalities during intoxications with cocaine but not opiates .|This is a case report of euphoria and choreoathetoid movements both transiently induced by rapid adjustment to the selective mu - opioid receptor agonist methadone in an inpatient previously abusing heroine and cocaine .|In addition , minor EEG abnormalities occurred .|Possible underlying neurobiological phenomena are discussed .	1:CID:2	R2L	NON-CROSS	9-11	7-8	D008691	methadone|methadone	Chemical	7:50	8:51	0:2	D002819	Choreoathetoid movements|Choreatiform hyperkinesias|choreoathetoid movements	Disease	0:9:34	2:11:36	0:1:2	1:CID:2	R2L	NON-CROSS	21-22	9-11	D003042	cocaine|cocaine	Chemical	21:58	22:59	1:2	D002819	Choreoathetoid movements|Choreatiform hyperkinesias|choreoathetoid movements	Disease	0:9:34	2:11:36	0:1:2	1:CID:2	R2L	NON-CROSS	21-22	9-11	D003042	cocaine|cocaine	Chemical	21:58	22:59	1:2	D006948	Choreatiform hyperkinesias	Disease	9	11	1	1:NR:2	R2L	NON-CROSS	56-57	34-36	D003932	heroine	Chemical	56	57	2	D002819	Choreoathetoid movements|Choreatiform hyperkinesias|choreoathetoid movements	Disease	0:9:34	2:11:36	0:1:2	1:NR:2	L2R	CROSS	7-8	9-11	D008691	methadone|methadone	Chemical	7:50	8:51	0:2	D006948	Choreatiform hyperkinesias	Disease	9	11	1	not_include	L2R	CROSS	7-8	16-18	D008691	methadone|methadone	Chemical	7:50	8:51	0:2	D020820	movement abnormalities	Disease	16	18	1	1:NR:2	R2L	CROSS	56-57	9-11	D003932	heroine	Chemical	56	57	2	D006948	Choreatiform hyperkinesias	Disease	9	11	1	not_include	R2L	NON-CROSS	21-22	16-18	D003042	cocaine|cocaine	Chemical	21:58	22:59	1:2	D020820	movement abnormalities	Disease	16	18	1	1:NR:2	R2L	CROSS	56-57	16-18	D003932	heroine	Chemical	56	57	2	D020820	movement abnormalities	Disease	16	18	1
10365197	Cocaine - induced mood disorder : prevalence rates and psychiatric symptoms in an outpatient cocaine - dependent sample .|This paper attempts to examine and compare prevalence rates and symptom patterns of DSM substance - induced and other mood disorders .|243 cocaine - dependent outpatients with cocaine - induced mood disorder ( CIMD ) , other mood disorders , or no mood disorder were compared on measures of psychiatric symptoms .|The prevalence rate for CIMD was 12 % at baseline .|Introduction of the DSM - IV diagnosis of CIMD did not substantially affect rates of the other depressive disorders .|Patients with CIMD had symptom severity levels between those of patients with and without a mood disorder .|These findings suggest some validity for the new DSM - IV diagnosis of CIMD , but also suggest that it requires further specification and replication .	1:CID:2	L2R	NON-CROSS	0-1	3-5	D003042	Cocaine|cocaine|cocaine|cocaine	Chemical	0:14:42:47	1:15:43:48	0:0:2:2	D019964	mood disorder|mood disorders|mood disorder|mood disorders|mood disorder|mood disorder	Disease	3:38:50:57:62:118	5:40:52:59:64:120	0:1:2:2:2:5	not_include	L2R	NON-CROSS	9-10	14-15	D003042	Cocaine|cocaine|cocaine|cocaine	Chemical	0:14:42:47	1:15:43:48	0:0:2:2	D001523	psychiatric|psychiatric	Disease	9:69	10:70	0:2	1:NR:2	L2R	NON-CROSS	47-48	53-54	D003042	Cocaine|cocaine|cocaine|cocaine	Chemical	0:14:42:47	1:15:43:48	0:0:2:2	D019970	CIMD|CIMD|CIMD|CIMD|CIMD	Disease	53:76:91:105:134	54:77:92:106:135	2:3:4:5:6	1:NR:2	L2R	CROSS	47-48	100-102	D003042	Cocaine|cocaine|cocaine|cocaine	Chemical	0:14:42:47	1:15:43:48	0:0:2:2	D003866	depressive disorders	Disease	100	102	4
10704919	Hemolysis of human erythrocytes induced by tamoxifen is related to disruption of membrane structure .|Tamoxifen ( TAM ) , the antiestrogenic drug most widely prescribed in the chemotherapy of breast cancer , induces changes in normal discoid shape of erythrocytes and hemolytic anemia .|This work evaluates the effects of TAM on isolated human erythrocytes , attempting to identify the underlying mechanisms on TAM - induced hemolytic anemia and the involvement of biomembranes in its cytostatic action mechanisms .|TAM induces hemolysis of erythrocytes as a function of concentration .|The extension of hemolysis is variable with erythrocyte samples , but 12 . 5 microM TAM induces total hemolysis of all tested suspensions .|Despite inducing extensive erythrocyte lysis , TAM does not shift the osmotic fragility curves of erythrocytes .|The hemolytic effect of TAM is prevented by low concentrations of alpha - tocopherol ( alpha - T ) and alpha - tocopherol acetate ( alpha - TAc ) ( inactivated functional hydroxyl ) indicating that TAM - induced hemolysis is not related to oxidative membrane damage .|This was further evidenced by absence of oxygen consumption and hemoglobin oxidation both determined in parallel with TAM - induced hemolysis .|Furthermore , it was observed that TAM inhibits the peroxidation of human erythrocytes induced by AAPH , thus ruling out TAM - induced cell oxidative stress .|Hemolysis caused by TAM was not preceded by the leakage of K ( + ) from the cells , also excluding a colloid - osmotic type mechanism of hemolysis , according to the effects on osmotic fragility curves .|However , TAM induces release of peripheral proteins of membrane - cytoskeleton and cytosol proteins essentially bound to band 3 .|Either alpha - T or alpha - TAc increases membrane packing and prevents TAM partition into model membranes .|These effects suggest that the protection from hemolysis by tocopherols is related to a decreased TAM incorporation in condensed membranes and the structural damage of the erythrocyte membrane is consequently avoided .|Therefore , TAM - induced hemolysis results from a structural perturbation of red cell membrane , leading to changes in the framework of the erythrocyte membrane and its cytoskeleton caused by its high partition in the membrane .|These defects explain the abnormal erythrocyte shape and decreased mechanical stability promoted by TAM , resulting in hemolytic anemia .|Additionally , since membrane leakage is a final stage of cytotoxicity , the disruption of the structural characteristics of biomembranes by TAM may contribute to the multiple mechanisms of its anticancer action .	1:CID:2	R2L	NON-CROSS	82-83	80-81	D013629	tamoxifen|Tamoxifen|TAM|TAM|TAM|TAM|TAM|TAM|TAM|TAM|TAM|TAM|TAM|TAM|TAM|TAM|TAM|TAM|TAM|TAM	Chemical	6:15:17:51:64:80:106:121:136:168:197:208:222:232:270:302:323:342:391:419	7:16:18:52:65:81:107:122:137:169:198:209:223:233:271:303:324:343:392:420	0:1:1:2:2:3:4:5:6:6:7:8:8:9:10:11:12:13:14:15	D006461	Hemolysis|hemolysis|hemolysis|hemolysis|hemolytic|hemolysis|hemolysis|Hemolysis|hemolysis|hemolysis|hemolysis	Disease	0:82:94:109:133:171:200:229:257:315:345	1:83:95:110:134:172:201:230:258:316:346	0:3:4:4:6:6:7:9:9:12:13	1:CID:2	L2R	NON-CROSS	64-65	67-69	D013629	tamoxifen|Tamoxifen|TAM|TAM|TAM|TAM|TAM|TAM|TAM|TAM|TAM|TAM|TAM|TAM|TAM|TAM|TAM|TAM|TAM|TAM	Chemical	6:15:17:51:64:80:106:121:136:168:197:208:222:232:270:302:323:342:391:419	7:16:18:52:65:81:107:122:137:169:198:209:223:233:271:303:324:343:392:420	0:1:1:2:2:3:4:5:6:6:7:8:8:9:10:11:12:13:14:15	D000743	hemolytic anemia|hemolytic anemia|hemolytic anemia	Disease	42:67:395	44:69:397	1:2:14	1:NR:2	R2L	NON-CROSS	143-146	133-134	D024502	alpha - tocopherol|alpha - T|alpha - tocopherol acetate|alpha - TAc|alpha - T|alpha - TAc	Chemical	143:147:152:157:290:294	146:150:156:160:293:297	6:6:6:6:11:11	D006461	Hemolysis|hemolysis|hemolysis|hemolysis|hemolytic|hemolysis|hemolysis|Hemolysis|hemolysis|hemolysis|hemolysis	Disease	0:82:94:109:133:171:200:229:257:315:345	1:83:95:110:134:172:201:230:258:316:346	0:3:4:4:6:6:7:9:9:12:13	1:NR:2	R2L	NON-CROSS	171-172	164-165	D017665	hydroxyl	Chemical	164	165	6	D006461	Hemolysis|hemolysis|hemolysis|hemolysis|hemolytic|hemolysis|hemolysis|Hemolysis|hemolysis|hemolysis|hemolysis	Disease	0:82:94:109:133:171:200:229:257:315:345	1:83:95:110:134:172:201:230:258:316:346	0:3:4:4:6:6:7:9:9:12:13	1:NR:2	R2L	NON-CROSS	200-201	187-188	D010100	oxygen	Chemical	187	188	7	D006461	Hemolysis|hemolysis|hemolysis|hemolysis|hemolytic|hemolysis|hemolysis|Hemolysis|hemolysis|hemolysis|hemolysis	Disease	0:82:94:109:133:171:200:229:257:315:345	1:83:95:110:134:172:201:230:258:316:346	0:3:4:4:6:6:7:9:9:12:13	1:NR:2	R2L	CROSS	229-230	217-218	C046728	AAPH	Chemical	217	218	8	D006461	Hemolysis|hemolysis|hemolysis|hemolysis|hemolytic|hemolysis|hemolysis|Hemolysis|hemolysis|hemolysis|hemolysis	Disease	0:82:94:109:133:171:200:229:257:315:345	1:83:95:110:134:172:201:230:258:316:346	0:3:4:4:6:6:7:9:9:12:13	1:NR:2	R2L	NON-CROSS	240-241	229-230	D011188	K	Chemical	240	241	9	D006461	Hemolysis|hemolysis|hemolysis|hemolysis|hemolytic|hemolysis|hemolysis|Hemolysis|hemolysis|hemolysis|hemolysis	Disease	0:82:94:109:133:171:200:229:257:315:345	1:83:95:110:134:172:201:230:258:316:346	0:3:4:4:6:6:7:9:9:12:13	1:NR:2	R2L	NON-CROSS	317-318	315-316	D024505	tocopherols	Chemical	317	318	12	D006461	Hemolysis|hemolysis|hemolysis|hemolysis|hemolytic|hemolysis|hemolysis|Hemolysis|hemolysis|hemolysis|hemolysis	Disease	0:82:94:109:133:171:200:229:257:315:345	1:83:95:110:134:172:201:230:258:316:346	0:3:4:4:6:6:7:9:9:12:13	1:NR:2	L2R	NON-CROSS	17-18	30-32	D013629	tamoxifen|Tamoxifen|TAM|TAM|TAM|TAM|TAM|TAM|TAM|TAM|TAM|TAM|TAM|TAM|TAM|TAM|TAM|TAM|TAM|TAM	Chemical	6:15:17:51:64:80:106:121:136:168:197:208:222:232:270:302:323:342:391:419	7:16:18:52:65:81:107:122:137:169:198:209:223:233:271:303:324:343:392:420	0:1:1:2:2:3:4:5:6:6:7:8:8:9:10:11:12:13:14:15	D001943	breast cancer	Disease	30	32	1	1:NR:2	R2L	CROSS	143-146	30-32	D024502	alpha - tocopherol|alpha - T|alpha - tocopherol acetate|alpha - TAc|alpha - T|alpha - TAc	Chemical	143:147:152:157:290:294	146:150:156:160:293:297	6:6:6:6:11:11	D001943	breast cancer	Disease	30	32	1	1:NR:2	R2L	CROSS	164-165	30-32	D017665	hydroxyl	Chemical	164	165	6	D001943	breast cancer	Disease	30	32	1	1:NR:2	R2L	CROSS	187-188	30-32	D010100	oxygen	Chemical	187	188	7	D001943	breast cancer	Disease	30	32	1	1:NR:2	R2L	CROSS	217-218	30-32	C046728	AAPH	Chemical	217	218	8	D001943	breast cancer	Disease	30	32	1	1:NR:2	R2L	CROSS	240-241	30-32	D011188	K	Chemical	240	241	9	D001943	breast cancer	Disease	30	32	1	1:NR:2	R2L	CROSS	317-318	30-32	D024505	tocopherols	Chemical	317	318	12	D001943	breast cancer	Disease	30	32	1	1:NR:2	R2L	CROSS	143-146	67-69	D024502	alpha - tocopherol|alpha - T|alpha - tocopherol acetate|alpha - TAc|alpha - T|alpha - TAc	Chemical	143:147:152:157:290:294	146:150:156:160:293:297	6:6:6:6:11:11	D000743	hemolytic anemia|hemolytic anemia|hemolytic anemia	Disease	42:67:395	44:69:397	1:2:14	1:NR:2	R2L	CROSS	164-165	67-69	D017665	hydroxyl	Chemical	164	165	6	D000743	hemolytic anemia|hemolytic anemia|hemolytic anemia	Disease	42:67:395	44:69:397	1:2:14	1:NR:2	R2L	CROSS	187-188	67-69	D010100	oxygen	Chemical	187	188	7	D000743	hemolytic anemia|hemolytic anemia|hemolytic anemia	Disease	42:67:395	44:69:397	1:2:14	1:NR:2	R2L	CROSS	217-218	67-69	C046728	AAPH	Chemical	217	218	8	D000743	hemolytic anemia|hemolytic anemia|hemolytic anemia	Disease	42:67:395	44:69:397	1:2:14	1:NR:2	R2L	CROSS	395-397	240-241	D011188	K	Chemical	240	241	9	D000743	hemolytic anemia|hemolytic anemia|hemolytic anemia	Disease	42:67:395	44:69:397	1:2:14	1:NR:2	R2L	CROSS	395-397	317-318	D024505	tocopherols	Chemical	317	318	12	D000743	hemolytic anemia|hemolytic anemia|hemolytic anemia	Disease	42:67:395	44:69:397	1:2:14
10706004	Changes of sodium and ATP affinities of the cardiac ( Na , K ) - ATPase during and after nitric oxide deficient hypertension .|In the cardiovascular system , NO is involved in the regulation of a variety of functions .|Inhibition of NO synthesis induces sustained hypertension .|In several models of hypertension , elevation of intracellular sodium level was documented in cardiac tissue .|To assess the molecular basis of disturbances in transmembraneous transport of Na + , we studied the response of cardiac ( Na , K ) - ATPase to NO - deficient hypertension induced in rats by NO - synthase inhibition with 40 mg / kg / day N ( G ) - nitro - L - arginine methyl ester ( L - NAME ) for 4 four weeks .|After 4 - week administration of L - NAME , the systolic blood pressure ( SBP ) increased by 36 % .|Two weeks after terminating the treatment , the SBP recovered to control value .|When activating the ( Na , K ) - ATPase with its substrate ATP , no changes in Km and Vmax values were observed in NO - deficient rats .|During activation with Na + , the Vmax remained unchanged , however the K ( Na ) increased by 50 % , indicating a profound decrease in the affinity of the Na + - binding site in NO - deficient rats .|After recovery from hypertension , the activity of ( Na , K ) - ATPase increased , due to higher affinity of the ATP - binding site , as revealed from the lowered Km value for ATP .|The K ( Na ) value for Na + returned to control value .|Inhibition of NO - synthase induced a reversible hypertension accompanied by depressed Na + - extrusion from cardiac cells as a consequence of deteriorated Na + - binding properties of the ( Na , K ) - ATPase .|After recovery of blood pressure to control values , the extrusion of Na + from cardiac cells was normalized , as revealed by restoration of the ( Na , K ) - ATPase activity .	1:CID:2	L2R	NON-CROSS	19-21	22-23	D009569	nitric oxide|NO|NO|NO|NO|NO|NO|NO	Chemical	19:29:43:94:102:196:238:297	21:30:44:95:103:197:239:298	0:1:2:4:4:7:8:11	D006973	hypertension|hypertension|hypertension|hypertension|hypertension|hypertension	Disease	22:47:53:97:246:303	23:48:54:98:247:304	0:2:3:4:9:11	1:NR:2	L2R	NON-CROSS	303-304	307-308	D012964	sodium|Na|sodium|Na|Na|Na|Na|Na|Na|Na|Na|Na|Na|Na|Na|Na|Na	Chemical	2:10:58:77:87:175:204:216:232:252:284:288:307:319:327:346:361	3:11:59:78:88:176:205:217:233:253:285:289:308:320:328:347:362	0:0:3:4:4:7:8:8:8:9:10:10:11:11:11:12:12	D006973	hypertension|hypertension|hypertension|hypertension|hypertension|hypertension	Disease	22:47:53:97:246:303	23:48:54:98:247:304	0:2:3:4:9:11	1:NR:2	L2R	NON-CROSS	306-307	307-308	D012964	sodium|Na|sodium|Na|Na|Na|Na|Na|Na|Na|Na|Na|Na|Na|Na|Na|Na	Chemical	2:10:58:77:87:175:204:216:232:252:284:288:307:319:327:346:361	3:11:59:78:88:176:205:217:233:253:285:289:308:320:328:347:362	0:0:3:4:4:7:8:8:8:9:10:10:11:11:11:12:12	D003866	depressed	Disease	306	307	11	1:NR:2	L2R	NON-CROSS	4-5	22-23	D000255	ATP|ATP|ATP|ATP	Chemical	4:184:266:279	5:185:267:280	0:7:9:9	D006973	hypertension|hypertension|hypertension|hypertension|hypertension|hypertension	Disease	22:47:53:97:246:303	23:48:54:98:247:304	0:2:3:4:9:11	1:NR:2	L2R	CROSS	279-280	306-307	D000255	ATP|ATP|ATP|ATP	Chemical	4:184:266:279	5:185:267:280	0:7:9:9	D003866	depressed	Disease	306	307	11	1:NR:2	L2R	NON-CROSS	89-90	97-98	D011188	K|K|K|K|K|K|K|K	Chemical	12:89:177:214:254:282:329:363	13:90:178:215:255:283:330:364	0:4:7:8:9:10:11:12	D006973	hypertension|hypertension|hypertension|hypertension|hypertension|hypertension	Disease	22:47:53:97:246:303	23:48:54:98:247:304	0:2:3:4:9:11	1:NR:2	L2R	NON-CROSS	306-307	329-330	D011188	K|K|K|K|K|K|K|K	Chemical	12:89:177:214:254:282:329:363	13:90:178:215:255:283:330:364	0:4:7:8:9:10:11:12	D003866	depressed	Disease	306	307	11	1:NR:2	L2R	NON-CROSS	297-298	306-307	D009569	nitric oxide|NO|NO|NO|NO|NO|NO|NO	Chemical	19:29:43:94:102:196:238:297	21:30:44:95:103:197:239:298	0:1:2:4:4:7:8:11	D003866	depressed	Disease	306	307	11	1:NR:2	R2L	NON-CROSS	113-125	97-98	D019331	N ( G ) - nitro - L - arginine methyl ester|L - NAME|L - NAME	Chemical	113:126:141	125:129:144	4:4:5	D006973	hypertension|hypertension|hypertension|hypertension|hypertension|hypertension	Disease	22:47:53:97:246:303	23:48:54:98:247:304	0:2:3:4:9:11	1:NR:2	L2R	CROSS	141-144	306-307	D019331	N ( G ) - nitro - L - arginine methyl ester|L - NAME|L - NAME	Chemical	113:126:141	125:129:144	4:4:5	D003866	depressed	Disease	306	307	11
10721819	Effects of long - term pretreatment with isoproterenol on bromocriptine - induced tachycardia in conscious rats .|It has been shown that bromocriptine - induced tachycardia , which persisted after adrenalectomy , is ( i ) mediated by central dopamine D2 receptor activation and ( ii ) reduced by 5 - day isoproterenol pretreatment , supporting therefore the hypothesis that this effect is dependent on sympathetic outflow to the heart .|This study was conducted to examine whether prolonged pretreatment with isoproterenol could abolish bromocriptine - induced tachycardia in conscious rats .|Isoproterenol pretreatment for 15 days caused cardiac hypertrophy without affecting baseline blood pressure and heart rate .|In control rats , intravenous bromocriptine ( 150 microg / kg ) induced significant hypotension and tachycardia .|Bromocriptine - induced hypotension was unaffected by isoproterenol pretreatment , while tachycardia was reversed to significant bradycardia , an effect that was partly reduced by i . v .|domperidone ( 0 . 5 mg / kg ) .|Neither cardiac vagal nor sympathetic tone was altered by isoproterenol pretreatment .|In isolated perfused heart preparations from isoproterenol - pretreated rats , the isoproterenol - induced maximal increase in left ventricular systolic pressure was significantly reduced , compared with saline - pretreated rats ( the EC50 of the isoproterenol - induced increase in left ventricular systolic pressure was enhanced approximately 22 - fold ) .|These results show that 15 - day isoproterenol pretreatment not only abolished but reversed bromocriptine - induced tachycardia to bradycardia , an effect that is mainly related to further cardiac beta - adrenoceptor desensitization rather than to impairment of autonomic regulation of the heart .|They suggest that , in normal conscious rats , the central tachycardia of bromocriptine appears to predominate and to mask the bradycardia of this agonist at peripheral dopamine D2 receptors .	1:CID:2	L2R	NON-CROSS	92-93	98-100	D007545	isoproterenol|isoproterenol|isoproterenol|Isoproterenol|isoproterenol|isoproterenol|isoproterenol|isoproterenol|isoproterenol|isoproterenol	Chemical	7:52:81:92:134:175:184:190:215:239	8:53:82:93:135:176:185:191:216:240	0:1:2:3:5:7:8:8:8:9	D006332	cardiac hypertrophy	Disease	98	100	3	1:CID:2	L2R	NON-CROSS	134-135	143-144	D007545	isoproterenol|isoproterenol|isoproterenol|Isoproterenol|isoproterenol|isoproterenol|isoproterenol|isoproterenol|isoproterenol|isoproterenol	Chemical	7:52:81:92:134:175:184:190:215:239	8:53:82:93:135:176:185:191:216:240	0:1:2:3:5:7:8:8:8:9	D001919	bradycardia|bradycardia|bradycardia	Disease	143:251:298	144:252:299	5:9:10	1:CID:2	L2R	NON-CROSS	125-126	127-128	D001971	bromocriptine|bromocriptine|bromocriptine|bromocriptine|Bromocriptine|bromocriptine|bromocriptine	Chemical	9:22:84:114:127:246:290	10:23:85:115:128:247:291	0:1:2:4:5:9:10	D013610	tachycardia|tachycardia|tachycardia|tachycardia|tachycardia|tachycardia|tachycardia	Disease	12:25:87:125:138:249:288	13:26:88:126:139:250:289	0:1:2:4:5:9:10	1:CID:2	L2R	NON-CROSS	127-128	130-131	D001971	bromocriptine|bromocriptine|bromocriptine|bromocriptine|Bromocriptine|bromocriptine|bromocriptine	Chemical	9:22:84:114:127:246:290	10:23:85:115:128:247:291	0:1:2:4:5:9:10	D007022	hypotension|hypotension	Disease	123:130	124:131	4:5	1:CID:2	R2L	CROSS	156-157	143-144	D004294	domperidone	Chemical	156	157	6	D001919	bradycardia|bradycardia|bradycardia	Disease	143:251:298	144:252:299	5:9:10	1:NR:2	L2R	NON-CROSS	134-135	138-139	D007545	isoproterenol|isoproterenol|isoproterenol|Isoproterenol|isoproterenol|isoproterenol|isoproterenol|isoproterenol|isoproterenol|isoproterenol	Chemical	7:52:81:92:134:175:184:190:215:239	8:53:82:93:135:176:185:191:216:240	0:1:2:3:5:7:8:8:8:9	D013610	tachycardia|tachycardia|tachycardia|tachycardia|tachycardia|tachycardia|tachycardia	Disease	12:25:87:125:138:249:288	13:26:88:126:139:250:289	0:1:2:4:5:9:10	1:NR:2	L2R	NON-CROSS	130-131	134-135	D007545	isoproterenol|isoproterenol|isoproterenol|Isoproterenol|isoproterenol|isoproterenol|isoproterenol|isoproterenol|isoproterenol|isoproterenol	Chemical	7:52:81:92:134:175:184:190:215:239	8:53:82:93:135:176:185:191:216:240	0:1:2:3:5:7:8:8:8:9	D007022	hypotension|hypotension	Disease	123:130	124:131	4:5	1:NR:2	L2R	CROSS	84-85	98-100	D001971	bromocriptine|bromocriptine|bromocriptine|bromocriptine|Bromocriptine|bromocriptine|bromocriptine	Chemical	9:22:84:114:127:246:290	10:23:85:115:128:247:291	0:1:2:4:5:9:10	D006332	cardiac hypertrophy	Disease	98	100	3	1:NR:2	L2R	NON-CROSS	246-247	251-252	D001971	bromocriptine|bromocriptine|bromocriptine|bromocriptine|Bromocriptine|bromocriptine|bromocriptine	Chemical	9:22:84:114:127:246:290	10:23:85:115:128:247:291	0:1:2:4:5:9:10	D001919	bradycardia|bradycardia|bradycardia	Disease	143:251:298	144:252:299	5:9:10	1:NR:2	R2L	NON-CROSS	39-40	25-26	D004298	dopamine|dopamine	Chemical	39:304	40:305	1:10	D013610	tachycardia|tachycardia|tachycardia|tachycardia|tachycardia|tachycardia|tachycardia	Disease	12:25:87:125:138:249:288	13:26:88:126:139:250:289	0:1:2:4:5:9:10	1:NR:2	R2L	CROSS	156-157	138-139	D004294	domperidone	Chemical	156	157	6	D013610	tachycardia|tachycardia|tachycardia|tachycardia|tachycardia|tachycardia|tachycardia	Disease	12:25:87:125:138:249:288	13:26:88:126:139:250:289	0:1:2:4:5:9:10	1:NR:2	L2R	CROSS	39-40	98-100	D004298	dopamine|dopamine	Chemical	39:304	40:305	1:10	D006332	cardiac hypertrophy	Disease	98	100	3	1:NR:2	L2R	CROSS	39-40	123-124	D004298	dopamine|dopamine	Chemical	39:304	40:305	1:10	D007022	hypotension|hypotension	Disease	123:130	124:131	4:5	1:NR:2	L2R	NON-CROSS	298-299	304-305	D004298	dopamine|dopamine	Chemical	39:304	40:305	1:10	D001919	bradycardia|bradycardia|bradycardia	Disease	143:251:298	144:252:299	5:9:10	1:NR:2	R2L	CROSS	156-157	98-100	D004294	domperidone	Chemical	156	157	6	D006332	cardiac hypertrophy	Disease	98	100	3	1:NR:2	R2L	CROSS	156-157	130-131	D004294	domperidone	Chemical	156	157	6	D007022	hypotension|hypotension	Disease	123:130	124:131	4:5
10737864	A developmental analysis of clonidine 's effects on cardiac rate and ultrasound production in infant rats .|Under controlled conditions , infant rats emit ultrasonic vocalizations during extreme cold exposure and after administration of the alpha ( 2 ) adrenoceptor agonist , clonidine .|Previous investigations have determined that , in response to clonidine , ultrasound production increases through the 2nd - week postpartum and decreases thereafter .|Given that sympathetic neural dominance exhibits a similar developmental pattern , and given that clonidine induces sympathetic withdrawal and bradycardia , we hypothesized that clonidine 's developmental effects on cardiac rate and ultrasound production would mirror each other .|Therefore , in the present experiment , the effects of clonidine administration ( 0 . 5 mg / kg ) on cardiac rate and ultrasound production were examined in 2 - , 8 - , 15 - , and 20 - day - old rats .|Age - related changes in ultrasound production corresponded with changes in cardiovascular variables , including baseline cardiac rate and clonidine - induced bradycardia .|This experiment is discussed with regard to the hypothesis that ultrasound production is the acoustic by - product of a physiological maneuver that compensates for clonidine 's detrimental effects on cardiovascular function .	1:CID:2	L2R	NON-CROSS	172-173	175-176	D003000	clonidine|clonidine|clonidine|clonidine|clonidine|clonidine|clonidine|clonidine	Chemical	4:42:53:82:92:117:172:202	5:43:54:83:93:118:173:203	0:1:2:3:3:4:5:6	D001919	bradycardia|bradycardia	Disease	87:175	88:176	3:5
10743446	Differential effects of systemically administered ketamine and lidocaine on dynamic and static hyperalgesia induced by intradermal capsaicin in humans .|We have examined the effect of systemic administration of ketamine and lidocaine on brush - evoked ( dynamic ) pain and punctate - evoked ( static ) hyperalgesia induced by capsaicin .|In a randomized , double - blind , placebo - controlled , crossover study , we studied 12 volunteers in three experiments .|Capsaicin 100 micrograms was injected intradermally on the volar forearm followed by an i . v .|infusion of ketamine ( bolus 0 . 1 mg kg - 1 over 10 min followed by infusion of 7 micrograms kg - 1 min - 1 ) , lidocaine 5 mg kg - 1 or saline for 50 min .|Infusion started 15 min after injection of capsaicin .|The following were measured : spontaneous pain , pain evoked by punctate and brush stimuli ( VAS ) , and areas of brush - evoked and punctate - evoked hyperalgesia .|Ketamine reduced both the area of brush - evoked and punctate - evoked hyperalgesia significantly and it tended to reduce brush - evoked pain .|Lidocaine reduced the area of punctate - evoked hyperalgesia significantly .|It tended to reduce VAS scores of spontaneous pain but had no effect on evoked pain .|The differential effects of ketamine and lidocaine on static and dynamic hyperalgesia suggest that the two types of hyperalgesia are mediated by separate mechanisms and have a distinct pharmacology .	1:CID:2	R2L	NON-CROSS	50-51	47-48	D002211	capsaicin|capsaicin|Capsaicin|capsaicin	Chemical	16:50:75:140	17:51:76:141	0:1:3:5	D006930	hyperalgesia|hyperalgesia|hyperalgesia|hyperalgesia|hyperalgesia|hyperalgesia|hyperalgesia	Disease	12:47:171:186:206:237:244	13:48:172:187:207:238:245	0:1:6:7:8:10:10	1:CID:2	L2R	NON-CROSS	140-141	148-149	D002211	capsaicin|capsaicin|Capsaicin|capsaicin	Chemical	16:50:75:140	17:51:76:141	0:1:3:5	D010146	pain|pain|pain|pain|pain|pain	Disease	39:148:150:196:217:224	40:149:151:197:218:225	1:6:6:7:9:9	1:NR:2	L2R	NON-CROSS	171-172	173-174	D007649	ketamine|ketamine|ketamine|Ketamine|ketamine	Chemical	5:29:94:173:230	6:30:95:174:231	0:1:4:7:10	D006930	hyperalgesia|hyperalgesia|hyperalgesia|hyperalgesia|hyperalgesia|hyperalgesia|hyperalgesia	Disease	12:47:171:186:206:237:244	13:48:172:187:207:238:245	0:1:6:7:8:10:10	1:NR:2	L2R	NON-CROSS	224-225	230-231	D007649	ketamine|ketamine|ketamine|Ketamine|ketamine	Chemical	5:29:94:173:230	6:30:95:174:231	0:1:4:7:10	D010146	pain|pain|pain|pain|pain|pain	Disease	39:148:150:196:217:224	40:149:151:197:218:225	1:6:6:7:9:9	1:NR:2	L2R	NON-CROSS	7-8	12-13	D008012	lidocaine|lidocaine|lidocaine|Lidocaine|lidocaine	Chemical	7:31:121:198:232	8:32:122:199:233	0:1:4:8:10	D006930	hyperalgesia|hyperalgesia|hyperalgesia|hyperalgesia|hyperalgesia|hyperalgesia|hyperalgesia	Disease	12:47:171:186:206:237:244	13:48:172:187:207:238:245	0:1:6:7:8:10:10	1:NR:2	L2R	NON-CROSS	196-197	198-199	D008012	lidocaine|lidocaine|lidocaine|Lidocaine|lidocaine	Chemical	7:31:121:198:232	8:32:122:199:233	0:1:4:8:10	D010146	pain|pain|pain|pain|pain|pain	Disease	39:148:150:196:217:224	40:149:151:197:218:225	1:6:6:7:9:9
11007689	Cyclosporine and tacrolimus - associated thrombotic microangiopathy .|The development of thrombotic microangiopathy ( TMA ) associated with the use of cyclosporine has been well documented .|Treatments have included discontinuation or reduction of cyclosporine dose with or without concurrent plasma exchange , plasma infusion , anticoagulation , and intravenous immunoglobulin G infusion .|However , for recipients of organ transplantation , removing the inciting agent is not without the attendant risk of precipitating acute rejection and graft loss .|The last decade has seen the emergence of tacrolimus as a potent immunosuppressive agent with mechanisms of action virtually identical to those of cyclosporine .|As a result , switching to tacrolimus has been reported to be a viable therapeutic option in the setting of cyclosporine - induced TMA .|With the more widespread application of tacrolimus in organ transplantation , tacrolimus - associated TMA has also been recognized .|However , literature regarding the incidence of the recurrence of TMA in patients exposed sequentially to cyclosporine and tacrolimus is limited .|We report a case of a living donor renal transplant recipient who developed cyclosporine - induced TMA that responded to the withdrawal of cyclosporine in conjunction with plasmapheresis and fresh frozen plasma replacement therapy .|Introduction of tacrolimus as an alternative immunosuppressive agent resulted in the recurrence of TMA and the subsequent loss of the renal allograft .|Patients who are switched from cyclosporine to tacrolimus or vice versa should be closely monitored for the signs and symptoms of recurrent TMA .	1:CID:2	L2R	NON-CROSS	125-126	128-129	D016572	Cyclosporine|cyclosporine|cyclosporine|cyclosporine|cyclosporine|cyclosporine|cyclosporine|cyclosporine|cyclosporine	Chemical	0:21:34:103:125:166:185:195:235	1:22:35:104:126:167:186:196:236	0:1:2:4:5:7:8:8:10	D057049	thrombotic microangiopathy|thrombotic microangiopathy|TMA|TMA|TMA|TMA|TMA|TMA|TMA	Disease	5:11:14:128:144:160:188:220:252	7:13:15:129:145:161:189:221:253	0:1:1:5:6:7:8:9:10	1:CID:2	L2R	NON-CROSS	2-3	5-7	D016559	tacrolimus|tacrolimus|tacrolimus|tacrolimus|tacrolimus|tacrolimus|tacrolimus|tacrolimus	Chemical	2:88:111:136:141:168:209:237	3:89:112:137:142:169:210:238	0:4:5:6:6:7:9:10	D057049	thrombotic microangiopathy|thrombotic microangiopathy|TMA|TMA|TMA|TMA|TMA|TMA|TMA	Disease	5:11:14:128:144:160:188:220:252	7:13:15:129:145:161:189:221:253	0:1:1:5:6:7:8:9:10
11256525	Repeated transient anuria following losartan administration in a patient with a solitary kidney .|We report the case of a 70 - year - old hypertensive man with a solitary kidney and chronic renal insufficiency who developed two episodes of transient anuria after losartan administration .|He was hospitalized for a myocardial infarction with pulmonary edema , treated with high - dose diuretics .|Due to severe systolic dysfunction losartan was prescribed .|Surprisingly , the first dose of 50 mg of losartan resulted in a sudden anuria , which lasted eight hours despite high - dose furosemide and amine infusion .|One week later , by mistake , losartan was prescribed again and after the second dose of 50 mg , the patient developed a second episode of transient anuria lasting 10 hours .|During these two episodes , his blood pressure diminished but no severe hypotension was noted .|Ultimately , an arteriography showed a 70 - 80 % renal artery stenosis .|In this patient , renal artery stenosis combined with heart failure and diuretic therapy certainly resulted in a strong activation of the renin - angiotensin system ( RAS ) .|Under such conditions , angiotensin II receptor blockade by losartan probably induced a critical fall in glomerular filtration pressure .|This case report highlights the fact that the angiotensin II receptor antagonist losartan can cause serious unexpected complications in patients with renovascular disease and should be used with extreme caution in this setting .	1:CID:2	R2L	NON-CROSS	4-5	2-3	D019808	losartan|losartan|losartan|losartan|losartan|losartan|losartan	Chemical	4:43:69:82:109:204:227	5:44:70:83:110:205:228	0:1:3:4:5:9:10	D001002	anuria|anuria|anuria|anuria	Disease	2:41:87:130	3:42:88:131	0:1:4:5	1:NR:2	R2L	NON-CROSS	97-98	87-88	D005665	furosemide	Chemical	97	98	4	D001002	anuria|anuria|anuria|anuria	Disease	2:41:87:130	3:42:88:131	0:1:4:5	1:NR:2	R2L	NON-CROSS	99-100	87-88	D000588	amine	Chemical	99	100	4	D001002	anuria|anuria|anuria|anuria	Disease	2:41:87:130	3:42:88:131	0:1:4:5	1:NR:2	R2L	CROSS	189-190	130-131	D000809	angiotensin	Chemical	189	190	8	D001002	anuria|anuria|anuria|anuria	Disease	2:41:87:130	3:42:88:131	0:1:4:5	1:NR:2	R2L	CROSS	199-201	130-131	D000804	angiotensin II|angiotensin II	Chemical	199:223	201:225	9:10	D001002	anuria|anuria|anuria|anuria	Disease	2:41:87:130	3:42:88:131	0:1:4:5	1:NR:2	L2R	NON-CROSS	25-26	43-44	D019808	losartan|losartan|losartan|losartan|losartan|losartan|losartan	Chemical	4:43:69:82:109:204:227	5:44:70:83:110:205:228	0:1:3:4:5:9:10	D006973	hypertensive	Disease	25	26	1	1:NR:2	L2R	NON-CROSS	32-35	43-44	D019808	losartan|losartan|losartan|losartan|losartan|losartan|losartan	Chemical	4:43:69:82:109:204:227	5:44:70:83:110:205:228	0:1:3:4:5:9:10	D051436	chronic renal insufficiency	Disease	32	35	1	1:NR:2	L2R	CROSS	43-44	51-53	D019808	losartan|losartan|losartan|losartan|losartan|losartan|losartan	Chemical	4:43:69:82:109:204:227	5:44:70:83:110:205:228	0:1:3:4:5:9:10	D009203	myocardial infarction	Disease	51	53	2	1:NR:2	L2R	CROSS	43-44	54-56	D019808	losartan|losartan|losartan|losartan|losartan|losartan|losartan	Chemical	4:43:69:82:109:204:227	5:44:70:83:110:205:228	0:1:3:4:5:9:10	D011654	pulmonary edema	Disease	54	56	2	1:NR:2	L2R	NON-CROSS	67-69	69-70	D019808	losartan|losartan|losartan|losartan|losartan|losartan|losartan	Chemical	4:43:69:82:109:204:227	5:44:70:83:110:205:228	0:1:3:4:5:9:10	D006331	systolic dysfunction	Disease	67	69	3	1:NR:2	L2R	CROSS	109-110	147-148	D019808	losartan|losartan|losartan|losartan|losartan|losartan|losartan	Chemical	4:43:69:82:109:204:227	5:44:70:83:110:205:228	0:1:3:4:5:9:10	D007022	hypotension	Disease	147	148	6	1:NR:2	L2R	CROSS	169-172	204-205	D019808	losartan|losartan|losartan|losartan|losartan|losartan|losartan	Chemical	4:43:69:82:109:204:227	5:44:70:83:110:205:228	0:1:3:4:5:9:10	D012078	renal artery stenosis|renal artery stenosis	Disease	161:169	164:172	7:8	1:NR:2	L2R	CROSS	174-176	204-205	D019808	losartan|losartan|losartan|losartan|losartan|losartan|losartan	Chemical	4:43:69:82:109:204:227	5:44:70:83:110:205:228	0:1:3:4:5:9:10	D006333	heart failure	Disease	174	176	8	1:NR:2	L2R	NON-CROSS	227-228	236-238	D019808	losartan|losartan|losartan|losartan|losartan|losartan|losartan	Chemical	4:43:69:82:109:204:227	5:44:70:83:110:205:228	0:1:3:4:5:9:10	D014652	renovascular disease	Disease	236	238	10	1:NR:2	R2L	CROSS	97-98	25-26	D005665	furosemide	Chemical	97	98	4	D006973	hypertensive	Disease	25	26	1	1:NR:2	R2L	CROSS	99-100	25-26	D000588	amine	Chemical	99	100	4	D006973	hypertensive	Disease	25	26	1	1:NR:2	R2L	CROSS	189-190	25-26	D000809	angiotensin	Chemical	189	190	8	D006973	hypertensive	Disease	25	26	1	1:NR:2	R2L	CROSS	199-201	25-26	D000804	angiotensin II|angiotensin II	Chemical	199:223	201:225	9:10	D006973	hypertensive	Disease	25	26	1	1:NR:2	R2L	CROSS	97-98	32-35	D005665	furosemide	Chemical	97	98	4	D051436	chronic renal insufficiency	Disease	32	35	1	1:NR:2	R2L	CROSS	99-100	32-35	D000588	amine	Chemical	99	100	4	D051436	chronic renal insufficiency	Disease	32	35	1	1:NR:2	R2L	CROSS	189-190	32-35	D000809	angiotensin	Chemical	189	190	8	D051436	chronic renal insufficiency	Disease	32	35	1	1:NR:2	R2L	CROSS	199-201	32-35	D000804	angiotensin II|angiotensin II	Chemical	199:223	201:225	9:10	D051436	chronic renal insufficiency	Disease	32	35	1	1:NR:2	R2L	CROSS	97-98	51-53	D005665	furosemide	Chemical	97	98	4	D009203	myocardial infarction	Disease	51	53	2	1:NR:2	R2L	CROSS	99-100	51-53	D000588	amine	Chemical	99	100	4	D009203	myocardial infarction	Disease	51	53	2	1:NR:2	R2L	CROSS	189-190	51-53	D000809	angiotensin	Chemical	189	190	8	D009203	myocardial infarction	Disease	51	53	2	1:NR:2	R2L	CROSS	199-201	51-53	D000804	angiotensin II|angiotensin II	Chemical	199:223	201:225	9:10	D009203	myocardial infarction	Disease	51	53	2	1:NR:2	R2L	CROSS	97-98	54-56	D005665	furosemide	Chemical	97	98	4	D011654	pulmonary edema	Disease	54	56	2	1:NR:2	R2L	CROSS	99-100	54-56	D000588	amine	Chemical	99	100	4	D011654	pulmonary edema	Disease	54	56	2	1:NR:2	R2L	CROSS	189-190	54-56	D000809	angiotensin	Chemical	189	190	8	D011654	pulmonary edema	Disease	54	56	2	1:NR:2	R2L	CROSS	199-201	54-56	D000804	angiotensin II|angiotensin II	Chemical	199:223	201:225	9:10	D011654	pulmonary edema	Disease	54	56	2	1:NR:2	R2L	CROSS	97-98	67-69	D005665	furosemide	Chemical	97	98	4	D006331	systolic dysfunction	Disease	67	69	3	1:NR:2	R2L	CROSS	99-100	67-69	D000588	amine	Chemical	99	100	4	D006331	systolic dysfunction	Disease	67	69	3	1:NR:2	R2L	CROSS	189-190	67-69	D000809	angiotensin	Chemical	189	190	8	D006331	systolic dysfunction	Disease	67	69	3	1:NR:2	R2L	CROSS	199-201	67-69	D000804	angiotensin II|angiotensin II	Chemical	199:223	201:225	9:10	D006331	systolic dysfunction	Disease	67	69	3	1:NR:2	L2R	CROSS	97-98	147-148	D005665	furosemide	Chemical	97	98	4	D007022	hypotension	Disease	147	148	6	1:NR:2	L2R	CROSS	97-98	161-164	D005665	furosemide	Chemical	97	98	4	D012078	renal artery stenosis|renal artery stenosis	Disease	161:169	164:172	7:8	1:NR:2	L2R	CROSS	97-98	174-176	D005665	furosemide	Chemical	97	98	4	D006333	heart failure	Disease	174	176	8	1:NR:2	L2R	CROSS	97-98	236-238	D005665	furosemide	Chemical	97	98	4	D014652	renovascular disease	Disease	236	238	10	1:NR:2	L2R	CROSS	99-100	147-148	D000588	amine	Chemical	99	100	4	D007022	hypotension	Disease	147	148	6	1:NR:2	L2R	CROSS	99-100	161-164	D000588	amine	Chemical	99	100	4	D012078	renal artery stenosis|renal artery stenosis	Disease	161:169	164:172	7:8	1:NR:2	L2R	CROSS	99-100	174-176	D000588	amine	Chemical	99	100	4	D006333	heart failure	Disease	174	176	8	1:NR:2	L2R	CROSS	99-100	236-238	D000588	amine	Chemical	99	100	4	D014652	renovascular disease	Disease	236	238	10	1:NR:2	R2L	CROSS	189-190	147-148	D000809	angiotensin	Chemical	189	190	8	D007022	hypotension	Disease	147	148	6	1:NR:2	R2L	CROSS	199-201	147-148	D000804	angiotensin II|angiotensin II	Chemical	199:223	201:225	9:10	D007022	hypotension	Disease	147	148	6	1:NR:2	R2L	NON-CROSS	189-190	169-172	D000809	angiotensin	Chemical	189	190	8	D012078	renal artery stenosis|renal artery stenosis	Disease	161:169	164:172	7:8	1:NR:2	R2L	CROSS	199-201	169-172	D000804	angiotensin II|angiotensin II	Chemical	199:223	201:225	9:10	D012078	renal artery stenosis|renal artery stenosis	Disease	161:169	164:172	7:8	1:NR:2	R2L	NON-CROSS	189-190	174-176	D000809	angiotensin	Chemical	189	190	8	D006333	heart failure	Disease	174	176	8	1:NR:2	R2L	CROSS	199-201	174-176	D000804	angiotensin II|angiotensin II	Chemical	199:223	201:225	9:10	D006333	heart failure	Disease	174	176	8	1:NR:2	L2R	CROSS	189-190	236-238	D000809	angiotensin	Chemical	189	190	8	D014652	renovascular disease	Disease	236	238	10	1:NR:2	L2R	NON-CROSS	223-225	236-238	D000804	angiotensin II|angiotensin II	Chemical	199:223	201:225	9:10	D014652	renovascular disease	Disease	236	238	10
11334364	In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen - induced nephrotoxicity , amiodarone - induced lung toxicity and doxorubicin - induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract .|Grape seed extract , primarily a mixture of proanthocyanidins , has been shown to modulate a wide - range of biological , pharmacological and toxicological effects which are mainly cytoprotective .|This study assessed the ability of IH636 grape seed proanthocyanidin extract ( GSPE ) to prevent acetaminophen ( AAP ) - induced nephrotoxicity , amiodarone ( AMI ) - induced lung toxicity , and doxorubicin ( DOX ) - induced cardiotoxicity in mice .|Experimental design consisted of four groups : control ( vehicle alone ) , GSPE alone , drug alone and GSPE + drug .|For the cytoprotection study , animals were orally gavaged 100 mg / Kg GSPE for 7 - 10 days followed by i . p .|injections of organ specific three drugs ( AAP : 500 mg / Kg for 24 h ; AMI : 50 mg / Kg / day for four days ; DOX : 20 mg / Kg for 48 h ) .|Parameters of study included analysis of serum chemistry ( ALT , BUN and CPK ) , and orderly fragmentation of genomic DNA ( both endonuclease - dependent and independent ) in addition to microscopic evaluation of damage and / or protection in corresponding PAS stained tissues .|Results indicate that GSPE preexposure prior to AAP , AMI and DOX , provided near complete protection in terms of serum chemistry changes ( ALT , BUN and CPK ) , and significantly reduced DNA fragmentation .|Histopathological examination of kidney , heart and lung sections revealed moderate to massive tissue damage with a variety of morphological aberrations by all the three drugs in the absence of GSPE preexposure than in its presence .|GSPE + drug exposed tissues exhibited minor residual damage or near total recovery .|Additionally , histopathological alterations mirrored both serum chemistry changes and the pattern of DNA fragmentation .|Interestingly , all the drugs , such as , AAP , AMI and DOX induced apoptotic death in addition to necrosis in the respective organs which was very effectively blocked by GSPE .|Since AAP , AMI and DOX undergo biotransformation and are known to produce damaging radicals in vivo , the protection by GSPE may be linked to both inhibition of metabolism and / or detoxification of cytotoxic radicals .|In addition , its ' presumed contribution to DNA repair may be another important attribute , which played a role in the chemoprevention process .|Additionally , this may have been the first report on AMI - induced apoptotic death in the lung tissue .|Taken together , these events undoubtedly establish GSPE 's abundant bioavailability , and the power to defend multiple target organs from toxic assaults induced by structurally diverse and functionally different entities in vivo .	1:CID:2	R2L	NON-CROSS	13-14	9-10	D000082	acetaminophen|acetaminophen|AAP|AAP|AAP|AAP|AAP	Chemical	13:84:86:167:254:360:385	14:85:87:168:255:361:386	0:2:2:5:7:11:12	D009336	necrotic|necrosis	Disease	9:371	10:372	0:11	1:CID:2	R2L	NON-CROSS	18-19	9-10	D000638	amiodarone|amiodarone|AMI|AMI|AMI|AMI|AMI|AMI	Chemical	18:92:94:177:256:362:387:457	19:93:95:178:257:363:388:458	0:2:2:5:7:11:12:14	D009336	necrotic|necrosis	Disease	9:371	10:372	0:11	1:CID:2	R2L	NON-CROSS	371-372	364-365	D004317	doxorubicin|doxorubicin|DOX|DOX|DOX|DOX|DOX	Chemical	24:102:104:189:258:364:389	25:103:105:190:259:365:390	0:2:2:5:7:11:12	D009336	necrotic|necrosis	Disease	9:371	10:372	0:11	1:CID:2	L2R	NON-CROSS	13-14	16-17	D000082	acetaminophen|acetaminophen|AAP|AAP|AAP|AAP|AAP	Chemical	13:84:86:167:254:360:385	14:85:87:168:255:361:386	0:2:2:5:7:11:12	D007674	nephrotoxicity|nephrotoxicity	Disease	16:90	17:91	0:2	1:CID:2	L2R	NON-CROSS	18-19	21-23	D000638	amiodarone|amiodarone|AMI|AMI|AMI|AMI|AMI|AMI	Chemical	18:92:94:177:256:362:387:457	19:93:95:178:257:363:388:458	0:2:2:5:7:11:12:14	D008171	lung toxicity|lung toxicity	Disease	21:98	23:100	0:2	1:CID:2	L2R	NON-CROSS	24-25	27-28	D004317	doxorubicin|doxorubicin|DOX|DOX|DOX|DOX|DOX	Chemical	24:102:104:189:258:364:389	25:103:105:190:259:365:390	0:2:2:5:7:11:12	D066126	cardiotoxicity|cardiotoxicity	Disease	27:108	28:109	0:2	1:NR:2	R2L	NON-CROSS	382-383	371-372	C511402	IH636 grape seed proanthocyanidin extract|Grape seed extract|IH636 grape seed proanthocyanidin extract|GSPE|GSPE|GSPE|GSPE|GSPE|GSPE|GSPE|GSPE|GSPE|GSPE	Chemical	31:37:74:80:125:131:148:250:314:321:382:405:474	36:40:79:81:126:132:149:251:315:322:383:406:475	0:1:2:2:3:3:4:7:8:9:11:12:15	D009336	necrotic|necrosis	Disease	9:371	10:372	0:11	1:NR:2	R2L	CROSS	45-46	9-10	D044945	proanthocyanidins	Chemical	45	46	1	D009336	necrotic|necrosis	Disease	9:371	10:372	0:11	1:NR:2	L2R	NON-CROSS	13-14	21-23	D000082	acetaminophen|acetaminophen|AAP|AAP|AAP|AAP|AAP	Chemical	13:84:86:167:254:360:385	14:85:87:168:255:361:386	0:2:2:5:7:11:12	D008171	lung toxicity|lung toxicity	Disease	21:98	23:100	0:2	1:NR:2	L2R	NON-CROSS	13-14	27-28	D000082	acetaminophen|acetaminophen|AAP|AAP|AAP|AAP|AAP	Chemical	13:84:86:167:254:360:385	14:85:87:168:255:361:386	0:2:2:5:7:11:12	D066126	cardiotoxicity|cardiotoxicity	Disease	27:108	28:109	0:2	1:NR:2	L2R	CROSS	254-255	297-299	D000082	acetaminophen|acetaminophen|AAP|AAP|AAP|AAP|AAP	Chemical	13:84:86:167:254:360:385	14:85:87:168:255:361:386	0:2:2:5:7:11:12	D017695	tissue damage	Disease	297	299	8	1:NR:2	R2L	NON-CROSS	18-19	16-17	D000638	amiodarone|amiodarone|AMI|AMI|AMI|AMI|AMI|AMI	Chemical	18:92:94:177:256:362:387:457	19:93:95:178:257:363:388:458	0:2:2:5:7:11:12:14	D007674	nephrotoxicity|nephrotoxicity	Disease	16:90	17:91	0:2	1:NR:2	R2L	NON-CROSS	24-25	16-17	D004317	doxorubicin|doxorubicin|DOX|DOX|DOX|DOX|DOX	Chemical	24:102:104:189:258:364:389	25:103:105:190:259:365:390	0:2:2:5:7:11:12	D007674	nephrotoxicity|nephrotoxicity	Disease	16:90	17:91	0:2	1:NR:2	R2L	NON-CROSS	90-91	80-81	C511402	IH636 grape seed proanthocyanidin extract|Grape seed extract|IH636 grape seed proanthocyanidin extract|GSPE|GSPE|GSPE|GSPE|GSPE|GSPE|GSPE|GSPE|GSPE|GSPE	Chemical	31:37:74:80:125:131:148:250:314:321:382:405:474	36:40:79:81:126:132:149:251:315:322:383:406:475	0:1:2:2:3:3:4:7:8:9:11:12:15	D007674	nephrotoxicity|nephrotoxicity	Disease	16:90	17:91	0:2	1:NR:2	R2L	CROSS	45-46	16-17	D044945	proanthocyanidins	Chemical	45	46	1	D007674	nephrotoxicity|nephrotoxicity	Disease	16:90	17:91	0:2	1:NR:2	L2R	NON-CROSS	18-19	27-28	D000638	amiodarone|amiodarone|AMI|AMI|AMI|AMI|AMI|AMI	Chemical	18:92:94:177:256:362:387:457	19:93:95:178:257:363:388:458	0:2:2:5:7:11:12:14	D066126	cardiotoxicity|cardiotoxicity	Disease	27:108	28:109	0:2	1:NR:2	L2R	CROSS	256-257	297-299	D000638	amiodarone|amiodarone|AMI|AMI|AMI|AMI|AMI|AMI	Chemical	18:92:94:177:256:362:387:457	19:93:95:178:257:363:388:458	0:2:2:5:7:11:12:14	D017695	tissue damage	Disease	297	299	8	1:NR:2	R2L	NON-CROSS	24-25	21-23	D004317	doxorubicin|doxorubicin|DOX|DOX|DOX|DOX|DOX	Chemical	24:102:104:189:258:364:389	25:103:105:190:259:365:390	0:2:2:5:7:11:12	D008171	lung toxicity|lung toxicity	Disease	21:98	23:100	0:2	1:NR:2	R2L	NON-CROSS	31-36	21-23	C511402	IH636 grape seed proanthocyanidin extract|Grape seed extract|IH636 grape seed proanthocyanidin extract|GSPE|GSPE|GSPE|GSPE|GSPE|GSPE|GSPE|GSPE|GSPE|GSPE	Chemical	31:37:74:80:125:131:148:250:314:321:382:405:474	36:40:79:81:126:132:149:251:315:322:383:406:475	0:1:2:2:3:3:4:7:8:9:11:12:15	D008171	lung toxicity|lung toxicity	Disease	21:98	23:100	0:2	1:NR:2	R2L	CROSS	45-46	21-23	D044945	proanthocyanidins	Chemical	45	46	1	D008171	lung toxicity|lung toxicity	Disease	21:98	23:100	0:2	1:NR:2	L2R	CROSS	258-259	297-299	D004317	doxorubicin|doxorubicin|DOX|DOX|DOX|DOX|DOX	Chemical	24:102:104:189:258:364:389	25:103:105:190:259:365:390	0:2:2:5:7:11:12	D017695	tissue damage	Disease	297	299	8	1:NR:2	R2L	NON-CROSS	31-36	27-28	C511402	IH636 grape seed proanthocyanidin extract|Grape seed extract|IH636 grape seed proanthocyanidin extract|GSPE|GSPE|GSPE|GSPE|GSPE|GSPE|GSPE|GSPE|GSPE|GSPE	Chemical	31:37:74:80:125:131:148:250:314:321:382:405:474	36:40:79:81:126:132:149:251:315:322:383:406:475	0:1:2:2:3:3:4:7:8:9:11:12:15	D066126	cardiotoxicity|cardiotoxicity	Disease	27:108	28:109	0:2	1:NR:2	R2L	CROSS	45-46	27-28	D044945	proanthocyanidins	Chemical	45	46	1	D066126	cardiotoxicity|cardiotoxicity	Disease	27:108	28:109	0:2	1:NR:2	L2R	NON-CROSS	297-299	314-315	C511402	IH636 grape seed proanthocyanidin extract|Grape seed extract|IH636 grape seed proanthocyanidin extract|GSPE|GSPE|GSPE|GSPE|GSPE|GSPE|GSPE|GSPE|GSPE|GSPE	Chemical	31:37:74:80:125:131:148:250:314:321:382:405:474	36:40:79:81:126:132:149:251:315:322:383:406:475	0:1:2:2:3:3:4:7:8:9:11:12:15	D017695	tissue damage	Disease	297	299	8	1:NR:2	L2R	CROSS	45-46	297-299	D044945	proanthocyanidins	Chemical	45	46	1	D017695	tissue damage	Disease	297	299	8
11642480	Palpebral twitching in a depressed adolescent on citalopram .|Current estimates suggest that between 0 . 4 % and 8 . 3 % of children and adolescents are affected by major depression .|We report a favorable response to treatment with citalopram by a 15 - year - old boy with major depression who exhibited palpebral twitching during his first 2 weeks of treatment .|This may have been a side effect of citalopram as it remitted with redistribution of doses .	1:CID:2	R2L	NON-CROSS	7-8	0-2	D015283	citalopram|citalopram|citalopram	Chemical	7:41:73	8:42:74	0:2:3	D004409	Palpebral twitching|palpebral twitching	Disease	0:55	2:57	0:2	1:NR:2	R2L	NON-CROSS	7-8	4-5	D015283	citalopram|citalopram|citalopram	Chemical	7:41:73	8:42:74	0:2:3	D003866	depressed	Disease	4	5	0	1:NR:2	L2R	NON-CROSS	41-42	51-53	D015283	citalopram|citalopram|citalopram	Chemical	7:41:73	8:42:74	0:2:3	D003865	major depression|major depression	Disease	30:51	32:53	1:2
12063090	Metamizol potentiates morphine antinociception but not constipation after chronic treatment .|This work evaluates the antinociceptive and constipating effects of the combination of 3 . 2 mg / kg s . c .|morphine with 177 . 8 mg / kg s . c .|metamizol in acutely and chronically treated ( once a day for 12 days ) rats .|On the 13th day , antinociceptive effects were assessed using a model of inflammatory nociception , pain - induced functional impairment model , and the charcoal meal test was used to evaluate the intestinal transit .|Simultaneous administration of morphine with metamizol resulted in a markedly antinociceptive potentiation and an increasing of the duration of action after a single ( 298 + / - 7 vs . 139 + / - 36 units area ( ua ) ; P < 0 . 001 ) and repeated administration ( 280 + / - 17 vs . 131 + / - 22 ua ; P < 0 . 001 ) .|Antinociceptive effect of morphine was reduced in chronically treated rats ( 39 + / - 10 vs . 18 + / - 5 au ) while the combination - induced antinociception was remained similar as an acute treatment ( 298 + / - 7 vs . 280 + / - 17 au ) .|Acute antinociceptive effects of the combination were partially prevented by 3 . 2 mg / kg naloxone s . c .|( P < 0 . 05 ) , suggesting the partial involvement of the opioidergic system in the synergism observed .|In independent groups , morphine inhibited the intestinal transit in 48 + / - 4 % and 38 + / - 4 % after acute and chronic treatment , respectively , suggesting that tolerance did not develop to the constipating effects .|The combination inhibited intestinal transit similar to that produced by morphine regardless of the time of treatment , suggesting that metamizol did not potentiate morphine - induced constipation .|These findings show a significant interaction between morphine and metamizol in chronically treated rats , suggesting that this combination could be useful for the treatment of chronic pain .	1:CID:2	L2R	NON-CROSS	332-333	335-336	D009020	morphine|morphine|morphine|morphine|morphine|morphine|morphine|morphine	Chemical	2:33:100:173:270:318:332:344	3:34:101:174:271:319:333:345	0:2:5:6:9:10:10:11	D003248	constipation|constipating|constipating|constipation	Disease	6:17:305:335	7:18:306:336	0:1:9:10	1:NR:2	L2R	NON-CROSS	0-1	6-7	D004177	Metamizol|metamizol|metamizol|metamizol|metamizol	Chemical	0:45:102:328:346	1:46:103:329:347	0:3:5:10:11	D003248	constipation|constipating|constipating|constipation	Disease	6:17:305:335	7:18:306:336	0:1:9:10	1:NR:2	L2R	CROSS	77-78	102-103	D004177	Metamizol|metamizol|metamizol|metamizol|metamizol	Chemical	0:45:102:328:346	1:46:103:329:347	0:3:5:10:11	D010146	pain	Disease	77	78	4	1:NR:2	L2R	NON-CROSS	346-347	363-365	D004177	Metamizol|metamizol|metamizol|metamizol|metamizol	Chemical	0:45:102:328:346	1:46:103:329:347	0:3:5:10:11	D059350	chronic pain	Disease	363	365	11	1:NR:2	L2R	CROSS	77-78	100-101	D009020	morphine|morphine|morphine|morphine|morphine|morphine|morphine|morphine	Chemical	2:33:100:173:270:318:332:344	3:34:101:174:271:319:333:345	0:2:5:6:9:10:10:11	D010146	pain	Disease	77	78	4	1:NR:2	L2R	NON-CROSS	344-345	363-365	D009020	morphine|morphine|morphine|morphine|morphine|morphine|morphine|morphine	Chemical	2:33:100:173:270:318:332:344	3:34:101:174:271:319:333:345	0:2:5:6:9:10:10:11	D059350	chronic pain	Disease	363	365	11	1:NR:2	R2L	CROSS	86-87	17-18	D002606	charcoal	Chemical	86	87	4	D003248	constipation|constipating|constipating|constipation	Disease	6:17:305:335	7:18:306:336	0:1:9:10	1:NR:2	R2L	CROSS	305-306	240-241	D009270	naloxone	Chemical	240	241	7	D003248	constipation|constipating|constipating|constipation	Disease	6:17:305:335	7:18:306:336	0:1:9:10	1:NR:2	R2L	NON-CROSS	86-87	77-78	D002606	charcoal	Chemical	86	87	4	D010146	pain	Disease	77	78	4	1:NR:2	R2L	CROSS	240-241	77-78	D009270	naloxone	Chemical	240	241	7	D010146	pain	Disease	77	78	4	1:NR:2	L2R	CROSS	86-87	363-365	D002606	charcoal	Chemical	86	87	4	D059350	chronic pain	Disease	363	365	11	1:NR:2	L2R	CROSS	240-241	363-365	D009270	naloxone	Chemical	240	241	7	D059350	chronic pain	Disease	363	365	11
12084448	Ifosfamide encephalopathy presenting with asterixis .|CNS toxic effects of the antineoplastic agent ifosfamide ( IFX ) are frequent and include a variety of neurological symptoms that can limit drug use .|We report a case of a 51 - year - old man who developed severe , disabling negative myoclonus of the upper and lower extremities after the infusion of ifosfamide for plasmacytoma .|He was awake , revealed no changes of mental status and at rest there were no further motor symptoms .|Cranial magnetic resonance imaging and extensive laboratory studies failed to reveal structural lesions of the brain and metabolic abnormalities .|An electroencephalogram showed continuous , generalized irregular slowing with admixed periodic triphasic waves indicating symptomatic encephalopathy .|The administration of ifosfamide was discontinued and within 12 h the asterixis resolved completely .|In the patient described , the presence of asterixis during infusion of ifosfamide , normal laboratory findings and imaging studies and the resolution of symptoms following the discontinuation of the drug suggest that negative myoclonus is associated with the use of IFX .	1:CID:2	L2R	NON-CROSS	0-1	1-2	D007069	Ifosfamide|ifosfamide|IFX|ifosfamide|ifosfamide|ifosfamide|IFX	Chemical	0:13:15:61:125:149:178	1:14:16:62:126:150:179	0:1:1:2:6:7:7	D001927	encephalopathy|structural lesions of the brain|encephalopathy	Disease	1:96:120	2:101:121	0:4:5	1:CID:2	L2R	NON-CROSS	171-172	178-179	D007069	Ifosfamide|ifosfamide|IFX|ifosfamide|ifosfamide|ifosfamide|IFX	Chemical	0:13:15:61:125:149:178	1:14:16:62:126:150:179	0:1:1:2:6:7:7	D009207	myoclonus|myoclonus	Disease	50:171	51:172	2:7	not_include	L2R	NON-CROSS	0-1	4-5	D007069	Ifosfamide|ifosfamide|IFX|ifosfamide|ifosfamide|ifosfamide|IFX	Chemical	0:13:15:61:125:149:178	1:14:16:62:126:150:179	0:1:1:2:6:7:7	D020820	asterixis|asterixis|asterixis	Disease	4:133:145	5:134:146	0:6:7	1:NR:2	L2R	NON-CROSS	61-62	63-64	D007069	Ifosfamide|ifosfamide|IFX|ifosfamide|ifosfamide|ifosfamide|IFX	Chemical	0:13:15:61:125:149:178	1:14:16:62:126:150:179	0:1:1:2:6:7:7	D010954	plasmacytoma	Disease	63	64	2	1:NR:2	L2R	CROSS	102-104	125-126	D007069	Ifosfamide|ifosfamide|IFX|ifosfamide|ifosfamide|ifosfamide|IFX	Chemical	0:13:15:61:125:149:178	1:14:16:62:126:150:179	0:1:1:2:6:7:7	D008659	metabolic abnormalities	Disease	102	104	4
12684739	Sub - chronic low dose gamma - vinyl GABA ( vigabatrin ) inhibits cocaine - induced increases in nucleus accumbens dopamine .|RATIONALE : gamma - Vinyl GABA ( GVG ) irreversibly inhibits GABA - transaminase .|This non - receptor mediated inhibition requires de novo synthesis for restoration of functional GABA catabolism .|OBJECTIVES : Given its preclinical success for treating substance abuse and the increased risk of visual field defects ( VFD ) associated with cumulative lifetime exposure , we explored the effects of sub - chronic low dose GVG on cocaine - induced increases in nucleus accumbens ( NAcc ) dopamine ( DA ) .|METHODS : Using in vivo microdialysis , we compared acute exposure ( 450 mg / kg ) to an identical sub - chronic exposure ( 150 mg / kg per day for 3 days ) , followed by 1 - or 3 - day washout .|Finally , we examined the low dose of 150 mg / kg ( 50 mg / kg per day ) using a similar washout period .|RESULTS : Sub - chronic GVG exposure inhibited the effect of cocaine for 3 days , which exceeded in magnitude and duration the identical acute dose .|CONCLUSIONS : Sub - chronic low dose GVG potentiates and extends the inhibition of cocaine - induced increases in dopamine , effectively reducing cumulative exposures and the risk for VFDS .	1:CID:2	L2R	NON-CROSS	73-74	91-92	D020888	gamma - vinyl GABA|vigabatrin|gamma - Vinyl GABA|GVG|GVG|GVG|GVG	Chemical	5:10:24:29:91:185:214	9:11:28:30:92:186:215	0:0:1:1:3:6:7	D005128	visual field defects|VFD	Disease	69:73	72:74	3:3	1:NR:2	L2R	NON-CROSS	62-64	91-92	D020888	gamma - vinyl GABA|vigabatrin|gamma - Vinyl GABA|GVG|GVG|GVG|GVG	Chemical	5:10:24:29:91:185:214	9:11:28:30:92:186:215	0:0:1:1:3:6:7	D019966	substance abuse	Disease	62	64	3	1:NR:2	L2R	NON-CROSS	62-64	93-94	D003042	cocaine|cocaine|cocaine|cocaine	Chemical	13:93:191:221	14:94:192:222	0:3:6:7	D019966	substance abuse	Disease	62	64	3	1:NR:2	L2R	NON-CROSS	73-74	93-94	D003042	cocaine|cocaine|cocaine|cocaine	Chemical	13:93:191:221	14:94:192:222	0:3:6:7	D005128	visual field defects|VFD	Disease	69:73	72:74	3:3	1:NR:2	L2R	NON-CROSS	62-64	103-104	D004298	dopamine|dopamine|DA|dopamine	Chemical	20:103:105:226	21:104:106:227	0:3:3:7	D019966	substance abuse	Disease	62	64	3	1:NR:2	L2R	NON-CROSS	73-74	103-104	D004298	dopamine|dopamine|DA|dopamine	Chemical	20:103:105:226	21:104:106:227	0:3:3:7	D005128	visual field defects|VFD	Disease	69:73	72:74	3:3	1:NR:2	L2R	CROSS	51-52	62-64	D005680	GABA|GABA	Chemical	33:51	34:52	1:2	D019966	substance abuse	Disease	62	64	3	1:NR:2	L2R	CROSS	51-52	69-72	D005680	GABA|GABA	Chemical	33:51	34:52	1:2	D005128	visual field defects|VFD	Disease	69:73	72:74	3:3
12716030	Amount of bleeding and hematoma size in the collagenase - induced intracerebral hemorrhage rat model .|The aggravated risk on intracerebral hemorrhage ( ICH ) with drugs used for stroke patients should be estimated carefully .|We therefore established sensitive quantification methods and provided a rat ICH model for detection of ICH deterioration .|In ICH intrastriatally induced by 0 . 014 - unit , 0 . 070 - unit , and 0 . 350 - unit collagenase , the amount of bleeding was measured using a hemoglobin assay developed in the present study and was compared with the morphologically determined hematoma volume .|The blood amounts and hematoma volumes were significantly correlated , and the hematoma induced by 0 . 014 - unit collagenase was adequate to detect ICH deterioration .|In ICH induction using 0 . 014 - unit collagenase , heparin enhanced the hematoma volume 3 . 4 - fold over that seen in control ICH animals and the bleeding 7 . 6 - fold .|Data suggest that this sensitive hemoglobin assay is useful for ICH detection , and that a model with a small ICH induced with a low - dose collagenase should be used for evaluation of drugs that may affect ICH .	1:CID:2	R2L	NON-CROSS	146-147	143-144	D006493	heparin	Chemical	143	144	5	D006406	hematoma|hematoma|hematoma|hematoma|hematoma	Disease	4:101:108:116:146	5:102:109:117:147	0:3:4:4:5	not_include	R2L	NON-CROSS	162-163	143-144	D006493	heparin	Chemical	143	144	5	D006470	bleeding|bleeding|bleeding	Disease	2:82:162	3:83:163	0:3:5	1:NR:2	R2L	NON-CROSS	143-144	133-134	D006493	heparin	Chemical	143	144	5	D002543	intracerebral hemorrhage|intracerebral hemorrhage|ICH|ICH|ICH|ICH|ICH|ICH|ICH|ICH|ICH|ICH	Disease	11:20:23:46:51:55:129:133:158:179:189:207	13:22:24:47:52:56:130:134:159:180:190:208	0:1:1:2:2:3:4:5:5:6:6:6	1:NR:2	R2L	CROSS	143-144	29-30	D006493	heparin	Chemical	143	144	5	D020521	stroke	Disease	29	30	1
12757899	Estradiol reduces seizure - induced hippocampal injury in ovariectomized female but not in male rats .|Estrogens protect ovariectomized rats from hippocampal injury induced by kainic acid - induced status epilepticus ( SE ) .|We compared the effects of 17beta - estradiol in adult male and ovariectomized female rats subjected to lithium - pilocarpine - induced SE .|Rats received subcutaneous injections of 17beta - estradiol ( 2 microg / rat ) or oil once daily for four consecutive days .|SE was induced 20 h following the second injection and terminated 3 h later .|The extent of silver - stained CA3 and CA1 hippocampal neurons was evaluated 2 days after SE .|17beta - Estradiol did not alter the onset of first clonus in ovariectomized rats but accelerated it in males .|17beta - Estradiol reduced the argyrophilic neurons in the CA1 and CA3 - C sectors of ovariectomized rats .|In males , estradiol increased the total damage score .|These findings suggest that the effects of estradiol on seizure threshold and damage may be altered by sex - related differences in the hormonal environment .	1:CID:2	R2L	CROSS	52-53	21-23	D008094	lithium	Chemical	52	53	2	D001930	hippocampal injury|hippocampal injury	Disease	5:21	7:23	0:1	1:CID:2	R2L	CROSS	54-55	21-23	D010862	pilocarpine	Chemical	54	55	2	D001930	hippocampal injury|hippocampal injury	Disease	5:21	7:23	0:1	1:CID:2	R2L	NON-CROSS	57-58	52-53	D008094	lithium	Chemical	52	53	2	D013226	status epilepticus|SE|SE|SE|SE	Disease	29:32:57:82:113	31:33:58:83:114	1:1:2:4:5	1:CID:2	R2L	NON-CROSS	57-58	54-55	D010862	pilocarpine	Chemical	54	55	2	D013226	status epilepticus|SE|SE|SE|SE	Disease	29:32:57:82:113	31:33:58:83:114	1:1:2:4:5	1:NR:2	L2R	NON-CROSS	0-1	2-3	D004958	Estradiol|17beta - estradiol|17beta - estradiol|17beta - Estradiol|17beta - Estradiol|estradiol|estradiol	Chemical	0:40:64:115:135:157:171	1:43:67:118:138:158:172	0:2:3:6:7:8:9	D012640	seizure|seizure	Disease	2:173	3:174	0:9	1:NR:2	L2R	NON-CROSS	0-1	5-7	D004958	Estradiol|17beta - estradiol|17beta - estradiol|17beta - Estradiol|17beta - Estradiol|estradiol|estradiol	Chemical	0:40:64:115:135:157:171	1:43:67:118:138:158:172	0:2:3:6:7:8:9	D001930	hippocampal injury|hippocampal injury	Disease	5:21	7:23	0:1	1:NR:2	L2R	NON-CROSS	113-114	115-118	D004958	Estradiol|17beta - estradiol|17beta - estradiol|17beta - Estradiol|17beta - Estradiol|estradiol|estradiol	Chemical	0:40:64:115:135:157:171	1:43:67:118:138:158:172	0:2:3:6:7:8:9	D013226	status epilepticus|SE|SE|SE|SE	Disease	29:32:57:82:113	31:33:58:83:114	1:1:2:4:5	1:NR:2	R2L	CROSS	25-27	2-3	D007608	kainic acid	Chemical	25	27	1	D012640	seizure|seizure	Disease	2:173	3:174	0:9	1:NR:2	R2L	CROSS	52-53	2-3	D008094	lithium	Chemical	52	53	2	D012640	seizure|seizure	Disease	2:173	3:174	0:9	1:NR:2	R2L	CROSS	54-55	2-3	D010862	pilocarpine	Chemical	54	55	2	D012640	seizure|seizure	Disease	2:173	3:174	0:9	1:NR:2	R2L	CROSS	173-174	100-101	D012834	silver	Chemical	100	101	5	D012640	seizure|seizure	Disease	2:173	3:174	0:9	1:NR:2	R2L	NON-CROSS	25-27	21-23	D007608	kainic acid	Chemical	25	27	1	D001930	hippocampal injury|hippocampal injury	Disease	5:21	7:23	0:1	1:NR:2	R2L	CROSS	100-101	21-23	D012834	silver	Chemical	100	101	5	D001930	hippocampal injury|hippocampal injury	Disease	5:21	7:23	0:1	1:NR:2	L2R	NON-CROSS	25-27	29-31	D007608	kainic acid	Chemical	25	27	1	D013226	status epilepticus|SE|SE|SE|SE	Disease	29:32:57:82:113	31:33:58:83:114	1:1:2:4:5	1:NR:2	R2L	NON-CROSS	113-114	100-101	D012834	silver	Chemical	100	101	5	D013226	status epilepticus|SE|SE|SE|SE	Disease	29:32:57:82:113	31:33:58:83:114	1:1:2:4:5
12905102	Delirium during clozapine treatment : incidence and associated risk factors .|BACKGROUND : Incidence and risk factors for delirium during clozapine treatment require further clarification .|METHODS : We used computerized pharmacy records to identify all adult psychiatric inpatients treated with clozapine ( 1995 - 96 ) , reviewed their medical records to score incidence and severity of delirium , and tested associations with potential risk factors .|RESULTS : Subjects ( n = 139 ) were 72 women and 67 men , aged 40 . 8 + / - 12 . 1 years , hospitalized for 24 . 9 + / - 23 . 3 days , and given clozapine , gradually increased to an average daily dose of 282 + / - 203 mg ( 3 . 45 + / - 2 . 45 mg / kg ) for 18 . 9 + / - 16 . 4 days .|Delirium was diagnosed in 14 ( 10 . 1 % incidence , or 1 . 48 cases / person - years of exposure ) ; 71 . 4 % of cases were moderate or severe .|Associated factors were co - treatment with other centrally antimuscarinic agents , poor clinical outcome , older age , and longer hospitalization ( by 17 . 5 days , increasing cost ) ; sex , diagnosis or medical co - morbidity , and daily clozapine dose , which fell with age , were unrelated .|CONCLUSIONS : Delirium was found in 10 % of clozapine - treated inpatients , particularly in older patients exposed to other central anticholinergics .|Delirium was inconsistently recognized clinically in milder cases and was associated with increased length - of - stay and higher costs , and inferior clinical outcome .	1:CID:2	R2L	NON-CROSS	2-3	0-1	D003024	clozapine|clozapine|clozapine|clozapine|clozapine|clozapine	Chemical	2:20:41:110:232:252	3:21:42:111:233:253	0:1:2:3:5:6	D003693	Delirium|delirium|delirium|Delirium|Delirium|Delirium	Disease	0:18:58:152:245:267	1:19:59:153:246:268	0:1:2:4:6:7	not_include	L2R	NON-CROSS	37-38	41-42	D003024	clozapine|clozapine|clozapine|clozapine|clozapine|clozapine	Chemical	2:20:41:110:232:252	3:21:42:111:233:253	0:1:2:3:5:6	D001523	psychiatric	Disease	37	38	2
14513889	Ketoconazole - induced neurologic sequelae .|A 77 - y - old patient developed weakness of extremities , legs paralysis , dysarthria and tremor 1 h after ingestion of 200 mg ketoconazole for the first time in his life .|All complaints faded away within 24 h .|Few days later , the patient used another 200 mg ketoconazole tablet , and within an hour experienced a similar clinical picture , which resolved again spontaneously within hours .|Laboratory evaluations , including head CT scan , were normal .|This case illustrates the need for close vigilance in adverse drug reactions , particularly in the elderly .	1:CID:2	L2R	NON-CROSS	0-1	14-17	D007654	Ketoconazole|ketoconazole|ketoconazole	Chemical	0:31:58	1:32:59	0:1:3	D018908	weakness of extremities	Disease	14	17	1	1:CID:2	L2R	NON-CROSS	18-20	31-32	D007654	Ketoconazole|ketoconazole|ketoconazole	Chemical	0:31:58	1:32:59	0:1:3	D010243	legs paralysis	Disease	18	20	1	1:CID:2	L2R	NON-CROSS	21-22	31-32	D007654	Ketoconazole|ketoconazole|ketoconazole	Chemical	0:31:58	1:32:59	0:1:3	D004401	dysarthria	Disease	21	22	1	1:CID:2	L2R	NON-CROSS	23-24	31-32	D007654	Ketoconazole|ketoconazole|ketoconazole	Chemical	0:31:58	1:32:59	0:1:3	D014202	tremor	Disease	23	24	1	not_include	L2R	NON-CROSS	0-1	3-5	D007654	Ketoconazole|ketoconazole|ketoconazole	Chemical	0:31:58	1:32:59	0:1:3	D009422	neurologic sequelae	Disease	3	5	0	1:NR:2	L2R	CROSS	58-59	98-101	D007654	Ketoconazole|ketoconazole|ketoconazole	Chemical	0:31:58	1:32:59	0:1:3	D064420	adverse drug reactions	Disease	98	101	5
15009014	Noxious chemical stimulation of rat facial mucosa increases intracranial blood flow through a trigemino - parasympathetic reflex - - an experimental model for vascular dysfunctions in cluster headache .|Cluster headache is characterized by typical autonomic dysfunctions including facial and intracranial vascular disturbances .|Both the trigeminal and the cranial parasympathetic systems may be involved in mediating these dysfunctions .|An experimental model was developed in the rat to measure changes in lacrimation and intracranial blood flow following noxious chemical stimulation of facial mucosa .|Blood flow was monitored in arteries of the exposed cranial dura mater and the parietal cortex using laser Doppler flowmetry .|Capsaicin ( 0 . 01 - 1 mm ) applied to oral or nasal mucosa induced increases in dural and cortical blood flow and provoked lacrimation .|These responses were blocked by systemic pre - administration of hexamethonium chloride ( 20 mg / kg ) .|The evoked increases in dural blood flow were also abolished by topical pre - administration of atropine ( 1 mm ) and [ Lys1 , Pro2 , 5 , Arg3 , 4 , Tyr6 ] - VIP ( 0 . 1 mm ) , a vasoactive intestinal polypeptide ( VIP ) antagonist , onto the exposed dura mater .|We conclude that noxious stimulation of facial mucosa increases intracranial blood flow and lacrimation via a trigemino - parasympathetic reflex .|The blood flow responses seem to be mediated by the release of acetylcholine and VIP within the meninges .|Similar mechanisms may be involved in the pathogenesis of cluster headache .	1:CID:2	R2L	CROSS	106-107	40-43	D002211	Capsaicin	Chemical	106	107	5	D002561	vascular dysfunctions|intracranial vascular disturbances	Disease	23:40	25:43	0:1	1:CID:2	L2R	NON-CROSS	106-107	122-129	D002211	Capsaicin	Chemical	106	107	5	D006940	increases in dural and cortical blood flow|increases in dural blood flow	Disease	122:154	129:159	5:7	1:NR:2	R2L	CROSS	143-145	40-43	D018738	hexamethonium chloride	Chemical	143	145	6	D002561	vascular dysfunctions|intracranial vascular disturbances	Disease	23:40	25:43	0:1	1:NR:2	R2L	CROSS	168-169	40-43	D001285	atropine	Chemical	168	169	7	D002561	vascular dysfunctions|intracranial vascular disturbances	Disease	23:40	25:43	0:1	1:NR:2	R2L	CROSS	244-245	40-43	D000109	acetylcholine	Chemical	244	245	9	D002561	vascular dysfunctions|intracranial vascular disturbances	Disease	23:40	25:43	0:1	1:NR:2	R2L	CROSS	106-107	29-31	D002211	Capsaicin	Chemical	106	107	5	D003027	cluster headache|Cluster headache|cluster headache	Disease	26:29:260	28:31:262	0:1:10	1:NR:2	R2L	CROSS	143-145	29-31	D018738	hexamethonium chloride	Chemical	143	145	6	D003027	cluster headache|Cluster headache|cluster headache	Disease	26:29:260	28:31:262	0:1:10	1:NR:2	R2L	CROSS	260-262	168-169	D001285	atropine	Chemical	168	169	7	D003027	cluster headache|Cluster headache|cluster headache	Disease	26:29:260	28:31:262	0:1:10	1:NR:2	R2L	CROSS	260-262	244-245	D000109	acetylcholine	Chemical	244	245	9	D003027	cluster headache|Cluster headache|cluster headache	Disease	26:29:260	28:31:262	0:1:10	1:NR:2	R2L	CROSS	154-159	143-145	D018738	hexamethonium chloride	Chemical	143	145	6	D006940	increases in dural and cortical blood flow|increases in dural blood flow	Disease	122:154	129:159	5:7	1:NR:2	R2L	NON-CROSS	168-169	154-159	D001285	atropine	Chemical	168	169	7	D006940	increases in dural and cortical blood flow|increases in dural blood flow	Disease	122:154	129:159	5:7	1:NR:2	R2L	CROSS	244-245	154-159	D000109	acetylcholine	Chemical	244	245	9	D006940	increases in dural and cortical blood flow|increases in dural blood flow	Disease	122:154	129:159	5:7
15120741	Recurrent excitation in the dentate gyrus of a murine model of temporal lobe epilepsy .|Similar to rats , systemic pilocarpine injection causes status epilepticus ( SE ) and the eventual development of spontaneous seizures and mossy fiber sprouting in C57BL / 6 and CD1 mice , but the physiological correlates of these events have not been identified in mice .|Population responses in granule cells of the dentate gyrus were examined in transverse slices of the ventral hippocampus from pilocarpine - treated and untreated mice .|In Mg ( 2 + ) - free bathing medium containing bicuculline , conditions designed to increase excitability in the slices , electrical stimulation of the hilus resulted in a single population spike in granule cells from control mice and pilocarpine - treated mice that did not experience SE .|In SE survivors , similar stimulation resulted in a population spike followed , at a variable latency , by negative DC shifts and repetitive afterdischarges of 3 - 60 s duration , which were blocked by ionotropic glutamate receptor antagonists .|Focal glutamate photostimulation of the granule cell layer at sites distant from the recording pipette resulted in population responses of 1 - 30 s duration in slices from SE survivors but not other groups .|These data support the hypothesis that SE - induced mossy fiber sprouting and synaptic reorganization are relevant characteristics of seizure development in these murine strains , resembling rat models of human temporal lobe epilepsy .	1:CID:2	L2R	NON-CROSS	20-21	23-25	D010862	pilocarpine|pilocarpine|pilocarpine	Chemical	20:80:127	21:81:128	1:2:3	D013226	status epilepticus|SE|SE|SE|SE|SE	Disease	23:26:135:138:206:219	25:27:136:139:207:220	1:1:3:4:5:6	1:CID:2	L2R	NON-CROSS	20-21	34-35	D010862	pilocarpine|pilocarpine|pilocarpine	Chemical	20:80:127	21:81:128	1:2:3	D012640	seizures|seizure	Disease	34:232	35:233	1:6	1:NR:2	R2L	CROSS	20-21	11-14	D010862	pilocarpine|pilocarpine|pilocarpine	Chemical	20:80:127	21:81:128	1:2:3	D004833	temporal lobe epilepsy|temporal lobe epilepsy	Disease	11:244	14:247	0:6	1:NR:2	R2L	CROSS	88-89	11-14	D008274	Mg	Chemical	88	89	3	D004833	temporal lobe epilepsy|temporal lobe epilepsy	Disease	11:244	14:247	0:6	1:NR:2	R2L	CROSS	98-99	11-14	D001640	bicuculline	Chemical	98	99	3	D004833	temporal lobe epilepsy|temporal lobe epilepsy	Disease	11:244	14:247	0:6	1:NR:2	R2L	CROSS	244-247	179-180	D018698	glutamate|glutamate	Chemical	174:179	175:180	4:5	D004833	temporal lobe epilepsy|temporal lobe epilepsy	Disease	11:244	14:247	0:6	1:NR:2	R2L	NON-CROSS	135-136	88-89	D008274	Mg	Chemical	88	89	3	D013226	status epilepticus|SE|SE|SE|SE|SE	Disease	23:26:135:138:206:219	25:27:136:139:207:220	1:1:3:4:5:6	1:NR:2	R2L	NON-CROSS	135-136	98-99	D001640	bicuculline	Chemical	98	99	3	D013226	status epilepticus|SE|SE|SE|SE|SE	Disease	23:26:135:138:206:219	25:27:136:139:207:220	1:1:3:4:5:6	1:NR:2	R2L	NON-CROSS	206-207	179-180	D018698	glutamate|glutamate	Chemical	174:179	175:180	4:5	D013226	status epilepticus|SE|SE|SE|SE|SE	Disease	23:26:135:138:206:219	25:27:136:139:207:220	1:1:3:4:5:6	1:NR:2	R2L	CROSS	88-89	34-35	D008274	Mg	Chemical	88	89	3	D012640	seizures|seizure	Disease	34:232	35:233	1:6	1:NR:2	R2L	CROSS	98-99	34-35	D001640	bicuculline	Chemical	98	99	3	D012640	seizures|seizure	Disease	34:232	35:233	1:6	1:NR:2	R2L	CROSS	232-233	179-180	D018698	glutamate|glutamate	Chemical	174:179	175:180	4:5	D012640	seizures|seizure	Disease	34:232	35:233	1:6
15275829	The alpha3 and beta4 nicotinic acetylcholine receptor subunits are necessary for nicotine - induced seizures and hypolocomotion in mice .|Binding of nicotine to nicotinic acetylcholine receptors ( nAChRs ) elicits a series of dose - dependent behaviors that go from altered exploration , sedation , and tremors , to seizures and death .|nAChRs are pentameric ion channels usually composed of alpha and beta subunits .|A gene cluster comprises the alpha3 , alpha5 and beta4 subunits , which coassemble to form functional receptors .|We examined the role of the beta4 subunits in nicotine - induced seizures and hypolocomotion in beta4 homozygous null ( beta4 - / - ) and alpha3 heterozygous ( + / - ) mice .|beta4 - / - mice were less sensitive to the effects of nicotine both at low doses , measured as decreased exploration in an open field , and at high doses , measured as sensitivity to nicotine - induced seizures .|Using in situ hybridization probes for the alpha3 and alpha5 subunits , we showed that alpha5 mRNA levels are unchanged , whereas alpha3 mRNA levels are selectively decreased in the mitral cell layer of the olfactory bulb , and the inferior and the superior colliculus of beta4 - / - brains .|alpha3 + / - mice were partially resistant to nicotine - induced seizures when compared to wild - type littermates .|mRNA levels for the alpha5 and the beta4 subunits were unchanged in alpha3 + / - brains .|Together , these results suggest that the beta4 and the alpha3 subunits are mediators of nicotine - induced seizures and hypolocomotion .	1:CID:2	L2R	NON-CROSS	11-12	14-15	D009538	nicotine|nicotine|nicotine|nicotine|nicotine|nicotine|nicotine	Chemical	11:22:95:133:157:223:268	12:23:96:134:158:224:269	0:1:4:5:5:7:9	D012640	seizures|seizures|seizures|seizures|seizures|seizures	Disease	14:50:98:160:226:271	15:51:99:161:227:272	0:1:4:5:7:9	1:NR:2	L2R	NON-CROSS	5-6	14-15	D000109	acetylcholine|acetylcholine	Chemical	5:25	6:26	0:1	D012640	seizures|seizures|seizures|seizures|seizures|seizures	Disease	14:50:98:160:226:271	15:51:99:161:227:272	0:1:4:5:7:9	1:NR:2	L2R	NON-CROSS	16-17	25-26	D000109	acetylcholine|acetylcholine	Chemical	5:25	6:26	0:1	D006948	hypolocomotion|hypolocomotion|hypolocomotion	Disease	16:100:273	17:101:274	0:4:9	1:NR:2	L2R	NON-CROSS	25-26	47-48	D000109	acetylcholine|acetylcholine	Chemical	5:25	6:26	0:1	D014202	tremors	Disease	47	48	1	1:NR:2	L2R	NON-CROSS	25-26	52-53	D000109	acetylcholine|acetylcholine	Chemical	5:25	6:26	0:1	D003643	death	Disease	52	53	1	1:NR:2	L2R	NON-CROSS	11-12	16-17	D009538	nicotine|nicotine|nicotine|nicotine|nicotine|nicotine|nicotine	Chemical	11:22:95:133:157:223:268	12:23:96:134:158:224:269	0:1:4:5:5:7:9	D006948	hypolocomotion|hypolocomotion|hypolocomotion	Disease	16:100:273	17:101:274	0:4:9	1:NR:2	L2R	NON-CROSS	22-23	47-48	D009538	nicotine|nicotine|nicotine|nicotine|nicotine|nicotine|nicotine	Chemical	11:22:95:133:157:223:268	12:23:96:134:158:224:269	0:1:4:5:5:7:9	D014202	tremors	Disease	47	48	1	1:NR:2	L2R	NON-CROSS	22-23	52-53	D009538	nicotine|nicotine|nicotine|nicotine|nicotine|nicotine|nicotine	Chemical	11:22:95:133:157:223:268	12:23:96:134:158:224:269	0:1:4:5:5:7:9	D003643	death	Disease	52	53	1
15602202	Recurrent acute interstitial nephritis induced by azithromycin .|A 14 - year - old girl is reported with recurrent , azithromycin - induced , acute interstitial nephritis .|The second episode was more severe than the first ; and although both were treated with intensive corticosteroid therapy , renal function remained impaired .|Although most cases of antibiotic induced acute interstitial nephritis are benign and self - limited , some patients are at risk for permanent renal injury .	1:CID:2	R2L	NON-CROSS	6-7	2-4	D017963	azithromycin|azithromycin	Chemical	6:20	7:21	0:1	D009395	interstitial nephritis|interstitial nephritis|interstitial nephritis	Disease	2:25:60	4:27:62	0:1:3	not_include	L2R	CROSS	20-21	76-78	D017963	azithromycin|azithromycin	Chemical	6:20	7:21	0:1	D007674	renal injury	Disease	76	78	3
16181582	Valproate - induced encephalopathy .|Valproate - induced encephalopathy is a rare syndrome that may manifest in otherwise normal epileptic individuals .|It may even present in patients who have tolerated this medicine well in the past .|It is usually but not necessarily associated with hyperammonemia .|The EEG shows characteristic triphasic waves in most patients with this complication .|A case of valproate - induced encephalopathy is presented .|The problems in diagnosing this condition are subsequently discussed .	1:CID:2	L2R	NON-CROSS	3-4	5-6	D014635	Valproate|Valproate|valproate	Chemical	0:5:64	1:6:65	0:1:5	D001927	encephalopathy|encephalopathy|encephalopathy	Disease	3:8:67	4:9:68	0:1:5	1:NR:2	L2R	NON-CROSS	5-6	19-20	D014635	Valproate|Valproate|valproate	Chemical	0:5:64	1:6:65	0:1:5	D004827	epileptic	Disease	19	20	1	1:NR:2	L2R	CROSS	46-47	64-65	D014635	Valproate|Valproate|valproate	Chemical	0:5:64	1:6:65	0:1:5	D022124	hyperammonemia	Disease	46	47	3
16298782	Nitro - L - arginine methyl ester : a potential protector against gentamicin ototoxicity .|The nitric oxide ( NO ) inhibitor nitro - L - arginine methyl ester ( L - NAME ) may act as an otoprotectant against high - frequency hearing loss caused by gentamicin , but further studies are needed to confirm this . Aminoglycoside antibiotics are still widely used by virtue of their efficacy and low cost .|Their ototoxicity is a serious health problem and , as their ototoxic mechanism involves the production of NO , we need to assess the use of NO inhibitors for the prevention of aminoglycoside - induced sensorineural hearing loss .|In this experimental study we used 30 Sprague - Dawley rats , 27 of which had gentamicin instilled into the middle ear .|The otoprotectant L - NAME was administered topically to 12 / 27 animals .|Its effect was determined in terms of attenuation of hearing loss , measured by shifts in the auditory brainstem response threshold .|L - NAME reduced gentamicin - induced hearing loss in the high - frequency range , but gave no protection in the middle or low frequencies .	1:CID:2	L2R	NON-CROSS	175-176	178-180	D005839	gentamicin|gentamicin|gentamicin|gentamicin	Chemical	12:47:128:175	13:48:129:176	0:1:3:6	D034381	hearing loss|hearing loss	Disease	158:178	160:180	5:6	1:NR:2	L2R	NON-CROSS	0-7	13-14	D019331	Nitro - L - arginine methyl ester|nitro - L - arginine methyl ester|L - NAME|L - NAME|L - NAME	Chemical	0:22:30:137:171	7:29:33:140:174	0:1:1:4:6	D006311	ototoxicity|ototoxicity|ototoxic	Disease	13:74:84	14:75:85	0:2:2	1:NR:2	L2R	NON-CROSS	30-33	40-45	D019331	Nitro - L - arginine methyl ester|nitro - L - arginine methyl ester|L - NAME|L - NAME|L - NAME	Chemical	0:22:30:137:171	7:29:33:140:174	0:1:1:4:6	D006316	high - frequency hearing loss	Disease	40	45	1	1:NR:2	L2R	CROSS	108-111	137-140	D019331	Nitro - L - arginine methyl ester|nitro - L - arginine methyl ester|L - NAME|L - NAME|L - NAME	Chemical	0:22:30:137:171	7:29:33:140:174	0:1:1:4:6	D006319	sensorineural hearing loss	Disease	108	111	2	1:NR:2	L2R	NON-CROSS	171-174	178-180	D019331	Nitro - L - arginine methyl ester|nitro - L - arginine methyl ester|L - NAME|L - NAME|L - NAME	Chemical	0:22:30:137:171	7:29:33:140:174	0:1:1:4:6	D034381	hearing loss|hearing loss	Disease	158:178	160:180	5:6	not_include	L2R	NON-CROSS	12-13	13-14	D005839	gentamicin|gentamicin|gentamicin|gentamicin	Chemical	12:47:128:175	13:48:129:176	0:1:3:6	D006311	ototoxicity|ototoxicity|ototoxic	Disease	13:74:84	14:75:85	0:2:2	1:NR:2	L2R	NON-CROSS	40-45	47-48	D005839	gentamicin|gentamicin|gentamicin|gentamicin	Chemical	12:47:128:175	13:48:129:176	0:1:3:6	D006316	high - frequency hearing loss	Disease	40	45	1	1:NR:2	L2R	CROSS	108-111	128-129	D005839	gentamicin|gentamicin|gentamicin|gentamicin	Chemical	12:47:128:175	13:48:129:176	0:1:3:6	D006319	sensorineural hearing loss	Disease	108	111	2	1:NR:2	R2L	NON-CROSS	16-18	13-14	D009569	nitric oxide|NO|NO|NO	Chemical	16:19:90:99	18:20:91:100	1:1:2:2	D006311	ototoxicity|ototoxicity|ototoxic	Disease	13:74:84	14:75:85	0:2:2	1:NR:2	R2L	NON-CROSS	74-75	58-59	D000617	Aminoglycoside|aminoglycoside	Chemical	58:105	59:106	1:2	D006311	ototoxicity|ototoxicity|ototoxic	Disease	13:74:84	14:75:85	0:2:2	1:NR:2	L2R	NON-CROSS	19-20	40-45	D009569	nitric oxide|NO|NO|NO	Chemical	16:19:90:99	18:20:91:100	1:1:2:2	D006316	high - frequency hearing loss	Disease	40	45	1	1:NR:2	L2R	NON-CROSS	99-100	108-111	D009569	nitric oxide|NO|NO|NO	Chemical	16:19:90:99	18:20:91:100	1:1:2:2	D006319	sensorineural hearing loss	Disease	108	111	2	1:NR:2	L2R	CROSS	99-100	158-160	D009569	nitric oxide|NO|NO|NO	Chemical	16:19:90:99	18:20:91:100	1:1:2:2	D034381	hearing loss|hearing loss	Disease	158:178	160:180	5:6	1:NR:2	R2L	NON-CROSS	58-59	40-45	D000617	Aminoglycoside|aminoglycoside	Chemical	58:105	59:106	1:2	D006316	high - frequency hearing loss	Disease	40	45	1	1:NR:2	L2R	NON-CROSS	105-106	108-111	D000617	Aminoglycoside|aminoglycoside	Chemical	58:105	59:106	1:2	D006319	sensorineural hearing loss	Disease	108	111	2	1:NR:2	L2R	CROSS	105-106	158-160	D000617	Aminoglycoside|aminoglycoside	Chemical	58:105	59:106	1:2	D034381	hearing loss|hearing loss	Disease	158:178	160:180	5:6
16428221	Cerebral vasculitis following oral methylphenidate intake in an adult : a case report .|Methylphenidate is structurally and functionally similar to amphetamine .|Cerebral vasculitis associated with amphetamine abuse is well documented , and in rare cases ischaemic stroke has been reported after methylphenidate intake in children .|We report the case of a 63 - year - old female who was treated with methylphenidate due to hyperactivity and suffered from multiple ischaemic strokes .|We consider drug - induced cerebral vasculitis as the most likely cause of recurrent ischaemic strokes in the absence of any pathological findings during the diagnostic work - up .|We conclude that methylphenidate mediated vasculitis should be considered in patients with neurological symptoms and a history of methylphenidate therapy .|This potential side - effect , though very rare , represents one more reason to be very restrictive in the use of methylphenidate .	1:CID:2	R2L	NON-CROSS	4-5	0-2	D008774	methylphenidate|Methylphenidate|methylphenidate|methylphenidate|methylphenidate|methylphenidate|methylphenidate	Chemical	4:14:43:64:108:123:148	5:15:44:65:109:124:149	0:1:2:3:5:5:6	D020293	Cerebral vasculitis|Cerebral vasculitis|cerebral vasculitis	Disease	0:23:80	2:25:82	0:2:4	1:NR:2	R2L	CROSS	23-25	21-22	D000661	amphetamine	Chemical	21	22	1	D020293	Cerebral vasculitis|Cerebral vasculitis|cerebral vasculitis	Disease	0:23:80	2:25:82	0:2:4	1:NR:2	L2R	NON-CROSS	14-15	27-29	D008774	methylphenidate|Methylphenidate|methylphenidate|methylphenidate|methylphenidate|methylphenidate|methylphenidate	Chemical	4:14:43:64:108:123:148	5:15:44:65:109:124:149	0:1:2:3:5:5:6	D019969	amphetamine abuse	Disease	27	29	2	1:NR:2	L2R	NON-CROSS	37-39	43-44	D008774	methylphenidate|Methylphenidate|methylphenidate|methylphenidate|methylphenidate|methylphenidate|methylphenidate	Chemical	4:14:43:64:108:123:148	5:15:44:65:109:124:149	0:1:2:3:5:5:6	D002544	ischaemic stroke|ischaemic strokes|ischaemic strokes	Disease	37:72:89	39:74:91	2:3:4	1:NR:2	L2R	NON-CROSS	64-65	67-68	D008774	methylphenidate|Methylphenidate|methylphenidate|methylphenidate|methylphenidate|methylphenidate|methylphenidate	Chemical	4:14:43:64:108:123:148	5:15:44:65:109:124:149	0:1:2:3:5:5:6	D006948	hyperactivity	Disease	67	68	3	not_include	L2R	NON-CROSS	108-109	110-111	D008774	methylphenidate|Methylphenidate|methylphenidate|methylphenidate|methylphenidate|methylphenidate|methylphenidate	Chemical	4:14:43:64:108:123:148	5:15:44:65:109:124:149	0:1:2:3:5:5:6	D014657	vasculitis	Disease	110	111	5	1:NR:2	L2R	CROSS	21-22	27-29	D000661	amphetamine	Chemical	21	22	1	D019969	amphetamine abuse	Disease	27	29	2	1:NR:2	L2R	CROSS	21-22	37-39	D000661	amphetamine	Chemical	21	22	1	D002544	ischaemic stroke|ischaemic strokes|ischaemic strokes	Disease	37:72:89	39:74:91	2:3:4	1:NR:2	L2R	CROSS	21-22	67-68	D000661	amphetamine	Chemical	21	22	1	D006948	hyperactivity	Disease	67	68	3	1:NR:2	L2R	CROSS	21-22	110-111	D000661	amphetamine	Chemical	21	22	1	D014657	vasculitis	Disease	110	111	5
16858720	Cerebral haemorrhage induced by warfarin - the influence of drug - drug interactions .|PURPOSE : To evaluate the frequency , severity and preventability of warfarin - induced cerebral haemorrhages due to warfarin and warfarin - drug interactions in patients living in the county of Osterg tland , Sweden .|METHODS : All patients with a diagnosed cerebral haemorrhage at three hospitals during the period 2000 - 2002 were identified .|Medical records were studied retrospectively to evaluate whether warfarin and warfarin - drug interactions could have caused the cerebral haemorrhage .|The proportion of possibly avoidable cases due to drug interactions was estimated .|RESULTS : Among 593 patients with cerebral haemorrhage , 59 ( 10 % ) were assessed as related to warfarin treatment .|This imply an incidence of 1 . 7 / 100 , 000 treatment years .|Of the 59 cases , 26 ( 44 % ) had a fatal outcome , compared to 136 ( 25 % ) among the non - warfarin patients ( p < 0 . 01 ) .|A warfarin - drug interaction could have contributed to the haemorrhage in 24 ( 41 % ) of the warfarin patients and in 7 of these ( 12 % ) the bleeding complication was considered being possible to avoid .|CONCLUSIONS : Warfarin - induced cerebral haemorrhages are a major clinical problem with a high fatality rate .|Almost half of the cases was related to a warfarin - drug interaction .|A significant proportion of warfarin - related cerebral haemorrhages might have been prevented if greater caution had been taken when prescribing drugs known to interact with warfarin .	1:CID:2	R2L	NON-CROSS	4-5	0-2	D014859	warfarin|warfarin|warfarin|warfarin|warfarin|warfarin|warfarin|warfarin|warfarin|warfarin|Warfarin|warfarin|warfarin|warfarin	Chemical	4:25:32:34:79:81:124:168:179:197:220:245:254:276	5:26:33:35:80:82:125:169:180:198:221:246:255:277	0:1:1:1:3:3:5:7:8:8:9:10:11:11	D002543	Cerebral haemorrhage|cerebral haemorrhages|cerebral haemorrhage|cerebral haemorrhage|cerebral haemorrhage|cerebral haemorrhages|cerebral haemorrhages	Disease	0:28:57:89:111:223:257	2:30:59:91:113:225:259	0:1:2:3:5:9:11	not_include	L2R	NON-CROSS	179-180	188-189	D014859	warfarin|warfarin|warfarin|warfarin|warfarin|warfarin|warfarin|warfarin|warfarin|warfarin|Warfarin|warfarin|warfarin|warfarin	Chemical	4:25:32:34:79:81:124:168:179:197:220:245:254:276	5:26:33:35:80:82:125:169:180:198:221:246:255:277	0:1:1:1:3:3:5:7:8:8:9:10:11:11	D006470	haemorrhage|bleeding	Disease	188:209	189:210	8:8
17466854	Side effects of postoperative administration of methylprednisolone and gentamicin into the posterior sub - Tenon 's space .|PURPOSE : To assess the incidence of postoperative emetic side effects after the administration of methylprednisolone and gentamicin into the posterior sub - Tenon 's space at the end of routine cataract surgery .|SETTING : St .|Luke 's Hospital , Gwardamangia , Malta .|METHODS : A double - blind double - armed prospective study comprised 40 patients who had uneventful sutureless phacoemulsification under sub - Tenon 's local infiltration of 3 mL of plain lignocaine .|At the end of the procedure , Group A ( n = 20 ) had 20 mg / 0 . 5 mL of methylprednisolone and 10 mg / 0 . 5 mL of gentamicin injected into the posterior sub - Tenon 's space and Group B ( n = 20 ) had the same combination injected into the anterior sub - Tenon 's space .|Postoperatively , all patients were assessed for symptoms of nausea , vomiting , and headache .|A chi - square test was used to assess the statistical significance of results .|RESULTS : Sixty percent in Group A developed postoperative emetic symptoms , headache , or both ; 1 patient in Group B developed symptoms .|CONCLUSIONS : The administration of methylprednisolone and gentamicin in the posterior sub - Tenon 's space was related to a high incidence of side effects including nausea , vomiting , and headache .|All adverse effects were self - limiting .	1:CID:2	L2R	NON-CROSS	223-224	244-247	D008775	methylprednisolone|methylprednisolone|methylprednisolone|methylprednisolone	Chemical	6:33:120:223	7:34:121:224	0:1:5:9	D020250	nausea , vomiting|postoperative emetic symptoms|nausea , vomiting	Disease	171:201:244	174:204:247	6:8:9	1:CID:2	L2R	NON-CROSS	205-206	223-224	D008775	methylprednisolone|methylprednisolone|methylprednisolone|methylprednisolone	Chemical	6:33:120:223	7:34:121:224	0:1:5:9	D006261	headache|headache|headache	Disease	176:205:249	177:206:250	6:8:9	1:CID:2	L2R	NON-CROSS	225-226	244-247	D005839	gentamicin|gentamicin|gentamicin|gentamicin	Chemical	8:35:130:225	9:36:131:226	0:1:5:9	D020250	nausea , vomiting|postoperative emetic symptoms|nausea , vomiting	Disease	171:201:244	174:204:247	6:8:9	1:CID:2	L2R	NON-CROSS	205-206	225-226	D005839	gentamicin|gentamicin|gentamicin|gentamicin	Chemical	8:35:130:225	9:36:131:226	0:1:5:9	D006261	headache|headache|headache	Disease	176:205:249	177:206:250	6:8:9	1:NR:2	L2R	NON-CROSS	33-34	49-50	D008775	methylprednisolone|methylprednisolone|methylprednisolone|methylprednisolone	Chemical	6:33:120:223	7:34:121:224	0:1:5:9	D002386	cataract	Disease	49	50	1	1:NR:2	L2R	NON-CROSS	35-36	49-50	D005839	gentamicin|gentamicin|gentamicin|gentamicin	Chemical	8:35:130:225	9:36:131:226	0:1:5:9	D002386	cataract	Disease	49	50	1	1:NR:2	R2L	CROSS	95-96	49-50	D008012	lignocaine	Chemical	95	96	4	D002386	cataract	Disease	49	50	1	1:NR:2	L2R	CROSS	95-96	171-174	D008012	lignocaine	Chemical	95	96	4	D020250	nausea , vomiting|postoperative emetic symptoms|nausea , vomiting	Disease	171:201:244	174:204:247	6:8:9	1:NR:2	L2R	CROSS	95-96	176-177	D008012	lignocaine	Chemical	95	96	4	D006261	headache|headache|headache	Disease	176:205:249	177:206:250	6:8:9
17562951	Cardiac Angiography in Renally Impaired Patients ( CARE ) study : a randomized double - blind trial of contrast - induced nephropathy in patients with chronic kidney disease .|BACKGROUND : No direct comparisons exist of the renal tolerability of the low - osmolality contrast medium iopamidol with that of the iso - osmolality contrast medium iodixanol in high - risk patients .|METHODS AND RESULTS : The present study is a multicenter , randomized , double - blind comparison of iopamidol and iodixanol in patients with chronic kidney disease ( estimated glomerular filtration rate , 20 to 59 mL / min ) who underwent cardiac angiography or percutaneous coronary interventions .|Serum creatinine ( SCr ) levels and estimated glomerular filtration rate were assessed at baseline and 2 to 5 days after receiving medications .|The primary outcome was a postdose SCr increase > or = 0 .